<SEC-DOCUMENT>0001185185-25-000706.txt : 20250627
<SEC-HEADER>0001185185-25-000706.hdr.sgml : 20250627
<ACCEPTANCE-DATETIME>20250627161432
ACCESSION NUMBER:		0001185185-25-000706
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		114
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250627
DATE AS OF CHANGE:		20250627

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IGC Pharma, Inc.
		CENTRAL INDEX KEY:			0001326205
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				202760393
		STATE OF INCORPORATION:			MD
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32830
		FILM NUMBER:		251086448

	BUSINESS ADDRESS:	
		STREET 1:		10224 FALLS ROAD
		CITY:			POTOMAC
		STATE:			MD
		ZIP:			20854
		BUSINESS PHONE:		301-983-0998

	MAIL ADDRESS:	
		STREET 1:		10224 FALLS ROAD
		CITY:			POTOMAC
		STATE:			MD
		ZIP:			20854

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	India Globalization Capital, Inc.
		DATE OF NAME CHANGE:	20050505
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>igc10k033125.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Jun 27 19:48:36 UTC 2025 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:igc="http://www.indiaglobalcap.com/20250331" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0px; margin-bottom: 0px; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 16pt"><b>UNITED
STATES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 16pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0px auto; width: 10%"><div style="font-size: 1pt; border-top: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 16pt"><b>FORM
<ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-14753">10-K</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0px auto; width: 10%"><div style="font-size: 1pt; border-top: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport" id="ixv-52"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric> <span style="font-size: 10pt"><b>Annual report pursuant to Section</b>&#160;<b>13 or 15(d) of the Securities Exchange Act of 1934</b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>For Fiscal</b>&#160;<b>Year Ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-14754"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-14755">March 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-14756">2025</ix:nonNumeric></ix:nonNumeric>.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="ixv-68"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric> <b>Transition report pursuant to Section</b>&#160;<b>13 or 15(d) of the Securities Exchange Act of 1934 </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>For the transition period from <span style="text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;to <span style="text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Commission file number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-14757">001-32830</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><img alt="" src="image_001.jpg"/>&#160;</b></p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-94"><b><span style="text-decoration:underline">IGC PHARMA, INC.</span></b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="border-bottom: Black 1pt solid; text-align: center; width: 49%"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-105"><span style="font-family: Times New Roman, Times, Serif"><b>Maryland</b></span></ix:nonNumeric></td> <td style="padding-bottom: 1pt; text-align: center; width: 2%">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: center; width: 49%"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber" id="ixv-110"><span style="font-family: Times New Roman, Times, Serif"><b>20-2760393</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(State or other jurisdiction<br/> of incorporation or organization)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(I.R.S. Employer <br/>
Identification No.)</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: top"> <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-14758">10224 Falls Road</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-14759">Potomac</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-14760">Maryland</ix:nonNumeric></b></span></td> <td style="padding-bottom: 1pt; text-align: center">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-131"><span style="font-family: Times New Roman, Times, Serif"><b>20854</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Address of Principal Executive Offices)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Zip Code)</span></td></tr> </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">(<ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-14761">301</ix:nonNumeric>) <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-14762">983-0998</ix:nonNumeric></span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered pursuant to Section 12(b)
of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; width: 32%; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-14763">Common Stock</ix:nonNumeric> </b></span></td> <td style="padding-bottom: 1pt; width: 2%">&#160;</td> <td style="border-bottom: Black 1pt solid; width: 32%; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-162"><span style="font-size: 10pt"><b>IGC</b></span></ix:nonNumeric></td> <td style="padding-bottom: 1pt; width: 2%">&#160;</td> <td style="border-bottom: Black 1pt solid; width: 32%; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-167"><span style="font-size: 10pt"><b>NYSE American LLC</b></span></ix:nonNumeric></td></tr> <tr> <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt; text-align: center"><span style="font-size: 10pt">(Title of each class)</span></td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt; text-align: center"><span style="font-size: 10pt">(Trading Symbol)</span></td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt; text-align: center"><span style="font-size: 10pt">(Name of each exchange on which registered)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered pursuant to Section 12(g)
of the Act: None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &#9744; Yes &#9745; <ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-14764">No</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. &#9744; Yes &#9745;
&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-14765">No</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. &#9745; &#160;<ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-14766">Yes</ix:nonNumeric> &#9744; No</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). &#9745; &#160;<ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-14767">Yes</ix:nonNumeric> &#9744; No</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="vertical-align: bottom; width: 34%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &#9744;</span></td> <td style="vertical-align: top; width: 33%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="vertical-align: bottom; width: 33%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer &#9744;</span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-14768">Non-accelerated filer</ix:nonNumeric> &#9745;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness" id="ixv-14769">&#9745;</ix:nonNumeric></span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-14770">&#9744;</ix:nonNumeric></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management assessment of the effectiveness of its Internal Control Over Financial Reporting
under section 404 (b) of the Sarbanes-Oxley by the registered public accounting firm that prepared or issued its annual report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag" id="ixv-241"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-247"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
Yes <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-14771">&#9745;</ix:nonNumeric> &#160;No</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate market value of the voting and non-voting
stock held by non-affiliates of the Registrant, as of September 30, 2024, the last business day of the Registrant&#8217;s most recently
completed second fiscal quarter, was approximately $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="dei:EntityPublicFloat" scale="0" unitRef="usd" id="ixv-14772">29,724,689</ix:nonFraction>. Solely for the purposes of this disclosure, shares of common stock held
by executive officers and directors of the Registrant as of such date have been excluded because such persons may be deemed to be affiliates.
This determination of executive officers and directors as affiliates is not necessarily a conclusive determination for any other purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14773">83,891,586</ix:nonFraction> shares of our common stock were outstanding
as of June 20, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0px; margin-bottom: 0px; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>IGC PHARMA, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM 10-K</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FOR THE FISCAL YEAR ENDED MARCH 31, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="TableOfContents"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">TABLE OF CONTENTS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 8%">&#160;</td>
    <td style="width: 84%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 8%; text-align: center"><span style="font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><b>PART I</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 1.</span></td>
    <td><a href="#a_002"><span style="font-size: 10pt">Business</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">5</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 1A.</span></td>
    <td><a href="#a_003"><span style="font-size: 10pt">Risk Factors</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">25</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 1B.</span></td>
    <td><a href="#a_004"><span style="font-size: 10pt">Unresolved Staff Comments</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">39</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 1C.</span></td>
    <td><a href="#a_005"><span style="font-size: 10pt">Cybersecurity</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">39</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 2.</span></td>
    <td><a href="#a_006"><span style="font-size: 10pt">Properties</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">40</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 3.</span></td>
    <td><a href="#a_007"><span style="font-size: 10pt">Legal Proceedings</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">40</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 4.</span></td>
    <td><a href="#a_008"><span style="font-size: 10pt">Mine Safety Disclosures</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">40</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><b>PART II</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 5.</span></td>
    <td><a href="#a_010"><span style="font-size: 10pt">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">41</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 6.</span></td>
    <td><a href="#a_011"><span style="font-size: 10pt">[Reserved]</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">42</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 7.</span></td>
    <td><a href="#a_012"><span style="font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">42</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 7A.</span></td>
    <td><a href="#a_013"><span style="font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">51</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 8.</span></td>
    <td><a href="#a_014"><span style="font-size: 10pt">Financial Statements and Supplementary Data</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">51</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 9.</span></td>
    <td><a href="#a_015"><span style="font-size: 10pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">78</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 9A.</span></td>
    <td><a href="#a_016"><span style="font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">78</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 9B.</span></td>
    <td><a href="#a_017"><span style="font-size: 10pt">Other Information</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">78</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 9C.</span></td>
    <td><a href="#a_018"><span style="font-size: 10pt">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">78</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><b>PART III</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 10.</span></td>
    <td><a href="#a_020"><span style="font-size: 10pt">Directors, Executive Officers, and Corporate Governance</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">79</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 11.</span></td>
    <td><a href="#a_021"><span style="font-size: 10pt">Executive Compensation</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">85</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 12.</span></td>
    <td><a href="#a_022"><span style="font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">87</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 13.</span></td>
    <td><a href="#a_023"><span style="font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">88</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 14.</span></td>
    <td><a href="#a_024"><span style="font-size: 10pt">Principal Accountant Fees and Services</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">88</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><b>PART IV</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 15.</span></td>
    <td><a href="#a_026"><span style="font-size: 10pt">Exhibits and Financial Statement Schedules</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">91</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Item 16.</span></td>
    <td><a href="#a_027"><span style="font-size: 10pt">Form 10-K Summary</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">92</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><a href="#a_028"><span style="font-size: 10pt">Signatures</span></a></td>
    <td style="text-align: right"><span style="font-size: 10pt">93</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 2; Options: NewSection --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 8pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 8pt; text-align: center"><b>FORWARD-LOOKING STATEMENTS AND IMPORTANT
FACTORS</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 8pt; text-align: justify; text-indent: 0.5in">This Annual Report
on Form 10-K and the documents incorporated in this report by reference contain &#8220;forward-looking statements&#8221; within the meaning
of federal securities laws. Additionally, we or our representatives may, from time to time, make other written or verbal forward-looking
statements. In this report and the documents incorporated by reference, we discuss plans, expectations, and objectives regarding our
business, financial condition, and results of operations. Without limiting the foregoing, statements that are in the future tense, and
all statements accompanied by terms such as &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;project,&#8221; &#8220;expect,&#8221;
&#8220;trend,&#8221; &#8220;estimate,&#8221; &#8220;forecast,&#8221; &#8220;assume,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221;
&#8220;target,&#8221; &#8220;anticipate,&#8221; &#8220;outlook,&#8221; &#8220;preliminary,&#8221; &#8220;will likely result,&#8221; &#8220;will
continue,&#8221; and variations of them and similar terms are intended to be &#8220;forward-looking statements&#8221; as defined by federal
securities laws. We caution you not to place undue reliance on forward-looking statements, which are based upon assumptions, expectations,
plans, and projections. In addition, our goals and objectives are aspirational and are not guarantees or promises that such goals and
objectives will be met. Forward-looking statements are subject to risks and uncertainties, including those identified in the &#8220;Risk
Factors&#8221; included in this report and in the documents incorporated by reference that may cause actual results to differ materially
from those expressed or implied in the forward-looking statements. Forward-looking statements speak only as of the date when they are
made. Except as required by law, we assume no obligation to update forward-looking statements to reflect events, circumstances, changes
in expectations, or the occurrence of unanticipated events after the date of those statements.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 8pt; text-align: justify; text-indent: 0.5in">Forward-looking statements
are based upon, among other things, our assumptions with respect to:&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the sufficiency of our existing cash and cash equivalents and marketable securities to fund our future operating and capital expenses;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to successfully implement and deploy our artificial intelligence initiatives;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our disposal of non-core Company assets;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to successfully register trademarks and patents, create and market new products and services, and achieve customer acceptance in the industries we serve;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">current and future economic and political conditions, including in North America, Colombia, Europe, and India;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to accurately predict the future demand for our products and services;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to successfully market our products in countries and states where our products are legal;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to maintain a stock listing on a national securities exchange;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to obtain and maintain regulatory approval of our existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to timely complete regulatory filings;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to obtain the U.S. Food and Drug Administration (FDA) approval for an Investigational New Drug Application (INDA) and to successfully run medical trials, including a Phase 2 trial for IGC-AD1;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our reliance on third parties to conduct clinical trials and for the manufacture of IGC-AD1 for clinical and non-clinical studies and clinical trials;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our financial performance;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the outcome of medical trials that are conducted on our Investigational Drug Candidates and products;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to fund the costs of clinical trials and other related expenses;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to maintain our intellectual property position and our ability to maintain and protect our intellectual property rights;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">competition and general acceptance of alternative, pharmaceutical, and nutraceutical therapies;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to effectively compete and our dependence on market acceptance of our brands and products within and outside the United States;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">federal and state legislation and administrative policy regulating our formulations;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability (based in part on regulatory concerns) to license our products to processors that can produce pharmaceutical-grade formulations;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to obtain and protect patents for the use of our formulations;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to obtain and install equipment for processing and manufacturing our products;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to successfully navigate disruptions of information technology systems or data security breaches that could adversely affect our business; and</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to successfully implement our strategy.</span></td></tr>
  </table><div>
</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 8pt; text-align: justify; text-indent: 0.5in">You should consider
the limitations on, and risks associated with, forward-looking statements and not unduly rely on the accuracy of predictions contained
in such forward-looking statements. As noted above, these forward-looking statements speak only as of the date when they are made. Moreover,
in the future, we may make forward-looking statements through our senior management that involve the risk factors and other matters described
in this report, as well as other risk factors subsequently identified, including, among others, those identified in our filings with
the SEC in our quarterly reports on Form 10-Q and our current reports on Form 8-K.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 8pt; text-align: justify; text-indent: 0.5in">This document contains
statements and claims that are not approved by the FDA, including statements on hemp and hemp extracts, including cannabinoids. These
statements and claims are intended to be in compliance with federal and state laws.&#160;</p><div>

</div><!-- Field: Page; Sequence: 4 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>In this report, unless
the context requires otherwise, all references in this report to </i>&#8220;<i>IGC,</i>&#8221; &#8220;<i>the Company,</i>&#8221; &#8220;<i>we,</i>&#8221;
&#8220;<i>our,</i>&#8221; <i>and </i>&#8220;<i>us</i>&#8221; <i>refer to IGC Pharma, Inc., together with the subsidiaries </i>identified
<i>in Exhibit 21.1 of this Annual Report on Form 10-K. We exclude our investments and minority non-controlling interests, and any information
provided by them is not incorporated by reference in this report. They should not be considered part of this report.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1. BUSINESS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Overview</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IGC is a Maryland corporation
established in 2005 with a fiscal year ending on March 31, spanning a 52- or 53-week period. Please refer to Note 1, &#8220;Nature of
Operations&#8221; and Item 8 of this Annual Report on Form 10-K, for further information on business segments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our mission is to improve
the lives of individuals affected by Alzheimer&#8217;s disease by addressing both its symptoms and the disease. Our near-term focus is
on advancing IGC-AD1, our lead drug candidate currently in Phase 2 clinical trials targeting agitation in Alzheimer&#8217;s patients.
We are also investing in our early-stage pipeline of investigational therapies and exploring Artificial Intelligence (AI) powered models
designed to identify early markers of Alzheimer&#8217;s. We believe that combining scientific innovation with operational execution, including
leveraging our internal contract research organization, positions us to efficiently advance our pipeline toward commercialization, although
there can be no assurance thereof. Our long-term strategy is to build a portfolio of differentiated therapies that not only address symptomatic
needs but also target disease-modifying mechanisms, thereby creating sustainable value for patients, caregivers, and shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our lead investigational drug,
IGC-AD1, has progressed through preclinical evaluations and a successful Phase 1 safety trial, and is currently being evaluated in a multicenter,
randomized, double-blind, placebo-controlled Phase 2 clinical trial, officially named &#8220;CALMA&#8221; (Calming Agitation in Alzheimer&#8217;s).
Interim data from this trial have demonstrated encouraging signs of efficacy, with patients receiving IGC-AD1 experiencing a statistically
significant reduction in agitation compared to placebo within the first 2-6 weeks of treatment. This reduction in agitation is particularly
notable as it could, although there can be no assurance, significantly improve patient care and represents a potential breakthrough in
managing Alzheimer&#8217;s-related agitation. In addition, IGC-AD1, Phase 2 clinical trial interim data also demonstrate a clinical and
statistically significant reduction in sleep disturbances among Alzheimer&#8217;s patients&#160;receiving the active medication compared
to placebo.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During fiscal 2025, the Company
reassessed its reportable segment structure in connection with its strategic realignment toward Life Sciences. As a result, management
determined that the Company operates as a single reportable segment, focused on the vision to make the world free from Alzheimer&#8217;s.
Historically, the Company reported two operating segments: Life Sciences and Infrastructure. While the Infrastructure segment generated
revenues in fiscal 2024, it did not generate any revenues in fiscal 2025 and is no longer actively managed or evaluated as a discrete
operating segment by the Company&#8217;s Chief Operating Decision Maker. For more information, please refer to &#8220;Note 18 &#8211;
Segment Information&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our Drug Development Pipeline</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IGC Pharma is on a mission to transform Alzheimer&#8217;s
treatment. We are building a robust pipeline of drug candidates, each targeting different aspects of the disease. Our product candidate
pipeline and anticipated milestones include the followings: -</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border: Black 1pt solid; padding-bottom: 3pt; width: 10%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Asset</b></span></td>
    <td style="border-top: Black 1pt solid; padding-bottom: 3pt; width: 27%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Target Indication</b></span></td>
    <td style="border-top: Black 1pt solid; padding-bottom: 3pt; width: 23%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Mechanism of Action</b></span></td>
    <td style="border-top: Black 1pt solid; padding-bottom: 3pt; width: 18%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Development Stage</b></span></td>
    <td style="border-top: Black 1pt solid; padding-bottom: 3pt; width: 22%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Key Milestones</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">IGC- AD1</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Agitation in Alzheimer&#8217;s dementia</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">CB1 receptor partial agonist; reduces neuroinflammation and restores neurotransmitter balance</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Phase 2 clinical trial (CALMA study)</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Interim Phase 2 data analysis suggests cognitive improvements in the active treatment group versus the placebo group.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">TGR-63</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Early to moderate Alzheimer&#8217;s disease</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Disrupts amyloid-beta (A&#946;) plaque formation; crosses blood-brain barrier</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Preclinical</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Demonstrated favorable safety profile; advancing towards clinical trials</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">LMP</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Alzheimer&#8217;s disease</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Targets neuroinflammation, neurotransmitter imbalance, and inflammasome-3</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Preclinical</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Bioequivalence to IGC-AD1 anticipated in 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">IGC-M3</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Early-stage Alzheimer&#8217;s disease</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Inhibits A&#946; plaque aggregation</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Preclinical</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Toxicology studies planned for mid-2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">IGC-1C</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Alzheimer&#8217;s disease and metabolic disorders</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Targets tau protein phase separation; potential GLP-1 receptor agonist</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Preclinical</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Exhibits strong binding affinity to tau protein; potential for weight loss applications</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">IGC-1A</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Metabolic disorders (e.g., type 2 diabetes, obesity)</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Potential GLP-1 and GIP receptor agonist; CB1 receptor inverse agonist</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Preclinical</span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 3pt; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Identified through AI modeling; toxicology and dosing studies underway</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 5; Options: NewSection; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This pipeline reflects IGC
Pharma&#8217;s strategic focus on addressing neurodegenerative diseases, particularly Alzheimer&#8217;s, through innovative mechanisms
targeting key pathological features like amyloid plaques and tau protein aggregation. Additionally, the expansion into metabolic disorders
showcases the versatility of our drug discovery platform, leveraging AI to identify promising therapeutic candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is also attempting
to harness the power of AI to develop early detection models, optimize clinical trials, and explore new applications for our drugs. Additionally,
our 31 patent filings, including for IGC-AD1, demonstrate our commitment to innovation and protecting our intellectual property.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Artificial Intelligence (AI)/Machine Learning (ML)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In our pursuit of innovation,
we leverage AI and ML. AI refers to the development of intelligent systems that can learn and act autonomously. ML is a branch of AI that
allows computers to learn from data without the need for explicit programming. This technology plays a role in our efforts and could allow
companies of our size to do what previously was the domain of much larger pharmaceutical companies. For instance, we are utilizing ML
by training transformers, a powerful neural network architecture, to analyze vast datasets from our Phase 1 and unblinded Phase 2 interim
clinical trial to identify patterns and optimize the clinical trial protocol for a potential Phase 3 trial. The AI model, for example,
has the potential to tell us if a particular neuropsychiatric scale that we used in Phase 1 and Phase 2 added valuable information to
the trial, and if it did not, we could remove that scale from a future Phase 3 trial, thus saving money and time in the overall trial
management. In the long term, with more data, the trained AI model could allow us to consider incoming patient signatures, such as scans,
symptoms, patient history, among others, and predict outcomes for our drug, including adverse effects, thus personalizing the delivery
of IGC-AD1, of which there can be no assurance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, the AI team is
working on developing a Multimodal Interpretable Transformer for Alzheimer&#8217;s Disease (MINT-AD). This tool aims to support clinicians
in real-world decision-making towards reducing Alzheimer&#8217;s false negatives and delayed diagnosis. We are developing MINT-AD for
three aims/phases: risk stratification for AD, cognitive decline prediction 2-5 years in advance, and deployment as a physician&#8217;s
tool.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have collected and started
harmonizing a group of 32 worldwide databases that include longitudinal aging data, clinical and neuroimaging, and omics data. The databases
represent participants from various countries, with a large representation from North, Central, and South America, and Asia. A detailed
map of the databases is shown in Fig. 1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the first phase, we are
pretraining and finetuning state-of-the-art Large Language Models (LLMs) to extract intricate patterns in the data that uncover groups
of interacting risk factors for early detection. Our first efforts have focused on the longitudinal data due to its compatibility and
ease of use in LLMs. To input the data into language models, we are building prompts in two formats: semi-structured prompts made up by
the original variable names and their values, and descriptive prompts made up by tailored text for each database. Also, we are implementing
masked attention strategies to help the model focus on the data that is available for each database. By leveraging LLMs, we aim to enhance
interpretability, generalizability, and clinical usability. Regarding interpretability, we have tested adversarial attack approaches that
can help understand the decision-making of the model and expose wanted and unwanted behaviors in early stages. Additionally, to define
a training target, we have extracted cognitive scales so that the model identifies which risk factors impact the patient the most. Some
of the scales we have found across databases include the Mini-Mental State Examination (MMSE), the Community Screening Interview for Dementia
(CSI-D), and the Montreal Cognitive Assessment (MoCA). We are also working on incorporating clinical and imaging data, including MRI and
PET scans, and varied omics data, such as RNA sequencing, whole genome sequencing, and DNA methylations. Each group of data types will
be developed in modules and then integrated through a Mixture-of-Experts (MoE) architecture. Fig. 2 shows a general overview of our approach
with MoE. Our next steps will focus on finishing the harmonization process and incorporating the remaining databases. Once we have various
modules, we plan to train their ensemble in the MoE and test gating strategies to properly direct the input to the most appropriate expert.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">So far, the first phase is
focused on the current cognitive state and the factors that have the most significant impact on that state. In the second phase, we want
to focus on understanding how cognitive abilities evolve over time and how modifiable risk factors lead to a positive or negative cognitive
trajectory. For this task, we will include datapoints throughout time, focusing on the importance of temporality and causality in the
data. Also, we can leverage strategies like chain-of-thought (CoT) in the transformer-based models from the previous phase to train the
models to understand how the reasoning behind a risk factor leads to the cognitive outcome. This strategy will be implemented with help
from experts that can provide examples of the analysis process on a case-by-case basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the last phase, we will
deploy the final model with insights from both previous phases to conduct further real-world validation and assess the impact of the model
in early detection and cognitive trajectory improvements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;<img alt="" src="image_002.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Fig. 1: Overview of the database for MINT-AD</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;<img alt="" src="image_003.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.75in"><b>Fig. 2: MINT-AD architecture using MoE</b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our goal is to develop product
candidates to diagnose and/or treat central nervous system disorders, such as Alzheimer&#8217;s disease and neurodegenerative conditions.
Key elements of our business strategy to achieve this mission include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 0.5in">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Advance Differentiated Therapies for High-Need
    CNS Indications<i>: - </i></b>Subject to FDA approval and clinical trials, IGC Pharma is advancing IGC-AD1 as a potential treatment for
    agitation in dementia due to Alzheimer&#8217;s disease&#8212;an area with limited effective therapies and significant unmet medical need.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 0.5in; padding: 0.25pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px; padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; padding: 0.25pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Expand IGC-AD1&#8217;s therapeutic potential
    to treat AD, subject to FDA approval: -</b> Subject to FDA approval, IGC Pharma aims to broaden the clinical application of IGC-AD1 beyond
    agitation to target core Alzheimer&#8217;s disease symptoms, contingent upon regulatory approval and support clinical data. Although there
    can be no assurance, this expansion could significantly enhance the drug&#8217;s value and impact in addressing a major unmet medical
    need.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 0.5in; padding: 0.25pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px; padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; padding: 0.25pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Advance the development of TGR-63 as a potential
    therapeutic for AD: - </b>IGC Pharma is progressing TGR-63, a preclinical candidate designed to target amyloid-beta plaque formation,
    a hallmark of Alzheimer&#8217;s pathology. This molecule represents a key component of the Company&#8217;s long-term strategy to diversify
    its Alzheimer&#8217;s pipeline and address the disease at its biological core.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 0.5in; padding: 0.25pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px; padding: 0.25pt">&#160;</td>
    <td style="vertical-align: top; padding: 0.25pt">&#160;</td></tr>
  <tr>
    <td style="padding: 0.25pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding: 0.25pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; padding: 0.25pt; text-align: justify"><span style="font-size: 10pt"><b>Publish scientific findings in peer-reviewed journals to strengthen clinical credibility and visibility: -</b> IGC Pharma actively disseminates research through peer-reviewed publications to validate its scientific approach, enhance transparency, and support regulatory engagement. This strategy reinforces the Company&#8217;s reputation within the medical and investor communities and underpins the advancement of its drug development programs.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Allocate Capital to Enhance Shareholder Value: -</b> IGC Pharma Inc. is committed to strategically allocating capital to enhance shareholder value by advancing its AD pipeline, optimizing operational efficiency, and maintaining a robust financial position. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe developing a drug
for both symptom and disease-modifying agents has less risk due to the need for expensive multi-year trials. However, there is considerable
upside and significant value creation to the extent we obtain a first-in-class advantage, of which there can be no assurance. If we were
to obtain a first-in-class advantage, such an advantage could result in significant growth if and when an approved drug such as IGC-AD1
launches.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that additional
investment in clinical trials, AI, R&amp;D, facilities, marketing, advertising, and the acquisition of complementary products and businesses
will be critical to the ongoing growth of the Life Sciences segment. Although there can be no assurance, we believe these investments
will fuel the development and delivery of innovative products that drive positive patient and customer experiences. We hope to leverage
our R&amp;D and intellectual property to develop ground-breaking, science-based products that are proven effective through clinical trials,
subject to FDA approval. Although there can be no assurance, we believe this strategy can improve our existing products and lead to the
creation of new products that can provide treatment options for multiple conditions, symptoms, and side effects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 8; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Core business competencies and advantages</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our core competencies include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 0.5in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a network of doctors, scientists with Ph.D. degrees, and intellectual property legal experts with a sophisticated understanding of drug discovery, research, FDA filings, intellectual protection, and product formulation;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">knowledge of various cannabinoid strains, their phytocannabinoids profile, extraction methodology, and impact on various pathways;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">knowledge of plant and cannabinoid-based combination therapies;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">knowledge of research and development in the field;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">approximately thirty-one (31) patent applications out of which our portfolio includes twelve (12) granted patents. For more information, please refer to Item I, &#8220;Business&#8221;&#160;of Part I;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">facilities and a team with experience in manufacturing, marketing, and selling products. These competencies have enabled us to make progress on our business goals, specifically completing the Phase 1 clinical trial of IGC-AD1, which has the potential to positively impact on the lives of millions of patients suffering from the symptoms of Alzheimer&#8217;s disease, subject to FDA approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Background on Alzheimer</b>&#8217;<b>s Disease
(AD) Pathology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AD pathology can be divided
into two categories: familial or inherited AD and sporadic AD. The histopathology of early-onset familial AD and late-onset sporadic AD
is indistinguishable. Both forms of AD are characterized by extracellular amyloid-&#946; (A&#946;) plaques and intracellular tau-containing
neurofibrillary tangles (G&#1255;tz, et al., 2011). Simplistically, in normal brain functioning, a large protein called Amyloid Precursor
Protein (APP) is cleaved into smaller fragments called A&#946; proteins. In a normal brain, these are subsequently broken down further
and cleared. However, in AD brains, these A&#946; proteins are not broken down and cleared; they instead stick to one another and deposit
as inter-neuronal sticky plaque&#8212;that is, they deposit as plaque between neurons. In the brain, within a neuron, tau (&#964;) is a
key protein that holds together the transport scaffold. As an analogy, it is the brick-and-mortar of the highway over which nutrients
are transported within a neuron. In an AD brain, tau breaks down due to a process called hyperphosphorylation and is unable to hold the
transport highway. The breakdown results in neurofibrillary tangles (NFTs) and eventually leads to neuronal death.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The misfolded structure of
A&#946; proteins, along with NFTs, generates a characteristic tendency for their aggregation (Chiti &amp; Dobson, 2006) around damaged
or dead neurons and within cerebral vasculature in the brain. It manifests in memory loss followed by progressive dementia. It has long
been believed that A&#946;1&#8211;40 (A&#946;40) and A&#946;1&#8211;42 (A&#946;42) aggregates are the constituents of the insoluble plaques
that are characteristic of AD. This disease is also associated with neuroinflammation, excitotoxicity, and oxidative stress (Campbell
&amp; Gowran, 2007; Rich, et al., 1995). However, the continuous aggregation of A&#946; proteins along with hyperphosphorylation of tau
protein inside the cell, causing NFT formation, are generally accepted as the major etiological factors of the neuronal cell death associated
with the progression of Alzheimer&#8217;s disease (Octave, 1995; Reitz, et al., 2011; Pillay, et al., 2004). The two hallmarks of Alzheimer&#8217;s
are shown in Figure 3.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 50%"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"><b>Figure
                         3: Hallmarks of Alzheimer</b>&#8217;<b>s</b></span></p>
                         <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>
                         <p style="font: normal 10pt Times New Roman; margin: 0pt 0pt 0pt 36pt; text-align: justify; text-indent: -14pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Extracellular
                         Plaque: &#946;-amyloid (A&#946;)</span></p>
                         <p style="font: normal 10pt Times New Roman; margin: 0pt 0pt 0pt 36pt; text-align: justify; text-indent: -14pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Tau
                         Neurofibrillary Tangles (NTFs).</span></p>
                         <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>
                         <p style="font: normal 10pt Times New Roman; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif">Causes
                         loss of neurons &amp; critical neuronal connections.</span></p>
                         <p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
                         <p style="font: normal 10pt Times New Roman; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif">Also
                         linked to Alzheimer&#8217;s:&#160;</span></p>
                         <p style="font: normal 10pt Times New Roman; margin: 0pt 0pt 0pt 77pt; text-align: justify; text-indent: -18pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Metabolism
                         disruption</span></p>
                         <p style="font: normal 10pt Times New Roman; margin: 0pt 0pt 0pt 77pt; text-align: justify; text-indent: -18pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mitochondrial
                         dysfunction</span></p>
                         <p style="font: normal 10pt Times New Roman; margin: 0pt 0pt 0pt 77pt; text-align: justify; text-indent: -18pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neuroinflammation</span></p>
                         <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>
                         <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>
                         <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>
                         <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>
                         <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p></td>
  <td style="text-align: center; width: 50%"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_004.jpg"/>&#160;</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Alzheimer&#8217;s affects
not only cognition but also mood and behavior, changes which increase in intensity as the disease progresses. Approximately 6.9 million
Americans aged 65 and older are living with Alzheimer&#8217;s dementia, according to the Alzheimer&#8217;s Association&#8217;s 2024 Facts
and Figures report. In 2025, it is estimated that&#160;7.2 million Americans&#160;aged 65 and older have Alzheimer&#8217;s dementia, reflecting
the growing aging population. Alzheimer&#8217;s is the most common cause of dementia, accounting for an estimated 60% to 80% of cases.
Most individuals also have the brain changes of one or more other causes of dementia. This is called mixed pathologies, and if recognized
during life it is called mixed dementia. There are various symptoms associated with this medical condition, such as screaming, pacing,
biting, disrobing, excessive motor movements, physical aggression, and verbal aggression, among others. These behaviors make up clinical
agitation in dementia due to Alzheimer&#8217;s disease and it they make it very difficult for caregivers to manage their loved ones. Agitation
is associated with increased hospitalization and accelerated cognitive decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Symptoms of AD depend on the
stage of the disease: preclinical, mild, moderate, or severe. NPS, such as agitation, apathy, delusions, hallucinations, and sleep impairment,
are common accompaniments of dementia. Loss of functionality, including progressive difficulty in performing instrumental and basic activities
of daily living, is also seen with disease progression (Tang et al., 2019). There is a spectrum of behavioral disorders that can affect
patients with AD. These include agitation, anxiety, disturbance of the sleep cycle, depression, inappropriate sexual behavior, disinhibition,
and irritability, among others (Lyketsos, et al., 2011). These behavioral disturbances not only affect the patient&#8217;s quality of
life but also cause extreme emotional distress for the caregivers. These disturbances can become very difficult to manage, so most of
the time, combined therapy is used (Matsunaga et al., 2015). This can cause secondary undesirable effects, such as excessive sleepiness,
which diminishes the capability of the patient to be active and alert during the day; dizziness, which can increase the risk for falls
(Allan, et al., 2005); worsening of cognitive function, which in turn worsens functionality (Paterniti S, et al., 2002); and even death
due to cardiovascular complications (Qiu, et. Al., 2006).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Background on Agitation in Alzheimer</b>&#8217;<b>s
dementia </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Agitation is a prevalent neuropsychiatric
symptom among individuals with Alzheimer&#8217;s disease, characterized by restlessness, aggression, and emotional distress. Studies indicate
that up to 80% of individuals with Alzheimer&#8217;s experience agitation during the course of the disease. Based on these figures, approximately
5.8 million Americans with Alzheimer&#8217;s may experience agitation in 2025. This substantial number underscores the critical need for
effective interventions targeting agitation to improve patient quality of life and reduce caregiver burden. Agitation is a behavioral
syndrome characterized by increased, often undirected, motor activity, restlessness, aggressiveness, and emotional distress. While there
can be no guarantee, we expect the Phase 2 trial to take between 12 and 18 months to complete, barring a variety of unknown factors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently developing
IGC-AD1 for the treatment of Agitation in Alzheimer&#8217;s dementia (AAD). There is only one FDA-approved pharmacological treatment for
the indication of AAD.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The National Institute on
Aging (NIA) at the National Institutes of Health (NIH) defines AD as an irreversible, progressive brain disorder that destroys memory
and thinking skills. AD is a progressive neurodegenerative disorder that manifests initially as forgetfulness, advancing to severe cognitive
impairment and memory loss. Emotional distress, aggressive behaviors, disruptive irritability, and disinhibition characterize agitation.
Agitation in Alzheimer&#8217;s dementia has been associated with increased caregiver burden, decreased functioning, earlier nursing home
placement, and death.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The NIA categorizes Alzheimer&#8217;s
in three stages- mild, moderate, and severe (NIA, 2019). Symptoms of mild Alzheimer&#8217;s can include wandering (getting lost, not remembering
the way home), trouble handling money and paying bills, repeating questions, and personality or behavior changes. As the disease progresses
to moderate, there is damage to the areas of the brain that control language, reasoning, sensory processing, and conscious thought. Patients
can have difficulty with multi-step tasks such as getting dressed. Behavioral problems, including hallucinations, delusions, paranoia,
and impulsive behavior, can also increase. When severe Alzheimer&#8217;s sets in, plaques and tangles spread throughout the patient&#8217;s
brain, and the brain shrinks significantly. People with severe Alzheimer&#8217;s are completely dependent on others for care. They cannot
communicate, and near the end of their life, they may be largely bedridden as the body shuts down (NIA, 2021).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patients with AD are currently
treated with various medications, including antipsychotics, which have been considered the mainstay of treatment. These treatments, however,
are limited by safety concerns. Typical antipsychotics prescribed for agitation, aggression, or insomnia are associated with functional
decline in patients with AD, while studies indicate that atypical antipsychotics may be associated with increased rates of cerebrovascular
events and death in patients with dementia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, there are limited
options to help Alzheimer&#8217;s patients with agitation or relief the burden placed on their caregivers (Cheng, 2017).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, IGC-AD1 is in a
Phase 2 clinical trial, and on March 20, 2024, and on November 14, 2024, IGC announced the &#8220;Positive Interim Results for IGC-AD1
in Reducing Alzheimer&#8217;s agitation&#8221; and &#8220;Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1
for Alzheimer&#8217;s Treatment&#8221;, respectively. The interim data validates IGC-AD1&#8217;s potential as a transformative therapeutic
option with a large market opportunity in Alzheimer&#8217;s disease management, although there can be no assurance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>IGC-AD1 as a Treatment for Agitation in Alzheimer</b>&#8217;<b>s
Dementia</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Approximately 6.9 million
Americans aged 65 and older are living with Alzheimer&#8217;s dementia, according to the Alzheimer&#8217;s Association&#8217;s 2024 Facts
and Figures report. AAD is associated with an accelerated cognitive decline, increased caregiver burden, increased hospitalization, and
increased need for medication, all significantly diminishing the quality of life for patients. Current therapies carry black box warnings,
indicative of serious adverse reactions that may lead to death or serious injury. IGC-AD1 is designed to target AAD&#8217;s underlying
causes and address the unmet need for safe and effective therapy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As illustrated in Figure 2,
neuroinflammation, neurotransmitter imbalance, and CB1 receptor dysfunctions are all associated with AAD (Yasuno et al., 2023; Manuel
et al., 2014). In addition, upregulation of inflammasome-3 has been shown to lead to neuroinflammation, consequently leading to aggressive
behavior (Yu et al., 2023). IGC-AD1&#8217;s formulation combines a CB1 receptor partial agonist with anti-neuroinflammatory properties
that help balance neurotransmitter imbalance and an inflammasome inhibitor that targets the upregulation of inflammasome-3.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 146-patient IGC-AD1 Phase
2 trial, for which these interim results are presented, continues to enroll in the U.S. and Canada. As the interim results are based on
a small number of patients (n=26), there is no guarantee that the positive interim results will hold up as more patients are enrolled
in the trial. Learn more and find information about recruitment centers at https://clinicaltrials.gov/study/NCT05543681.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Figure 4: Damaged and Healthy Neurons</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 50%; padding: 0.25pt; text-align: center"><img alt="" src="image_005.jpg"/></td>
    <td style="text-align: center; width: 50%; padding: 0.25pt">
    <img alt="" src="image_006.jpg"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>IGC-AD1 Clinical Trial Data</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the best of our knowledge,
the Company&#8217;s Phase 2 clinical trial of IGC-AD1 is the first human clinical trial using low doses of THC, in combination with another
molecule, to treat symptoms of dementia in Alzheimer&#8217;s patients. THC is a naturally occurring cannabinoid produced by the cannabis
plant. It is known for being a psychoactive substance that can impact mental processes in a positive or negative way, depending on the
dosage. THC is biphasic, meaning that low and high doses of the substance may affect mental and physiological processes in substantially
different ways. For example, in some patients, low doses may relieve a symptom, whereas high doses may amplify a symptom. IGC&#8217;s
trial is based on low dosing and controlled trials on patients suffering from Alzheimer&#8217;s disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted a double-blind,
single-site, randomized, three-cohort, multiple-ascending dose (MAD) clinical trial (FDA IND Number: 146069, NCT04749563) using the investigational
new drug (IND) IGC-AD1. In this trial, we looked at safety, tolerability, neuropsychiatric symptoms, and pharmacokinetics, among others.
The trial concluded that all three dosing levels (once a day, twice a day, and twice a day) were safe, with no serious or life-threatening
events or deaths reported.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 1, 2021, IGC submitted
the Clinical/Statistical Report (CSR) to the FDA on its Phase 1 trial titled &#8220;A Phase I Randomized Placebo-Controlled MAD Study
to Evaluate Safety and Tolerability of IGC-AD1 in Subjects with Dementia Due to Alzheimer&#8217;s Disease.&#8221; The already disclosed
data is presented here for a better understanding of the safety profile of IGC-AD1. The data presented here is not exhaustive and represents
a small portion of the data submitted to the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 11; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Phase 1 Primary Endpoint: Safety &amp; Tolerability</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Safety and tolerability (S&amp;T)
were assessed by recording both solicited and non-solicited Adverse Events (AEs). The solicited AEs, assessed daily, were somnolence,
falls, dizziness, asthenia, suicidal ideation, hypertension, psychiatric symptoms, and paradoxical nausea. All AEs were graded as mild,
moderate, severe, life-threatening, and serious (SAE). In the phase 1 trial, a) there were no SAEs, b) no life-threatening AEs, and c)
no deaths.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Phase 1 Secondary Endpoints: Neuropsychiatric Inventory (NPI)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neuropsychiatric Symptoms
(NPS) such as agitation/aggression, depression, anxiety, elation/euphoria, apathy, disinhibition, irritability, delusions, hallucinations,
aberrant motor behavior, sleep disorders, and appetite/eating disorders are prevalent in patients who have AD (Phan et al., 2019). NPS
in Alzheimer&#8217;s is a significant burden on patients and caregivers, and at some point in the progression of Alzheimer&#8217;s disease,
more than 97% of patients suffer from at least one symptom. The Neuropsychiatric Inventory (NPI) is a scale that measures the severity
of each symptom and establishes both individual symptom scores as well as an overall NPI score. Separately, the NPI also scores caregiver
distress (NPI-D). The NPI is used by about 50% of neurologists to assess and treat Alzheimer&#8217;s patients (Fernandez et al., 2010).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the Phase 1 trial conducted
on patients with AD, we measured changes in NPS as assessed by the NPI as well as caregiver distress as assessed by the NPI-D. In the
Phase 1 trial (N=10), seven received the active medication, and at baseline, they had agitation scores between two and twelve. The three
Cohorts shown in Table 1 received the medication once a day (qd), twice a day (bid), and three times a day (tid). We measured and analyzed
the change in the mean NPI score for agitation between Day 1 and Day 10 and between Day 1 and Day 15 for all three cohorts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">As shown in the Table 1, our
analysis shows Cohort 2 (bid) had the largest absolute change in the mean agitation score between Day one and Day ten (53% drop, p=.085)
as well as between Day 1 and Day 15 (67% drop, p=.05).</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Table 1: NPI (Agitation) analysis for each
of the three cohorts</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Domain</b></span></td>
    <td colspan="3" style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cohort
    1 (n=7) qd</b></span></td>
    <td colspan="3" style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cohort
    2 (n=6) bid</b></span></td>
    <td colspan="3" style="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cohort
    3 (n=5) tid</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NPI
    (Agitation)</b></span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Baseline</b></span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Day</b></span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Day</b></span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Baseline</b></span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Day</b></span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Day</b></span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Baseline</b></span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Day</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Day</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Day
    0</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Day
    0</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Day
    0</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mean
    Score</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mean
    Change</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mean
    Change%</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37%</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48%</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>53%</b></span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>67%</b></span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23%</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p-values</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.058</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.045</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>0.085</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>0.05</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.29</span></td>
    <td style="border: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1pt 3pt 1pt 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.045</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the NPI, a reduction
of 4 points or 30% in the score is considered clinically meaningful (Cummings et al., 1994). In addition, we used a paired 2-tailed t-test
with 9 degrees of freedom to assess the statistical significance of the decrease in the overall NPI agitation domain. As seen in Table
1, the NPI score for Agitation in Cohort 2 at day 15 shows a reduction of 67% (<i>p</i> = .05). Based on this study the dosing of twice
a day or bid was selected for the Phase 2 trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>IGC-AD1 Phase 2 Clinical Trial Update</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IGC Pharma launched a Phase
2 trial with a protocol titled &#8220;A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled, trial of the safety and efficacy
of IGC-AD1 on agitation in participants with dementia due to Alzheimer&#8217;s disease&#8221; (clinicaltrials.gov, Identifier: CT05543681).
The trial treatment duration is 6 weeks, with the intervention, IGC-AD1 or placebo, administered twice a day. The study is powered to
include 146 Alzheimer&#8217;s patients; as a superiority trial with parallel groups, half of the participants will receive a placebo,
and the other half will receive IGC-AD1. The primary and secondary endpoints are the mean change in agitation scores from baseline, compared
to placebo, as assessed by the Cohen-Mansfield Agitation Inventory (CMAI) in Alzheimer&#8217;s patients after 6 weeks of treatment and
the mean change in CMAI scores after 2 weeks of treatment, respectively. Agitation is rated at the trial site, at baseline, week 2, and
week 6, by a trained practitioner using the CMAI, a scale designed and widely used to measure agitation in Alzheimer&#8217;s dementia
(AAD) in clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The IGC-AD1 Phase 2 is an
ongoing clinical trial that continues to enroll. IGC-AD1 is an oral liquid formulation administered twice daily (bid) for six weeks with
no placebo run-in and titration to full dose over two days. To date over 1,000 oral doses have been administered, with no dose-limiting
adverse events observed, highlighting the safety profile of IGC-AD1. The Investigational product targets different pathways implicated
in AAD, including CB1 receptor dysfunction, neuroinflammation and neurotransmitter imbalance. The investigational drug contains THC, the
principal psychoactive cannabinoid found in Cannabis, as one of two active pharmaceutical agents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 12; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Pre-Specified Interim Results</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An experienced third party
conducted a protocol pre-specified interim analysis, mean changes from baseline were analyzed using a mixed-effects model for repeated
measures (MMRM). Findings showed that patients taking IGC-AD1, on average, experienced a significant reduction in agitation scores compared
to those on placebo, and the positive effects were observed as early as week two of the trial. Interim results will be discussed in the
following sections.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>IGC-AD1 Trial Interim Primary and Secondary
Endpoints Results</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The primary objective is to
assess the efficacy of IGC-AD1 in AAD after six weeks of treatment using the CMAI scale. The secondary objective is to assess IGC-AD1
efficacy and early response in AAD using also the CMAI scale, after 2 weeks of treatment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the CMAI interim
results shown in Table 2 below, IGC-AD1 demonstrated a clinical and statistically significant agitation reduction compared to placebo
in patients with AD, indicating strong therapeutic potential and meeting the primary endpoint. The CMAI least-squared (LS) mean difference
at week 6 was -10.46 (95% CI: -20.53 to -0.40) with a Cohen&#8217;s d effect size of 0.79 (p= .042), indicating a large and significant
IGC-AD1 effect over placebo. Cohen&#8217;s d is a standardized statistical effect size that describes the magnitude of the difference
between two groups, taking into account the variability in outcomes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the interim results,
the secondary endpoint was also met; the data demonstrates a clinically significant reduction, approaching statistical significance, in
agitation in Alzheimer&#8217;s at week two compared to placebo. CMAI LS mean difference at week 2, assessing early response, was -12.19
with an ES of 0.79 (p= .071). The ES, similarly, to the primary endpoint, indicates a large magnitude of difference between the active
and placebo groups<b>.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span style="text-decoration:underline">Table 2:- Interim CMAI Results for Week
2 and Week 6</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.25pt 0.25pt 0.4pt">&#160;</td>
    <td style="border-top: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.25pt 0.25pt 0.4pt; text-align: center"><span style="font-size: 10pt"><b>Week 2 </b></span></td>
    <td colspan="5" style="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.4pt 0.25pt; text-align: center"><span style="font-size: 10pt"><b>Week 6 (EOT)</b></span></td></tr>
  <tr>
    <td style="width: 8%; border-top: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.25pt 0.25pt 0.4pt; text-align: center"><span style="font-size: 10pt"><b>Scale </b></span></td>
    <td style="width: 29%; border-top: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.25pt 0.25pt 0.4pt; text-align: center"><span style="font-size: 10pt"><b>LS Mean Change (95% CI) </b></span></td>
    <td style="width: 8%; border-top: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.25pt 0.25pt 0.4pt; text-align: center"><span style="font-size: 10pt"><b>p value </b></span></td>
    <td style="width: 11%; border-top: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.25pt 0.25pt 0.4pt; text-align: center"><span style="font-size: 10pt"><b>Cohen&#8217;s d </b></span></td>
    <td style="width: 25%; border-top: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.25pt 0.25pt 0.4pt; text-align: center"><span style="font-size: 10pt"><b>LS Mean Change (95% CI) </b></span></td>
    <td style="width: 8%; border-top: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.25pt 0.25pt 0.4pt; text-align: center"><span style="font-size: 10pt"><b>p value </b></span></td>
    <td style="width: 11%; border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.4pt 0.25pt; text-align: center"><span style="font-size: 10pt"><b>Cohen&#8217;s d </b></span></td></tr>
  <tr>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.25pt 0.4pt 0.4pt; text-align: center"><span style="font-size: 10pt">CMAI</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.25pt 0.4pt 0.4pt; text-align: center"><span style="font-size: 10pt">-12.19 (-25.52, 1.14)</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.25pt 0.4pt 0.4pt; text-align: center"><span style="font-size: 10pt">.071</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.25pt 0.4pt 0.4pt; text-align: center"><span style="font-size: 10pt">0.79</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.25pt 0.4pt 0.4pt; text-align: center"><span style="font-size: 10pt">-10.46 (-20.53, -0.4)</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.25pt 0.4pt 0.4pt; text-align: center"><span style="font-size: 10pt">.042</span></td>
    <td style="border: black 1pt solid; padding: 0.4pt; text-align: center"><span style="font-size: 10pt">0.79</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>IGC-AD1 Clinical Trial Interim Data Demonstrates
Significant Reduction in Sleep Disturbances&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of an interim analysis,
the Company observed statistically and clinically significant reductions in sleep disturbances, as measured by the Neuropsychiatric Inventory
(NPI-12) Sleep Subscale. At week 2, patients receiving the active medication experienced a 71% reduction in sleep disturbance (p = 0.012),
which improved further to 78% at week 6 (p = 0.02), compared to placebo. These findings suggest that IGC-AD1 may reduce the frequency
and/or severity of nighttime behavioral disturbances, an underrecognized but impactful symptom affecting up to 44% of individuals with
AD.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Figure 5: - <span style="text-decoration:underline">Shows the clinically and statistically
significant decrease in the frequency and/or severity of sleep disturbances (B) for the active group versus the placebo group (A) as measured
by the NPI Sleep Subscale.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sleep disturbances are known
to exacerbate cognitive and behavioral symptoms in AD and are a common contributor to caregiver distress and early institutionalization.
The ability to improve sleep quality represents an important potential therapeutic benefit, as enhanced sleep has been linked to reduced
amyloid-beta accumulation and slower disease progression in preclinical studies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_007.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beyond its implications in Alzheimer&#8217;s care,
sleep disorders affect over 30 million Americans and are associated with increased risk for cognitive decline and cardiovascular disease.
If the sleep-related benefits of IGC-AD1 are confirmed in larger clinical trials, the candidate may address a significant unmet need within
the broader global sleep aid market, which is projected to exceed $100 billion by 2030.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Previously reported data from
the ongoing Phase 2 trial also demonstrated notable reductions in agitation, further supporting IGC-AD1&#8217;s potential as a multi-targeted
therapy for managing neuropsychiatric symptoms in AD. The Company anticipates additional data readouts from the CALMA trial in late 2025,
including further analysis of sleep-related outcomes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In parallel, IGC Pharma plans
to initiate future studies evaluating IGC-AD1 as a disease-modifying therapy, reflecting the Company&#8217;s strategic commitment to advancing
innovative, mechanism-driven treatments for central nervous system disorders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Existing Treatments for Agitation in Alzheimer</b>&#8217;<b>s
Dementia </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2023, the U.S. Food
and Drug Administration (FDA) approved the first medication for the treatment of AAD, Brexpiprazole, an atypical antipsychotic, with a
boxed warning. This approval followed a significantly larger 12-week Phase 3 trial, which showed a CMAI LS mean difference from baseline
at week 12, between active treatment and placebo of -5.32 with a Cohen&#8217;s d effect size of 0.35, and a p-value of 0.003 (Lee et al.,
2023).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Regulatory Environment for IGC-AD1</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IGC-AD1 is currently made
from federally legal hemp In addition, IGC-AD1 contains the federally legal amount of THC as defined in the 2018 Farm Bill. Therefore,
IGC-AD1 is federally legal based on the amount of THC in the formulation and the origin of the THC. The Company grew hemp under a license
in the state of Arizona. Manufacturing IGC-AD1 from hemp is an extremely inefficient process requiring vast amounts of hemp to manufacture
the investigational medication. The regulatory landscape appears to be changing in that the U.S. government is seeking to reschedule THC
from Schedule 1 to Schedule 3. The Company use hemp to manufacture IGC-AD1 , which is egal. The Company has received permission from the
regulators to conduct the IGC-AD1 Phase 2 trial in the U.S., Canada, and Colombia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>TGR-63 and Alzheimer</b>&#8217;<b>s disease </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TGR-63 was licensed from the
Jawaharlal Nehru Centre for Advanced Scientific Research in India and developed by Prof. T Govindaraju, who designed several naphthalene
monoimide compounds and compared their capacity to inhibit A&#946; aggregation, their cytotoxicity, and their neuronal rescue capacity,
in which TGR-63 excelled.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Researchers at the Jawaharlal
Nehru Centre for Advanced Scientific Research (JNCASR), in India, conducted approximately 10 years of research on Naphthalene Monoimide
(NMI) compounds and the activity of NMI compounds on neurotoxicity associated with AD.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 14; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Alzheimer&#8217;s patients,
neurotoxicity is linked to beta-amyloid (A&#946;) plaques and Neuro Fibrillary Tangles (NFT). JNCASR&#8217;s research based on Alzheimer&#8217;s
cell lines identified one lead NMI molecule, TGR-63, from a family of NMI molecules with the potential to reduce amyloid beta (A&#946;)
plaques. Further, they demonstrated that the molecule reduces cognitive decline in a transgenic mouse model of Alzheimer&#8217;s. Their
results were published in <i>Advanced Therapeutics</i> under the title &#8220;Naphthalene Monoimide Derivative Ameliorates Amyloid Burden
and Cognitive Decline in a Transgenic Mouse Model of Alzheimer&#8217;s Disease&#8221; on January 28, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the signed agreement
dated March 28, 2022, IGC Pharma (through Hamsa Biopharma India Pvt. Ltd.) acquired exclusive intellectual property rights to the molecule,
which it intends to pursue as a potential new drug candidate, subject to further study, research, and development. IGC Pharma is conducting
human trials with IGC-AD1, which is currently being tested as a symptom-modifying agent in Alzheimer&#8217;s dementia. TGR-63, on the
other hand, could act as a potential disease-modifying agent to expand the Company&#8217;s pursuit of a drug that can treat AD.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Figures 6 and 7: - Show the destabilization
of A&#946; plaques and A&#946;42 peptide with the help of TGR-63.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Computational Studies: A Plausible Mode of Action</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 49%; text-align: center"><img alt="" src="image_008.jpg"/></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_009.jpg"/></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td></tr>
  <tr>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Figure 6: </b>In silico analysis demonstrated
    that TGR-63 molecular design enables it to interact with amyloid aggregates, disrupting various types of bonds. This destabilizes plaque&#8217;s
    structure, facilitating their breakdown.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(*Adv. Therap. 2021, 4 2000225)</i>.</p></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Figure 7: </b>TGR-63 also shows high
    affinity for the A&#223;42 peptide, compromising its tertiary structure and promoting the formation of globular non-toxic structures
    that can be metabolized.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><i>(*Adv. Therap. 2021, 4 2000225)</i>.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Pre-clinical studies of TGR-63</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TGR-63 is a patent-pending
molecule designed to disrupt the structure of the amyloid beta (A&#946;) plaque, one of the key hallmarks of AD, associated with neuronal
toxicity and cognitive decline. TGR-63 targets plaques by inhibiting the aggregation of A&#946;42 peptides and destabilizing their tertiary
structure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Specifically, the pre-clinical
research on TGR-63 showed the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Impact on plaque levels:
</b>Studies in PC12 and SHSY5Y cell lines grown in an AD-like environment have showed TGR-63&#8217;s ability in decreasing A&#946; plaque
levels, leading to an increase in 26% neuron viability (neuronal rescue). TGR-63&#8217;s potential as a treatment for AD was further evaluated
in a genetically modified mouse model mimicking Alzheimer&#8217;s amyloid pathology. In that assay, the group treated with TGR-63, compared
to the vehicle-treated group, showed a 78% and 85% reduction in the cortical and hippocampal amyloid load, respectively, demonstrating
its potential to alleviate amyloid burden. Figure 5 shows the reduction of the amyloid burden by TGR-63 in the APP/PS1 AD mouse model.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 15; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 50%; padding: 0.25pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_010.jpg"/></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p></td>
    <td style="padding: 0.25pt; width: 50%; text-align: center"><img alt="" src="image_011.jpg"/></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Figure 8:</b> Reduction of the amyloid burden
by TGR-63 in the APP/PS1 AD phenotypic mice model. A) Visualization of amyloid plaques in the half hemisphere: Confocal microscopy images
of coronal section of WT, AD mice, and TGR-63 treated AD mice brain. B) Reduction of cortical and hippocampal amyloid burden by TGR-63
treatment: Higher magnification images of vehicle and TGR-63 treated mice (WT and AD) brain sections to visualize and compare the A&#946;
plaques deposition in the cortex and hippocampus areas. C, D) Quantification of A&#946; plaques: The amount of A&#946; plaques (%area)
deposited in different regions (cortex and hippocampus) of vehicle and TGR63 treated mice (WT and AD) brain was analyzed. Data represent
mean &#177; SEM, number of mice = 3 per group (*<i>p &lt; </i>0.05). Scale bar: 20 &#181;m. <i>(*Adv. Therap. 2021, 4 2000225)</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Behavioral Impact: </b>During the investigation,
two groups of APP/PS1 mice undertook an Open-Field (OF) test, a behavioral assessment designed to measure aberrant behavior, stress and
coping responses, and emotional state, among others, in rodent models. The mice in the APP/PS1 group that received TGR-63 treatment showed
a 43% reduction in their overall movement within the test area (p&lt;.0001), a 59% reduction in movement within the central zone of the
test area (p&lt;.01), and a 55% reduction in entries to the center zone compared to the untreated group (p&lt;.05). These are shown in
Figure 6. The results from these multiple tests indicate that TGR-63 treatment helped to improve in their anxious-like and aggressive-like
behaviors compared to the group that did not receive the treatment, normalizing emotional and behavioral responses in the mouse model,
reinforcing its potential as a promising treatment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Figure 9 Behavioral Tests</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;<img alt="" src="image_012.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Impact on memory</b>: The
cognitive impact of TGR-63 was assessed using two renowned behavioral tests, the Novel Object Recognition (NOR) Test and the Morris Water
Maze (MWM), conducted on APP/PS1 genetically modified Alzheimer&#8217;s mice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the NOI Test, mice
were familiarized with two identical objects, followed by exploration of both novel and familiar objects after 24 and 48 hours, to establish
the discrimination index (DI). AD mice displayed a significantly lower DI (-3, p&lt;0.0001, 24h; -7, p&lt;0.0001, 48h) compared to wild-type
(WT) mice (+49, 24h; +43 48h), indicating impaired long-term memory formation, while AD mice treated with TGR-63 exhibited an improved
DI (+50, p&lt;0.0001; +38, p&lt;0.001), indicative of healthy long term memory formation and successful memory retrieval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the MWM test, the time
to reach a platform hidden in a pool for four training days showed a remarkable improvement for the TGR-63 treated AD model compared to
the AD-vehicle group, indicating enhanced spatial memory, as demonstrated by a significant reduction (~60% reduction; p &lt; 0.05) in
the time required by the TGR-63 treated AD mice to locate the hidden platform, exhibiting a similar behavior to healthy mice. The results
of the novel recognition test and the MWM are shown in Figures 7 and 8 respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="text-align: center; width: 49%"><img alt="" src="image_013.jpg"/></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 49%; text-align: center"><img alt="" src="image_014.jpg"/></td></tr>
  <tr>
    <td style="text-align: justify"><b>Figure 10: </b>In the Novel Object Recognition test, mice treated with TGR-63 showed increased exploration of a new object over a familiar one, indicating enhanced learning capacity. <i>(*Adv. Therap. 2021, 4 2000225)</i>.</td>
    <td>&#160;</td>
    <td style="text-align: justify"><b>Figure 11: </b>During the Morris Water Maze test, mice treated with TGR-63 exhibited improved spatial memory, with decreased latency in finding the target compared to the untreated group. (<i>*Adv. Therap. 2021, 4 2000225).</i></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Contract Research Organization (CRO) and Clinical
Trial Software</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The IGC-Pharma Electronic
Data Capture system (IGC-EDC) is a secure and user-friendly data management software designed to collect clinical trial data in electronic
format. The software incorporates rigorous security measures that help IGC to protect data and ensure compliance with regulatory requirements
and industry standards. This format is designed for our clinical trials, especially our Phase 2 trial. The EDC system is designed to store
and organize handwritten source documents, including medical history, concomitant medications, laboratory results, neuropsychiatric scale
scores, adverse events, vital signs, safety calls, and demographics, among others. The system allows users to generate data reports that
will be used for data analysis and generate computational models to simulate the effects of our investigational drug IGC-AD1 on participants&#8217;
outcomes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At IGC Pharma, we recognize
the significance of operational excellence and cost management in clinical trials. One major cost driver in conducting trials is the expense
associated with engaging CROs. These costs can significantly impact the overall budget of a trial. To address this challenge and optimize
trial costs, we have established an internal CRO, including proprietary software, that we believe sets us apart from the traditional approach
of outsourcing. We believe this strategic move should enable us to reduce the costs associated with clinical trials compared to relying
on external CROs, although there can be no assurance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IGC Pharma, is committed to
building a strong and defensible intellectual property (IP) portfolio that supports our strategic focus on neurodegenerative diseases
and related therapeutic areas. Our IP strategy is centered on securing exclusive rights to proprietary technologies, inventions, and product
candidates through the development, acquisition, and licensing of patents and related protections both in the United States and internationally.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We actively seek to protect
our innovations by filing patent applications that cover novel methods, compositions, and uses associated with our investigational drug
candidates, formulations, and related technologies. Our patent strategy is designed to cover key elements of our research and development
efforts, particularly in the fields of AD, epilepsy, pain management, and other central nervous system (CNS) disorders. In addition to
patent protection, we intend to leverage data exclusivity, market exclusivity, and patent term extensions, where applicable, to maximize
the commercial potential and lifecycle of our assets, although there can be no assurance thereof.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 17; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our commercial success depends in part on our
ability to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtain
                                            and maintain strong patent and proprietary protection;</span></td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
                                                                                                                                                                                                                      </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protect
                                            our trade secrets and proprietary know-how;</span></td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
                                                                                                                                                                                                            </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secure
                                            necessary licenses for third-party intellectual property;</span></td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
                                                                                                                                                                                                                         </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enforce
                                            our rights against infringement; and</span></td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
                                                                                                                                                                                                     </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operate
                                            without infringing valid, enforceable third-party patents.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We aim to commercialize our intellectual property
through multiple channels:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">1.</td><td style="text-align: justify">Pharmaceutical products are subject to U.S. Food and Drug Administration (FDA) approval. Our lead candidate,
IGC-AD1, is currently in a Phase 2 clinical trial for treating agitation in AD. We are also developing TGR-63, a pre-clinical candidate
with potential disease-modifying effects in Alzheimer&#8217;s.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">2.</td><td style="text-align: justify">Branded wellness and lifestyle products, offered through retail and online distribution channels, in compliance
with applicable federal, state, and local laws.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">3.</td><td style="text-align: justify">Partnerships and licensing agreements with third parties to accelerate product development and market
entry.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hold exclusive rights
to all patents filed with the U.S. Patent and Trademark Office (USPTO). In Fiscal 2017, we acquired exclusive rights to data and a patent
application from the University of South Florida (USF), and following Fiscal 2022, we acquired similar exclusive rights from the Jawaharlal
Nehru Centre for Advanced Scientific Research (JNCASR).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While patent registration
is a key component of our business strategy, we cannot guarantee that all provisional or non-final patent applications will result in
granted patents. Please refer to Item 1A. Risk Factors &#8211; &#8220;We may not successfully register the provisional patents with the
USPTO.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 31, 2025, our
intellectual property portfolio comprised twelve (12) issued patents and thirty-one (31) pending patent applications across the United
States and international jurisdictions. Of the twelve issued patents, four (4) patents are licensed from third parties. These patents
and applications cover compositions, methods of treatment, and formulations relevant to our core therapeutic areas, including AD, epilepsy,
pain, and other neurodegenerative and central nervous system disorders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Table 3 below provides the status of our patent
filings:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Table 3 <b>Patent Filings &amp; Status</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="border: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt"><b>TARGET</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt"><b>DESCRIPTION</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PATENT </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PENDING</b></p></td>
    <td colspan="2" style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt"><b>GRANTED PATENTS</b></span></td></tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; width: 26%">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; width: 44%">&#160;</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; width: 10%">&#160;</td>
    <td style="border-right: black 1pt solid; width: 10%; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt"><b>US</b></span></td>
    <td style="border-right: black 1pt solid; width: 10%; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt"><b>FOREIGN</b></span></td></tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt"><span style="font-size: 10pt">Alzheimer&#8217;s Disease (IGC-AD1)</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt"><span style="font-size: 10pt">Method &amp; Composition for Treating CNS Disorders</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">12</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt"><span style="font-size: 10pt">Alzheimer&#8217;s Disease (IGC-AD1)</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt"><span style="font-size: 10pt">Method &amp; Composition for Treating CNS Disorders</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">1</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">2</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">-</span></td></tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt"><span style="font-size: 10pt">Alzheimer&#8217;s Disease (TGR-63) </span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt"><span style="font-size: 10pt">Naphthalene Monoimide Derivatives with the ability to impact A&#946;&#160;protein build-up</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">6</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">-</span></td></tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt"><span style="font-size: 10pt">Alzheimer&#8217;s Disease (IGC-1C)</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt"><span style="font-size: 10pt">Naphthalene Monoimide Derivatives with the ability to impact Tau aggregation and neurofibrillary tangle formation</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">5</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">-</span></td></tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt"><span style="font-size: 10pt">Alzheimer&#8217;s Disease (IGC-M3)</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt"><span style="font-size: 10pt">Naphthalene Monoimide Derivatives with the ability to impact A&#946;&#160;plaque buildup and neurofibrillary tangle formation</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">4</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">-</span></td></tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt"><span style="font-size: 10pt">Cancer (Naphthalene Diimdes)</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt"><span style="font-size: 10pt">Naphthalene Diimide Derivatives with the ability to self-assemble molecular interactions for biological and nonbiological systems</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">1</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt"><span style="font-size: 10pt">Alzheimer&#8217;s Disease (IGC-LMP)</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt"><span style="font-size: 10pt">Composition, Synthesis, &amp; Medical use of Hybrid Cannabinoid</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">1</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">-</span></td></tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt"><span style="font-size: 10pt">Epilepsy</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt"><span style="font-size: 10pt">Composition &amp; Method for Treating Seizures in humans &amp; cats/dogs</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">2</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">-</span></td></tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt"><span style="font-size: 10pt">Eating Disorders</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt"><span style="font-size: 10pt">Cannabis formulation with Cyproheptadine for treating Cachexia &amp; Eating Disorders</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">1</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">-</span></td></tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt"><span style="font-size: 10pt">Stuttering &amp; Tourette Syndrome</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt"><span style="font-size: 10pt">Cannabinoid-Based formulation for Treating Stuttering &amp; Symptoms of Tourette Syndrome</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">1</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">-</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">-</span></td></tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt"><span style="font-size: 10pt">Pain</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt"><span style="font-size: 10pt">Cannabinoid-Based Formulation combined with Cobalamin and method for Pain Management</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">1</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">2</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt">2</span></td></tr>
  <tr>
    <td colspan="2" style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TOTAL</td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt"><b>31</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt"><b>8</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 3pt; text-align: center"><span style="font-size: 10pt"><b>4</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 18; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Patent Term Extension</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After NDA approval, owners of relevant drug patents
may apply for up to a five-year patent extension. The allowable patent term extension is calculated as half of the drug&#8217;s testing
phase &#8212; the time between IND submission and NDA submission &#8212; and all of the review phase &#8212; the time between NDA submission
and approval up to a maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue approval
with due diligence. The total patent term after the extension may not exceed 14 years.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For patents that might expire
during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent
term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is
reduced by one year. The director of the PTO must determine that approval of the drug covered by the patent for which a patent extension
is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been submitted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Products and Services in the Life Sciences
segment</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe developing a drug
for either symptoms or as a disease-modifying agent has less risk due to the need for multi-year trials and FDA approval. However, there
is a considerable upside and significant value creation to the extent we obtain a first-to-market advantage, of which there can be no
assurance. If we were to obtain a first-to-market advantage, such an advantage could result in significant growth if and when an approved
drug launches.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that additional
investment in clinical trials, research and development (R&amp;D), facilities, marketing, advertising, and acquisition of complementary
products and businesses will be critical to the ongoing growth of the Life Sciences segment. These investments will fuel the development
and delivery of innovative products that drive positive patient and customer experiences. We hope to leverage our R&amp;D and intellectual
property to develop ground-breaking, science-based products that are proven effective through clinical trials, subject to FDA approval.
Although there can be no assurance, we believe this strategy can improve our existing products and lead to the creation of new hemp-based
products that can provide treatment options for multiple conditions, symptoms, and side effects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Markets and Distribution</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Fiscal 2025, our Life Sciences
segment is focused on the Phase 2 clinical trial for IGC-AD1 and building a pipeline of other assets. In addition, the Company sells over-the-counter
products and formulations made in Vancouver, Washington facilities. Our Life Sciences revenue is less than 1% of the relevant global market,
which implies a good opportunity for growth. In Fiscal 2025, our sales and suppliers were concentrated, which represents some risk. Two
customers individually accounted for over 10% of total sales.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Overview</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our industry is highly competitive
and subject to rapid and significant technological change. The large size and expanding scope of the CNS markets make them attractive
therapeutic areas for biopharmaceutical businesses. Our competitors include well-funded pharmaceutical companies, companies in the food
and skincare industries, and companies with experience in providing white labeling and tolling services. While we believe that our employees
and consultants, scientific knowledge, technology, and development experience provide us with competitive advantages, we face competition
from many different sources. Many of our competitors may have significantly greater financial resources and expertise in research and
development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products
than we do.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competition for the Company&#8217;s
investigational medications, products, and services:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-size: 10pt"> We are aware of other companies working to develop therapeutics for the treatment of AAD, including Axsome Therapeutics, Inc., which is working to develop a combination of dextromethorphan and bupropion, and Otsuka and Lundbeck A/S, which recently received approval for Rexulti for this indication.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 19; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interim data from our Phase
2 trial of IGC-AD1 for agitation in Alzheimer&#8217;s disease show a statistically significant improvement in symptoms compared to placebo
over six weeks, as measured by the Cohen-Mansfield Agitation Inventory (CMAI). IGC-AD1 demonstrated a large effect size (Cohen&#8217;s
d = 0.79) and showed improvement as early as Week 2. For context, Brexpiprazole (Rexulti), the currently approved therapy, reported a
moderate effect size (Cohen&#8217;s d = 0.4) and showed separation from placebo only by Week 6, based on published trial data, albeit
with a significantly larger patient base.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;<img alt="" src="image_015.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to efficacy, IGC-AD1 has shown a favorable safety profile
to date. As of the 6-week interim analysis:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            serious adverse events (SAEs) were reported</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            adverse events (AEs) led to treatment discontinuation</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            deaths occurred in the treatment or placebo arms</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While cross-trial comparisons must be interpreted
with caution due to differences in trial design and patient populations, these early findings suggest that IGC-AD1 may offer faster symptom
relief with a potentially improved safety profile compared to the currently approved therapy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The study remains ongoing to further assess efficacy, durability, and
long-term safety.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Licenses, Technology, and Cybersecurity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have intellectual property
attorneys that advise, counsel, and represent the Company regarding the filing of patents or provisional patent applications, copyright
applications, and trademark applications; trade secret laws of general applicability; employee confidentiality and invention assignment.
Most of our data, including our accounting data, is stored in the cloud, which helps us mitigate the overall risk of losing data. We have
a cybersecurity policy in place and are in the process of implementing tighter cybersecurity measures to safeguard against hackers. The
Company holds all rights to the patents that have been filed by us with the USPTO.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below summarizes
the nature of the activity, the type of license required and held, and encumbrances in obtaining permits for each location where the Company
operated through its subsidiaries in Fiscal 2025:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 14%; border: black 1pt solid; padding: 0.4pt"><span style="font-size: 10pt"><b>Location</b></span></td>
    <td style="width: 26%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 0.25pt; text-align: center"><span style="font-size: 10pt"><b>Nature of Activity</b></span></td>
    <td style="width: 23%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 0.25pt; text-align: center"><span style="font-size: 10pt"><b>Type of License Required</b></span></td>
    <td style="width: 23%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 0.4pt 0.4pt 0.4pt 0.25pt; text-align: center"><span style="font-size: 10pt"><b>Type of License held</b></span></td>
    <td style="width: 14%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Encumbrances<br/>
 in Obtaining<br/>
 Permit</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.25pt 0.4pt 0.4pt"><span style="font-size: 10pt">U.S.</span></td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 3pt 0.4pt; border-right: black 1pt solid"><span style="font-size: 10pt">Life Sciences Products and General Management</span></td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.4pt 0.4pt 0.25pt; border-right: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt">General business</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt">Clinical Trials;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt">Good Manufacturing Practices (GMP) certification.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt">FDA approval to run a trial</p></td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.4pt 0.4pt 0.25pt; border-right: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt">General business licenses;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt">Industrial Alcohol User Permit; FDA approval to run a trial.</p></td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.4pt 0.4pt 3pt; border-right: black 1pt solid"><span style="font-size: 10pt">None.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.25pt 0.4pt 0.4pt"><span style="font-size: 10pt">India</span></td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 3pt 0.4pt; border-right: black 1pt solid"><span style="font-size: 10pt">Infrastructure Contract, Rental of heavy equipment, and land</span></td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 3pt 0.4pt; border-right: black 1pt solid"><span style="font-size: 10pt">General business license</span></td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 3pt 0.4pt; border-right: black 1pt solid"><span style="font-size: 10pt">Business registrations with tax authorities in various states in India</span></td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.4pt 0.4pt 3pt; border-right: black 1pt solid"><span style="font-size: 10pt">None.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.25pt 0.4pt 0.4pt"><span style="font-size: 10pt">Colombia</span></td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 3pt 0.4pt; border-right: black 1pt solid"><span style="font-size: 10pt">Life Sciences Products and General Management</span></td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.4pt 0.4pt 0.25pt; border-right: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt">General business license;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt">Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA)
    Permits;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt">Fondo Nacional De Estupefacientes (FNE) Permits.</p></td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.4pt 0.4pt 0.25pt; border-right: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt">General business license;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt">Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA)
    Permits;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt">Fondo Nacional De Estupefacientes (FNE) Permits.</p></td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.4pt 0.4pt 3pt; border-right: black 1pt solid"><span style="font-size: 10pt">None.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 0.25pt 0.4pt 0.4pt"><span style="font-size: 10pt">Canada</span></td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 3pt 0.4pt; border-right: black 1pt solid"><span style="font-size: 10pt">Clinical Trials</span></td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.4pt 0.4pt 0.25pt; border-right: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt">Permit from Health Canada to conduct a trial in Canada.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt">Permit to import IGC-AD1 into Canada.</p></td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 3pt 0.4pt; border-right: black 1pt solid"><span style="font-size: 10pt">Permit to conduct a trial and to import IGC-AD1 into Canada.</span></td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.4pt 0.4pt 3pt; border-right: black 1pt solid"><span style="font-size: 10pt">None</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Governmental Regulations </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the U.S., we are subject
to oversight and regulations, for some or all of our activities, by the following agencies: SEC, state regulators, NYSE, FTC, FINRA, and
the FDA. Hemp is cannabis plant. Under the 2018 Farm Bill, Hemp is classified as a cannabis plant that has 0.3% or less THC by dry weight.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2018 Farm Bill, which
was effective January 1, 2019, contains provisions that make industrial hemp, defined as a cannabis plant that has 0.3% of less THC by
dry weight, legal. Although hemp is legal at the federal level, most states have created licensing and testing processes for the growing,
processing, and sale of hemp and hemp-derived products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For our business, we must
apply for licenses in states where we desire to grow and process hemp. For example, in the state of Arizona, where we grew hemp, we were
required to apply for licenses and register with the state the geo-location of all our operations, including the land on which hemp was
grown and the facilities where hemp would be processed. These regulations are evolving, differ from jurisdiction to jurisdiction, and
are subject to change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>FDA Approval Process</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the U.S., pharmaceutical
products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and
state statutes and regulations, govern the research, development, testing, manufacturing, storage, recordkeeping, approval, labeling,
promotion and marketing, distribution, post-approval monitoring, and reporting, sampling, and importing and exporting of pharmaceutical
products, among other things. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative
or judicial sanctions, such as the imposition of clinical holds, FDA refusal to approve pending New Drug Applications (NDA), warning letters,
product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government
contracts, restitution, disgorgement, civil penalties, and criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pharmaceutical product development
in the U.S. typically involves pre-clinical laboratory and animal tests and the submission to the FDA of an Investigational New Drug (IND),
which must become effective before clinical testing may commence. For commercial approval, the sponsor must submit adequate tests by all
methods reasonably applicable to show that the drug is safe for use under the conditions prescribed, recommended, or suggested in the
proposed labeling. The sponsor must also submit substantial evidence, generally consisting of adequate, well-controlled clinical trials,
to establish that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended,
or suggested in the proposed labeling. In certain cases, the FDA may determine that a drug is effective based on one clinical study plus
confirmatory evidence. Satisfaction of FDA premarket approval requirements typically takes many years, and the actual time required may
vary substantially based upon the type, complexity of the product, or disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pre-clinical tests include
laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal trials to assess the characteristics and potential
safety and efficacy of the product. The conduct of the pre-clinical tests must comply with federal regulations and requirements, including
the FDA&#8217;s good laboratory practices regulations and the U.S. Department of Agriculture&#8217;s (USDA&#8217;s) regulations implementing
the Animal Welfare Act. The results of pre-clinical testing are submitted to the FDA as part of an IND along with other information, including
information about product chemistry, manufacturing, and controls, and a proposed clinical trial protocol. Long-term pre-clinical tests,
such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A 30-day waiting period after
the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has not imposed a clinical
hold on the IND or otherwise commented on or questioned the IND within this 30-day period, the clinical trial proposed in the IND may
begin.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials involve the
administration of an investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical
trials must be conducted: (i) in compliance with federal regulations; (ii) in compliance with Good Clinical Practice (GCP), an international
standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors;
and (iii) under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness
criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the
FDA as part of the IND.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may order the temporary
or permanent discontinuation of a clinical trial at any time or impose other sanctions if it believes that the clinical trial either is
not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The trial protocol
and informed consent information for patients in clinical trials must also be submitted to an institutional review board, or IRB, for
approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply
with the IRB&#8217;s requirements or may impose other conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials to support
NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In general, in Phase 1, the
initial introduction of the drug into healthy human subjects or patients, the drug is tested to assess metabolism, pharmacokinetics, pharmacological
actions, side effects associated with increasing doses, and, if possible, early evidence on effectiveness. Phase 2 usually involves trials
in a limited patient population to determine the effectiveness of the drug for a particular indication, dosage tolerance, and optimum
dosage and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable
safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain additional information about clinical efficacy and safety
in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall
benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug. In most cases, the FDA requires
two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug. The FDA may, however, determine that
a drug is effective based on one clinical study plus confirmatory evidence. Only a small percentage of investigational drugs complete
all three phases and obtain marketing approval. In some cases, the FDA may require post-market studies, known as Phase 4 studies, to be
conducted as a condition of approval in order to gather additional information on the drug&#8217;s effect in various populations and any
side effects associated with long-term use. Depending on the risks posed by the drugs, other post-market requirements may be imposed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 21; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After completion of the required
clinical testing, an NDA is prepared and submitted to the FDA. The FDA approval of the NDA is required before marketing of the product
may begin in the U.S. The NDA must include the results of all pre-clinical, clinical, and other testing and a compilation of data relating
to the product&#8217;s pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting an NDA is substantial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA has 60 days from its
receipt of an NDA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination
that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth
review. Under the statute and implementing regulations, the FDA has 180 days (the initial review cycle) from the date of filing to issue
either an approval letter or a complete response letter unless the review period is adjusted by mutual agreement between the FDA and the
applicant or as a result of the applicant submitting a major amendment. In practice, the performance goals established pursuant to the
Prescription Drug User Fee Act have effectively extended the initial review cycle beyond 180 days. The FDA&#8217;s current performance
goals call for the FDA to complete a review of 90 percent of standard (non-priority) NDAs within 10 months of receipt and within six months
for priority NDAs, but two additional months are added to standard and priority NDAs for a new molecular entity (NME).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may also refer applications
for novel drug products, or drug products that present difficult questions of safety or efficacy, to an advisory committee, which is typically
a panel that includes clinicians and other experts, for review, evaluation, and a recommendation as to whether the application should
be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before
approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will
inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve the product unless compliance with
the current GMP is satisfactory, and the NDA contains data that provides substantial evidence that the drug is safe and effective in the
indication studied.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the FDA evaluates the
NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter generally
outlines the deficiencies in the submission and may require substantial additional testing or information for the FDA to reconsider the
application. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA
will issue an approval letter. The FDA has committed to reviewing 90 percent of resubmissions within two to six months, depending on the
type of information included.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An approval letter authorizes
commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA
may require a risk evaluation and mitigation strategy (REMS) to help ensure that the benefits of the drug outweigh the potential risks.
REMS can include medication guides, communication plans for health care professionals, and elements to assure safe use (ETASU). ETASU
can include but is not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances,
special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability
of the drug. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the drug&#8217;s safety
or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained, or problems are
identified following initial marketing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Expedited Development:</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Designations such as Breakthrough Therapy Designation (BTD) and Fast
Track Designation can speed up the development process by allowing for more frequent communication with the FDA and potentially faster
review timelines. This can translate to getting the drug to market quicker.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Breakthrough Therapy Designation
(BTD):</b>&#160;This designation is given by the FDA to drugs that have the potential to significantly improve treatment for serious
or life-threatening conditions. It allows for more intensive interaction with the FDA during development and can expedite the review
process.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Fast Track Designation:</b>&#160;This
designation is designed to facilitate the development and expedite the review of drugs that address unmet medical needs. It offers some
advantages like more frequent meetings with the FDA and potential for rolling review (reviewing data as it becomes available).</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Disclosure of Clinical Trial Information</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sponsors of clinical trials
of certain FDA-regulated products, including prescription drugs, are required to register and disclose certain clinical trial information
on a public website maintained by the U.S. National Institutes of Health. Information related to the product, patient population, phase
of the investigation, study sites, investigator, and other aspects of the clinical trial is made public as part of the registration. Disclosure
of the results of these trials can be delayed for up to two years if the sponsor certifies that it is seeking approval of an unapproved
product or that it will file an application for approval of a new indication for an approved product within one year. Competitors may
use this publicly available information to gain knowledge regarding the design and progress of our development programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 22; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The Hatch-Waxman Act</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Orange Book Listing</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In seeking approval for a
drug through an NDA, applicants are required to list with the FDA each patent the claims of which cover the applicant&#8217;s product.
Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Approved Drug
Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be
cited by potential generic competitors in support of approval of an abbreviated new drug application (ANDA). An ANDA provides for the
marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been
shown through bioequivalence testing to be bioequivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA
applicants are not required to conduct or submit results of pre-clinical or clinical tests to prove the safety or effectiveness of their
drug product. Drugs approved in this way are considered to be therapeutically equivalent to the listed drug, are commonly referred to
as &#8220;generic equivalents&#8221; to the listed drug and can often be substituted by pharmacists under prescriptions written for the
original listed drug in accordance with state law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ANDA applicant is required
to certify to the FDA concerning any patents listed for the approved product in the FDA&#8217;s Orange Book. Specifically, the applicant
must certify that: (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the listed patent
has not expired but will expire on a particular date, and approval is sought after patent expiration; or (iv) the listed patent is invalid
or will not be infringed by the new product. The ANDA applicant may also elect to submit a section viii statement, certifying that its
proposed ANDA labeling does not contain (or carves out) any language regarding the patented method-of-use rather than certify to a listed
method-of-use patent. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the
listed patents claiming the referenced product have expired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A certification that the new
product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid is called a Paragraph IV
certification. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the
Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders
may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement
lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the
earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to
the ANDA applicant. The ANDA application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book
for the referenced product has expired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Exclusivity</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon NDA approval of a new
chemical entity or NCE, which is a drug that contains no active component that has been approved by the FDA in any other NDA, that drug
receives five years of marketing exclusivity, during which time the FDA cannot receive any ANDA or 505(b)(2) application seeking approval
of a drug that references a version of the NCE drug. Certain changes to a drug, such as the addition of a new indication to the package
insert, are associated with a three-year period of exclusivity during which the FDA cannot approve an ANDA or 505(b)(2) application that
includes the change. An ANDA or 505(b)(2) application may be submitted one year before NCE exclusivity expires if a Paragraph IV certification
is filed. If there is no listed patent in the Orange Book, there may not be a Paragraph IV certification, and thus, no ANDA or 505(b)(2)
application may be filed before the expiration of the exclusivity period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a botanical drug, the
FDA may determine that the active moiety is one or more of the principal components or the complex mixture as a whole. This determination
would affect the utility of any five-year exclusivity as well as the ability of any potential generic competitor to demonstrate that it
is the same drug as the original botanical drug. Five-year and three-year exclusivities do not preclude FDA approval of a 505(b)(1) application
for a duplicate version of the drug during the period of exclusivity, provided that the 505(b)(1) applicant conducts or obtains a right
of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 23; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Orphan Drug Act</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Orphan Drug Act,
the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, generally a disease or condition that
affects fewer than 200,000 individuals in the U.S. (or affects more than 200,000 in the U.S. and for which there is no reasonable expectation
that the cost of developing and making available in the U.S. a drug for such disease or condition will be recovered from sales in the
U.S. of such drug). Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation,
the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey
any advantage in or shorten the duration of the regulatory review and approval process. The first NDA applicant to receive FDA approval
for a particular active ingredient to treat a particular disease with FDA orphan drug designation is entitled to a seven-year exclusive
marketing period in the U.S. for that product for that indication. During the seven-year exclusivity period, the FDA may not approve any
other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority
to the product with orphan drug exclusivity. If the FDA designates an orphan drug based on a finding of clinical superiority, the FDA
must provide a written notification to the sponsor that states the basis for orphan designation, including &#8220;any plausible hypothesis&#8221;
relied upon by the FDA. The FDA must also publish a summary of its clinical superiority findings upon granting orphan drug exclusivity
based on clinical superiority. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or
condition or the same drug for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for
certain research and a waiver of the NDA application user fee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Special Protocol Assessment</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A company may reach an agreement
with the FDA under the Special Protocol Assessment (SPA), process as to the required design and size of clinical trials intended to form
the primary basis of an efficacy claim. According to its performance goals, the FDA is supposed to evaluate the protocol within 45 days
of the request to assess whether the proposed trial is adequate, and that evaluation may result in discussions and a request for additional
information. A SPA request must be made before the proposed trial begins, and all open issues must be resolved before the trial begins.
If a written agreement is reached, it will be documented and made part of the administrative record. Under the FDC Act and FDA guidance
implementing the statutory requirement, an SPA is generally binding upon the FDA except in limited circumstances, such as if the FDA identifies
a substantial scientific issue essential to determining safety or efficacy after the study begins, public health concerns emerge that
were unrecognized at the time of the protocol assessment, the sponsor and the FDA agree to the change in writing, or if the study sponsor
fails to follow the protocol that was agreed upon with the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>U.S. Coverage and Reimbursement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Significant uncertainty exists
as to the coverage and reimbursement status of our lead product candidates, such as IGC-AD1 or any other for which we may seek regulatory
approval. Sales in the U.S. will depend in part on the availability of adequate financial coverage and reimbursement from third-party
payors, which include government health programs such as Medicare, Medicaid, TRICARE, and the Veterans Administration, as well as managed
care organizations and private health insurers. Prices at which we or our customers seek reimbursement for our product candidates can
be subject to challenge, reduction, or denial by payors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process for determining
whether a payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the
payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list or formulary, which might
not include all the FDA-approved products for a particular indication. Also, third-party payors may refuse to include a branded drug on
their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or another alternative
is available. Medicare Part D, Medicare&#8217;s outpatient prescription drug benefit, contains protections to ensure coverage and reimbursement
for oral oncology products, and all Part D prescription drug plans are required to cover substantially all oral anti-cancer agents. However,
a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be available. Private
payors often rely on the lead of the governmental payors in rendering coverage and reimbursement determinations. Sales of products such
as IGC-AD1 or any other product candidates will, therefore, depend substantially on the extent to which the costs of our products will
be paid by third-party payors. Achieving favorable coverage and reimbursement from the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;)
and/or the Medicare Administrative Contractors is typically a significant gating issue for the successful introduction of a new product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Third-party payors are increasingly
challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their
safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for marketing, we may need to
conduct studies in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to the
costs expended to obtain regulatory approvals. Third-party payors may not consider our product candidates to be medically necessary or
cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an
adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment
in drug development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 24; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Human Capital Management and Environment, Health, and Safety</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Human Capital Management</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our ability
to attract, retain, and develop exceptional talent is critical to our success, particularly in advancing our clinical development programs
and scientific research. As of March 31, 2025, our full-time employee headcount worldwide was 70.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We foster a culture of collaboration,
accountability, and innovation. We comply with all applicable labor, health, and safety laws and support employee well-being through flexible
work policies and safe workplace practices. We invest in employee development, offering training and learning opportunities to help our
teams grow professionally and contribute to our long-term success. We are committed to providing equal opportunities for all employees.
Our compensation and equity programs are designed to retain talent and align with long-term shareholder value.8</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Environment, Health, and Safety (EHS)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are committed to health,
safety, and environmental compliance in all our operations in the U.S., Colombia and India. While our operations have a limited environmental
impact, we promote responsible practices to minimize waste and ensure safety in our research and office environments. Management oversees
our EHS practices and updates them as needed to meet regulatory and operational requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Available Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to reports filed pursuant to Sections
13(a) and 15(d) of the Exchange Act are filed with the Securities and Exchange Commission (the SEC&#8221;). The Company is subject to
the informational requirements of the Exchange Act and files or furnishes reports, proxy statements, and other information with the SEC.
Such reports and other information filed by the Company with the SEC are available free of charge on the Company&#8217;s website at www.igcpharma.com
when such reports are available on the SEC&#8217;s website. The SEC maintains an Internet site that contains reports, proxy and information
statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov. The contents of these websites
are not incorporated into this filing. Further, the Company&#8217;s references to the URLs for these websites are intended to be inactive
textual references only.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1A. RISK FACTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>You should carefully consider
the following risk factors, together with all other information included in this report, in evaluating the Company and our common stock.
If any of the following risks and uncertainties develop into actual events, they could have a material adverse effect on our business,
financial condition, or results of operations. In that case, the trading price of our common stock and other securities also could be
adversely affected. We make various statements in this section, which constitute </i>&#8220;<i>forward-looking statements.</i>&#8221;
<i>See </i>&#8220;<i>Forward-Looking Statements.</i>&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Business, Industry, and Operations:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have incurred significant losses and
have an accumulated deficit. If we cannot achieve profitability, the market price of our common stock could decline significantly.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 31, 2025, we had
cash and cash equivalents of approximately $405 thousand and working capital of approximately $639 thousand compared to cash and cash
equivalents of $1.2 million and working capital of $1.4 million as of March 31, 2024, for continuing operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have had a history of operating
losses. Our net losses decreased by approximately $6 million from $13 million in Fiscal 2024 to approximately $7.1 million in Fiscal 2025.
We expect to continue incurring substantial expenses as we advance the clinical development of IGC-AD1 and our other product candidates.
Our ability to achieve or sustain profitability depends on our success in developing, obtaining regulatory approval for, and commercializing
our product candidates, which is highly uncertain and subject to significant risks. If we fail to achieve profitability or improve our
financial condition, our ability to raise additional capital may be limited, and the market price of our common stock could decline significantly.
Additionally, continued losses could impact our ability to maintain compliance with applicable stock exchange listing requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We may not be successful
in our artificial intelligence initiatives, which could adversely affect our business, reputation, or financial results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are making investments
in AI initiatives, including generative AI, to, among other things, recommend relevant unconnected content across our products, enhance
our advertising tools, develop new products, and develop new features for existing products. In particular, we expect our AI initiatives
will require increased investment in infrastructure and headcount.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are significant risks
involved in developing and deploying AI, and there can be no assurance that the usage of AI will enhance our products or services or be
beneficial to our business, including our efficiency or profitability. For example, our AI-related efforts, particularly those related
to generative AI, subject us to risks related to harmful content, accuracy, bias, discrimination, toxicity, intellectual property infringement
or misappropriation, defamation, data privacy, cybersecurity, and sanctions and export controls, among others. It is also uncertain how
various laws related to online services, intermediary liability, and other issues will apply to content generated by AI. In addition,
we are subject to the risks of new or enhanced governmental or regulatory scrutiny, litigation, or other legal liability, ethical concerns,
negative consumer perceptions as to automation and AI, or other complications that could adversely affect our business, reputation, or
financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the complexity
and rapid development of AI, it is also the subject of evolving review by various U.S. governmental and regulatory agencies, and other
foreign jurisdictions are applying, or are considering applying, their platform moderation, intellectual property, cybersecurity, and
data protection laws to AI and/or are considering general legal frameworks on AI. We may not always be able to anticipate how to respond
to these frameworks, given that they are still rapidly evolving. We may also have to expend resources to adjust our offerings in certain
jurisdictions if the legal frameworks on AI are not consistent across jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As such, it is not possible
to predict all of the risks related to the use of AI, and changes in laws, rules, directives, and regulations governing the use of AI
may adversely affect our ability to develop and use AI or subject us to legal liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our cannabinoid medication makes it difficult to raise money
as a public company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Within the species Cannabis
sativa L, most countries define hemp by the amount of THC. Under the 2018 Farm Bill, hemp is classified as a cannabis plant that has 0.3%
or less THC by dry weight.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite deriving IGC-AD1 from
legal hemp, the Company is often incorrectly classified as a &#8220;cannabis company&#8221;, with all the nuances that accompany that
label, including being blacklisted by banks, investment banks, and until recently by the largest stock clearing services company. The
near-monopoly nature of some of these institutions, especially clearing houses, makes it difficult for the Company to raise money, deposit
share certificates, or even have investment banking relationships. As we cannot control how others perceive us, there can be no assurance
that we will be able to raise enough capital for our planned expansion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may engage in strategic transactions that could impact our
liquidity, increase our expenses, and present significant distractions to our management, which ultimately may not be successful. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
consider strategic transactions, such as acquisitions of companies, asset purchases, and out-licensing or in-licensing of products, product
candidates, or technologies, particularly those arrangements that seek to leverage other organizations&#8217; internal platforms or competencies
for the benefit of our products or potential products. Additional potential transactions that we may consider may include a variety of
different business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations,
and investments. Any such transaction may require us to incur non-recurring or other charges that may increase our near and long-term
expenditures and may pose significant integration challenges or disrupt our management or business, which could adversely affect our operations
and financial results. For example, these transactions may entail numerous operational and financial risks, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; vertical-align: top; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">exposure to unknown or unanticipated liabilities, including foreign laws with which we are unfamiliar;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; vertical-align: top; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">disruption of our business and diversion of our management&#8217;s time and attention to develop acquired products, product candidates, or technologies;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the incurrence of substantial debt or dilutive issuances of equity securities to pay for acquisitions, which we may not be able to obtain on favorable terms, if at all;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">higher than expected acquisition and integration costs;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">write-downs of assets or goodwill or impairment charges;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">increased amortization expenses;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">entering a long-term relationship with a partner that proves to be unreliable or counterproductive;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify; vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify; vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">inability to retain key employees of any acquired businesses.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that we will undertake or successfully complete any transactions of the nature described above. Any transactions that we do complete could
have a material adverse effect on our business, results of operations, financial condition, and prospects if we are unable to execute
the planned objectives or capitalize on the relationship in the manner that was originally contemplated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Global Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently operate in the
U.S., Canada, Colombia, and India, and buy raw materials and equipment from China, and our operations and expenses could be affected by
currency fluctuations, capital and exchange controls, economic conditions including inflation, expropriation, and other restrictive government
actions, changes in intellectual property legal protections and remedies, trade regulations, tax laws, and regulations, and procedures
and actions affecting approval, production, pricing, and marketing of, reimbursement for and access to our products, as well as impacts
of political or civil unrest or military action, including but not limited to the current conflicts, terrorist activity, unstable governments,
and legal systems, inter-governmental disputes, public health outbreaks, epidemics, pandemics, natural disasters or disruptions related
to climate change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">India, and Colombia may be
particularly vulnerable to periods of financial or political instability or significant currency fluctuations or may have limited resources
for healthcare spending.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Government financing and economic
pressures can lead to negative pricing pressure in various markets where governments take an active role in setting prices, access criteria
(e.g., through health technology assessments), or other means of cost control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We continue to monitor the
global trade environment, especially with China and the countries we operate in, and potential trade conflicts and impediments that could
impact our business. If trade restrictions or tariffs reduce global economic activity, potential impacts could include declining sales,
increased costs, volatility in foreign exchange rates, a decline in the value of our financial assets and pension plan investments, required
increases of our pension funding obligations, increased government cost control efforts, delays or failures in the performance of customers,
suppliers and other third parties on whom we may depend for the performance of our business, and the risk that our allowance for doubtful
accounts may not be adequate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 27; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Legal claims could be filed that may have
a material adverse effect on our business, operating results, and financial condition. We may, in the future, face risks of litigation
and liability claims. The extent of such exposure can be difficult or impossible to estimate, which can negatively impact our financial
condition and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations are subject
to numerous laws and regulations in the U.S., India, and Colombia, relating to the protection of the public and necessary disclosures
regarding financial services. Liability under these laws involves inherent uncertainties. Violations of financial regulation laws are
subject to civil and, in some cases, criminal sanctions. We may not have been, or may not be, or may be alleged to have not been or to
not be, at all times, in complete compliance with all requirements, and we may incur costs or liabilities in connection with such requirements
or allegations. We may also incur unexpected interruptions to our operations, administrative injunctions requiring operation stoppages,
fines judgments, settlements, or other financial obligations or penalties, which could negatively impact our financial condition and results
of operations. See Item 3, Legal Proceedings of this report, for further information on the current status of legal proceedings, if any.
There can also be no assurance that any insurance coverage we have will be adequate or that we will prevail in any future cases. We can
provide no assurance that we will be able to obtain liability insurance that would protect us from any such lawsuits. In the event that
we are not covered by insurance, our management could spend significant time and resources addressing any such issues. The legal fees
necessary to defend against multiple lawsuits can be significant, impacting the Company&#8217;s overall bottom line when not covered by
insurance or where the fees exceed the Company&#8217;s insurance policy limits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Company is in a highly regulated industry.
Significant and unforeseen changes in policy may have material impacts on our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Continued development in the
phytocannabinoids industry is dependent upon continued state legislative authorization of cannabinoids as well as legislation and regulatory
policy at the federal level. The federal Controlled Substances Act currently makes cannabinoids use and possession illegal on a national
level. While there may be ample public support for legislative authorization, numerous factors impact the legislative process. Any one
of these factors could slow or halt the use and handling of cannabinoids in the U.S. or in other jurisdictions, which would negatively
impact our development of phytocannabinoids-based therapies and our ability to test and productize these therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many U.S. state laws conflict
with the federal Controlled Substances Act. It is unclear whether regulatory authorities in the U.S. would object to the registration
or public offering of securities in the U.S. by our Company; the status of our Company as a reporting company; or investors investing
in our Company, if we engage in legal cannabinoids cultivation and supply pursuant to the laws and authorization of the jurisdiction where
the activity takes place. In addition, the status of cannabinoids under the Controlled Substances Act may have an adverse effect on federal
agency approval of pharmaceutical use of phytocannabinoid products. Any such objection or interference could delay indefinitely or increase
substantially the costs to access the equity capital markets, test our therapies, or create products from the Life Sciences segment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Company is inexperienced in conducting
pre-clinical and clinical trials.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Company is inexperienced
in conducting pre-clinical and clinical trials. Our attempt at demonstrating safety, efficacy, and ultimate useability may fail because
of our lack of experience in designing, managing, and conducting clinical trials, resulting in unanticipated or adverse outcomes. Such
outcomes may have an adverse effect on our stock price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical trials are expensive, time-consuming,
and difficult to design and implement, and involve an uncertain outcome.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical testing is expensive
and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial
process. Because the results of preclinical studies and early clinical trials are not necessarily predictive of future results, IGC-AD1
and our other compounds may not have favorable results in later preclinical and clinical studies or receive regulatory approval. We may
experience delays in initiating and completing any clinical trials that we intend to conduct, and we do not know whether planned clinical
trials will begin on time, need to be redesigned, enroll patients on time, or be completed on schedule, or at all. Clinical trials can
be delayed or terminated for a variety of reasons, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify"/></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">obtaining regulatory approval to commence a trial;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reaching an agreement on acceptable terms with prospective contract research organizations (CROs), and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">obtaining Institutional Review Board (IRB) approval at each site or Independent Ethics Committee (IEC) approval at sites outside the United States;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 28; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">recruiting suitable patients to participate in a trial in a timely manner and in sufficient numbers;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">having patients complete a trial or return for post-treatment follow-up;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">imposition of a clinical hold by regulatory authorities, including as a result of unforeseen safety issues or side effects or failure of trial sites to adhere to regulatory requirements or follow trial protocols;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">clinical sites deviating from trial protocol or dropping out of a trial;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">addressing patient safety concerns that arise during the course of a trial;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">adding a sufficient number of clinical trial sites; or</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">manufacturing sufficient quantities of the product candidate for use in clinical trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We could also encounter delays
if a clinical trial is suspended or terminated by us, the IRBs or IECs of the institutions in which such trials are being conducted, the
Data Safety Monitoring Board (DSMB), for such trial or the FDA or other regulatory authorities. Such authorities may impose such a suspension
or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements
or our clinical protocols, an inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting
in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a
drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Furthermore,
we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we have agreements
governing their committed activities, we have limited influence over their actual performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The regulatory approval processes of the
FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable, and if we are ultimately unable to obtain
regulatory approval for IGC-AD1 or any other product candidates, our business will be substantially harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The time required to obtain
approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical
trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies,
regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s
clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate, and it is possible
that we will never obtain regulatory approval for IGC-AD1 or any other product candidate. We are not permitted to market any of our pharmaceutical
product candidates in the United States until we receive regulatory approval of an NDA from the FDA. The regulatory approval process can
be affected by, among other things, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 0.5in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates or other products containing the active ingredient in our product candidates;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and/or we may be required to conduct additional clinical trials;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the FDA or comparable foreign authorities may disagree regarding the formulation, labeling, and/or specifications of our product candidates;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the FDA or comparable foreign regulatory authorities may fail to approve or find deficiencies with the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to obtaining approval
to commercialize a product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled
clinical trials and to the satisfaction of the FDA or foreign regulatory agencies that such product candidates are safe and effective
for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if the preclinical
or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory
authorities. For diseases like Alzheimer&#8217;s, the FDA has stated that one single Phase 3 trial is adequate for approval if it demonstrates
robust and unquestionable efficacy. However, the circumstances under which a single adequate and controlled study can be used as the sole
basis for demonstrating the efficacy of a drug are exceptional.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 29; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA or any foreign regulatory
bodies can delay, limit, or deny approval of our product candidates or require us to conduct additional preclinical or clinical testing
or abandon a program for many reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 0.5in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the FDA or comparable foreign regulatory authorities may disagree with our safety interpretation of our drug;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the FDA or comparable foreign regulatory authorities may disagree with our efficacy interpretation of our drug; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the FDA or comparable foreign regulatory authorities may regard our Chemistry Manufacturing and Controls package as inadequate.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Of the large number of drugs
in development, only a small percentage successfully complete the regulatory approval processes and are commercialized. This lengthy approval
process, as well as the unpredictability of future clinical trial results, may result in us failing to obtain regulatory approval to market
IGC-AD1 or another product candidate, which would significantly harm our business, results of operations, and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the FDA or the
applicable foreign regulatory agency may also approve a product candidate for a more limited indication or patient population than we
originally requested, and the FDA or applicable foreign regulatory agency may approve a product candidate with a label that does not include
the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios
could materially harm the commercial prospects for our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have concentrated our research and development
efforts on the treatment of Alzheimer</i></b>&#8217;<b><i>s Disease, which has seen limited success in drug development. Further, IGC-AD1
is based on a new approach to treating symptoms of Alzheimer</i></b>&#8217;<b><i>s Disease, which makes it difficult to predict the time
and cost of development and subsequent obtaining of regulatory approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Efforts by biopharmaceutical
and pharmaceutical companies in treating Alzheimer&#8217;s Disease have seen limited success in drug development, and there are no FDA-approved
disease-modifying therapeutic options available for patients with Alzheimer&#8217;s Disease. We cannot be certain that our approach will
lead to the development of approvable or marketable products. The only drugs approved by the FDA to treat Alzheimer&#8217;s Disease to
date address the disease&#8217;s symptoms. Alzheimer&#8217;s Disease drug candidates have the highest failure rate of approximately 99.6%.
As a result, the FDA has a limited set of products to rely on in evaluating IGC-AD1. This could result in a longer-than-expected regulatory
review process, increased expected development costs, or the delay or prevention of commercialization of IGC-AD1 for the treatment of
Alzheimer&#8217;s Disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Enrollment and retention of patients in
clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors
outside our control.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The timely completion of clinical
trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain
in the study until its conclusion. We may encounter delays in enrolling or be unable to enroll a sufficient number of patients to complete
any of our clinical trials, and even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our
trials. Patient enrollment and retention in clinical trials depend on many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 0.5in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">the patient eligibility criteria defined in the protocol;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">the nature of the trial protocol;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">the existing body of safety and efficacy data with respect to the product candidate;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">the proximity of patients to clinical sites;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">clinicians&#8217;&#160;and patients&#8217;&#160;perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">competing clinical trials being conducted by other companies or institutions;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">our ability to maintain patient consent; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates may cause serious
adverse events or undesirable side effects, which may delay or prevent marketing approval or, if approved, require them to be taken off
the market, require them to include safety warnings, or otherwise limit their sales.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Serious adverse events or
undesirable side effects caused by IGC-AD1 or any other product candidates could cause us or regulatory authorities to interrupt, delay,
or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other
comparable foreign authorities. The results of any clinical trial we conduct could reveal a high and unacceptable severity and prevalence
of side effects or unexpected characteristics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 30; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If unacceptable side effects
arise in the development of our product candidates, we, the FDA, or the IRBs at the institutions in which our studies are conducted, or
the DSMB, if constituted for our clinical trials, could recommend a suspension or termination of our clinical trials, or the FDA or comparable
foreign regulatory authorities could order us to cease further development of or deny approval of a product candidate for any or all targeted
indications. In addition, drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete a
trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed
by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect
profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or
managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm
our business, financial condition, and prospects significantly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, if one or more
of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products,
a number of potentially significant negative consequences could result, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulatory authorities may withdraw approvals of such products;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221;&#160;warning or contraindication;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we may be required to implement a REMS or create a medication guide outlining the risks of such side effects for distribution to patients;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we could be sued and held liable for harm caused to patients;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the product may become less competitive; and</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our reputation may suffer.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these events could
prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business,
results of operations, and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates may be unable to
achieve the expected market acceptance, consequently limiting our ability to generate revenue from new products. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even when product development
is successful and regulatory approval has been obtained, our ability to generate sufficient revenue depends on the acceptance of our products
by customers. We cannot assure you that our products will achieve the expected level of market acceptance and revenue. The market acceptance
of any product depends on several factors, such as the price of the product, the effect of the product, the taste of the product, the
reputation of the Company, competition, and marketing and distribution support.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The success and acceptance
of a product in one state may not be replicated in other states or may be negatively affected by our activities in another state. Any
factors preventing or limiting the market acceptance of our products could have a material adverse effect on our business, results of
operations, and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Business interruptions could delay us in
the process of developing our product candidates and could disrupt our product sales.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Loss of our manufacturing
facilities, stored inventory, or laboratory facilities through fire, theft, natural disasters, or other causes, or loss of our botanical
raw material due to pathogenic infection, waste, destruction, or other causes, could have an adverse effect on our ability to meet demand
for our products or to continue product development activities and to conduct our business. Failure to supply our partners with commercial
products may lead to adverse consequences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Climate change concerns could disrupt our
businesses, adversely affect client activity levels, adversely affect the creditworthiness of our counterparties, and damage our reputation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Climate change may cause extreme
weather events that, among other things, could damage our facilities and equipment, injure our employees, disrupt operations at one or
more of our primary locations, negatively affect our ability to service and interact with our clients, and adversely affect the value
of our assets. Any of these events may increase our costs including our costs to insure against these events.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Climate change may also have
a negative impact on the financial condition of our clients, which may decrease revenues from those clients and increase the credit exposures
to those clients. Additionally, our reputation and client relationships may be damaged as a result of our involvement, or our clients&#8217;
involvement, in certain industries associated with causing or exacerbating, or alleged to cause or exacerbate, climate change. We also
may be negatively impacted by any decisions we make to continue to conduct or change our activities in response to considerations relating
to climate change. New regulations or guidance relating to climate change, as well as the perspectives of shareholders, employees, and
other stakeholders regarding climate change, may affect whether and on what terms and conditions we engage in certain activities or offer
certain products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Currency fluctuations may reduce our assets
and profitability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have assets located in
foreign countries that are valued in foreign currencies. Fluctuation of the U.S. dollar relative to the foreign currency may adversely
affect our assets and profit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business relies heavily on our management
team, and any unexpected loss of key officers may adversely affect our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The continued success of our
business is largely dependent on the continued services of our key employees. The loss of the services of certain key personnel, without
adequate replacement, could have an adverse effect on our performance. Our senior management, as well as the senior management of our
subsidiaries, plays a significant role in developing and executing the overall business plan, maintaining client relationships, proprietary
processes, and technology. While no one is irreplaceable, the loss of the services of any would be disruptive to our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our quarterly revenue, operating results, and profitability will
vary.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Factors that may contribute to the variability
of quarterly revenue, operating results, or profitability include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 0.5in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Fluctuations in revenue due to the seasonality of the marketplace, which results in uneven revenue and operating results over the year;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Additions and departures of key personnel;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Strategic decisions made by us and our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments, and changes in business strategy; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Economic conditions, including but not limited to the adverse impact on operating results due to the COVID-19 pandemic.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may not successfully register the provisional patents with
the USPTO.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed thirty-one (31)
patent applications with the USPTO and also in other different countries in the combination therapy space for the indications of pain,
Alzheimer&#8217;s, medical refractory epilepsy, eating disorders, and Tourette syndrome as part of our intellectual property strategy
focused on the phytocannabinoid-based health care industry. Although twelve patents have been issued, there is no guarantee that our remaining
applications will result in a successful registration with the USPTO. If we are unsuccessful in registering patents, our ability to create
a valuable line of products can be adversely affected. This, in turn, may have a material and adverse impact on the trading price of our
common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 32; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may be unable to protect our intellectual property rights
and/or intellectual property rights licensed to us and may be subject to intellectual property litigation and infringement claims by third
parties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to protect our intellectual
property through limited patents and our unpatented trade secrets and know-how through confidentiality or license agreements with third
parties, employees, and consultants, and by controlling access to and distribution of our proprietary information. However, this method
may not afford complete protection, particularly in foreign countries where the laws may not protect our proprietary rights as fully as
in the U.S., and unauthorized parties may copy or otherwise obtain and use our products, processes, or technology. Additionally, there
can be no assurance that others will not independently develop similar know-how and trade secrets. We are also dependent upon the owners
of intellectual property rights licensed to us under various wholesale license agreements to protect and defend those rights against third
party claims. If third parties take actions that affect our rights, the value of our intellectual property, similar proprietary rights
or reputation, or the licensors who have granted us certain rights under wholesale license agreements, or we are unable to protect the
intellectual property from infringement or misappropriation, other companies may be able to offer competitive products at lower prices,
and we may not be able to effectively compete against these companies. We also face the risk of claims that we have infringed third parties&#8217;
intellectual property rights. Any claims of intellectual property infringement, even those without merit, may require us to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 0.5in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">defend against infringement claims, which are expensive and time-consuming;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">cease making, licensing, or using, either temporarily or permanently, products that incorporate the challenged intellectual property;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">re-design, re-engineer, or re-brand our products or packaging; or</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">enter into royalty or licensing agreements to obtain the right to use a third party&#8217;s intellectual property.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of claims by
third parties for infringement of intellectual property rights, we license from third parties under wholesale license agreements, we could
be liable for costs of defending allegations of infringement, and there are no assurances the licensors will either adequately defend
the licensed intellectual property rights or that they would prevail in the related litigation. In that event, we would incur additional
costs and may be deprived of generating royalties from these agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may face risks relating to health care
privacy and security laws. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to various
privacy and security regulations, including but not limited to the Health Insurance Portability and Accountability Act of 1996 (HIPAA),
as amended by The Health Information Technology for Economic and Clinical Health Act (HITECH), and their respective implementing regulations,
including the related final published omnibus rule. HIPAA mandates, among other things, the adoption of uniform standards for the electronic
exchange of information in common health care transactions, as well as standards relating to the privacy and security of individually
identifiable health information. These obligations would require the Company to adopt administrative, physical, and technical safeguards
to protect such information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to &#8220;business
associates&#8221; &#8212; independent contractors or agents of covered entities that receive or obtain protected health information in
connection with providing a service on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be
imposed against covered entities, business associates, and possibly other persons and gave state attorneys general new authority to file
civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs
associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain
circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have
the same effect, thereby complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition
of significant civil and criminal penalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Some of our lines of business will rely
on third-party service providers to host and deliver services and data, and any interruptions or delays in these hosted services, security
or privacy breaches, including cybersecurity attacks or failures in data collection, could expose us to liability claims, increased costs,
reduced revenue, and harm our business and reputation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our lines of business and
services, but especially our development of hemp-based cannabinoid combination therapies for products, and our long-term use and/or development
of software to solve critical issues facing the pharmaceutical industry, rely on services hosted and controlled directly by our suppliers
and distributors and their third-party service providers. We do not have redundancy for all our systems; many of our critical applications
reside in only one of our data centers, and our disaster recovery planning may not account for all eventualities. These facts could cause
reputational harm, loss of customers, or loss of future business, thereby reducing our revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 33; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our suppliers and distributors
and their third-party service providers hold customer data, some of which is hosted in third-party facilities. A security incident or
cybersecurity attack at those facilities or ours may compromise the confidentiality, integrity, or availability of customer data. We have
a cybersecurity policy in place; however, unauthorized access to customer data stored on our computers or networks may be obtained through
break-ins, breaches of our secure network by an unauthorized party, employee theft or misuse, or other misconduct. It is also possible
that unauthorized access to customer data may be obtained through inadequate use of security controls by customers. Accounts created with
weak passwords could allow cyber-attackers to gain access to customer data. If there were an inadvertent disclosure of customer information,
or if a third party were to gain unauthorized access to the information we possess on behalf of our customers, our operations could be
disrupted, our reputation could be damaged, and we could be subject to claims or other liabilities. In addition, such perceived or actual
unauthorized disclosure of the information we collect or breach of our security could damage our reputation, result in the loss of customers,
and harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Hardware or software failures
or errors in our systems or those of our suppliers and distributors or their third-party service providers could result in data loss or
corruption, cause the information that we collect to be incomplete or contain inaccuracies that our customers regard as significant, or
cause us to fail to meet committed service levels. Furthermore, our ability to collect and report data may be delayed or interrupted by
several factors, including access to the internet, the failure of our network or software systems, or security breaches. In addition,
computer viruses or other malware may harm our systems, causing us to lose data, and the transmission of computer viruses or other malware
could expose us to litigation. We may also find, on occasion, that we cannot deliver data and reports in near real time because of several
factors, including failures of our network or software. If we supply inaccurate information or experience interruptions in our ability
to capture, store and supply information in near real time or at all, our reputation could be harmed, we could lose customers, or we could
be found liable for damages or incur other losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All our data is stored on
the cloud on multiple servers, which helps us mitigate the overall risk of losing data. We are in the process of implementing tighter
cybersecurity measures to safeguard against hackers. Complying with these security measures and compliances would incur further costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The states in which we and
our distributors and suppliers and their service providers operate require that we maintain certain information about our customers and
transactions. If we fail to maintain such information, we could be in violation of state laws. Laws and regulations relating to the handling
of personal data may impede the adoption of our services or result in increased costs, legal claims, fines against us, or reputational
damage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face risks associated with the manufacture
of our products, which could adversely affect our business and financial results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the risks
inherent in manufacturing our products, including industrial accidents, environmental events, strikes and other labor disputes, disruptions
in supply chain or information systems, loss or impairment of key manufacturing sites or suppliers, product quality control, safety, increase
in commodity prices and energy costs, licensing requirements and other regulatory issues, as well as natural disasters and other external
factors over which we have no control. If such an event were to occur, it could have an adverse effect on our business and financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Potential Risks Associated with the Disposal of Non-Core Assets</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While our current focus is
on advancing our Life Sciences business, we continue to own certain non-core assets, including infrastructure-related properties and equipment.
We have not made a formal decision to dispose of these assets, other than &#8220;Asset held for sale&#8221;. Our decision to dispose of
these non-core assets is aimed at monetizing non-core assets, streamlining operations, and optimizing resource allocation. However, if
we decide to proceed with a sale, divestiture, or shutdown in the future, we may face various risks, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment
                                            charges or write-downs that could negatively impact our financial results and stockholders&#8217;
                                            equity;</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                    </table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
                                            related to the termination of leases, contracts, or employee arrangements;</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                       </table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Challenges
                                            in finding suitable buyers or partners, potentially resulting in unfavorable pricing or delayed
                                            transactions;</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                          </table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
                                            or legal risks associated with asset disposal, including environmental, labor, or tax compliance
                                            matters;</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                     </table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distraction
                                            of management&#8217;s attention from our core Life Sciences operations.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these factors could
negatively affect our business, financial condition, or results of operations.&#160;Investors should be aware of the potential risks associated
with this process and its potential impact on our financial performance before investing in our company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 34; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Company is exposed to the risk of write-downs
on the value of its inventory and other assets, in addition to purchase commitment cancellation risk.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company records a write-down
for product and component inventories that become obsolete or exceed anticipated demand or for which cost exceeds net realizable value.
The Company may also accrue necessary cancellation fee reserves for orders of excess products and components. The Company reviews long-lived
assets, including capital assets held at its suppliers&#8217; facilities and inventory prepayments, for impairment whenever events or
circumstances indicate the assets may not be recoverable. If the Company determines that an impairment has occurred, it records a write-down
equal to the amount by which the carrying value of the asset exceeds its fair value. Although the Company believes its inventory, capital
assets, inventory prepayments, and other assets and purchase commitments are currently recoverable, no assurance can be given that the
Company will not incur write-downs, fees, impairments, and other charges given the rapid and unpredictable pace of product obsolescence
in the industries in which the Company competes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company orders components
for its products and builds inventory in advance of product announcements and shipments. Manufacturing purchase obligations cover the
Company&#8217;s forecasted component and manufacturing requirements, typically for periods of up to 150 days. Because the Company&#8217;s
markets are volatile, competitive, and subject to rapid technology and price changes, there is a risk the Company will forecast incorrectly
and order or produce excess or insufficient amounts of components or products or not fully utilize firm purchase commitments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our accounting personnel may make unintentional errors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Given our small size and foreign
operations, a small unrectified mistake in the preparation of financial statements and the maintenance of our books and records in accordance
with U.S. GAAP and SEC rules and regulations may constitute a material weakness in our internal controls over financial reporting. For
more information, please see Item 9A, &#8220;Controls and Procedures.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Company is subject to complex and changing
laws and regulations worldwide related to climate change and ESG initiatives, which expose the Company to potential liabilities, increased
costs, and other adverse effects on the Company</i></b>&#8217;<b><i>s business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to transitional
and physical risks related to climate change. Transitional risks include, for example, a disorderly global transition away from fossil
fuels that may result in increased energy prices; customer preference for low or no-carbon products; stakeholder pressure to decarbonize
assets; or new legal or regulatory requirements that result in new or expanded carbon pricing, taxes, restrictions on greenhouse gas emissions,
and increased greenhouse gas disclosure and transparency. These risks could increase operating costs, including the cost of our electricity
and energy use or other compliance costs. Physical risks to our operations include water stress and drought, flooding and storm surge,
wildfires, extreme temperatures, and storms, which could impact pharmaceutical production, increase costs, or disrupt the supply chains
of medicines for patients. Our supply chain is likely subject to these same transitional and physical risks and would likely pass along
any increased costs to us. We do not anticipate that these risks will have a material financial impact on the Company in the near term,
although there can be no assurance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Governmental authorities,
non-governmental organizations, customers, investors, employees, and other stakeholders are increasingly sensitive to ESG matters, such
as equitable access to medicines and vaccines, product quality and safety, diversity, equity and inclusion, environmental stewardship,
support for local communities, value chain environmental and social due diligence, corporate governance, and transparency, and addressing
human capital factors in our operations. This focus on ESG matters may lead to new expectations or requirements that could result in increased
costs associated with the research, development, manufacture, or distribution of our products. Our ability to compete could also be affected
by changing customer preferences and requirements, such as growing demand for companies to establish validated Net Zero targets or offer
more sustainable products. While we strive to improve our ESG performance and meet our voluntary goals, if we do not meet, or are perceived
not to meet, our goals or other stakeholder expectations in key ESG areas, we risk negative stakeholder reaction, including from proxy
advisory services, as well as damage to our brand and reputation, reduced demand for our products or other negative impacts on our business
and operations. While we monitor a broad range of ESG matters, we cannot be certain that we will manage such matters successfully or that
we will successfully meet the expectations of investors, employees, consumers, governments, and other stakeholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 35; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to ownership of our common stock:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future sales of common stock by us could
cause our stock price to decline and dilute your ownership in our Company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our certificate of incorporation
authorizes the issuance of up to 150,000,000 shares of common stock, par value of $0.0001 per share, and 1,000,000 shares of preferred
stock, par value of $0.0001 per share. We are not restricted from issuing additional shares of our common stock or preferred stock, including
any securities that are convertible into or exchangeable for or that represent the right to receive common stock or preferred stock or
any substantially similar securities. The market price of our common stock could decline as a result of sales of a large number of shares
of our common stock by us in the market or the perception that such sales could occur. If we raise funds by issuing additional securities
in the future or stock options to purchase our common stock are exercised, the newly issued shares will also dilute your percentage ownership
in our Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our common stock price has fluctuated considerably
and has recently reached our highest price levels, which may not be sustained.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of shares
of our common stock has fluctuated substantially in recent years and is likely to fluctuate significantly from its current level. Our
common stock has also been volatile, with our 52-week closing price range being at a low of $0.27 and a high of $0.69 per share. Future
announcements concerning the introduction of new products, services, or technologies or changes in product pricing policies by us or our
competitors, or changes in earnings estimates by analysts, among other factors, could cause the market price of our common stock to fluctuate
substantially. Also, stock markets have experienced extreme price and volume volatility in the last year. This volatility has had a substantial
effect on the market prices of securities of many public companies for reasons frequently unrelated to the operating performance of the
specific companies. These broad market fluctuations may also cause declines in the market price of our common stock. Investors seeking
short-term liquidity should be aware that we cannot assure you that the stock price will continue at these or any higher levels.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A possible </i></b>&#8220;<b><i>short squeeze</i></b>&#8221;
<b><i>due to a sudden increase in demand of our common stock that largely exceeds supply may lead to further price volatility in our common
stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investors may purchase shares
of our common stock to hedge existing exposure in our common stock or to speculate on the price of our common stock. Speculation on the
price of our common stock may involve long and short exposures. To the extent aggregate short exposure exceeds the number of shares of
our common stock available for purchase in the open market, investors with short exposure may have to pay a premium to repurchase our
common stock for delivery to lenders of our common stock. Those repurchases may, in turn, dramatically increase the price of our common
stock until investors with short exposure are able to purchase additional shares of common stock to cover their short position. This is
often referred to as a &#8220;short squeeze.&#8221; A short squeeze could lead to volatile price movements in shares of our common stock
that are not directly correlated to the performance or prospects of our Company, and once investors purchase the shares necessary to cover
their short position, the price of our common stock may decline. We believe that the recent volatility in our common stock may be due,
in part, to short squeezes that may be temporarily increasing the price of our common stock, which could result in a loss of some or all
of your investment in our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our management team will have broad discretion
over the use of Company funds.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management will use their
discretion to direct the use of Company funds. We intend to use the net proceeds from the sale of IGC shares in ATM offerings, sales proceeds,
sale of capital assets, and other funds to fund working capital and capital expenditure requirements. It may also be used for clinical
trials, share repurchases, debt repayments, and investments, including but not limited to mutual funds, treasury bonds, cryptocurrencies,
and other asset classes. Management&#8217;s judgments may not result in positive returns on investor investment, and the investor will
not have an opportunity to evaluate the economic, financial, or other information upon which the Management bases its decisions. The Company
may invest the funds, pending their use, in a manner that does not produce income or that loses value. The failure of management to apply
these funds effectively could result in financial losses, and these financial losses could have a material adverse effect on our business
and cause the price of our common stock to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our publicly filed reports are subject to
review by the SEC, and any significant changes or amendments required as a result of any such review may result in material liability
to us and may have a material adverse impact on the trading price of our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The reports of publicly traded
companies are subject to review by the SEC from time to time for the purpose of assisting companies in complying with applicable disclosure
requirements, and the SEC is required to undertake a comprehensive review of a company&#8217;s reports at least once every three years
under the Sarbanes-Oxley Act of 2002. SEC reviews may be initiated at any time. We could be required to modify, amend, or reformulate
information contained in prior filings as a result of an SEC review, as well as the state in filings that we have inadequate control or
expertise over financial reporting. Any modification, amendment, or reformulation of information contained in such reports could be significant
and result in material liability to us and have a material and adverse impact on the trading price of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 36; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We do not anticipate declaring any cash
dividends on our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid cash dividends on our common stock and do not plan to pay any cash dividends in the near future. Our current policy is to retain
all funds and earnings for use in the operation and expansion of our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Maryland anti-takeover provisions and certain
anti-takeover effects of our Charter and Bylaws may inhibit a takeover at a premium price that may be beneficial to our stockholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Maryland anti-takeover provisions
and certain anti-takeover effects of our charter and bylaws may be utilized, under some circumstances, as a method of discouraging, delaying,
or preventing a change of control of our Company at a premium price that would be beneficial to our stockholders. For more detailed information
about these provisions, please see &#8220;Anti-takeover Law, Limitations of Liability and Indemnification&#8221; as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Business Combinations</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Maryland General
Corporation Law, some business combinations, including a merger, consolidation, share exchange, or, in some circumstances, an asset transfer
or issuance or reclassification of equity securities, are prohibited for a period of time and require an extraordinary vote. These transactions
include those between a Maryland corporation and the following persons (a Specified Person):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An interested stockholder
who is defined as any person (other than a subsidiary) who beneficially owns 10% or more of the corporation&#8217;s voting stock or who
is an affiliate or an associate of the corporation who, at any time within a two-year period prior to the transaction, was the beneficial
owner of 10% or more of the voting power of the corporation&#8217;s voting stock; or an affiliate of an interested stockholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A person is not an interested
stockholder if the board of directors approves in advance the transaction by which the person otherwise would have become an interested
stockholder. The board of directors of a Maryland corporation also may exempt a person from these business combination restrictions prior
to the time the person becomes a Specified Person and may provide that its exemption be subject to compliance with any terms and conditions
determined by the board of directors. Transactions between a corporation and a Specified Person are prohibited for five years after the
most recent date on which such stockholder becomes a Specified Person. After five years, any business combination must be recommended
by the board of directors of the corporation and approved by at least 80% of the votes entitled to be cast by holders of voting stock
of the corporation and two-thirds of the votes entitled to be cast by holders of shares other than voting stock held by the Specified
Person with whom the business combination is to be effected, unless the corporation&#8217;s stockholders receive a minimum price as defined
by Maryland law and other conditions under Maryland law are satisfied.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A Maryland corporation may
elect not to be governed by these provisions by having its board of directors exempt various Specified Persons, by including a provision
in its charter expressly electing not to be governed by the applicable provision of Maryland law, or by amending its existing charter
with the approval of at least 80% of the votes entitled to be cast by holders of outstanding shares of voting stock of the corporation
and two-thirds of the votes entitled to be cast by holders of shares other than those held by any Specified Person. Our Charter does not
include any provision opting out of these business combination provisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Control Share Acquisitions</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Maryland General Corporation
Law also prevents, subject to exceptions, an acquirer who acquires sufficient shares to exercise specified percentages of the voting power
of a corporation from having any voting rights except to the extent approved by two-thirds of the votes entitled to be cast on the matter
not including shares of stock owned by the acquiring person, any directors who are employees of the corporation and any officers of the
corporation. These provisions are referred to as the control share acquisition statute.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The control share acquisition
statute does not apply to shares acquired in a merger, consolidation, or share exchange if the corporation is a party to the transaction,
or to acquisitions approved or exempted prior to the acquisition by a provision contained in the corporation&#8217;s charter or bylaws.
Our Bylaws include a provision exempting us from the restrictions of the control share acquisition statute, but this provision could be
amended or rescinded either before or after a person acquired control shares. As a result, the control share acquisition statute could
discourage offers to acquire our common stock and could increase the difficulty of completing an offer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 37; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Board of Directors</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Maryland General Corporation
Law provides that a Maryland corporation which is subject to the Exchange Act and has at least three outside directors (who are not affiliated
with an acquirer of the company) under certain circumstances may elect by resolution of the board of directors or by amendment of its
charter or bylaws to be subject to statutory corporate governance provisions that may be inconsistent with the corporation&#8217;s charter
and bylaws. Under these provisions, a board of directors may divide itself into three separate classes without the vote of stockholders
such that only one-third of the directors are elected each year. A board of directors classified in this manner cannot be altered by amendment
to the charter of the corporation. Further, the board of directors may, by electing to be covered by the applicable statutory provisions
and notwithstanding the corporation&#8217;s charter or bylaws:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 0.5in">&#160;</td>
    <td style="vertical-align: top; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">provide that a special meeting of stockholders will be called only at the request of stockholders entitled to cast at least a majority of the votes entitled to be cast at the meeting;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reserve for itself the right to fix the number of directors;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">provide that a director may be removed only by the vote of at least two-thirds of the votes entitled to be cast generally in the election of directors; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">retain for itself the sole authority to fill vacancies created by an increase in the size of the board or the death, removal, or resignation of a director.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, a director elected
to fill a vacancy under these provisions serves for the balance of the unexpired term instead of until the next annual meeting of stockholders.
A board of directors may implement all or any of these provisions without amending the charter or bylaws and without stockholder approval.
Although a corporation may be prohibited by its charter or by resolution of its board of directors from electing any of the provisions
of the statute, we have not adopted such a prohibition. We have adopted a staggered board of directors with three separate classes in
our charter and given the board the right to fix the number of directors, but we have not prohibited the amendment of these provisions.
The adoption of the staggered board may discourage offers to acquire our common stock and may increase the difficulty of completing an
offer to acquire our stock. If our Board chooses to implement the statutory provisions, it could further discourage offers to acquire
our common stock and could further increase the difficulty of completing an offer to acquire our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Effect of Certain Provisions of our Charter and Bylaws</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the Charter
and Bylaws provisions discussed above, certain other provisions of our Bylaws may have the effect of impeding the acquisition of control
of our Company by means of a tender offer, proxy fight, open market purchases, or otherwise in a transaction not approved by our Board
of Directors. These provisions of the Bylaws are intended to reduce our vulnerability to an unsolicited proposal for the restructuring
or sale of all or substantially all of our assets or an unsolicited takeover attempt, which our Board believes is otherwise unfair to
our stockholders. These provisions, however, also could have the effect of delaying, deterring, or preventing a change in control of our
Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Bylaws provide that with
respect to annual meetings of stockholders, (i) nominations of individuals for election to our Board of Directors and (ii) the proposal
of business to be considered by stockholders may be made only pursuant to our notice of the meeting, by or at the direction of our Board
of Directors, or by a stockholder who is entitled to vote at the meeting and has complied with the advance notice procedures set forth
in our Bylaws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Special meetings of stockholders
may be called only by the chief executive officer, the board of directors or the secretary of our Company (upon the written request of
the holders of a majority of the shares entitled to vote). At a special meeting of stockholders, the only business that may be conducted
is the business specified in our notice of meeting. With respect to nominations of persons for election to our Board of Directors, nominations
may be made at a special meeting of stockholders only pursuant to our notice of meeting, by or at the direction of our Board of Directors,
or if our Board of Directors has determined that directors will be elected at the special meeting, by a stockholder who is entitled to
vote at the meeting and has complied with the advance notice procedures set forth in our Bylaws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These procedures may limit
the ability of stockholders to bring business before a stockholders meeting, including the nomination of directors and the consideration
of any transaction that could result in a change in control and that may result in a premium to our stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 38; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33pt"><b><i>Our executive officers
and large shareholders concentrated insider ownership of our common stock, which will limit your influence on corporate matters.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 20, 2025, our executive
officers and largest shareholders beneficially owned 21.01% based on 83,891,586 outstanding shares of common stock. As a result, our insiders
have the ability to influence our management and affairs through the election and removal of our Board and all other matters requiring
stockholder approval, including any future merger, consolidation, or sale of all or substantially all of our assets. This concentrated
voting power could discourage others from initiating any potential merger, takeover or other change-of-control transaction that may otherwise
be beneficial to our stockholders. Further, this concentrated insider ownership will limit the practical effect of your influence over
our business and affairs, through any stockholder vote or otherwise. Any of these effects could depress the price of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1B. UNRESOLVED STAFF COMMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1C. CYBERSECURITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risk Management and Strategy</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="ixv-4331"><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="ixv-4332"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="ixv-14774">At IGC, we are committed to
maintaining the confidentiality, integrity, and availability of our information systems and data.</ix:nonNumeric> As part of this commitment, we have
implemented a comprehensive cybersecurity program to protect against unauthorized access, use, disclosure, modification, or destruction
of our information assets. We are committed to ensuring the security and protection of our company&#8217;s information assets and the
personal information of our employees, customers, and stakeholders.</p></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_2" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognize that cybersecurity
threats are constantly evolving and have the potential to cause significant harm to our company and our stakeholders. In order to address
these risks, we have established a cybersecurity risk management framework that is aligned with industry best practices and regulatory
requirements.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="ixv-4342"><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_3" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our program includes regular
risk assessments, vulnerability management, access controls, incident response planning, and employee training and awareness programs.
We also work closely with <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="ixv-14775">third-party</ix:nonNumeric> service providers to ensure that they are meeting our cybersecurity standards.</p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of a cybersecurity
incident, we have established procedures for prompt investigation, containment, and remediation to minimize the impact on our operations
and stakeholders. We believe that our cybersecurity program is robust and effective, and we will continue to invest in and improve our
capabilities to address evolving threats, although there can be no assurance, that our cybersecurity program will prevent all incidents.
We are committed to transparency and will provide updates on any material cybersecurity incidents that may impact our company or our stakeholders.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During Fiscal year ended March
31, 2025, we did not identify any cybersecurity threats that have <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="ixv-14776">materially</ix:nonNumeric> affected or are reasonably likely to materially affect our
business strategy, results of operations, or financial condition. However, despite our efforts, we cannot eliminate all risks from cybersecurity
threats, or provide assurances that we have not experienced undetected cybersecurity incidents. For additional information about these
risks, see Part I, Item 1A, &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Governance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="ixv-4363"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="ixv-4364"><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="ixv-4365"><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="ixv-4366"><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag-c0_cont_1" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="ixv-4367"><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="ixv-4368"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors addresses
the Company&#8217;s cybersecurity risk management as part of its general oversight function. <ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="ixv-14777">The <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="ixv-14778">board</ix:nonNumeric> of directors&#8217; audit committee
is responsible for overseeing Company&#8217;s cybersecurity risk management processes, including oversight and mitigation of risks from
cybersecurity threats.</ix:nonNumeric></p></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock-c0_cont_2" id="_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock-c0_cont_1"><ix:continuation continuedAt="_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock-c0_cont_2" id="_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock-c0_cont_1"><ix:continuation continuedAt="_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag-c0_cont_2" id="_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag-c0_cont_1"><ix:continuation continuedAt="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_2" id="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="ixv-4377"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cybersecurity risk assessment
and management processes are implemented and maintained by certain Company management, including our IT Lead. Our IT Lead has 5 years
of experience in roles that include oversight of cybersecurity risk management programs. In addition, the IT Lead is assisted by an external
agency with about 15 years of expertise in cybersecurity.</p></ix:nonNumeric></ix:continuation></ix:continuation></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock-c0_cont_2"><ix:continuation continuedAt="_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock-c0_cont_3" id="_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock-c0_cont_2"><ix:continuation continuedAt="_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag-c0_cont_3" id="_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag-c0_cont_2"><ix:continuation continuedAt="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_3" id="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our IT Lead is responsible
for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management
strategy, communicating key priorities to relevant personnel, helping prepare for cybersecurity incidents, approving cybersecurity processes,
and reviewing security assessments and other security-related reports.</p></ix:continuation></ix:continuation></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 39; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock-c0_cont_3"><ix:continuation id="_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag-c0_cont_3"><ix:continuation continuedAt="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_4" id="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cybersecurity incident
response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including
the CEO, who help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the Company&#8217;s
incident response processes include reporting to the audit committee for certain cybersecurity incidents.</p></ix:continuation></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The audit committee will receive
periodic reports from our management concerning cybersecurity issues, including certain threats and risks and the processes the Company
has implemented to address them, as applicable. The audit committee also has access to various reports, summaries or presentations related
to cybersecurity threats, risk, and mitigation.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 2. PROPERTIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our corporate headquarters
is located in Potomac, Maryland. We own approximately 40,000 square feet of property used for general management and R&amp;D operations.
In addition, we are leasing, through September 2025, approximately 16,000 square feet in Vancouver, Washington, for manufacturing, sales,
and distribution of our Life Sciences segment products and services. In addition, we own and have short-term lease facilities in the U.S.
and India that are used for sales, storage, accounting, management, and R&amp;D. The Company believes its existing facilities and equipment,
which are used by all reportable segments, are in good operating condition and suitable for conducting its business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We own approximately 5 acres
of land in India, classified as &#8220;Asset Held for Sale&#8221; as on March 31, 2025. Please refer, Note 6 &#8211; &#8220;Property,
Plant and Equipment&#8221;, for more information on Part II, Item 8.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 3. LEGAL PROCEEDINGS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company may be involved
in legal proceedings, claims, and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties,
and outcomes are not predictable with assurance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 31, 2025, the
following material litigation is pending:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Engineering and Consulting
Group SAS et al. v IGC Pharma Inc</b>., case file no. 110016000050202247710 (Prosecutor&#8217;s Office 393 Sectional Economic Crimes Unit, Bogota,
Colombia). The Company and the ECG corporation are in a contractual dispute. The Company filed a complaint against four (4) individuals
with the Prosecutor&#8217;s Office 393 Sectional Economic Crimes Unit, Bogota, Colombia, under file no. 110016000050202247710 for charges of
fraud, falsification of a private document, and conspiracy to commit a crime. The complaint was filed in 2022. In December 2023, the case
was reviewed by the investigator and scheduled and accepted for a hearing by the prosecutor in calendar 2024. During the fiscal year ended
2025, the Company met with the prosecutors and pressed the urgency of moving the case through the legal system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4. MINE SAFETY DISCLOSURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 40; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 5. MARKET FOR REGISTRANT</b>&#8217;<b>S
COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is listed
on the NYSE American under &#8220;IGC&#8221; symbol with CUSIP number 45408X308. The common stock of the Company is also quoted on the
Frankfurt, Berlin, and Stuttgart (XETRA2) stock exchanges in Germany (ticker symbol: IGS1). We also have 91,472 units outstanding that
can be separated into common stock. Ten units may be separated into one share of common stock. The unit holders are requested to contact
the Company or our transfer agent, Continental Stock Transfer &amp; Trust, to separate their units into common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further information on the
securities can be referred to in Note 13, &#8220;Securities&#8221; of Part II, Item 8.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Securities authorized for issuance under equity compensation plans</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table shows,
as of March 31, 2025, information regarding outstanding awards available under our compensation plans (including individual compensation
arrangements) under which our equity securities may be delivered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1pt solid">Plan category</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><b>(a)<br/> Number of<br/> securities<br/> to be<br/> issued upon<br/> exercise of<br/> outstanding<br/> options,<br/> warrants<br/> and<br/> rights <br/> (in thousands)</b></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><b>(b)<br/> Weighted-<br/> average<br/> exercise<br/> price of<br/> outstanding<br/> options,<br/> warrants and<br/> rights</b></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><b>(c)<br/> Number of<br/> securities<br/> available for<br/> future<br/> issuance<br/> (excluding<br/> shares in<br/> column (a)<br/> (in thousands)</b></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Equity compensation plans approved by security holders:</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0.25pt">2018 Omnibus Incentive Plan (1)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">2,106</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">0.34</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">1,821</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Special Grant (2)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">9,203</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">0.51</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4,224</td>
    <td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(1)</td><td style="text-align: justify">Consists of our 2018 Omnibus Incentive Plans, as approved by our stockholders on November 8, 2017. See
Note 14, &#8220;Stock-Based Compensation&#8221; of the Notes to the Consolidated Financial Statements included in this report.</td></tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(2)</td><td style="text-align: justify">Consists of 2 million shares as a special grant of common stock, as approved by our stockholders on January
7, 2020, 2.5 million shares as a special grant of common stock, as approved by our stockholders on January 11, 2021, 3.5 million shares
as a special grant of common stock, as approved by our stockholders on October 15, 2021, 3 million shares as a special grant of common
stock, as approved by stockholders on September 9, 2022, 3 million shares as special grant of common stock, as approved by stockholders
on August 18, 2023 and 5 million shares as special grant of common stock, as approved by stockholders on August 23, 2024.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Holders of Record</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 20, 2025, we had
approximately 46 registered shareholders of record of our common stock and 2 registered unit holders. The number of record holders does
not include persons who held our common stock in nominee or &#8220;street name&#8221; accounts through brokers. Continental Stock Transfer
&amp; Trust Company is the transfer agent and registrar for our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dividend policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not declared or paid
any dividends on our common stock. We currently anticipate that we will retain future earnings, if any, for the development, operation,
and expansion of our business and do not anticipate declaring or paying any dividends in the foreseeable future. Any future determinations
related to the dividend policy will be made at the discretion of our Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Unregistered sales of equity securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the first quarter of Fiscal
2026, the Company entered into a Share Purchase Agreement (the 2025 SPA) with multiple investors, relating to the sale and issuance by
our company to investors of an aggregate of 2,803,333 shares of our common stock, for a total purchase price of $841,000, or $0.30 per
share, subject to the terms and conditions set forth in the 2025 SPA. The investment is subject to customary closing conditions, including
NYSE approval. As per the 2025 SPA, the investor received piggyback registration rights subject to certain restrictions. Shares are intended
to be exempt from registration under the Securities Act, by virtue of the provisions of Section 4(a)(2) of Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Purchases of equity securities by the issuer and affiliated purchasers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 6. [RESERVED] </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 7. MANAGEMENT</b>&#8217;<b>S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a discussion
and analysis of the consolidated statement of operations, liquidity, and capital resources, and a summary of cash flows, which apply to
Fiscal 2025, ending on March 31, 2025, and Fiscal 2024, ending on March 31, 2024. These statements should be read in conjunction with
our consolidated financial statements and the related notes that appear elsewhere in this Annual Report on Form 10-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to historical
information, this report contains forward-looking statements that involve risks and uncertainties that may cause our actual results to
differ materially from the plans and results discussed in forward-looking statements. We encourage you to review the risks and uncertainties
discussed in the sections entitled Item 1A. &#8220;Risk Factors&#8221; and &#8220;Forward-Looking Statements&#8221; are included at the
beginning of this Annual Report on Form 10-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The risks and uncertainties
can cause actual results to differ significantly from those in our forward-looking statements or implied in historical results and trends.
We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are
made. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such
statements to reflect any change in our expectations or in events, conditions, or circumstances on which any such statements may be based,
or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IGC Pharma, a clinical-stage
pharmaceutical company developing treatments for Alzheimer&#8217;s disease (AD) and related neurodegenerative conditions, is committed
to transforming patient care by seeking to offer faster-acting and more effective solutions. The Company&#8217;s research and development
efforts are centered on addressing some of the most challenging and underserved symptoms of Alzheimer&#8217;s, with the lead investigational
candidate, IGC-AD1, positioned at the forefront of this strategy. It is designed to treat agitation in Alzheimer&#8217;s dementia, a common
and difficult-to-manage neuropsychiatric symptom that significantly impacts millions of patients&#8217; well-being and caregiver burden.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 42; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The Global Economic Environment</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the industry-specific
factors, such as regulations around cannabinoid research, we are exposed to economic cycles. Factors in the global economic environment
that may impact our operations include, among other things, currency fluctuations, capital and exchange controls, global economic conditions
including inflation, restrictive government actions, changes in intellectual property, legal protections and remedies, trade regulations,
tax laws and regulations and procedures and actions affecting approval, production, pricing, and marketing of our products, as well as
impacts of political or civil unrest or military action, terrorist activity, unstable governments, and legal systems, inter-governmental
disputes, public health outbreaks, epidemics, pandemics, natural disasters or disruptions related to climate change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Clinical Trial Operational Excellence</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of our commitment
to operational discipline and patient-centric innovation, we continue to focus not only on the scientific rigor of our clinical trials
but also on their cost-effectiveness. For our Phase 2 trial of IGC-AD1, we have successfully optimized trial operations to bring the cost
per patient enrolled to approximately $70 thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This represents a significant
improvement over industry norms for Alzheimer&#8217;s trials, where average per-patient costs can exceed $100 thousand to $150 thousand,
according to multiple industry benchmarks for mid-stage neurodegenerative clinical trials. These efficiencies reflect our strategic use
of:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">In-house site selection, training of clinical sites, monitoring, audit, scientific, and clinical trial operations</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">In house regulatory and marketing to potential patients for each of the clinical trial sites</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technology-enabled
                                            patient recruitment and monitoring</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By keeping trial costs below
market averages while maintaining robust clinical standards, we believe we are well-positioned to deliver high-quality data and extend
our cash runway, both critical to de-risking our development timeline and enhancing shareholder value, although there can be no assurance
thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Clinical Trial Updates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify">On
March 26, 2025, the Company announced additional positive interim results from its ongoing Phase 2 clinical trial on IGC-AD1, an investigational
treatment for agitation in dementia due to AD. The results suggest that IGC-AD1 may&#160;decrease the&#160;frequency&#160;and/or&#160;severity&#160;of
sleep disturbances and nighttime&#160;behaviors. Based on the interim&#160;analysis&#160;at week 2, sleep disturbance&#160;was reduced
by&#160;about&#160;71%&#160;(p=.012) and at week 6, about&#160;78% (p=.02)&#160;for those on the active medication.&#160;These values&#160;indicate&#160;a&#160;clinical
and&#160;statistically significant reduction in sleep disturbances among Alzheimer&#8217;s patients&#160;receiving the active medication
compared to placebo, as measured by the Neuropsychiatric Inventory (NPI-12) Sleep Subscale.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"><img alt="" src="image_016.jpg"/></p><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">During fiscal 2025, the Company
expanded the CALMA Phase 2 trial by adding 13 prestigious research sites, including Miami Jewish Health and Butler Hospital&#8217;s Memory
and Aging Program, to accelerate patient enrollment and diversify the study population.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Based on the interim results, the secondary endpoint showed a clinically significant reduction, approaching statistical significance, in agitation in Alzheimer&#8217;s at week two compared to placebo. CMAI LS mean difference at week 2, assessing early response, was -12.19 with an ES of 0.79 (p= .071)<b>.</b></span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span style="text-decoration:underline">Table 2:- Interim CMAI Results for Week
2 and Week 6</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td colspan="4" style="border-top: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Week 2</b></span></td>
    <td colspan="3" style="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Week 6 (EOT)</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 10%; border-top: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Scale</b></span></td>
    <td style="width: 21%; border-top: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>LS Mean Change (95% CI)</b></span></td>
    <td style="width: 14%; border-top: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>p value</b></span></td>
    <td style="width: 14%; border-top: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Cohen&#8217;s d</b></span></td>
    <td style="width: 21%; border-top: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>LS Mean Change (95% CI)</b></span></td>
    <td style="width: 10%; border-top: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>p value</b></span></td>
    <td style="width: 10%; border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Cohen&#8217;s d </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">CMAI</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">-12.19 (-25.52, 1.14)</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">.071</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">0.79</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">-10.46 (-20.53, -0.4)</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">.042</span></td>
    <td style="border: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">0.79</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interim data from our Phase
2 trial of IGC-AD1 for agitation in Alzheimer&#8217;s disease show a statistically significant improvement in symptoms compared to placebo
over six weeks, as measured by the Cohen-Mansfield Agitation Inventory (CMAI). IGC-AD1 demonstrated a large effect size (Cohen&#8217;s
d = 0.79) and showed improvement as early as Week 2. For context, Brexpiprazole (Rexulti), the currently approved therapy showed separation
from placebo only by Week 6, based on published trial data.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><img alt="" src="image_017.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to efficacy, IGC-AD1 has shown a favorable safety profile
to date. As of the 6-week interim analysis:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
serious adverse events (SAEs) were reported</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
adverse events (AEs) led to treatment discontinuation</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
deaths occurred in the treatment or placebo arms</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">While cross-trial comparisons must be interpreted with caution due
to differences in trial design and patient populations, these findings suggest that IGC-AD1 may offer faster symptom relief with a potentially
improved safety profile compared to the currently approved therapy.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Phase 2 trial remains ongoing to complete 146 patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Business Updates</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="width: 48px">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">On January 21, 2025, the Company appointed Terry McAuliffe, the 72<sup>nd</sup> Governor of Virginia, as a strategic advisor. Governor McAuliffe&#8217;s extensive leadership experience across public and private sectors will play a pivotal role in advancing IGC Pharma&#8217;s mission to redefine Alzheimer&#8217;s care and position for growth in the biotechnology and pharmaceutical industries.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Through Fiscal 2025 the Company raised over $4.64 million through different private equity placement SPAs and the ATM. Please refer to Note 13 &#8211; &#8220;Securities&#8221; for more information.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Fiscal 2025 compared to Fiscal 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table presents an overview of our
results of operations for Fiscal 2025 and Fiscal 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Statement of Operations (in thousands, audited)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><b>2025<br/> ($)</b></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><b>2024<br/> ($)</b></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><b>Change<br/> ($)</b></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><b>Percent <br/> Change</b></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-left: 0.25pt">Revenue</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">1,271</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">1,345</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">(74</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">(6</td>
    <td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Cost of revenue</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(652</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(612</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(40</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">7</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0.25pt">Gross profit</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">619</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">733</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">(114</td>
    <td style="font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">(16</td>
    <td style="font-weight: bold; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Selling, general, and administrative expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(4,410</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(6,758</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,348</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(35</td>
    <td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Research and development expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(3,655</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(3,773</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">118</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(3</td>
    <td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-left: 0.25pt">Operating loss</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">(7,446</td>
    <td style="font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">(9,798</td>
    <td style="font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">2,351</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right">(24</td>
    <td style="font-weight: bold; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Impairment Loss on PPE</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(3,345</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,345</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(100</td>
    <td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Other income, net</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">325</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">143</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">182</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">127</td>
    <td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Loss before income taxes</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(7,121</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(13,000</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">5,878</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(45</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Income tax expense/benefit</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Net loss attributable to common stockholders</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(7,121</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(13,000</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">5,878</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(45</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Revenue</i> &#8211; During
Fiscal 2025, the Company&#8217;s revenue decreased by $74 thousand from $1.3 million in Fiscal 2024 to $1.2 million in Fiscal 2025. The
primary source of revenue in both years was from the Life Sciences segment, encompassing the sale of our formulations as white-labeled
manufactured products, among others. Fiscal 2024, the Company also generated $164 thousand in revenue from the Infrastructure business.
However, in Fiscal 2025, revenue from Infrastructure was nil due to the completion of all infrastructure projects. Excluding Infrastructure,
revenue from the Life Sciences segment increased from $1181 thousand in Fiscal 2024 to $1271 thousand in Fiscal 2025. Our core focus is
on advancing IGC-AD1, the completion of the Phase 2 trial, and development of MINT-AD for early diagnosis of Alzheimer&#8217;s. In the
future, our revenue from white label may not increase as we allocate more resources to expanding our core pharma focused programs. &#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Cost of revenue </i>&#8211;
The cost of revenue amounted to approximately $652 thousand for Fiscal 2025, compared to $612 thousand utin Fiscal 2024, this represents
a gross margin of 49% and 54%, respectively. The cost of revenue is primarily attributable to the cost of raw materials, labor, and other
direct overheads required to produce our products and services in both segments. The slight decrease in gross margin is attributed to
the Company&#8217;s strategic efforts to develop new formulations using a broader range of active ingredients, which, while affecting
margins in the short term, are expected to open new commercial avenues in the long term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Selling, general, and
administrative (SG&amp;A) expenses </i>&#8211;SG&amp;A expenses primarily encompass various costs such as employee-related expenses,
sales commissions, professional fees, legal fees, marketing expenses, other corporate expenses, allocated general overhead,
provisions, depreciation, and write-offs related to doubtful accounts and advances. For Fiscal 2025, the Company reported SG&amp;A
expenses of approximately $4.4 million, representing a decrease of approximately $2.3 million, or 35%, compared to the $6.7 million
recorded in Fiscal 2024. This significant decline in SG&amp;A expenses is attributable to the Company&#8217;s focused efforts to
optimize corporate-level operational efficiency by lowering employee&#8211;related costs due to headcount alignment and compensation
restructuring, implementing better inventory management systems, and reducing spending on legal and professional services through
more efficient vendor management. In a demonstration of cost and cash discipline, management elected to convert approximately $750
thousand in accrued bonuses into performance-based compensation, payable only upon the achievement of defined business milestones,
which also align with shareholder interest. These optimizations allowed the Company to preserve capital and extend its operational
runway while maintaining the infrastructure necessary to support clinical development and strategic initiatives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Research and Development
(R&amp;D) expenses </i>&#8211; R&amp;D expenses were primarily associated with the Life Sciences segment, reflecting the Company&#8217;s
investment in R&amp;D activities. In Fiscal 2025, the Company reported R&amp;D expenses of approximately $3.7&#160;million, representing
a decrease of $118 thousand or 3% compared to approximately $3.8 million in Fiscal 2024. The R&amp;D expenses is primarily attributed
to the progression of Phase 2 trials on IGC-AD1 and pre-clinical studies on TGR-63, indicating the Company&#8217;s dedication to advancing
its product pipeline. As the development of TGR-63 and the Phase 2 trial on Alzheimer&#8217;s gains momentum, the Company anticipates
increase in R&amp;D expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Impairment loss on Property,
Plant, and Equipment (PPE)</i> &#8211; During Fiscal 2025, there was no impairment loss on PPE. During Fiscal 2024, as the Company focused
on liquidating all non-operating assets to reduce the cost and generate cash, the Company impaired the land situated in Nagpur, India,
by approximately $3.3 million to $720 thousand from $4.1 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Other Income, net</i> &#8211;
During Fiscal 2025, the Company reported approximately $325 thousand in other income, which represents an increase of approximately $182
thousand as compared to the $143 thousand recorded in Fiscal 2024. The increase in other income is attributable to the tax credit of $194
thousand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity and capital resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our sources of liquidity are
cash and cash equivalents, funds raised through the ATM offering, cash flows from operations, short-term and long-term borrowings, and
short-term liquidity arrangements. The Company continues to evaluate various financing sources and options to raise working capital to
help fund current research and development programs and operations. The Company does not have any material long-term debt, capital lease
obligations, or other long-term liabilities except as disclosed in this report. Please refer to Note 12, &#8220;Commitments and contingencies&#8221;,
Note 11, &#8220;Loans and Other Liabilities,&#8221; and Note 9, &#8220;Leases&#8221; in Item 1 of this report for further information
on the Company&#8217;s commitments and contractual obligations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Master Loan
and Security Agreement (the Credit Agreement) with O-Bank, Co., Ltd., the Company successfully obtained a working capital credit facility
totaling $12 million and, in addition, raised approximately $4.64 million in exchange for approximately 14.2 million shares. The equity
and the credit facility serve to minimize ongoing liquidity requirements and ensure the Company&#8217;s ability to sustain its operations.
Furthermore, the Company intends to raise additional funds through private placement and ATM offerings, subject to market conditions,
although there can be no assurance that such financing efforts will be successful or as to any private placement or the terms of such
offering. Any equity issuances would be dilutive to shareholders. Please refer to Note 13 &#8211; &#8220;Securities&#8221;, for more information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 29, 2024, the Company
entered into an amendment to extend the Credit Agreement, effective July 8, 2024. The amendment extends the term of the Credit Agreement,
which was set to expire, under the same terms and conditions as previously disclosed on the Company&#8217;s Current Report on Form 8-K
filed with the Securities Exchange Commission on July 7, 2023, with the exception of a reduction in the facility fees from $120,000 to
$84,000. All other material terms of the Loan Agreement remain unchanged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As disclosed in Subsequent Events, on June 24, 2025, IGC Pharma, Inc.
(&#8220;IGC&#8221; or the &#8220;Company&#8221;) entered into an amendment to extend its existing Master Loan and Security Agreement along
with the General Banking Facility Letter (collectively called the &#8220;Loan Agreement&#8221;) with O-Bank, CO., LTD., a banking corporation
incorporated under the laws of Taiwan, as administrative agent and lender (the &#8220;Lender&#8217;), effective June 24, 2024. The amendment
extends the term of the Loan Agreement, which was set to expire, under the same terms and conditions as previously disclosed on the Company&#8217;s
Current Report on Form 8-K filed with the Securities Exchange Commission on August 2, 2024, with the exception of i) a reduction in the
facility fees from $84,000 to $48,000 and ii) interest, calculated according to the interest rate mentioned in the Certificate of Deposit,
as the case may be, plus an applicable margin of 1.2%, instead of 1% . All other material terms of the Loan Agreement remain unchanged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 27, 2023, the Company
entered into a Sales Agreement (the Sales Agreement) with A.G.P./Alliance Global Partners (the Agent) pursuant to which the Company may
offer and sell, from time to time, through the Agent, as sales agent and/or principal, shares of its common stock having an aggregate
offering price of up to $60 million , subject to certain limitations on the amount of Common Stock that may be offered and sold by the
Company set forth in the Sales Agreement (the Offering). As of March 31, 2025 the Company has sold approximately $2.1 million, under the
Sales Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 22, 2024, the Company
entered into a Share Purchase Agreement (the March 2024 SPA) with Bradbury Strategic Investment Fund A, resulting in approximately $3
million in gross proceeds. During the quarter ended June 30, 2024, the Company issued approximately 8.8 million shares of unregistered
common stock at a price of $0.34 per share. Shares are intended to be exempt from registration under the Securities Act of 1933, as amended
(the Securities Act), by virtue of the provisions of Section 4(a)(2) of Securities Act and Regulation D and/or Regulation S adopted thereunder.
During fiscal 2024, the Company had received $500 thousand of the total $3 million due under the March 2024 SPA, while the remaining $2.5
million was received in, the Company has sold approximately $2.1 million April 2024. Please refer to Note 13 &#8211; &#8220;Securities&#8221;,
for more information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 25, 2024, the Company entered into the 2024 Share Purchase Agreement (the &#8220;September 2024 SPA&#8221;) with Moran Global
Strategies, Inc., a Virginia corporation (&#8220;MGS&#8221;), which is owned by James Moran, a director of IGC, relating to the sale
and issuance by our company to the investors of an aggregate of 588,235 shares of our common stock, for a total purchase price of $200,000,
or $0.34 per share, subject to the terms and conditions set forth in the September 2024 SPA. The investment is subject to customary closing
conditions, including NYSE approval. As per the September 2024 SPA, the investor received piggyback registration rights subject to certain
restrictions. Shares are intended to be exempt from registration under the Securities Act by virtue of the provisions of Section 4(a)(2)
of Securities Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the first quarter of Fiscal 2026, the Company entered into the 2025 Share Purchase Agreement with multiple investors, relating to the
sale and issuance by our company to the investors of an aggregate of 2,803,333 shares of our common stock, for a total purchase price
of $841,000, or $0.30 per share, subject to the terms and conditions set forth in the 2025 SPA. The investment is subject to customary
closing conditions, including NYSE approval. As per the 2025 SPA, the investor received piggyback registration rights subject to certain
restrictions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to raise capital for its trials as and when it is able to do so, but there can be no assurance thereof. In addition,
there can be no assurance of the terms thereof, and any subsequent equity financing sought may have dilutive effects on our current shareholders.
While there is no guarantee that we will be successful, we are applying to non-dilutive funding opportunities such as Small Business
Research and Development programs. In addition, subject to limitations on the amount of capital that can be raised, the Company expects
to utilize its shelf registration on statement on Form S-3 to raise capital through at-the-market offerings or otherwise.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
refer to Item 1A. &#8220;Risk Factors&#8221; for further information on the risks related to the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center">(in thousands, audited)</td>
    <td style="font-weight: bold; font-style: italic">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of  <br/>
March 31, <br/>
2025 <br/>
($)</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of  <br/>
March 31, <br/>
2024<br/>
 ($)</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Change <br/>
($)</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percent <br/>
 Change</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 0pt">Cash, cash equivalents</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">405</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">1,198</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">(793</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">(66</td>
    <td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Working capital</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">639</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,365</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(726</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(53</td>
    <td style="text-align: left">)%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
and cash equivalents </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents decreased by approximately $793 thousand to $405 thousand in Fiscal 2025 from $1.2 million in Fiscal 2024, a decrease
of approximately 66%. This is discussed in the summary of cash flows, as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands, audited)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percent<br/> Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 0.25pt">Cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(4,794</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(5,199</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">405</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(8</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(442</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(317</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(126</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,451</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,524</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">927</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Effects of exchange rate changes on cash and cash equivalents</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(7</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"><b>Net decrease in cash and cash equivalents</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>(792</b></td><td style="padding-bottom: 1pt; text-align: left"><b>)</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>(1,998</b></td><td style="padding-bottom: 1pt; text-align: left"><b>)</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>1,206</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>(60</b></td><td style="padding-bottom: 1pt; text-align: left"><b>)%</b></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Cash and cash equivalents at the beginning of the period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,198</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,196</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,998</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(63</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"><b>Cash and cash equivalents at the end of the period</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>405</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>1,198</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>(792</b></td><td style="padding-bottom: 1pt; text-align: left"><b>)</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>(66</b></td><td style="padding-bottom: 1pt; text-align: left"><b>)%</b></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities for Fiscal 2025 was approximately $4.8 million. It consists of a net loss of approximately $7.1 million,
a positive impact on cash due to non-cash expenses of approximately $2.3 million, and changes in operating assets and liabilities of
approximately $70 thousand. Non-cash expenses consist of an amortization and depreciation charge of approximately $618 thousand, stock-based
expenses of approximately $1.6 million, impairment loss of approximately $152 thousand and an approximately $12 thousand decrease in
other non-cash items. In addition, changes in operating assets and liabilities had a positive impact of approximately $70 thousand on
cash, of which approximately $180 thousand is due to an adjustment in inventory, approximately $107 thousand increase in accounts payable,
approximately $187 decrease in deposit and advances, approximately $195 thousand decrease in accrued and other current liabilities, approximately
$100 thousand increase in operating lease assets, and approximately $75 thousand increase in other net current assets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities for Fiscal 2024 was approximately $5.2 million. It consists of a net loss of approximately $13 million,
a positive impact on cash due to non-cash expenses of approximately $5.9 million, and changes in operating assets and liabilities of
approximately $1.9 million. Non-cash expenses consist of an amortization and depreciation charge of approximately $637 thousand, stock-based
expenses of approximately $1.7 million, impairment loss of approximately $3.4 million, and an approximately $49 thousand decrease in
other non-cash items. In addition, changes in operating assets and liabilities had a positive impact of approximately $1.9 million on
cash, of which approximately $1 million is due to an adjustment in inventory, approximately $243 thousand increase in accounts payable,
approximately $315 thousand increase in claims and advances and approximately $328 thousand increase in other net current assets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
Activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities for Fiscal 2025, was approximately $442 thousand, which comprises approximately $370 thousand for the
acquisition and development of intangible assets, and approximately $72 thousand from the net purchase of property, plant, and equipment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities for Fiscal 2024, was approximately $317 thousand, which comprises approximately $377 thousand for the
acquisition and development of intangible assets, approximately $94 thousand from the net purchase of property, plant, and equipment,
and approximately $154 thousand from a short-term investment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financing
Activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was approximately $4.4 million for Fiscal 2025, which comprises net proceeds from the issuance
of equity stock of approximately $4.4 million and re-payment of a long-term loan of approximately $3 thousand.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was approximately $3.5 million for Fiscal 2024, which comprises net proceeds from the issuance
of equity stock of approximately $3.5 million and re-payment of a long-term loan of approximately $3 thousand.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements and related disclosures in conformity with U.S. GAAP and the Company&#8217;s discussion and analysis
of its financial condition and operating results require the Company&#8217;s management to make judgments, assumptions, and estimates
that affect the amounts reported in its consolidated financial statements and accompanying notes. We base our estimates on historical
experience, as appropriate, and on various other assumptions that we believe to be reasonable under the circumstances. Actual results
may differ from these estimates, and such differences may be material. For further information on significant accounting policies, see
discussion in Note 2 to the consolidated financial statements included in Item 8 of this Annual Report on Form 10-K.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
believes that the following accounting policies are the most critical to understanding and evaluating our consolidated financial condition
and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
Recognition</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue under ASC 606, <i>Revenue from Contracts with Customers</i> (ASC 606). The core principle of this standard
is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects
the consideration to which the Company expects to be entitled in exchange for those goods or services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
606 prescribes a 5-step process to achieve its core principle. The Company recognizes revenue from trading, rental, or product sales
as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.
Identify the contract with the customer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.
Identify the contractual performance obligations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">III.
Determine the amount of consideration/price for the transaction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IV.
Allocate the determined amount of consideration/price to the performance obligations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">V.
Recognize revenue when or as the performing party satisfies performance obligations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consideration/price for the transaction (performance obligation(s)) is determined as per the agreement or invoice (contract) for the
services and products Life Sciences segment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the Life Sciences segment, the revenue from the wellness and lifestyle business is recognized once goods have been sold to the customer
and the performance obligation has been completed. In retail sales, we offer consumer products through our online stores. Revenue is
recognized when control of the goods is transferred to the customer. This generally occurs upon our delivery to a third-party carrier
or to the customer directly. Revenue from white label services is recognized when the performance obligation has been completed and output
material has been transferred to the customer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
sales disaggregated by significant products and services for Fiscal 2025 and 2024 are as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(in
thousands)<br/>
Year ended March 31,</i></b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025<br/>
($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024<br/>
($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wellness and lifestyle <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">113</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">228</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">White labeling services <sup>(2)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,158</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">953</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other<sup>(3)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">164</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,271</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,345</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from wellness and lifestyle consists of the sale of products such as gummies, hand sanitizers, bath bombs, lotions, beverages, hemp crude
extract, hemp isolate, and hemp distillate.</span></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from white label services consists of rebranding our formulations or the customer&#8217;s products as per the customer&#8217;s requirement.</span></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
consists of income from the rental of heavy construction equipment and the execution of contracts directly or through subcontractors.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property,
plant, and equipment </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property, plant, and equipment
are recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful
lives of the assets. Please refer to Note 2, &#8220;Significant accounting policies&#8221; and Note 6, &#8220;Property, plant, and equipment&#8221;
of Item 8 in this document, for more information. Property, plant, and equipment are reviewed for impairment when events or changes in
circumstances indicate the carrying amount of an asset may not be recoverable. If property, plant, and equipment are considered to be
impaired, an impairment loss is recognized.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
Fiscal 2025, there was no impairment loss on PPE. During Fiscal 2024, as the Company focused on liquidating all non-operating assets
to reduce costs and generate cash, the Company impaired the land situated in Nagpur, India, by approximately $3.3 million to $720 thousand
from $4.1 million. The Company believes it can sell the above-said non-operating land as it is without any improvement. Selling this
land will give immediate cash, which the company can use in its operating segments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Software
Development Costs</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is developing two proprietary software platforms intended to be commercialized:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            <b>clinical data management platform</b> designed for the collection, analysis, and real-time
                                            monitoring of clinical trial data; and;</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                    </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            <b>MINT- AD - AI-driven diagnostic and treatment personalization platform</b> aimed at assisting
                                            in the early detection of Alzheimer&#8217;s disease and providing data-informed therapeutic
                                            suggestions.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with <b>ASC 985-20</b>, <i>Software to Be Sold, Leased, or Marketed</i>, the Company capitalizes development costs incurred
after technological feasibility has been established and before the software is available for general release. Costs incurred during
the research, planning, or preliminary design phase are expensed as incurred.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized
costs include direct labor, third-party development services, cloud computing infrastructure directly related to model development and
deployment, and associated overhead. These costs are amortized on a straight-line basis over their estimated useful lives, typically
<b>five to ten years</b>, beginning when the software is ready for its intended commercial use.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
Fiscal 2024, the Company began working on overlaying machine learning technologies and Artificial Intelligence (AI) into the internal
clinical trial software framework for trial management with the expectation that this can lead to improved decision-making, contextual
data entry, computational models, trial design (Phase 3), and data analysis, the company believes it is probable that the project will
be completed and the software will be used to perform the function intended. As of Fiscal year ended 2025, the Company capitalized approximately
$863 thousand in software development costs. Please refer to Note 5, &#8220;Intangible Assets,&#8221; for more information.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
currency translation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IGC
operates in India, U.S., and Colombia, and a substantial portion of the Company&#8217;s financials are denominated in the Indian Rupee
(INR), or the Colombian Peso (COP). As a result, changes in the relative values of the U.S. Dollar (USD), the INR, or the COP affect
financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements are reported in USD. The INR, and COP are the functional currencies for certain subsidiaries of the
Company. The translation of the functional currencies into U.S. dollars is performed for assets and liabilities using the exchange rates
in effect at the balance sheet date and for revenues and expenses using average exchange rates prevailing during the reporting periods.
Adjustments resulting from the translation of functional currency financial statements to reporting currency are accumulated and reported
as other comprehensive income/(loss), a separate component of shareholders&#8217; equity. Transactions in currencies other than the functional
currency during the year are converted into the functional currency at the applicable rates of exchange prevailing when the transactions
occurred. Transaction gains and losses are recognized in the consolidated statements of operations. The exchange rates used for translation
purposes are as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="5" style="padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period
    End Average Rate</b></span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="5" style="padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period
    End Rate</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period</b></span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: black 1pt solid; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(P&amp;L
    rate)</b></span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: black 1pt solid; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Balance
    sheet rate)</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended March
    31, 2025</span></td>
    <td style="padding: 0pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INR</span></td>
    <td style="padding: 0pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84.54</span></td>
    <td style="padding: 0pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per</span></td>
    <td style="padding: 0pt; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD</span></td>
    <td style="padding: 0pt; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INR</span></td>
    <td style="padding: 0pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85.45</span></td>
    <td style="padding: 0pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per</span></td>
    <td style="padding: 0pt; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COP</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,140.74</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COP</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,200</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended March 31, 2024</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INR</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82.79</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INR</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83.38</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COP</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,114</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COP</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,862</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cybersecurity</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a cybersecurity policy in place and have implemented tighter cybersecurity measures to safeguard against hackers. Complying with
these security measures and compliances is expected to incur further expenses. In Fiscal 2025 and Fiscal 2024, there were no known or
detected material breaches in cybersecurity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-balance
sheet arrangements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any outstanding derivative financial instruments, off-balance sheet guarantees, interest rate swap transactions or foreign
currency forward contracts. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated
entity that serves as credit, liquidity, or market risk support to such entity. We do not have any variable interest in an unconsolidated
entity that provides financing, liquidity, market risk or credit support to us or that engages in leasing, hedging or research and development
services with us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
7A does not apply to us because we are a smaller reporting company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 90%; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><b>Index to Consolidated Financial Statements</b></td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; width: 9%; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><b>Page</b></td></tr> <tr style="vertical-align: top"> <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&#160;</td> <td>&#160;</td> <td style="text-align: right; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><a href="#f_001">Report of Independent Registered Public Accounting Firms (PCAOB ID <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-14779">5341</ix:nonNumeric>)</a></td> <td>&#160;</td> <td style="text-align: right; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">52</td></tr> <tr style="vertical-align: top"> <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><a href="#f_002">Consolidated Balance Sheets</a></td> <td>&#160;</td> <td style="text-align: right; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">53</td></tr> <tr style="vertical-align: top"> <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><a href="#f_003">Consolidated Statements of Operations and Comprehensive Loss</a></td> <td>&#160;</td> <td style="text-align: right; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">54</td></tr> <tr style="vertical-align: top"> <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><a href="#f_004">Consolidated Statements of Stockholders&#8217;&#160;Equity</a></td> <td>&#160;</td> <td style="text-align: right; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">55</td></tr> <tr style="vertical-align: top"> <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><a href="#f_005">Consolidated Statements of Cash Flows</a></td> <td>&#160;</td> <td style="text-align: right; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">56</td></tr> <tr style="vertical-align: top"> <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><a href="#f_006">Notes to Consolidated Financial Statements</a></td> <td>&#160;</td> <td style="text-align: right; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">57</td></tr> </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Report
of Independent Registered Public Accounting Firm</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>To
the shareholders and the board of directors of IGC Pharma, Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Consolidated Financial Statements </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of IGC Pharma, Inc.&#160;and its subsidiaries (the &#8220;Company&#8221;) as
of March 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and
cash flows, for each of the two years in the period ended March 31, 2025, and the related notes (collectively referred to as the &#8220;consolidated
financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated
financial position of the Company as of March 31, 2025, and 2024, and the consolidated results of its operations and its cash flows for
each of the two years in the period ended March 31, 2025, in conformity with accounting principles generally accepted in the United States
of America.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on the Company&#8217;s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform an audit of its internal control over financial reporting. As part
of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing
an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated
financial statements, whether due to error or fraud and performing procedures that respond to those risks. Such procedures included examining,
on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating
the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated
financial statements. We believe that our audit provides a reasonable basis for our opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matters</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical
audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required
to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the consolidated financial
statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit
matters.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-6529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manohar
Chowdhry &amp; Associates</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chartered
Accountants</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
have served as the Company&#8217;s auditor since 2018.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-6548"><b>Chennai, India</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>June 27, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>UDIN:&#160;2523783OBMNTMJ2350</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IGC
Pharma, Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(In
thousands, except share data)</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, <br/> 2025 <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, <br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="text-decoration:underline">ASSETS</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Current assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-14780">405</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-14781">1,198</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" unitRef="usd" id="ixv-14782">34</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" unitRef="usd" id="ixv-14783">39</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd" id="ixv-14784">1,360</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd" id="ixv-14785">1,540</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Asset held for sale</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" scale="3" unitRef="usd" id="ixv-14786">702</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" scale="3" unitRef="usd" id="ixv-14787">720</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Deposits and advances</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-14788">395</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-14789">208</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Total current assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-14790">2,896</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-14791">3,705</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-left: 0.25pt">Non-current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-14792">1,852</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-14793">1,616</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Property, plant and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-14794">3,220</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-14795">3,695</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Claims and advances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-14796">681</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-14797">688</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Operating lease asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-14798">98</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-14799">198</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Total non-current assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd" id="ixv-14800">5,851</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd" id="ixv-14801">6,197</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Total assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-14802">8,747</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-14803">9,902</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-weight: bold; text-align: center; padding-left: 0.25pt">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0.25pt">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-14804">883</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-14805">773</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Accrued liabilities and others</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-14806">1,374</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-14807">1,567</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Total current liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-14808">2,257</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-14809">2,340</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-left: 0.25pt">Non-current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Long-term loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" unitRef="usd" id="ixv-14810">134</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" unitRef="usd" id="ixv-14811">137</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Other liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" unitRef="usd" id="ixv-14812">16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" unitRef="usd" id="ixv-14813">20</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Operating lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-14814">10</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-14815">84</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Total non-current liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitRef="usd" id="ixv-14816">160</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitRef="usd" id="ixv-14817">241</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Total liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-14818">2,417</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-14819">2,581</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0.25pt">Commitments and Contingencies &#8211; See Note 12</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CommitmentsAndContingencies" scale="3" unitRef="usd" id="ixv-14820">&#160;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CommitmentsAndContingencies" scale="3" unitRef="usd" id="ixv-14821">&#160;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0.25pt">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Preferred stock, $<ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-14822"><ix:nonFraction contextRef="c4" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-14823">0.0001</ix:nonFraction></ix:nonFraction> par value: authorized <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-14824"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-14825">1,000,000</ix:nonFraction></ix:nonFraction> shares, <ix:nonFraction contextRef="c3" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-14826"><ix:nonFraction contextRef="c4" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-14827"><ix:nonFraction contextRef="c3" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14828"><ix:nonFraction contextRef="c4" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14829">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding as of March 31, 2025, or March 31, 2024.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" unitRef="usd" id="ixv-14830">&#160;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" unitRef="usd" id="ixv-14831">&#160;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Common stock and additional paid-in capital, $<ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-14832"><ix:nonFraction contextRef="c4" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-14833">0.0001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-14834"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-14835">150,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-14836"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14837">80,878,058</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-14838"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14839">66,691,195</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March 31, 2025, and March 31, 2024, respectively.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStocksIncludingAdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-14840">130,570</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStocksIncludingAdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-14841">124,409</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Accumulated other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-14842">3,496</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-14843">3,423</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-14844">120,744</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-14845">113,665</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Total stockholders&#8217; equity</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-14846">6,330</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-14847">7,321</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt">Total liabilities and stockholders&#8217; equity</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-14848">8,747</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-14849">9,902</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes should be read in connection with these consolidated financial statements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IGC
Pharma, Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(in
thousands, except loss per share and share data)</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-left: 0.25pt">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-14850">1,271</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-14851">1,345</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Cost of revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" unitRef="usd" id="ixv-14852">652</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" unitRef="usd" id="ixv-14853">612</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt">Gross profit</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="3" unitRef="usd" id="ixv-14854">619</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="3" unitRef="usd" id="ixv-14855">733</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Selling, general and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-14856">4,410</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-14857">6,758</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-14858">3,655</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-14859">3,773</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt">Operating loss</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-14860">7,446</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-14861">9,798</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Impairment loss on PPE</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="3" unitRef="usd" id="ixv-14862">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="3" unitRef="usd" id="ixv-14863">3,345</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Other income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-14864">325</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-14865">143</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt">Loss before income taxes</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-14866">7,121</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-14867">13,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Income tax expense/benefit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-14868">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-14869">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Net loss attributable to common stockholders</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-14870">7,121</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-14871">13,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-14872">30</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-14873">34</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Comprehensive loss</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-14874">7,151</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-14875">13,034</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt">Net loss per share attributable to common stockholders:</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-14876"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-14877">0.09</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-14878"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-14879">0.22</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Weighted-average number of shares used in computing loss per share amounts:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-14880"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-14881">76,517,175</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-14882"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-14883">58,839,868</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes should be read in connection with these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IGC
Pharma, Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENT OF STOCKHOLDERS</b>&#8217; <b>EQUITY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(in
thousands)</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&#160;of <br/> Common<br/> Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Common&#160;Stock <br/> and Additional <br/> Paid in Capital<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated <br/> Deficit<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated<br/> Other <br/> Comprehensive <br/> Loss<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total <br/> Stockholders&#8217;<br/> Equity<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; width: 40%; font-weight: bold; padding-left: 10pt">Balances as of April 1, 2023</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" unitRef="shares" id="ixv-14884">53,077</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-14885">118,965</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-14886">100,665</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-14887">3,389</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-14888">14,911</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; text-align: left; padding-left: 10pt">Common stock-based compensation &amp; expenses, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" unitRef="shares" id="ixv-14889">3,534</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-14890">1,917</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-14891">1,917</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; text-align: left; padding-left: 10pt">Issuance of common stock through offering (net of expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" unitRef="shares" id="ixv-14892">10,580</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-14893">3,027</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-14894">3,027</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; text-align: left; padding-left: 10pt">Share money received but not allotted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="3" unitRef="usd" id="ixv-14895">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Cancellation/forfeiture of shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" scale="3" sign="-" unitRef="shares" id="ixv-14896">500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; text-align: left; padding-left: 10pt">Common stock subscribed</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="igc:AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock" scale="3" unitRef="usd" id="ixv-14897">500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="igc:AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock" scale="3" unitRef="usd" id="ixv-14898">500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; text-align: left; padding-left: 10pt">Other adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd" id="ixv-14899">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; text-align: left; padding-left: 10pt">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-14900">13,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-14901">13,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-14902">34</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-14903">34</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; font-weight: bold; padding-bottom: 2.5pt; padding-left: 10pt">Balances as of March 31, 2024</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" unitRef="shares" id="ixv-14904">66,691</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-14905">124,409</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-14906">113,665</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-14907">3,423</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-14908">7,321</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; font-weight: bold; padding-left: 10pt">Balances as of April 1, 2024</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" unitRef="shares" id="ixv-14909">66,691</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-14910">124,409</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-14911">113,665</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-14912">3,423</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-14913">7,321</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; text-align: left; padding-left: 10pt">Common stock-based compensation &amp; expenses, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-14914">1,709</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-14915">1,709</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; text-align: left; padding-left: 10pt">Issuance of common stock through offering (net of expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" unitRef="shares" id="ixv-14916">14,187</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-14917">4,252</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-14918">4,252</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; text-align: left; padding-left: 10pt">Share money received but not allotted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="3" unitRef="usd" id="ixv-14919">200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="3" unitRef="usd" id="ixv-14920">200</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Cancellation/forfeiture of shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; text-align: left; padding-left: 10pt">Common stock subscribed</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="igc:AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock" scale="3" unitRef="usd" id="ixv-14921">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; text-align: left; padding-left: 10pt">Other adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd" id="ixv-14922">43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" sign="-" unitRef="usd" id="ixv-14923">43</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; text-align: left; padding-left: 10pt">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-14924">7,122</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-14925">7,122</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-14926">30</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-14927">30</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; font-weight: bold; padding-bottom: 2.5pt; padding-left: 10pt">Balances as of March 31, 2025</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" unitRef="shares" id="ixv-14928">80,878</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-14929">130,570</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-14930">120,744</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-14931">3,496</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-14932">6,330</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes should be read in connection with these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IGC
Pharma, Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(in
thousands)</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Cash flows from operating activities:</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 76%; text-align: left; padding-left: 0.25pt">Net loss</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-14933">7,121</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-14934">13,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt"><i>Adjustment to reconcile net loss to net cash:</i></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" unitRef="usd" id="ixv-14935">618</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" unitRef="usd" id="ixv-14936">637</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Provision for bad debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" unitRef="usd" id="ixv-14937">13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" unitRef="usd" id="ixv-14938">93</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">Impairment of assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="3" unitRef="usd" id="ixv-14939">152</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="3" unitRef="usd" id="ixv-14940">3,448</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Common stock-based compensation and expenses, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-14941">1,640</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-14942">1,773</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Profit/Loss on sale of fixed assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" unitRef="usd" id="ixv-14943">25</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" unitRef="usd" id="ixv-14944">44</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt"><i>Changes in:</i></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Accounts receivables, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" unitRef="usd" id="ixv-14945">8</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" unitRef="usd" id="ixv-14946">25</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" sign="-" unitRef="usd" id="ixv-14947">180</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" sign="-" unitRef="usd" id="ixv-14948">1,008</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Deposits and advances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd" id="ixv-14949">187</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" sign="-" unitRef="usd" id="ixv-14950">150</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Claims and advances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" sign="-" unitRef="usd" id="ixv-14951">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" sign="-" unitRef="usd" id="ixv-14952">315</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" unitRef="usd" id="ixv-14953">106</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" unitRef="usd" id="ixv-14954">243</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Accrued and other liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-14955">196</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" unitRef="usd" id="ixv-14956">197</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Operating lease asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" sign="-" unitRef="usd" id="ixv-14957">100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" sign="-" unitRef="usd" id="ixv-14958">129</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Operating lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-14959">74</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-14960">123</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Net cash used in operating activities</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-14961">4,795</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-14962">5,199</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt">Cash flow from investing activities:</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Purchase of property, plant, and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-14963">112</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-14964">138</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Sale of property, plant, and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-14965">40</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-14966">44</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Proceeds from short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsForProceedsFromInvestments" scale="3" unitRef="usd" id="ixv-14967">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromInvestments" scale="3" sign="-" unitRef="usd" id="ixv-14968">154</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Acquisition and development of intangible assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" unitRef="usd" id="ixv-14969">370</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" unitRef="usd" id="ixv-14970">377</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Net cash used in investing activities</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-14971">442</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-14972">317</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt">Cash flows from financing activities:</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Net proceeds from the issuance of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-14973">4,454</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-14974">3,027</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Proceeds from common stock subscribed</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" unitRef="usd" id="ixv-14975">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" unitRef="usd" id="ixv-14976">500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Repayment of long-term loan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfDebt" scale="3" sign="-" unitRef="usd" id="ixv-14977">3</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfDebt" scale="3" sign="-" unitRef="usd" id="ixv-14978">3</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Net cash provided by financing activities</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-14979">4,451</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-14980">3,524</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Effects of exchange rate changes on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" sign="-" unitRef="usd" id="ixv-14981">7</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" sign="-" unitRef="usd" id="ixv-14982">6</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt">Net decrease in cash and cash equivalents</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-14983">793</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-14984">1,998</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Cash and cash equivalents at the beginning of the period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-14985">1,198</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-14986">3,196</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"><b>Cash and cash
    equivalents at the end of the period</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-14987">405</ix:nonFraction></b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-14988">1,198</ix:nonFraction></b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt">Supplementary information:</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt">Non-cash items:</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Common stock issued/granted for stock-based compensation, including patent acquisition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" scale="3" unitRef="usd" id="ixv-14989">1,640</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" scale="3" unitRef="usd" id="ixv-14990">1,773</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes should be read in connection with these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="f_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IGC
Pharma, Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
Fiscal Years Ended March 31, 2025, and 2024</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context requires otherwise, all references in this report to &#8220;IGC,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221;
refer to IGC Pharma, Inc., together with our subsidiaries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:NatureOfOperations" id="ixv-8279"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 </b>&#8211; <b>NATURE OF OPERATIONS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IGC
Pharma is on a mission to transform Alzheimer&#8217;s treatment. We are building a robust pipeline of drug candidates, each targeting
different aspects of the disease. Our product candidate pipeline and anticipated milestones include the following: -</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 0pt; width: 10%; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Asset</b></span></td>
    <td style="vertical-align: bottom; text-align: center; padding-right: 0pt; padding-bottom: 0pt; width: 1%; padding-left: 0pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 0pt; width: 28%; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Target
    Indication</b></span></td>
    <td style="vertical-align: bottom; text-align: center; padding-right: 0pt; padding-bottom: 0pt; width: 1%; padding-left: 0pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 0pt; width: 22%; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mechanism
    of Action</b></span></td>
    <td style="vertical-align: bottom; text-align: center; padding-right: 0pt; padding-bottom: 0pt; width: 1%; padding-left: 0pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 0pt; width: 15%; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Development
    Stage</b></span></td>
    <td style="vertical-align: bottom; text-align: center; padding-right: 0pt; padding-bottom: 0pt; width: 1%; padding-left: 0pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 0pt; width: 21%; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
    Milestones</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IGC-
    AD1</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agitation
    in Alzheimer&#8217;s dementia</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CB1
    receptor partial agonist; reduces neuroinflammation and restores neurotransmitter balance</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    2 clinical trial (CALMA study)</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    Phase 2 data analysis suggests cognitive improvements in the active treatment group versus the placebo group,</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TGR-63</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Early
    to moderate Alzheimer&#8217;s disease</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disrupts
    amyloid-beta (A&#946;) plaque formation; crosses blood-brain barrier</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Demonstrated
    favorable safety profile; advancing towards clinical trials</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LMP</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alzheimer&#8217;s
    disease</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Targets
    neuroinflammation, neurotransmitter imbalance, and inflammasome-3</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bioequivalence
    to IGC-AD1 anticipated in 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IGC-M3</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Early-stage
    Alzheimer&#8217;s disease</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inhibits
    A&#946; plaque aggregation</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Toxicology
    studies planned for mid-2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IGC-1C</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alzheimer&#8217;s
    disease and metabolic disorders</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Targets
    tau protein phase separation; potential GLP-1 receptor agonist</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits
    strong binding affinity to tau protein; potential for weight loss applications</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IGC-1A</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Metabolic
    disorders (e.g., type 2 diabetes, obesity)</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
    GLP-1 and GIP receptor agonist; CB1 receptor inverse agonist</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identified
    through AI modeling; toxicology and dosing studies underway</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
pipeline reflects IGC Pharma&#8217;s strategic focus on addressing neurodegenerative diseases, particularly Alzheimer&#8217;s, through
innovative mechanisms targeting key pathological features like amyloid plaques and tau protein aggregation. Additionally, their expansion
into metabolic disorders showcases the versatility of their drug discovery platform, leveraging artificial intelligence to identify promising
therapeutic candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, the Company had the following operating subsidiaries: Techni Bharathi Private Limited (TBL), HH Processors, LLC, IGCare
LLC, Sunday Seltzer LLC, IGC Pharma IP, LLC, IGC Pharma, LLC, SAN Holdings, LLC, Hamsa Biopharma India Pvt. Ltd. And Colombia-based beneficially-owned
subsidiary IGC Pharma SAS. The Company&#8217;s fiscal year is the 52- or 53-week period that ends on March 31. The Company&#8217; principal
office is in Maryland established in 2005. Additionally, the Company has offices in Washington state, Colombia, South America, and India.
The Company&#8217;s filings are available on www.sec.gov.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal 2025, the Company reassessed its reportable segment structure in connection with its strategic realignment toward Life Sciences.
As a result, management determined that the Company operates as a <b>single reportable segment</b>, focused on the vision to make the
world free from Alzheimer&#8217;s. Historically, the Company reported two operating segments: Life Sciences and Infrastructure. While
the Infrastructure segment generated revenues in fiscal 2024, it did not generate any revenues in fiscal 2025 and is no longer actively
managed or evaluated as a discrete operating segment by the Company&#8217;s Chief Operating Decision Maker. For more information, please
refer to &#8220;Note 18 &#8211; Segment Information&#8221;.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-8432"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2</b> &#8211; <b>SIGNIFICANT ACCOUNTING POLICIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" id="ixv-8439"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a)
Principles of consolidation</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ConsolidationPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of the Company and all its subsidiaries. Intercompany accounts and transactions
have been eliminated. In the opinion of the Company&#8217;s management, the consolidated financial statements reflect all adjustments,
which are normal and recurring in nature, necessary for fair financial statement presentation. Transactions between the Company and its
subsidiaries are eliminated in the consolidated financial statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-8450"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b)
Use of estimates</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_UseOfEstimates-c0_cont_2" id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with accounting principles generally accepted in the U.S. (U.S. GAAP) requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual
results could differ from those estimates.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_UseOfEstimates-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
believes that the estimates and assumptions used in the preparation of the consolidated financial statements are prudent and reasonable.
Significant estimates and assumptions are generally used for, but not limited to, allowance for uncollectible accounts receivable; sales
returns; normal loss during production; future obligations under employee benefit plans; the useful lives of property, plant, and equipment;
intangible assets; valuations; impairment of goodwill and investments; recoverability of advances; the valuation of options granted,
and warrants issued; and income tax and deferred tax valuation allowances, if any. Actual results could differ from those estimates.
Appropriate changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. Critical
accounting estimates could change from period to period and could have a material impact on IGC&#8217;s results, operations, financial
position, and cash flows. Changes in estimates are reflected in the financial statements in the period in which changes are made, and
if material, their effects are disclosed in the notes to the consolidated financial statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="ixv-8466"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c)
Revenue recognition</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue under ASC 606, <i>Revenue from Contracts with Customers </i>(ASC 606). The core principle of this standard
is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects
the consideration to which the Company expects to be entitled in exchange for those goods or services.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_3" id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
606 prescribes a 5-step process to achieve its core principle. The Company recognizes revenue from trading, rental, or product sales
as follows:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_4" id="_RevenueRecognitionPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.
Identify the contract with the customer.</span></p></ix:continuation>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_5" id="_RevenueRecognitionPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.
Identify the contractual performance obligations.</span></p></ix:continuation>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_6" id="_RevenueRecognitionPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">III.
Determine the amount of consideration/price for the transaction.</span></p></ix:continuation>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_7" id="_RevenueRecognitionPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IV.
Allocate the determined amount of consideration/price to the contractual obligations.</span></p></ix:continuation>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_8" id="_RevenueRecognitionPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">V.
Recognize revenue when or as the performing party satisfies performance obligations.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consideration/price for the transaction (performance obligation(s)) is determined as per the agreement or invoice (contract) for the
services and products. Refer to Note 17 &#8211; &#8220;Revenue Recognition.&#8221;</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CostOfSalesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CostOfSalesPolicyTextBlock" id="ixv-8505"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>d)
Cost of Revenue</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_CostOfSalesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cost of revenue includes costs associated with in-house and outsourced distribution, labor expenses, components, manufacturing overhead,
and outbound freight for our products division. In our products division, the cost of revenue also includes the cost of refurbishing
or repackaging, if required, on products returned by customers that will be offered for resale.</span></p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-8533"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>e)
Loss per Share</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
computation of basic loss per share for Fiscal 2025 excludes potentially dilutive securities of approximately shares, which includes
share options, unvested shares such as restricted shares and restricted share units granted to employees, non-employees, and advisors,
and shares from the conversion of outstanding units, if any, because their inclusion would be anti-dilutive.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average number of shares outstanding for Fiscal 2025 and 2024, used for the computation of basic earnings per share (EPS) is
<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-14991">76,517,175</ix:nonFraction> and <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-14992">58,839,868</ix:nonFraction>, respectively. Due to the loss incurred during Fiscal 2025 and 2024, all the potential equity shares are anti-dilutive,
and accordingly, the fully diluted EPS is equal to the basic EPS.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="igc_GoingConcernPolicyPolicyTextblock-c0_cont_1" escape="true" name="igc:GoingConcernPolicyPolicyTextblock" id="ixv-8549"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f)
Going Concern:</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="igc_GoingConcernPolicyPolicyTextblock-c0_cont_2" id="igc_GoingConcernPolicyPolicyTextblock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses and determines its ability to continue as a going concern in accordance with the provisions of ASC Subtopic 205-40,
&#8220;<i>Presentation of Financial Statements</i>&#8212;<i>Going Concern</i>&#8221;, which requires the Company to evaluate whether there
are conditions or events that raise substantial doubt about its ability to continue as a going concern.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="igc_GoingConcernPolicyPolicyTextblock-c0_cont_3" id="igc_GoingConcernPolicyPolicyTextblock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is currently in a clinical trial stage and, thus, has not yet achieved profitability. The Company expects to continue to incur
significant operating and net losses and negative cash flows from operations in the near future.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="igc_GoingConcernPolicyPolicyTextblock-c0_cont_4" id="igc_GoingConcernPolicyPolicyTextblock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended March 31, 2025, and March 31, 2024, the Company incurred net losses of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" sign="-" unitRef="usd" id="ixv-14993">7.1</ix:nonFraction> million and $<ix:nonFraction contextRef="c5" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" sign="-" unitRef="usd" id="ixv-14994">13</ix:nonFraction> million, respectively. During
fiscal 2025, the Company renewed the facility with O-bank. In addition, the Company raised approximately $<ix:nonFraction contextRef="c27" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" unitRef="shares" id="ixv-14995">4.64</ix:nonFraction> million through private
placements and an at-the-market offering program. The at-the-market program and the credit facility serve to minimize ongoing liquidity
requirements and ensure the Company&#8217;s ability to sustain its operations. The Company has taken several steps to extend its operational
runway, including narrowing its strategic focus to Life Sciences, limiting investment in non-core infrastructure operations, and managing
expenses related to clinical development with a disciplined approach. While management believes these actions improve the Company&#8217;s
financial position, there can be no assurance that additional financing will be available on acceptable terms, or at all.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="igc_GoingConcernPolicyPolicyTextblock-c0_cont_5" id="igc_GoingConcernPolicyPolicyTextblock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
first quarter of Fiscal 2026, the Company entered into the 2025 Share Purchase Agreement with multiple investors, relating to the sale
and issuance by our company to the investors of an aggregate of <ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-14996">2,803,333</ix:nonFraction> shares of our common stock, for a total purchase price of $<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-14997">841,000</ix:nonFraction>,
or $<ix:nonFraction contextRef="c29" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-14998">0.30</ix:nonFraction> per share, subject to the terms and conditions set forth in the 2025 SPA. The investment is subject to customary closing conditions,
including NYSE approval. As per the 2025 SPA, the investor received piggyback registration rights subject to certain restrictions.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="igc_GoingConcernPolicyPolicyTextblock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates that its current cash and cash equivalents balance, with the working capital and investments, and with an available
overdraft facility of $12 million from O-Bank, is sufficient to support operations beyond the twelve months following the date these
consolidated financial statements and footnotes were issued. These estimates are based on assumptions that may prove to be wrong, and
the Company could use its available capital resources sooner than it currently expects.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-8582"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>g)
Income taxes</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes under the asset and liability method, in accordance with ASC 740, Income Taxes, which requires an entity
to recognize deferred tax liabilities and assets. Deferred tax assets and liabilities are recognized for the future tax consequence attributable
to the differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases and operating
loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using the enacted tax rate expected to apply to
taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax
assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance
is established and recorded when management determines that some or all of the deferred tax assets are not likely to be realized and,
therefore, it is necessary to reduce deferred tax assets to the amount expected to be realized.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_3" id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
evaluating a tax position for recognition, management evaluates whether it is more-likely-than-not that a position will be sustained
upon examination, including the resolution of related appeals or litigation processes, based on the technical merits of the position.
If the tax position meets the more-likely-than-not recognition threshold, the tax position is measured and recognized in the Company&#8217;s
financial statements as the largest amount of tax benefit that, in management&#8217;s judgment, is greater than 50% likely to be realized
upon settlement. As of March 31, 2025, and 2024, there was no significant liability for income tax associated with unrecognized tax benefits.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the last quarter of fiscal 2025, the Company received a tax credit of approximately $<ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="3" unitRef="usd" id="ixv-14999">194</ix:nonFraction> thousand, which has been recorded as other income
in the accompanying consolidated statements of operations. The credit relates to qualifying expenditures under applicable federal tax
incentive programs. The Company has submitted additional claims and expects to receive approximately $<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="3" unitRef="usd" id="ixv-15000">600</ix:nonFraction> thousand in tax credits during
fiscal 2026. However, there can be no assurance as to the timing or certainty of receipt, as the claims are subject to review and approval
by the Internal Revenue Service (IRS). The Company will recognize any additional credits as income when collection is deemed probable
in accordance with applicable accounting standards.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="ixv-8620"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>h)
Accounts receivable</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
make estimates of the collectability of our accounts receivable by analyzing historical payment patterns, customer concentrations, customer
creditworthiness, and current economic trends. If the financial condition of a customer deteriorates, additional allowances may be required.
We had $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="3" unitRef="usd" id="ixv-15001">34</ix:nonFraction> thousand of accounts receivable, net of provision for doubtful debt of $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" unitRef="usd" id="ixv-15002">12</ix:nonFraction> thousand as of March 31, 2025, as compared to $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="3" unitRef="usd" id="ixv-15003">39</ix:nonFraction>
thousand of accounts receivable, net of provision for doubtful debt of $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" unitRef="usd" id="ixv-15004">24</ix:nonFraction> thousand as of March 31, 2024.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-8631"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>i)
Cash and cash equivalents</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
financial statement purposes, the Company considers all highly liquid debt instruments with a maturity of three months or less to be
cash equivalents. The Company maintains its cash in bank accounts in the U.S., India, and Colombia, which at times may exceed applicable
insurance limits. The cash and cash equivalents of the Company on March 31, 2025, and 2024 were approximately $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-15005">405</ix:nonFraction> thousand and $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" unitRef="usd" id="ixv-15006">1.2</ix:nonFraction>
million, respectively. The company&#8217;s cash balance also includes approximately $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="3" unitRef="usd" id="ixv-15007">8</ix:nonFraction> thousand in restricted cash.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_InvestmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InvestmentPolicyTextBlock" id="ixv-8642"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>j)
Short-term and long-term investments</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_InvestmentPolicyTextBlock-c0_cont_2" id="_InvestmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
policy for short-term and long-term investments is to establish a high-quality portfolio that preserves principal, meets liquidity needs,
avoids inappropriate concentrations, and delivers an appropriate yield in relation to our investment guidelines and market conditions.
Short-term and long-term investments consist of corporate, various government agencies, and municipal debt securities, as well as certificates
of deposit that have maturity dates that are greater than 90 days. Certificates of deposit and commercial paper are carried at a cost
that approximates fair value. Available-for-sale securities: Investments in debt securities that are classified as available for sale
shall be measured subsequently at fair value in the statement of financial position.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_InvestmentPolicyTextBlock-c0_cont_3" id="_InvestmentPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments
are initially measured at cost, which is the fair value of the consideration given for them, including transaction costs. Where the Company&#8217;s
ownership interest is in excess of 20% and the Company has a significant influence, the Company has accounted for the investment based
on the equity method in accordance with ASC Topic 323, &#8220;<i>Investments </i>&#8211; <i>Equity method and Joint Ventures.</i>&#8221;
Under the equity method, the Company&#8217;s share of the post-acquisition profits or losses of the equity investee is recognized in
the consolidated statements of operations, and its share of post-acquisition movements in accumulated other comprehensive income / (loss)
is recognized in other comprehensive income / (loss). Where the Company does not have significant influence, the Company has accounted
for the investment in accordance with ASC Topic 321, &#8220;<i>Investments-Equity Securities.</i>&#8221;</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_InvestmentPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, had no marketable investments.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-8683"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>k)
Property, plant, and equipment (PP&amp;E) </b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PP&amp;E
are recorded at cost net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful
lives of the assets, which are reviewed periodically to ensure consistency with expected economic benefits. Depreciation begins when
the asset is available for use and continues until the asset is retired or fully depreciated.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
retirement or disposition, cost and related accumulated depreciation of the PP&amp;E are de-recognized, and any gain or loss is reflected
in the results of the operation. The cost of additions and substantial improvements to property and equipment are capitalized. The cost
of maintenance and repairs of the property and equipment are charged to operating expenses as incurred. Please refer &#8220;Note 6 &#8211;
Property, Plant, and Equipment&#8221; for more information.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-8699"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>l)
Fair value of financial instruments</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
820, &#8220;Fair Value Measurement&#8221; defines fair value as the exchange price that would be received for an asset or paid to transfer
a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between
market participants on the measurement date. It also establishes a three-tier fair value hierarchy, which prioritizes the inputs used
in measuring fair value as follows:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Observable inputs such as quoted prices in active markets;</span></p></ix:continuation>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></p></ix:continuation>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable,
and accrued liabilities, approximately their fair values due to the nature of the items. Please refer to Note 15, &#8220;Fair value of
financial instruments,&#8221; for further information.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-8726"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>m)
Concentration of credit risk and significant customers</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments, which potentially expose the Company to concentrations of credit risk, are primarily comprised of cash and cash equivalents,
investments, accounts receivable, and unbilled accounts receivable, if any. The Company places its cash investments in highly rated financial
institutions. The Company adheres to a formal investment policy with the primary objective of preservation of principal, which contains
credit rating minimums and diversification requirements. Management believes its credit policies reflect normal industry terms and business
risk. The Company does not anticipate non-performance by the counterparties and, accordingly, does not require collateral. During Fiscal
2025, sales were spread across customers in Asia and U.S., and the credit concentration risk is low.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-8737"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>n)
Stock </b>&#8211; <b>Based Compensation</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation to employees and non-employees in conformity with the provisions of ASC Topic 718, &#8220;<i>Stock-Based
Compensation.</i>&#8221; The Company expenses stock-based compensation to employees over the requisite vesting period based on the estimated
grant-date fair value of the awards. The Company accounts for forfeitures as they occur. Stock-based awards are recognized on a straight-line
basis over the requisite vesting period. For stock-based employee compensation, the cost recognized at any date will be at least equal
to the amount attributable to the share-based compensation that is vested at that date.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
performance-based awards, stock-based compensation expense is recognized over the expected performance achievement period of individual
performance milestones when the achievement of each individual performance milestone becomes probable. For performance-based awards with
a vesting schedule based entirely on the attainment of performance conditions, stock-based compensation expense associated with each
tranche is recognized over the expected achievement period for the operational milestone, beginning at the point in time when the relevant
operational milestone is considered probable to be achieved.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
market-based awards, stock-based compensation expense is recognized over the expected achievement period. The fair value of such awards
is estimated on the grant date using Monte Carlo simulations.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates the fair value of stock option grants using the Black-Scholes option-pricing model. The assumptions used in calculating
the fair value of stock-based awards represent Management&#8217;s best estimates. Generally, the closing share price of the Company&#8217;s
common stock on the date of grant is considered the fair value of the share. The volatility factor is determined based on the Company&#8217;s
historical stock prices. The expected term represents the period that our stock-based awards are expected to be outstanding. The Company
has never declared or paid any cash dividends. For further information, refer to Note 14, &#8220;Stock-Based Compensation&#8221; of Notes
to Consolidated Financial Statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="ixv-8782"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>o)
Commitments and contingencies</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities
for loss contingencies arising from claims, assessments, litigations, fines and penalties, and other sources are recorded when it is
probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. We record
associated legal fees as incurred. Information regarding our commitments and contingencies is incorporated by reference in Note 12, &#8220;Commitments
and contingencies&#8221; of this Annual Report on Form 10-K.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="ixv-8793"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>p)
Impairment of long </b>&#8211; <b>lived assets</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews its long-lived assets, with finite lives, for impairment whenever events or changes in business circumstances indicate
that the carrying amount of assets may not be fully recoverable. Such circumstances include, though are not limited to, significant or
sustained declines in revenues or earnings, future anticipated cash flows, business plans, and material adverse changes in the economic
climate, such as changes in the operating environment, competitive information, and the impact of changes in government policies. For
assets that the Company intends to hold for use, if the total of the expected future undiscounted cash flows produced by the assets or
subsidiary company is less than the carrying amount of the assets, a loss is recognized for the difference between the fair value and
carrying value of the assets. For assets, the Company intends to dispose of by sale, a loss is recognized for the amount by which the
estimated fair value less cost to sell is less than the carrying value of the assets. Fair value is determined based on quoted market
prices, if available, or other valuation techniques, including discounted future net cash flows. Unlike goodwill, long-lived assets are
assessed for impairment only where there are any specific indicators for impairment.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_1" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="ixv-8805"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>q)
Intangible assets</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_2" id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s intangible assets are accounted for in accordance with ASC Topic 350, <i>Intangibles </i>&#8211; <i>Goodwill and Other.
</i>Intangible assets having indefinite lives are not amortized, but instead are reviewed annually or more frequently if events or changes
in circumstances indicate that the assets might be impaired, to assess whether their fair value exceeds their carrying value. We perform
an impairment analysis on March 1 annually on the indefinite-lived intangible assets following the steps laid out in ASC 350-30-35-18.
Our annual impairment analysis includes a qualitative assessment to determine if it is necessary to perform the quantitative impairment
test. In performing a qualitative assessment, we review events and circumstances that could affect the significant inputs used to determine
if the fair value is less than the carrying value of the intangible assets. If quantitative analysis is necessary, we would analyze various
aspects including revenues from the business, associated with the intangible assets. In addition, intangible assets will be tested on
an interim basis if an event or circumstance indicates that it is more likely than not that an impairment loss has been incurred. The
Company has analyzed a variety of factors on its business to determine if a circumstance could trigger an impairment loss, and, at this
time and based on the information presently known, does not believe it is more likely than not that an impairment loss has been incurred.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_3" id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets with finite useful lives are amortized using the straight-line method over their estimated period of benefit. In accordance with
ASC 360-10-35-21, definite lived intangibles are reviewed annually or more frequently if events or changes in circumstances indicate
that the assets might be impaired, to assess whether their fair value exceeds their carrying value.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to capitalize trademarks and related expenses exceeding $2,500 per trademark. Management may also capitalize trademarks
and related expenses up to $2,500 per trademark based on its potential and benefit in coming years.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" id="ixv-8845"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>r)
Software Development Costs</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock-c0_cont_2" id="_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is developing two proprietary software platforms intended to be commercialized:-</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock-c0_cont_3" id="_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
A <b>clinical data management platform</b> designed for the collection, analysis, and real-time monitoring of clinical trial data; and</span></p></ix:continuation>

<ix:continuation continuedAt="_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock-c0_cont_4" id="_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
An <b>MINT- AD - AI-driven diagnostic and treatment personalization platform</b> aimed at assisting in the early detection of Alzheimer&#8217;s
disease and providing data-informed therapeutic suggestions.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock-c0_cont_5" id="_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with <b>ASC 985-20</b>, <i>Software to Be Sold, Leased, or Marketed</i>, the Company capitalizes development costs incurred
after technological feasibility has been established and before the software is available for general release. Costs incurred during
the research, planning, or preliminary design phase are expensed as incurred.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock-c0_cont_6" id="_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized
costs include direct labor, third-party development services, cloud computing infrastructure directly related to model development and
deployment, and associated overhead. These costs are amortized on a straight-line basis over their estimated useful lives, typically
<b><ix:nonNumeric contextRef="c32" continuedAt="_PropertyPlantAndEquipmentUsefulLife-c32_cont_1" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-15008">five</ix:nonNumeric> to <ix:nonNumeric contextRef="c33" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-15009">ten<ix:continuation id="_PropertyPlantAndEquipmentUsefulLife-c32_cont_1"> years</ix:continuation></ix:nonNumeric></b>, beginning when the software is ready for its intended commercial use.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
Fiscal 2024, the Company began working on overlaying machine learning technologies and AI into the internal clinical trial software framework
for trial management with the expectation that this can lead to improved decision-making, contextual data entry, computational models,
trial design (Phase 3), and data analysis, the company believes it is probable that the project will be completed and the software will
be used to perform the function intended. As of Fiscal 2025, the Company capitalized approximately $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalizedComputerSoftwareGross" scale="3" unitRef="usd" id="ixv-15011">863</ix:nonFraction> thousand in software development
costs. For more information, please refer to Note 5, &#8220;Intangible Assets&#8221;.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock" id="ixv-8884"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>s)
Inventory</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_InventoryPolicyTextBlock-c0_cont_2" id="_InventoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
is valued at the lower of cost or net realizable value, which is defined as estimated selling prices in the ordinary course of business,
less reasonably predictable costs of completion, disposal, and transportation.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_InventoryPolicyTextBlock-c0_cont_3" id="_InventoryPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
consists of finished goods related to wellness products, hand sanitizers, finished hemp-based products, beverages. Work-and in-progress
consist of products in the manufacturing process as on reporting date, including but not limited to primary cost. Inventory is primarily
accounted for using the weighted average cost method. Primary costs include raw materials, packaging, direct labor, overhead, shipping,
and the depreciation of manufacturing equipment. Manufacturing overhead and related expenses include salaries, wages, employee benefits,
utilities, maintenance, and property taxes.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_InventoryPolicyTextBlock-c0_cont_4" id="_InventoryPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
capitalize inventory costs related to our investigational drug, provided that management determines there is a potential alternative
use for the inventory in future research and development projects or other purposes. As of March 31, 2025, and 2024, our consolidated
balance sheet reported approximately $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd" id="ixv-15012"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd" id="ixv-15013">392</ix:nonFraction></ix:nonFraction> thousand of clinical trial-related inventory, respectively.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_InventoryPolicyTextBlock-c0_cont_5" id="_InventoryPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abnormal
amounts of idle facility expense, freight, handling costs, scrap, discontinued products, and wasted material (spoilage) are expensed
in the period they are incurred.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_InventoryPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
refer to Note 3, &#8220;Inventory,&#8221; for further information.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" continuedAt="igc_CybersecurityPolicyPolicyTextBlock-c0_cont_1" escape="true" name="igc:CybersecurityPolicyPolicyTextBlock" id="ixv-8932"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>t)
Cybersecurity Costs</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="igc_CybersecurityPolicyPolicyTextBlock-c0_cont_2" id="igc_CybersecurityPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains information technology systems and security protocols designed to protect sensitive clinical, corporate, and financial
data. Costs incurred in connection with the ongoing maintenance, enhancement, and monitoring of cybersecurity infrastructure are expensed
as incurred and classified within general and administrative expenses.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="igc_CybersecurityPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews cybersecurity risks on an ongoing basis and implements technical and administrative controls in line with applicable
data protection standards. As of March 31, 2025, the Company had not capitalized any cybersecurity-related development costs, and no
material cybersecurity incidents have been identified.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-8948"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>u)
Research and Development Expenses</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_2" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development (R&amp;D) expenses include costs incurred to develop the Company&#8217;s clinical-stage drug candidates, including IGC-AD1
and other investigational therapies. These costs consist primarily of:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_3" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
                                            trial site payments</span></td></tr></table></ix:continuation>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_4" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract
                                            research organization (CRO) fees</span></td></tr></table></ix:continuation>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_5" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
                                            compensation for R&amp;D personnel</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>

<tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
                                            and medical affairs consulting</span></td></tr></table></ix:continuation>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_6" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_5"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laboratory
                                            supplies and materials</span></td></tr></table></ix:continuation>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_7" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_6"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
                                            studies and formulation development</span></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D
expenses are expensed as incurred in accordance with ASC 730. Non-refundable advance payments for goods or services that will be used
in future R&amp;D activities are deferred and recognized as the related goods or services are received. During Fiscal 2025 and 2024,
the Company recorded research and development expenses of approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" unitRef="usd" id="ixv-15014">3.7</ix:nonFraction> million and $<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" unitRef="usd" id="ixv-15015">3.8</ix:nonFraction> million, respectively.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-9020"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>v)
Leases</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lessor
Accounting</i></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_3" id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the current ASU guidance, contract consideration will be allocated to its lease components and non-lease components (such as maintenance).
For the Company as a lessor, any non-lease components will be accounted for under ASC Topic 606, &#8220;<i>Revenue from Contracts with
Customers,</i>&#8221; unless the Company elects a lessor practical expedient to not separate the non-lease components from the associated
lease component. The amendments in ASU 2018-11 also provide lessors with a practical expedient, by class of underlying asset, to not
separate non-lease components from the associated lease component and, instead, to account for those components as a single component
if the non-lease components otherwise would be accounted for under the new revenue guidance (Topic 606). To elect the practical expedient,
the timing and pattern of transfer of the lease and non-lease components must be the same and the lease component must meet the criteria
to be classified as an operating lease if accounted for separately. If these criteria are met, the single component will be accounted
for under either Topic 842 or Topic 606 depending on which component(s) are predominant. The lessor practical expedient to not separate
non-lease components from the associated component must be elected for all existing and new leases.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_4" id="_LesseeLeasesPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a lessor, the Company expects that post-adoption substantially all existing leases will have no change in the timing of revenue recognition
until their expiration or termination. The Company expects to elect the lessor practical expedient to not separate non-lease components
such as maintenance from the associated lease for all existing and new leases and to account for the combined component as a single lease
component. The timing of revenue recognition is expected to be the same for the majority of the Company&#8217;s new leases as compared
to similar existing leases; however, certain categories of new leases could have different revenue recognition patterns as compared to
similar existing leases.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_5" id="_LesseeLeasesPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
leases that are accounted for as operating leases, income is recognized on a straight-line basis over the term of the lease contract.
Generally, when a lease is more than 180 days delinquent (where more than three monthly payments are owed), the lease is classified as
being nonaccrual and the Company stops recognizing leasing income on that date. Payments received on leases in nonaccrual status generally
reduce the lease receivable. Leases on nonaccrual status remain classified as such until there is sustained payment performance that,
in the Company&#8217;s judgment, would indicate that all contractual amounts will be collected in full.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_6" id="_LesseeLeasesPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lessee
Accounting</i></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_7" id="_LesseeLeasesPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted ASU 2016-02 effective April 1, 2019, using the modified retrospective approach. The standard establishes a right-of-use
model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer
than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense
recognition in the income statement. In connection with the adoption, the Company will elect to utilize the modified retrospective presentation
whereby the Company will continue to present prior period financial statements and disclosures under ASC Topic 840. In addition, the
Company will elect the transition package of three practical expedients permitted within the standard, which eliminates the requirements
to reassess prior conclusions about lease identification, lease classification and initial direct costs. Further, the Company will adopt
a short-term lease exception policy, permitting us to not apply the recognition requirements of this standard to short-term leases (i.e.,
leases with terms of 12 months or less), and an accounting policy to account for lease and non-lease components as a single component
for certain classes of assets.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_8" id="_LesseeLeasesPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASU 2016-02 (Topic 842), lessees are required to recognize the following for all leases (with the exception of short-term leases) on
the commencement date: (i) lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured
on a discounted basis; and (ii) right-of-use asset, which is an asset that represents the lessee&#8217;s right to use, or control the
use of, a specified asset for the lease term.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_9" id="_LesseeLeasesPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the commencement date, the Company recognizes the lease liability at the present value of the lease payments not yet paid, discounted
using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company&#8217;s incremental borrowing
rate for the same term as the underlying lease. The right-of-use asset is recognized initially at cost, which primarily comprises the
initial amount of the lease liability, plus any initial direct costs incurred, consisting mainly of brokerage commissions, less any lease
incentives received. All right-of-use assets are reviewed for impairment. There was no impairment for right-of-use lease assets as of
March 31, 2025.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company categorizes leases at their inception as either operating or finance leases. On certain lease agreements, the Company may receive
rent holidays and other incentives. The Company recognizes lease costs on a straight-line basis without regard to deferred payment terms,
such as rent holidays, that defer the commencement date of required payments. Please refer to Note 9, &#8220;Leases,&#8221; for further
information.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-9091"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>w)
Recently issued and adopted accounting pronouncements</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
to U.S. GAAP are established by the Financial Accounting Standards Board (FASB) in the form of accounting standards updates (ASUs) to
the FASB&#8217;s Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. Newly issued ASUs
not listed are expected to have no impact on the Company&#8217;s consolidated financial position and results of operations because either
the ASU is not applicable or the impact is expected to be immaterial. Recent accounting pronouncements which may be applicable to us
are described in Note 2, &#8220;Significant Accounting Policies&#8221; in our Consolidated Financial Statements contained herein in Part
II, Item 8.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_InventoryDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryDisclosureTextBlock" id="ixv-9104"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 </b>&#8211; <b>INVENTORY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="ixv-9111"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center">(in thousands)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31, <br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="3" unitRef="usd" id="ixv-15016">1,104</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="3" unitRef="usd" id="ixv-15017">1,099</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Finished goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="3" unitRef="usd" id="ixv-15018">256</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="3" unitRef="usd" id="ixv-15019">441</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd" id="ixv-15020">1,360</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd" id="ixv-15021">1,540</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
Fiscal 2025, and Fiscal 2024, the Company wrote off approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="3" unitRef="usd" id="ixv-15022">217</ix:nonFraction> thousand and $<ix:nonFraction contextRef="c5" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="6" unitRef="usd" id="ixv-15023">1</ix:nonFraction> million of inventory due to abnormal loss, NRV
adjustment, product expiration, idle facility expense, freight, handling costs, scrap, and wasted material (spoilage). This charge was
recorded in Selling, General, and Administrative Expenses.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_InventoryDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
capitalize inventory costs related to our investigational drug, provided that management determines there is a potential alternative
use for the inventory in future research and development projects or other purposes. As of March 31, 2025, and March 31, 2024, our consolidated
balance sheet reported approximately $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd" id="ixv-15024"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd" id="ixv-15025">392</ix:nonFraction></ix:nonFraction> thousand of clinical trial-related inventory, respectively.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="igc:DepositsAndAdvancesTextBlock" id="ixv-9191"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 </b>&#8211; <b>DEPOSITS AND ADVANCES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="ixv-9198"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center">(in thousands)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
of <br/>
March 31,<br/>
2025<br/>
($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
of <br/>
March 31,<br/>
2024<br/>
($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Advances to suppliers and consultants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" unitRef="usd" id="ixv-15026">10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" unitRef="usd" id="ixv-15027">41</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Other receivables and deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherInventoryNetOfReserves" scale="3" unitRef="usd" id="ixv-15028">43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherInventoryNetOfReserves" scale="3" unitRef="usd" id="ixv-15029">52</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Prepaid expense and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-15030">342</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-15031">115</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-15032">395</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-15033">208</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Advances to suppliers and consultants primarily relate to advances to vendors. Prepaid expense and other current assets include approximately
$<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="igc:StatutoryAdvances" scale="3" unitRef="usd" id="ixv-15034">49</ix:nonFraction> thousand and approximately $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="igc:StatutoryAdvances" scale="3" unitRef="usd" id="ixv-15035">39</ix:nonFraction> thousand in statutory advances for Fiscal 2025 and Fiscal 2024, respectively.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="ixv-9273"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 </b>&#8211; <b>INTANGIBLE ASSETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="ixv-9280"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Amortized intangible assets</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center">(in thousands)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31, <br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-left: 0.25pt">Patents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" unitRef="usd" id="ixv-15036">530</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" unitRef="usd" id="ixv-15037">836</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Other intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" unitRef="usd" id="ixv-15038">34</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" unitRef="usd" id="ixv-15039">34</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" unitRef="usd" id="ixv-15040">205</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" unitRef="usd" id="ixv-15041">181</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Total amortized intangible assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" unitRef="usd" id="ixv-15042">359</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" unitRef="usd" id="ixv-15043">689</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; font-style: italic; text-align: left; padding-left: 0.25pt">Unamortized intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">Patents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" unitRef="usd" id="ixv-15044">630</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" unitRef="usd" id="ixv-15045">521</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Software development cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" unitRef="usd" id="ixv-15046">863</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" unitRef="usd" id="ixv-15047">406</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Total unamortized intangible assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" unitRef="usd" id="ixv-15048">1,493</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" unitRef="usd" id="ixv-15049">927</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt">Total intangible assets</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-15050">1,852</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-15051">1,616</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of intangible assets includes the cost of acquiring patent rights, supporting data, and the expense associated with filing various
patent applications in different countries along with granted patents. It also includes acquisition costs related to domains and licenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amortization of patent and patent rights with finite life is up to <ix:nonNumeric contextRef="c36" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-15052">20</ix:nonNumeric> years, commencing from the date of grant or acquisition. The note
reflects the abandonment and expiration of certain non-core patent applications that management determined no longer aligned with the
Company&#8217;s strategic focus or had limited commercial potential. The related assets were fully impaired and removed from the balance
sheet. The expense was recognized in the consolidated statements of operations as part of general and administrative expenses. The Company
continues to evaluate its intellectual property portfolio to ensure alignment with its long-term development and commercialization strategy.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="ixv-9411"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"><b>Estimated amortization expense</b></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><b>(in thousands)<br/>
 ($)</b></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0.25pt">For the year ended 2026</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" unitRef="usd" id="ixv-15053">55</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">For the year ended 2027</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" unitRef="usd" id="ixv-15054">60</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">For the year ended 2028</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" unitRef="usd" id="ixv-15055">66</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">For the year ended 2029</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" unitRef="usd" id="ixv-15056">73</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">For the year ended 2030</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" unitRef="usd" id="ixv-15057">80</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-9470"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 </b>&#8211; <b>PROPERTY, PLANT, AND EQUIPMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c45" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-9477"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="10" style="font-weight: bold; font-style: italic; text-align: center">(in thousands, except useful life)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Useful Life<br/> (years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31,<br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0.25pt">Buildings and facilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><ix:nonNumeric contextRef="c46" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-15058">25</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-15059">2,341</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-15060">2,303</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Plant and machinery</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c48" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-15061">5</ix:nonNumeric>-<ix:nonNumeric contextRef="c49" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-15062">20</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-15063">3,087</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-15064">3,334</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Computer equipment&#8217;s</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c52" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-15065">3</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-15066">187</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-15067">166</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Office equipment&#8217;s</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c54" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-15068">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c55" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-15069">5</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-15070">144</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-15071">140</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c58" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-15072">5</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-15073">96</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-15074">93</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Vehicles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c60" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-15075">5</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-15076">58</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-15077">101</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt; padding-left: 0.25pt">Total gross value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-15078">5,913</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-15079">6,137</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-15080">2,693</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-15081">2,442</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt">Total property, plant, and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-15082">3,220</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-15083">3,695</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depreciation expense in Fiscal 2025 and 2024 amounted to approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-15084">567</ix:nonFraction> thousand and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-15085">563</ix:nonFraction> thousand, respectively. During Fiscal 2025,
the Company focused on liquidating all non-operating assets to reduce costs and generate cash. For more information, please refer to
Note 18, &#8220;Segment Information,&#8221; for the non-current assets other than financial instruments held in the country of domicile
and foreign countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Asset
Held For Sale</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
Fiscal 2024, the Company focused on liquidating all non-operating assets to reduce costs and generate cash. As a result, the Company
impaired the land situated in Nagpur, India, by approximately $<ix:nonFraction contextRef="c44" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="6" unitRef="usd" id="ixv-15086">3.3</ix:nonFraction>&#160;million to $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LandAvailableForSale" scale="3" unitRef="usd" id="ixv-15087">720</ix:nonFraction>&#160;thousand from $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Land" scale="6" unitRef="usd" id="ixv-15088">4.1</ix:nonFraction>&#160;million to bring
it closer to the fair market value. The Company believes it can sell the above-said non-operating land as it is without any improvement.
Selling this land will give immediate cash, which the Company can use in its operating segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
Fiscal 2025, the Company entered into an agreement with the buyer to sell the said land for a net realizable value of approximately $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LandAvailableForSale" scale="3" unitRef="usd" id="ixv-15089">702</ix:nonFraction>&#160;thousand.
The agreement is subject to the final registration and execution. The Company received a net of approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDepositsOnRealEstateSales" scale="3" unitRef="usd" id="ixv-15090">580</ix:nonFraction>&#160;thousand as a
deposit. The Company holds the ownership and possession of the said land. For further information, please refer to Note 19- &#8220;Subsequent
Events&#8221;.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 </b>&#8211; <b>LEFT BLANK INTENTIONALLY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherAssetsDisclosureTextBlock" id="ixv-9660"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 </b>&#8211; <b>CLAIMS AND ADVANCES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock" id="ixv-9667"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31,<br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Claims receivable (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:OtherReceivables" scale="3" unitRef="usd">680</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:OtherReceivables" scale="3" unitRef="usd">686</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Non-current deposits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="igc:OtherAdvances" scale="3" unitRef="usd" id="ixv-15093">1</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="igc:OtherAdvances" scale="3" unitRef="usd" id="ixv-15094">2</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25pt"><b>Total</b></td><td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-15095">681</ix:nonFraction></b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-15096">688</ix:nonFraction></b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
claims receivable is due from different vendors. While the Company has initiated collection proceedings internally or with the appropriate
authorities, it believes receiving the amount in the next 12 months will be challenging because of the time required for collection proceedings.</span></ix:footnote></td>
</tr></table></ix:nonNumeric></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-9755"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 </b>&#8211; <b>LEASES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has short-term leases primarily consisting of space with the remaining lease term being less than or equal to 12 months. The
Company has one short-term lease as of March 31, 2025. The total short-term lease expense and cash paid for Fiscal 2025 and 2024 are
approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="3" unitRef="usd" id="ixv-15097">39</ix:nonFraction> thousand and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="3" unitRef="usd" id="ixv-15098">100</ix:nonFraction> thousand, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has operating leases primarily consisting of spaces with the lease term being more than or equal to 12 months. The Company has
two operating leases as of March 31, 2025. The total operating leases expense and cash paid for Fiscal 2025 and 2024 are approximately
$<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd" id="ixv-15099">135</ix:nonFraction> thousand and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd" id="ixv-15100">141</ix:nonFraction> thousand, respectively.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_LeaseCostTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LeaseCostTableTextBlock" id="ixv-9769"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">(in thousands) <br/> Year Ended <br/> March 31, <br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">(in thousands) <br/> Year Ended <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Operating lease costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd" id="ixv-15101">135</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd" id="ixv-15102">141</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Short term lease costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="3" unitRef="usd" id="ixv-15103">39</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="3" unitRef="usd" id="ixv-15104">100</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt">Total lease costs</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd" id="ixv-15105">174</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd" id="ixv-15106">241</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
of use assets and lease liabilities for our operating leases were recorded in the consolidated balance sheet as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_LeaseCostTableTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended<br/> March 31, <br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Operating lease asset</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-15107">98</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-15108">198</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"><b>Total lease assets</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-15109">98</ix:nonFraction></b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-15110">198</ix:nonFraction></b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt"><b>Liabilities</b></td><td><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="text-align: left"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="text-align: left"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Accrued liabilities and others (current portion &#8211; operating lease liability)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">93</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">124</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Noncurrent liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Operating lease liability (non-current portion &#8211; operating lease liability)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-15111">10</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-15112">84</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"><b>Total lease liability</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-15113">103</ix:nonFraction></b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-15114">208</ix:nonFraction></b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">Supplemental cash flow and non-cash information related to leases is as follows:</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">(in thousands) <br/> Year Ended <br/> March 31, <br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">(in thousands) <br/> Year Ended<br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">&#8211;Operating cash flows from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd" id="ixv-15115">129</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd" id="ixv-15116">140</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Right-of-use assets obtained in exchange for operating lease obligations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-15117">98</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-15118">198</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-10023"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td colspan="5">As of March 31, 2025, the following table summarizes the maturity of our lease liabilities:</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; padding-left: 0.25pt">Mar-26</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-15119">96</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Mar-27</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd" id="ixv-15120">10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">Mar-28</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" unitRef="usd" id="ixv-15121">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Mar-29</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" unitRef="usd" id="ixv-15122">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Less: Present value discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-15123">3</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Total Lease liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-15124">103</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="igc:AccruedLiabilitiesDisclosureTextBlock" id="ixv-10086"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 </b>&#8211; <b>ACCRUED LIABILITIES AND OTHERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="ixv-10093"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31, <br/> 2025 <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Compensation and other contributions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-15125">160</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-15126">816</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Provision for expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-15127">117</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-15128">208</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Short-term lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-15129">94</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-15130">124</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Other current liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-15131">1,003</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-15132">419</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25pt"><b>Total</b></td><td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-15133">1,374</ix:nonFraction></b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-15134">1,567</ix:nonFraction></b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
and other contribution-related liabilities consist of accrued salaries to employees. In addition, provision for expenses includes provision
for legal, professional, and marketing expenses. Other current liability also includes statutory payables of approximately $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-15135">19</ix:nonFraction> thousand
and $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-15136">25</ix:nonFraction> thousand as of March 31, 2025, and March 31, 2024, respectively, and approximately $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="3" unitRef="usd" id="ixv-15137"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="3" unitRef="usd" id="ixv-15138">3</ix:nonFraction></ix:nonFraction> thousand of short-term loans as of March
31, 2025, and March 31, 2024, respectively. &#160;In addition, Other current liabilities for Fiscal 2025 consist of approximately $<ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDepositsOnRealEstateSales" scale="3" unitRef="usd" id="ixv-15139">580</ix:nonFraction>&#160;thousand
and $<ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDepositsOnRealEstateSales" scale="3" unitRef="usd" id="ixv-15140">46</ix:nonFraction> thousand related to asset held for sale and provision for a statutory liability, respectively. Please refer to Note 6 &#8211;
&#8220;Property, plant and, equipment&#8221;, for more information.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="igc:LoansAndOtherLiabilitiesTextBlock" id="ixv-10181"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 </b>&#8211; <b>LOANS AND OTHER LIABILITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Loan
as of March 31, 2025:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 11, 2020, the Company received an Economic Injury Disaster Loan (EIDL) for approximately $<ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" unitRef="usd" id="ixv-15141">150</ix:nonFraction> thousand at an annual interest rate
of <ix:nonFraction contextRef="c63" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-15142">3.75</ix:nonFraction>%. The Company must pay principal and interest payments of $<ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPayment" scale="3" unitRef="usd" id="ixv-15143">731</ix:nonFraction> every month beginning June 5, 2021. The SBA will apply each installment
payment first to pay interest accrued to the day SBA receives the payment and will then apply any remaining balance to reduce the principal.
All remaining principal and accrued interest are due and payable <ix:nonNumeric contextRef="c64" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-15144">30</ix:nonNumeric> years from the date of the loan. For Fiscal 2025, the interest expense
and principal payment for the EIDL were approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="3" unitRef="usd" id="ixv-15145">5</ix:nonFraction> thousand and $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="3" unitRef="usd" id="ixv-15146">3</ix:nonFraction> thousand, respectively. As of March 31, 2025, approximately
$<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermLoansPayable" scale="3" unitRef="usd" id="ixv-15147">134</ix:nonFraction> thousand of the loan is classified as Long-term loans and approximately $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableCurrent" scale="3" unitRef="usd" id="ixv-15148">3</ix:nonFraction> thousand as Short-term loans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" id="ixv-10197"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Liability:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center">(in thousands)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Statutory reserve</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" scale="3" unitRef="usd" id="ixv-15149">16</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" scale="3" unitRef="usd" id="ixv-15150">20</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" unitRef="usd" id="ixv-15151">16</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" unitRef="usd" id="ixv-15152">20</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
statutory reserve is a gratuity reserve for employees in our subsidiaries in India.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-10252"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12 </b>&#8211; <b>COMMITMENTS AND CONTINGENCIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may be involved in legal proceedings, claims, and assessments arising in the ordinary course of business. Such matters are subject
to many uncertainties, and outcomes are not predictable with assurance. There are no such matters that are deemed material to the consolidated
financial statements as of March 31, 2025, except as disclosed in Item 3 &#8211; Legal Proceedings and Note 19 &#8211; Subsequent Events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., we provide health insurance, life insurance, and a 401(k) plan wherein the Company matches up to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" unitRef="pure" id="ixv-15153">6</ix:nonFraction>% of the employee&#8217;s
pre-tax contribution up to a maximum annual amount determined by the IRS. In addition, under applicable Indian laws, the Company provides
for gratuity, a defined benefit retirement plan (Gratuity Plan) covering certain categories of employees. The Gratuity Plan provides
a lump sum payment to vested employees, at retirement or termination of employment, an amount based on the respective employee&#8217;s
last drawn salary and the years of employment with the Company. In addition, employees receive benefits from a provident fund, a defined
contribution plan. The employee and employer each make monthly contributions to the plan as required by the law. The contribution is
made to the Foreign Government&#8217;s funds.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-10283"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13 </b>&#8211; <b>SECURITIES </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, the Company was authorized to issue up to <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-15154">150,000,000</ix:nonFraction> shares of common stock, par value of $<ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-15155">0.0001</ix:nonFraction> per share, and
<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-15156"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-15157">80,878,058</ix:nonFraction></ix:nonFraction> shares of common stock were issued and outstanding. The Company is also authorized to issue up to <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-15158">1,000,000</ix:nonFraction> shares of preferred
stock, par value of $<ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-15159">0.0001</ix:nonFraction> per share, and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-15160"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-15161">no</ix:nonFraction></ix:nonFraction> preferred shares were issued and outstanding as of March 31, 2025. We have one security
listed on the NYSE American: common stock, $0.0001 par value (ticker symbol: IGC). This security also trades on the Frankfurt, Stuttgart,
and Berlin stock exchanges (ticker symbol: IGS1).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also has <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="igc:UnitsOutstanding" scale="0" unitRef="shares" id="ixv-15162">91,472</ix:nonFraction> units outstanding that can be separated into common stock. <ix:nonNumeric contextRef="c0" name="igc:UnitDescription" id="ixv-15163">Ten units may be separated into one share of common
stock.</ix:nonNumeric> The unit holders are requested to contact the Company or our transfer agent, Continental Stock Transfer &amp; Trust, to separate
their units into common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 22, 2024, the Company entered into a Share Purchase Agreement (the March 2024 SPA) with Bradbury Strategic Investment Fund A, resulting
in approximately $<ix:nonFraction contextRef="c65" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" unitRef="usd" id="ixv-15164">3</ix:nonFraction> million in gross proceeds. The completion of the private placement is subject to customary closing conditions, including
approval by the NYSE. Under the terms of the private placement, IGC will issue approximately <ix:nonFraction contextRef="c65" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" unitRef="shares" id="ixv-15165">8.8</ix:nonFraction> million shares of unregistered common
stock at a price of $<ix:nonFraction contextRef="c66" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-15166">0.34</ix:nonFraction> per share. In addition, the Company issued <ix:nonFraction contextRef="c65" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="6" unitRef="shares" id="ixv-15167">2</ix:nonFraction> million shares of unregistered common stock for consulting services
related to raising capital, including the March 2024 capital raised. Shares are intended to be exempt from registration under the Securities
Act of 1933, as amended (the Securities Act), by virtue of the provisions of Section 4(a)(2) of the Securities Act and Regulation D and/or
Regulation S adopted thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 25, 2024, the Company entered into the Share Purchase Agreement (the September 2024 SPA) with Moran Global Strategies, Inc.,
a Virginia corporation (MGS), which is owned by James Moran, a director of IGC, relating to the sale and issuance by our company to the
investors of an aggregate of <ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-15168">588,235</ix:nonFraction> shares of our common stock, for a total purchase price of $<ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-15169">200,000</ix:nonFraction> or $<ix:nonFraction contextRef="c68" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-15170">0.34</ix:nonFraction> per share, subject to
the terms and conditions set forth in the September 2024 SPA. The investment is subject to customary closing conditions, including NYSE
approval. As per the September 2024 SPA, the investor received piggyback registration rights subject to certain restrictions. During
the fiscal year ended March 31, 2025, the Company received the purchase price, and the issuance of common stock is in process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 27, 2023, the Company entered into a Sales Agreement (the Sales Agreement) with A.G.P./Alliance Global Partners (the Agent) pursuant
to which the Company may offer and sell, from time to time, through the Agent, as sales agent and/or principal, shares of its common
stock, having an aggregate offering price of up to $<ix:nonFraction contextRef="c69" decimals="-6" format="ixt:num-dot-decimal" name="igc:SalesAgreementMaximum" scale="6" unitRef="usd" id="ixv-15171">60</ix:nonFraction> million, subject to certain limitations on the amount of common stock that may
be offered and sold by the Company set forth in the Sales Agreement. During Fiscal 2025, the company raised approximately $<ix:nonFraction contextRef="c70" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" unitRef="usd" id="ixv-15172">1.8</ix:nonFraction> million
against <ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-15173">5,363,334</ix:nonFraction> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the first quarter of Fiscal 2026, the Company entered into Share Purchase Agreements with multiple investors (the 2025 Share Purchase
Agreements), relating to the sale and issuance by our company to the investors of an aggregate of <ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-15174">2,803,333</ix:nonFraction> shares of our common stock,
for a total purchase price of $<ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-15175">841,000</ix:nonFraction>, or $<ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-15176">0.30</ix:nonFraction> per share, subject to the terms and conditions set forth in the 2025 Share Purchase
Agreements. The investment is subject to customary closing conditions, including NYSE approval. As per the 2025 Share Purchase Agreements,
the investor received piggyback registration rights subject to certain restrictions.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-10316"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
14 </b>&#8211; <b>STOCK-BASED COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, under both the Company&#8217;s previous 2008 and current 2018 Omnibus Incentive Plans, approximately <ix:nonFraction contextRef="c73" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" unitRef="shares" id="ixv-15177">9.1</ix:nonFraction> million shares
of common stock have been issued to employees, non-employees, and advisors. In addition, <ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" scale="6" unitRef="shares" id="ixv-15178">7.3</ix:nonFraction> million restricted share units (RSUs) fair
valued at $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="6" unitRef="usd" id="ixv-15179">4.3</ix:nonFraction> million with a weighted average value of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="igc:WeightedAveragePricePerShare" scale="0" unitRef="usdPershares" id="ixv-15180">0.59</ix:nonFraction> per share, have been granted but not yet issued from different Incentive
Plans and Grants. This includes <ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="6" unitRef="shares" id="ixv-15181">4.7</ix:nonFraction> million RSUs granted to employees and directors, which consists of a vesting schedule based entirely
on the attainment of either operational milestones (performance conditions) or market conditions, assuming continued employment either
as an employee, or director with the Company. The performance-based RSUs are accounted for upon certification by the management, confirming
the probability of achievement of milestones. As of March 31, 2025, the management confirmed that five milestones had been achieved,
and the rest were probable to be achieved by March 31, 2028.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
options held by advisors and directors to purchase <ix:nonFraction contextRef="c74" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" unitRef="shares" id="ixv-15182">4</ix:nonFraction> million shares of common stock fair valued at $<ix:nonFraction contextRef="c74" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-15183">1</ix:nonFraction> million with a weighted average
of $<ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15184">0.26</ix:nonFraction> per share, which have been granted but are to be issued over a vesting period between Fiscal 2022 and Fiscal 2027. Options granted
and issued before the vesting period are expensed when issued.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-10348"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
options are fair valued using a Black-Scholes Pricing Model, and market-based RSU are valued based on a lattice model with the following
assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td colspan="2" style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Granted
in <br/>
Fiscal 2025</b></span></p></td> <td style="padding: 0.25pt 0.25pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td colspan="2" style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Granted
in <br/>
Fiscal 2024</b></span></p></td> <td style="padding: 0.25pt 0.25pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life of options</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td colspan="2" style="padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-15185">5</ix:nonNumeric> years</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td colspan="2" style="padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-15186">5</ix:nonNumeric> years</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding: 0.25pt; width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested options</span></td> <td style="width: 1%; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="width: 1%; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="width: 9%; padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" unitRef="pure" id="ixv-15187">100</ix:nonFraction></span></td> <td style="white-space: nowrap; width: 1%; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="width: 1%; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="width: 1%; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="width: 9%; padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" unitRef="pure" id="ixv-15188">100</ix:nonFraction></span></td> <td style="white-space: nowrap; width: 1%; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk free interest rate</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-15189">3.93</ix:nonFraction></span></td> <td style="white-space: nowrap; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-15190">5.24</ix:nonFraction></span></td> <td style="white-space: nowrap; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-15191">171</ix:nonFraction></span></td> <td style="white-space: nowrap; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-15192">175</ix:nonFraction></span></td> <td style="white-space: nowrap; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td colspan="2" style="padding: 0.25pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-2; font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td colspan="2" style="padding: 0.25pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-3; font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expense associated with share-based payments to employees, directors, advisors, and contractors is allocated over the vesting or service
period and recognized in the Selling, general, and administrative expenses (including research and development). For Fiscal 2025, the
Company&#8217;s share-based expense and option-based expense, shown in Selling, general, and administrative expenses (including research
and development), were $<ix:nonFraction contextRef="c75" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="6" unitRef="usd" id="ixv-15193">1</ix:nonFraction> million and $<ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" scale="3" unitRef="usd" id="ixv-15194">590</ix:nonFraction> thousand, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="ixv-10468"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Fiscal 2024, the Company&#8217;s share-based expenses and option-based expenses shown in Selling, general, and administrative expenses
(including research and development) were $<ix:nonFraction contextRef="c77" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="6" unitRef="usd" id="ixv-15195">1.7</ix:nonFraction> million and $<ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-15196">59</ix:nonFraction> thousand, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Non-vested shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares <br/> (in thousands)<br/> (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <br/> average<br/> grant date <br/> fair value<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-left: 0.25pt">Non-vested shares as of March 31, 2024 </td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" unitRef="shares" id="ixv-15197">7,452</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-15198">0.61</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Granted </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="3" unitRef="shares" id="ixv-15199">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-15200">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">Vested </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" unitRef="shares" id="ixv-15201">1,443</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-15202">0.34</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">Cancelled/Forfeited </td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" scale="3" unitRef="shares" id="ixv-15203">212</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-15204">0.33</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt"><b>Non-vested shares as of March 31, 2025</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" unitRef="shares" id="ixv-15205">5,796</ix:nonFraction></b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-15206">0.64</ix:nonFraction></b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-10549"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Options</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares <br/> (in thousands) <br/> (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<br/> average <br/> grant date <br/> fair value<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<br/> average <br/> exercise <br/> price<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-left: 0.25pt">Options outstanding as of March 31, 2024</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" unitRef="shares" id="ixv-15207">3,710</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-15208">0.25</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15209">0.39</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" unitRef="shares" id="ixv-15210">250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-15211">0.34</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15212">0.34</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="3" unitRef="shares" id="ixv-15213">628</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-15214">0.25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="igc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15215">0.25</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">Cancelled/forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" unitRef="shares" id="ixv-15216">150</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-15217">1.39</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15218">0.39</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt; padding-left: 0.25pt">Options outstanding as of March 31, 2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" unitRef="shares" id="ixv-15219">3,182</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-15220">0.30</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15221">0.34</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was a combined unrecognized expense of $<ix:nonFraction contextRef="c79" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" unitRef="usd" id="ixv-15222">1.7</ix:nonFraction> million related to non-vested shares and share options that the Company expects to be recognized
over a life of up to <ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-15223">4</ix:nonNumeric> (four) years.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_FairValueDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-10650"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
15 </b>&#8211; <b>FAIR VALUE OF FINANCIAL INSTRUMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, the Company&#8217;s marketable securities consist of liquid funds, which have been classified as Level 1 of the fair
value hierarchy because they have been valued using quoted prices in active markets. The Company&#8217;s cash and cash equivalents have
also been classified as Level 1 on the same principle. Financial instruments are classified as current if they are expected to be liquidated
within the next twelve months. The Company&#8217;s remaining investments have been classified as Level 3 instruments as there is little
or no market data. Level 3 investments are valued using the cost method. For further information refer Note 7, &#8220;Investments in
Non-Marketable Securities.&#8221;</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_FairValueDisclosuresTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="ixv-10678"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s assets that are measured at fair value on a recurring basis as of March
31, 2025, and 2024, and indicates the fair value hierarchy of the valuation techniques the Company used to determine such fair value:</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(in
thousands)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>As
of March 31, 2025</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_2" id="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Particular</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Adjusted<br/> Cost<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gain <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Loss<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Cash &amp;<br/> Cash <br/> Equivalents<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Short Term<br/> Investments <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><b>Level 1</b></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; padding-left: 0.25pt">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueAdjustment" scale="3" unitRef="usd" id="ixv-15224">368</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" scale="3" unitRef="usd" id="ixv-15225">&#160;&#160;&#160;-</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings" scale="3" unitRef="usd" id="ixv-15226">&#160;&#160;&#160;&#160;-</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15227">368</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15228">368</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15229">&#160;&#160;&#160;&#160;-</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Money Market Fund</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueAdjustment" scale="3" unitRef="usd" id="ixv-15230">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" scale="3" unitRef="usd" id="ixv-15231">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings" scale="3" unitRef="usd" id="ixv-15232">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c83" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15233">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c83" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15234">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c83" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15235">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Debt Funds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c84" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueAdjustment" scale="3" unitRef="usd" id="ixv-15236">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c84" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" scale="3" unitRef="usd" id="ixv-15237">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c84" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings" scale="3" unitRef="usd" id="ixv-15238">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c85" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15239">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c85" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15240">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c85" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15241">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">Mutual Fund</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c86" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueAdjustment" scale="3" unitRef="usd" id="ixv-15242">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c86" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" scale="3" unitRef="usd" id="ixv-15243">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c86" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings" scale="3" unitRef="usd" id="ixv-15244">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c87" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15245">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c87" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15246">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c87" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15247">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt"><b>Level 2</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">Certificates of Deposit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueAdjustment" scale="3" unitRef="usd" id="ixv-15248">37</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c88" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" scale="3" unitRef="usd" id="ixv-15249">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c88" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings" scale="3" unitRef="usd" id="ixv-15250">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c89" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15251">37</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c89" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15252">37</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c89" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15253">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt"><b>Level 3</b></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueAdjustment" scale="3" unitRef="usd" id="ixv-15254">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" scale="3" unitRef="usd" id="ixv-15255">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings" scale="3" unitRef="usd" id="ixv-15256">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c91" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15257">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c91" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15258">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c91" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15259">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25pt"><b>TOTAL</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueAdjustment" scale="3" unitRef="usd" id="ixv-15260">405</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" scale="3" unitRef="usd" id="ixv-15261">-</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings" scale="3" unitRef="usd" id="ixv-15262">-</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15263">405</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15264">405</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15265">-</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>As
of March 31, 2024</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_2"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Particular</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Adjusted<br/> Cost<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gain <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Loss<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Cash &amp; <br/> Cash<br/> Equivalents <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Short Term <br/> Investments<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Level 1</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; padding-left: 0.25pt">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueAdjustment" scale="3" unitRef="usd" id="ixv-15266">912</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c92" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" scale="3" unitRef="usd" id="ixv-15267">&#160;&#160;&#160;-</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c92" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings" scale="3" unitRef="usd" id="ixv-15268">&#160;&#160;&#160;&#160;-</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15269">912</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15270">912</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15271">&#160;&#160;&#160;&#160;&#160;-</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Money Market Fund</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c94" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueAdjustment" scale="3" unitRef="usd" id="ixv-15272">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c94" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" scale="3" unitRef="usd" id="ixv-15273">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c94" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings" scale="3" unitRef="usd" id="ixv-15274">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15275">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15276">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15277">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Debt Funds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueAdjustment" scale="3" unitRef="usd" id="ixv-15278">13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c96" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" scale="3" unitRef="usd" id="ixv-15279">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c96" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings" scale="3" unitRef="usd" id="ixv-15280">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15281">13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15282">13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c97" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15283">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">Mutual Fund</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueAdjustment" scale="3" unitRef="usd" id="ixv-15284">123</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c98" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" scale="3" unitRef="usd" id="ixv-15285">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c98" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings" scale="3" unitRef="usd" id="ixv-15286">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15287">123</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15288">123</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c99" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15289">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0.25pt">Level 2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">Certificates of Deposit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c100" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueAdjustment" scale="3" unitRef="usd" id="ixv-15290">150</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c100" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" scale="3" unitRef="usd" id="ixv-15291">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c100" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings" scale="3" unitRef="usd" id="ixv-15292">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15293">150</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15294">150</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c101" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15295">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt; padding-left: 0.25pt">Level 3</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c102" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueAdjustment" scale="3" unitRef="usd" id="ixv-15296">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c102" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" scale="3" unitRef="usd" id="ixv-15297">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c102" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings" scale="3" unitRef="usd" id="ixv-15298">-</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c103" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15299">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c103" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15300">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c103" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15301">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt">TOTAL</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueAdjustment" scale="3" unitRef="usd" id="ixv-15302">1,198</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" scale="3" unitRef="usd" id="ixv-15303">-</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings" scale="3" unitRef="usd" id="ixv-15304">-</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15305">1,198</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15306">1,198</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-15307">-</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-11227"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
16 </b>&#8211; <b>INCOME TAXES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company calculates its provision for foreign and U.S. federal income taxes based on the current tax law. As the Company maintains a full
valuation allowance against its deferred tax assets, there is no income tax expense recorded related to this change other than the Federal
AMT credit which are refundable due to the passage of tax reform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the Company&#8217;s history of losses and uncertainty of future taxable income, a valuation allowance sufficient to fully offset net
operating losses and other deferred tax assets has been established. The valuation allowance will be maintained until sufficient positive
evidence exists to support a conclusion that a valuation allowance is not necessary.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-11259"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense/(benefit) for each of the years ended March 31 consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended March 31,<br/>
 (in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Income Tax Expense</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Net income loss before tax</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-15308">7,121</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-15309">13,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Tax rate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-15310">21</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-15311">21</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Expected income tax recovery</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" sign="-" unitRef="usd" id="ixv-15312">1,495</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" sign="-" unitRef="usd" id="ixv-15313">2,730</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Impact of tax rate differences in foreign jurisdictions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" scale="3" unitRef="usd" id="ixv-15314">72</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" scale="3" unitRef="usd" id="ixv-15315">151</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Tax rate changes and other adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" sign="-" unitRef="usd" id="ixv-15316">2,305</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" unitRef="usd" id="ixv-15317">1,475</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" unitRef="usd" id="ixv-15318">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" unitRef="usd" id="ixv-15319">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" unitRef="usd" id="ixv-15320">3,872</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" unitRef="usd" id="ixv-15321">1,406</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-15322">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-15323">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="ixv-11381"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
significant components of deferred income tax expense/(benefit) from operations before non-controlling interest for each of the years
ended March 31 are approximated as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">Year Ended March 31, <br/> (in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Deferred income taxes</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Net operating loss carry-forwards foreign</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign" scale="3" unitRef="usd" id="ixv-15324">332</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign" scale="3" unitRef="usd" id="ixv-15325">287</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Non-capital loss carry-forwards &#8211; U.S.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="3" unitRef="usd" id="ixv-15326">18,365</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="3" unitRef="usd" id="ixv-15327">14,272</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Temporary differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" unitRef="usd" id="ixv-15328">427</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" unitRef="usd" id="ixv-15329">418</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Net deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-15330">19,124</ix:nonFraction>
</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-15331">14,977</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-15332">19,124</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-15333">14,977</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd" id="ixv-15334">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd" id="ixv-15335">-</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="ixv-11508"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth the details of expiration of the non-financial carried forward losses of the Company as of March 31, 2025, as
under:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><b>Year</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><b>Amount<br/>
 (in thousands)<br/>
 ($)</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0.25pt">2029</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c104" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-15336">16</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">2030</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c105" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-15337">37</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">2031</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c106" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-15338">3,081</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">2032</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c107" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-15339">4,141</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">2033</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-15340">627</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">2034</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c109" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-15341">1,269</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">2035</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c110" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-15342">1,735</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">2036</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c111" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-15343">1,176</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">2037</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c112" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-15344">819</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">No expiry</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c113" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-15345">1,256</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">No expiry</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c114" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-15346">4,132</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">No expiry</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-15347">7,932</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">No expiry</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-15348">8,841</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">No expiry</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-15349">14,966</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">No expiry</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-15350">8,552</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">No expiry</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c119" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-15351">6,884</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">No expiry</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c120" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-15352">22,006</ix:nonFraction></td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-15353">87,469</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Realization
of deferred tax assets, including those related to net operating loss carryforwards, are dependent upon future earnings, if any, of which
the timing and amount are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. Based
upon the Company&#8217;s current operating results management cannot conclude that it is more likely than not that such assets will be
realized. The Company files income tax returns in India, Colombia, and the U.S. The Company has a carry-forward R&amp;D tax credit of
approximately $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" unitRef="usd" id="ixv-15354">4,542</ix:nonFraction> thousand.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromContractWithCustomerTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="ixv-11641"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
17 </b>&#8211; <b>REVENUE RECOGNITION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
in the renting business when the equipment is rented, and the terms of the agreement have been fulfilled during the period. Revenue from
the execution of infrastructure contracts is recognized on the basis of the output method as and when part of the performance obligation
has been completed, and approval from the contracting agency has been obtained after a survey of the performance completion as of that
date. The revenue from the wellness and lifestyle business is recognized once goods have been sold to the customer and the performance
obligation has been completed. In retail sales, we offer consumer products through our online stores. Revenue is recognized when control
of the goods is transferred to the customer. This generally occurs upon our delivery to a third-party carrier or to the customer directly.
Revenue from white labelling services is recognized when the performance obligation has been completed, and output material has been
transferred to the customer.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="ixv-11668"><ix:continuation id="_RevenueFromContractWithCustomerTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
sales disaggregated by significant products and services for Fiscal 2025 and 2024 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">(in thousands) <br/> Year ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wellness and lifestyle <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c121" decimals="-3" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:Revenues" scale="3" unitRef="usd">113</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c122" decimals="-3" format="ixt:num-dot-decimal" id="ix_3_fact" name="us-gaap:Revenues" scale="3" unitRef="usd">228</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">White labeling services <sup>(2)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c123" decimals="-3" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:Revenues" scale="3" unitRef="usd">1,158</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:Revenues" scale="3" unitRef="usd">953</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other<sup>(3)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:fixed-zero" id="ix_6_fact" name="us-gaap:Revenues" scale="3" unitRef="usd">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" id="ix_7_fact" name="us-gaap:Revenues" scale="3" unitRef="usd">164</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-15361">1,271</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-15362">1,345</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from wellness and lifestyle consists of the sale of products such as gummies, hand sanitizers, bath bombs, lotions, beverages, hemp crude
extract, hemp isolate, and hemp distillate.</span></ix:footnote></td>
</tr></table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from white labelling services consists of rebranding our formulations or the customer&#8217;s products as per the customer&#8217;s requirement.</span></ix:footnote></td>
</tr></table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
consists of income from the rental of heavy construction equipment and the execution of contracts directly or through subcontractors.</span></ix:footnote></td>
</tr></table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock" id="ixv-11767"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
18 </b>&#8211; <b>SEGMENT INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB
ASC 280, &#8220;<i>Segment Reporting,</i>&#8221; establishes standards for reporting information about reportable segments. Operating
segments are defined as components of an enterprise about which separate financial information is available and is evaluated regularly
by the chief operating decision maker, or decision-making group (CODM), in deciding how to allocate resources and in assessing performance.
The CODM evaluates revenues and gross profits based on product lines and routes to market. The Company&#8217;s CODM is the Company&#8217;s
Chief Executive Officer (CEO). The CEO reviews financial information presented on an operating segment basis for the purposes of making
operating decisions and assessing financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal 2025, the Company reassessed its reportable segment structure in connection with its strategic realignment toward Life Sciences.
As a result, management determined that the Company operates as a <b>single reportable segment</b>. Historically, the Company reported
<ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="segment" id="ixv-15363">two</ix:nonFraction> operating segments: Life Sciences and Infrastructure. While the Infrastructure segment generated revenues in fiscal 2024, it did
not generate any revenues in fiscal 2025 and is no longer actively managed or evaluated as a discrete operating segment by the Company&#8217;s
Chief Operating Decision Maker.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has not made a formal decision to dispose of or exit the Infrastructure business, and therefore, the Infrastructure operations have not
been classified as discontinued operations. The results of the Infrastructure activities have been aggregated into the single reportable
segment presentation for all periods presented in this Annual Report on Form 10-K. This change in segment reporting has no impact on
the Company&#8217;s previously reported consolidated financial position, results of operations, or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following provides information required by ASC 280-10-50-38 &#8220;Entity-wide Information&#8221;:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="ixv-11792"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)
The table below shows revenue reported by segments:</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
&amp; Service</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Segments</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Life Sciences segment</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c128" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-15364">1,271</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c129" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-15365">1,345</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25pt"><b>Total</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-15366">1,271</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-15367">1345</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_2" id="_SegmentReportingDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Fiscal 2024, $<ix:nonFraction contextRef="c127" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-15368">164</ix:nonFraction> thousand belongs to the previously reported Infrastructure Segment.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
information on revenue by product and service, refer to Note 17, &#8220;Revenue Recognition.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="ixv-11875"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)
The table below shows the attributes to the country of domicile (U.S.) and foreign countries. Revenue is generally attributed to the
geographic location of customers:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center">(in thousands)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Segments</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Country</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage&#160;of <br/> Total<br/> Revenue <br/> (%)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">Asia</td><td>&#160;</td>
    <td style="text-align: left">India</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c130" decimals="-3" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-15369">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c130" decimals="2" format="ixt:fixed-zero" name="igc:TotalRevenuePercentage" scale="-2" unitRef="pure" id="ixv-15370">-</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 60%; padding-left: 0.25pt">America</td><td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: left">U.S.</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c131" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-15371">1,269</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c131" decimals="3" format="ixt:num-dot-decimal" name="igc:TotalRevenuePercentage" scale="-2" unitRef="pure" id="ixv-15372">99.8</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">Colombia</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c132" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-15373">2</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c132" decimals="3" format="ixt:num-dot-decimal" name="igc:TotalRevenuePercentage" scale="-2" unitRef="pure" id="ixv-15374">0.2</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-15375">1,271</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="igc:TotalRevenuePercentage" scale="-2" unitRef="pure" id="ixv-15376">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Segments</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Country</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage&#160;of <br/> Total<br/> Revenue<br/> (%)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; padding-left: 0.25pt">Asia</td><td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: left">India</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c133" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-15377">164</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c133" decimals="2" format="ixt:num-dot-decimal" name="igc:TotalRevenuePercentage" scale="-2" unitRef="pure" id="ixv-15378">12</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">America</td><td>&#160;</td>
    <td style="text-align: left">U.S.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c134" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-15379">1,179</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c134" decimals="2" format="ixt:num-dot-decimal" name="igc:TotalRevenuePercentage" scale="-2" unitRef="pure" id="ixv-15380">87</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">Colombia</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c135" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-15381">2</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c135" decimals="2" format="ixt:num-dot-decimal" name="igc:TotalRevenuePercentage" scale="-2" unitRef="pure" id="ixv-15382">1</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-15383">1,345</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="igc:TotalRevenuePercentage" scale="-2" unitRef="pure" id="ixv-15384">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="ixv-12044"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)
The table below shows the non-current assets other than financial instruments held in the country of domicile and foreign countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="10" style="font-weight: bold; font-style: italic; text-align: center">(in thousands)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Nature of Assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">U.S. <br/> (Country of <br/> Domicile)<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Foreign <br/> Countries <br/> (India and <br/> Colombia) <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total as of <br/> March 31, <br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0.25pt">Intangible assets, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-15385">1,852</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-15386">-</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-15387">1,852</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Property, plant, and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-15388">3,171</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-15389">49</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-15390">3,220</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Claims and advances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-15391">410</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-15392">271</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-15393">681</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Operating lease asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-15394">80</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-15395">18</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-15396">98</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt">Total non-current assets</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd" id="ixv-15397">5,513</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd" id="ixv-15398">338</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd" id="ixv-15399">5,851</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock-c0_cont_1"><ix:continuation id="_SegmentReportingDisclosureTextBlock-c0_cont_2"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Nature of Assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">U.S. <br/> (Country of <br/> Domicile) <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Foreign <br/> Countries<br/> (India and <br/> Colombia)<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total as of <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0.25pt">Intangible assets, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-15400">1,616</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c139" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-15401">-</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-15402">1,616</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Property, plant, and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-15403">3,620</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c139" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-15404">75</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-15405">3,695</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Claims and advances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-15406">410</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c139" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-15407">278</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-15408">688</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Operating lease asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-15409">193</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c139" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-15410">5</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-15411">198</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt"><b>Total non-current assets</b></td><td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd" id="ixv-15412">5,839</ix:nonFraction></b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction contextRef="c139" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd" id="ixv-15413">358</ix:nonFraction></b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 2.5pt double; text-align: right"><b><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd" id="ixv-15414">6,197</ix:nonFraction></b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td></tr>
  </table></ix:continuation></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-12280"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
19 </b>&#8211; <b>SUBSEQUENT EVENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the first quarter of Fiscal 2026, the Company entered into a Share Purchase Agreement (the &#8220;2025 SPA&#8221;) with multiple investors,
relating to the sale and issuance by our company to investors of an aggregate of <ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-15415">2,803,333</ix:nonFraction> shares of our common stock, for a total purchase
price of $<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-15416">841,000</ix:nonFraction>, or $<ix:nonFraction contextRef="c29" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-15417">0.30</ix:nonFraction> per share, subject to the terms and conditions set forth in the 2025 SPA. The investment is subject to customary
closing conditions, including NYSE approval. As per the 2025 SPA, the investor received piggyback registration rights subject to certain
restrictions. Shares are intended to be exempt from registration under the Securities Act, by virtue of the provisions of Section 4(a)(2)
of Securities Act.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2025, IGC Pharma expanded its CALMA Phase 2 trial for agitation in Alzheimer&#8217;s dementia to two renowned research sites: Butler
Hospital&#8217;s Memory and Aging Program (a nationally recognized research center affiliated with the Warren Alpert Medical School of
Brown University) in Rhode Island and the MIND Institute at Miami Jewish Health in Florida.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Asset held for sale has been sold for a value of approximately $<ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" scale="0" unitRef="usd" id="ixv-15418">701</ix:nonFraction> thousand, and the ownership of the land has been wholly transferred
to the respective purchasers.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">On June 24, 2025, IGC Pharma, Inc. (&#8220;IGC&#8221; or the &#8220;Company&#8221;) entered into an amendment to extend its existing Master Loan and Security Agreement along with the General Banking Facility Letter (collectively called the &#8220;Loan Agreement&#8221;) with O-Bank, CO., LTD., a banking corporation incorporated under the laws of Taiwan, as administrative agent and lender (the &#8220;Lender&#8217;), effective June 24, 2024. The amendment extends the term of the Loan Agreement, which was set to expire, under the same terms and conditions as previously disclosed on the Company&#8217;s Current Report on Form 8-K filed with the Securities Exchange Commission on August 2, 2024, with the exception of i) a reduction in the facility fees from $<ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityCollateralFeesAmount" scale="0" unitRef="usd" id="ixv-15419">84,000</ix:nonFraction> to $<ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityCollateralFeesAmount" scale="0" unitRef="usd" id="ixv-15420">48,000</ix:nonFraction> and ii) interest, calculated according to the interest rate mentioned in the Certificate of Deposit, as the case may be, plus an applicable margin of <ix:nonFraction contextRef="c143" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-15421">1.2</ix:nonFraction>%, instead of <ix:nonFraction contextRef="c144" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-15422">1</ix:nonFraction>% . All other material terms of the Loan Agreement remain unchanged.</span></td></tr> </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_015"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
9 </b>&#8211; <b>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in and disagreements with accountants on accounting and financial disclosures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9A. Controls and Procedures</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)
Evaluation of disclosure controls and procedures</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Management maintains disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act
of 1934 (the Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed in our reports
filed or submitted under the Exchange Act is processed, recorded, summarized and reported within the time periods specified in the SEC&#8217;s
rules and forms, and that such information is accumulated and communicated to Management, including our Chief Executive Officer (our
principal executive officer) and Principal Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Management conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered
by this report. Based on this evaluation, our Chief Executive Officer and Principal Financial Officer concluded that our disclosure controls
and procedures were effective to ensure that the information required to be disclosed in the reports filed or submitted by us under the
Exchange Act was recorded, processed, summarized and reported within the requisite time periods specified in SEC rules and forms and
that such information was accumulated and communicated to our Management, including our Chief Executive Officer and Principal Financial
Officer, as appropriate to allow for timely decisions regarding required disclosure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)
Management</b>&#8217;<b>s annual report on internal control over financial reporting</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined
in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including
our Principal Executive Officer and Principal Financial Officer, we conducted an evaluation of the effectiveness, as of March 31, 2025,
of our internal control over financial reporting based on the framework in 2013 Internal Control - Integrated Framework issued by the
Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under this framework, our management concluded
that our internal control over financial reporting was effective as of March 31, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)
Changes in internal control over financial reporting</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Management, including our Chief Executive Officer and Principal Financial Officer, evaluated our &#8220;internal control over financial
reporting&#8221; as defined in Exchange Act Rule 13a-15(f) to determine whether any changes in our internal control over financial reporting
occurred during Fiscal 2025 that materially affected, or are reasonably likely to materially affect, our internal control over financial
reporting. Based on that evaluation, there were no changes in our internal control over financial reporting during Fiscal 2025 that have
materially affected or are reasonably likely to materially affect our internal control over financial reporting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9B. Other Information</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c30" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="ixv-15423"><ix:nonNumeric contextRef="c30" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="ixv-15424"><ix:nonNumeric contextRef="c30" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="ixv-15425"><ix:nonNumeric contextRef="c30" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="ixv-15426">None</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
III</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Information
about our executive officers and directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
names, ages, and positions of our executive officers and directors as of March 31, 2025, were as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="border-bottom: black 1pt solid; padding: 0pt; vertical-align: bottom; width: 26%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="padding: 0pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding: 0pt; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class</b></span></td>
    <td style="padding: 0pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding: 0pt; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="padding: 0pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding: 0pt; vertical-align: bottom; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td>
    <td style="padding: 0pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; border-bottom: black 1pt solid; padding: 0pt; vertical-align: bottom; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
    Since</b></span></td>
    <td style="padding: 0pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; border-bottom: black 1pt solid; padding: 0pt; vertical-align: bottom; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Term
    will Expire</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ram Mukunda</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive
    Officer, and Director</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2005</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard Prins</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2007</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Moran</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terry L. Lierman</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claudia Grimaldi</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President, Principal Financial
    Officer, Chief Compliance Officer, and Director</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td style="padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal occupations for the past five years (and, in some instances, for prior years) of each of our executive officers and directors
are as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ram
Mukunda</b> has served as Founder, Director, CEO, and President since inception. He is responsible for general management and, over the
past 11 years, has been largely responsible for the Company&#8217;s strategy and positioning in the pharmaceutical industry. He has been
the chief inventor and architect of most of the Company&#8217;s patent filings and the thrust into R&amp;D and medical trials, which
support the Company&#8217;s desire to bring low-cost medications that address diseases and ailments that affect humankind. Prior to IGC,
from January 1990 to May 2004, Mr. Mukunda served as Founder and CEO of Startec Global Communications, which he took public in 1997 on
NASDAQ. Prior to Startec, he served as a Strategic Planning Advisor at Intelsat, a communications satellite services provider and prior
to that worked in the bond market for a boutique firm on Wall Street. Mr. Mukunda serves as an Emeritus member on the Board of Visitors
at the University of Maryland, School of Engineering. From 2001 to 2003, he was a Council Member at Harvard&#8217;s Kennedy School of
Government, Belfer Center of Science and International Affairs. Mr. Mukunda is the recipient of several awards including, among others,
the 2013 University of Maryland&#8217;s International Alumnus of the year award, the 2001 Distinguished Engineering Alumnus Award, the
1998 Ernst &amp; Young, LLP&#8217;s Entrepreneur of the Year Award. He holds a B.S. degree in Electrical Engineering, a B.S. degree in
Mathematics, and a M.S. in Engineering from the University of Maryland. Mr. Mukunda has traveled extensively and managed companies in
Europe and Asia. He has over 25 years of experience managing public companies and has acquired and integrated over 20 companies. His
in-depth business experience in the pharmaceutical and OTC industries, his knowledge of U.S. capital markets, capital structuring, international
joint ventures, and broad science and engineering background make him qualified to serve as a director of our Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Richard
Prins </b>has been our Chairman, Audit Committee, and Compensation Committee Chairman since 2012 and has served as an Independent Director
since May 2007. Mr. Prins has extensive experience in private equity investing and investment banking. From March 1996 to 2008, he was
the Director of Investment Banking at Ferris, Baker Watts, Incorporated (&#8220;FBW&#8221;). Mr. Prins served in a consulting role for
RBC until January 2009. Since February 2003, he has been on the board of Amphastar Pharmaceuticals, Inc. Mr. Prins holds a B.A. degree
from Colgate University and an M.B.A. from Oral Roberts University. Mr. Prins has substantial knowledge and experience with U.S. capital
markets, has served on and chaired audit and compensation committees of boards, and has extensive experience in finance, accounting,
and internal controls over financial reporting. His knowledge of the pharmaceutical industry and experience with U.S. capital markets
make him qualified to serve as a director of our Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>James
Moran (Congressman Moran) </b>has served on the Board as an Independent Director since January 2022. He served on Virginia&#8217;s 8th
Congressional District for 24 years, where he was known as a &#8220;Problem Solver.&#8221; Throughout his tenure, he demonstrated bipartisan
leadership and worked across the aisle to find common ground to resolve complex issues. He served on the Appropriation, Banking and Finance,
and Budget committees. He played a leadership role in the areas of defense, health, and the environment. During his 24 years in Congress,
Congressman Moran was recognized as a champion of innovative research and development in areas including healthcare and national security,
environmental protection and sustainability, and international trade and fiscal responsibility. He rose to senior leadership on the Appropriations
Committee enabling him to bring billions of dollars into his Northern Virginia communities of Alexandria, Arlington, and Fairfax County.
Having retired after 35 years in elected office, Congressman Moran is now with a major law firm and represents international and domestic
clients in the defense, technology, entertainment, and international diplomacy sectors. He also serves in leadership roles for several
non-profit foundations and is also a member of the Government Blockchain Association. Congressman Moran received a Master&#8217;s Degree
in Public Administration from the University of Pittsburgh Graduate School of Public and International Affairs and a Bachelors in Economics
from the College of the Holy Cross.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Congressman
Moran introduced the AUTISM Educators Act in 2012, which funded partnerships between public schools and higher education and non-profit
organizations to promote teaching skills for educators working with high functioning autism students. He understands that treatment and
education for conditions such as Autism and Alzheimer&#8217;s disease have the potential to positively impact millions of lives. With
his extensive experience in Congress and as a policy advisor on topics including health, technology, and education, we are confident
Congressman Moran will be a great asset to IGC, especially at a time when we pursue Phase 2/3 human trials on IGC- AD1 on individuals
that have Alzheimer&#8217;s disease. Congressman Moran&#8217;s extensive experience makes him qualified to serve as a director of our
Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 27, 2022, the Board of Directors appointed Mr. James Moran as a member of both the Company&#8217;s Audit and Compensation Committee,
effective immediately.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Terry
L. Lierman </b>has served on the Board as an Independent Director since March 2024. Mr. Lierman is currently Co-Chair of the Board of
Advisors at the Institute of Human Virology (&#8220;IHV&#8221;), a center in the U.S. focused on accelerating the discovery of diagnostics
and therapeutics for deadly viral and immune disorders, and a member of the Board of Visitors at the La Follette School of Public Affairs
at the University of Wisconsin, his alma mater. Mr. Lierman founded the Children&#8217;s Research Institute, one of America&#8217;s top
children&#8217;s research programs, the Pancreatic Cancer Action Network (&#8220;PanCAN&#8221;), and the National Organization on Fetal
Alcohol Syndrome (&#8220;NOFAS&#8221;). In addition, from 1987 to 1999, he served as a director/trustee of the NY Life-Mainstay Funds.
His distinguished career includes serving at the National Institutes of Health (&#8220;NIH&#8221;), as the chief administrator for drug
research and development at the National Cancer Institute (&#8220;NCI&#8221;), and as the Staff Director for the Committee on Appropriations
at the U.S. Senate and the Chief of Staff and White House liaison to the U.S. House of Representative&#8217;s Majority Leader. Mr. Lierman&#8217;s
vast healthcare expertise will undoubtedly play a pivotal role in driving our mission to develop innovative therapeutics for crucial
unmet needs. His extensive experience uniquely qualifies him to serve as a director of our company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Claudia
Grimaldi</b>, Vice-president, PFO, Chief Compliance Officer, and Director, is responsible for managing the accounting and finance teams
in various countries and is responsible for ensuring timely and accurate statutory and regulatory compliance (SEC, FINRA, NYSE, IRS,
XETRA 2, among others). In addition, she is responsible for building and managing an international team of doctors, scientists, and advisors
that conduct and manage pre-clinical and FDA registered trials focused on Alzheimer&#8217;s disease. She is also responsible for relationships
with partners that provide, among others, animal studies, cannabinoids, and software for AI. She has more than thirteen (13) years of
experience with SEC filings, regulatory compliance, and disclosures, having held increasing responsibilities first as Manager of financial
reporting and compliance from May 2011 to 2013 and then as General Manager of financial reporting and compliance from 2013 to May 2018.
She also serves as a Director/Manager for some of our subsidiaries. Ms. Grimaldi graduated summa cum laude from Javeriana University,
a top five university in Colombia, with a Bachelor of Arts in Psychology. She holds an MBA in General Management, graduating with Highest
Honors, from Meredith College, in North Carolina. She is a member of Delta Mu Delta International Honor Society. She has also completed
Executive Education courses on SEC compliance, finance from UVA, and corporate governance from the Columbia Business School. In addition,
she has attended the Darden School of Business Financial Management Executives program at the University of Virginia, and SEC reporting
and compliance seminars. She also completed her certification program of the National Association of Corporate Directors (NACD). She
is also fluent in both English and Spanish.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 18, 2023, the Board of Directors of the Company elected Ms. Claudia Grimaldi to serve on the Board as a non-independent director
Class A until the Company&#8217;s 2026 annual meeting of stockholders upon the election and qualification of successor directors, her
earlier death, resignation, or removal. Ms. Grimaldi brings a wealth of experience and qualifications that make her an excellent fit
for the board. Ms. Grimaldi&#8217;s experience with SEC filing procedures is invaluable in ensuring regulatory compliance and transparency
within our public company. Additionally, her in-depth understanding of Colombia, and South America where our company has invested in
human capital, provides valuable insights into the market dynamics, cultural nuances, and business opportunities within the region. Her
SEC filing experience, understanding of Colombia, qualifications in business administration, and general business acumen make her qualified
to serve as a director of our Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
officers are appointed by our Board of Directors. Each executive officer holds his or her office until he or she resigns or is removed
by the Board or his or her successor is elected and qualified. All directors hold office until the annual meeting of the stockholders
in the year set forth above in the table and until their successors have been duly elected or qualified. There are no family relationships
between any of our executive officers or directors. For information on legal proceedings against the Company, please refer to Item 3.
Legal Proceedings. There are currently no legal proceedings against the Company&#8217;s directors or officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Terry
McAuliffe, </b>served as an Advisor since December 2024. He was sworn in as governor of Virginia on January 11, 2014. He is a businessman,
entrepreneur and who lived in Fairfax County, Virginia, for more than 20 years. In politics and business, McAuliffe has worked with people
from all walks of life and different political backgrounds.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amb.
(Ret.) Howard Gutman, </b>serves as a strategic advisor to IGC Pharma Inc., bringing extensive experience in international law, diplomacy,
and public policy. He served as the U.S. Ambassador to Belgium from 2009 to 2013 and has had a distinguished career in both government
and private sector advisory roles. Ambassador Gutman contributes to IGC&#8217;s corporate strategy and global partnership initiatives,
leveraging his expertise in regulatory, political, and international affairs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prof.
Chuanhai Cao, Ph.D., </b>is a scientific advisor to IGC Pharma Inc., with deep expertise in neuroimmunology and Alzheimer&#8217;s disease
research. He is an Associate Professor at the University of South Florida&#8217;s Morsani College of Medicine and College of Pharmacy.
His work focuses on the therapeutic potential of cannabinoids and immune modulation in neurodegenerative conditions. Prof. Cao&#8217;s
research contributions align closely with IGC&#8217;s mission to develop innovative treatments for Alzheimer&#8217;s disease.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prof.
James A. Saunders, Ph.D., </b>is a scientific advisor to IGC Pharma Inc., bringing decades of academic and research experience in biotechnology
and plant sciences. He has held faculty and leadership roles at respected academic institutions and has contributed to numerous peer-reviewed
publications. Prof. Saunders provides guidance on natural compounds and their therapeutic potential, supporting IGC&#8217;s research
in cannabinoid-based treatments for Alzheimer&#8217;s disease.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prof.
Elliot L. Hong, M.D., </b>is a scientific advisor to IGC Pharma Inc., offering expertise in translational neuroscience and psychiatric
research. He is a professor of psychiatry at the University of Maryland School of Medicine and a leading investigator in the fields of
brain imaging, schizophrenia, and neurodevelopment. Prof. Hong&#8217;s insights support IGC&#8217;s efforts to develop therapeutics for
neuropsychiatric symptoms associated with Alzheimer&#8217;s disease.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prof.
Jeffrey L. Cummings, M.D., Sc.D.</b>, serves as a scientific advisor to IGC Pharma Inc. He is a world-renowned neurologist and expert
in Alzheimer&#8217;s disease research, drug development, and clinical trials. Dr. Cummings is the founding director of the Cleveland
Clinic Lou Ruvo Center for Brain Health and a Research Professor at the University of Nevada, Las Vegas. His contributions support IGC&#8217;s
mission to advance innovative therapies for neurodegenerative diseases through expert guidance in clinical strategy and trial design.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prof.
Pablo Arbel&#225;ez</b> is a scientific advisor to IGC Pharma, contributing expertise in biomedical image analysis and artificial intelligence.
He is a professor at Universidad de los Andes in Colombia and a former researcher at &#201;cole Normale Sup&#233;rieure in Paris.
Prof. Arbel&#225;ez&#8217;s research focuses on deep learning in medical imaging and its application to neurodegenerative diseases, aligning
with IGC&#8217;s mission to develop innovative therapies for Alzheimer&#8217;s disease.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of directors and independence</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors is divided into three classes (Class A, Class B, and Class C) with only one class of directors being elected each
year and each class serving a three-year term. The term of office of the Class A director, consisting of Claudia Grimaldi, will expire
at the 2026 annual meeting of stockholders. The term of office of the Class B director, currently consisting of Richard Prins and Terry
L. Lierman, will expire at the 2027 annual meeting of stockholders. The term of office of the Class C director, currently consisting
of Ram Mukunda and James Moran, will expire at the 2025 annual meeting of stockholders. These individuals have played a key role in identifying
and evaluating prospective acquisition candidates, selecting the target businesses, and structuring, negotiating, and consummating acquisitions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NYSE American, upon which our shares are listed, requires the majority of our Board, or in the case of a smaller reporting Company, at
least 50% of our Board, to be &#8220;independent.&#8221; The NYSE American listing standards define an &#8220;independent director&#8221;
generally as a person, other than an officer or an employee of the Company, who does not have a relationship with the Company that would
interfere with the director&#8217;s exercise of independent judgment. Consistent with these standards, the Board of Directors has determined
that Messrs. Prins, Moran, and Lierman are independent directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
leadership structure</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board believes its current leadership structure best serves the objectives of the Board&#8217;s oversight of management, the Board&#8217;s
ability to carry out its roles and responsibilities on behalf of IGC&#8217;s shareholders, and IGC&#8217;s overall corporate governance.
The Board also believes that the separation of the Chairman and CEO roles allows the CEO to focus his time and energy on operating and
managing IGC, while leveraging the Chairman&#8217;s experience and perspectives. The Board periodically reviews its leadership structure
to determine whether it continues to best serve IGC and its shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
oversight of risk management</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board is responsible for overseeing the major risks facing the Company, while management is responsible for assessing and mitigating
the Company&#8217;s risks on a day-to-day basis. The Board has designated the Audit Committee with the responsibility for overseeing
enterprise risk management. The Audit Committee discusses the steps management has taken to monitor and mitigate these risks, if any.
In establishing and reviewing IGC&#8217;s executive compensation, the Compensation Committee considers whether the compensation program
is focused on long-term shareholder value creation and whether it encourages short-term risk taking at the expense of long-term results.
The Compensation Committee has also reviewed IGC&#8217;s compensation program and has concluded that these programs do not create risks
that are reasonably likely to have a material adverse effect on IGC. Other Board committees also consider risks within their areas of
responsibility and apprise the Board of significant risks and management&#8217;s response to those risks.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
committee</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has established an Audit Committee, currently composed of two independent directors who report to the Board of Directors.
Messrs. Prins and Moran, each of whom is an independent director under the NYSE American listing standards, serve as members of our Audit
Committee. Mr. Prins is the Chairman of our Audit Committee. In addition, we have determined that Messrs. Prins and Moran are &#8220;audit
committee financial experts,&#8221; as that term is defined under Item 407 of Regulation S-K. The Audit Committee is responsible for
meeting with our independent accountants regarding, among other issues, audits and the adequacy of our accounting and control systems.
The audit committee charter is followed by the committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
committee</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has established a Compensation Committee composed of two independent directors, Messrs. Moran and Prins. Mr. Prins
is the current Chairman of our Compensation Committee. The Compensation Committee&#8217;s purpose is to review and approve the compensation
paid to our officers and directors and to administer our 2018 Omnibus Incentive Plan. As per the compensation committee charter, candidate
experience, knowledge, and performance are used to evaluate the candidate. The compensation is accordingly decided for the candidate
as per the industry standards.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
committee interlocks and insider participation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Compensation Committee is comprised of two independent members of the Board of Directors, Richard Prins and James Moran. No executive
officer of the Company served as a director or member of the Compensation Committee of any other entity. The Compensation Committee was
responsible for determining executive compensation and the award of stock and stock options to employees, advisors, and directors during
Fiscal 2025. No consultants were used by the Compensation Committee during this fiscal year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nominating
and corporate governance committee</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, we intend to establish a nominating and corporate governance committee. The primary purpose of the nominating and corporate
governance committee will be to identify individuals qualified to become directors, recommend to the Board of Directors the candidates
for election by stockholders or appointment by the Board of Directors to fill a vacancy, recommend to the Board of Directors the composition
and chairs of Board of Directors committees, develop and recommend to the Board of Directors guidelines for effective corporate governance,
and lead an annual review of the performance of the Board of Directors and each of its committees. We do not have any formal process
for stockholders to nominate a director for election to our Board of Directors. Currently, nominations are selected or recommended by
a majority of the independent directors as stated in Section 804(a) of the NYSE American Company Guide. Since the Company is a small
reporting company with limited officers and directors, the committee currently does not have a nomination committee charter. The Board
of Director nominations occur by either selection or recommendation of a majority of the independent directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosure
Committee</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CEO and the PFO supervise and oversee the Disclosure Committee. The Board has appointed Mr. Richard Prins as the Chairperson of the Disclosure
Committee. The Disclosure Committee&#8217;s responsibilities are to design, implement, and regularly evaluate the Company&#8217;s internal
controls and procedures, to ensure that the company provides the stakeholders, including the Securities and Exchange Commission (SEC),
security holders, and the investment community, disclosures that comply with regulations and other compliance obligations. The Disclosure
Committee will review all required material and relevant reports related to disclosure statements, including annual reports on Form 10-K,
quarterly reports on Form 10-Q, press releases, and social media containing financial information and other related public documents.
The Disclosure Committee meets not less than once per quarter and reviews and reassesses the adequacy of the Disclosure Committee&#8217;s
Charter at least annually.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Committee Financial Expert</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee will at all times be composed exclusively of &#8220;independent directors&#8221; who are &#8220;financially literate,&#8221;
as defined under the NYSE American listing standards, who understand the audit committee functions. The NYSE American&#8217;s listing
standards define &#8220;financially literate&#8221; as being able to read and understand fundamental financial statements, including
a company&#8217;s balance sheet, income statement, and cash flow statement. In addition, we must certify to the NYSE American that the
Audit Committee has, and will continue to have, at least one member who has past employment experience in finance, accounting, or auditing,
requisite professional certification in accounting, or other comparable experience or background that results in the individual&#8217;s
financial sophistication, along with an understanding of internal control over financial reporting. The Board of Directors has determined
that Messrs. Prins and Moran satisfy the NYSE American&#8217;s definition of financial sophistication and qualify as &#8220;audit committee
financial experts,&#8221; as defined under the rules and regulations of the SEC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
and committee meetings</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
Fiscal 2025, there were six (6) Board meetings, five (5) meetings of the Audit Committee, and two (2) Compensation Committee meetings,
all of which were attended, either in person or telephonically, by all our directors of the Board and all of the members of the committees,
respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Communications
with the Board</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
matter intended for the Board or any individual member of the Board should be directed to Investor Relations at the Company&#8217;s principal
executive office, with a request to forward the communication to the intended recipient. In general, any shareholder communication delivered
to the Company for forwarding to Board members will be forwarded in accordance with the shareholder&#8217;s instructions. However, the
Company reserves the right not to forward to Board members any abusive, threatening, or otherwise inappropriate materials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnification
agreements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are party to indemnification agreements with each of the executive officers and directors. Such indemnification agreements require us
to indemnify these individuals to the fullest extent permitted by law. Under the terms of the indemnification agreements, we intend to
agree to indemnify our officers and directors against expenses, judgments, fines, penalties, or other amounts actually and reasonably
incurred by the independent director in connection with any proceeding if the officer or director acted in good faith and did not derive
an improper personal benefit from the transaction or occurrence that is the basis of the proceeding.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Annual
meeting attendance</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
directors, either in person or telephonically, attended the 2024 annual shareholder&#8217;s meeting. We have a formal policy requiring
the members of our Board of Directors to attend annual stockholder meetings in person or by telephone or video conference.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
governance, code of conduct, and ethics</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
code of business conduct and ethics is a written standard designed to deter wrongdoing and to promote (a) honest and ethical conduct,
(b) full, fair, accurate, timely, and understandable disclosure in regulatory filings and public statements, (c) compliance with applicable
laws, rules, and regulations, (d) the prompt reporting violation of the code and (e) accountability for adherence to the code. The Company
has adopted a written code of ethics (the &#8220;Code of Ethics&#8221;) that applies to the Company&#8217;s Chief Executive Officer and
senior financial officers, including the Company&#8217;s Principal Accounting Officer, Controller, and persons performing similar functions
(collectively, the &#8220;Senior Financial Officers&#8221;), in accordance with applicable federal securities laws and the rules of the
NYSE American, and to all employees. Investors or any other person may view our Code of Ethics free of charge on the corporate governance
subsection of the investor relations portion of our website at www.igcinc.us. The Company has established separate audit and compensation
committees that are described elsewhere in this report. The Company does not have a separate nominating committee. Accordingly, Board
of Director nominations occur by either selection or recommendation of a majority of the independent directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
our data, except accounting data, is stored in the cloud on multiple servers, which helps us mitigate the overall risk of losing data.
As part of corporate governance, we also have a cybersecurity policy that employees are required to comply with to safeguard their systems
from cyber-attacks.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insider
Trading Policy</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have an insider trading policy governing the purchase, sale, and other dispositions of our securities (the &#8220;Insider Trading Policy&#8221;)
that applies to all of our directors, officers, employees, and other covered persons identified within the Insider Trading Policy. We
believe that the Insider Trading Policy is reasonably designed to promote compliance with applicable U.S. federal securities laws, rules,
and regulations, as well as applicable listing standards relating to insider trading. In addition, with regard to our trading in our
own securities, it is our policy to comply with applicable federal securities laws and applicable listing requirements. The Insider Trading
Policy is filed as Exhibit 19.1 to this Annual Report on Form 10-K.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delinquent
Section 16(a) reports</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(a) of the Securities and Exchange Act of 1934, as amended, requires our officers, directors, and beneficial owners of more than 10%
of our equity securities to timely file certain reports regarding ownership of and transactions in our securities with the Securities
and Exchange Commission. Copies of the required filings must also be furnished to us. Section 16(a) compliance was required during Fiscal
2025. Based solely on a review of Forms 3, 4, and 5 and amendments thereto furnished to us pursuant to Rule 16a-3(e) under the Exchange
Act, we believe that Fiscal 2025&#8217;s filing requirements under Section 16(a) of the Exchange Act have been satisfied, except for
(1) a Form 5 for Claudia Grimaldi reporting the vesting of RSUs on March 31, 2025; (2) a Form 5 for James Moran reporting the vesting
of RSUs on March 31, 2025, (3) a Form 5 for Ram Mukunda reporting the vesting of RSUs on March 31, 2025 and (4) a Form 5 for Richard
Prins reporting the vesting of RSUs on March 31, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
11. EXECUTIVE COMPENSATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
for executive officers of the Company</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning all cash and non-cash compensation awarded to, earned by, or paid to (i) all individuals
serving as the smaller reporting company&#8217;s principal executive officer or acting in a similar capacity during the last completed
fiscal year (PEO), regardless of compensation level; (ii) the smaller reporting company&#8217;s two most highly compensated executive
officers other than the PEO who was serving as executive officers at the end of the last completed fiscal year and whose compensation
exceeded $100,000.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(in
thousands)</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Name and Principal Position</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Salary <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Bonus<br/> ($)(1)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock<br/> Awards (2) <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Other<br/> compensation<br/> (3) ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<br/> Compensation <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; padding-left: 0.25pt">Ram Mukunda</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">396</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">80</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">568</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">President and CEO</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">360</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">320</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,066</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,821</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Claudia Grimaldi</td><td>&#160;</td>
    <td style="text-align: center">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">226</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">259</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Vice President, CCO, and PFO</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">717</td><td style="text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal 2025, the outstanding bonus of Ram Mukunda of approximately $423 thousand and of Claudia Grimaldi of approximately $327 thousand
has been converted into performance-based bonuses and will be paid upon achieving the following milestones. Completion of CALMA Phase
2 Clinical Trial; 2. Successful fundraising of at least $5 million via equity, debt, partnerships, or non-dilutive grants.</span></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Stock Awards represent the fair value of stock awards to the named executive officer as computed using the closing price at the day of
grant or using an appropriate pricing model depending on the terms of the award. The Stock Awards include vested and unvested grants
of stock awards as reflected in the table titled &#8220;Stock Awards at Fiscal Year End.&#8221;&#160;&#160;This also includes two categories
of Stock Awards that are set out in the tables titled &#8220;Performance-Based Stock Awards&#8221;&#160;and &#8220;Market Price-Based
Stock Awards,&#8221;&#160;which account for approximately $689 thousand in fiscal 2024 and Nil in fiscal 2025.</span></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
life insurance, 401 (k) contribution, health insurance(s), and other applicable compensation.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
to Directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(in
thousands)</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
fiscal 2025, no compensation was awarded to, earned by, or paid to non-employee directors who served on the Board during the fiscal year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
Awards at Fiscal Year End</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(in
thousands)</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> unvested Stock<br/> Awards <br/> (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value of <br/> unvested Stock <br/> Awards<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value&#160;of vested <br/> Stock Awards<br/> in Fiscal Year <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total <br/> Value of <br/> Stock Awards<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 0.25pt">Ram Mukunda</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,527</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">274</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,474</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Claudia Grimaldi</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,230</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">371</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">452</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Richard Prins</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">936</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">540</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">618</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">James Moran</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">294</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">130</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Terry L. Lierman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Stock Awards reflect the grant date fair value, in accordance with Accounting Standards Codification (ASC) Topic 718, Compensation &#8212;
Stock Compensation (formerly Statement of Financial Accounting Standards (SFAS) No. 123R) for awards pursuant to the Company&#8217;s
equity incentive program.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
in the tables above are two categories of Stock Awards: (i) performance-based stock awards that are based on achieving milestones in
the area of drug development; and (ii) market price-based awards, based on advancing the IGC stock price.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
contracts</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ram
Mukunda has served as President and Chief Executive Officer of our Company since its inception. On November 18, 2021, the Company, and
Mr. Mukunda entered into the 2021 CEO Employment Agreement that expires on November 17, 2026. Pursuant to the 2021 CEO Employment Agreement,
we pay Mr. Mukunda a base salary of $360,000 per year. The Employment Agreement provides that the Board of Directors of our Company may
review and update the targets and amounts for the net revenue and salary and contract bonuses on an annual basis. Mr. Mukunda is entitled
to benefits, including insurance, participation in company-wide 401(k), reimbursement of business expenses, 20 days of annual paid vacation,
sick leave, domestic help, driver, cook, and a car (subject to partial reimbursement by Mr. Mukunda of rental payments for the car and
reimbursement of business expenses). In the event of termination without cause, including a change of control, we would be required to
pay Mr. Mukunda 1.5 times the average of the total compensation as disclosed in the previous two 10-K filings prior to termination. In
addition, all unvested shares would be subject to immediate vesting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claudia
Grimaldi has served as Vice President, Principal Financial Officer, Chief Compliance Officer, and Director of our subsidiaries since
May 9, 2018. On May 5, 2023, the Company and Ms. Grimaldi entered into an Employment Agreement that expires on May 8, 2028 (the 2023
Employment Agreement). Pursuant to the Employment Agreement, we pay Ms. Grimaldi a base salary of $200,000 per year. The Employment Agreement
provides that the Company may review and update performance targets and contract bonuses on an annual basis. Ms. Grimaldi is entitled
to benefits, including insurance, participation in company-wide 401(k), reimbursement of business expenses, 20 days of annual paid vacation,
sick leave, and a car (subject to partial reimbursement by Ms. Grimaldi for personal use of the car). In the event of termination without
cause, including a change of control, we would be required to pay Ms. Grimaldi 1.5 times her compensation. In addition, unvested shares
that would otherwise vest in a 12-month period would be subject to immediate vesting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
non-employee directors, the Company has a standard compensation arrangement such as fees for committee service, service as chairman of
the board, or a committee, and meeting attendance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
risk assessment</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
setting compensation, the Compensation Committee considers the risks to our stockholders and to the achievement of our goals that may
be inherent in our compensation programs. The Compensation Committee reviewed and discussed its assessment with management and concluded
that our compensation programs are within industry standards and are designed with the appropriate balance of risk and reward to align
employees&#8217; interests with those of our Company and do not incent employees to take unnecessary or excessive risks. Although a portion
of our executives&#8217; and employees&#8217; compensation is performance-based and &#8220;at risk,&#8221; we believe our compensation
plans are appropriately structured and are not reasonably likely to result in a material adverse effect on our Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Policies
and practices related to the grant of equity awards close in time to the release of material nonpublic information</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the Board nor the Compensation Committee takes material nonpublic information into account when determining the timing or terms of equity
awards, including with respect to options, nor do we time the disclosure of material nonpublic information for the purpose of affecting
the value of executive compensation. Although we do not have a formal policy with respect to the timing of our equity award grants we
have generally granted such awards once a year to directors and executive officers and equity awards may be granted at other times during
the year to newly hired or promoted employees, and in other special circumstances. In fiscal 2025, we did not grant any stock options,
stock appreciation rights, or similar option-like instruments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information regarding the beneficial ownership of our common stock as of June 20, 2025, by each person known
by us to be the beneficial owner of more than 5% of our outstanding shares of common stock, each of our executive officers and directors,
and all our officers and directors as a group.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC and does not necessarily indicate beneficial ownership for any other
purpose. Under these rules, beneficial ownership includes those shares of common stock over which the stockholder has sole or shared
voting or investment power. It also includes shares of common stock that the stockholder has a right to acquire within 60 days through
the exercise of any option or other right. The percentage ownership of the outstanding common stock, which is based upon shares of common
stock outstanding as of June 20, 2025, is based on the assumption, expressly required by the rules of the SEC, that only the person or
entity whose ownership is being reported has exercised options to purchase shares of our common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, we believe that all persons named in the table have sole voting and investment power with respect to all shares
of common stock beneficially owned by them. Unless otherwise noted, the nature of the ownership set forth in the table below is the common
stock of the Company. The table below sets forth as of June 20, 2025, except as noted in the footnotes to the table, certain information
with respect to the beneficial ownership of the Company&#8217;s common stock by (i) all persons or groups, according to the most recent
Schedule 13D or Schedule 13G filed with the SEC or otherwise known to us, to be the beneficial owners of more than 5% of the outstanding
common stock of the Company, (ii) each director of the Company, (iii) the executive officers named in the Summary Compensation Table,
and (iv) all such executive officers and directors of the Company as a group.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center">Shares Owned (in thousands)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1pt solid">Name and Address of Beneficial Owners/Named Executive Officers and Directors: (1)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> Shares <br/> Beneficially <br/> Owned</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage <br/> of Class*</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Ram Mukunda (2)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,092,678</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.88</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Claudia Grimaldi</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,184,252</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.41</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Richard Prins</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,271,251</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.52</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">James Moran</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,105,735</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.32</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Terry L. Lierman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,411</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.04</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">Bradbury Strategic Fund (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,623,529</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21.01</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0.25pt">All Executive Officers and Directors as a group (5 persons)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">25,306,856</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">30.17</td><td style="font-weight: bold; text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*Based</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
83,891,586 shares of common stock outstanding as of June 20, 2025.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, the address of each of the individuals listed in the table is c/o IGC Pharma, Inc., 10224 Falls Road, Potomac, MD
20854.</span></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
beneficial ownership table does not include 810,752 shares of common stock that are owned by Mr. Mukunda&#8217;s spouse for which Mr.
Mukunda has no voting or financial rights.</span></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
individual who holds voting and investment power in the investment manager is Mr. Loo See Yuen, the Director of Bradbury Asset Management.
The address of the entity is Unit 5106-7, 51st Floor, The Center, 99 Queen&#8217;s Road Central, Central, Hong Kong.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as described below, during the last two fiscal years, we have not entered into any material transactions or series of transactions
that would be considered material in which any officer, director, or beneficial owner of 5% or more of any class of our capital stock,
or any immediate family member of any of the preceding persons, had direct or indirect material interest, nor are there any such transactions
presently proposed, other than the agreements with the affiliates of our CEO as described under &#8220;Executive Compensation &#8211;
Compensation for Executive Officers of the Company.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Review,
approval, or ratification of related party transactions</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a written policy for the review and approval of transactions with related persons. It is our policy for the disinterested members
of our Board to review all related party transactions on a case-by-case basis. To receive approval, a related-party transaction must
have a business purpose for us and be on terms that are fair and reasonable to us and as favorable to us as would be available from non-related
entities in comparable transactions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transaction
with Related Parties</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 22, 2024, the Company entered into the SPA with Bradbury Strategic Investment Fund A, resulting in approximately $3 million in
gross proceeds. The completion of the private placement is subject to customary closing conditions, including approval by the NYSE. Under
the terms of the private placement, IGC will issue approximately 8.8 million shares of unregistered common stock at a price of $0.34
per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no related party transactions in Fiscal 2025 and through the date of this Form 10-K.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manohar
Chowdhry &amp; Associates (MCA) is our Principal Independent Registered Public Accounting Firm engaged to examine our financial statements
for Fiscal 2025. During the Company&#8217;s two most recent fiscal years ended March 31, 2025, and 2024, and through July 6, 2023, the
Company did not consult with MCA on (i) the application of accounting principles to a specified transaction, either completed or proposed,
or the type of audit opinion that may be rendered on the Company&#8217;s financial statements, and MCA has not provided either a written
report or oral advice to the Company that was an important factor considered by the Company in reaching a decision as to any accounting,
auditing, or financial reporting issue; or (ii) the subject of any disagreement, as defined in Item 304(a)(1)(iv) of Regulation S-K and
the related instructions, or a reportable event within the meaning set forth in Item 304(a)(1)(v) of Regulation S-K.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
related and other fees</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below shows the fees that we paid or accrued for the audit and other services provided by Manohar Chowdhry &amp; Associates for
Fiscal 2025 and Fiscal 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
fees</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
category includes the audit of our annual financial statements, review of financial statements included in our annual and quarterly reports
and services that are normally provided by the independent registered public accounting firms in connection with engagements for those
fiscal years. This category also includes advice on audit and accounting matters that arose during, or as a result of, the audit or the
review of interim financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Internal
control audit fees</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
category includes the audit of the Company&#8217;s internal control over financial reporting based on criteria established in Internal
Control&#8212;Integrated Framework: (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit-related
fees</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
category consists of assurance and related services by the independent registered public accounting firms that are reasonably related
to the performance of the audit or review of our financial statements and are not reported above under &#8220;Audit Fees.&#8221; The
services for the fees disclosed under this category include services relating to our registration statement and consultation regarding
our correspondence with the SEC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Tax
fees</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
category consists of professional services rendered for tax compliance, tax planning, and tax advice. These services include tax return
preparation and advice on state and local tax issues.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>All
other fees</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
category consists of fees for other miscellaneous items.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center">(in thousands)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Audit fees - Manohar Chowdhry &amp; Associates</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">69</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">69</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Audit-related fees - Manohar Chowdhry &amp; Associates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Tax fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">All other fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">69</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">78</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Policy
on pre-approval of audit and permissible non-audit services of independent auditors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consistent
with SEC policies regarding auditor independence, the audit committee of our Board of Directors has responsibility for appointing, setting
compensation, and overseeing the work of the independent auditor. In recognition of this responsibility, our Board of Directors has established
a policy to pre-approve all audit and permissible non-audit services provided by the independent auditor. Prior to the engagement of
the independent auditor for the next year&#8217;s audit, management may submit, if necessary, an aggregate of services expected to be
rendered during that year for each of the following four categories of services to our Board of Directors for approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit</i>&#160;services
include audit work performed in the preparation of financial statements and audit of internal controls, as well as work that generally
only the independent auditor can reasonably be expected to provide, including comfort letters, statutory audits, and attest services
and consultation regarding financial accounting and/or reporting standards.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit-Related</i>&#160;services
are for assurance and related services that are traditionally performed by the independent auditor, including due diligence related to
mergers and acquisitions, employee benefit plan audits, and special procedures required to meet certain regulatory requirements.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Tax</i>&#160;services
include all services performed by the independent auditor&#8217;s tax personnel except those services specifically related to the audit
of the financial statements and includes fees in the areas of tax compliance, tax planning, and tax advice.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other</i>&#160;Fees
are those associated with services not captured in the other categories.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to engagement, our Board of Directors pre-approves these services by category of service. The fees are budgeted, and our Board of Directors
requires the independent auditor and management to report actual fees versus the budget periodically throughout the year by category
of service. During the year, circumstances may arise when it may become necessary to engage the independent auditor for additional services
not contemplated in the original pre-approval. In those instances, our Board of Directors requires specific pre-approval before engaging
the independent auditor.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee may delegate pre-approval authority to one or more of its members. The member to whom such authority is delegated must
report, for informational purposes only, any pre-approval decisions to our Board of Directors at its next scheduled meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-approved
services</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee&#8217;s charter provides for pre-approval of audit, audit-related and tax services to be performed by the independent
auditors. The Audit Committee approved the audit, audit-related and tax services to be performed by independent auditors and tax professionals
in Fiscal 2025. The charter also authorizes the Audit Committee to delegate to one or more of its members pre-approval authority with
respect to permitted services. The decisions of any Audit Committee member to whom pre-approval authority is delegated must be presented
to the full Audit Committee at its next scheduled meeting. The Audit Committee has not delegated such authority to its members.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
committee report</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee of the Board is composed of two directors, each of whom meets the current NYSE American test for independence. The Committee
acts under a written charter adopted by the Board. The Audit Committee has prepared the following report on its activities with respect
to the Company&#8217;s audited financial statements for Fiscal 2025 (the Audited Financial Statements):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee reviewed and discussed the Company&#8217;s Audited Financial Statements with management;</span></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
     </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee discussed with Manohar Chowdhry &amp; Associates, the Company&#8217;s independent auditors for Fiscal 2025, the matters
required to be discussed by AS 1300, as adopted by the Public Company Accounting Oversight Board;</span></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
     </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee received from the independent auditors the written disclosures regarding auditor independence and the letter required
by Independence Standards Board Standard No. 1 (Independence Discussions with Audit Committees), discussed with Manohar Chowdhry &amp;
Associates, its independence from the Company and its management, and considered whether Manohar Chowdhry &amp; Associates&#8217;&#160;provision
of non-audit services to the Company was compatible with the auditor&#8217;s independence; and</span></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
     </table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the review and discussion referred to above, and in reliance thereon, the Audit Committee recommended to the Board that the Audited
Financial Statements be included in the Company&#8217;s Annual Report on Form 10-K for Fiscal 2025, for filing with the U.S. Securities
and Exchange Commission.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
members of the Audit Committee concur in this report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AUDIT
COMMITTEE:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
Prins</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
Moran</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
IV</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center">&#160;</p><div>

</div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify">The exhibits listed in the accompanying index
to exhibits are filed, furnished, or incorporated by reference as part of this Annual Report on Form 10-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify">(a) All Financial Statements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Index
    to Consolidated Financial Statements</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#f_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report
    of Independent Registered Public Accounting Firms</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">52</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#f_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Balance Sheets</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">53</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#f_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Operations and Comprehensive Loss</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">54</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#f_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Stockholders&#8217;&#160;Equity</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">55</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#f_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Cash Flows</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">56</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#f_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    to Consolidated Financial Statements</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">57</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify">(b) Exhibits required by Item 601 of Regulation
S-K</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518512001643/ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended&#160;and Restated Articles of Incorporation of the Registrant, as amended on August 1, 2012. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on August 6, 2012).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518521000102/ex_222078.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment&#160;to the Amended and Restated Articles of Incorporation of the Registrant as amended on August 2, 2014. (incorporated by reference to Exhibit 3.3 to the Company&#8217;s Post-Effective Amendment No.1 to Form S-3 filed on January 22, 2021).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518523000238/ex_490458.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles&#160;of Amendment to the Company&#8217;s Amended and Restated Articles of Incorporation filed with the State Department of Assessments and Taxation of Maryland on March 7, 2023 (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on March 21, 2023).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518521000102/ex_222077.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By-laws&#160;of the Registrant. (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Post-Effective Amendment No.1 to Form S-3 filed on January 22, 2021).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518523000238/ex_490459.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment&#160;to the Bylaws of the Company dated March 2, 2023 (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on March 21, 2023).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518524000300/igcpharma20240320_424b5.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description&#160;of Common Stock (incorporated by reference to a prospectus supplement filed on March 22, 2024, to Prospectus effective January 8, 2024)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.01**</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518517002130/ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018&#160;Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Definitive Proxy Statement on Form DEF 14A dated October 10, 2017).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.02**</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518521001711/ex_309900.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment&#160;Agreement, effective as of November 18, 2021, by and between India Globalization Capital Inc. and Mr. Ram Mukunda (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on November 19, 2021).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.03**</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518521001863/ex_318372.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted&#160;Stock Unit Agreement with CEO Mr. Ram Mukunda (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-8 filed on December 23, 2021).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.04**</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518523000448/ex_514800.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment&#160;Agreement, effective as of May 9, 2023, by and between IGC Pharma, Inc. and Ms. Claudia Grimaldi (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on May 5, 2023).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.05</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518517001372/ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The&#160;definitive license agreement with the University of South Florida making IGC the exclusive licensee of the U.S. patent filing entitled &#8220;THC as a Potential Therapeutic Agent for Alzheimer&#8217;s Disease&#8221;&#160;(incorporated by reference to Exhibit 99.1 to the Company&#8217;s Current Report on Form 8-K dated June 12, 2017).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.06</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518523001111/ex_587005.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales&#160;Agreement dated March 19, 2024, by and between IGC Pharma, Inc. and A.G.P./Alliance Global Partners (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on March 21, 2024).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.07</span></td>
    <td>&#160;</td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518523000691/ex_541634.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Master&#160;Loan Agreement, dated June 30, 2023, between IGC Pharma, Inc. and O-Bank, CO., LTD (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on July 7, 2023).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.08</span></td>
    <td>&#160;</td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518524000755/ex_707439.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extension of Master Loan Agreement between IGC Pharma, Inc. and O-Bank, CO., LTD. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on August 2, 2024).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.09</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518523000688/ex_541546.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of Share Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on July 7, 2023).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518524000324/ex_645636.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Purchase Agreement, dated March 22, 2024, between IGC Pharma, Inc. and Bradbury Asset Management (Hong Kong) Limited (&#8220;Bradbury&#8221;) (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K on March 28, 2024). &#8224;</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518524000233/ex_637840.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IGC&#160;Form of Board of Directors Agreement&#160;(incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on March 13, 2024).</span></a></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518524000923/ex_727832.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Purchase Agreement, dated September 25, 2024, between IGC Pharma, Inc. and Moran Global Strategies, Inc. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on September 27, 2024).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><a href="igcex19-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider Trading Policy</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><a href="igcex21-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries&#160;of India Globalization Capital, Inc.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><a href="igcex23-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent&#160;of Manohar Chowdhry &amp; Associates.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><a href="igcex31-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate&#160;pursuant to 17 CFR 240.13a-14(a).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><a href="igcex31-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate&#160;pursuant to 17 CFR 240.13a-14(a).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><a href="igcex32-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate&#160;pursuant to 18 USC. &#167;&#160;1350.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><a href="igcex32-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate&#160;pursuant to 18 USC. &#167;&#160;1350.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518524000650/ex_691490.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dodd-Frank Clawback Policy (incorporated by reference to Exhibit 97.1 to the Company&#8217;s Annual Report on Form 10-K filed on June 24, 2024)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1326205/000118518525000657/igcex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical Study Presentation, dated June 17, 2025 (incorporated by reference to Exhibit 99.1 to the Company&#8217;s Registration Statement on Form 8-K filed on June 17, 2025).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS***</span></td>
    <td>&#160;</td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH***</span></td>
    <td>&#160;</td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL***</span></td>
    <td>&#160;</td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF***</span></td>
    <td>&#160;</td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB***</span></td>
    <td>&#160;</td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE***</span></td>
    <td>&#160;</td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 10%"><div style="font-size: 1pt; border-top: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 0.35in">*</td>
    <td>Filed herewith.</td></tr>
  <tr style="vertical-align: bottom">
    <td>**</td>
    <td>Indicates management contract or compensatory plan or arrangement.</td></tr>
  <tr style="vertical-align: bottom">
    <td>***</td>
    <td>Furnished herewith</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#8224;</td>
    <td style="text-align: justify">Certain schedules or similar attachments to this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K.</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
16. FORM 10 - K SUMMARY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center">&#160;</p><div>

</div><div><a id="a_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify">Pursuant to the requirements of Section 13 or
15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IGC PHARMA, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 27, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ram Mukunda</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ram Mukunda</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">President and Chief Executive Officer<br/> (Principal Executive Officer)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 27, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Claudia Grimaldi</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claudia Grimaldi</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">Vice-president &amp; Chief Compliance Officer<br/> (Principal Financial Officer)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and
on the dates indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 27, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ram Mukunda</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ram Mukunda</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">President, Chief Executive Officer, and Director<br/> (Principal Executive Officer)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 27, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Claudia Grimaldi</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">Claudia Grimaldi<br/> Vice-president &amp; Chief Compliance Officer, and Director <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/> (Principal Financial Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 27, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Rohit Goel</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rohit Goel</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accounting Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 27, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Richard Prins</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard Prins</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 27, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ James Moran</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Moran</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 27, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Terry L. Lierman</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terry L. Lierman</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center">93</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center">&#160;</p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c3" id="hidden-fact-0" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">http://fasb.org/us-gaap/2025#AccruedLiabilitiesCurrent</ix:nonNumeric>
<ix:nonNumeric contextRef="c4" id="hidden-fact-1" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">http://fasb.org/us-gaap/2025#AccruedLiabilitiesCurrent</ix:nonNumeric>
<ix:nonFraction contextRef="c0" id="hidden-fact-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-15433">0001326205</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-15434">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-15435">FY</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="igc-20250331.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact ix_1_fact" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_2_fact ix_3_fact" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_4_fact ix_5_fact" toRefs="ix_2_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_6_fact ix_7_fact" toRefs="ix_3_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-20</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">igc:SharePurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">igc:SharePurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">igc:FiscalYear2026Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">igc:ClinicalTrialInventoryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">igc:ClinicalTrialInventoryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="igc:PropertyPlantAndEquipmentTableTypeAxis">igc:PropertyPlantAndEquipmentTableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-11</xbrli:startDate>
    <xbrli:endDate>2020-06-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">igc:March2024SPAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-22</xbrli:startDate>
    <xbrli:endDate>2024-03-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">igc:March2024SPAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">igc:September2024SPAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-25</xbrli:startDate>
    <xbrli:endDate>2024-09-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">igc:September2024SPAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">igc:SalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">igc:SharePurchaseAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">igc:SharePurchaseAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">igc:ESOP2008OmnibusPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">igc:ESOP2008OmnibusPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLAKD9Z7zGpK2qQstFsfCu8xSrtW9H2+v0Xv0rh9+KH/Pz8D0bXTVzCQTQCC6nPug5x2WprRNZyO0vKrGf3yPx7zySn86Xz+cpPHpOaLInCIyy5s5q8xj2k941QApP+Uc6E50B2zYbnR/55u68AGKs/8SiUy11i4tM/dKp4JuQDXDaZK3azYQ8+FvMTMkrrL0geMSLbxuaBiHnRwR+bXpnAtJyE4+eDKkLzE=] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">igc:DebtFundsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">igc:DebtFundsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">igc:DebtFundsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">igc:DebtFundsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2029Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2030Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2031Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2032Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2033Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2034Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2035Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2036Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2037Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2038Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2039Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2040Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2041Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2042Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2043Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2044Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2045Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">igc:WellnessAndLifestyleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">igc:WellnessAndLifestyleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">igc:TollingWhiteLabelingServiceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">igc:TollingWhiteLabelingServiceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">igc:OtherRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">igc:OtherRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">igc:InfrastructureSegmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">igc:PlantAndCannabinoidMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">igc:PlantAndCannabinoidMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CO</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CO</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-06-24</xbrli:startDate>
    <xbrli:endDate>2025-06-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-06-24</xbrli:startDate>
    <xbrli:endDate>2025-06-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="segment">
  <xbrli:measure>igc:segment</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>2
<FILENAME>igcex19-1.htm
<DESCRIPTION>EXHIBIT 19.1
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="text-align: right; margin-top: 0px; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
19.1</b></font></p>

<p style="margin-top: 0px; font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-bottom: 0px">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: center; margin-bottom: 0px">INSIDER TRADING AND REPORTING POLICY</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: center; margin-bottom: 0px">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: center; margin-bottom: 0px">IGC PHARMA, INC.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: center; margin-bottom: 0px">(formerly known as
India Globalization Capital, Inc.)</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: center; margin-bottom: 0px">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: center; margin-bottom: 0px">(NYSE: IGC) Adopted 2005</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: center; margin-bottom: 0px">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: center; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amended
</b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><b>, 2025</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: center; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">IGC Pharma, Inc. and its subsidiaries
and related corporations and partnerships (collectively, &ldquo;IGC&rdquo; or the &ldquo;Corporation&rdquo;) are always firmly committed
to the principles of fair and open markets for publicly traded securities. This policy specifically addresses employee trading in publicly
traded securities and the reporting of such trades by the employee when applicable.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">The securities law of the United States
prohibits trading in the securities of a company based on &ldquo;inside&rdquo; information. Anyone violating these laws is subject to
personal liability and could face criminal penalties. IGC takes seriously its obligation, and that of its employees, to prevent insider
trading violations. Accordingly, IGC has established this Insider Trading and Reporting Policy to assist all Employees in complying with
their obligations. This policy does not replace the individual responsibility to understand and comply with the legal prohibitions on
insider trading.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">This policy applies equally to all
Employees of IGC regardless of their position, level, or function. For purposes of this policy, the term &ldquo;Employees&rdquo; includes
employees, officers, and directors, including officers and directors of subsidiaries of IGC. It applies to all transactions in IGC securities,
including common stock, options for common stock, any other securities IGC may issue from time to time, and derivative securities relating
to IGC securities, whether issued by IGC. It also applies to the securities of other companies under the circumstances described below.
It applies not only to securities owned by an Employee (legally or beneficially) but also to securities over which an Employee exercises
control or direction.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">Please note that the laws of the United
States regarding insider trading and reporting apply to persons living outside the United States, regardless of nationality, when the
securities are traded in a United States market such as NYSE AMERICAN.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warning:
</b></font>The responsibility for complying with the insider trading policy and related reporting requirements rest with the individual
insider. Securities laws vary from one jurisdiction to another and may change over time. The consequences of non-compliance can be serious.
If uncertain about the legal obligations, one should seek advice from legal counsel independent of IGC and practicing in the area of
securities law.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><b>1.</b></td><td style="text-align: justify"><b>Disclosure of Material Non-public Information</b></td>
</tr></table>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">Maintaining the confidentiality of
IGC&rsquo;s information is essential for competitive, security, and other business reasons, as well as complying with securities laws.
Employees must treat all the information they learn about the Corporation or its business plans in connection with their employment as
confidential and proprietary to the Corporation. Inadvertent disclosure of confidential information or nonpublic information may expose
IGC and its Employees to significant risk of investigation and litigation.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">Accordingly, Employees should be discreet
with confidential information and not discuss it in public places where it can be overheard, such as elevators, restaurants, dinner parties,
taxis, and airplanes. Further, discussion of confidential information should be discouraged on cellular phones or other wireless devices.
To avoid even the appearance of impropriety, Employees should refrain from always providing advice or making recommendations regarding
the purchase or sale of IGC securities.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">The timing and nature of the Corporation&rsquo;s
disclosure of material information to outsiders is subject to legal rules, the breach of which could result in substantial liability
to IGC and its Employees. Responses to inquiries about the Corporation by the press, investment analysts, or others in the financial
community must be made on the Corporation&rsquo;s behalf only through authorized individuals.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: justify; margin-bottom: 0px"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">IGC Insider Trading and Reporting Policy - FYE2025</TD></TR></TABLE></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify">Material Non-public Information</td>
</tr></table>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&ldquo;Material Non-public Information&rdquo;
is defined as information that a reasonable investor would consider important in making an investment decision regarding the purchase
or sale of the securities in question and that has not been previously disclosed to the general public or is otherwise not readily available
to the general public. Material Non-public Information, once it becomes generally known, may reasonably be expected to affect the market
price of the securities in question. Either positive or negative information may be material.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">While it is not possible to define
all categories of material information, examples of information that, as a general rule, should be considered material are as follows:
Financial results, changes in dividend policy, news of a pending or proposed merger, new equity or debt offerings, news of a pending
or proposed significant acquisition or disposition, significant acquisitions or divestitures, impending bankruptcy or financial liquidity
problems, significant exposure due to actual or threatened litigation, gain of a significant client, changes in senior management, etc.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">Information is not public merely because
it is reflected by rumors or unofficial statements in the marketplace. Generally, information regarding relatively simple matters, such
as earnings results, will be considered to have been adequately disseminated and absorbed by the marketplace two full trading days after
the issuance of a press release by IGC. When more complex matters, such as a prospective major acquisition or disposition, are announced,
it may be necessary to allow additional time for the information to be processed by investors. IGC may circulate a notice, if and when
appropriate, advising as to the amount of additional time required for the information relating to more complex matters to be disseminated
and absorbed by the marketplace and before trading in securities of the Corporation may commence.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">3.</td><td style="text-align: justify">Insider Trading</td>
</tr></table>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">The term &ldquo;insider trading&rdquo;
generally refers to buying or selling a security while in possession of Material Non-public information about the security. Insider trading
violations may also include &ldquo;tipping&rdquo; such information, securities trading by the person &ldquo;tipped&rdquo;, and securities
trading by those who misappropriate such information.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">No Employee who is aware of Material
Non-public Information regarding IGC may, directly or indirectly (including through a Related Person), (a) purchase or sell the Corporation&rsquo;s
securities, (b) gift the Corporation&rsquo;s securities, (c) engage in any other action to take advantage of that information or (d)
provide that information to others outside the Corporation, including family and friends. For purposes of this policy, a &ldquo;Related
Person&rdquo; includes a spouse, minor children, and anyone else living in an Employee&rsquo;s household; partnerships in which Employees
are a general partner; trusts of which Employees are a trustee; and estates of which Employees are an executor.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">In addition, this rule applies to
trading in the publicly traded securities of other companies. If Employees obtain Material Non-public Information concerning a customer,
a supplier, a potential customer or supplier or other company doing or contemplating doing business with IGC, the law considers that
individual to be an insider of that company for securities trading purposes and, therefore, he/she may not purchase or sell such company&rsquo;s
securities or make trading recommendations to others until the information becomes public or is no longer material. Employees must also
always remember that information that may not be material to IGC may be material to a supplier or other company.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">If Employees are aware of Material
Non-public Information, they must forego a transaction in the relevant securities, even though: (i) the transaction was planned before
learning of the Material Non-public Information; (ii) money or a potential profit may be lost by not completing the transaction; or</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">(iii) the transaction may be necessary
or seem justifiable for independent reasons (including a need to raise money for a personal financial reason).</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: justify; margin-bottom: 0px"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: left">IGC Insider Trading and Reporting Policy - FYE2025</TD></TR></TABLE></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">This rule does not apply to the purchase
of stock under the IGC Employee Stock Plan. However, stock that has been acquired through the IGC Employee Stock Plan is subject to this
policy and may not be sold by an Employee who is in possession of Material Non-public Information.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">This policy continues to apply to
an Employee&rsquo;s transactions in IGC securities even after such Employee has terminated employment or other services to IGC. If the
individual is aware of Material Non-public Information when the employment or service relationship with IGC terminates, he/she may not
trade in the relevant securities until that information has become public or is no longer material.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">An individual Employee resident in
the United States may be able to engage in trading while in possession of Material Non-public Information if, prior to the receipt of
such information, he or she has already implemented a trading plan under SEC Rule 10b5-1. Such a trading plan involves the automatic
trading of securities in such a way that the individual does not have discretion over whether the securities are purchased or sold. It
must be entered into in good faith and at a time when the individual is not in possession of any Material Non-public Information. If
you wish to implement a Rule 10b5-1 trading plan, you must contact IGC&rsquo;s General Counsel for review of the plan and approval prior
to doing so.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: justify; text-indent: 0px; margin-bottom: 0px">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">4.</td><td style="text-align: justify">Restrictions on Options Trading and Short Sales</td>
</tr></table>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">Employees may not trade in unexercised
IGC stock options, Restricted Stock Units, or Performance Stock Units issued pursuant to IGC&rsquo;s Long Term Incentive Plan, or derivatives
of the same.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">Employees may not trade in put, call,
or other financial market options involving IGC securities without prior authorization from IGC&rsquo;s General Counsel. Approval of
such transactions will generally only be granted for estate planning transactions.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">Employees shall refrain from all short
sales of IGC securities.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">5.</td><td style="text-align: justify">Blackout Policy (applicable to Restricted Persons)</td>
</tr></table>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">Restricted Persons are those most
likely to have knowledge of undisclosed material facts or material changes with respect to the Corporation.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">Accordingly, they are subject to a
more restrictive trading policy. Restricted Persons include: (i) the members of the Corporation&rsquo;s Board of Directors; (ii) those
persons designated as &ldquo;executive officers&rdquo; of the Corporation by the Board of Directors from time to time, as well as their
spouses and immediate family members sharing the same household; (iii) entities controlled by any such person; and (iv) any other person
(and their spouses and immediate family members sharing the same household and entities controlled by any such person) designated by
IGC&rsquo;s Chief Executive Officer, General Counsel or Chief Financial Officer, including, in some cases, persons designated as such
for specific limited time periods.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">In addition to the rules on trading
outlined above, IGC has adopted the following policy to regulate the trading of securities of the Corporation by Restricted Persons:</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">(a)</td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
Persons may not engage in transactions involving the securities of the Corporation during the period commencing and ending on each of
the following dates in any given year (&ldquo;Quarterly Blackout Periods&rdquo;):</font></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 19%; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Start
    Date</b></font></td>
    <td style="padding-bottom: 1pt; width: 1%">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>End
    Date</b></font></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31</font></td>
    <td>&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4
    hours following disclosure by IGC of its annual financial results for the preceding year on Form 10-K.</font></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    30</font></td>
    <td>&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4
    hours following disclosure by IGC of its financial results for the first quarter on Form 10-Q.</font></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    30</font></td>
    <td>&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4
    hours following disclosure by IGC of its financial results for the second quarter on Form 10-Q.</font></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31</font></td>
    <td>&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4
    hours following disclosure by IGC of its financial results for the third quarter on Form 10-Q.</font></td></tr>
  </table>
<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">(b)</td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
Persons shall refrain from purchasing or selling securities of the Corporation frequently so as to appear to be speculating in securities
of the Corporation. Certain Restricted Persons may become liable pursuant to Section 16(b) of the Exchange Act to pay over to the Corporation
any &ldquo;short swing&rdquo; profits realized by them from the purchase and sale of IGC securities, where such purchase and sale take
place within a period of less than six months; and</font></td>
</tr></table>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: justify; margin-bottom: 0px"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: left">IGC Insider Trading and Reporting Policy - FYE2025</TD></TR></TABLE></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">(c)</td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
Persons shall inform the General Counsel or, failing him, the Chief Financial Officer of the Corporation, not less than one trading day
immediately prior to buying or selling securities of the Corporation to allow for responsible monitoring of trades by insiders, officers
and senior Employees to ensure that no material information exists or material event has transpired that could cause a breach of this
policy in the event of a purchase or sale by that Restricted Person of securities of the Corporation.</font></td>
</tr></table>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">From time to time, the Corporation
may circulate notices to Restricted Persons, alerting them to material events and information and specifying blackout periods during
which securities of the Corporation should not be bought or sold by Restricted Persons. It should be noted that these unscheduled trading
blackout periods are in addition to the prohibition on trading at any time when an individual has knowledge of Material Non-public Information.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">6.</td><td style="text-align: justify">Insider Reporting Obligations</td>
</tr></table>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">IGC is subject to the securities laws
of the United States.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: justify; margin-bottom: 0px">IGC&rsquo;s Legal Department will
assist insiders with the completion and filing of the necessary forms. Nevertheless, responsibility for complying with insider reporting
obligations rests with the individual Employee, and IGC assumes no responsibility for any errors or omissions that may occur in providing
such assistance to Employees.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">Warning: The responsibility for complying
with the insider reporting requirement rests with the individual insider. Securities laws vary from one jurisdiction to another and may
change over time. The consequences of non-compliance can be serious. If uncertain about the legal obligations, one should seek advice
from legal counsel independent of IGC and practicing in the area of securities law. The following summary descriptions of the applicable
law and reporting procedure is offered for information purposes only, and is not a substitute for legal advice regarding individual circumstances.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">U.S. Federal Law</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">The federal securities laws, rules,
and regulations which impose insider trading and reporting restrictions include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
                                            16 of the Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;).</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
                                            10(b), Rule 10b-5 and related rules, all adopted under the Exchange Act.</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
                                            144, adopted under the Securities Act of 1933 (the &ldquo;Securities Act&rdquo;).</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation
                                            13D-G, adopted under the Exchange Act.</font></td></tr></table>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">Section 16 Reporting and Shortswing
Profit Liability</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section
16(a) </b></font>of the Exchange Act requires directors, officers, and 10% or greater shareholders (&ldquo;Section 16 insiders&rdquo;)
to file reports which disclose the insider&rsquo;s beneficial ownership of, and transactions in, the company&rsquo;s equity securities.
These reports, called Forms 3, 4, and 5, must be filed within specific time frames with the SEC, the applicable stock exchange, and the
company itself.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">Section 16(a) of the Exchange Act
requires insiders to file an initial report on Form 3 within ten days after the date the person acquires insider status. Subsequently,
most transactions involving the Corporation&rsquo;s securities, including the purchase and sale of shares, must be reported on Form 4
before the end of the second business day following the day on which a reportable transaction has been executed. There is also a requirement
to file an annual report on Form 5 within 45 days after the end of the Corporation&rsquo;s fiscal year (March 31), if the insider has
had any transactions in IGC securities during the fiscal year that were not previously reported.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section
16(b) </b></font>of the Exchange Act presumes that every director, officer and 10% or greater shareholder has the benefit of material
nonpublic information concerning the company and imposes an arbitrary limit on trading in the company&rsquo;s securities: The profits
of any purchase and sale, or any sale and purchase, of securities made by a Section 16 insider within any six-month period are recoverable
by the company, either in a suit by the company or by a shareholder on behalf of the company.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: justify; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section
16(c) </b></font>of the Exchange Act prohibits Section 16 insiders from selling short (selling securities which they do not own) and
from selling against the box (selling securities which they own, but which would not be delivered within 20 days of the sale, or which
would not be deposited in the mail within five days of the sale). Section 16(c) prevents Section 16 insiders from engaging in such transactions
because such transactions allow them to either reap a profit or avoid a loss based on material nonpublic information, to which they presumably
have access.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: justify; margin-bottom: 0px"></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: left">IGC Insider Trading and Reporting Policy - FYE2025</TD></TR></TABLE></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">Insider Trading Prohibitions</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section
10(b) </b></font>of the Exchange Act and <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rule 10b-5 </b></font>make
it unlawful for any person to engage in fraudulent activity in connection with the purchase or sale of any security. Section 10(b) and
Rule 10b-5 apply to insider transactions regardless of whether the issuer is private or public. Although there is not a well-recognized
definition of insider trading, insider trading typically assumes one of two forms.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">Rule 10b-5 insiders are prohibited
from:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading
                                            either for themselves or on behalf of others on the basis of material, nonpublic information,
                                            and</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosing
                                            or &ldquo;tipping&rdquo; material, nonpublic information to others such as family members
                                            or friends. If the recipient of the material nonpublic information, the &ldquo;tippee,&rdquo;
                                            trades on the basis of such information and has reason to know that the insider, or &ldquo;tipper,&rdquo;
                                            unlawfully disclosed such information, then both the tippee and the tipper are subject to
                                            liability, even if the insider who discloses the information receives no pecuniary benefit
                                            from the transaction.</font></td></tr></table>

<p style="margin-top: 0px; font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">Restrictions on Resales of Securities
&mdash; Rule 144</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">Under the Securities
Act, it is unlawful for any person to sell or offer to sell securities unless the transaction either has been registered under the
Securities Act or is exempt from registration. Rule 144 under the Securities Act provides a &ldquo;safe harbor&rdquo; from the
Securities Act&rsquo;s registration requirements for public sales of restricted securities (securities originally issued in a
transaction other than a public offering) and securities owned by &ldquo;affiliates&rdquo; such as directors, officers, principal
shareholders and others in a control relationship with the company. Although Rule 144 is not the exclusive means for shareholders to
make unregistered sales of their shares, compliance with Rule 144 is the simplest and most certain way to ensure that sales of
restricted securities and securities owned by affiliates comply with the registration requirements of the Securities Act.</p>

<p style="margin-top: 0px; font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">Reporting Obligation of 5% Shareholders
&mdash; Regulation 13D-G</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation
13D-G </b></font>under the Exchange Act requires that persons or groups of persons who acquire or beneficially own more than 5% of a
public company&rsquo;s equity securities (&ldquo;5% holders&rdquo;) disclose their ownership and transactions in such securities either
on Schedule 13G or Schedule 13D. Like Section 16(a) reports, these forms must be filed within specific time frames with the SEC, the
applicable stock exchange, and the company.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">Regulation 13D-G refers to beneficial
(as opposed to record) ownership of securities. Unlike the definition for purposes of Section 16 described above, a beneficial owner
of a security includes any person who, directly or indirectly, has or shares voting power and/or investment power. A person is also treated
as the beneficial owner of a security if he or she has the right to acquire beneficial ownership of the security at any time within 60
days, such as through the exercise of options or conversion of other securities.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">7.</td><td style="text-align: justify">Consequences of Violation of this Policy</td>
</tr></table>

<p style="margin-top: 0px; font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">Failure to follow this policy may
lead to disciplinary action, as well as civil and criminal liability.</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">The following are some of the potential
consequences:</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liability
for Insider Trading: Employees may be subject to disgorgement of profits (or losses avoided), trebled in some cases, monetary penalties,
and time in prison for engaging in transactions in securities made on the basis of Material Non-public Information regarding the issuer
of the securities.</font></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td>&nbsp;</td><td style="text-align: left">&nbsp;</td><td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td></td><td style="text-align: left">&#9679;</td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liability
for Tipping. An Employee may also be liable for improper transactions by any tippee who receives Material Non-public Information from
that Employee. The SEC has imposed large penalties even when the disclosing person did not profit from the trading. The SEC, stock exchanges,
and the National Association of Securities Dealers, Inc. use sophisticated electronic surveillance techniques to uncover insider trading.</font></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td>&nbsp;</td><td style="text-align: left">&nbsp;</td><td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Possible
Disciplinary Actions. Employees who violate this Policy shall also be subject to disciplinary action by the Corporation, which may include
immediate termination of employment.</font></td>
</tr></table>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px">&nbsp;</p>

<p style="margin-top: 0px; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0px"></p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: left">IGC Insider Trading and Reporting Policy - FYE2025</TD></TR></TABLE></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; text-align: justify; margin-bottom: 0px"></p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>igcex21-1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0px; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
21.1</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below lists our subsidiaries.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Subsidiaries</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Ultimate<BR> holding <BR> company</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Jurisdiction&nbsp;of<BR> Incorporation</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage&nbsp;of<BR> holding<BR> as of <BR> March&nbsp;31, <BR> 2025</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage&nbsp;of<BR> holding<BR> as of <BR> March&nbsp;31, <BR> 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left">IGCare, LLC</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 11%">IGC</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 11%; text-align: left">Maryland, USA</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">IGC Pharma, LLC</td><td>&nbsp;</td>
    <td>IGC</td><td>&nbsp;</td>
    <td style="text-align: left">Colorado, USA</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">HH Processors, LLC (formerly Holi Hemp, LLC)</td><td>&nbsp;</td>
    <td>IGC</td><td>&nbsp;</td>
    <td style="text-align: left">Maryland, USA</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Sunday Seltzer, LLC</td><td>&nbsp;</td>
    <td>IGC</td><td>&nbsp;</td>
    <td style="text-align: left">Maryland, USA</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">SAN Holdings, LLC</td><td>&nbsp;</td>
    <td>IGC</td><td>&nbsp;</td>
    <td style="text-align: left">Maryland, USA</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">IGC Pharma SAS (1)</td><td>&nbsp;</td>
    <td>IGC</td><td>&nbsp;</td>
    <td>Colombia</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Techni Bharathi Private Limited (TBL)</td><td>&nbsp;</td>
    <td>IGC</td><td>&nbsp;</td>
    <td>India</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">India Mining and Trading Private Limited (IGC-IMT) (2)</td><td>&nbsp;</td>
    <td>IGC</td><td>&nbsp;</td>
    <td>India</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">IGC Materials Private Limited (IGC-MPL) (2)</td><td>&nbsp;</td>
    <td>IGC</td><td>&nbsp;</td>
    <td>India</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">IGC Enterprises Limited (IGC-ENT)</td><td>&nbsp;</td>
    <td>IGC</td><td>&nbsp;</td>
    <td style="text-align: left">Hong Kong</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Hamsa Biopharma India Pvt. Ltd.</td><td>&nbsp;</td>
    <td>IGC</td><td>&nbsp;</td>
    <td>India</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">IGC Pharma IP, LLC</td><td>&nbsp;</td>
    <td>IGC</td><td>&nbsp;</td>
    <td style="text-align: left">Maryland, USA</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"></p>

<!-- Field: Rule-Page --><div style="width: 10%"><div style="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficially
    owned by IGC</font></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IGC-IMT
    and IGC-MPL are non-operating subsidiaries. These subsidiaries did not have a material impact on the balance sheet or statement of
    operations.</font></td></tr>

  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"></p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>igcex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0px; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
23.1</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IGC
Pharma, Inc.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation by reference to the Registration Statement No. 333-274853, 333-261861, No. 333-226960, and No. 333-236615
on Form S-8 pertaining to the IGC Pharma, Inc. 2018 Omnibus Incentive Plan and Special Grants, and (ii) Registration Statement No. 333-274802,
No. 333-276330, and No. 333-278775 on Form S-3, of our report dated June 27, 2025, with respect to the consolidated financial statements of
IGC Pharma Inc. included in this Annual Report (Form 10-K) for the fiscal year ended March 31, 2025.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 40%">/s/ Manohar Chowdhry &amp; Associates</td>
    <td style="width: 60%">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Manohar Chowdhry &amp; Associates</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Chennai, India</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>June 27, 2025</td>
    <td>&nbsp;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify"></p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>igcex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0px; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
31.1</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"><b>CERTIFICATION OF PRINCIPAL
EXECUTIVE OFFICER PURSUANT TO 17 CFR 240.13(a)-14(a)<br>
(SECTION 302 CERTIFICATION)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Ram Mukunda, certify that:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have reviewed this annual report on Form 10-K of IGC Pharma, Inc.;</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal
control over financial reporting.</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 27, 2025</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ram Mukunda</font></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ram Mukunda</font></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</font></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify"></p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>igcex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0px; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
31.2</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CERTIFICATION
OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 17 CFR 240.13(a)-14(a)</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(SECTION
302 CERTIFICATION)</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Claudia Grimaldi, certify that:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have reviewed this annual report on Form 10-K of IGC Pharma, Inc.;</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal
control over financial reporting.</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 60%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 27, 2025</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 4%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 36%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Claudia Grimaldi</font></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claudia Grimaldi<br>
Vice-president &amp; Chief Compliance Officer</font></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer)</font></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify"></p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>igcex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0px; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
32.1</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CERTIFICATION
PURSUANT TO 18 USC. SECTION 1350</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AS
ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the annual report on Form 10-K of IGC Pharma, Inc. (the &ldquo;Company&rdquo;) for the year ended March 31, 2025, as
filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Ram Mukunda, Chief Executive Officer,
and President of the Company, certify, pursuant to 18 USC. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002, that:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    of the Company.</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    June 27, 2025</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Ram Mukunda</font></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ram
    Mukunda</font></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer<br>
 (Principal Executive Officer)</font></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0; text-align: justify"></p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>igcex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0px; margin-bottom: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
32.2</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CERTIFICATION
PURSUANT TO 18 USC. SECTION 1350</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AS
ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the annual report on Form 10-K of IGC Pharma, Inc. (the &ldquo;Company&rdquo;) for the year ended March 31, 2025, as
filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Claudia Grimaldi, Vice President,
Principal Financial Officer of the Company, certify, pursuant to 18 USC. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    of the Company.</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0px 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 60%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 27, 2025</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 4%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 36%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Claudia Grimaldi</font></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claudia
    Grimaldi<br>
Vice-president &amp; Chief Compliance Officer<br>
 (Principal Financial Officer)</font></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0px; margin-bottom: 0px; text-align: center"></p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !9 %D# 2(  A$! Q$!_\0
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M5"+G9KF]E"$N2#TA*;E:[5O4"=H&<GI_]?U&?QH!# Y''0_3'//^?6OY@?\
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+ %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $B =L# 2(  A$! Q$!_\0
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M.#\^P\7)86&(BKW^K5Z=65EU5.7LIN_1)2;VM<ZJ6=Y=4=G6E2>G\6G."_\
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M K2&*5D#,A->+:;K%YI:ZD+-H@NKZ?<:9>B6)9 ]K<E6D" X$<H*C9(!F/D
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ML3R$J$B90=J-&-R//YL%RN]6V.FP=6=5\%?%1?L5_#_PCOB),K87#R1,\Q?
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ME2G*$G3G:4=4FOEJ&-Q.&@X4:KA"52-222C=RCRZ<UN=1DHI3BI)26CT;O\
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M)YGMT6((]X9?EBEPN[;$)2/D5UX:OQ,_X(5_ OXVZKI/QM_X*!_M/ZW?ZO\
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M\ #J3Z4 %='X<\*ZSXIN7@TN!?*A :ZOKAC%96B$9W33$'+8!81QJ\A56(7
M)K\QOBI_P56_8J^#GQ?OO@KXT^(VK#Q-H>JPZ%XNUO1/"NK:UX,\&:U,ZQ_V
M;XB\1V<;6T,]I(P34VM$NHM,=95NY$,,FW]9O@_XEUK4I;+3O"NJ:1=:#K=M
M'KT-\Z1WUG/IUS;V\T6I:;-!*ANH[VTDMI+<+(T4L;QRDH@8T^)<MX@R'**>
M8U\LKY='&89XO 8G-L/B,+A<1A8QA.IB*$I4Y>V<*52E5A2:IN<:U&;A[*K3
MG4G*L7EF8XV>%I8NGBI4*OL<32P56G6K4JS<HQIU(J2Y$YPG"4TY*+A.*ESP
ME&/Y!?\ !8WXF?'7]G']E32_$?PSU/6? -MXU^*WA3X?^+?BOH]E)<7_ (/\
M&:U]M:]U;1&"_:+2YU,6PAM[]5@O(X5:&SDAN;N*5?(/^".?Q>\22_MO?'+]
MFWP)^TMXF_;?_9ATSX):#\0(OB]X^L]1NM1\(^.;Z]T>WN/#^GZEKHFOIK'4
M9;_5-.N[0R"Q:YTA6MHA+:W<L_\ 0?\ M/\ P$\"?M)? 3XA?!GXF:1-XB\,
M^+?#EY8W-M:*(KV.]2(RZ=J6F*JND&J:9?);WVFRA&-O=V\3KT.?CO\ X)O_
M +"WPJ_X)I? B]\+_P!L-XB^)'Q U^XUWX@^-[O3TAUSQ%-;37%MX8\/V6F6
MCW3V6E>'-%DBC2R21@^JWFJ7\[J]Y'!!I@_$7AW&>#W$&08C+?:\88W,,3E>
M!P>%P.%JPQ\<QJY9CL+Q#4S">'EF^%Q'#.'RK&87#8?"8W!X2M/-[5L/7I^V
M='/$<+YI0XXRW,J6*Y,CH8:EB\37K8BM"6&>%AB\/6RN&%C56"K4LVJXRA6J
MU*V'KUX1P-X5:<N13]#_ &S/VX+O]E_Q-\*_A%\-O@+XM_:)^,_Q<TOQEKWA
MGX;^%->TKP9;6G@GX>:?#?>+M?O_ !)JUG?6EM]@M;B-;#3+>RDGO&68^;;B
M*,3=Q^Q/\5OA)^U#\"?!'[1'P\T+6K&R\8Q:I!-IGB\07&M^'=<T35;W1M?T
M:=H-UC--IVIVES9C4;0;+V"*.X7RC+)$OP?_ ,%2_P!E>X_;O\*>#D^&>JS?
M#_XM?"K69I/!_CF8ZK87;>'?$WDZ;X\\-ZHVC^9?P6%]I\<%]8QK\TFH::+2
MX5+?4)VC_3W]E?X#^$OV9OV?/A7\#_!,#Q:%X"\*6.F_:)T1+S5-4N U_K>M
M7X0 &^UG5[N]U&Z!+;);@Q!BL:U_+]/#\=9/GN;TLR<\)PUCL'@ZF 5.MA$\
M15G&G+V,E0;QZQ.&Y<=+,EBZSPTX8O+%AHN:KN7]G<2/Z.N,^CWX<8KA;ZU7
M\>UQ7G6$XVHU)9_)X+)L!+-)5,?C%C*TN%)Y+G-''\'T>"J>0X/#9[A,;DO'
M4^),3B\/B,IAA_?T1(D2.-%CCC541$4*B(H"JJJ  JJ        ,4ZBBNMMM
MMMW;U;>K;>K;;NVVVVVW=L_!PHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH CFABN(I()XTFAE4I)%*JO'(C##*Z,"K*1U!!%?+?BWX;S6OB2^M]"CBAL!
MH\FN6UM-,^^1+5A%?6=F65S+/&S+-'$[ B*098_+GZHKF/$]E?3066I:7Y9U
M#1+P:C'"R M>VHBDBOM.24?-$UW;NP4C*/-'"LBE>5]S(<UQ.68N7L:L80Q-
M.5&4:K?L/:-)T9U(WY4U./LO:63IQQ#E?EIM'GYC@Z6+HKVD'*5*2FG!)5.7
M55(Q=K_"^?EU4I4DK7DC^0;XB_#?XY^%?B;XZ_8G\.Z)H^H^%OCA\2K;XA:-
MXCO/#L5UJ\V@37WVTZU%XC<&6RT_0;>)XO$$9_>07-E-'&\7VY%?]_\ PWHD
M'AGPYX?\-VTTEQ;>'M#TG0H+B8EIIX=)L+>PCFE8\EY5@#L3R2QSS7J_Q&\'
M:-:ZKIGC?2+&SFL=8L[E=.U'[)"UYI7]H/#<:EI<%V4,]K:WLL$,TMHDD<;S
M6[1.C&W7'CGBSQIX-\!:2=>\=>+O#'@O0UF2V_MCQ9KVE^'M-:YD!,=M'>:K
M=6L$MRZJS);Q.\S*K,$*JQ']>\9>*^+\4LIX3P\,FPV73RZA4K9M]1IU*F+X
M@XNKX7+\GS+.<91A&K.CBYY;D.4X%X.C3Y8U</BJ\8.%>@J7C<2Y]6S&&#PV
M)H8;"+ TY5L77IS489AC:M'#T)YG4G.484XUL'A<'&,>:,(M59-^]%1=XQ\(
M^&?'_A/Q'X&\9Z-8^(?"7B[1K_P_XBT/4HEFLM4TG4X&M[NUGC;IN1M\4J%9
M;>=(KB%TFB1UX']F[]F_X<_LX_#;P]\$?@?X9N=/\-:3-?7<5N\S:GKNMZK?
MRM<:CK6NZDZI-J6I3@)')=3A5AM+>WMT"10KG[?^ EEX6\2>&8O'&FRZ1XCM
M=3G=M"\0:=>V6LZ3=Z>B(!=:1>V<MS8W$;S>:C7=O))ED,:R+L9:]W_L72!>
MQZBNF6*7\6[9>QVT45T ZE'!GC59&5E)5E=F4@X(K\*S3C^ME<LPR"G3QLL-
M3Q,:M?#2Q,J6#J9IA:,Z-&M6P5DY3P\:U2A[22A7@G4BJ<7%<G!A.'*>,6%S
M*4L.JTJ+A2K*DIUX8.M.-2<*=?5*-65.-3E7-3E:+<FF^;XBO?#^MZ8T8U32
M[W38Y)D@\^\MY(X$=V"C=* 4X!W8#$D [<FOLCPEX7T[PKI,5C8J'DD"37EX
MP'FWEP5&9'.,B-<E8(A\L4> ,L69K'BO1_[?\.ZOI(5#+=V<J6Q<#"72KOMG
M!;A")E3#\;<D],UF:#JFH1:3HD6JP+:W8T_3X;^"Z6>.ZBE5Y;.>X+JDD,J,
M\4$C#*"%)C+/*B/$&^,S?/<3GV74$O9X>5'%5(XG"4JLG&M'V$:N'K\L_P!Y
M*,)1K4^5\T(U7"5U.4#W,%E]++L54;YJJG2BZ5:<$G3?M'"K3O'W$Y)TY<RM
M)PYE9Q4CLZB=)&DA9)BD:%S+$$1A.&0J@+M\T?EL0^4P6(VM\N:EKSGQ9\8?
MA+X"US1O#'CGXH?#SP;XD\1%!H&@>*O&GASP_K6M>9(T,1TO2]6U*TO;\2SH
MUO$UK!*LEP! A:4A#\I0H8C$5/987#U\35Y*DO98?#UL34Y(0<JD_94*.(J<
MM."E.<_9\M.*<Y3@H\R]BI4I4H\]:K3I0YHKGJU84H<TI)0CSU*E.-Y2M&,>
M:\V^51DW9^C4445B:!1110 4444 %1;9O/+>8GV?RE41>6?,$P=BTAEWX*%"
MJB/8"&4MO.<"6L:[1[8:C>W.HM96"PR2R.C9:&)+95:;?.)$@:%D>1%A39(7
MS*CMBM*4>>3CS)-I1BG"4W*4I0BHPC%.3F[KELKOX5K(F;Y4G9M*[;344DDW
M>3;2Y=-;Z=7L<_\ $77;WP[X6O+_ $Z2.&]>:WM()G"L8C<2;7DB1@5>5(PY
MC!!"D;R"$(/QI++)/+)//(\T\TCRRRR,7DDDD)9W=SDLS,26)/)-=IXV\;W_
M (OO2&9HM(M)7_LZSX!*@;!=W1&/,N95!;^Y"KE(U&6)X>OV?A?)YY1E_+B(
M4EC,1-U:S@DYP@U'V5"=3>3IKF<HQ?)&I.27-*+F_A<VQT<;B;TI3="E%0IJ
M3M&4DWSU(QZ<[LDW[SC%/W4U$*<CO&Z21LR21NLD;J<,CHP9'4]F5@&![$ T
MVBOI6DTT]4TTT]4TU9IKJFFTUU39Y9[CX9^-&H6TD5MXFMUOK7"H;^SC$5[%
MC"^9-!N$5R,#+F/RI"26 ;[I['Q;\7=.TZUL&\,2V.LW-TYDG$IG6*TMU7.V
M9%\J5;B5R%5"0457++]VOEVBOF:W"625L73Q7U;V:BY.IA:<G'"UVXR2<Z=^
M:'*Y<S5&=.,VDI126OJPSG'PHRH^UYFTE&M)7K4TFK\L[6E=*UYQDTF[-O;Z
M:T?XVZ-<(J:WI]WILP'S2VH^VVS$#DA0$N(P3T4I+ZE_2SJ?QC\-/I.I'3FO
M3J0AFAL8)[1XA+*ZE(Y_-!>-(HRWF,)&27"X"$D5\N5W7P^U?3--UV.VUJTM
M;K2M6,%I<_:8DD6VGCF$EE<C>#M2.<[)AT:.0E@P3:>'&<)9-AX5<;1PF+JR
MH)8A8.CBK1J*C)5)TX*K3J-\T(R_=N;YE%PA*+DF;T,YQU24*%2M1BJEZ;KS
MH^]!S3C&<G"45I*2]Y15FU*2:BSA2222Q+,Q+,QZLS$EF/NQ))]S1TZUU_CO
MP_'X:\37^FV__'F^R]L03DK:76YDBSU(@D62$,>66,$X)KD",@@]#P:^MPV(
MI8O#T,31=Z6(I4ZM-VL^2<4TFNCCK&2Z2@ULD>-5ISHU*E*:M.G.4):W]Z+:
M=GU3T:?5-/J:%]I.IZ6+=M1T^[L5NXA-:M<PO$MQ$<$/$6&&&""1PP!!( (K
M/KZ0\'_V?\2?![>'M=E9M1T21$M[J-E%]%!LV6=XA8'?A=]K,&#)*(U\P;V#
M#B=2^%=S]GF?PWJ/]NWEE.D6I:;)%%97=D)8S)$KAIF1K@+CS8<JP!!4<,!X
M>'XBP\:^(P69\N"QF&Q$J,WRU7A)4YR;PV(6(G'EI4ZT'!7KN"55\D9RYHI>
MA4RRJZ=.OA;UZ%6FIQU@JRDDO:TW2B[SE3DI?P^9N"YG%6;?DM%=;)X"\9Q[
MMWAK5"%SDI"D@P!DXV2,3^ YKE'1XG>.1'CDC=HY(Y%9'C="59'1@&5E((96
M ((P17N4<3AL1?ZOB,/7Y;.7L:]*JXI[.2IU)N*=G9R23M9.^AP3I5:=O:4J
ME.^WM*<X7MO;GC&]NMKC:*@N;JULK>:\OKJVLK.W4/<7E[<0VEI;H2%#SW-P
M\<$*EB%#22*"2!G)J2.2.:**>&6*>">-)H)X)$F@GAD&4EAFC9HY8G'*21LR
M,.58BM[.U[.U[7L[7M>U[6O;6U[VUM;4SNKVNKVO:ZO;:]KWM?2]K7TO?0?1
M110 5)%(8I8Y0 3'(D@!Z$HP8 ^Q(YJ.BAI--/9II^C33_!L#^/O]I_X1_M2
M?!S]H/X]?L"_#;PGH'B;P+^WA\3],^(GA'Q+J_A&VU?Q%>:1<ZT=7N;C3?%U
MP#+HT7@VY:[B\8F3<;&ULC>0M;0ZC')+_73^S[X,B^$'A7X/_#K3M7N9H?AY
MX8\)>#(]9?;)+?+HFEVNF7%S*+F2%/L]])'+E9I$\NVE4-EDP;D^DZ5=:EIV
MLW.EZ=<ZQH\5_!H^K7%E;3:GI,&JQPQ:I#IM])&UU8Q:E%;P1W\=M+$MW'#$
MDX=44#U7X:^$AXFUQ)KR%FT72RMS>NPQ%-.A#6UF7. =[@23*IR(4(.WS%-?
M4<>\>/B#A[ X;'8+"X"EEF"K5,UQ%!*=7.\XJ9?ALFCF5:%1N"K3RO 9;@X8
M>*4)5H5ZKCRS@J?C<-\-K*\SQ-;#UZV)GB\13A@Z51M1R_!1Q-7'/"PE'5TX
MXS$8JO*K)\RING"]XR<_KV6(3Q[/,EC!:-P\,AC?Y'60 .N?E;:%<#AD+*>#
M7E>H?#>'6O&0U?5X8)]*.E)]J2&62W^W:N)9(@Y@CD\R"..U6%G9)1YTJJQ)
M(<5Z=<74<".D7ES77ER&WLQ-%%+<2QPM*D";R I=5X9AM5<N?E!I+(7!A$UT
M'BGN%BFEM6ECG2RD:&-9+6&:..+S(TD5CO(8L[.RD(54?RO@\9B\O5:KAJKH
M2K4JF'4EI5Y:RBY2IM.,XM1IIQJ^]",[J#56UOV"O0HXEPA5A[10G&K;>%X-
MI*=[Q=W+6&DG&S:<!MGIFGZ?YGV*SM[8S&,S-%&JM*8HDAC,CXW.5CC506)/
M!))9F)O445PRG*<G*<I3D]Y3E*4G965Y2<F[))+71))62L="2BK12BELHI)=
M]DDM_(****D84444 %%%% !1110 4444 9%]?W.G/-<3VZ2:5%;SW,]U"^)[
M..VA61S+ Q)N1*V\JT&P0QQL9=V0:TXI8YXHYH766*9$EBD1@R21R*&1T89#
M*RD,I'!!!%+)''+&\4J))%(C1R1R*'1T<%61U8%65E)#*0002",41QQQ1I%$
MB1Q1(L<<<:A$CC10J(B* JHJ@*JJ %    %:2E3E3BE#EJQ=G*+]R<.71RBV
MVJO/O*+4)0M>"G=N$I*3]Z\&KI->]&5]4FK+DY=DTY*7VG&R3Z***S+"BBB@
M HHHH YV]\+:/?:7J.CRV^+'47DF: ',=K<R?,;BR0\6SB;_ $C;%M3SF=@H
M$CAOX_/^"SUMX?\ A]^U)^RW\2OVCOAOXA^-G[)&C^'O'7A#6_AKI>MWGA^S
MF^):7-]<17=W-#);1IJ$^GRZ5J%NDUQ:S:C9:5=6,%Q'':2AO[):^9?VG_V1
M?@?^UY\,]?\ A5\:/"PUGPWXA:RGN)[&=M/U6TO]-N$N=/U/3[^)3)::C:NK
M1Q7D06<6\T]N9/*E9:_6?"3Q"PO O%%+,,ZIX_%93BJ>(P>.E@*TZ>8X.CC\
M+/ 8G'9=6A.G7HX^C0E3J4*^'K4L0I46HU%.HJD?B^->&:W$.43PV EAZ.-H
MRI5\.L13C+"UZF&K1Q-+#XJ$HSIU,-.HI1J4ZM.=-J:O"T>5_DE_P;I:9XLM
M/V1/BAK%Y;ZOH'PL\8?'SQ?XE^ W@C6]3N-3G\*?#>:TTZR^SV$]RJ--I5QK
MEIJ*0WL,<=MJ%W:7EXB*TSY_=;Q?XVTGP;!:R:A'=7$UZTJVUM:(C2,(0IED
M=I'C2.-=Z#))9BV%5L-CY]\(_ G7_A;INC^&_AH-&\/^&_"FAV>@^&K#1V&F
M6=IHNF01VUCI$5@\4D,:QQ1K@2M) T@::28RNS'F-3OM:E\0V(\<OJ,K65W
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M@CEOC:V[PZA-9QO?1VDMLC2CZ?\ C3^QA^SW\?\ XH?!GXR_%#P)8^)_B%\
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MKM]DKJ[VU7<+I;]79>O;UT):***0!1110 4444 %%%% !1110 4444 %%%%
M!1110 5E:KH>D:Y#Y&K:=:W\8SL\^)6>/.03%*,2Q$YZQNI]ZU:*NG4J4IQJ
M4JDZ52+O&=.<J<XOO&<)1DGZ27G=:$RC&<7&<8SB]'&45*+7FI)I_-'\O?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ KYA^-6@BSUFSUV! (=6A,%T5'
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MHY0E3J*%>M[&K%\U*HX33BXJ2_DDTG]@'PY_P4;O?'/Q+TJR7]G/X?Z7X_\
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M7D%O-<PR.H2VDO\ :7MXM4:#^T+>QN;JP@N([2XEB;ZN^#'AF[LX;SQ#>)/
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MLKMV5OU^AAJ&&BX4*4*46TY<JLY-*R<FVW)VZM]79*X4445QFX4444 %%%%
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M  !DDD\  <DGH*@H6BH+:ZM;V%;BSN(+J!B0LUO*DT1(X8!XV9<J>&&<@\$
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M$%G)J_AOQ#XOTFWN]#DTB6^%QJGAWPOK&HZ>D"7 NUAM[:!GN[VSMYN T/\
MX*&_ .:P\1ZGXTO-;^'46A^.O$/@6VTKQ+X>\4IXMU"Y\/>+O&_A6ZU2X\(I
MX=37-&L5'@75-8ODU"V6YT73GC?68K(- ]S>N_V<OV,)]<\'^$-3L-.O]4\6
M>&;N;P7X2U3XB>-KZWU[0/[*\3VJ:MI>A77B:2SO9M'\/>+/$&E:'K(MWO\
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1 55    X    X%.HHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %( ;T# 2(  A$! Q$!_\0
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M?_P=7G_R+1_PWAXA_P"B>:/_ .#J\_\ D6O@FBOQ#_B)'&__ $/\1_X39?\
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MDTKV7[B?\-4>)_\ H4]!_P# _4/_ (W1_P -4>)_^A3T'_P/U#_XW7X$^/\
M_@HGJ^E>%==U@_"K5_!GA?Q(W[0?AKX/?$S3/&/ACQ;J^O>.?V9M:71OB;9Z
MQ\/=6\,06_AC2Y;JTUD>$=6U2^UV/5K:QCEUK2?#UU?V=NNO?_\ !0+XF/XF
M/A_PG^RI-XHL=2\7_'_P'X-\07_QR\.>&O\ A(]<_9KT73_$/Q!U'6-);P1J
M<OA?0]2TB^3_ (1F>.XUJ_O=;!TV\TK3M/QK /\ 6#C[E4O[6KI:WYJF6024
M5>7ORH*'-%\RG!/VE-PFIQ7+=BSCBYI/^T*J6NLI8&*7*KOWI4E&ZU4HIN<7
M&7-%6U_=_P#X:H\3_P#0IZ#_ .!^H?\ QNC_ (:H\3_]"GH/_@?J'_QNOPCT
M_P#X*9^$]5\>_#30-/\ A5K=[X*^(VC_  ^F'BRP\5V>I^(O#WB;XC_!+5_C
MCH_AO5?!VFZ#=:3:/:Z'I#Z)=_VUXZT+Q#/J=W:W^F>%+[0R^H+Y/X5_X*@:
M[X[FT7QS:?#>TTCX4+'=:GI\GA#QCIOCL^/#%^S#\3/V@M0\):[XJU'PEHFF
M^%O$OA:W\*Z/H7B3P[X9CU#4?#GC)Y;'4_$.JZ(TD<CCGOB"TV\SQ4$H\UY_
MV>KMRJ1C326&;]JY4Y1]F^62MS/W+R36;<8--O'8B*23O+ZFM6YQ4$O8-\[E
M"2Y-&E[S]V[7]&G_  U1XG_Z%/0?_ _4/_C='_#5'B?_ *%/0?\ P/U#_P"-
MU_/WXF_X*?7?@;P^Y\>_ .R\$>.[Z/X>:GX=T'Q!\;M'C\$WGA[XH?!/Q1\;
M?"4^M_$6T\"7)T7Q1J&F^$M4\(VWA*S\*:W]N\8W&D6%IK36FH->VWZ/?"'Q
M5XD\=_"KX<>-_&'AY?"/BCQCX+\/>*-=\*K%?P_\(Y?Z[IT.I2:*\>J :@LN
MGI<1V\QNU25Y4>0QQJRQKS8GBGCG!TXU<1F^(ITYU'3IR3R^I[248\\G#V>&
MGS02T<T^52]UVEH\*^?<58:$:E;,:T(3FX0:>#GSRC'F;CR4)<T4M'-/EYO=
MT>_Z>_"SX\P>.]7_ .$=UC2HM&U:>*6;3Y+:X>XL;WR5WRVX,R)+%<K&&D56
MW+*BMM(9<'Z'K\S?@Q_R5+P;_P!A"X_]-UY7Z95^M^'V>9AGF35ZV955B,1A
M<=/#*OR0A.K2=&E6C[54XP@YP=24.>,(N4>7F7,KO]#X/S3&9KEE6IC:BK5J
M&*E057EC&4X>RIU8\ZA&,7*+FX\RC'FC:ZNKLHHHK[L^K/G#]I']J+X;?LP^
M&=/UWQU)?W^IZ[/<6OAKPOHD44^LZU/:QI)=2HLTD4-IIUF)8!>7]PXCB:>&
M...:5Q'7P)_P^%^'W_1%?''_ (47A_\ ^-5X#_P5[DD/QH^%<1=C$GPQN)$C
M+$HDDOBG6$D=5SM#NL42NP ++&@)(48_)>OWS@[P^X<S'AW+LRS*AB<7BL?3
MGB)R6,KX>G2C[>O2A2ITZ%DU&-&\IS<I3G-OW8J,3ZS+LHP=;!T:U:,ZE2K%
MS;524%%<THJ*4;;*-VW=MOHE8_>;_A\+\/O^B*^./_"A\/\ _P :H_X?"_#[
M_HBOCC_PH?#_ /\ &J_FN^,OQ'\3>"KCX9^$_ NDZ%J?CSXN>-9_!WAF?Q7-
M?Q>%-"BTS0[WQ)K^OZ]%I,D.JZA%I^E6+"RTC3KBTN-2O9HHS>6T,<LE>-0?
MM87O@[7/$_PZ^*?@;5->^)WA37]3TUH/@OI4^L:%XBT#3O!%I\06\5VMIXGU
MJTOO#T,7A^XF2_TO4]4OI(=0M!!:W=RU]912>Q6X$X!P]65*O@<73Y91A*K+
M'9BZ"JSH_6(4'5A[2]>=#][&G&E*\=.?G_=G1/*LIA+EG3J1LTG)U:W)S./.
MH<RO[SC[R2B].M]#^K;_ (?"_#[_ *(KXX_\*'P__P#&J/\ A\+\/O\ HBOC
MC_PH?#__ ,:K^6"S_:]\#:X-!DT_3_$OA>WU+5_ ET\OCWPQ/8'5OA_X_P##
M/B;Q-H7C#0DL-8>6UL[ZR\-W;)+K,4=Y9F%X[O0B;FUE%O4/VOO FD^"8?'V
MK^!/BUI&@ZG<^%4\+RZOX6TW2HO%VF^-;6_O?#>O:1J]_K]OX<LM+OK/3YIY
M(_$>M:'JEE]HTV"]TZ"YU73H;F5P3X=M2DJ4^6$/:2G_ &GF/*H63<VU3;C%
M7C&\XTE*4HQA[1RC<_LO)[-V=DKW]M6M9;OX=%JEJHW;27-<_J4_X?"_#[_H
MBOCC_P *'P__ /&J/^'POP^_Z(KXX_\ "A\/_P#QJOYG?%WQHEL8?A4WA/2!
M=S?$O2/%_B[R?$<-WIUQI'A'P5X"U3QGJ4MQ9Q.LT>L7-U;:7H-O;R.T$,^I
M&Y<S0QH7^(M$_;U^*VK>!-7\0Z%X,^%GQ+\0V_@[X6>*K32/!DWC7PY:Z=K?
MQ%\<V?A=/AIKDOBJ[NOM?B6XTZ2_OM"U[1[D:+]ML&MM6M88YX&?+%<&^'F#
MJ*G6P6-<G"51>RQF8U5*,:5.LU!0FIU)>SJTWRTZ<VG.*ER<R;F>6Y13ERRI
MU;V;7+4K2NE%2TL[MVDG:,6]4G:Z/[/_ /A\+\/O^B*^./\ PH?#_P#\:H_X
M?"_#[_HBOCC_ ,*'P_\ _&J_DPUK]L_3G\,?%?Q1X0T_P]>6WAOPU\%H_AY:
M^)=2GT*74_B;\7M8\6>&G\$>.Y)9HT\/MX2\0>&Y+?7DB$%[9V]AK;2_O(8
M/IWX-_$>S^+GPM\#_$:S2U@;Q1H<-SJ=E9727MII?B"SEFTSQ-HT%Y&\BW46
MC^(+'4M,2X#L+A+59PS+(K'?#\"\ 8NLZ&'PE>K45&5>T<RQ_*Z4:[P[G&3E
M:5ZB;223=-JI91=E4,JRFI+DA"<I<KG95JOPJ;A=.^OO+[K/1:']&B?\%A/A
MV70/\%_'*(64.XU_0'**2 S!!&N\J,D+N&XC&1G-?I+\#/CK\/\ ]H7P):^/
MOAY?SW&FR7,VGZEIVH0BTUG0M6M@C7&F:M9B240W"I)'-#)'++;W5M+%/!*Z
M.=O\>5?N)_P2&GF3PM\<HEED6(>)/!<HC#D())-)UM)) N<!W2&)78#++%&#
MPHQ\]QSP%P_E.05\SRNCB,+B<)6PJ:EBJV)I5J>(KQH3A.%=-PE'GC4A.G)-
M.+C*,HRO'DS3*,)0PDZ^'C.$Z<H:.I*<91G)0::ELU=--/HTTT]/J[]M3_D)
M> _^O/6/_1UK7P[7W%^VI_R$O ?_ %YZQ_Z.M:^':]K@C_DELI_Z]XC_ -3,
M2?RMQG_R4N9_X\/_ .HM ^2?VAOBEJ'PY^-7[&FE2^.K'P3X+^('Q3^*&@^/
M1K&LZ3H.@Z_IND_ ?X@^)M#TW5]0UB:VM4CMO$FE:9J5G&+J"22^M(%4R?ZM
MO"M=_;K\0Z?\6]=T#2='^%>L_#S3/C?>_ &PTBT\6W5W\8=6U:'X3R?$JW^+
MMEIME=2Z)=?"AY ELS6ME(TGAT/XEB\2@D::OZ ^+? ?@;Q_8V^F>/?!?A/Q
MOIMG=?;K/3_%WA[2O$5E:7HB>#[9:VVK6MU#;W7D2RP_:(D24PR21EMCLII6
M7PQ^&>F:K::[IOPY\!Z?KEAH0\+V.LV7A'0;75;+PVML;)= M=0AL$NH-(6Q
M9K!;&.58!8,UD%^RDQ5[5;#XZ=6<J.+A1ISK4JMN6I*:C&A"E.G9\U/D<H2J
MJ,>13G4?M6N2+EX]+$8*-*$:V%E5J0HU*;=Z<8.4JTZL:ETXU.=1G&DY2YG"
M-->S3YY*/Y3:A_P4E^*7@KP7X=\0?%/PE\%/"DOC_P *?LY^//#OB33-6\;Z
MQX1\#>%?CUJOC31W/C?3':T\0>)]2T"Z\*6@MQX8GTBWU!M9*2&!-.:XNLGP
MW^U]^U%JD/@B]O-4^&/@_P 3^(/C3^R)X9^)5IXN%]>^!-(\-_'7X9?&/QC/
MX?\ "MDGB!X_!\C77A/0["YU236[K4]6U%+%W>UO)KJSD_2OXO\ [-?PH^-&
MA>&]#\2:(-&;P=K6@Z]X5U7PM;Z7IM[H]WX:COH=%LFM;C3K[1]6T&PBU._%
MMX=UK3;_ $6WFN6N[>SBNDCF73^''[//P>^%GPXTOX4^&O!&BWG@_37BN9+;
MQ-8V?B2\U;4H-8U#Q!;ZMK-YJEO.]_J%EK.K:E?:3(ZK'H?VM[718["S2.!>
M%X#.)5G&69/ZO"G3]G44I1J2J)P=13A3IQ?O.,U&K=\E.;@H2TY>WZ]E2H\T
M<!%5YU)\]/EC*G&G[Z@X2G4E'W8R@W3LE*I!2<EKS?G_ *O_ ,%+;JV\$>$]
M;TCP]\,]4\4>(/@YXA\=:YHI\9R"S^'_ (JM?VC-'^ 6D0^.&M;BZU#P]X0T
MW^V1XK\77&J06NJ6UCIE^EM)!$HG3RJ']N#XR> _$7[16K^)=>\#_$_5/AE!
M^V-XAT#2?!OC747^#5S_ ,*7T;]G,^'= T\QB\OSHS7WQ"U.22YN+[5-1\-7
M%QJ<$%UJ N2!^OUM\)OA19S>(KBS^%WPYM9_%\6H6_BV:V\$>&H)?%-OJS^9
MJMOXADBTU7UFWU*4"6^@OS/%<S?OI4:4ES+I_P +?AAI&G?V1I/PV\ Z7I/V
M74;$Z7IWA#0++3S9:N+,:Q:/9V]A' ]OJXT[3CJL3HRZB;"S:\$QMH2FDL!F
MLY0E+-(IP4[<E*K&/,Z;IQDX:1G*_+5;J749J4:<'"5U$<=ED%-1RV34W'F4
MZE-MQ513E%3UE!)7I)02<X6G4FIKE/S)^*/_  4#^+?PEA^(?@[Q1X5^#7_"
MV/AYXR\165TNEW'CK4_"&M>$-#^ FA_'4SZ?9R3Z;J5EJ=O;^(=-\+:SK&L:
MYI^DV3/_ ,)!::7?":/0E^G?V-/CAK7QU7XZ^(]9U9WAA\>_#;5/#'A&XU&T
MOKCP'X5\=?L\?"/QY!H4"Q1P77]DS:]X@U^]L;ZZMT7499;R6!B$DCB^G]?^
M&OPX\5^9_P )3\/? _B8S:A#J\Q\0>%-"UDSZI;Z>NDP:C.=0L;CSKR+2DCT
MQ)Y=[_V?''9$FWC2-=K2_#7AO0[F[O=$\/:%HUYJ%KIECJ%WI.D6&FW-_9:)
M;M::+:7T]G;PRW=OH]H[VFEPW#2)I]JQMK410X0=%'"8Z&*56KCW6P\.=1H2
MA)3M*-6,7.:48SG%3IW;BXS<.?EA-1;YZV*P4\-*E2P7L<1/D<JRE!Q7+*E)
MJ$7S2C&3C-I*2<5/DYIQ;2VJ^U?V*_\ D8_'?_8&TC_TMN:^*J^U?V*_^1C\
M=_\ 8&TC_P!+;FO*XU_Y);./^O%'_P!2\*>GP=_R4N5?]?JO_J+B3]"Z***_
MF\_H,*_ GQW_ ,COXQ_[&C7?_3E<U^^U?@3XZ_Y'?QC_ -C1KO\ Z<KFOPWQ
MN_W'A[_L-S#_ -1,.?TC]'3_ )&'%?\ V+\J_P#4[%G*T445_/)_4Y\%_MB:
MKI$/Q%_9J\/?%KQ5XB\%?LQ^(M3^*"_%76]%US7O"NC:AXZTWP]H<_PC\+^/
M_%?AIX-6T+PCJDTOBZ\BQ>:?8:KKVFZ=97MV"EO!-\;WWQ0M/#=WIEO\+?'O
MQ@^(/PSU/X>:?IOPQN?BG<>*Q=>(;>Q_:]TK1-8D\-:E%#IFJ^)/#OACPUJ@
M@\)>)]7DDUK5?"*6LNH76I:4JRO^W$T,%S!-:W4%O=VMPGEW%K=P0W5K<1[@
MVR>VN$D@F0,JL%EC90RJP&0"!X8)!$LEO;R+  MNLEO"ZVZJJJJVZLA6!%6.
M-56$(H6.-0 $0#W<)G%+#8>A0GA)5E2A4A*'MJ4,/4<ZM2LL0Z;PDZJQ3YXT
M9U?K*C*A2IQC%22C'YO'9#6Q>*Q&)IXZ%!UZE*I&?U>M4Q--0H4Z#PJJK'4Z
M+P2Y)XBE1>$<XXJO5G.;BW*?XQ>-_P!IS]IB;P-JVJ^+I/"^N>'OB%HOQNOO
M#GA[P]X$\1^%M7\#S_!G]H_X;> - :^\1:=K$FH:Y+XI\*^*+Z]U*,1:9$UU
MIL=SID(T]KV%^U\<?MM?%#PO-\>]4G\:^ K+Q!X1\5?&+PCH/P%/PG\4:IXS
M^'UCX&^(&F>$?!/Q"\2>)X=5TW1KW2?%>D7T7B.]N?%%]H/A*:'6-,DT?4HK
M#3]0,OZSFWMB-IMK4J P"FV@*@.P=P%,94"1U620  22*LC[G4,$:VM7>YD>
MTLWDO8$M;Z5[2V>6^M8P5CM;Z1HB][:QJ2L=M=-+ BDJL8!(K19OE[Y5/),-
MRQDI<M.<(1:56G+DY94IQCS4J<:=2I3M6FXJ7-%5:ZGD\BS5<SI\18M2E!QY
MJL*E22DZ-6*J<T*].4^2M5G6I4:C>'@IN/))TL.X?E#^S1^T;\1OC#\<?@U=
M_$+57M[:/_AK+X76UUIMM%IOAKX@:CX+U#P#J?A35KNT\/7FJ>#;CQ&=#OM2
M^R7.B:A/I%W#8WMWHLS1R2J/UDJ)(+>-(XX[:UBCA*M!'%;01I RH(E:!$C5
M866("(-$$81 1 ^6-M2UYN8XNCC*\:E#"0P=.%)4HT*<E*"2J5:BDFH0LW[6
M2:?,EHHM048Q];*L#B,!AYTL3C9YA5G6=:6(J0<)MNC1I.+3J5+I>QBXM<K:
MNYQ=1SG,I&Z'Z'^5+2-T/T/\JX#U%NO5?FC]S?@?_P D@^'/_8IZ1_Z3+7JE
M>5_ _P#Y)!\.?^Q3TC_TF6O5*_N3)/\ D2Y/_P!BG+/_ %7X(_S>XB_Y*#/O
M^QWG'_JTS$*\-_:*_P"27:K_ -?VE_\ I4*]RKPW]HG_ ))?JO\ U_:9_P"E
M(KEXH_Y)O/?^Q5C?_3)\CGW_ "),U_[ ,3_Z;/SQKYS^*^H_LK>&-6\72_&W
M4?A-HFJ_$[X>>'_AMXZ'Q O+*W'C'X8:YXKO_"OA?PEXCAU&0V4_AC6/&OBW
M4M TB"Z2&.^UW6KFSAFDE#"'Z,K\A?VK/V>=3^/_ ,>?C%\+=:\&'Q?H?Q(7
M]@KQ:EOJDWV#1;[X'_";XT7]Q\:-&L-8N +.+6_#FHG4_%HT6"9-5GEUC2K^
MRAEFFB9?Y>RRC2KXB4:V)JX6E"DZE2K1E&-3DC5HWY7.<(OD]VK9R^*G3LXM
M*=/\)P-.G4K-5:TZ%.,'.<Z<HQGRQG2OR\TH1?+[M2S>\(6LTI0^DO&W@W_@
MGC\'?&.CZQX_T_X&_#_QI\"? OP_N=/M=:U2[L[KP%X"LKZY\"_"K4=3\+1:
MA/8WEI8:C)=>%? 6IZ]H^JZK:3NUEH]PBB(K3^"OPI_X)RB\\+:S\"/#?P/N
M]1\7>*3J/@RY\-:MJVI:CJ/BSX-7=[XS^S:):ZMJMS>:7=_#&ZU2_P#$$7AY
M+;3;7PZE_+<1Z7'!.@;X6^)/_!-3XPZ1XD\1S> _&OBOXG>)/&WA;X"6?BS]
MH#Q7J_A*Q^(]YJ7PS_:4T3Q/I=I%IVJV]]HWD?"WX+Z'I.F>'/M6FWMGK,^E
MR37\%[K6IWAD]6\-?L]_&O\ 9Z^,NJ?&'6O#^K_&#PY\+OBU^V!\;K[XCOJW
MA:#XE_&_3OB?^SKX?TKP3'J/AC1+72=(LO&__"4Z:WPFM[31- T32FLM$T;7
M);"..^N+F3VY4<++#VHY_BZU:=%\M-XF=*%:252U+V56JI0C/%5?W<*M3VW+
M6G.=-7J3AZ;IT'1M2S?$5:LJ>E-UI4XU&E*T.2=2ZC*O4]V-2?M>6I*4H).<
MH?4GQ;\ _P#!/KX)^(-9\<_&S0/@U\/?$'QS7Q3HNI:IXODU>,^.!?"SUSQW
M#IVD17%[86$NIK966K^-M2T+3-)EU)(([S7KV=3([MO_ (H?\$]/"7B72]!N
M_&WP1L/%5F?$_C_2;&PN=1U6[MO^%]Z!#)XI\4P3Z+!J5FB_%+PU:02W-P]Q
MLU73($EM8XU&XY7QX^#'Q=_: ^*'[''Q"\'^(/%WP(TWPMX3^-UY\2/$&DVG
MPWUSQQX)3XJ?"W2-(TWP;)H7CW0/&'AO4KB_U!KG1=:O;+2+N;2I+0W-M=6Z
M,9&\%^!G[+GQ'_9?_:8\1:7\//"O[0,G[/<W_#.GA_P;J7@[XG?"*'P+?Z!\
M./ M[X3\0ZE\8?#7BIH/'6JWUG>W?VR1/"T$$=U9M)'IMJC+# O-2IX:IA5*
MOFF,>+AA:M26&6+2I_N:T\-"@JM23A&2HPYH4XRJRG2E=*%-057&G"C.AS5<
M?B'B(T)S=%5TH?NZDZ$:2G.3BI*G'FC"+J.5.3:48<JJ>R?##X8_\$X?V@=0
MUO4/@'9_"GQ7XH\$:#IGAY_$7PUO?$/VWX<-IWA+4/AGX:U/3K.[EC\-V'BW
MP]X6>Y\+V&IS:7>:Y;:? FGZF[PHJ%_P+_X)R? W]G_1M1F\6ZC+\1O#5OX4
MTCPOHUEXVTW2/"O@'P?HVB^$O$W@+5?$%GH^CRV.@V_B[QCX/\8Z[X;\=^*W
M:W.L:5=QV0@M(X8!'TW[-EOX\^!>MI\)?%_PRUK4/^%S_M'_ +6'Q5?Q7H%]
MI=YX<\$>!)-=T/Q!X2U3Q7,DJ212^.H]2.F:1IML9=0L[ZVG%Y;I$&D3\V_B
M5^PQ^U_\49/VM/#/C:#Q%XRC^)_AW]H".VU2^^(N@Z3\/?B9;:QXO\+>)?V?
M?#T-HGB:ZURVU#PII^CS:59Q:GX?\':3X+:'4(KR]UBT\0*HWI>TJ5L3AWGE
M7"X%K"RA4Q.)AB:U>DZT*4Y4IJ=/V?LI2KR<8RI-J"<HRISJ5EK3YYU*]'^U
M)X?"OV$HSK5HUJE6#J0IRE3FIPY/9N563BI4VU%-QE"4ZB_2+]J#]B/X(_$[
M0M%\:ZS/8?"1/A1_9^MZIXM7PUI6N>'W\-^ _AWK_@#P_9^+M/U])H!IWP\\
M&ZYJC>&KZSGL;W1&0SSRW=N9XF^GO@QX)T?X;_"+X9^ ?#OBO7O'?A_PGX)T
M#2-#\:^*-8_X2#Q!XKTF*QCFT_7]5UL$KJ<^IVL\5S'=(3&;5X$B)C1"?S:T
MCX4_$'P3\8/%7Q,^(/P0^(LOP^T^./Q!X>\5'X]VY\+_  I_9LT?X$OH_BCX
M ^(OA?I>LZW<?$'Q"?%-OK=K<:+::1J6F^,]2UNT\3#Q2KVPA7[?_8X\/>*/
M"7[)W[.?AKQK'<P>*='^$?A*WU>UO%=;NR>6T:\L;"Y23]Y'/8Z7<V-G)"^'
M@:$P.%:,J.#'JK# T*<LP>+I4ZT'3IWI2C"5:A4JS491J5JO-2DG":G.,5SO
MEIV]E4J<F*52.%I0>,>(IPJQ<(7IRC%U:4YRM)3JU+P:<9*4HQ7,[0M[.4_M
M_P"#'_)4O!O_ &$+C_TW7E?IE7YF_!C_ )*EX-_["%Q_Z;KROTRK]C\)_P#D
M19C_ -C:7_J%AS])\/O^15C/^Q@__4:B%%%%?J1]X?SZ?\%>_P#DMGPM_P"R
M72_^I7K=?DU7ZR_\%>_^2V?"W_LETO\ ZE>MU^"?[4%W\0++X7I/\-]6\1Z)
MK8\7>&/[2U'PQI&H:M>KX;%U*VL6MX^B07OB'1-*O4$5O?>(_#NF:OJ^CAXY
MXM,N87F4?U;P966&X'R6NZ<ZJHY;.HZ=.SJ3Y<7C/=AS:7=^NB2DWL??9;+D
MRO#3LY<M!NRW=IU-%?3K^#/1_B-\,O"_Q1TK2],\2'6;.Y\/:[9>*/"_B+PS
MK%WX=\5>%/$FGI-%:ZUX>URQ(N;"[^SW%Q:7*8DMKVRN)K6[AFA?:.$T+]FW
MX9:#=PZLB>*-9\2&Y\=7^K>+/$?BC4M9\3>)=1^(OA[3?"OB2]\1ZI<$/J4B
M:!I-AINB1>7#;:#;P;=.AB+N6^*-%\9_MH7GC7X?O=V/CK1C<Z%\+Y-)\/:W
MHLM_I&NV5SH.M#XB2^/KC2- L_#EKJ\.M1V$E]J6KW_A_5=(MCI#:7I*R7^H
MVY[C]GKXL?$&T^(NH:+X_P!2^/?BB:'X#^ /$'BOPGXS\%)%?Z1\6?$/Q._X
M1+Q3<>#--T^QLIKKPCI4LZ6UW<6\ESHND:/:)>6,C0FX=^V&9Y=B<52E6RO$
M4ZE6K"A'$8K#\B35)RIRLU>4H13CI36(A1<)*<J%3V$-%7HU)IRH33E)14ZD
M+;1NGW;25OA4U&VKB^5?3,O[-WP<BF\,2WMA>D>'M&^'WA+1;?4/$5PMM=:;
M\.-"U[P]X3TRX@GE5=3G.D>(-8AOXSON-5+K-*&:W!7GH/V7OA5;^')_"T7C
M3XER:=$^A>&]+-W\5]2U%O#6F:#:ZEI6A^ -)M;V6XTR+28K/7+[3V\.ZA87
MEU?K-9+<+--8Z<T-#XS:RWQ;^!7C#QC\*]'UO7O%OP@\?/XI\&Z/-IT^G:EX
M@^('P*\5V^HWFAZ)'.P6_LO$YT_4?#%CJ$4ALM2M]3N$5P!(J_$EK\!/C]/=
MR>#=+TKQ#8Q_%;PSK?[7.O>*+V\:VM?#7[0K^&/$GAS2/AS<WDDKG2]:74M;
M\'>((8HE%O;7OAN[N Z&%FJ<;6PM"M&&'R2&.IUJ,9PKX>-3EG&M[3#0IN4(
MJ+;Q&%G1:E.U*G&EB/W:FIR565.,TH8558R@FIP4K-2O!1NE:_/3<=7:*49Z
M)W?Z!/\ "'P)-:?"G1O 7B31K'1?@9;:_P"$+[3(]<M=?G'P_P#%/A#5/"7B
M;PUK%]#J#7>C:H;:ZCU:SU/4#&]KJ.FQO)!Y"LBH/V>?@IXJT[X?W.GR7.KZ
M;\/?"FA^!O"VI:#XQ?4+6X\/>$_$^B^+=%L-3U'3;FYM];ETGQ#X?T^XCEN)
M9)H0U[;$JEY<*_PK>>!8_$NE7>@>"OV=/'OA?P;8_LYZCX)^)D'AKP)K7P^^
M,%AK6SPPUSX?T[7M8\3'P;\9/$%]XGL;[Q#&EWH%_,^B66IK'K,SZ]Y%Q[[^
MRYXIA\%:]K7@G6O"-]I5I\2?'"6_PX\7V'PDU;X2Q>/Y/#GP_AU+Q5JWB/X<
M/J%]IO@I] M]-M]&E\0Z7;:1H?BG4ROE:=;7L;F><-B\+6Q-.C7RW#PHUU&G
M[9QQ<J*G0CAH8:%&%?"T5"DI1H4/:/DC+%48TU&G-*$R%2G.<8SHP49V7-^\
M<;Q4%!14H12C=1C=V7M(VM%V3]PE_91^!MW\0_$7Q(N/!<=[KGC'QMH_Q#\3
MZ+>3MJ/@S7_&FA:%JWAW2]:U'P9>QW.A74\-GKFIW;PR6C03ZW<MK4D3:@S3
M'TSP+\//!GPJTG7-*\'V,?A[P_JOB;6_&5SI0G2#0]%U'7/L\NK1Z)9D0V/A
M_0VGMC?+I=FD&GVES<WMQ&D?VB2OS=^(R?M:^,]>_:%\&-??$>SL=1T#X^66
MAZ/X8L-3L]-;PQ8Z$ES\&;KPEX@&E6>C:7K>MS1Q6DDFDZ[?Z[KFI7NK:7JM
MO:1VUM)!ZQH&M?$"X\>PZ5XJU']H!_!TMAX'L_"6F7WA/3Y_ >O_  LN/AWJ
M#?$35_B_J>LVT)T_Q%:>(A<6^LRWMW;Z]IK0Z-;Z/9S6]_>;M*&/P5/$2=')
MJF&FZU:"Q$J%*@Y5JE>M2KRDXT93C"HXJI)<ZYY5E%4XU).O)PJTU-N.&<'S
M27.XQC>4IRC-NT6TFUS/75RT2D^9_H*K*RJR,KHZAD=&5T=& 971U)5T92&5
ME)5E(9200:_<#_@D1_R+/QR_[&'P1_Z:]?K^<C]E^6_F_9Y^$,FHO<22'PA"
MMA)=M(US)X;BU'4(?!TLKS?OI&D\'QZ#())?WLB,KR$NQ)_HW_X)$?\ (L_'
M+_L8?!'_ *:]?KQO$"K[?@?&5^5P]O'*:W(]7'VN*PU3E;LK\O/:]E=<LK+F
MLL,UESY94G:W,J$K=N:<)6_'\NY^F'Q_^#,WQ8T739-(N[>R\1Z#+/+8->%U
ML[VVN447%C<.BNT+,T:26\X1E20,)!L<LOQ:?V4OC-D_\2G0C[CQ%:8/OS$#
M^8!]J_5.BOPO*.-<ZR7!QP&%>$JX:G.<J4<5AW5E2]I)SG"$XUJ3]FYMS49*
M7+*4N5I2:/QO->#\GSC%RQN)6*IXB<81J2PU=4XU.2/+"4X2I55SJ"47*+CS
M)1YDVDW^5G_#*?QG_P"@1H7_ (45I_\ &Z/^&4_C/_T"-"_\**T_^-U^J=%>
MI_Q$KB'_ )]97_X1U/\ YK/-_P"(>9#_ ,_,R_\ "JG_ /,I^5G_  RG\9_^
M@1H7_A16G_QNL_5OV9OBWHFEZCK.H:7HL=AI5C=:C>O%KUK+(EK9P/<3M'$L
M8:1UBC8J@.7("CDU^L=<3\2AGX>>.O\ L4?$1_+2;L_TK?"^(V?UL5AJ,Z66
M*%;$X>E/EPE12Y*N(H4I<K^MNSY:DK.SL[.SM9XXGP_R.EAL15A4S%SI8>O5
M@GBJ;3E3H5JD;KZLKKFIQNKJZNKJ]U^;%C^R_P#%_4;*SU"UTK1&M;^UM[RV
M9_$%JCM!=0I/"S(8\HQCD4LIY4D@\BK7_#*?QG_Z!&A?^%%:?_&Z_2_P:<^$
M/"A]?#>AG\]+M3725-?Q'X@IUJU.-++.6G6K4XWPE1OEIU:M-7?UM7=H*[LK
MN[L51\/LBJ4:-253,>:I2I5';%4TKSI4INR^K.RO-V5WI;5GY6?\,I_&?_H$
M:%_X45I_\;H_X93^,_\ T"-"_P#"BM/_ (W7ZIT5E_Q$KB'_ )]97_X1U/\
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M7/\ ^6G\ND7_  38_:Y@01P?#C0H(U+,L<'B[P_#&K.[22,L<3J@:21WED8
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M%1OB5&RA2J2E*4HQBHN[/ZFS\>_A201_PE"C(QD:9J^1]/\ 0>M>;?#KXF^
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M'\!6UK>>./&'AGPA:7TS6]E<>)=<TW1(;N=%WO#;2:C<VRSR(A#.D18HI4L
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M]VTDVNB?#V&A&4Y8JNHQ5Y/V=)V6BVOYH_N#_P"&COV?O^BV_"G_ ,+[PO\
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M<\<TFJDZKC*K*2GB)QYJDHQE4<8PYY1C.7--*:_E\UO_ ()=^$=270_"FO\
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M]'_^2:_AA\B#_GC%_P!^T_PH\B#_ )XQ?]^T_P */^()9/\ ]#W-/_"7+_\
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M5D^6MRE&*7UC'*[E*,4KO17<DKO17N]$S^XG_ALO]E'_ *.%^$W_ (6>C_\
MR31_PV7^RC_T<+\)O_"ST?\ ^2:_E8^+W[#L_@[4+#2?!=QXPBU>Z\?^/O!H
MT[XOZ-X>\&)J'AWX>:,-<U[XJZ3J>FW5U;)X!L+0%=1NK^!;NWEEMEM4O'E:
M-? [_P#9D^)EC<Z!"-/\,ZA:^+/%?@7PAX5UK2]<M+W0_$FH?$C2=2UKPAJ&
MD:@L"&;0]1L=)O\ SK^:"WEL+F!K2\LXKA6C7R\-X7<)8NE"K2XIQZC44I05
M7#8"E-Q@FY/EE*:MRQE-6JR;A"I)*U*K[+T<1XB<38:I.G5X<P3E3<8R=.OC
MJD4Y-)+FBHOXG&.M.*4IPBW>I3]I_9'_ ,-E_LH_]'"_";_PL]'_ /DFC_AL
MO]E'_HX7X3?^%GH__P DU_(C_P ,;?$&[MO"$^A:Y\/=:;Q'X"N/'^N"+5[J
MWB\":;!XRUCP-':^)93I5Q(\][KVCR6-E)IMO=K+?-/:O'%'8SW;>8_$#X!^
M._A?H,&O^.+/PWHJW?B?Q%X1M=#;7=.N?$]QJGA/4/[+\07$6B6PEE;1].O6
MBB;5O.%I/Y\)MVEWD+M1\)^%J]2-*CQ5C9U9RY(TE0P*JRES5H65.4(SUEAZ
MUFXJ+C!SYE3E"=3*KXE<2482J5>',)"G&/-*HZN-=-1Y:4KNI&<H;5Z5US.7
M--0Y7.,X0_L\_P"&R_V4?^CA?A-_X6>C_P#R31_PV7^RC_T<+\)O_"ST?_Y)
MK^&'R(/^>,7_ '[3_"CR(/\ GC%_W[3_  KT/^()9/\ ]#W-/_"7+_\ ,XO^
M(MYK_P!"?+?_  HQQ_<]_P -E_LH_P#1POPF_P#"ST?_ .2:/^&R_P!E'_HX
M7X3?^%GH_P#\DU_##Y$'_/&+_OVG^%'D0?\ /&+_ +]I_A1_Q!+)_P#H>YI_
MX2Y?_F'_ !%O-?\ H3Y;_P"%&./[GC^V7^RB0?\ C(7X3#W'C/1L_P#I37FG
MPY_:?_9Q\+?\)4-=_:<^%&J#5O$U_J>GC_A,=!7;:W&PBZF,<D9^UW8"_:(Q
MF*)H1Y0 <U_%9Y$'_/&+_OVG^%'D0?\ /&+_ +]I_A7)6\!LBKXK!XR>>YS[
M; _6?8*-+!0IOZW1A0J^UIQDHU;0A%T^=/DE=J][+"IXI9A5KX;$RRC >TPO
MM_9<N+S",']8IQI5/:07NU+1BG#F7NRNU?9?W/?\-E_LH_\ 1POPF_\ "ST?
M_P"2:/\ ALO]E'_HX7X3?^%GH_\ \DU_##Y$'_/&+_OVG^%'D0?\\8O^_:?X
M5U_\02R?_H>YI_X2Y?\ YF__ !%O-?\ H3Y;_P"%&./[GO\ ALO]E'_HX7X3
M?^%GH_\ \DT?\-E_LH_]'"_";_PL]'_^2:_AA\B#_GC%_P!^T_PH\B#_ )XQ
M?]^T_P */^()9/\ ]#W-/_"7+_\ ,/\ B+>:_P#0GRW_ ,*,<?W/?\-E_LH_
M]'"_";_PL]'_ /DFC_ALO]E'_HX7X3?^%GH__P DU_##Y$'_ #QB_P"_:?X4
M>1!_SQB_[]I_A1_Q!+)_^A[FG_A+E_\ F'_$6\U_Z$^6_P#A1CC^Y[_ALO\
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MVDVS^#[_ (9D_:2_Z-_^,O\ X;GQ1_\ *VC_ (9D_:2_Z-_^,O\ X;GQ1_\
M*VO[P:*U_P"(W9E_T3^7?^%V/_\ E1E_Q"+ _P#0\QW_ (18/_Y:?P;G]F_]
MH<72V)^!'Q>%ZT#7*V9^'WB;[2ULKB-[A8?[.\PP+(1&TN-@<A2=Q J?_AF3
M]I+_ *-_^,O_ (;GQ1_\K:_MGNR1\<-'&2 _PTU<$<X.WQ'I[<]N..O^&/6J
MZL3XS9CAUA6LAR^7UG!T<4[XW'+EE5GB8N"M3UC'V":;U?,[K1'-A_"K!5WB
M4\ZQL?J^+K896P>#?,J<</)3=ZBLW[9II:+E5GJS^#[_ (9D_:2_Z-_^,O\
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M/_0\QW_A%@__ ):?P??\,R?M)?\ 1O\ \9?_  W/BC_Y6T?\,R?M)?\ 1O\
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MVZ-)'$KS?#WQ-&K2RL$BC5GTX R2.0J(/F=B%4$D"I?^&9/VDO\ HW_XR_\
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M$6!_Z'F._P#"+!__ "T_@^_X9D_:2_Z-_P#C+_X;GQ1_\K:/^&9/VDO^C?\
MXR_^&Y\4?_*VO[P:*/\ B-V9?]$_EW_A=C__ )4'_$(L#_T/,=_X18/_ .6G
M\'W_  S)^TE_T;_\9?\ PW/BC_Y6T?\ #,G[27_1O_QE_P##<^*/_E;7]X-%
M'_$;LR_Z)_+O_"['_P#RH/\ B$6!_P"AYCO_  BP?_RT_@^_X9D_:2_Z-_\
MC+_X;GQ1_P#*VC_AF3]I+_HW_P",O_AN?%'_ ,K:_O!HH_XC=F7_ $3^7?\
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M4\0^)A:6;7#2W$L$FN7T\LLJLB! +R6Y@M]A836\$<_R^:!7Y;_&7Q%K]_\
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M6DZ;E^(8&C&.)RBJJ-:'M,;@KU9UJ,J=1_7(1E[*C%*K&-X;SNTU)2TE!O\
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MO#OBW4)V^VPF2\U"8VQN?-C_ *2_VU/^0EX#_P"O/6/_ $=:U_*)^TY#??\
M#>Q5/C1H>C:1?ZA\-M!UKQ7>:E\?X9O@5?:KJOP\U;PAX3:+PCH=U\$K'6-0
MN?#.KR^'!XM\3^'9=4/Q!ND\66FIVD=O#=?,9#.5+A'A^I%SNL14@X1K2HQG
M&KB<7"2J<N(P[E%6BU>;A!WG44:?/(_EW.Z<:O%6>TY*&N'I34I48U90E2P^
M&FG#FH5U&3NT[14IJT(<U3EB?UC?L6<W7Q'^55^7P[\JXVK\^L_*N"1M'08)
M&,8-6_VU?^/3P!_U]:[_ .B=/JK^Q<<WOQ(.SR\_\(\?+_YY_O-9^3_@/W?P
MJU^VK_QZ> /^OK7?_1.GUXTO^3IKUC_ZI6>K#_DVDO2?_JV1_-/\7OB!\8O#
M7[3'QC^'WBG]K+XB_"KX<^*-%^$^I_#RP\'_ +)EY\1EMM(U5_$UGXHT+PI\
M2M'TK6X= \4VEQ:64>JZIJ,!O?)U73]2^S[;($?T8_L3@+K_ (S56D=5\-Z"
MJR2G,TBK<S@2S$A29I0!)-E5/F,V54Y4?RO_ +?:WJ?M8:-/!\7=#T;39/AW
MH6A^)KO5-1_:#MT_9YTCQ7)J^BZ1XTOHOA9H>I_#RS74?$:67C'0[_QSK/A*
MZGUGPQ%:ZGJ4_AC[3'7]3_[$P*Z[XP4W#7A3PQX>0WK;-U\4GE4WS&,F,F](
M^U$QDH3+\A*X->WQ'.3R'BRE)SDJ,J:A*I6G5?+/'8>HHQ4J]6,81<FHJ%.D
MHI*E/]Y!PAXV04XQSOA>JE"+K*;E&%*--<T,%7IN3<:%.4I248N3G4J-MNI!
M>SFISF_;1VGQ-X##DJAT;5=S!=Q5?MUON(7(W$#)"Y&3QD=:_!30/VCOVH/%
M/QD^+OPJB\)?LP^$K+X??&_0?!\6M^)?CPK>,K#X=ZA:Z+KT=['\+Y?!>GWG
MBCQ)XD\-W=S-H+V^NV-I;:I=Q6WFWJ:<\MS^]/[:?_(R>!?^P+JW_I;;U_+7
M\>/#OQ'NO^"A.GV=I\,/ FJZQKVO^!=8^'.L77P]_9SU'2Y?#>A:QX-GO?$/
MC#Q7XFF'Q?\ ^$@;0H_'\%[]E@?5;"XT[PNO@.*X7S)5TR"M5H<)\.3I3KQ4
MISI5(4;WJ0K8K%Q492C2JRBU)+V=E'FFW'FBWS1G.Z5*MQ/Q!"I"C)QA&K3E
M6LU3E2P^%DW&,JE.+O%M3NY<L4I<DDG&7]7/[%>/LWQ"P"!]KT' ;[P'DZG@
M'W Z^]4?VU_]=\.?]SQ/_/0ZT/V+2#;_ !$*DE3>Z$5+?>(,6IX+9YR1R<]\
MUG_ML?Z[X<_[GBC^>AUX,/\ DZ<O^W__ %2H]N7_ ";2/I#_ -6\C^:SQ1X_
M^,>D_M,?&KX7>._VMOB1X"\&ZM\2_AEJOP]\/^%?V2[WQ1'=^!]9TOPY?-X0
M\+?%W2=)UJPT%DU/3[SPWXOU.['VV&VU*YUNY%I)?NUM_25^Q=C^U_'^%"#[
M%HN%!W!1Y][@;N=V!QGOUK^4;]KB*]_X;?*K\9=#TC1M0N?A/I.O^([_ %+]
MH*$_L]RWFJ>$KOPMH$L?@71+OX06.I>)-6TR[U;P_+XQ\3>&+C4+CQ_-;>)H
M=4T9=+MYOZN_V+\_VQ\0<YS]CT;.=N2?M%[DG8 F2>3L 3)^4!<5[/$=24N'
M.*:;<Y*C7HPC*I6E5DXRQ\*BBN:O648QYVH\D*4;)4VG4I3A2\G((1CG_#51
M*$76HU9RC"C&DN98*4')\M"DY2ER)RYY5)7;G&U.K&53[\HHHK\)/VH*_FT_
M:Q.DCP-^TL=?TG6M>T+_ (13XM#6M#\.7 L]?U?23I>MC4-/T:]:VO18:C<V
MOFQVVH?8[MM/<B]2VG>!8F_I+K^;S]J6]U_3?"7[16H>%-;3PWXHL?#_ ,4;
MKPYXADN+*SCT/7(;'6'TO57O=2>/3K!;&\$,_P#:%\ZVE@4%Y/F.!E/XGXRW
M=+A6SL_[6Q%GS2A9\F7V;G!2G!)V;E",IQMS0C*48QE_1'@!;VO&]TVO[$PE
MTHQFVO:9I=*$Y0A-M72A.<(3;Y)RC"4I1_,'_@FO\6[SQ[=^+_#<GC[QQ\0K
M3P[X'MECGU;XWR?&KPMX//AWQ]K_ (%L?#R7UQX)\*W6G:YKFBZ)IOB32+V:
M[O)=:T!M0FFL;-8+>:?^T+X4?\DP^'?_ &)'A;_TR65?Q5_L0WGCOP5\8;_P
M+HGP[\9:?\.O%?PG\%^,/&UCKG[2_P '?C>?#WQ U2XN9KWXM-_PB^OW&LV6
MC^,K;R]+M[33X;J37YKB+6?[-TNUTTF?^U3X4?\ ),/AW_V)'A;_ -,EE4^&
MT(1XKXEE2C"-*MD^65::A*DW:6/KQDZD:/N4ZCG";<4FG%PJ*4W.<D_%RI4G
MP5PA"M*I*M0SW.:%1U(5HJ\<NPTHJG*O>I5IQISII3DTXS]I2<*:ITXR_"C]
MJ8V"S?M$'5=-U76=+$'Q/_M+1]"V?VWJNGFUU<7FG:07AN$34KRW,D%G(\$Z
MQSNDAAEV^6WXY_\ !-#XO/XSUO6/!5IXZ\=^-M&\,_#S['I^EZG\>)?C3X;^
M'NG>&-:L-#T'2;\W'@;PO=:;J^KZ)/:IHVIS7LTNIKHGB"VDTV".RCN9OV2_
M:>OM8TR__: U+P[?PZ5XAT__ (61>Z#JER+0V^G:S;1:I+IM]/\ ;Y[:P$5K
M>+#,[WUS!9H$WW4J0*YK\;?V-/$OQ:\(?&'P[X5NO 'QWNO#7Q,^#OA[QA\2
MI/B!\:?V;OB=!;?$F]U#_3_C%HT/@/QR_B#3_A_J\#W%BEQIVEZ@NN37%@MA
MHMFNF7$\_P"3N$:E#B^#C2E4_M/&U*7M*M.#BZ.*Q\ZLHJI:TO9.T'2DIU)K
MV%3DIN#J_M\:DJ6*X#J)UHT_['R^E7=*A4JJ2KX++*=&$Y4I7Y775YQJPE"E
M!_6::J58U(T?[2?@1_R1OX;?]BEI/_I.*_ []L[0_"OB3P7^U%HGC>ZT[3_"
M5_X8^+,6O:MJNDKKMEH>GC1M9:;7GT<Q3MJ,VB ?VG:VD437$]S;116^)G0C
M]\?@1_R1SX;?]BEI/_H@5^%7[56I3:-I'[2&L6_AK3_&<^E:#\5]1A\'ZLDD
MNE^*Y+/1=:N$\-ZE#"DDT]AK;1C3;RW@0W%Q;W,D,&)I$8?I'B.Y1X<\/'!M
M33P+BXRC"2DLIR5Q<9S]R#YK6G/W(NTI^Y&:?Y+X2J,N+?%6,U%PE#,E-3A*
MI!P>>\0*:E3A[]2/+S<T*?[R:O&G:I*FU^;O[ 'Q'UG71J/@SQ!:^#])N+;X
M>VVKZ39Z%^SQ:_ O7-?M_!/C&]^%^O\ B'7&TWQAXKL=5GL]:TR*WNM-F%C=
M6;ZWIUY#YL<]U!:?V#?!K_DDWPV_[$GPU_Z:;6OX>/\ @G;XW^#7P[^*>I_#
M7PS<^!-1NOC!X"T/Q?IWBCPG\)OC9X OM,\;7NJW>J:Q\%KE_B;JWBF";2]*
MAN=4\2Q26E_H_P!COK:4:_'=:AJ6G2#^X?X-?\DF^&W_ &)/AK_TTVM=_AO1
M]CQ=Q'RTITJ=7)L!5I\\'#G4LPJQG.,7[T5[2,X-2]Y2A=VC4I)>9XM8AXC@
M7A)2KTZ]6AG^9T*OLY^T]FXY72E3IRFFXR?LITYJ4/<<:G*G*=*M)_SY_MAG
M1Q\//VHSXBT?7?$/A\^&OBZNN:#X8NDL?$>L:4\&LI>Z?H=]):7Z6.IW$#,M
MI>M8W@M) +G[+.8A&WYN_P#!-_XOWOQ%N/'>@S?$+QK\2;70?A]X0O4U#5/C
MA)\;?"?A2[MO$OB_PG)X6MM2N/!GA:YT[7KNRT"Q\0V]Y<76H7.O^%]0TN^N
M[.PF DN?TM_:TU3Q3HG@K]I?6/ ^K0:#XTTO1/BM?^$];N9M+MH-)\06J:Q+
MI>H27.N7-EHEJ+6Z6.076L7=MIELP6>^FCMXY#7YG?L:Z_\ $CPA\9O$GPT7
MX=?':T^&_B/X7^"?&6LP_%+XQ?L[_%/4/!7Q%U.7Q+/K7CVYG^'7C>XU^S\'
M_$"RMM*TC0UMM%U%-6U>SGUB&STC37<C\C4(U,LXGCRTY5%F.*JTW4JTX."I
M5JSK2A&HD^?V<XJ'LI*5:7-2J\L8T%7_ '2525+.>#IJ5:-.64X*A5=.A4J1
MDZ^&PZP\)SI2:Y/:PFZGMJ;CAX\E>CSRGB)8;^S[X5_\DU\!_P#8IZ%_Z;K>
MN^K@?A7_ ,DU\!_]BGH7_INMZ[ZOZ]RO_D69;_V+L!_Z@X,_A+.?^1QF_P#V
M-<S_ /5CCPKROXV_\DK\9?\ 8/M__3C95ZI7E?QM_P"25^,O^P?;_P#IQLJY
M\_\ ^1%G7_8IS+_U"Q!\YF__ "*<S_[%V-_]1:Y_,)_P54\6:-X%^'WP3\8:
MHNLZ->^'OB=JVH:)\1+#XE>+?A7IW@6X/A.[L]3@OO$G@S3;[5;G5O%^C7=[
MI'AO1+V>QT+4+JUO9M2DGEL[&W?[N_X)K>*+KQE\-_@-X@NI/$%V;G7M?L[7
M6_$?B?7/&=WXKTW2O%6MZ7IGC'3_ !/XEL=-U_5O#WBFQM(-8\/SZM9170TV
MYB16GMU@N)?E[]O:+Q/JMK\!/"FF1^*M>\(>*?B/X@M?B'\.?!'QQ\&?L]^*
M/B#I&G^#KW4-'M-.\>^,]8T.WNXM UE(M7O?">F:A;7FM08NY+B.+25ANO8?
M^"4/C?XI>,O _P ,4^)^DZ[)+H'C+6](\+>/-;^)O@/XL/XW\*VOB76X-"A7
MQEX&U.^BU^[\(:3%8^&-2\0:G;V$VM7=@]Q ES&AN9?YWRN*EAN'FE#GI9_@
MI-NJN=4ZF94HQC"$DI-^TA)SA%NFH.-6'-4E7]G^.8!*5')VE#FIYOA6VYKF
M4)XV$8I1=F_?BW*,;Q4>6I&\G5Y/W4^,O_)+O&O_ &!I/_1T-?S ?\%5O%FB
M^!/AS\#/&&J0ZUI=YX?^,4EWH_Q#TWXD>+/A79?#Y[KPS>:3KLM]XF\&:;J&
MJSZAXJ\.:CJ>@^'=&O)+#0=0U4K_ &S<3VT/V63^G_XR_P#)+O&O_8&D_P#1
MT-?SF?M\Q>*-3L/V?_"NE+XHUSP?XK^*FNZ;\2/ASX)^-W@S]G[Q5\1M$M/A
M]K^I:)IVF>/?&>L:';747A[Q#;6?B/4/">FZC;7GB"TLGCDGAMK:1S]IX@R4
M>+LBE*SC'+*DIIRY+P5?'N:4OANX<RBIM4I2:C5E&G*<E]-Q@TN(LJ<M8K 3
M<E?EO%5<6Y*[TNXW24K0DVHS:@Y-?2W_  38\4W7C/X:? W7[N?7=0\WQ=XN
MTZSU_P 0>*-=\9W/B_2M%\<>*-(TCQOIGB?Q/8Z;X@U;PSXRTVRM?$7A6;5;
M.*ZB\/ZAI\&^XCBCN)?V!_:"_P"26>(/^NNF?^G"WK\0/^"4_C?XI>,O!/P^
MC^)NC:\5\/?$/Q+I'@SQUKOQ1\ _%R;QGX.MO&7BVV\/Z:?&?@74[Z/7M0^'
MNB6FE>"M9\1ZK;Z?+XEU'39=4LXYX7>4_M_^T%_R2SQ!_P!==,_].%O6G#D/
M9\*\?0M!6K8^RIR4X)/*U)*,E9;25U:+C+F@XQY4B\ECR9!Q='W=)XNW))2C
M9X!M6:\FKJR<7S1:7*D?S3?\%"=6D\(_$7]E?Q;X1U46'Q5EUCXB>"]#TUO@
MWX&^+NGZYX1\<77PS\,:_<^)K?QUXE\*66B:-X=\3:IX&>VO=/U"]U=KS6&6
MVTR2Q74[FV_2S_@GSX_F^*7AKX!>/[K4_P"U[[Q%H&K-JE]_PB]AX))UG1Y?
M$'AW6K,^$])U+6M)T)M)U;1[W2&L]*UC5-,=K W6GW]U9W$,K?F#_P %/='\
M-^,K;X ?#WQ_H^DVWP\\0Z_\1-9UKXE7'P"\8_M"ZYX$\0>$]%\.7WA'2]&\
M,^#+BTOO#]MXTO+J]CU7Q#=S-;,_A[3=,AB6^NK2Y@^Y_P#@D[\6=,^+'P^^
M"<MMX3B\!ZUX(TZ^\%>*/!NG_#WQ1\-/#N@ZCI%IK$&FKX:\->*K.VN[33M5
MT"+2]>N+.VN-3CT?4]5O='N]0GO[*Y-?&9/2YO\ 52LJ<I3IY[@H3JW@U&C/
M,)^RA=)3Y744TH-MTI6<VXUZ*C\UEL$WP_4Y&Y0S;#1E4O!\M.>,E[.-TN:S
MFI+D=W3=G)VK4TOV6^.'_)+/%_\ UX1?^EEO7\OW_!5O7]-\)^!/@5XJU+0+
MME\/?%2ZNHOB+%XJ^*GA&W^'4&H:,FB:RD>J_".YLM>36/&&@ZGJ6DZ1_;E[
M;^%0]K/_ &FEW+]GMC_4#\</^26>+_\ KPB_]++>OYQ/^"@":W>R_LYZ+"TF
MM^#M8^(?C*+QQ\-8_P!H<?LQ/\0K:T^'>LWF@HGQ)!MY+MO">L0IXD;PH=1T
M^#6$MFDEED-HL9^MX^:CQCDTI*\8Y7*4ES.'-%5,P<HJ2LN:4;J*FU2<FE5:
MIN1]#Q<TN),LD]4L W)7<;Q53&.236EVKI*7N-M*I[CD?7__  3:U:^USX>_
M +4=0L-6LG?5O$UM93ZUJOC+6KOQ!HNG^(_%-AH/C*WU#XAO)XX?2?&VC6]E
MXJT.W\3NVJV6D:M96DQ*PI7[IU_/)_P28\6?%/Q3X"^%1^)FF-)#I7BG7;'P
M/XVD^*UE\7Y?&_@X:YXM71P_BR#2]*O]47P;ID.F^$(O$6KQ37?B^/3E\0+,
MT=SO?^ANOI/#:#IX3/X/DO'/JG\.7/"SPE)JTO1JZ:3C+F@U%QLO:X)BX8;-
MXOETS:I\$N:.N'IM6?H]4TG&7-%I.-D4445^D'VI_.-_P5D57_:4T%&&5?X5
MZ,K#D95M:UU6&001D$C((([$'FOY@/@YIGPK\ _M$:K\/[?X5_!BXU[3?C?X
MRGT#QW8?&'7+WQ-X?E\7W?B+Q+HUH_@35="OM''CNWLX=6L&M+/Q#'J6ZVN0
MMRE\LT,G]0/_  5A_P"3EO#_ &_XM;HG_I[UROY1]/U?P1X>_:FG\9ZSXHT?
M2?A[<?M&ZMX*/PZU+XXZ)#K7AWXE^']9\6ZQ!\4-<\ 7/AVUFM/!R^)=;\0^
M)[;2I_%\BZ=;:_::Q(DRM'80_P!+Y1.-+A?@:LXT+PIT8N=94;4Z,Y/VLTZ]
M*I%1B_9.4J;A6A)TITD_WDZ'VV&:C@<KE:-THJ\N7W8M^\_>C))+W;M-23Y7
M'[3A_<E_P2+_ .2$>/?^RGW_ /Z8]'KY1_X*[DCXU?"\CJ/AO?$?^%%+ZU]6
M?\$B'23X"^.I(V5XY/B9>21NC!DDCDT'1G1T9259'0AD92592&!((-?*7_!7
MC_DM/PO_ .R;WW_J12U\SE'_ "=_-?\ NJ?^JW '#0_Y**O_ -QO_3%(_E'T
MO0?A=\/_ -J/QGX4O_ 'P]\27VJ_'30/&VBZ[JG[1/CR'5_"FH^,UTR;2SK/
MPSU"RU;PG>>);/Q'I=W>>&+"]U%+V:=M,MHY;.9M*CC_ +0?^"/N?^%<?&?.
M<_\ "?Z)G/!S_P (U%G/OZU_%?\ $&7P=IW[3WB3QEJ5U=Z?\/M%^-_@'P9X
M[\+W7QS\):#<:O\ $;5-8\(:WI'C>'X6W_AUM<G\$VGB3_A&-=U,?\)IIJ:C
M'H=UJT>FM9V,\-Q_:9_P1XFBN/AI\8Y[>>&Y@G\=Z#-#<V\L<]O<12^&(7CG
M@GA9XIH9499(I8G:.1&5T9E()]'B]QCPAQ+1C&A"-/.,#[.-)4U)TI9EB7&<
MN6E2G.'/[6$)U>>:E"M3O&$*;K;9BU_9V-BE%*.)I64;)\KK3LW:,6U?F2<K
MNZE'1)<WQ=_P5.5G_:GO460PL_P^\*HLRJK-"SQ7BK*JO\C-$2'57^0E0&^4
MFOYU/@E_PF,'Q*C\'?$;XG?M/ZYJWAGXO?$2^T[1-:^'G]F_#?7+$ZWKEYX6
MU;4_'>FZ/"]UX3GT6[AN[/1[J\M](69(+2..2SMK8M_1=_P5*_Y.KN>,_P#%
M!>$N/7Y+OC\>E?S!^ ?#%G;_ +7MWK__  D%[+X1UOXTZ@VA^/Y/A;X_L[CQ
M9\2?#%U\0_MOPQ'Q.O-4E\'W4$:^*-0\)7KP:9%8ZUI?@[3-#TM(KVVN)'][
M*)RI\.\#3BI2YL+A:,X^UG"'LZD8-RJ0C7HJ2A.%.U2HJE*G*483BW7I0GU8
M9M8/*VKN\(1:YFE9V=VE**=FEJ[I-I-/GBG_ '*?\$F/^39=<_[*WXM_],_A
M:ODO_@L$2/B;\%2.H\#>*2. >1X@TPC@Y!^AXKZT_P""3'_)LNN?]E;\6_\
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MUK7MFMD]%?\ LS V3[*]D^ROV."A_P E%7M_T^M_X(I6/Y8?&^A?\)E\;/\
MA.I],^"_B;X#>(/&GPDU#4[V_P!#^'.I_&+6K'XE1Z-IG@?4=-U?4_#DX'P?
M\5ZC>6-M)HVLWY^(VI6[WD6BW%KI,HL9O[*/^".5I:Z?\+OB]86-K;V5C8^-
M_#UG9V5I"EO:6=I;>%H(;>UM;>)4C@M[>)$B@AC14BC141550!_&[8_"KX'>
M /'_ (7\ ZU^UO\ %C5=7T[Q5\'O!J^ M5TSP1)IE_J7P;NO#VK_  U\)ZYJ
MVC?"^UFL;32Y[GPW8W5[%KEC)=WNIZ?I>HZB=0O5B;^RK_@CZ2?AQ\9R>"?'
M^B$CT/\ PC46:]3C*G)<(<0U*L*,*]3,<JE6C3Q>%QDJ=66,G.K2Y\-!.C1C
M-MTJ%64YIJI-RDW)PWS)/^SL6Y**DZV'<DJE.HU)U&Y1O!)QBG\,)-M/F=WJ
MU\5_\%372/\ :INY)'2-$\ ^$V=Y'6-%54NR6=W(15 Y+,0H').*_F'MO 5M
MXG_:&3PUJWA+XO>$O!5W\:O&WB#1/BSIWQ5^,>D^ ?$?C*X%S=3:+X!\)Q&W
ML/"WC.XFNM0CNO$5[-_P@]]]BU!O";ZC=W;06O\ 2%_P68\+7OCCXR?$3P7I
MU]#IFH>*_@MIWA^QU*Y\\V]A=ZIIVH6MO=SBU_TDPP2NKRBW_?% WEY; /X9
M>"_@G^T5:>/_  _J?C_QS\&;CP]#\3?!?Q)U32_"D_C\^()/^$!^&&B_#NWT
M/1(-<AAL?[.O(](M->U+S]J0W5[<-L)=)']O)Z-3$\.<'TEA*]:E3R_ U9U*
M=.C.EK/V<Z%=U*U&I1IN$%5=2CS57R14=%)2Z<-%SP671]G.25&G)RC&+CJ^
M5QFW.+BK)2;C>6FFSO\ V-_\$E4$?[,6LQ@LPC^*_BJ,,[%Y&$>B>%4#2.V6
M>1@H:1V^9W+.V68FODC_ (+$2QP?$;X-SS.L<-O\/_%\\TC<+'#!KFGRRR,1
MDA8XT9V.#A5/%?7/_!)C_DV77/\ LK?BW_TS^%J^1/\ @L9 EW\0OA!:2[O*
MO/AWXSM)=IPPBNM9L+>4H<$!Q'(VTD$!L$@XQ7P^3_\ )WLSMO\ 6LZMZ_V;
MA[?*]OE<\O#_ /)15K?\_,3;_P $QM^A_*'X^T4>-?C0?'AT[X,>)_@/KGB?
MX2:KJ]]J.B?#K5/C'K&E?$!]-T?PCJGA_6-4\.3B/X2>)]4NK"QGTG7]1/Q!
MU&-K^'P[/9:?(MG<?U]_\$?;*STWP?\ &G3M.M+6PL+#6O =G96-E!':V=G:
MV^D:[%!:VEM"J16]O!&JQPPQHJ1HJJJ@ "OY%;?X,?!#X>^-?"_@;7OVOOB1
M<:I;:]\)/!-M\.]8C^'QM]5N/A1J&C>)OAOX+U2]T?X90W=E%833:(MS=_VU
MIUS<G4;"RU+4Q>7]O#)_7G_P2*)/AOXYD\$^(O!)(]#_ &7K^:^BXNISCPEQ
M'4JTZ,*]3&97*M&GB\)C)0JRQJG4I<V&BI4*49.].A6E*HFIU'*3<N3NQR:P
M&,<HQC*52BY)5*=1J3J)R5X*\(WVA)MWN[N[M]9?MJ?\A+P'_P!>>L?^CK6O
MYB?VO/VNOC;\/?&?Q+^#VN^%M%M_#B>.?"3_  U\>^&/#7[1<6N^%O#\MQX8
M\5:%\2_B/>?#_0G\,:U\-/#MY!K>A^--+T+QO9:QXA:S&G:EI%IIEQJ$=?T[
M?MJ?\A+P'_UYZQ_Z.M:_F&^,?BC3]#_;LUSP]X\N['QG_P )%XH^#Y^'$,O[
M8?QF^%%I\,[&]TFTM#X9\0?#3P3I2?"P7/B/Q EQK7AW2O&^LQZQXY%V+299
MX9X(SYF0RJ1X.R14J\\.ZM6K1E4CR\G+5Q.+CRU(M.4DVDH<G+*-1J7-!14E
M_,>=PIRXMSAU*,*ZITJ590DGS\U/#X9\U-IJ,6DVY\]XRIWCRS;<7_1G_P $
MOO&VM_$GX41_$#Q+I<.BZ_XP\(>#-;U;3+:VO;*TAN[B77X_M5E9:E'%J%EI
M^K0PPZUIUG?1K=VMAJ-M;W&Z6-F/KG[:O_'IX _Z^M=_]$Z?53]BPDW7Q&SU
MV^'/X!'T;6  (UPL8 X"* J#Y0  *M_MJ_\ 'IX _P"OK7?_ $3I]>&HRCXH
M4HRDYRC&E&4VDG.4<C493:6B<VG)I:)NR/9<HR\-ZLHP4(RE5E&";:A&6<-J
M";U:BFHIO=11_,K^VS^U=\9_A/XI^)_PHO/ MGKWP\\1Z'X1'@36O!>A_'ZT
M^)EC#XGL9?M7BJ;Q#\-- U#PZ?"WPU\9>&Y)_')MO%7ASQ9?>'_$VEZ3I^GE
M5GN[S]T?^"2OQ&\2?%GX9IX_\70:;%K^M>&GM[N[T73-8T;1/$$&@>-/$?AS
M3?&&B:1X@']MZ9HGC32])L_%>D6.J-)>VVGZQ;QSS3,OG/\ @9^U[XIT[PO^
MUREKX^O++Q;X;\0^"_A1%X)\.R?M@?&;X"1_#6_;Q#XBT[7-5\1^%OAAI,GA
M*'1O&^H7.BIINO\ Q&UBR&MW^C3Z1:2_8XW0?TS?L4C;X@\:+M50OAW0E"HP
M=$"W4ZJB.O$B* %64?ZU0)/XJ]SB9UJF3\4RGBJDZ=&G3H1P\U!NFGC\+4@W
M**7NI<_L4^::ISY9R5G!>-P\J4,UX:C'#4X5*U2=:6(AS)3M@<33DN63?O-J
M/M6E&,IQYHQ::FW_ +:>/^$E\"9.!_8NK9/7 ^W6_..^*_GV^/'[?R>!=;\9
M_#73_ OQ!\*_$#PM\6O#_P /O"&J^;\.=1\,?%_Q##X@\$W$OP_T:_USQ%9M
MX5;QKX<\5V\4OBCQ#I<-EX:MVU&[@FN[VPACG_H(_;3_ .1D\"_]@75O_2VW
MK^97XQ>"?#OQ._;*\<^'_C1X O+FPG\3> O#O@2+3/V*OA[\4]&^(OPY&A64
MMY=>*/C1XCN6\56K6.K7NJZ1JU]IUE%:>%K&-&TZ6?8[KKD57$TN#\A6%J*E
M4K>THN4J;G&T\3C+7FO>I.,DI0G&[E*T+27-&>6=4L-4XKSQXFFZM.DZ=9*,
M^6:<*&%ORP>E5-.TXRTC"\[Q=I0_I9_X)P^.]+^*'PSOOB-HMI=V&E>-=)\)
M:_9Z?J#1/?:<+NWU5+C3KN2W9[>>?3[R*XLWN;9VMKOR!=6S-!-&3U'[:_\
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M ?\ V*>A?^FZWKOJ_L#*_P#D69;_ -B[ ?\ J#@S^#LY_P"1QF__ &-<S_\
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MM_6/[:I"ZAX%8D!4L=:=B> JI);,S$]@J@DGL 37\P7[2'Q"_9/N]<\8>+?
MG[86F^)Y_B%\2_A%<?$']E+P9X]\%76B_%OQMH7BSPWX7L[J6==+OO'6B26=
MI;6EUXDT?P]?0VVKKH821K!)+AS_ $_?MJ?\A'P)[V>L@_0S6N1^-? J>'?#
MD<HGC\.>'DG5_,6=-"TI)UE#;A*LRV8D67=\WF!@^[YMV>:YN%<-/%<)913B
MZ,?<Q+YJL*\Y0;Q6(BI4U1K44WRN<9PJ\]*I%J,X2AS1?\L\38F&%XIS2I)5
MI-RPR4:4Z,8R2PU"34_:T:S7O*,H3I<E6G).4)QDU)?H1^QB"+_XEAFWL&T
M,^ -Q$NM M@<#<><#@9P*L_MJ FU^'X ))N]<  Y))AT\ #W)JA^Q3S/\1">
MOE^&_P#T+6*O?MJ_\>G@#_KZUW_T3I]?-R_Y.FO6/_JE9]!#_DVDO2?_ *MD
M?R^?MB_$/]E*9?C=XOT']LW3=(\4ZQX1T?PA\6_V</!GCWP05^.-UX!U*]M=
M'\$:BNH:5JGBOPIKLT>L:IX<U6;PG-#?W^GS&T\J"ZA6Z']*O[#I1M4\3M'
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MYQC%>QHTDU"-))3J.I5<>2#GR4X17Z 4445_/Q^ZA7\O/[<GBZ[\#Z!XVU^
MZHUHWQ&N="U2VTWQ=\/?!BZC;^*-2O\ P_::9?:G\3(IO#=[#>ZEJ%I';:*L
M<FH:K?BUMX(IHC-$_P#4-7\P/[9?PM\8_$K5K+4_AW+X-E\>_"7X]6OQ7\*Z
M%\18K^3P%XJO_#U]J]I/H'B2?2X+O4=):>RU&>?0_$5G8ZC/X?UJ"SU$:?>*
MCPG\8\7W22X4=>4(45F6/<Y5':%E@J;BIRM+DC*HJ4)5.62I*;JM-4VC^@O
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M*E&R7K\#2YL'FDG)2YLUF^9-24KX>GJFK)IZ6:25K625DBBBBOTT^X/YKO\
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M_!8F:&V^(OP<N;B18;>V^'WC"YN)6^[%!;ZWI\TTK8YVQQ(SG') X&:^N?\
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MOAVOVU\6>!O"7CFUM[/Q9H5CK<%G,T]H+M&\RUE9=CO!-$\<T7F* LBI(%D
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MJP&3W..:]3^![,_Q7\*N[,[M+J19F)9F/]EW>2S'))]R:^Q/^%!_"K_H6/\
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M_P ->8?_ "PZ/K68_P#0I?\ X<L#_P#*CV&BO'O^%23_ /14/BG_ .%-#_\
M*ZC_ (5)/_T5#XI_^%-#_P#*ZCZIEO\ T.(_^&O,/_E@?6LQ_P"A2_\ PY8'
M_P"5'L-%>/?\*DG_ .BH?%/_ ,*:'_Y74?\ "I)_^BH?%/\ \*:'_P"5U'U3
M+?\ H<1_\->8?_+ ^M9C_P!"E_\ ARP/_P J/8:*\>_X5)/_ -%0^*?_ (4T
M/_RNH_X5)/\ ]%0^*?\ X4T/_P KJ/JF6_\ 0XC_ .&O,/\ Y8'UK,?^A2__
M  Y8'_Y4>PT5X]_PJ2?_ **A\4__  IH?_E=1_PJ2?\ Z*A\4_\ PIH?_E=1
M]4RW_H<1_P##7F'_ ,L#ZUF/_0I?_ARP/_RH]@;H?H?Y5XW\ @1\+]$R,?\
M$Q\3_P#J3ZN/Y\5(?A'.01_PM#XI_CXEA(_'_B75@:9^S_::+9II^D_$WXK:
M=8QR3RQ6EIXHAB@C>YGDN9V1/[-.#+/+)*_/+NQXSBOG<WPLZ&89=C<ME#-H
MTL+F6&Q%)-Y9.B\3++YT9J6/56%:,OJU6,HT^6<'RMWC+3Z?)<70KY7FN79I
M*>3SKXW*<7AJOLY9K3K1PE/,Z=>G*.7RHU*$H_6Z,X2J<T*BYXKEE'7Z HKP
M[_A2D_\ T5OXO_\ A5P__*RC_A2D_P#T5OXO_P#A5P__ "LKG^N9K_T)'_X>
M,L_^4&_U#)?^BB7_ (8<W_\ FD]QHKP[_A2D_P#T5OXO_P#A5P__ "LH_P"%
M*3_]%;^+_P#X5</_ ,K*/KF:_P#0D?\ X>,L_P#E ?4,E_Z*)?\ AAS?_P":
M3W&BO#O^%*3_ /16_B__ .%7#_\ *RC_ (4I/_T5OXO_ /A5P_\ RLH^N9K_
M -"1_P#AXRS_ .4!]0R7_HHE_P"&'-__ )I/;I)8XED>61(TB1I97D=46.-0
M2TDC,0$10K%G8A0%))P#7\A'[6W_  6]_:G^,O[2P_9M_P"">]OH>@Z9/XZ;
MX:^#_%UQHFB:_P",OBGXNBNY=.DFT<>+DE\+^'?#UQ?V]U!I0N["XO+V"-+Z
MXO;-95ME_I2U[]FO4-5U'5=1@^+?Q#+7O@G7/"T4>H:NMS-+/J]GJEK&][=+
M B2:7:/?QW"6(LW<W"22K.C%-O\ %)^P_P"*? O[&_[;O@GX"?M)_LQ?#"]^
M)GA#]IZQM;_X^?$OQQXU\(:]\(]-AN4M;'Q!I=G8ZK8^";_08H[=O$VF:QKT
M5Q9W@UEQ//+;)!Y?ZIX782EF-+B?,<VX>IXG,,GHJ65957QN QU+$T)4,34J
M9I.C!T(5(4:U*GAY8:2JUK2E*C3E5K44OP[QLQ^)RBOP7E&1<5U<#E7$&*E#
M/,]PV79IEM;!XB&)P=*EDM/$3CB:E&IB</7K8J.,@Z.'YH1AB:T*%#$-_I!_
MP3X_X+H?'F']H#1/V<OVXV\.^(-+\3>,#\.H/B?I^C:;X:\0^!_';ZD^BV=C
MXKM-!6#PWK'A^]UO9I-QJ-C8Z?<:5/+#=M)>V7G>7_7%N7=MW#=C=MR-VTG
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M'QLZF+]K"O+$X"5;$4J%>O+!*G0FZ]6,VG6<(5:E*=!GU/\ %$$Z#I( )/\
MPF/A#@ D_P#(=L_2O2*^.KS]D'^T8XX;_P#:+_:4O(HKB"ZCCG^(5JZ)<VT@
MEMYU!T+B2&55DC;^%@#VJ[_PRE>_]'*?M,?^'$M?_E%7YA2RK+*>-QF*>?4W
M#$TL#3C!9/FG-%X6&)C-R;K<K4W7BX\NJ49<VZ/V&GA*4,3B:[Q<'&O#"PC%
M8?$7BZ$*\9-N]FI.JN6VR3OT/KBBOD?_ (92O?\ HY3]IC_PXEK_ /**C_AE
M*]_Z.4_:8_\ #B6O_P HJ[/J65?]#R/_ (9\S_\ EQT^SH?]!2_\)Z_^9]<4
M5\C_ /#*5[_T<I^TQ_X<2U_^45'_  RE>_\ 1RG[3'_AQ+7_ .45'U+*O^AY
M'_PSYG_\N#V=#_H*7_A/7_S/KBBOD?\ X92O?^CE/VF/_#B6O_RBH_X92O?^
MCE/VF/\ PXEK_P#**CZEE7_0\C_X9\S_ /EP>SH?]!2_\)Z_^9]<5YK\4@3H
MFB  D_\ ":^$.@)_YC5N.WN0/J:\1_X92O?^CE/VF/\ PXEK_P#**JE[^R'_
M &C''#?_ +17[25W%#<V]Y%'-\0K1U2ZM9!-;3J#H7$D,JK)&>S*#VKBS#*<
MLQF"Q.%AGU.$Z]+DC.>3YHXQ?M*$[R4:W,U:DUIK=KI<YL9A*6)PM?#QQ<8R
MJT^12EA\0TGSTI7:4KVM3:T[KS/L.BODG_AE2]_Z.3_:8_\ #B6?_P H*/\
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MJ&G:,UR^EV=S,?#SEX+%KRZ:W4 %3<2DD[S71_\ #,%W_P!'&_M+?^'$L/\
MYFZ[,?')\75H3AG+BJ. R_"/FRC,;RG@\*J$YJU?X9R7-!/WE'XDF:55AZDH
MM8FW+2HT]</6U=.GR-Z2V;U76VY]445\K_\ #,%W_P!'&_M+?^'$L/\ YFZ/
M^&8+O_HXW]I;_P .)8?_ #-UP_4\J_Z'<?\ PT9E_P#+C+V5#_H*7_A/7_\
MDCZHHKY7_P"&8+O_ *.-_:6_\.)8?_,W1_PS!=_]'&_M+?\ AQ+#_P"9NCZG
ME7_0[C_X:,R_^7![*A_T%+_PGK__ "1'X<_Y/.^)W_9!?AO_ .I?XOKZLKP;
MX7_ '1?ACXN\1>.5\;?$;QSXF\2Z%I/AN]U+Q_XAM]=E@TG1KR]OK*VLO(TS
M3_)"W%_<,Y;S-X8< @D^\U&:UL/6KX=86K*O2P^7X#">VE1J4/:5,-0G"I*-
M*K*=2,>:=H\TKM)NR32%7E"4X<DG.,*-*GS<KA=P@U)J,FVE=Z7W"BBBO,,
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MQBM$HI:[O]:/^'T'[8G_ #Z?"?\ \)&^_P#EU1_P^@_;$_Y]/A/_ .$C??\
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M^75'_#Z#]L3_ )]/A/\ ^$C??_+JOR7HH_U'X/\ ^B:RC_PE?_S0'^M_%/\
MT/\ ,_\ PHC_ /*#]:/^'T'[8G_/I\)__"1OO_EU1_P^@_;$_P"?3X3_ /A(
MWW_RZK\EZ*/]1^#_ /HFLH_\)7_\T!_K?Q3_ -#_ #/_ ,*(_P#R@_6C_A]!
M^V)_SZ?"?_PD;[_Y=4?\/H/VQ/\ GT^$_P#X2-]_\NJ_)>BC_4?@_P#Z)K*/
M_"5__- ?ZW\4_P#0_P S_P#"B/\ \H/UH_X?0?MB?\^GPG_\)&^_^75'_#Z#
M]L3_ )]/A/\ ^$C??_+JOR7HH_U'X/\ ^B:RC_PE?_S0'^M_%/\ T/\ ,_\
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M]EC_ *'7XS_^%+H7_P S-?LK11_K_P :?]%)F?\ X,H?_,8?ZE<*?]"'+_\
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M_!E#_P"8P_U*X4_Z$.7_ /@NM_\ -1^-7_#D+]EC_H=?C/\ ^%+H7_S,T?\
M#D+]EC_H=?C/_P"%+H7_ ,S-?LK11_K_ ,:?]%)F?_@RA_\ ,8?ZE<*?]"'+
M_P#P76_^:C\:O^'(7[+'_0Z_&?\ \*70O_F9H_X<A?LL?]#K\9__  I="_\
MF9K]E:*/]?\ C3_HI,S_ /!E#_YC#_4KA3_H0Y?_ ."ZW_S4?C5_PY"_98_Z
M'7XS_P#A2Z%_\S-'_#D+]EC_ *'7XS_^%+H7_P S-?LK11_K_P :?]%)F?\
MX,H?_,8?ZE<*?]"'+_\ P76_^:C\:O\ AR%^RQ_T.OQG_P#"ET+_ .9FC_AR
M%^RQ_P!#K\9__"ET+_YF:_96BC_7_C3_ **3,_\ P90_^8P_U*X4_P"A#E__
M (+K?_-1^-#?\$/_ -E5\;_&7QE;'(W>)- ;!]1GPR<4'_@B!^RLQ4GQG\92
M5.5)\2:"2I]5SX9X/N,5^R]%'^O_ !I_T4F9_P#@RC_\QA_J5PG_ -"#+_\
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M8;F2)I8HW=490QS^E7P$U33-9^"/PDU#2-0LM4L)?ASX-BCO=/NH;RTDEM-
ML+2ZC2XMWDB9[:Z@FMIU#$Q3Q21. Z,!ZU6.,XZXRABL32?$&9Q5'%XB,:<I
M4?W;I8G$1@E&>";C*FHI1=E.-MTVV]<+P=PK/#8>I_8F7R=7"T)2G&-7W_:8
M>A*;<HXM*2FVW)7<9=4TDE^- _X(?_LJKG'C+XRC+;CCQ)H RW]XX\,\M[GF
MG?\ #D+]EC_H=?C/_P"%+H7_ ,S-?LK16'^O_&G_ $4F9_\ @RC_ /,9M_J5
MPG_T(,O_ /!=7_YJ/QJ_X<A?LL?]#K\9_P#PI="_^9FC_AR%^RQ_T.OQG_\
M"ET+_P"9FOV5HH_U_P"-/^BDS/\ \&4/_F,/]2N%/^A#E_\ X+K?_-1^-7_#
MD+]EC_H=?C/_ .%+H7_S,T?\.0OV6/\ H=?C/_X4NA?_ #,U^RM%'^O_ !I_
MT4F9_P#@RA_\QA_J5PI_T(<O_P#!=;_YJ/QJ_P"'(7[+'_0Z_&?_ ,*70O\
MYF:/^'(7[+'_ $.OQG_\*70O_F9K]E:*/]?^-/\ HI,S_P#!E#_YC#_4KA3_
M *$.7_\ @NM_\U'XU?\ #D+]EC_H=?C/_P"%+H7_ ,S-'_#D+]EC_H=?C/\
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M\.0OV6/^AU^,_P#X4NA?_,S1_P .0OV6/^AU^,__ (4NA?\ S,U^RM%'^O\
MQI_T4F9_^#*'_P QA_J5PI_T(<O_ /!=;_YJ/QJ_X<A?LL?]#K\9_P#PI="_
M^9FC_AR%^RQ_T.OQG_\ "ET+_P"9FOV5HH_U_P"-/^BDS/\ \&4/_F,/]2N%
M/^A#E_\ X+K?_-1^-7_#D+]EC_H=?C/_ .%+H7_S,T?\.0OV6/\ H=?C/_X4
MNA?_ #,U^RM%'^O_ !I_T4F9_P#@RA_\QA_J5PI_T(<O_P#!=;_YJ/QJ_P"'
M(7[+'_0Z_&?_ ,*70O\ YF:/^'(7[+'_ $.OQG_\*70O_F9K]E:*/]?^-/\
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9HHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $+ 0X# 2(  A$! Q$!_\0
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MP^D\VRVI3B[>\TW%7MIS64=WT>K3L>C#D ^H%+29'J/S%+2/ "BBB@ HHHH
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M'7Q>TR\N]+\(W?C'3M5\=>*L>(->T%M"_L$,A\/>$?$G@?7" RMX*/@S7O\
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M>ZL[2XO;:"\OMYL[8SJ&NMB[FV J"X [@<]MW2M.L=C$**** "BBB@ HHHH
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MQ'HX/AW4?'BC^W]#T/5];((:3:"8D8;6?:K%5)(_J,/ 8@G[BD<G^(CM]/\
M(-?Q6?L6_!>;]I[_ (*%?"#XH6,L'A3X7^#?&.D?$RT\0ZH1I@\=:GX(8:YH
M?A#P4S%1KT<7B%O,E;DK&OBHJ'8*A_KLNO&^O:MJU_X9^'&C6FL76B736&O^
M*_$-X;'PCH>IPA(FTI88#+XCU_6_ECG-O!!%9J)U6?Q9'(QC/Y[XU9?EF69Y
ME.$P,VW_ *M495(W<E?FDW9_S-)\WO2?NK2+TE]%P&\3BL'F4I))1JZ/1)-+
M9[6W22M>[LD^GN Z#Z"EKS#3M'^(BWMC>ZYXVT>[TY=PO=*TCP-_9AO5QU$D
MOB?Q6PX[JY(QUKT^OQY;+T7Y(^W"BBBF UONG_/>OECXH:MK7CCQC;_"+PC.
M+:)K/[9XZU4A0=.TIR&$:]&W8$<;#=AO[:C/!!)^J!AAR.O;\:\5^%'@O5=$
MA\2>(_$<"0^+?'/B;5]:U<A@XL=,CU:1="T4 9)\K0O*4MGY6)W8*YIW_'<U
MP]?ZL^9:NS2\F[ZV\KNW9V.Q\(^!O#G@72DTSP_8+;J8]UU>7.)-3OV4%B^J
M:NJ,\K#.<GD  H.6W==+;P31^3-"LXZXN #G_@1'/X5<H)P"?09I&?-*]^:5
M^_,[_?>_XGC7BKX.^!?$<5PZZ/::+JX#?9M<T*R&F:HI";@7EC4#5L 9<3"4
M'Y57:V2?C+Q%H>J>$M8U?1=<_P!?I@%[]JM1@W^E]]9(/(8'(((R&!!P1BOT
MN+$@,.,'&.WX^OZ=?QK\R_VK?CAX'T7XJ6/@&6S\1?\ "6:=;>&/#>K7%G9
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MDHI&6^Y/VJ-8^'^G2_#>^\8WUS_Q2_B3_A)]8L])L_[2_P"*7_L4?\237/[
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M)?!M_#\(;("_VG=#]V.GW5/7/]YB?H*\CO+R^U*7S[^>YN;C_I[]A_@?Y'Z
M'HNN?$N^O 8=$A_L^ J ;JZR-0&.H5"S!<XZ\GW->9333SR^?/.;FXNA_P ?
M8^OI]?0]NOJ44 %%%% !116/KW_"1SZ7Y'AR?3;;4+J\^Q?VO=_\P'2\XU[6
MO[#Z^(/H>.G&* TZ[=?3K^%ROXD\2:5X5L+>^UVXN;:WNKP:+9VEI9?VEJ=_
MJG_0%T/0^#^E?/OQ!^,_BN'3Y['P3X36U\17=WI5E:Z1JFM:,WQ*OM,UW61_
M;XT+P21XL+>(1X=SAO%GBY2>I53T]9F^%7@"\C)UW1#XDU#(^U^(/$5YK&I>
M)A_W'/\ F7\]_P#A%/\ A#_Z5V.@Z!H?A6U^P^'=#TW1+?\ Y]-)L_[-^W_G
M^OZ]*YW];L[[:W]+._X7/H\OQ?#^5:O*Y9U+HV]%+=/5]):[W26USXW^(7AN
M#P'X7T;Q'XXU73=-M]>\8:7HNC_#W5M8.I#Q;X\UW_D!:UXXUTC_ (N!XBZ?
M\4M_R)?@ROE_4OAQXQ^%>O7'B/P=/<ZEX@U[1_\ D$ZM>?\ $L_LOI_W+_\
M@#QTKZX_;&T&#_A'/ _Q&U72M2\2:/\ "_6=4O;S2+2\Q_Q--=T7_B1:U_X4
M?X_\3\U\#^%?VHO&/P]\1Z/8_M&>%=-TT^*-'SH_B'P[9ZSJ6F?]QS0^GIGQ
M3_.OWWPYRUQX>EC<I2YF_>C:SEKK%IV;N[J[O\5NA^3<:YWBLTS:V*7+"-W&
M"VBE=I);*R26BZ>9Y/XPU+X_:G\&]0\#_P#"JM-^WG6-4^Q_V3XCT;]>WO\
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MFMZ7XG;P_=WNLKI>F^ ]%98O#L'B_0%V1ZSX\^*&O^7XBMX?$ZJW@[P7X?\
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M2R\!:MX3\>?\*W\36'_%SO .O:]_8?CC_F7_ /BG/[<[]Q]1^8%G^P)^UO\
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MAO@OP7_Q4_\ P@7@?_BK\5^L%3S8\VX\C]<],\8]L?C^%04 %%%%&^G?3[]
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MO^>V*^;_ -I#XS?#+QWX-\<:YI.AZW_PE&J?\(OK5WJMWX/UG3=4T'XH#1=
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J#TWPYX?TP$66DZ59C3M/LP.3M5  <\$XR !R,<UUM%%(CUU"BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $! 1$# 2(  A$! Q$!_\0
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MFX>_Y'_#W'YT;A_D'V]O<?G6?UK%:WJ2U:;]^6Z=[_%IKK9-*_35W1^=$_\
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MFO[!>@6>H7^I_M6_"ZVLM*UKPCH^J7,FL:A>"PU'QQX./CW18I'M;9R6?X<
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MUGX%BTI0RK%HWAGXT^)-8\1PJ7$03'A<LUNWD)XM\2_^".O[$/Q?\&:/\/\
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M^$:Z1I*^$;BXT^[\!XM/&X_XIHQCQMH7]LY/7_A(2IW>"%R0/&K^&<9&<\V
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MT^6RE9W5FHVOUT*.O?LN^ -8^+1@\?\ Q&UOQM;W7@/5-:O?A[=_\2W[>?\
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MHSPU\0?$^B:YIGP^^'VJMX]UKQ#K]I_9NFXT5"NB:*IQU'B$Z&<XSQZ5M_\
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M=[Q_];]>G\J_&?X5:Q/>75N?\^^:^T->\2?V#H-M;P3_ /$PU3/V/Z9['_\
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MTXS;A:<)*,DXK^6CXC:SX6T:.X-[?"ZU$'_D$:5@ZEWZ@Y!^A![Y]:^+]?\
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MG^=3W/[":*** "BBB@ HHHH **** "BBB@ HHHH ***K74WDQD]S_+_/^>M
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M77G_ !-URV^$OA_5/^//PGX>_P")EXGO^_\ Q/-=X_\ +3_+I7Z(?!/]E?\
M9L_9%TO[#X.\'>$KG6+;_C\\6:M9_P!I:G?ZI_T&NW7&.]?DV9>%^+S7%O\
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MS_\ LW_\(Q_Y>'I7A_Q(_8_^ -G_ &A/\3?@M\'/"7_/G:>(/!^C?#?5.?\
MLH/[?GA'Q/\ ^6?W&.F:+ON_O?\ F.[[O[W_ )GY+_$CQMI6I?$:W\C5;807
M5Y_IEW:7G^?3I^?I7<3?$+X<PQ"QG\1VUMJ';[7K&C']/;\O:M#XD?!G]D.R
MNM0L8/ _P;\26_\ SZ?;-9[?]D__ &V/%W//]>M?!_C?]F/]E#6/]/\ ^%9?
M"7PE_IG_ "Z?&#QEX;U/_P $?Q ^&_B[U_Z''Z=J!/7?7UU_.Y^C'A77O"LW
M^HUS1+KT^UZQHW3_  /_ .KI5?QY-8Z#_P OUM_VZ9]L]/P_R:_,?0?V)_@M
MJ5UCPY_PB7V>Z_YA7_"X/!O]IW__ & ]<_YE_P 1=O\ H2_T%?:'P9_8_P#^
M$.M/#^AP>/\ Q)<^'],O/[:^R?\ "U/!OB3PSKVE\_\ $E&A_$#Q(?$_P_\
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MJ333>BLE%\SU3M%Z6U/@CQ'^QS\ ?VA-+N/[*_XHGQAZ&S_Q_P G'MFOS?\
M%7P-_::_X)U^//\ A8WAS2K;Q)X7U3_0M9N_L>L_\(SKVE_\P(:Y_P (_P#\
M5/X?\1>%/^9(\5?\R7]*_2#XA:#\5/V>[_\ X22"#Q)\6OA/:WGV+_2_^2O_
M  T[?V+_ &X?^1@_X1/_ *%;Q9U_YD+QOX-XKZ?^%G[0G@_XA>$K>QUJ?1/'
M_@#7?]"&J_8^"?\ H":[H?B#GP]XA_ZE;Q7_ (5^Q<"^->!XQEFF472G!O\
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MO%U_T^<]:^C+RSAO+:>SG&8;D%6'?G!/MU P*\#O+.:TN;BQFP9[4 Y['_\
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M/^$L\.=_?CH:]8GFL-'TNXO;^XMM-TC2[/[;>7?_ ##;#2^3C_//?M7Y;_\
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M]5^8'-_">WU"#X:> +?5-%\/>&M3@\'^'?M?A[PF2/#.B7QTBV\S2]$"H/\
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MK\2]2\=>(?AAX-^'EW<?L_G6/'?C[P!\3O'/PC^+6AZ!KI^-A\(06_PO\?\
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M[1[?35^Z/Q_F:=45GS1;[MZ>J>P!1115@%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
)110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #] 1@# 2(  A$! Q$!_\0
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MJ:C5C!JI7NVZWUW=M;RLM5_AZ:O31O3[P;]MSQO\5/&.H^$/V1?V>+WX^?\
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M7,W%ZQ;<?LF[^[R[?U_P>H4445SB"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **,@]"#10 4444 %%%% !7SK\8?B=\4?A[>^'D^'O[./Q'^/,
M.KK>MJUSX*\9_!GPM'X59%&Q-7/Q8^)7@AIUEZJGAU[H!A@1D+L7Z*J%_O'\
M/Y54)<KO92\GM^&H'Q/_ ,-*_M,_](\OC_\ ^'?_ &./_HD/?^?H:/\ AI7]
MIG_I'E\?_P#P[W[''_T1_O\ S]#7VYM]E_[Y_P#KT;?93[;<9_6M/K=)?\R^
MGI_U_P"GIB/R^0[Q[?BO\CXD_P"&E/VEO^D=_P ?O_#P?L<?_1(?YY]33/\
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M^%7B3XK_  ;NO%7@KP7*?!$_A^#QK!X+\>RGP;7Z!^$?V//@3X+O_%%IX;\
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MZT>:<W'\.OVS/BS^WO\ #K]C#XHV/Q3\;_!?XB^)_P!JBW\ _ /]G33/V?\
MX5_$;P;X@D\5?%36IM$UC6-:'B/Q1XS,>@1^ 9C<*T21E'C)9UW*)/SC\'^!
M?B+^R5J'[77[.OC_ . FN_!#PQ\?_P!A7Q_XG^%'A^YUW1_B$#\5OA5\'9?
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M8[ZIP(O[$R924I*VZ4DVM;7NDUN]S^XC0?'EC\3OAA;^./@[JVFZV?%&C?\
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M3DKZJS;3;M=7U:/V+P6R3&9/P]FEURQSK6"DG&R3NFHR4>5-););G#PS7O\
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M.;&S"?%K7KY/"/V.'_A7?A&T3QV+W U,IKGCI_\ A"1H^ -OAI/^*@,B]?\
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MGVCQ3)''WGAW]E_]O7P)X9\/>$?AUXUTWP7>>'OAWX[2R\2>'/&NE/X;OOB
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29%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #@ 1(# 2(  A$! Q$!_\0
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M_GIU>_9;_P"2A?MJ?]G57?\ ZHWX)5]A4 ?%_P#P[Z_94_Z$KQQ_X?O]H/\
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M4ZM-X7%8=Q4\9@\%4@YXG#TJ2KX:OCJ"Q6&YWB*%^6I3C)QO] _\.^OV5/\
MH2O''_A^_P!H/_YZ='_#OK]E3_H2O''_ (?O]H/_ .>G7AG[+_\ P45\0?M
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MJ+I.I*.'=18JI2HR^]_^'?7[*G_0E>./_#]_M!__ #TZ/^'?7[*G_0E>./\
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M5X>THUJM)T*4HXBA1K5*-1>S:E^V/QF^$WA/X[_"OQY\'?'0U(^#_B-X<O\
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M>#-/\4>![FVM'_L34=2\-2-I6O\ FK?0:M;X$\*L%(_/75_^"COQ_P#BM<?
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M".0:?7G---IIIIV:::::T:::333T::33W2.Z]]5JGJFM4T]FFKIKS3"BBB@
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M$QVNDF=M+MH_"VAI!IS7-O):W#6,*V(CM3/;2RV\Q@5#)#(\;DJS VK;X>^
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M?8=Z1"2JDD$E5)(Z$D#D>QZCVH =1110 4444 %%%% 'Y._LK?\ )K_[-_\
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MPYOY/./A+2K"X"NJW.BQ-H4X+DL9"^D/9"24,2PDE61@>^.*SO\ A5\E@O\
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M6=O86%I$"3Y=O:6T<4$2Y)8A$&6))R236K110 4444 ?D[^RM_R:_P#LW_\
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MS<'D],#MC%/A51&A7/*)R222 H SDG''I0!+1110 4444 %%%% 'Y._LK?\
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M3 (&Q< \D#:, ^XZ&@@?1110 4444 %%%% 'Y._LK?\ )K_[-_\ V07X/_\
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MX^_\.9X]_P#FAH_X4'X$_P"?WQ]_X<SQ[_\ -#0!['YS8SY$WW]N-JYQ_?\
MO?=]^OM2F4@/^YF.P@ !5._/=/FY [YQQZ]*\;_X4'X$_P"?WQ]_X<SQ[_\
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M'_#&A_Z.J_;*_P##YW'_ ,H*/^&^6G^2^X+NS71VNN]G=7]'JO,^T**^+_\
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MNR6/5(?LWD07GFDQV]Q<QA#YI(^A: "BBB@#\G?V5O\ DU_]F_\ [(+\'_\
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M0HKXO_X;,/\ T:G^V5_X9>R_^;*C_ALP_P#1J?[97_AE[+_YLJ /M"BOB_\
MX;,/_1J?[97_ (9>R_\ FRH_X;,/_1J?[97_ (9>R_\ FRH ^T**^+_^&S#_
M -&I_ME?^&7LO_FRH_X;,/\ T:G^V5_X9>R_^;*@#[0HKXO_ .&S#_T:G^V5
M_P"&7LO_ )LJ/^&S#_T:G^V5_P"&7LO_ )LJ /M"BOB__ALP_P#1J?[97_AE
M[+_YLJ/^&S#_ -&I_ME?^&7LO_FRH ^T**^+_P#ALP_]&I_ME?\ AE[+_P";
M*C_ALP_]&I_ME?\ AE[+_P";*@#[0HKXO_X;,/\ T:G^V5_X9>R_^;*C_ALP
M_P#1J?[97_AE[+_YLJ /M"BOB_\ X;,/_1J?[97_ (9>R_\ FRH_X;,/_1J?
M[97_ (9>R_\ FRH ^T**^+_^&S#_ -&I_ME?^&7LO_FRH_X;,/\ T:G^V5_X
M9>R_^;*@#[0HKXO_ .&S#_T:G^V5_P"&7LO_ )LJ/^&S#_T:G^V5_P"&7LO_
M )LJ /M"BOB__ALP_P#1J?[97_AE[+_YLJ/^&S#_ -&I_ME?^&7LO_FRH ^T
M**^+_P#ALP_]&I_ME?\ AE[+_P";*C_ALP_]&I_ME?\ AE[+_P";*@#YM_96
M_P"37_V;_P#L@OP?_P#5>^':*]#_ &:_A-\2/#_[.GP"T'Q'X/U;P_XAT3X*
M?"O2-=T#5OLD.JZ)K.F^!=!L]4TC4HH+JXABU#3;Z&>RO(X;B>)+F&18YI4
%=B@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $= 0X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ JM*?+&1ST_7\OZ59K/O(!=P^PZ=^?
M\\>GO0!.LT4W^J()]ACV]N^*LUS]G9SPRW'[_IUYZ_\ Z^F:U]\OH/T_QH L
MT57\_P!OT_\ KU8H **** "BBB@ HHHH ***3(]1^8H 6BJQQ$#,?3D?_6QW
M]??-6<C&<C'KVH *K_\ +7_/]ZK%4_\ E^_[=_\ V>@"Y1110 4444 %%%%
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MO;T2]=4EKU;2[.]DS3KMU].OX7/5(I$EVL(S_JSL8D\X).T@'&?UY'>OAO\
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M4_=A"I%2C*4:CBG\_B'BU=ZZ:Z.^J=TK:73M9KI=6TN?F%_P<"?#SXT:Y;_
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M+/"GB+2? &K>"?$8C"_VSX*;P_X>B?P_<L  '+W1VIEMY;Y?DC_@G_XA\7_
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M/7P__P!ASTZXY]>-^&'QY^#_ ,3K2W@\ ^,-+U*ZM6:RL](NF.G:E?KH3_V
M#H?_  D" ^(- /B#'AD^)\$!LIO8 .?:J_,<6L30Q5\;!2A-N45."::=Y+2<
M6M4XN]GN?U/36(P<8*ER.GM'V?)[.7(TGR^SO"5I:/EYFF[.S>OSO9_ WP=\
M//L]C\*_A9X)MOM?@0^&+SQ;XAQJ6J6&J>!=&)\"_P!N?\S/XAQT^@SUYKTC
M3=!\8C6;?6]5\8VWV<7GVV\\)Z3HVC?V;_Q/=%T ?V+_ &Y_V,?]N>*.N?\
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M@)RPK6BT/0;&6Z\5>$M$T&_UG6X$GO-32=4U#6['"E"-;*3.0VY67?(\.2I
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M^;PD5\1^(;_3]>E/A_QUX$US0- =9O$'ASQ3$43QCX;V!9(8@3Y1$:M\4_\
M!5'_ ((?VUSX7\0_M _L!3:Y\)/'-J!K/CGX0^"=5UC2O#'C#3@I:35="T/@
M:-XCC7!.@0QI;S;F$:1F-EJUX)_9D\6?L<_L6:!I]E#<>+?C-KNBB^\7^*]5
MNSJ1O_%.NX_MTDX^[X5Y '^R0<YK];\.. .&\WS3A?,\GXLC66)Q/U2?#%7#
M4Z<^6M&I"I1Q+G4="I2E3G)*I&+4Z<U[DFY.'YIQMQOBLFRO-L/Q#EO]B1IP
MYH\3*I%TWR/FA*-K2C)J*5G)+5^3?W[\-/\ @JYJWBC]FB[\;^./@7J/PO\
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M?_0;.A^(./#_ (B_ZE;Z$C'7^M#]E#SO%7P6\,>.+[PMIOAK4/$]Y_;)N_\
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M " ];[GGH3UKWK3?[*O(?[<TK[-<V^J?Z;_:UIC_ $_'U[>E?D#\;/AY\#M
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MO/%4UWXOM6\-^*O"G@<*VI^-O#0']M:YI()!VN8]&TE/EVN%89^5V5OZW?\
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M3O&4G3C43DH.FIQG=2<9?)\:8E8/A^223DU*UUKK:TM5?EZII;]4?LK^Q?\
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M?%GXH>)_L9_XE%WXOUGPW\--!/KH?PL_X27IC&5\6K[Y[#[Y_P"%?033?O\
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MTUUY;+@:='Z[C,XK_P!DP3C+/L/2C*FZBDXN*NJDW:5XK5)W3]UZ'Z<^&/\
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MG]/Y_7BNLV+C.2![D=_PJ3(QG(QZ]J\.Z>M[^?\ 7D<&VVB,^&S\GW_+^O\
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M!9WFO"]\5@HRMFS<&I05I**5VKNZBG>/,HI2U2^%V_@\T'_@G9^TEH_Q!O\
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M>$O#_P 1KS^Q;/P]X>\!_P#%#^$O^$$UK0->\=?V'_PC_P#Q3'_"1>$_$?\
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M-SC)*4II.S4ES*+:=E=25E9:VVU/V&MK6"TM8+:RAA@@MK9;:WM[=%"6V%
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MY5P6L7GDVMQ ?\D<>OKT'?GWK1)RDHK>4E%>LFHK\6@LY:17O2TBN\GI%?\
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M9O[5I17/]>MI^K7@[6$\4?"W3O[-L?$>G/KW@,V?A^T^**,/$NH$Z-_Q)?\
MA-%)9LY+-C+.3D#+&OR,_P"#=;]HWQ3XJ^ 'Q:_8[^*RR:=\5_V,/BAK/@D:
M7-@-IO@;6]8U]]#T(DDLY\+^(M"\:^&[?:F8O"5KX58-F3C] /AEXD^'5G-H
MW@?Q%I?@@W]U9$>$-?\ #]YHWB33-?TS_D! @\XZ8/!'.01CG\7OV>-:\-?
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M^Q_$;P9I=YJ^HZ3_ &9K[HFM>,?!/@C7R/#/A[Q'X8=E">)PN/!W]O>* O(
MK\6/^"7-V?A7_P %H?\ @J'\$;[%J/B);ZI\3]*M#D&_&B>+]$\< +[GP_\
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M@^M:/KFA$'POX>;Q2ZJZD?\ %&>,W52/F K'^ /_  6 L?AC\1M/\ ?\%-/
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M[5QJ:PC[-[WCYZ^2[?AK;;IIYGY"7'_!8*\^*6H:3X7\,>!M:^%4FO?%_P"
MY\#>)?"WCOX:_$GQ5J/PQUO]M7P]^RGXUT/XW>"_$7AHO\ /'_B>776>/PDC
M>+_%T7@YO%*Q^,O!?COPB$C[W]DW_@I7\1/VN?VT_A=X4TW0_"WP]^!_B_\
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M .H]:LT4 8VHZ=!-">,=OPY_/\?6O*->\-_;(L].OM_/\?3->X5CS6</F_\
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M&UI;27+^);BT\.^*)8$TJ24V<PC0GY2\!?&GQ/\ M$_%G_@E;\<O''PH\4_
M[Q9\1_A+^U#XFUCX3^,E=?$G@C4M8\%?#XC2M95X;6<;T19X?.M;:94DB66&
M-PPKU,HR_$^SJ9I[O]GRI9[1C[U-OVD<BK58Q5/GE425G-2=.*?V7)KF0MDO
M5]>Z5[VMKM:]^K.?_P""BO[8?Q1_9Z^+6G>'/!/QQ^%'P?T_0OV4?C+\?M(\
M/?$SPDOB9?CM\3O OBSP+H/@CX+Z2%\3^%/$CQ>*3X@FC,7PO,OC+SCE5(\J
MO']8_P""TGB'1[OX_:9-^RW>:=J_P2ATVTO+3QM\7M&\$?V;X@/Q*\"> =;B
M^)YUWPZI\!:"6\<KXM\%W'AX^.V\:^$-#N'A%N9(EA^A_P!O#5OCYIOQS^$D
MOPO'C]]*L/!$FKZ7:>$=(\97L5SXX'QA\ (^!H?PW\4>&==UL?#Z/7XXO"_Q
M1\7^$O!;>8DQ9MTTR\=X0^/?[7WB^^T36O&WPJ\.?#7P]-\8-,\,_$;PGI'P
M<\9^,O$FMZ1<?#?XN_V=\(]>?Q$OA9)YE\0Z1\+M"_X6GX<67P7/<>.]Q9/
M\DDM?58#"Y5#),NQF+RJCG"J03DOK4<)6IRC6Y$E&$(SJPJQBY2JS<G3J7HI
MPA[1I]%OIY73NN[=DT]+=5J[GC&J_P#!8[Q-X3M_CYXTUOX9_!^;P5H*_L?W
MW[/F@#XG>+M \2>+-+_:2^"\/Q5DUKQK+-\-)C:^'G&@ZWX7\#^)8O"4:3>,
M]$N?!3Q/.3-'Y-X._P""T?CWQIHWQ_O8?"NG-H^OZ/XF\;? Q=*\3>$Q\?\
MX4>&3^PC\/?VJM#_ .$W^!S>'95U_P"' U_6M=\+CXXGQ@T;>-_$/A?P6_@;
MSCY]?=?@C]H+]I+XH?LQ_'3Q#KGP$O;7XVVGB7P[\-_@S::#\/\ 7O#-YK,?
MCKP]\/M9T+7&3X@JT)'PG\2^--8/C3Q*S1>"5;P'<W",7657RO!GCK]M:YTS
MPEX;B\ Z%I/B'P=I7PI^%7Q/\5?%7X,ZWXA\2>.=4U;XS^/?A3XX\8PZS\/?
M$O@WPJOASPQ\/-#\%_'>9O"V[P=.GB5H)I?!]L(XH^NA2X>P\:L<7PO"52G5
M?,WQ"H)4X0IU'RJ/.VK2Y>?EFW4O0<7*\8JRTTT:]=6VE?;[NVI\P67_  59
M^+OP_MO&VH>+X/AWXZ\13^.].^'?@/P7X\\>:+^S_P"&]=O_ !!^UM^UK\)]
M'CT/QQ_PK;Q>3X@\,?#GX2>'?$GC=O$P'A)/!?A[Q+XX@>+:6\8>F7__  6A
M4>)?C/X9C_9OO=.B^&WQ;\.?"/2?'/C+XIZ5X,\$:!JOB#XQ:]\(I-:_:&U=
MO#=P?@'X;8Z#_P )9X(U^1/'">./".O^%9'3PE+XJB*]GXC^.O[2_P 1M'N_
MA/??!NV\-^/K+P)X$^,VK:WX>\$ZZ;ZQ\#ZYXN;X??\ "'Z1HGB F31/B'XK
M^(.A>.?$P265K?\ X4X1.8C>;9A/J/[1'[56H'4M3C_9Y?Q1J%C)J6L:]ING
M_#'XD^#-.T7Q._PR^/!_X4YXQS-(_P ?E^%4VE>"->/BCPL(_!WC=]>$?@*-
MO&S>!O,Z94.'<0W*'"M"#=XQ2XFIQC"46I1EHHPJ*45;DJ2IJ<H^S4TIM4\-
M[;^MF_\ @Z/M?O;O]??\$Z?CAXW_ &E/V/?A+\;OB0^B2>+_ !P/&]YJ4_AL
M2G1FAT/XF>./#N@C1I "NL11>']&T=$\0PAD\4('O60K-L'W/!W_ !_I7Q!^
MQ1XH^)_C/0?C7J_Q%U'5M6LH?CIJ%K\/-3U#X8>,OA)I6L^!$^%WPD*:MX,\
M$>.7D\2:)H/_  D[^-8I4,KQR>+QXI,;R!!N^Y1]YOP_E7YMFRC#-,?&$8Q@
MZ\G&,+\L(N7/&"O&/P*:@URQ2<6N6-G&.SW^[\%;]!U%%%><(XU_#WAR3Q'8
M^,)]$TZ3Q1I>D:IX:TO7WLT_M*STG7I](UK6]*BU98U/]BW4V@Z#*ZE #)HR
M#]XX*-Y)J_[,G[.VO:[HWC+6O@O\,[[Q1H6N7WB31M?O/"6A2:IIOB;5_' \
M?2ZP)Y8"[:Y/\0!_PD[3R;ICXIS=QLEP2U?1FX'O^A_P]Q2U>'Q.)P[O&I.+
MM;FIU)P?*NEXSB[:MV3MJWN-.W]7/AT?L$?LNP^.O$GC2+X4^";.P\8>!D\&
M>+_ =MX1\.CP5XEC@\;P^/-&UO6M _X1TQRZ_P"%]>\QO"4JB-H%D(@B\U5:
M/U+2?V6_V=='O_!&IZ9\%OAG87_PN)MOAW<6/@K2-/F\& ZO<:V?[!,0!LH_
M[?U75]?0P>7FZUB>9<W4DTTOT?@^OY@?_6__ %>_-'/J/R_^O6]?-LTQ"2>9
M5FHQY%>I.7N\G(T_WBO>#<6W=M.S;"[_ *LOT%Z4445RB"J]6** *_D>_P"O
M_P!:K%%% !1110 5!-_J3]!_*IZ* (.9H?<_CT_K^9R.YJM-9P=\C./\/3G/
M\NW>IXFVN8>H S_G_P"OV_2S0!S\^CP?CQS_ )^F.?Z5!_8-O_SP/Y__ &5=
M/11V\MO+T[?*P;;:>FGY6.?_ +&A_P">/ZG_  JQ_9L'G?K_ )]\^_MFMBJ\
M'?\ '^E $NP>I_3_  I]%% %<@1=0#]><Y_+T]NGY_!GQS7'[=/[!(''_%/?
MM?C('IX+^'?\NM??0R0,]>?YURFH>'-#O-1TG6KK1]-NM;T9=5_LK5KJR2;4
M='760%U<:7JY5Y=*:YC&R;R74RQQK#C;S6^&J^RJ/=<U.I#3_IY3G3?5*RY]
M>^PT[/[OSO\ H?!7[1WP+^-GQ@_:$^'TO@SQOXC^&WP]\-?#'5I=5\;Z?K/B
M\/H_C0_$[P'JUJOA31M(\7>'- F\32:!HNL6\LOC+PCXN\*S^&'"RV\;2M$?
MCWP7XO\ ^"FWA'_A&_!%MX!\46_@'PO\&O 'AO7+RZ\/^#?&WCK0)]"T'X.K
MK?C3P3KNO>)2?'WQ%>$_&M&\*^+?^$Q$GBW0_"ZNKQ2%?&G[P $_>YQT_K]?
MQ]*@(/\ "0!]/\_TKTL-Q!/!X5X7$991S:%FJ:J1:=&3<KSBX.+3:EJK\ONI
MV;<G-IKK?[]UV>C_ *\C\7_A5\??V\?$<7B*&T\&^)O'0N/BY+X2\%:]KW@K
MX=^'%T'0/!'QC^*WAOQMI'QM_P"$>\30Q:+K:>%X_ADH/AFV!+CQ#/$D3J^?
ML/\ 8JUC]J;Q!\/M=O\ ]J"5!XO;Q+91Z=;7O@?2O!FI:9IJ:!I/]MZ5"-!\
M07%KXAT&'Q.=>A\)>)6CAE^SM&)+GQA';Q>)[K[82"VB $4,,.[_ $@X&/F;
MJQ ''N<X'XU;QP-GT)/7MZ_KC\*G'YMAZ]"4:>5T*5^6TH*7MEI%-6]V"3L]
M%I'5ZWM$NGW^;TZ^K.8MM T6RUG4=<M-.T^WUO6[73;#4]7MK1?[1U.QT%KF
M71XM5U1 3(+8ZQJWDEPTBKK$AB/RR/)U6!Z#\A2T5Y%V^_SZ$A@#H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K2X'[X'H/\]_;^6/6K
M-%% !1110!6EP?W('4?Y[>_\L>E6:** "BBB@ HHHH KS]OP_K6?Y_M^G_UZ
DN[!ZG]/\*=]DA]#^8_PH 6#O^/\ 2K%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $6 0X# 2(  A$! Q$!_\0
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M#GCO0I?% P.6;PE)<1>)%'KOM(U [GFOKY'##*.K#T!#$=.@S[\_7UZ?-8K
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MPK)+,L:22W/AJUB4NWZ@7@VV5R-A YYR>6R.WHH(],GGZ?Q)_M4?LL_L@?\
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M_3..HJ:ZE*@0Q$">?(7V &"3Z<< ]JBXM(?)Z^G7_/0=_;WHT^3_ !76W?\
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MQ.\*:;X7U'P9\7_V=U\,VWQ2TIGU74_!-Z/$+^(-#3QAX&UK6U "KX@T37@
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M"A/XI2DYQCR4ZREI#F;LT_,M!_9C_97_ &J=+T?QQ8V.I> +CQ1>?\3CQO\
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M'Q[_ ."7/P.^)G_"!V7PTM?!WP>TWPSX?\?^#/$/ARR\':QJGAOQ3X4^*3>
MH_'A_L/P_P#$+P;_ ,7 ?_A!-"D3Q-XM_P"$W\).96/CGP1XT4!8N \*?\$]
M_%7B:'XAZ)\4?B'HWA?X>W7QE_;:\;?#_P %>&O 7A:3QQIR_M%Z3\5?A-H_
MC+6_B>-?5-?T!OAM\0'\5?\ "*MX1CO6\8#PR_C3Q;>MX+:W'Z$^)</7P#I1
MXJQ4?CE/AYTJ7+255NE4C1?LN1^ZYU80<%&*J5*KG&JK5<;W]YJ/1):ZVU3>
MM^R;OT2VV^#?%?\ P3K_ &:OBC\*_@1IGQ _X*!^)-,^"?[.7A'P#\*OA/\
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MXDU-?#&N @Z-H1)_Y&$^(3H8  &/F/S;CC] ?B-=_!#_ (*#?#WQM^SG\3O
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M[IG]*8S20IEF$R]2<@#KU)],]_YXY_'7]K'_ (+)_!#X)^/!^S]\ _"?B_\
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MU:NVE=+4_9.S^)7@34/"TOCNQ\;^&+SP9!9&\?Q-I_B'1[_PV(E'S.-;C>2
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M\!Z[XT_Y NMZ&0>G]AXY'L1@X/F^C_M1?$77?%O@_P")OC#P/XE\):OX#/\
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M)R<FDN6RYK;:-G/_ +47PQ_X5O\ 'W]A^^L?])U"Z\2>//MEW]L_XF?]E_\
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M!<0&VGAMY[>[!LKRVN2 U]Z$$YP<\\C'MUK\4_\ @GO)/^P1_P % OC_ /\
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MCC4&\6ZH1OUW^VW7_A%/^*@=MGB9O%&W@KN^?@5R?V=%\/K#833-/=CS-_\
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MXF:X3^SLWS/"6?[NM.U^J4I17?5KE?SO9-LNT4F1ZC\Q1D>H_,5Y)YYGV?\
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MK?B3P]H_B7QM=267A+1-5UE-,U'Q.4 *#15)#,9#P-@.".>,D?RD_P#!,?\
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M2Z/J,?K7C7_!0[]O_P"&7_!.CX!GQ/J<VG^+?C/XHM-6L/@M\-#>%=3\5^*
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M\1V^SQYK?Q>^&'@[Q+_8?AG0I(AX,0>,/%PBEUKQ$J) KR"7]-?*P/WLN1W
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M$/AB\.K>!-.L?A5KVC>#_'\&N>.=(@F\+:#J_ASQ!KD5K/X=U_Q$MX6,DH1
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M9\.-1O([#Q%\2_B3KGA#1/#H\ >$?"O]D^$/#JZ!X$_M?7];_L;^V]!\-_\
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M5KIVN^$O''A[7O" T;2= M([3_A((_'NM/<:_H"QW4S:%X<2),V;I<_?RC
MIJJ0<Y_#U]*?7@5\=BLQ?M,7=S4>7F]U-Q332O&,;VMVZO\ F8/^N@4445F(
M**** "BBB@ HHHH **** "BBB@ HHHH K+$'SYGS?3WS_G]<U9HHH **** "
MF_/_ +/ZT44 0^1[_K_]:K%%% !1110 4444 ,?H/K_0T^BB@ HHHHL 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #? 58# 2(  A$! Q$!_\0
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M (!G_"CSCZVW_@&?\*@HH G\X^MM_P" 9_PH\X^MM_X!G_"H** )_./K;?\
M@&?\*/./K;?^ 9_PJ"B@"?SCZVW_ (!G_"CSCZVW_@&?\*@HH G\X^MM_P"
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M:I8>._ OQ,^ J_%<:UHFOD>)E\/^+/#OQ6'_  A!_P"$/8;/#[*/&_C+_A,
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M,[?^44'C'_L\#XH?^H7\(J_AH_X+X_\ *9#_ (*#?]G ZS_Z9="KF _T]?\
MA]Y_P2$_Z2,?LN_^%V:/^'WG_!(3_I(Q^R[_ .%V:_QCZ,$]!F@#_9O_ .'W
MO_!(7_I(O^R]_P"%W_\ 7IW_  ^[_P""0W_21?\ 9>_\+H_X5_C)E >%')Z=
M?\?\:V(="UB5/-AT^[8=,BV./? V'C\/?GK79AL%C<4I?5*=225VW&G*2^<N
M1KRW^0Y5^6RE.*OLFTF[=DVC_92_X?>_\$A?^DB_[+W_ (7?_P!>C_A][_P2
M%_Z2+_LO?^%W_P#7K_&H.E7HN/LTL30R]U?C'Y=.I_%>.E7Y-$EAL8;TRMYS
M7.P6IMV!'<$L.",@?*5 QZ8.=O[-QEG[DM-]&M>WE\['*ZV%32<H7>VM][^=
MNY_LD?\ #[W_ ()#'I_P47_9>/\ W/?_ ->C_A][_P $AAU_X*+_ ++P_P"Y
M[_\ KU_CC6/AC[9:"<7!BFF.$M;9/MI91T+*C%@<C(&\D'.3S@5-2\+WNFR^
M5<2VY/7AB!D=^A/MU]L5U+AO-WA5BUEL^1OXN57MWM??KN'UC"7MS13OW>]]
MM_T/]D;_ (?=_P#!(;_I(O\ LO?^%TW^%)_P^\_X)"?])&/V7?\ PNS7^-;-
MH>J0QW$LMG<*MJ_V:Y)!^1NRG@Y &W)&1TQWK"P<X/'N>!7FXC"XO#-+$IW>
MJ32_-+IMKU^\Z$T]F?[-_P#P^\_X)"?])&/V7?\ PNS7M'P"_P""EG_!/[]J
M?X@6_P )OV=?VNO@K\:_B->:1J?B6Q\%^"/%YU+Q(VF:%M.O:RN-Q)4.A;(&
MU65NF&'^)/7]/_\ P:*?\I@-"_[-N^.W_IJT*N49_JH:7]^X^H_I11I?W[CZ
MC^E% &=/_K1_UYZ7_2H:FG_UH_Z\]+_I4- '\N__  =Y?\HCM-_[.P^!G_ID
M^+=?Y?\ 7^H!_P '>7_*([3?^SL/@9_Z9/BW7^7_ %]9DE_J<[;WT]>33\;'
MF8K9>C_-!0!DX'4\"BOI#X#?!2\^*OB07,T%W;>#M,(;5KOD&Z4$,NCJ01\[
M8XX.T#/#$5]APWPUF_%F<95DV37>;N2YFDW&$')7G-I-1C%-R;E9:6O=HX,Q
MS#"95@I8[&24%"#G>32U2?+&*;7-.4DE"*ZZNT5)KN_V>/V7]6^(KP>*O%%G
MJ$'@]<"U@L@/[2UIOE(" J,:(K!O,<9P>%.<M7Z'7NA:+X6\.P:)HEE;6\%M
M:&S)TH_V=IMB22<DD\GOD\D]:]0T>:#2+6W\.^';&VMC]D.B_9+2S))).3HN
MA\=?KFN&\;36/AO_ $'7?LUSK'_'Z/#UI=G_ $#2_P#J.?TZ_G7^F?"7A7PU
MP!P=3^K4Z<L\E&/^L_$\X0?,^5/EIJ47HI-Q2IWLK==3^4,^XQS?BO.'&LYT
MJ$)R]E2A.?)&/,TFW&24IN"BI3:N]ERP48+Y?\5:;?3>'+B^\^VMM0M;P_\
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M?/TZ<U\V?%WPW=WUII/B&RLC<0:;9"Q\17=IT+ \ \YY!(R..><<8_GGQ9X
MP<,(\XP.4M9PFW)05E97N^6*2VO+X;V7D?I7"'$TJF*C@,;--6M!SELTKQ2E
M)];**BW;F:2Y;GSG-_J3]!_*O]C;_@F#_P H6_V,/^T?'@+_ -4R*_QR/^67
M^?[M?[&__!,'_E"W^QA_VCX\!?\ JF17\EYS=.ST:=FNS5KKY-,_8,/MIV_1
M'^-7=_\ 'U/_ -=S_-JJ5;NO^/JX_P"NY_F:J5PQ_1?DRGLOG^@H!)QT/O\
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M?Y/TW3#%%Y$X/%YFSNN#]3^O/'?'/6B]M+VT$\'G6UQ;W5G@_:O^)C]A'?\
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MM[L+@#&2.23^9!_EWKP^9O\ 39AW^U$?7+M_3-?0_P ,YIKRVT\3&WTT6O\
M:>+O['W(!P0.ZYQQ_P#6K]/\%,-A,7QQE3:UBI6NKZV[N]M+6[?(^?XK;CD\
MT]$Y0N[I72;:73\^W='UE\+XX)-?L[V^'VF#0SJ6L7MJ#R!H7S$=^ZC) YY_
M'S[7KR?4=3U[5;C[3=:K;G)^U9R3K?\ S&,Y]\\\<@@GK7J'P4L[:S\0>1JE
M[Y]A=6NI65Y=VA[%6''?C';.<Y''%<AXU\*:KX1UJ>W\06]P(+NT^RBZM+L_
MV=?Z;G U8==W7CID GC)%?ZCYCEN+_XAYE>+7P.:Y^S2:7O+5:+6[37W'\Y8
M;$X7_6',TY:\EH)-W;E*3:2T3YG=26C=UNFK]5J.H'0]9TK0+(P7 T'2A=W%
MR+(_VA9,/F;DYPOB;Q 1ZD!UY /.59PPS2V\WD&XN,\Y)Q?9)/(]Q^?89Z9K
M27VO:UJFO7UG8?;M2.G6UK<VO"C3]%4(<9)SA44$D?AR17I.@Z1#-%<>1!]I
M^RC[;Z<<C'X^_4=:^HX0PN,S**YDHY,DN6Z4;622M=*_PMMZ[Z.VAXN;XJ&%
M<5%N3Y$IOFYN:<KRGULDG.,4DEI!IKF5W"(X=0L+#SH;>VGMN#=DD9'/!Y_'
M'Z=J['PYK4WAV3R3_I.DW1'VRTQ][/K@<$#OWZYZ8Y2\O+&*[\^"#_1Q>9X[
M_P"/;/XYX&:)]8ASYT/_ "]$C_ZWX?KG/6OTO#8C!X.RBU?HKKWFM%IUU2Z.
M_D?+8BC/%JRYG%O1:V3=GIKHTWTM^9F?$?PO_P )1#9:GHVI>0-- L[O-H1M
MT[^'201G<0"1SP0>HZ5\>1R1(QEBF-Q".Q!!'_ZSQ_C7V!9Z]_9UU<0B8^1<
M#YCQTSP>?K_*OG3QQX?%[K>J:EIL%M!!J-Y]L_LS[8?[/742#G5CD\@$D\\
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MS8'M_GI^5:%Y>3V=UY$'V:YQ_P >=W:7F/M_3_/MGUKYWF\Z&7R)X/\ 2/\
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M\5?'T'@;P0U_I?\ R,OB\:IH^E8ZZ>,A==UA?]IF(5?Q/.*_-QCEB?>OK?\
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MZYMK_'^AW>/?I_\ 6_#GK7YE_"'Q!::<TFFZI<VY$Q%SIL-P2R6DWS$R D
MR#YMH]V[FOKVRA\;3'S[BQ_LX<?8_M?]CZ;I@ /(&2O;UXXY]*_U!^CGQM'#
M\/Y5F="<<VJTFJ4Z<ZD(5:<J=H.-IU(R4DXV6VJ1_-/B-D4ZF+S/"J$E"K[R
M:A+DM.6\6HV<4VU>*DE9Z:'W/XJF\.^-H='_ .$JTK%QJN/['\;Z3_R$['5.
M".!Q]._ ]J^._&L/B/X-Z_J]CIER;:?[+J-EI-W:9)V:X,;L8Q_Q5*9 Z\-P
M,"M8>.K3PO806_B'Q[X=@M]3LLVEI9:L3_9^I#N< X&>IZ?RKP_X[_'#P]X@
MT>UET#Q!I^H>+;1Q827D%J+M$TOG T>60;(QUR6P<9[\C]H\5?%3@K#\-YIG
M%?.,/DG%^2V?+2J47Q%).VB]G-IJSLFD[1UW1\;PAP?GLL;#!RIU)9,W'6I"
MJX-W3UDX644[J5GLWHKG>^'/$7CSQ'=WMQ8^$CXST/PS>>&K*U\4Z59%EL=2
M&C*=9T<%5SKV[D8.3A0X^5E%>HQ:QY-_CQ'#_8I_X_;RU_Y!NIG@'O@GZ8_+
MBO)_AAX_^&.J> O"QA^+'B/X4Z]X*T!]%O-*TVX;3Y-:U;6I"SZL3&P;6-#7
M*^?$Q69%*Y558%O/O&&I:Y/,/%$_C^X\7Z1:76HV5EKNIG2VU(G0U!_L@B62
M1AH#_P!NJ2 =O)"J@"BOS_)/$.&4\-Y7FN&SJ&=O.XOB:7/Q/PY>G[O-*,J3
MFL]@XMRR=TW%:Q=U:S/H<VX4^N9JL+"#R14[4U;#XFU5QG*$6JG+.@Y58P55
M\DHW=7E4'*,V_2?$OC;0Q=W L;W^T=/_ ./*TNKP$8ZYZX/3'^<5Y?=^)!#*
M)_/_ ./K)[?Y^OX=.!7B&I>-898N9K?[0,_\>MWCD?ETQ_GG',7GCN(P^4)6
M,_K@X&/4X('YYY/2OR+B7QUP>)<VLUC%WD[1E%6=Y>[=-7L[J]];7W9]GEO
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M/PY/3_@G1XU/_=SND?\ SDZF[[O[W_F,_GR_XA>/^"V__1GUO_X?3]G_ /\
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M_9S_ /5FZ%7^3]7^L#_P=9_\H5_CQ_V5/]G/_P!6;H5?Y/U !1111N 4444
M%%%% #]A]1^O^%,J[Y$GE>9M_==,YX]/7K^M7I?)$=O.)_M)7.;6ZR2!TZ@X
MQGO]/2E?Y>O;N;^Q;6FFE]>OI;IV[Z:&)D^I_P __J'Y49/K_G_('Y444S *
M_P!I'_@D#_RB7_X)X?\ 9DWP;_\ 59"O\6ZO]I'_ () _P#*)?\ X)W_ /9D
MWP;_ /59"@#_ !C?$/\ R,/B#_L+ZG_Z=):P*W_$/_(P^(/^POJ?_ITEK H
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MB W?/3T&1Q^G:OZ&(?A[X'UCP)_PLWS[G1/"^O6>E_\ "'VEIH^C>)-,[_\
M"=#7.F/^*CUS_D5NWUYKX_U_]D?0/&UIK/B+3X/$>B^)K<_;[Y-!T4:KX"T3
M355EC;Q!%H6[Q%H1\3[G,6]&V%WZ@D5S9;QYA,3[F._=33M=I_$K*SB^5_$G
M=].Q?$/@_FF%E[3)K5H:R2O=<MN9-2CS6]WOK?UT_*;+^@_SGU^OZ?3"<D^A
M7Z'.1^5>J>.OA;XB\"S2W$\<.IZ$+Q[2T\0Z6POM+O6'(V2;L X&2&50#\H+
M$@UY8N-S'J"!C\B/T-?>8?$0Q*YH.$HN-U)671.TE>R;NNWG<_'L9@\7@<3+
M"XNG*G4@[6DI*^K3:O%75T]5?Y'^H[_P9^_\HC]2_P"SP?C/_P"H;\(:_A*_
MX+M_\IA/^"AO_9R7CS_T*.O[M/\ @S[_ .41VH_]G@?&;_U#?A#7\-7_  6U
ML]"N_P#@LU^WY9^(=5FT#1;C]IOQ8;W5;?2FU(V2;(AN_LE9(WFW;N$#$_>8
MJP<TV<E+5M=Y-:^;/QW#C R><<\'K^5+O7U_0U8G2.&::&&43PDX6?:02!SG
M!.3S],]:U]#T;^U+RUAG,]O8-=+;75XEL&V%CN ."0&  R&.1G)I7BM;K\/Z
M_$N-*4G:,;N]M$^Z71/O?[^NASYW,,;< ]R??T__ %UU=EX2UK4;#5]2LH!<
M6N@VGVO5W\]-UDA8C+C.21CH,]",DCGIM1;^SS_8AT/1+9[6U^R7-T%4WY;.
M?[7&KA=@!)&% V!<KL(((Q-6B/,LM[ WV8"TLP,@WVFJ2 P(ST#$=!][L<&N
M=UD]/Z_K_A_->J\O>'NYN[LO);7[^?WZ;F=%8KL-E=P!;VZ:P6SU*YN]EC91
M,26$C!67#(=@&Y@@!*K@ M:U/3M+LDN(+.>YO]MYMM-5"[=-O@#\P /(;J.<
M$G@FJL?V[3I;;5)EG!N ;NT()^;!^]R<>V0.@Z=A7FGA-S/A;FVMISG[*+KU
M/1CT(X.-V>I4'' 9S)*ZT6]NFU[;];_?K\CK[#PS9ZUHEI)8&Y?53=F.YM;2
MQU:_Q&3E7")N12\;-G:2!_8LF&.YBT:>#])EN?$$5MXHM7LM._Y ^J3:3J\=
MCK;F5@@YB)T+<-N/^$@*#:0'8$8J[I/B6#3],M]*O=)6X^S:P+W[4/EU$' S
MC\<YYY]><&WI7BV&V\^P@TJU:PNA]C&#_9NIH1G^Q=6;62H(=6(!'"@ D!@X
M-8-XI-VVOIZ7O^7_  3VUALJM'ZU=2MNKZNUNEK:O=:]4<4WA2^-MY]I/8ZM
MY0#7-OI5R+V^M(\D!FC1. <'F/>N[( _BK%N]/O[%A]LLYX!+EDW+C.3D@ C
MUYQG/;Z>O7EIX8T3Q)J-OH9U/4M/M[Q39W-UG3-2LM-7*ZT-:1!@$ D*,  ;
M@",XK"U?0#&D$^EQI%:ZA=_V/;6L%YINI7]WJ ."7,!#JK.RH""/G90""U)8
MG6UM^]]T[O;;9M?Y:G-B,FLFXRM:SLFGI]G??I_P^B\M .,!O_'1WYZ]_P "
M:_J1_P"#0D8_X*Z09/'_  R[\=OS_P"*)QT]\_G7\Y5_X)OH]1U?P_JUA=Z+
MXXTQM/C.@ZI9'3M3O=3;"MHR:,54B0*RL,A2?D#H V*_HU_X-"01_P %>+0'
MC'[,?QVX[]?!?_U_S%=5&NL3T:MNGVZ-6M=-)M/KL[.Z7C8G#8C"[KYK;T?9
MKM?J?ZG.E_?N/J/Z44:7]^X^H_I16QSF=/\ ZT?]>>E_TJ&II_\ 6C_KSTO^
ME0T ?SD?\'6?_*%?X\?]E3_9S_\ 5FZ%7^3]7^L#_P '6?\ RA7^/'_94_V<
M_P#U9NA5_D_4 %=+H^E#4TU+=J>FZ>-.TG4-01-6NPGV]HEC9=*TA&A/F:Q,
M7)2,,FX@ME<;7YJB@ HHJU!_K8OW/G\_=&?F]L 'IUY'_P!8 JT5H>=#_P \
M/T/_ ,34!E,G7M_GK[9]J"^1;<V_D$0\PX/'7]/S_K4^<1SP=2""/8CZ?Y_I
MGU8_<^7WSGWZ_P"/_LM!49-JSZ+6[W#R/?\ 7_ZU5ZL4HB,LA /7)[YXZ?08
MQ0$H;<J_K_@%:O\ :1_X) _\HE_^"=__ &9-\&__ %60K_%NK_:1_P""0/\
MRB7_ ."=_P#V9-\&_P#U60H,C_&3U]@NO>(1QG^V-4/(_O:A-C]>/7T[5GVD
M37$RP+"9GG/4<$'USZ^^1GD#WO>(A_Q4.N'UU;4C_P"3$HY_^O7UO^QSX%B\
M2^.=5\4:O*+:Q\%:1IVMV5YJOAQO$?A9=3DU[1-'T1/&D7"IX<+S-OX;[B!-
M@W;^;,<0LKP=3&WVC)V[RM:*6CZORV>J6K]O(LMQ&?9OEN4VLI5(J;_EBFG)
MMNRVNM7UVOM]D_LU?#G5_A//X1DTOP1X!^+%Q\4](:RL_A/\3-9T@G^U&_Y
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M,6. H^\V,@?&_BN\OO%-KX@\5?;[6VL =+LCX?&=.!_B&C:'HH)SX>\)YQP
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MY))Z\>O!Z8!-9U,B2M;YWU>]]7KW_P"&/0_#.M:9;VU]HVO6*W>E:DREKFW
M.HZ=C)WZ2TQ,0+, "K_(P^]W![G3/A]X&\26ERVE^.=3M]3MK8WAL]:\*QVU
ME=,A"LHUM/$,B1'G;\\'/.WD''BL CGFA1Y/L\2MAY\%B >^W.<9'X=>>W9:
MC>:C86+:9#.8='U*Z%]:VMMN;[<HPH)(.>,J%R<#@ < 5P5Z,^:^&DU=INZV
MOHVTKW=MK-:[L][+L3A%AI+%Y=&26TDVI/5M:W32VW3TTUUMN>,_#G@W2+/1
MIO#WCW3?%EU>PDZOI<7A_7?#M]H=[D@P3-K$(T69<@*7BG' (6(-AA_1O_P:
M$#'_  5T@]1^RY\=A^G@JOY=)>6&3G@'UQUZ>E?U%?\ !H42/^"NL'_9KOQV
M_GX)']37317*DKW=GY=E^+N>1CZZQ.);245LDMK*R[?+Y-]3_4YTO[]Q]1_2
MBC2_OW'U']**V.4SI_\ 6C_KSTO^E0U-/_K1_P!>>E_TJ&@#^<C_ (.L_P#E
M"O\ 'C_LJ?[.?_JS="K_ "?J_P!8'_@ZS_Y0K_'C_LJ?[.?_ *LW0J_R?J "
MBBB@!\?WU^M7IL_Z1!#G[.;OCI[@?EC_ /55>'_6P?7^@I/^6O\ G^]0:I65
MO.WWI%>BC!]/\_Y!_*C!]#_G/^!_(T&18_U7^<YS^7I[=/S(._X_TJO@^A_S
MG_ _D:N3P7%K,T,T+03 KFW8'OTS\QZX/?L?Q#1.[3M9+2R\_P#AMMWT)VAA
MANL&;SX!<C_2K;TSG@$<$YR!VZ@\XJ";[/YLWD>?Y&X_9,]>HSNSS^7..O-1
M_P#++_/]VJ] 2=K>:O\ U]]_6W8*_P!I'_@D#_RB7_X)W_\ 9DWP;_\ 59"O
M\6ZO]I'_ () _P#*)?\ X)W_ /9DWP;_ /59"@S/\9;4S_Q4^K9C\_\ XFNI
M87GYOWTQ/3IM.#]<<>G[0_!_X>>%O%.C>'_BIJWQ2;6_ '@3P?I7AG5O&^DZ
M,<^$O$^A^"] UX:+K>A]_#GA7_D5P1G_ (37Z=?Q<\0 ?\)#KI[_ -IZM_Z/
ME%?K_P#L?P_#C4O@%=^%+;7&_P"%N^.[7Q38W?AYK?0[/PY>^%=!UO0-=T'1
M-=\0(%\2:)_PE7B/0MN] L;CYE 4@#XSCM7RE8I7?O)6C;9M)Z6E;3K:RW>F
MA^L>$/\ M'$7U6\4Y1<TY.*O*WNJ\FE\5KW;OLO/YO\ VF_'6F_$_P 1KXIO
M/&GAS^TM3\/:I=ZOI7A+PTWASPY8-HH5?#ZXSC7_ !'XK8%O&>%5BS-\S[5"
M?I-_P3N^*GBKXD_#_4OV===\8^$5T?PSX1;Q1X/\07.CC4M2UW5==.?^$*&N
M+\H\09.!X6\5X!P> !4W@[]F35OV@_'FK^'?'W@'P#:Z5I/P4%]X"O/"7B0Z
M9X:\!$<YULC!U\@C6_%'C<>*\\]\CGRO0Y=-_8D\?^!]3^!?B3PGXV'C"\U/
MPSJNIW.D)?(NG%88]?D_MA?$070= \+:_$GB?P:P"R2LHEE=RK$_G6/S+*,^
MX?7">$O_ &Q'EG%QZ*+C.[G!))\D))QO>[5^A^U95D?$/"O%<N-\6XO)9QJ0
MXDA*2M[RG&'+3G+E^*4'>,=%>VA^5W[3.IZSXJ^-?Q3\07B01W5QXLU5;Z"S
MA8"QE%P=(&F!=F%9(PL. 3D('!#\#YU,A \C' /Y]\8_'^F.]?8'[57PKUKP
M=\9O%VGV?C#P1\23KEYI_B>[\1_"CQ%_PDGAR^U3Q#')K>-ZD-_;BM_;+-$P
M8Y\PQE?,D#>/Z1\*/$_B.+Q%=RZEH>FW/A>Q.J^([;7O$6DZ=J-KI8FT+11(
M1*P8ECK<,8&WB,9*>8OS?L&65L-'*,KBWK&E3@[JSO&$(6:4=TXM:V\W=Z_S
M3Q)@LQQG$>;SC9J56K.+YXOW)SE*-FY6MRR3=GHM-DK>3VAMS=8O9KFX'K:<
MGW.X\]L8''J*J1L8I_WT!.UN8,D9_P!GU'\S^=>E>)/ \F@Q?Z!?:;XDL;AL
M6NJ:#=_VAI@XQY;8 9-<& IC7 520@SR.$;2[B&4P7BSVLS ?9A< J#@].1N
M'' Z#/(%>M>+WMWWTV_R_J^WAU\-BL/;2_6\7S:VLM4Y7^^WEL2_VG/: _8Y
MH3#<VOV1[?);Y2,'((^\6.=Q89R01WJSJ?B37-=M-'L=3O6N;?0[);#2@P_X
M\=.!RR@ <#A2!U'!XX-6M)\&:_J6R6UL76U#9-]<J++3 /;59&2-CTX+*,]3
MQ@^D>!="T#3[";QA>ZIX,NI]!UC31<>%/%EV2=0.=S'^PP6&OZ <J7VG<!@-
MZG/_ &6^BN^^^NMNGG;T'AZ&+Q%[2<5K>\N7;?9QZ=.EKG,>&(="AO\ 3CK$
MEWK&F"0_V_H5KE7*[B0-&8$1EU_B9<%>>JXQ6^(OA:'P3XMU;2+#5H->TBVN
M7;0?$&FX.GZ[I19SI.L0L< +-$0S<;@VX#'5^POO%OA*#6IX5LUMM/T&ZOQH
MU[X5TM; ZXC:LK1G7%UUFD"K$%&-N$ "$*P"US/Q(^)^H>/H]!TXVT&GZ!X2
MLFT?POID 8_8M-:0OM=SS(SLJLQ."6/4X)KF2Q3Q6JO#9[:=K>>WR]$>EB'E
M<<K^JQ:]HFW=;MK=/=M.S3N[7OT;/],O_@S\.?\ @D=J1]?VP?C,?_+-^$-?
MPE?\%V_^4PG_  4-_P"SDO'G_H4=?W:?\&??_*(W4?\ L\#XS?\ J&?"&OX2
M_P#@NU_RF%_X*&_]G)>//_0HZ[SYP_,*SAN#);_Z#D:F,V0]OZ_3_ 5)KBWD
M/[XWD.I64^;.UNQCHI!Z8^4C!W$D^N!C%=O\,-/>]U[2)=3UB/PU:I_:;>'=
M6U'1CKM@^OQ!GT72E5HY@A?6E$C2.KK%EY'209-=-XV\!7&A7-E;^*=.\1Z7
MJ&I3->ZGK6KV+:<U]J,T1272!I7!VIX@BU:+_A)&8K(&+;,(Q/DRQ&'AB_J[
M^)JZT;5EYM6NG%)VDVGNM6?58?+\7B\K^M)K=+=7U:2T3;UOU25M;[7\7LH?
M-NH(//\ [/OQ=@?Z5D 9Q@\=P?48//XVM4%ZT@M]44P7UL<%3;!202/XA@$Y
MYSMY[#L.J\=?#W7/ NI:"OBVV8OKOAK2O%5CAC_IND:U$[:2XQ@ $("<]$!4
MYP#5+PMHVLZWIFNWMGI6IZCI?AFV76-=DTJT:^.G:?O41R:PX9-F@JP W%]L
M; G((!&[K8>4?K,5?=1TUO)M))Z/5VT?5J]KZ\\:&+PV+^J8O1>Z]6K6]W5V
M;2T;>COH_5:'Q!\"S^$VL;Q[RXOI;JRTF^U:<VC6 L=5UW1QK8TALGYI!&Y)
M=54<$A%SBO)'.5)P.V,#_/K]:]R\?ZEKFJPZ3<>(+BW:3Q19Z=XE.JW>IZIJ
M>HWR*O\ 8H?6)69R),HQ.V-2JKA93NP/%;F*".79!.)X03AAD'V!^G^'7%&7
M_6?JJEBK\ZG)Z;6;?+HNMGZ6MW,,_I82&926#^!QCI=Z-)7;W[W=W=_*Q#Y_
MM^G_ ->HI/OM]:95BN\\A7FFF[6:Z>I!D^I_.M+SF)@^U_:)[>W)& < @G[N
M2>F0!R?;/8YE6IXH89 ()A<#U (S^0_E^% HMV?RZ^?:^I5K^I7_ (-!_P#E
M+K!_V:Y\=O\ T'P/7\M5?U*_\&@__*76#_LUSX[?^@^!Z"#_ %.M+^_<?4?T
MHHTO[]Q]1_2B@#.G_P!:/^O/2_Z5#5\VLTHMYX2 /L>F#D@''X__ %Z3['<?
MW(_S'^- '\W7_!UG_P H5_CQ_P!E3_9S_P#5FZ%7^3]7^X'^W;^P9\)/^"AW
M[.OB+]EKX^S^-;7X:>+_ !!X<\2:O<?#WQ#I7A[Q6VH>"M<BUW1 FLZ]X>\6
M#'FQ1;V:-^ 4S&&8G\*/^(.K_@D]_P!!3]KK_P /-X*_^=G0!_EIT^/[Z_6O
M]2G_ (@ZO^"3W_04_:Z_\/-X*_\ G9T?\0=7_!)[_H*?M=?^'F\%?_.SH _R
MV\_]-_T_^O3X_(W?OMV/^G;&>W7=Q^5?ZD/_ !!U?\$GO^@I^UU_X>;P5_\
M.SH_X@ZO^"3W_04_:Z_\/-X*_P#G9T ?Y<V^S])_^_\ %_\ $UJ:;>Z+'+NU
M#1_M<?=8-6>P;\"5?CVX_6O]07_B#J_X)/?]!3]KK_P\W@K_ .=G1_Q!U?\
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D,X4 '[KZ7]^X^H_I14EE9SQEQ*0QP.C<=O\ Z_\ ]>B@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #3 60# 2(  A$! Q$!_\0
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MI?Y/^K@Y<OO3\^]GH]OD?A[IW_!.#]HVZO\ 2&URS\)ZA'?>.[7]CKQA>?\
M"3:0++5?^"7_ (-UC2M<\'7EE9=!XAU2X\.WWAB]\+];2S\8W-\,X-?K=\)?
MA9K'@[X^?M:?$&^\-Z/IFA?%SQ?\(-;\$ZG;3:;]HU+2_#GP3\*^#M<A-C;
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M9]3BQ%%8:?(W^NHM%%%<)D%-?[I_#^8IU-?[I_#^8H [;P__ ,>4O_7]>?\
MHTT4>'_^/*7_ *_KS_T::* ./_Y9_P"?[U1U)_RS_P _WJCH **** "BBB@
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M/\Q1SU.Z^_\ X ]MM/0DHHHI^TJ=_P 7_D.[[O[W_F%%%%2(**** "KFG_\
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M/Q+X7U2P^Q>&]5OH/(OM0^*/B&UM_P#B86\'_'SI-X;RS^T6)^QY^V6?NM%
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MN&Z_9IUBX_MCQ;K?A:^\':KXPU7_ (O9_I&L77A?5=5\+WNO?\OEE?7-B/\
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M>U31_%CP"VH:/I*ZUJ%E?:YJO]B:4]YX;\2:?_:6J'39]<GA^W:AHEI;V_\
MQ+["?_CZN^U>E^?.#&?.3]W-$Z%P?]9!,1!Q[]__ *U<=XH\*VOBC_A"YM6U
M"XM_^$'\8:7XULY/^7>_U/0]-U71)_J+6WU7[5Q_SPSTR0 =4\?E.VY?+D66
M6%X?[D0'^O'^1@T4,VZ63]WN?SKJ9YN/]5?3?;O;^6/7UHH *N:?_P ?MO\
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M\:/.N/\ GN/\_C0!YH_Q:\#L9'^V>(I/,F\[SG\'^,._;_D6^^/7^M1K\6O
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M_5^/G_!23]F']I+]H+QIX)UCX.:/9^)/"_@_P5%]ETWPQ?\ P2T?Q0_C>_\
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M7]]*_?;\?YBOX%O^#1[_ )/._:A_[-D\.?\ JR-#K^^E?OM^/\Q7^</TAO\
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M )V_/U_QKTHX3#_9QYS_ %S$P;G/ 7\]-K^7YG,?\%6R/^'9?[>/K_PRK\8
M/J/!NK]?P!K_ "3H/]5'_P!NO_IMMZ_U"?\ @HQ9_M6ZY^PI^U?X=UKX3>%]
M'L/%/P1\4>$AK$/QYBUW^R;OQ5!#X<LM3GTJX^']J)[>UO\ 58;F])O!]DM(
M+F\SDJ#_ "\Q_P#!IY_P4,7=';_%/]F1HXWNH4=_&OC&W\ZU@F'D3'[/X1N[
M;[1_RZWO^B9]N*_IKP!X[X,X)R_-(Y_FW+5Q.*4L,M=.6'(V_1V=[;66^WR6
M<8+&9E/GP^7[/N[=^K/YA*1/]8G_ %UB_P#1U?U ?\0G7_!1(_\ -5?V7O\
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M?[,GQS^,'@_1[;6?%/P[^'?B+Q#HEM?0"XTNSO[>S\F#7M6@(-Q/HWA@3?\
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MG@F@/_'M<?\ 3E]ES:6FCW'V[/V[5J )*:_W3^'\Q3J:_P!T_A_,4 =MX?\
M^/*7_K^O/_1IHH\/_P#'E+_U_7G_ *--% ''_P#+/_/]ZHZ[[^S++_GPM_R'
M_P 31_9EE_SX6_Y#_P")H X&BN^_LRR_Y\+?\A_\31_9EE_SX6_Y#_XF@#@:
M*[[^S++_ )\+?\A_\31_9EC_ ,^=N/\ ;_KTSS[GO0!P:LRM\K.K?WTS^/\
MC]/<TZ1YI$\MI)&7I\_/_P!8?7]*ZD7'AN,M&9](7R_OI/<P<'/?S_\ )SBD
M^V^%_P#GXT'_ +_:;3L^S^Y_Y"NNZ^]?YG+K*WF1R#<OE_)\@_4_YSS4B2W$
M:R?Z1<?O/U_ICG_ZV.O2?;?"_P#S\:#_ -_M-H^V^%_^?C0?^_VFT<L^S_\
M )?Y!==U]Z_S.;\ZXP?WTGK\_0?Y^H_G4;23,OS2;E_N=.G ^G\L5U'VWPO_
M ,_&@_\ ?[3:/MOA?_GXT'_O]IM')4_E?_@$_P#(+KNOO7^9R=%=9]M\+_\
M/QH/_?[3:/MOA?\ Y^-!_P"_VFU5I]I_=+_(+KNOO7^9R>,_WF]T_H._T_G5
MAKBX6(Q_:+CRP/GAD_U;YY_#W'3I72&Z\,'_ )>-#_";3O\ ]5.B/AZXE$5N
M^DSS2#Y8H9-.\QN,\>1^_P"!SD>O-3R3[/\ \ DOS"Z[K[U_F<CYN[Y<[?\
M;]?PQQ^GZ\!N+H?NUN/W?7_.?Y<_UKOO[,LO^?"W_(?_ !-']F67_/A;_D/_
M (FD,X'S9F^])N7NF<_K_P#7[=?4KOO[,LO^?"W_ "'_ ,31_9EE_P ^%O\
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MJCKOO[,LO^?"W_(?_$T?V99?\^%O^0_^)H X&FO]T_A_,5Z!_9EE_P ^%O\
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M=>N.P[DY[>U%%%WW?WL++LON7^0>8_\ >-'F/_>-%% P\Q_[QH\Q_P"\:**
M#S'_ +QH\Q_[QHHH /,?^\:/,?\ O&BB@ \Q_P"\:/,?^\:** #S'_O&CS'_
M +QHHH F))Z\U)Y:^K_]_)/_ (JBB@5EV7W+_(/+7U?_ +^2?_%5 W&Y@2"<
M9.X^OUHHH"R[+[E_D-1W;:"V1CIQZ9["G-QN8$@G&3N/K]:** LNR^Y?Y#4=
MVV@MD8Z<>F>PIS<;F!()QD[CZ_6BB@++LON7^0U'=MH+9&.G'IGL*DR?5O\
MOIO\:** LNR^Y?Y$7F/_ 'C1YC_WC110,/,?^\:/,?\ O&BB@ \Q_P"\:CFE
DD$388C &,8'0CVHHH R'GERAWG)CB)P%&3Y:\X Q1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %7 < # 2(  A$! Q$!_\0
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M)QR:*R-3U(:>8?W?F>9YG/\ =Q@C^H_"@#5WKZ_H?\*-Z^OZ'_"N5_X25_\
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M_P ?/^%'_"2O_P ^G_CY_P * .JWKZ_H?\*-Z^OZ'_"N5_X25_\ GT_\?/\
MA1_PDK_\^G_CY_PH ZK>OK^A_P *-Z^OZ'_"N5_X25_^?3_Q\_X4?\)*_P#S
MZ?\ CY_PH ZK>OK^A_PHWKZ_H?\ "N5_X25_^?3_ ,?/^%'_  DK_P#/I_X^
M?\* .JWKZ_H?\*-Z^OZ'_"N5_P"$E?\ Y]/_ !\_X4?\)*__ #Z?^/G_  H
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MC-+[W%()4JL/?E26NOW_ "/6P,MY?_+3?+#L_P"6CRP?Z^'_ !_/-!!5BO\
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M=*^=K'XG?&31OB1\._!/Q(\%_#/2=%^(DOBVSAU7P'\2/&'B#5+:7PYX5O\
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M[4_\_GV(>M>#+X=_::3_ %?Q8^"?[Q-Y'_"A_$EOLB_Y80_:#\6O](^R@?\
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MWDQ^;!$6; DC\Z:>$@$VEL/]?/C-I:>G^FB@!\ D:2/RV^;>?)*)B<3'&/\
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MK@M,_P"/ZV_ZZQ5WJ_Q?[Q_I0 C]!]?Z&N$U?_C_ )/^N<7_ *":[M^@^O\
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MPS]JZ>?;'_E[L\ !13&GC%NMUYG^CRP^<DV,V[_],?/Y_P!(_?\ _'KQ>?\
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M[MM"%[?Z->*+.[M/T12WDA2.".W\N.SMK6VA2UM_+LX;6#SS!#!]GS_QZ_\
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M_P"NL5=ZO\7^\?Z4 (_0?7^AKA-7_P"/^3_KG%_Z":[M^@^O]#7":O\ \?\
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MT8>3SCYV8"+L^1CFSN?M6+P\"SM/]#-ZI.U'?/[NWAEFD?TB@_S_ ,>O-Y0
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MG]M_]GGX?_M-_"BS\4:9X ^(J:PF@VGB_38=+UQ)?#FO7WAS5?MUO 3;6_\
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MS?+<O^Z?R89YY_(N/^O>"?Z^1[T 1T4^*&64R>3#-)Y>$=TA$D?_ "P _?\
M;_7P7/I>6F+W/V+@H5D\J.X\M_)D\HI-Y4WEOYY/D1?]=[KFU%K_ ,OGG6__
M #]6= 'P3_P42Y^$'P3S_%^W)^Q$F/\ NX3PK_@/UK[XF?\ TB1?,\OYY4>;
M]SE!!P/^/C_(^E? ?_!1&3S/A#\%A'^\D3]N']BCS B#*2P?'_P=/<0S@_\
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MC_2N(Z!'Z#Z_T-<)J_\ Q_R?]<XO_037=OT'U_H:X35_^/\ D_ZYQ?\ H)H
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MK:VY_>OXR\3?'#PTFD-_PBOPWO(-<\6Z/X9LT36/%WVP2ZW-/!#-??\ $C(
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M]:__  =Q_P#)VG[)/_9N_BS_ -6!>U_):/NI_NC^9K_07P'_ .3=<*^N+_\
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M[1_V&&60^3'KW[047DB7?'^XLO \'&>X[CL"!7]'G_!1>.1_A!\&8O,/EO\
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M *A7C^O\]=NK?]=I/_2BO[4^C;_R;6G_ -C[%_\ I1Y'$_\ R.:G^$C'WO\
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MJ!]Y/]X?R-!^^WX?S:@?>3_>'\C7^@<_@G_@G_Z3(_/I;?-?FC_2I_X(N_\
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M:M>:QK>M7]]=AC:VEKZ[01@[5_[[_O\ /''\SGJ** "B@G'WLJH)R[_NX_\
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M-Y:?,WZ_OYOL,&>1_P O%]!S[^M?Z:0FJKI0BUI'75=%KU_4_,Y3BM[OY/\
MR_0_MU_X-:?^32_VG_\ LXG1_P#U7WAFOZ=&^_)_OG^E?S$_\&M9Q^R7^T_)
M]V/_ (:)TCYW3RT_<?#C09__ &A/VXK^G=E;S)/W<OW\?<_Z903_ /I/-!T]
MC7^?'B<T^/>(YIK2HU>Z:T5#KM?;2^B/?P7\%?UU8C_<E^G_ +7@KWKX7?\
M(!U#_L/W7_HFWKP1E8HW[N7YGB3[@YZ\=/Y]OI7O/PM=3H%Y)]U9-;NG3?\
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M/K[9D]Z_H43]M3]FNUOO"]GXD^)FC^ H_&'P4\!_M$:#K?Q"ETCP7H]Y\/\
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MO ?Q?\ 0>+?#VE:]I^H>"_#GC'XP> /C%X-\">![[1_#?A[^S_AO=7'AS7/
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M .1R?5/^^Q1D^J?]]BNC_P"$>G_YZ6__ 'P:/^$>G_YZ6_\ WP: .<R?5/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'%:__P ?W_;)/ZUB5MZ__P ?W_;)/ZUB4 %%%% !1110 5XY^T-\4-4^"7P)
M^,GQCT/P/JGQ(USX5?#7QO\ $'2O .B#.K^,[[PKH%_?V7A72_\ B7:M<BXU
M^_$%H#:YP2#@U['0G^L1FV^7]R3U\KSH)^G>W_<?9;VJI^R4U[6G[:DK?[-Z
M-7UT>U];Z7OT*A*$)^^O7_@_D?RAQ?\ !RA^T*RCR_\ @C'^UXL:_N8<W/C#
MRA%#^Y_U ^%_^C?Z1!/V]?QD/_!R=^T3_P!(:/VO1_VT\7_U^%QK^KU;J[ ^
M:26222.&6Y=Y8(T%R(8()A!!]FX_U'VKT_?T&YN&[GZ"4<_^2W-?1SS7(J4*
M2EPU&[M_M/UN=?IU26GR78ZJ=?#0GSSI>5]'W/YX?V+_ /@N5\;/VK/VG/A/
M^S]XE_X)C_M*? ?1OB/J^J6%U\5/&<^N_P#"+^#Y=)\-:MXCAU+5?[0^&]G;
M>1=?V5_8&3>8^V:Y;<]Z]B_::_:J_:?^ ?QS^(FA:-<:U>_#/]GGQ/X7_:\^
M(<-KX)TW5[CQI^Q=XC\-:'\,M<^#_@V^T_1+L_\ "8> _BO>^./B.+46MYK-
MY9>#;?\ T('Q!X;_ +8_;F23S()8+N2407 BLY4278);:>;$Q,PMP8 +<],J
M2,C(.*9+IQNFDDEL(+N>:RCM[W.G0A+FU$.?[.OO]&N[BXMK6X!^QZ9=8L[S
M_2>O^AD>-CZ^'Q-:E/#T5079-OYW=NFGRUU.>M*$I\]'^O(_*/\ 9UT_]I2;
M]I#X(:=\4/VF?C7JNEZO^R+I7Q^\<_#JUT7X36_PS_X6#JOBFP\+7WAN'5=/
M^$ND>)+;0-+T^_G^Q:7:^(;2\QI0.;S-F*_3WQ%J\FB6#Z@NER:I<>=-"T*/
MD>9YT\$_D?\ 'WJ4^GY@/_'U_P >8GY^QC..C.FW:S27#V#W%S)#MN;A[2=[
MRYB\[SIH8)S;?Z!;ZG<V5A<G2^;*S)'_ $]UY[\:=5^)OA;X2_$#Q)\(_ X\
M>?$OP]X0O]3\!^#;^\&CZ?XG\26/GSV.D7U]<8MH+>ZGO9Q>?:KNS_U ]*YZ
M<X0G[YC4YYPM"UOZU_K7\2I'X^O"XA7PG>2-OV9_TS_6G'[G_#_G\]:>/']X
MR>8O@^[\O9YW^KO<I#_^OUX]Z^+K3XU_\%%O/T_S/V0_!ZQR?LJ7_P 2-0=/
M&W^CI^TC_P L/@_!_I/VD:?=BX!.J6O^AV?D V%[S>&N\^$/Q/\ VV/%7Q1^
M$'AOXK_LV^&/ 7PW\1_ 2U\2?$OQGIOB@:QK'@CXOSS?O_A[I5C]I_XF&GVF
M/^0I]DO+/'-_>C%G7;3Q&$A\5+Y_CV[F7L<3_P _%^!],2_$S1=&T?Q)XJ\6
M1R>$_#/@O0=4\5:[K=Y%YEE;:-X;@_M77+R"XN,_Z1I>GP3W6;47F++[3QV/
MXG_#S]O_ ./'Q%TKX;^"_B)\9/!_[,?C3X@?M&Z-J4WB35?AWH&AV_A+]E_X
MM_ WXJ?%3X.^ _[#^,&FV?A+4/%'A;Q/X._X5SXT\9#%G=ZS8_8=!UJ\OM6^
MQU^^EQI$FIV=Y9:IIK7MAJL$EMJ-A<V'VC3KJ*>#R)X;[2I[:[MK@&V\^UO;
M7/V+6//^PW_^@US/B3X;^$_&,8M_%GP]\+^*K>*TL[9;;Q3X2T;Q!NM-/FFN
M;*RAGU+36N+8:9/?W T>VM +2SNH;F_!4W=VPXZE2$Y\T!PIUH?'6_KSL>&?
MLC?%;Q/\9?@OIOC+QA<:/K&LVOBWXB^"X_&'A[38=#T3XA:-X'^(?B3PMHGQ
M"T/0P;NXT_1_%.GV-O=65I=7=Y9W>+F^T&SL]#O+.\N_IFJUI9VNFVMOIFG6
MB:?I^GQ16FFV%O:6EA86%A##]HL;/2]+L+>TMM/T>U@GAM;$<72K %OE6] %
M6:R-@HHHH *OZ/\ \A.U^LO]*H5?T?\ Y"=K]9?Z4 =\O5_K_4T^F+U?Z_U-
M/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH XK7_^/[_MDG]:Q*V]?_X_O^V2?UK$H *,C$F?
M^6:;WSZ^=!!^/^D3P=.O>BHI1&X\MY5B4/')YH0?:+0B6#_B;P9X^T:7<_9[
MH?:K6[LL_P"@D_Z79_; "5")&C6/YGG>)(>/]?Y\,$_G0'_GW_?P?Z4/]#^U
M_P"@X^W8LZ ?]B2/Y-^R9)HI/^_&.WY]L]Z_-KQ7^WQXC\)_$OXB?!/7/@!8
MR_$RSO\ X<Z5\+M!TWXIZ9JD'BK7OBWX]U;P1X'L_'&K3^ +31/ \]T-#'Q%
MO-4T&Z\>6>C6<_\ 8FH'2-<M/L=Y]*?"+]H?2?&7AGXH:A\3-+\/_!7Q)\%?
MB1JGP[^+5CK?C#1O^$7TC7H-'\.>(['Q'_PF$]MX>T7^Q_&.C^*=)UZSU75+
M/1M8O/M L;[1K2^M#9  ^D:.M<?X)^(GP_\ B7IFH:W\.?''@_Q]HNEZQ+H.
MH:QX,\2:/XHT>VUF"SL;Z?39]5\/W-Y;?VA:Z?JMC="U^U\^?763200PR7%Q
M<6]G:VZ2S75S=30V]O;100SSSS7$]Q_HUO;VMO!/_I=T/L??/H 2#G&.<]*"
M,*TGS;53>^Q/_(/_ %\=_LO-Y^M?GO\ M ?%3PK\3C\'[CX)_MT?#WX+V_A/
MXJ:#XQ^(26VHZ-K'_"R_ >E?:/[5\$_Z1@Z?;:K_ -!2UY[>M?.<TGQ$>*\C
M_P"'JW@?]]^U7:_&"V3R='^3X#P38G^ /_7O==/[>_X_<_6@#]EE=HI-WS?*
M\2.FR$[_ /2[&>>'-Q_T[_X]Z^6M'_9@\$ZQK_Q,\2?%CPW9^+M8\6?$[Q1X
MDT&_D\6^,/\ 0_"=]9Z5!I6F_8;?4K2VT[[+Y$_^BVO'?Z>._L_?$_PO\.];
M^-FH?&#]N?X<?&:Q^('Q3U3Q5\,;.\U/3='C^&/@B^A_T'P1YX)^T6]IU_M2
MZXY&/^7.OMGP7X^\$_$C2;C7/A]XHT/QIH^GZK=:)?W_ (8O!JEOI6LV4,$]
M]H^K?9\C3]8M;>^L;K^RM5^QWGV.]MK[_CQN[.@#RO\ X93_ &=_^B8V?_A2
M>,/_ )IJ!^RM^SVKJ%^%UC_?3_BI_&V4E'^HG_Y&3U)QT_"OH$%#_%&W]]$?
M[G^>V3QG%)0!\^_\,K?L_K&O_%M[>203B:1W\5>-L^;/S/-#_P 5)S<6HXL^
MX[8IQ_96_9['F*OPXM=F_?\ \C/XV^?_ *:S_P#%2#%Q<_\ +[T/KGDU] 4$
M\9^\VS>$1#)</V_<0<7-Q0!\]K^RG^SSPW_"K].BW?P)XD\;83V_Y&3_ #S[
M5(G[*W[/<9#1?#>VCDV;5V>)_&UOMD\Z#]]Y_P#;=T!]EM_/NLX(_F/H!F 2
MXE/[R.S25[EX?](CA\F'SI_/\C')MSCIR3P#S3BC!I%X/DOL?_8E_P">/_7?
M_IUQ_H= 'E?P1\':Q\//A+X%\#^(+C[9JGA?2;K3;FY_M*\U3=%_;%]/8_Z=
MJ'^DW&=.^P@5ZE110 4444 %7]'_ .0G:_67^E4*OZ/_ ,A.U^LO]* .^7J_
MU_J:?3%ZO]?ZFGT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 <5K_ /Q_?]LD_K6)T#%OECC^
M_*_[N)/>>X_0^O\ I)Z6E;>O_P#']_VR3^M8]NF;FU91_I$<T3PR;!+Y?'D3
MD"#_ $D6]S;S_9LGC]^,CFSH 14W/&OR_O/]5O<_O/W/G^__ "[SP77?_7YX
MS4)>9&CDACCWQ_/#YW\$O$$!G_T7[3;\^?\ ;;JU_P!,^Q?\N5X+O_0_QH_8
M,_:=\>>-/VF?C1^SYK'C3Q1XN\(>"?%OQON=!\)^*IM!U3QS\,]*LO$NDZKX
M=A^+6JZ?X;TG6]'']H^(O$>E^#+K5?$/B3[9X;T*UL;'['_9%W]L_9L=#_SS
M^^D:<6[?N8/],L?M'^D&WNA^?D>E 'Q5)^P-^SQ/>^,KR\L?BAJ-QXH^RQZ%
M>ZS\8/'FKZC\)(K#QK#XXL9_@1JL^M_VE\*-8TSQE!;^,K*YT'5KK%W8Z;99
MO;&ZO+*S]C\#_LX?!_P1\.-0^$?_  B[?$#P7XD\277B3QY#\8[^;XN:I\2/
M$>JS6,^J^*O'&J>./[6N?%&L:I<6.E?;;G7OMGV/[%]AL++1[&SL_MGN5*/]
M=%_OP_SH _.C_@GKX1\*^!M6_P""@'A+P/X7\.^#O"^C_M^?$N"P\/>%M"T?
MPWH=G)-\&?@#-/\ 8=*T?[+IUO;_ +^#-K:Z39_ZBZSS=FOT"UC3!K.A:]HL
MLDD<>N:)K.B3.C[!Y>JV<]C/^_\ LWVG[3^_S_HOV,9YKXA_8<_Y'/\ X*)_
M]I!OB/\ ^J3_ &>J^\J .6\'^&+/P?X/\*^#X)FU"T\)^&_#OABSN;BS\N>:
MU\.:#I6AP2W'_$Q_X^;JXL9[K_MOW[]*(K<_>MX/N;_^/8?G_P ?/O\ I[U)
M5/4':.QU"2/&Z.PNG1_[F3S_ )Z_RH7/-JG#R_%K_.Y%2HZ47,XOQWJ/Q TB
MUTY_AO\ #?P_X\N;DW4>J0ZWXPB^'_\ 9MA^X_?65]/X;\6?VA<:I^_M<VIL
MA:?\?O\ IF0+3Y:^$/B'XX'Q;\>[C2?V?_#,DM[\=Y/^$M>_^.-GY>CZS;_"
MOX2:)/\ \(Y /AQ_Q.-._L?2M#NO[4NSH^L7EZ;G[?9C-G]DU=>^*NG^$A;R
M>,/B-H?A./4OMZ:;_P )5XGT?P_'>?8?(GG^P_VQJ5I]H^RV\]O]M^R_\>?G
MVW_/Y9U\U_![X]_#V+Q-^T)N^-GP_C;4OVA-9FL/^+C>#X_MD7_"M_A78P>0
M#K8^T?Z18SVO^B\_N.W%?1K(*D_8S57=:>MO77YGG5<WA3C^']?YGZP0?:&A
M3[1;M;S^3$]S:I-->6]M+TGA@G_T3[0/?[)9_P!:DKYG\*>(-9O=:T?_ (J"
M\N+6XN;79Y-S#<6US:SY_?'_ "/SKZ8/67C'[Z5#T_STS]#7EXS UL'/W^[V
M=SLP^-AB*/.OP]>P*-S>6O#8X'I_G_/>A!O$=QY<DUO&_P!I1X4-Q&\HBG@@
MY_X]KBW\^<_\O?% ./\ EGYG^J?8G_/6":WG'_HC[+_VW[GK\Y^,OV=?!_Q/
M^,%]XX^)GAO1_&GA^V^%V@^#/#>CZK<ZE]HT_5+'6/$>JZY>0:5I]S:6UO\
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M4G\ 8,<X_P ??T^\J_-;_@FIKOC7Q*O[>6N?$/X?GX5^,M1_;\^)4VO> /\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'0+JUO!H^CPZ=8V(M,76V9_"_E^8+<\7_9)YG_X*>$#[W[;GQK*/_?S^SO\
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M\^ZS_P!_IZ93Y.9I?^N]U_Z-GIE?YOXC:7_85B?_ &X^HJ*T**\DO4W/"_\
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M?Z4@.^7J_P!?ZFGTQ>K_ %_J:?0 4444 %%%% !1110 4444 %%%% !1110
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MUK$_X%'_ -]__8T %%'_  */_OO_ .QH_P"!1_\ ??\ ]C0 44?\"C_[[_\
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MD8/^MS\Y[=_?Z>U '<KU?Z_U-/J-?OM^/\Q4E !1110 4444 %%%% !1110
M4444 %%%% !1110 W>OK^A_PHWKZ_H?\*** #>OK^A_PHWKZ_H?\*** #>OK
M^A_PHWKZ_H?\*** #>OK^A_PHWKZ_H?\*** #>OK^A_PHWKZ_H?\*** #>OK
M^A_PHWKZ_H?\*** #>OK^A_PHWKZ_H?\*** #>OK^A_PIK%<<_W._(QV'?FB
MB@#&U#3%O9ED-PUOL4I\B!]W\OISS^=5/^$?'_01D_\  6'_  HHH /^$?'_
M $$9/_ 6'_"C_A'Q_P!!&3_P%A_PHHH /^$?'_01D_\  6'_  H_X1\?]!&3
M_P !8?\ "BB@ _X1\?\ 01D_\!8?\*/^$?'_ $$9/_ 6'_"BB@ _X1\?]!&3
M_P !8?\ "C_A'Q_T$9/_  %A_P *** #_A'Q_P!!&3_P%A_PH_X1\?\ 01D_
M\!8?\*** #_A'Q_T$9/_  %A_P */^$?'_01D_\  6'_  HHH /^$?'_ $$9
M/_ 6'_"C_A'Q_P!!&3_P%A_PHHH /^$?'_01D_\  6'_  H_X1\?]!&3_P !
M8?\ "BB@ _X1\?\ 01D_\!8?\*/^$?'_ $$9/_ 6'_"BB@ _X1\?]!&3_P !
M8?\ "C_A'Q_T$9/_  %A_P *** #_A'Q_P!!&3_P%A_PJ>UT=+:XCN!=/+L[
M;!'^@)X_GSGTHHH W@RCH,?A_AFEWKZ_H?\ "BB@ WKZ_H?\*-Z^OZ'_  HH
MH -Z^OZ'_"C>OK^A_P *** #>OK^A_PHWKZ_H?\ "BB@ WKZ_H?\*-Z^OZ'_
M  HHH -Z^OZ'_"C>OK^A_P *** #>OK^A_PHWKZ_H?\ "BB@ WKZ_H?\*-Z^
*OZ'_  HHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #N 0(# 2(  A$! Q$!_\0
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M@\@#,[%<X'' /7KDY]L_G6!_;%Y_TP_\ _\ Z]7_ !%_JK'_ 'C_ .@K7,T
M:_\ ;%Y_TP_\ _\ Z]']L7G_ $P_\ __ *]9%% &O_;%Y_TP_P# /_Z]']L7
MG_3#_P  _P#Z]9%% &O_ &Q>?],/_ /_ .O1_;%Y_P!,/_ /_P"O6110!K_V
MQ>?],/\ P#_^O1_;%Y_TP_\  /\ ^O6110!K_P!L7G_3#_P#_P#KT?VQ>?\
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M\:_X@Z'QJ0S%@>0H4;OU:_L?0_\ H":)_P"";1_\:/['T/\ Z FB?^";1_\
M&@#\YOV5_AO^SG^RMXH^.'B.#]M+3?BC_P +N\8#QI]D^(7Q@\&ZEI?A(_\
M0%T/_BH_UX]Z_1#0=>T/Q5I>GZYX5US1/$GA_4S_ *'JWA[6-'U'3-0Z=-<\
M/_Y[=JL0Z/H4,O\ R ]#_P#!/HPX]_\ /Z<CS_X)^#[[X>^#8/#FJP:=:W%M
MX\\>:U_Q*<?V8-+UWXG:_KVA'O\ \RYKF,]* *TOQY^ ]I<SV5]\:?A-;3VU
MV+.\M+SXC^#E-AJA .&5O$:E2 >5(!&,$9%+_P +^^ '_1;_ (-_^'2\'?\
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MH_\ C2NNZ^]?YA^FYYM_PT)\ ?-Q_P +P^#G_AU/!N<]/^AD].<8]J/^%_?
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M'B>*94\OP?\ \+3\6>$Y?&&'V1R.NP '3_M7?\FJ_M0?]F]_&3_U67B"NH^
M'_)"/@;_ -D3^&'_ *A6@5S_ .U=_P FJ_M0?]F]_&3_ -5EX@KE=(\>S?"G
M]B/1OBI!I-OK=Q\,/V3=*^(%GI-U='3O[>/@?X,C7?[&..F3HN2V, $L2 "0
M\+AGBY1BMY2C&*;LW*4HPBM>\I17;77R'L[[)-OT2;?X)GTU>?;A87/]E36U
MMJ'V3_0_[6L\Z9S]?RYKPSQAK7QV\'^&-0\0_;?@]J7]EMIBBU_X1KQEIHS_
M &P-#S_R,A['@'NIXP!G^-BS_P"#O[XN36UM/_PPY\.1]JM#P/C!XOY'H?\
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MWI(T+P/HQT0^)?":Z_O\1_\ (Y^%#A_&$9*1K& RK\@?\$P;#X(>"/B+\7?
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M_1_^PSI/\C7U3_RU_P _WJ^2XD_WM>B_])1[V3?[F_Z[A1117S9[04?\M?\
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M4_\ +7_/]ZOB_0?&'@;^WM'_ .*Q\)9_MC2^?^$PT;_/(XQZ]>:^J/\ A-?
M_P#T/'@G_P +#1O_ )I:^2XC:>+5FGHMFG]E=FSW\F36#=TUZIKOW2.HHJO#
M>6%Y%;SV,]MJ=O=8^Q7=I>?VEIG^3[=NM6*^</9"C_EK_G^]11_RU_S_ 'J
M/4**** .5\1?ZJQ_WC_Z"M<S73>(O]58_P"\?_05KF: "BBB@#Y9_;<_M/\
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M7-B<YB\)916NFRO;MHKZ+SZ LN=]WO\ WCY/_P"&#_V(/^C2OV>?_#5^#_\
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M1!;6W/\ RZ6?\A_+\0: +%%%% 'S_P#M7?\ )JO[4'_9O?QD_P#59>(*ZCX
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M?^B/?MP_^(-_M+__ #MJ^\/.N/\ GN/\_C1YUQ_SW'^?QH ^#_\ AX%\)?\
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M+2_B'X-\/^-],TGQ9H=CXHLA?6ND>-O!^M^"O$>GYW8&M^"O$*IXFT'[I)
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M&OYMM"TWXP>-/VA_V';WX@V/[;^N?M(>"?V^/%/B3]I_2?%?AWXF3?LL^!?
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M_?+_ /Q- &)4_G7'_/<?Y_&M3^QKO_GO!_WR_P#\31_8UW_SW@_[Y?\ ^)H
MQ/-F]?U'^-%;?]C7?_/>#_OE_P#XFC^QKO\ Y[P?]\O_ /$T 8?G7'_/<?Y_
M&E\V;U_4?XUM_P!C7?\ SW@_[Y?_ .)H_L:[_P">\'_?+_\ Q- &)16W_8UW
M_P ]X/\ OE__ (FC^QKO_GO!_P!\O_\ $T 8E%;?]C7?_/>#_OE__B:/[&N_
M^>\'_?+_ /Q- &)1_P M?\_WJV_[&N_^>\'_ 'R__P 31_8UW_SW@_[Y?_XF
)@#M:*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #6 /L# 2(  A$! Q$!_\0
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MZYXK'@^OV)O_  EX7U?7/#?B;5/#]KJ&O>#_ .V?^$8U5_\ 2-4T&+Q'H_\
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M]&\%7GPWT_X4>!]/^'>H>/I?BI?^$K/01;^&]2^(]QXP@\?WOB6R@N-1M?\
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M*L+&&"QL;.#S[B[N?]$M[& =#D3@GG)(!J4444 %%%% "+T;_<E_F*])M/\
MCTM?^O>'_P!%K7FR]&_W)?YBO2;3_CTM?^O>'_T6M '!ZC_Q_P!Y_P!?$G]*
MIU<U'_C_ +S_ *^)/Z53H **** "BBB@ I&.!G&W_?X_/IVI:"H8,-VT[.Z0
MR?\ I3;7=M^G/MV (+FYMK*WFO+RXMK*SMX9;B:\O)H;>WBMH/\ 7RS3W -M
M!;VHR3=>@ST!-<WX5\>>!O'5I<ZAX'\:>$_&%I8_)>7GA7Q)H_B"WM/]><33
MZ/<W5M!Q!/\ \?0XQVXKD/BW\)-&^+W@WQ9X1U74?$&ER^*/"'B+PG_:FF^(
M_%-I'8_\)#I%[I9NQI5AXCL],N/LPO3<BV_LG@PYR.H^$_\ @G[_ ,$P/ G[
M!^A>/='T_P"(_B;XD'Q_K?AW7+B]ETVW\!RZ=-I5G/8B"]LO!.I67]KP'S_M
M(^U-=7=V2020,UA.I.%6C&%W>Z\UV[:/KJ?38"APW/A_&8['9]F6!SBA;"X3
M+'EWUA8N]^;_ &G7V%!;*M9;]4M/N7XP?'SX3? .'X<W'Q8\60^$X_BQ\4?"
M7P9^'J3:;J^H2>(?B#XYO/L/AS1_(T^VN_[/T\7'_'[KVO'1_#>CV8MO[>UJ
MS^UVGVSS1?VT/V?_ /A9&M?#*XU;QKI^I:!\7;3X"7?C#5?A7XVT;X3_ /"X
M[_3-#U6Q^'MC\3-0\-_\(4/$&J6_B/0_L7V;Q"+36+R^MK"PO1?_ &RSKR+]
MLG]BKQ;^UYXHL/M?Q??X=^ ] ^"?Q5\"^'=-T3PQH7B#Q1'\5/BG+I=CJGQ(
MFU3Q!IMY<:1!H.@:'I5KX8NM!\0KXDT?5S]NL#:%0I\M\-?L7?M':O+XJ\'?
M%3QS\%9/AS\3/VJ/A=^UO\2/$/@S2O%\GC_4O&7PZL_@]JG_  A&A:'X@MCX
M;T_POKOQ(^%<&JG7KKQ#K'B2S\':M<6/V*TUS[)C<^9/T]D\4>%UFNK6X\1:
M';W%EK%AX>N[>YUBST^>Q\1ZJ(/[*T&^AN+G[1I^KZIYT%U8Z9=8N[RSG^W6
M%E>61%Y7D?B/]IWX#^&];^&>BZQ\3?":V_Q8F\6V?ACQA:^*O#?_  K]+KP/
M#8S^([.^\1G4O[-M]8TNXU72M+LM*NKHWMYK%];6/V*\_P!+KY,_:H_8 U+]
MI#XK^-?%FG_%"X^'?@7XD?"+6='\5:#HD-Y<>($_:"\.>"?'_P .?@[\9H)_
M]$TVX'@WP?\ $WQ$+VU^UV>L7FL>%/ %]_S"+S['X!\%?^"3\WA"YT74/BEX
M@\ ^.OLLWQ:FU+0=5TW6/'FC)=>./@;X5^#OAS7K&?Q!;>'OM/B"UN/#D_BC
MQ/=?V1H_^F:K<V.@_;,?VQ9@'ZT6?Q7\"G^UEU[6M/\  ]GI?CR+X<Z;>>.=
M>T'0[?Q)XHOK2QU6Q'AR<:F?[7_M33KZQNM&M>#>^</L/VW_ $NL+P=\?/AG
MXX2;[/XLTW1[[_A:GCSX,V&E^+]8T?PYJ'B#X@_#+4M5T/QCIOA:QU"YM;KQ
M!J&@W^E7]K>VMK9WEY]DM_[;S]A(O#^9'AG_ ()L?%7P?<Z)KDGBC]GWXN:I
M)HFJ>$M>T'XX^#/&'C#PGIUKKG@GX$>'+[XD>')_M/\ :7_"T-+UCX5ZW<BZ
M^R6=EK&C^([FQ^V^&_LA^V<-\2O^"1WCCQ]\2;/QHOQLL[71]4\5>/+G5?#T
M5YXC\/V_ACPYXC_:*G^/^E:EX<GT?3=6N=0\4_N-)\+ZUH-U_8^CV?\ 96FW
MP\::S]D&CW@!^Z/WE_U<F.-Z"";S(?\ 4?N9X,_Z/<8G@/V6Z_E1*1% ]Q*_
MEV\"RRRW,A\NWBB@&9YII^;:WX&>.P)XP32S.+DB3R?E>;S4ANY9HI[;$-B/
MW\]N;OS[_P#<3\9X'4FN2\7^"M'\;V5Y:ZM-J4,EQIM_IB7-GK&L:/+:Q7UG
M/8S300Z-<VAN/]?_ ,>MU=V9O#Q656I6I4W/#I.O9_5K[7MUO?=_@9XB4X4:
MLZ7\;M_3?_#!X8^('@/QM->6_@SQQX/\67&G)$]_#X8\3:/X@GL//S!!]N@T
M?4;KR!UYN@0>H-<'\=/V@?@_^S=X2T'QO\;/&5OX(\+^*/B%X(^%V@W]Y9ZE
M>'4O'GC_ %B#0_#F@P0:?;7=SSJ'GW6LW5U]CT?PWH]AJ5]KU]H]CI-Y>6?P
M_P#L/_\ !+KP/^Q9JGQ,U32_BEXH^(,WQ(MM!A>&:PO/ 5OI4NAS:K?0S3_\
M(AXCM/\ A(+>ZN+Z WMUJGVN]S .E[7K?[7?['6J_M;Z_P""=)UCXFW?@3X2
M^#_AI\9- N=$TCP]H/B?Q1KGC+XMZ%_P@T&O0WWB_3;S^Q]1\"?#Z?Q';:)X
MHTO5K/Q)9>(_%5S>V-ZIM/ME>=ELLPQ>$<\VI>PK?6GIAO)NS>RL]'VU.?!8
MG,*L/WU+#4?^!IV_R/0]0_;,^ >C?$WQ'\,=0U+QYHM_X0\>>'/A7XG\<:E\
M+O&NG?!C1/B#XQTW0[[PKX5G^+9\-W?@#3]8UW_A*O#EI9?\5#]CO-9URVT/
M[:+[[99VE_XB?M7?"?X6?%KP/\$_%VA_%S_A,_'LETWA._T[X(>-]?\ !^I6
MNE:=!K?B.\G^(MAHEWX2L+?POX?G.J>)SJFK6?\ PCEG!<7^N_9!:WE?#NG?
ML,_M,>(_#WQ+^%?Q;^(WP<UGP#\=OB9\#/BU\9O'OAC3?&L?Q0U'5/A)HOP6
MAU72?"MCK%N-$L+_ ,4^(?@K8W%EXGU[5M9.CZ3XJ\1FP6SUH6;#[6_: _9Q
M/QY^*GP;\6ZIXA_LOPCX'\%_M(>"/&NDVR2_VIK=K\??AOHG@B&]\*_:!=Z=
MIYT+R=6N;ZZU2U(O+R86(L;RRNS7K'8<SJ/[?'[->C>$?$OCW4]2^*&D_#_P
MYX1UWXD6?C:\^!7Q.C\*>.?!'AV?2['5=8^$FMZAX2 \<"UN-;TG[%:Z#_;%
MYK-G?6][H-CJ]C=6=Y7N/PB^,_P_^.%AXGO/ [>)K/5/ _B&+PCXV\*^,_!^
MO> _B!X/UZ^T&Q\1V-GXQ\.>*+72=;T^WU3P_KFDZIHOVK239ZQ9WUM]@^V
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M_P!Y_P!?$G]*IT '7_:_CV;/-W]O)ZCT]L?K7S;^T=XH^+GAK1/!_P#PI?\
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M'=G+KAG):_\ #I--'LV+?_GZO?\ OB&C%O\ \_5[_P!\0U78[/O,OR8WOO\
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M:'U?P%I.N>&?VF]&T/X<7,VBZYIN@_&#3M2^T? _QG<SZ1>P6,4_B/41:?\
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MM\6OA-I0T_Q_IMB<6\TWC_X/ D:Q]F@(%YKOPZ.L$\7M]\/='L;2\UBS^@O
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M66E75W9ZQK'D7/\ 85E>"TO* /8+?_CXM_\ KM#_ "-? W_!./\ Y-U\4_\
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M>N&H45'$T/=LU[:,HZ?&]#F4L31@YT;JCVZ^?7\/RV/T\*X' ^Z_DGI_K?\
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M/A!8>#]<U73Y;;4O$7PCN=7^%^OZK]N/DW%[KD_P_N?#WAWQ!<70FN /[?\
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M5/\ X;[]E?\ ^<70!]Q[O]EORHW?[+?E7PY_PR=^T'_TDH_:I_\ #??LK_\
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MP];=_>NTNB:=M+$WFM9X3#:)OU]$_F<OXA\0_L)AI=5^)W_!-/XV>#;N[/\
MIFJZE^PIJ6I7B2S\&8^)/AOIGBSH<@W-J;3/L>G(VGBO_@E=IAADM/BQ^T/\
M!)/.WH-:\<_MX?!C1M'D[?\ $J\8:C9^ -/M_P#EV;_CTLQ[XY]%_P"&>?\
M@I7I;6\$G[8?Q0\8VZ?ZZ;P?K7[.NAW,W7_CWTKQ/^RIX>MM/./^72Z\0ZQ_
MU^^M.\\$?M<:3'=?\)G^T+_P47TNSMUE>]N='\ ?L3^.](L[0_\ 'Q>B?1O
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M8%>K6G_'I:_]>\/_ *+6L3H.#U'_ (_[S_KXD_I5.KFH_P#'_>?]?$G]*IT
M%%%% !1110!Y_P#%;6?$GASX8?$#Q!X*AM;CQAH/@OQ'K?A6&\TW^V+.;Q'I
M6CWU]H<,]C]IL_/M_P"T((.?M?\ .NC\+7]YJ?A?PWJFH6\5I>:AH.A7]W9V
MMM-IT<.IZWI%CJNJP>1<$YT^YO\ S[FSM?\ C\M#;D_+TK=!"G[NX=TX&_\
MQ_G^E&9/NR2>9GAWV?ZZ7KY\&?\ GUM\VI_*@ HHHH **** "N/^(.MR>&O
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K "BBB@ HHHH **** "BBB@!%Z-_N2_S%>DVG_'I:_P#7O#_Z+6BB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #- 20# 2(  A$! Q$!_\0
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M:-=>$/B9XP\%PV&FW6IW=[>7P@M/#]NESJ#S+'?W8GN[>WM+>:.VBD_9L_8
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M_P"*OPN^(?PUU6&&?3_'G@SQ-X5N8[A0\&W7-)NK"*212""L,LT<V"#S&,C
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MP37>=V@I;U,3D%?B+#+DM.2I<BO%-+]A:*0# ].F?R _I2UX*=]3\Y"BBB@
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MW4\P-*_7HV]-K/:_I;4_?SXI<^-_V?C_ -53U;_U4WQ*KVNOG3XG'Q6?BU\
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M[/2=4T#19M*CU&_T^]ATW482TDKGX _X) ?#?1K;Q'XCE\3^#/'NGZ];^'-
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M \7_ .$N)_\ F</[!SW_ *$>=?\ AGS;_P"=9[_17@'_  U9^S-_T<#\&O\
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M5OAAXUUIKF[O/M^KZKX53Q#?PWEU"^NQ^<7 -'U/\>M$DMOV,OBEX=3XA3_
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MYXE\&ZI;Z5KEI!J"1Q:KI4KWEEJ%G<Z;J,<,)EBEM6FAEC6:UEADRQY#1_\
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M:5\'_P#PGW_^2:^_**/[:SG_ *&V9_\ A?C/_F@/^(@<>?\ 1;\8?^)1G_\
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M)&RK5]T4?A0._DGZK_+4_D"\0?\ !?RXT+_@LQX2^ 6L?LE^,/"UC>7G@_\
M8Y\66WB7Q3IY^(V@^*/&7CG3-87Q5:Z!HD&IZ#?Z1INIZK9QI:VNN79U;0EF
MU:TO8I'BMU_K]K\E/%'@#X4/_P %-M'^,FJ_L9^,_$.O:5\+=-^'NG?'ZW^!
M6CZII.G_ !$O?&=K<6WB9?'+W:WT=MI7A2Y^Q7/BS[(\^F6L,UE%<*L C7]:
MZ!RMI:/+IWO?S"BBB@D**** "BBB@#P#]I/]FCX6?M6?#=_AE\5K/7QIMKKN
MD>+?#'B?P9XEU?P3X_\  /C7P[,]QX>\;> ?&GA^YM-:\+^*=%FDE-EJ=C/@
MQ37%I=0W-G<SV\GE?[*7["/P@_9'U#QAXH\*^*OC5\6OB9X\L=(T7Q3\8OVC
M/BSXF^-'Q5U#POX>N+R[T#P=#XK\32[M+\*:1>:A?WMMHNE6=C;RWMT]W?&[
MGC@>+[3HH"[VZ'@'Q>_91_9C_: UG1_$7QT_9\^#/QAU_P /:;/HV@ZW\2_A
MOX2\;:MHND75VM_<Z9I.H>(=*U"ZTZPN;U4N[BTM)8H)KA%FD1I%5AI^'/V;
M?@#X1^+/B+X\>%_@Y\.- ^,_BW1;3P[XE^)VD^$M'L?&>LZ)916L$&G7NN06
MJWLD!@L=/@N,2+)>0:=IT-X\\5A9I#[910!XI\4O^1W_ &?O^RIZM_ZJ;XE5
M[7D>HKQ3XI?\CO\ L_?]E3U;_P!5-\2JO_'+X>^,OBG\,?$W@;P#\7_%WP'\
M5:Y!:PZ7\4_ NE^&M8\4^%V@O8+F>;2M/\7:;K'A^>2Z@ADLI/M^FW*I#<2/
M$JRJCJ >MY'J/SJ);BW=S&D\+2#.465&<8ZY4,6&.^1QWK\YKO\ 8O\ VG[B
M;7)(O^"EW[2-FFJ_#;0O!%E##\/_ (#LFA>)=*MM,@O_ (FZ<9? +L_BK7I+
M"YN;^TO#<:#%+JEV+7388T@6+\<_V3_^"'G[?OP2_;7^.?[07C'_ (*%^(9O
M"OQ*T+XM:/X>\:^')KO6?BO8:EXYUNPU#1O%VH>$?&&CWOPDLM<B@M9GU"WT
MK0O[,L[BX>+2K:*WP%.VG_ '9?S+[F?U59'J/S%?%G[0/_!1+]C7]EGX@V7P
ML^/7QJL/A_XZOO"*>/AHUSX/^(FNP:?X)?4IM'_X2O7M<\*^$-=\/^&] CU&
MWGMKC5/$&J:9:6OE/+<R10*9:R?A=^RM^T#X#^(OAWQGXK_;V^.WQ5\-:/X.
MTSPSJ?PV\5^"_@[I_AOQ)K%C<6DMUXTU&^\/>#=-URWUW5(H)K>[AL;^#3$2
MZF>WLXI%B9?DW]IK_@G!XR_:M_;P\9?$#QGX]^)?P[_9B\;?L5VWP \<)\(O
M'FB>%/$/Q-N[_P"(VJZOXC^'/BV.[T/6=<@\&:AX8U!C/?Z'-H][)-//:1:C
M&':@-+ZO3NNY^GOP_P#CY\'?BIJ_Q"T/X?>/M#\4:A\*M5\-Z)X]%@UVEEH.
MI>,/"FC^.?#$/]J7=K;:7JD.M^$O$&C:YI][HUYJ-C-9ZA /M*S%HE]9-Q;K
M+' T\*SS(\D,)E02RI'C>\<9;>Z)D;V52%R,D9%?S0?M,?\ !-G]JG5)/VB_
M WP:^$OP[U?X0?%/X_\ @?4/"$%YXRTQ?$WA+X9> OV-] ^"/@/6?#NG^)=2
MB\,6]SX?\;:);:=JUQXJM?$7B#2_#\"Z_P"%-,GUPPW=OT/P;_8*_;"\+?$G
MX2:_\6?A9:_%3QGI_P *?V1_#7@OX_:G^TCKVF7O[)FK?!WX=W_A+XR6EOX:
ML;N2^^(Q\7>*2?&-E9V4=WH?CXZP+/QO<VHTQ54'9:6:^?337\;^MO.Q^]WQ
M8^.'PI^!OAFT\9?%;QGIOA#PS?>-/!OP[MM6NX=1OXG\:?$'Q'IWA+P=H#PZ
M/9:C=076M^(=6T[3899X(K2VDNDFOKBUM5DG3TPWUFL"7+W=JEO*R+'.UQ$(
M':1MD:I,7$;L[_*@5B6;Y5!/%?R*Z!_P26_;M3X*_%CP?XP\-GQKXFU;6OV:
M7\4>'=9^,GAO3/!W[0/B+X6?M,Q_%7Q[\2EU;2TN/$>F:_KWP_MKCP_#XT\8
M7-AXP>/Q ^A+HWD:)9WB^VZE_P $X/VLCX6T.YU;X#6'C_X+?\+3_;&\2^%?
MV&9_VCI]#L_@Y%\9M'\%Z?\  GQ=%\05NUT?6)?A_K&@>,=4E\/Z?J$\?@=?
M'SZUX12[UNTGAC :2M[R>^W0_I*^(_Q/\!_"/PY'XM^(OB2S\,>'YM?\,^%;
M:]NHKRZDO?$GC/7].\+>%M"TZPTVVO=1U'5=<U_5;#3;&RL;2XGDFN [(L,<
MLL?;)<VTDK0I<0/,B"1XDEC:5(V8HKM&&+JA=64,0%+ J#D$5^-OQI^$OQ@^
M%?[,?_!+O3?B_P"*K[XGZW^S=^T[^R?=_M%^+;?^T=7CU$VWA[Q#\-T\:ZA>
M/!)JNK:5X4^(?BWPG?7>M:C;K//;6O\ PE&L?9Y+:XEB\U_8[_X)]?'?X$_M
M'? ;XVZ_I,>GZI_PE/\ P4(_X:)\0Q_$_5?$%UXI\'?%OXKP>,?V9=(NM+O=
M6NK+4M.\/:8][/8Z7I]E;P^#IY7MMD9<@@65F[[7T[Z_TS]V?M]CYOV?[9:>
M?O\ +\G[1#YN_P#N>7OW[_\ 9VY]J\I\1_'[X-^$?B[\.O@)XB^(?AS3?C-\
M6=,\6:Y\//AQ)=23>*/$FA^!M.75O%>M16%K#.=/TC2+%E>34]6>PL;J<BRL
M9[F](MZ^!!_P35U4?ME-^U?_ ,+5\ &T;XK?\+*_X0S_ (4/:#Q*(OLRV_\
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MWP[\"_%/Q3<^"?AW\8O%?PY\ > ?B3X\UWX=>#O&_B[QQ?\ P[T!/"GA&_\
M%6A7.C7>K^+=-T!M+OB&U"WM[%X;R7Y,^&G[%FDZE^TG\;OB;\>/VJ-1U'X2
M:Y^U;\-?VDO!OPJ\/)X7_LKXG^*_A7\+O"WA?PCX]^(^HP^#(O%/AG6;/Q9I
ME_K&J>$_#.LZ?X>UV6ST>YN+2..W6)_)--_X)I?#:;XO>+O L/[6&N:%^Q_>
M_LG_  !_9P\4:/HM[X/U3Q[\88?AK\7/B/\ %#Q=X-^( OO ]Q/X)LKZ'Q;H
MD%KXE\%2:!KTVE7^IZ:93#,DH LN[5E?5:?+K^GXGZJW'_!4_P#9'$OQHBTK
M5/BUXI/P$\>)\,/B!-X3^ _Q>\06*^/O[4U?2KSPQX:U2P\(2:;XKOM)DT._
MO-:DT&\O+/2-,%KJ%_=06]]9/.VS_P""JW['&HZ_^SMHEAXI^(M[9_M66V@7
M/P(\96WP6^*\_P //&XUZPU#4Y(8_'</A*3PUI$WA>PTK4[OQXNM7^GKX%M[
M&XF\4MI<:JS?,GQ _84_98\8_"/6/A)HW[3WC[PAINL_M;^.?VN[RZ@A\-^(
M-,O_ !/\0YK[^WO WB'P;X@\*WGA/Q9X(L[?4KAO#MGXETO4[K2-7M]-UMY[
MV[L567B?@]_P3I_9N^"/C3X.^)?"7[:'Q2U+P_\ !;X)C]G?PSX!\7^&_A/X
MH\.Q_"?5-8U35_'NCZ3<:G\,)-8\%ZY\4/[4_L[QWXN\$7_A_P 1:GI=AIMA
M!?6EM:)$07N^>[^ZVGSN>Z_$W_@L7^S=IGPG^(GCOX+#6_B9XG\&:?X&\4>'
M/"OB?PWXS^%VF_%7X<^+_C!H/P=N?B;\*O%'BKPO#I_Q \#:1XAUKRY/$/A5
M=5T^:9+*,RQ6VI6MX_U1\,/^"@'[+'Q?^/&O?LW^ _B'-JGQ/T2?QK9VMO<^
M&O$>F>&O%VH?#.^M=,^).F^ _&&H:;;^'/&>H^ =0O;>T\66F@:C>RZ5*TAD
M#QP3R1_FC8_\$ROV1Y/"K^"_%_[6OQ4\<>'?"/PU\*_!#X!6^KP^#+*Z^!'P
M7\)_%/PO\6K3P1HE[I'@BR?QG?7FM^#_  _H5WXO\;)JWB >$M-M=&MIX)$E
MO9_;OV>?V1/V0OV:/VE?$OQW\)_':XOD\0ZM\5/$/@?X8ZSHG@R&U\'Z]\7M
M9_X27XEWNF^+K/PG:_$3Q7:27+7"Z-INN:]?6OA;2[Z_ME^T1SQRP >[;K?_
M (/^1VG@/_@IA=^-/VR7_9V_X4LUA\(]5^.7QG_9@\'_ !L3QW;7NM:K\=O@
M'\/-$^)/C_1]7^&ZZ!$VC^$9])U6\TWP]XCB\5:A<W>IZ+=B^TJQCN(0D7BO
M_@I?<:/_ ,%%8_V$-(^'GP\6RLHOA^NM?$CQY\:1\/\ 7-1U/QIX;UWQ;?Z-
M\.? 5_X!U"R\?:IX;T'28+RXL8/&VEW=\UW/%;0;M.F+\/#^QK^S/I_[1_C/
M]H70?VH_B'H UOQ1\7_BOX)^'&G+X:/A7X7?M!?'/X?:?\-/B%\;_#5]=>$+
MC7]2\077A_3+6YT;P]XBU#4_"^D:S)?7T>G3Q7AM8K'BW]DGX$_$CXK^ O'7
MQ5_;$^*GQ-\!>$?$'PQ^(^M_!;Q8OA*?P?XS^-'PF\#7_@+PW\2[W6;+P79^
M+-!CU*QU2_USQ3X'\-ZOIWA'7/$LJZ@UA;6BR:?,#]V^W3:VS^;WZGK?[:/[
M>/Q+_95U3PIK_A;]G:T^+_P5N=6^'7A_Q/\ $.R^+GA[0O$>N>,/B7\1;+X?
M:/\ #3X)_#^#1]?U+XF_$;2XKJ7QAK&BW=_X8LQX>L[A;74);E9##Z[^U)_P
M4&_9C_8XUJR\/_'7Q/XLT74;GX>^(/BQ=#PW\-_'GCJVT3X9>$=8TO0_%OCO
MQ)>^$- UBUT#PUX8O-9L)-<U'5);9+&RE:]=3!&[CX*\=_\ !/K]DV^^)WP4
M\?? G]IWQS^RIX=^ *^([OX<?"+X+:1X"'PPTCQ1XXU>/4O'WCV/0?&O@+Q5
M)%X\\7V4,?AV^\4VUS!J>G^'_.L=&FT]KJZFF^A/VJ?@)^RE^U'K7COQ1X\^
M-VL^%CXU_90^*'[)6LC0;G3;33[#P'\5?%WA#Q=K?B.&36- O5B\2V&H>#].
MM--FNY9-(6UN[M+O3[F9X7C!::;^9V5M_P %4/V.[WPI/XGLO%/Q"N[Q/B[I
M/P/L? $'P;^*+_%77O'^O^#H_B+H=MX=^&G_  BP\8:UHNJ_#QV\=V?B2QTJ
M70Y/"L,^K-?)%$PKH_%?_!0+X0/^QDO[9OPA%_\ $[P;XHO]+\*_"G2+FRU;
MP3J'CSX@^)/B3!\(/#/A>2V\1Z5!J^@I>?$&Y73;^ZO='::ST^WO-0BM+A8X
MEE_.S]IO]E'PW8ZWHWQG_97^)EWK?QJMOVBOA1\8Y[V_^(WAOX?:OX1TSX?_
M +/<O[.E_#X!NO$_PO\ &G@?6&\1>#(K6/7=!\?:1<V3O?7^J:'J&FW]CIMN
M=7P%^S,/#'_!*SX:_LCZG\7/ 5Y\?_AGK_ASXR:-J3:KJUWX3NOBIX4^/G_#
M0.D^'=8UW^QK*6_TV^U$#PIK&N1Z?:VTD]S<:M;VZ6:1(0++HV];6:U_#H??
M_A+_ (*/_LO>*?CM8?LTQ^*?$UO\6[OXB^-_@OMN?AO\0;#P!<_&?X:>&8_%
MWCCX9Z5\2-1\.6O@[4O$^E>'#<:Y:V-OJSOJ6DVEQ=6;2F%T%[XE?\%#?V=?
MA1\;(OV?_%D?Q?;XA3:IX;TA#X?^!7Q8\3^$OMGBHVXTK?XYT+PI?^$X[<&Z
MB&H7+ZLL&F?/]OD@\ML?.WA_]E[]E?3OB#X)^*DWQI\21>)/"7[8WQ:_;=CT
M?[7IL^D'XF_&CX97OPT\3^$II$\-QW$_@O2-.U*ZO-%$,T6K&_2.6ZU.YMBT
M#>P>.?@1_P $X_B9\58_CCX^^&WP@\5_%R*^T+4X_B!J^C7]QXB34/#/DG0;
ML7851YVE&W@-HWE_N_*3@XH!V3Z[/IU_RN:7[4W[<,W[-_QY_9/^!EK\%O'W
MC<_M,?%SPI\-=3^)T40T?X8?#2W\5+XF73_[1\230W2ZWXWU"3POJ,^F>"M/
M@CG;2;>YU;4=1T^W%FE[Y5:?\%$_'VA?M3?&;]G7XG?LQZYI*?#WX0^,?C7X
M.'PO\?:1\7_BGXI\'>&?%NF>$?#<.N_#/0M*T^#0_$'Q:DU(:M\/]!T7Q9XJ
MO;>QMY4\7CP\ZRRP>T?'C2OV<?VB]2^ NK>(?BXVG2_LZ_M!^%/CYX<7PW<0
M-#JOC#P/HWB;0[7P]XC:ZTJ_/]E/!XKNY-1MK-K+4XYX;4+<P+YB2>&?#O\
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M!)9;+289)A?7,,".\TT,$D",T,2QOOEXC5E*%PV%/I8Y /K0(**** "BBB@
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M^/L-E_SYVO\ X#Q?_$5^,W[:/_!.+XT?M#_M'>)_&'@#QS\-]%^"W[17A?\
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M@3Q#X>^._@Z>P\*>,CXS3SM%M8M5ELXKL7T<: U;KY_\ _<G[#9?\^=K_P"
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M;0>._%^I6?AO28K\R*VL;X?*AMHS<']+18V7&;.TSWQ;Q=>^/D[&OP%^-?\
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M?]IZ2;^QM[U[-[I/-(.ZLM/7S_X8_';XO?\ !;'QSXQ\)_M@:/\ !OX/>)?
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:BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #@ 1(# 2(  A$! Q$!_\0
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M_GIU>_9;_P"2A?MJ?]G57?\ ZHWX)5]A4 ?%_P#P[Z_94_Z$KQQ_X?O]H/\
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M4ZM-X7%8=Q4\9@\%4@YXG#TJ2KX:OCJ"Q6&YWB*%^6I3C)QO] _\.^OV5/\
MH2O''_A^_P!H/_YZ='_#OK]E3_H2O''_ (?O]H/_ .>G7AG[+_\ P45\0?M
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MJ+I.I*.'=18JI2HR^]_^'?7[*G_0E>./_#]_M!__ #TZ/^'?7[*G_0E>./\
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M5X>THUJM)T*4HXBA1K5*-1>S:E^V/QF^$WA/X[_"OQY\'?'0U(^#_B-X<O\
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M>#-/\4>![FVM'_L34=2\-2-I6O\ FK?0:M;X$\*L%(_/75_^"COQ_P#BM<?
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M".0:?7G---IIIIV:::::T:::333T::33W2.Z]]5JGJFM4T]FFKIKS3"BBB@
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M$QVNDF=M+MH_"VAI!IS7-O):W#6,*V(CM3/;2RV\Q@5#)#(\;DJS VK;X>^
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M?8=Z1"2JDD$E5)(Z$D#D>QZCVH =1110 4444 %%%% 'Y._LK?\ )K_[-_\
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MPYOY/./A+2K"X"NJW.BQ-H4X+DL9"^D/9"24,2PDE61@>^.*SO\ A5\E@O\
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M6=O86%I$"3Y=O:6T<4$2Y)8A$&6))R236K110 4444 ?D[^RM_R:_P#LW_\
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MS<'D],#MC%/A51&A7/*)R222 H SDG''I0!+1110 4444 %%%% 'Y._LK?\
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M3 (&Q< \D#:, ^XZ&@@?1110 4444 %%%% 'Y._LK?\ )K_[-_\ V07X/_\
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MX^_\.9X]_P#FAH_X4'X$_P"?WQ]_X<SQ[_\ -#0!['YS8SY$WW]N-JYQ_?\
MO?=]^OM2F4@/^YF.P@ !5._/=/FY [YQQZ]*\;_X4'X$_P"?WQ]_X<SQ[_\
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M'_#&A_Z.J_;*_P##YW'_ ,H*/^&^6G^2^X+NS71VNN]G=7]'JO,^T**^+_\
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MNR6/5(?LWD07GFDQV]Q<QA#YI(^A: "BBB@#\G?V5O\ DU_]F_\ [(+\'_\
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M0HKXO_X;,/\ T:G^V5_X9>R_^;*C_ALP_P#1J?[97_AE[+_YLJ /M"BOB_\
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M?"O2-=T#5OLD.JZ)K.F^!=!L]4TC4HH+JXABU#3;Z&>RO(X;B>)+F&18YI4
%=B@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image_017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #- 20# 2(  A$! Q$!_\0
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M:-=>$/B9XP\%PV&FW6IW=[>7P@M/#]NESJ#S+'?W8GN[>WM+>:.VBD_9L_8
M^ /[+OBP>/\ P/+\3O&'CFU^'>D?"+PYXK^,7Q0\7_%'5_!'PKT6X@O+3X?>
M!O\ A)K^XL_"?AB2]L[*[O++2+2WDO)[.V-Q-)'"L=>[_ 'X#?#G]F?X6:!\
M&_A1IU]I7@7PU?>)M1TJQU+4KC5[R*Z\7>*-9\8ZV\E_=$SRK/KFO:C/$C'$
M$4J0)B.-10#MT^6EN_GZ'LM%%% CSOXO^+[_ .'WPF^*'CW2K>UN]4\$?#OQ
MKXOTVUOA(;*YO_#7AK4]9L[>\$+QS&UGN+*.*X$4D<ODL_ENCX8?@_I__!4W
M]J;XO> M2\6_">/]E;X3V?P)_9;_ &6?CE^T/XH^/\/Q-N?"GB3XD_M2>![S
MQYX.^&7@,>";^34/!?A"WTFP\G5_B3XC'B7^RM0U*&!O#]U;:9?7C_O_ .,_
M"FD^._!_BOP/KPN&T/QEX:UWPIK*VD_V:[;2?$6EW6D:B+6YV2?9[@V=Y,()
M]C^5+MDV-MP?S<\;_P#!*3]E>Z\*^%[/3O&GQR^"^F>"/@)X<_9[\8^)/A?\
M9;[X>7'Q.^!7P^TNYM="\,?&J]6RETKQ-:>'M,N-42'Q,UKI'B+3M/O]1M(-
M<MM,?[+$#375=M=[?+^OP/#M)_;Q_:__ &F?'?Q(TC]BSP[^RM>Z!^SI\*OV
M;O'WQ,?XG^+_ !?J>D?&3Q5^T'X#'Q-M_"/PC^(GAK^R]"\,>"]&\)*([#XG
M^(=&UZ+6=8NX57PU:V,%S,OU?^V3^WGX"_9M_9[^,/C'PGXJ^%/C#]H3P-IW
M@[POH7P4;XB>';[4K/XQ?%?5]+\'_#'PWXWLM/U:'5="T2_\5ZY9RWFHZC'H
MR7.A6.H7=K<PD*Z>?:U_P2I_8:^*?AKP,_@JW\;>%OAB/A#\./A-?Z%\#_C3
MXL\,_#KXY?!+X=VL7_"M?"?Q.'AW6+BW^)/AW0]-:2TTC66U%-9N]'OKC3IM
M=N]+DCMX_7?CM^Q%^Q1\4M<^'OB;XN^ /AS80> ?'GA?Q'-I-Y:^#M$\._$?
MQ/%HU_X)^'&B_%NVO].,OQ$M-'FU03^ _#^O7LJ)XGM]-NK&*YN[6&*@--+^
M6EEJ?!VA_P#!2C]HSXW_  9_8,;X&:1\ O#7[0/[2GQJ^+O[/'QML_'@\5^,
MOAQ\+OBK\ O _C[7OB1I>CMX+UZSU2_M;K6? %P-!F.I:A%_8VNZ3<S7$ZB2
MX;,U_P#X*L?M*Z)^SIIOC2+]G'P=K'Q,\ _MK/\ L??M)>)M'\5W#?!OX?OH
M_P 9/A[\,6\<^&K74Y]-\;^('^(\/Q"TF?P7X<C@EF\/W4.M3>)[XP:/%;ZI
M]6Z]_P $BOV4;F^O+_X?7OQ>^ C-\:Y/V@O#UM\ _'\?PSL/ 'Q+OOAG_P *
ME\0:E\/M/TS09[7PE8>+/"!EC\4:7ID:6NK:I=7>J.L=S<S%_9++_@GI^S=I
MO[.5O^R[I^D>++;X;GXG^&OC1K>I2^,-4U/Q[XP^*7ASXFZ'\76\;>,O&>L?
MVCJ?B#7/$/CCP_8:AXEN[L[M2MO-L8A:6YB6(_K^NB^5A^[T7X?\'6VB7DC[
MAHHHH)"BBB@ HHK\W/&G[9O[3D>O^)&^#_[ ?C'X@?#3PGJ6N:?J'Q&^('[1
M'P,^!K:ZGAK4)=,UK5/!WA'Q3JVLZO=:+!=0L+75?&<_@.RNX7AG$L4,J.0#
M[F^*?Q)\*_!SX;>._BQXYNKBR\&_#CPGKWC3Q/=V=I+?W<&A^'--N=5U%[2R
M@!FN[K[-;2+;VZ8,LS(A=%)=?C3]CK_@HI\-_P!L'Q%J7@C2OAW\1_A;X\TS
MPAK?CF;PMX_A\-W$Q\/Z!\4/$7PKU0'4_">O>(-*75M/UK1=.O;W3OM3(EAX
METIK.[OGBU 6G>^.?C=XF\5_L8_&/XNQ_ WQ#X7\6Z3\+/BC<GX*?'#1+"[.
MHZUX=T/5X?[#UJV\):EXGT;Q=X0\1S0!;#4_#6IZII?BC1+N*XL9S'=%8_R;
M_P""'&A_";0?$'Q2E^&NN? ]=1\7^ /"OBKQCX-^%O[!_P ?/V4];\.:S=ZH
M)[BUU?QU\:/$WB.V\7Z7IM]J.H:?;^&O#@TZ".[>7Q UJ4DW4#MH_E;]>I_1
M<3CW/I_G_/K7YD_"O_@I/I'QA_;H^+?[%_@WX/7UY:?!?7-:\,^,OB^_Q<^$
M<=O#K>@>%O#OB#4X;/X22>)(_BU>Z;::CXDM?"]WKMGX;N-'L]9@N([J[B1#
MC[;^-_P2\#?M"?#[4_AC\16\5KX6U>ZTZ\O#X+\;^+?AYK_G:7=I>6HMO%/@
M?6-!\1641F11<0VFIPQW46Z"X62)F0_GWX*_X)A)X<_:]\$?M&:Y\;;SQ+X(
M^#WBKQ]X\^#GP[3X<>$- \;:)XC^(_@>U^'^LZ3X^^-6CI;>+?BIX*T?18KF
MY\/Z1XM@N-8;5KN*_P#$.OZY-I>G-"!IK??H?>?Q1=#XY_9^0.F__A:.K,4W
M#?M_X5-\2OFV_>V_[6,#(R1FOSC^)XN/V?\ _@KI\#OB)'(;7P9^V+\'=;^#
M?B@N=EM+\0?AT?[7\(MNXC:YN=/%E8VZ-B1_-N0A;) _0#XG^&=!3XL? 'Q8
MNFPCQ'+\0M5TE]5\RX^T'3O^%4_$B4VGE^:+;RS(B,6,'FY08< L#\7?\%>?
M"5TO[-&@?'[0H+@^+?V4OBU\/_CGI%S:*QNHM'T/7+6R\8PHT?S^5+X=OKN5
ME!P6MHF;.T8]SAZ499BL'4:5+-<-BLKGS?"I8RBXX:3_ .O>-I8.:=U9Z]S]
M!\,*M.KQ53R'$3C'"<997F_!M=S_ (<:V?X*='*:T[M+_9^(,'D5:+?PRES*
MS5S]63[@'D=?RKY@^(GAC5?AKXANOBKX'TTZGHFI(8?B?X*AB$EOJ^F.&\_7
M;&T*M&U_;HQ^U((R)HMQ=6C>85[QX*\4Z7XZ\(^%_&NB3)<:/XM\/:-XDTN9
M&5P^GZWI]OJ-J=ZY#,(KA%89RK*P.",5TSJKHR, RLI5E*A@RL"&4J>"&!((
M[@X/%<.#Q=7+<14YJ:J4IJ>&QV#J75+$T5-QJ4:B5G&4)PYZ56/[S#UZ<*M*
M2<6I_F>9Y<Z_/AZWM,+B\'7G[*K%<M?!XS#U*E*3LU]FI3J4:]&7N5J:JTJD
M6G%Q_B!_X. ?#\/["?@'PI\;/V./&EKX-^$?[:>N_P#"$>._V>;+PGX>'P>T
M3Q1X,\-WVJ)\5O"6BV45E+X7^)-U'J=Y97VIV#6]S%?J+R1[AE2&']6_^#;3
M]L]?VH_V';CPYXQO?A]IOQ;^&/Q'\6Z)K?ACPJVGZ)J6I>')/L%UHOC*?P?%
M,UQ86FHBXDL);V#[1;W5Y8R3S3I/.8Z[K_@J9^P7\"OVE-$\.?"CXH6&JW/@
MW^W-0^)7A*'2+Z2QU#P)XKN[=M#UNY\/2L7MDM]8M)$\ZWN+>6*$P1^4JGKY
MA^S?_P $@/V8/#?P2^'MM^SE\2/'7P(^/_P;U[XG>*_AOXU\,^-CIVJR>*O&
M=K"MF/B/ID$37'BWPA_:5AI=Q=:$Y2TN]/BN[1H76Y<#ULPX<Q6'R^GG>%_?
MY/BG"6'F^9XNG&HYI4\30C3:BZ$Z=2E5K*7L9.$)PDE527EX#B+"8C%RR;%M
MT,WPRDL1%)+"SE#E]ZA6E47-[:-2G5IT7%UHJ4XR3]G=_P!'5%?C/\*?^"A'
MQE_9S\7Z+^S]_P %1? ^D_#CQ:?#.@:G8_MC?#?2/$(_9"\8WNN:E_85GH?B
M?Q;K&FZ?:_"_QO+K#V&GR6.J2?\ ".7VHZM8P6-[8&>*WD_9&UNK6^MK>]LK
MFWO+.\@ANK2[M9H[BVNK:XC66WN+>>)GBG@GB=9(9HG:.6-E=&92"?FSWOZO
MT^\GHHHH **** "BBB@#\.?^"A?[%GQD_:V_;:^"MIX*N/"_@[X:O^QS^T?\
M.?B!\3_'OP,\/?''PQI5QXY\=?"Q;/PWHVG>)[_3]*\-^/=0TNRU;5M!UXM<
MS6\6EW2FTN(3)&_Q=\5?V<OVG/V4M=^.GP[_ &>OAM^TMXQ\#7>E?\$]_@IX
M:^,'@;4_$]MXDO/!WPA^#7C[PUX@\3ZTW@*./QMXMT:SU\Z!I_BG2_!EUH@T
MR\O-/?4]3L] AN8Y/ZEZ*!IO2^J71^I_,!\&KO\ X*//+^RA/^TUI_[>UYXA
MA_9Z^"NG>#8/@S;:)INFK^T-I/QJ\;67QFG_ &NAJ8/A^WTJY^'EMX E6^\4
MSOHFI^"3K\NA7%WXKO$N9?FCQO\ "K_@JE\7/A-^VCX-^,.G_M&>,M6U72+K
M^V/AQ;^!]>NM"UWQGIO[6/A77_AWKWP \7Z_XC/A".Y\/?"'3KN;1=-^'?A\
M>%I=)6RN/&]W9>(M*,5S_8M10-2MT3_#K?=:_CT/YBF3]NQ(+F37K;_@HG-^
MPP?VI?B-(+'0XBW[>8\#_P#"D=*3PD9(;<+XO?X.M^T(?$,UHEFLFJ+:C3+F
M=F\#")S^XG["Z?M#Q_LD? A/VK7NG^/R^!K,?$-M3_LTZ]]K^U7?]CKXI;1C
M_9+^,5\._P!D+XODTW-E)XE&J/;_ +MA7UC10*_EU"BBB@05^8'_  5ITK]H
M7XB_LM+^SS^S1\.[[QYX]_:5^(7A#X1^(+R6[U?0O!O@SX57=X_B+XJ:Y\0/
M&FBZ?JU[X*\/:QX,T#5?!$&NPZ;?W*ZQXJT^"TLKB>54'Z?T4!MJ?RA>!/"O
M[?7[/_P&^&W[)7CKX9?M/?"WX%?L[_M-?$+0?&FK?L4OXC^)WCJ\_9C\?_#3
M7_'_ .S9X?\ A%X\E\(V?B3QOX=^&?Q#U-?AUX]N-"\-VU[H;:%X9T[Q-%9:
M+/?W+37WP2_:CA^//QL\7R^#?VT];\2?%WQ+_P $F_%FF'XC>';/Q9X9N_ O
M@GQEX<T[XW:AXJ7P_H5_\-?#OQ7\ 6UE=ZEXGTW0;VWNO"R:IKVLZ?%';3"_
MC_JWHH'?=V5WY?IJ?S#^-=+_ ."N]AX._;$\.^'M6^.$K?LF:9_PJ#X%>++=
M9[[Q'^U;X5^*OQVT#XA>(/C1H4$5B+G7_&WPA_9NN&^&&DS: DNHP^+;+Q'+
MH\%SK[:>E?K-_P $PV_: ?\ 9G=_VA->^)'B#66^)7C]O %S\7_!GB#P1\2;
M/X6G5E'A'2_$NG^+[Z[\9:HNGQB\AT;Q#XRM=$\5ZMHIL9-:T2RN(@TWZ)44
M W=6LM[A1110(**** "OXJ_CFOQ[^#^K?%OX>:O\5_\ @GOHWP\\97_[:W['
MNC7_ (V_:IU;2M9GUW]J?XP>'OC/=_\ "0^%M/\ "6J:;I_Q$^'N@2:-;W6B
M7EP;"QAUU(]6U?3)'$#_ -JE?QY?$WX(_ #X=^._VH_!7Q)_:4^(/PFU[Q7#
M\</A7\(O 7Q?_80^(OB+4_"?@#]ICXTP_$[]HCQ9X(U_P;9^)?#?QW^)GC2S
MLXO#?P@\?V=[I]WX:\+2:%::SI4\D=Q;6P5%I/7\K_\ #>I^_'[7?@+XMC]E
M/X>:=\+-!T#Q-XE^'=IX5O?$3:G^T;XN_9L\+:7X:T+P+J&E>(_$EW\2?!6G
MZC>W.FZ5 [7<%A=PQZ8X$.L23PRZ9;N/A;_@C;XC?Q7XU^)FMVOBWPYXGT*_
M^']C-HTVD_\ !0;XW_M@W%U:V/C[6_"DVK1^#/B]HFC)X5TI]?\ "?B31X?&
M.EQR3:G>:3<Z<^+::"2;] ?%OCWX5>-_^">WQ0\0>*OAM\:K#X*V'P&\<^'[
M_P &>.M!N_AS\7/%/P_\.>$KW1([VUTS59H-0\/77BS3+1;S0-2UV/2[B*&Z
MMM5U;3]/B,MLGY&?\$/M3^$EU^T=^T-;^%-0^-?C[4QX(UJ3X8?%7XG^.?A5
MXFT?5OAA'\67;XDZ9H>D?"W0]$MK))/C1>WT=EXLU;[?!XWBT#4;CPZFDVFD
MW]I, OA>W3IK]]_T/Z<****"3Q3XI?\ ([_L_?\ 94]6_P#53?$JNE^+GP_T
M_P"*OPN^(?PUU6&&?3_'G@SQ-X5N8[A0\&W7-)NK"*212""L,LT<V"#S&,C
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MP37>=V@I;U,3D%?B+#+DM.2I<BO%-+]A:*0# ].F?R _I2UX*=]3\Y"BBB@
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MW4\P-*_7HV]-K/:_I;4_?SXI<^-_V?C_ -53U;_U4WQ*KVNOG3XG'Q6?BU\
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M[/2=4T#19M*CU&_T^]ATW482TDKGX _X) ?#?1K;Q'XCE\3^#/'NGZ];^'-
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M \7_ .$N)_\ F</[!SW_ *$>=?\ AGS;_P"=9[_17@'_  U9^S-_T<#\&O\
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M5OAAXUUIKF[O/M^KZKX53Q#?PWEU"^NQ^<7 -'U/\>M$DMOV,OBEX=3XA3_
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MYXE\&ZI;Z5KEI!J"1Q:KI4KWEEJ%G<Z;J,<,)EBEM6FAEC6:UEADRQY#1_\
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M:5\'_P#PGW_^2:^_**/[:SG_ *&V9_\ A?C/_F@/^(@<>?\ 1;\8?^)1G_\
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M)&RK5]T4?A0._DGZK_+4_D"\0?\ !?RXT+_@LQX2^ 6L?LE^,/"UC>7G@_\
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M9[F](MZ^!!_P35U4?ME-^U?_ ,+5\ &T;XK?\+*_X0S_ (4/:#Q*(OLRV_\
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MWP[\"_%/Q3<^"?AW\8O%?PY\ > ?B3X\UWX=>#O&_B[QQ?\ P[T!/"GA&_\
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M-#JOC#P/HWB;0[7P]XC:ZTJ_/]E/!XKNY-1MK-K+4XYX;4+<P+YB2>&?#O\
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M!)9;+289)A?7,,".\TT,$D",T,2QOOEXC5E*%PV%/I8Y /K0(**** "BBB@
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M^/L-E_SYVO\ X#Q?_$5^,W[:/_!.+XT?M#_M'>)_&'@#QS\-]%^"W[17A?\
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M@3Q#X>^._@Z>P\*>,CXS3SM%M8M5ELXKL7T<: U;KY_\ _<G[#9?\^=K_P"
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M;0>._%^I6?AO28K\R*VL;X?*AMHS<']+18V7&;.TSWQ;Q=>^/D[&OP%^-?\
MP2:^/'Q"U'X7>'/#/Q'^%EC\-_&/[.W[%7P$_:BGURU\4/XOTJ+]C?XC:-\3
M-/\ $'P86PB&EW\OCBXL;SPO=6GBN2P71[>>+6X9+BY06J?T"?7KS^O;^5 ]
M/Q?W="M]ALO^?.U_\!XO_B*R=>O_  SX7T/6/$OB.YT70O#WA[2]0US7=<U=
M[.PTK1M&TFTFO]4U74[^Y,5M9:?I]C;SW=Y=W$L<%M;PR32NJ(Q'053U'3M/
MUC3[[2=6L;/5-+U.TN+#4M-U&UAO=/U"PNXG@N[*^L[E)+>[M+J"22"XMIXY
M(9X7>.5'1F4@C\O[7_@IC^QIX@^%FB?M8?#?2/BO\7]#UKXA^/\ ]G_P*?A)
M\(O%/B_QEXSO_ 5S?ZKXRU+PQX8LXH'D\%65GHEWX@7Q7JCZ9;W&D1+-!N>X
MBMY/T"^#GQ:\"_'CX6> /C+\,=9'B#X??$SPKHWC+PAK'V6YL7OM#UNTCN[*
M6>SO(XKJTN51S%<VT\:203QR1-DKD_C/X\_8%_;N\*_LE_$S]G3]F;XG_!+P
M=JGQF_;#_:$^,7Q"UW5KCQKH ;X ?%OQYJGBZV^%/AC5O"]@=9\*:YK^G7MO
MX9\5Z_HJV]SI>C+?P>'+FWGNXKNV_7[]GGP3K?PV^!WPJ^'_ (C\/?#[PGK7
M@OP-X?\ #%_X9^%%OJ=K\-]"ET6QBL4TOP7!K1;5TT"TAABALFU1Y-0D53)=
MR/.SNP-VZ?U^'ZGLE%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ I#T/T-+10!_+?^V'_P41_;<^#?[3'QZ_9G^'7B_3;WQ'\$?C?:
M?M=Z]>WGA+3+R&/_ ()T:1\*O!.M^)_A]!LMH\ZU<>/]>U71M/\ %<C"^MWL
M9+66YF2WN6BZ#P1_P6T^)GAS0_#GB.7X2:_^T!9_&S5OC'^U!X5M=,&JZ#J/
MA']C8?'J7X,_![0/ ]GX;\$^)K3Q5XTO=+L'\;R:AXVU'P;X>GT]VTZ;Q&VK
M:KIJ#]_=<_9F^ /B;XB^-/BWK_PG\&:M\2OB+\)KGX$^.?&=[I4<VN>*/@]>
M7KZC=?#S5[IFQ=>&I[US<R610%I I,F$4#RS7/\ @GU^Q7XE\._!CPCKG[-W
MPQU'PS^SSH6F^%O@UH<VC.NG>!O"VD7.F7NF^%[&WBN8UU#PW:7VBZ5?QZ!K
M?]IZ2;^QM[U[-[I/-(.ZLM/7S_X8_';XO?\ !;'QSXQ\)_M@:/\ !OX/>)?
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:BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>26
<FILENAME>igc-20250331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Jun 27 19:48:35 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ConsolidatedBalanceSheet" roleURI="http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ConsolidatedIncomeStatement" roleURI="http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ConsolidatedCashFlow" roleURI="http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofInventoryCurrentTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofInventoryCurrentTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_DeferredCostsCapitalizedPrepaidandOtherAssetsDisclosureTable" roleURI="http://www.indiaglobalcap.com/role/DeferredCostsCapitalizedPrepaidandOtherAssetsDisclosureTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofIntangibleAssetsAndGoodwillTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_PropertyPlantandEquipmentTable" roleURI="http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofOtherAssetsNoncurrentTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofOtherAssetsNoncurrentTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_LeaseCostTable" roleURI="http://www.indiaglobalcap.com/role/LeaseCostTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofAccountsPayableandAccruedLiabilitiesTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofLoansandOtherLiabilitiesTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofLoansandOtherLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofEffectiveIncomeTaxRateReconciliationTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofComponentsofIncomeTaxExpenseBenefitTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofComponentsofIncomeTaxExpenseBenefitTable"/>
  <calculationLink xlink:role="http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStocksIncludingAdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.indiaglobalcap.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AssetImpairmentCharges" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLAKD9Z7zGpK2qQstFsfCu8xSrtW9H2+v0Xv0rh9+KH/Pz8D0bXTVzCQTQCC6nPug5x2WprRNZyO0vKrGf3yPx7zySn86Xz+cpPHpOaLInCIyy5s5q8xj2k941QApP+Uc6E50B2zYbnR/55u68AGKs/8SiUy11i4tM/dKp4JuQDXDaZK3azYQ8+FvMTMkrrL0geMSLbxuaBiHnSxcdkfrEJgOsTUKoAz7e4w=] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromInvestments" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRepaymentsOfDebt" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofInventoryCurrentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterials" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.indiaglobalcap.com/role/DeferredCostsCapitalizedPrepaidandOtherAssetsDisclosureTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherInventoryNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherInventoryNetOfReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherInventoryNetOfReserves" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofOtherAssetsNoncurrentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherReceivables" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="igc_OtherAdvances" xlink:href="igc-20250331.xsd#igc_OtherAdvances"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="igc_OtherAdvances" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.indiaglobalcap.com/role/LeaseCostTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofLoansandOtherLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="1" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsForeign" order="5" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofComponentsofIncomeTaxExpenseBenefitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>27
<FILENAME>igc-20250331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Jun 27 19:48:35 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ConsolidatedBalanceSheet" roleURI="http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ConsolidatedIncomeStatement" roleURI="http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ShareholdersEquityType2or3" roleURI="http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ConsolidatedCashFlow" roleURI="http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_NATUREOFOPERATIONS" roleURI="http://www.indiaglobalcap.com/role/NATUREOFOPERATIONS"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_SIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIES"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_INVENTORY" roleURI="http://www.indiaglobalcap.com/role/INVENTORY"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_DEPOSITSANDADVANCES" roleURI="http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCES"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_INTANGIBLEASSETS" roleURI="http://www.indiaglobalcap.com/role/INTANGIBLEASSETS"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_PROPERTYPLANTANDEQUIPMENT" roleURI="http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENT"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_CLAIMSANDADVANCES" roleURI="http://www.indiaglobalcap.com/role/CLAIMSANDADVANCES"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_LEASES" roleURI="http://www.indiaglobalcap.com/role/LEASES"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ACCRUEDLIABILITIESANDOTHERS" roleURI="http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERS"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_LOANSANDOTHERLIABILITIES" roleURI="http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIES"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_COMMITMENTSANDCONTINGENCIES" roleURI="http://www.indiaglobalcap.com/role/COMMITMENTSANDCONTINGENCIES"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_SECURITIES" roleURI="http://www.indiaglobalcap.com/role/SECURITIES"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_STOCKBASEDCOMPENSATION" roleURI="http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATION"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_FAIRVALUEOFFINANCIALINSTRUMENTS" roleURI="http://www.indiaglobalcap.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_INCOMETAXES" roleURI="http://www.indiaglobalcap.com/role/INCOMETAXES"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_REVENUERECOGNITION" roleURI="http://www.indiaglobalcap.com/role/REVENUERECOGNITION"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_SEGMENTINFORMATION" roleURI="http://www.indiaglobalcap.com/role/SEGMENTINFORMATION"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_SUBSEQUENTEVENTS" roleURI="http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTS"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_AccountingPoliciesByPolicy" roleURI="http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_INVENTORYTables" roleURI="http://www.indiaglobalcap.com/role/INVENTORYTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_DEPOSITSANDADVANCESTables" roleURI="http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCESTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_INTANGIBLEASSETSTables" roleURI="http://www.indiaglobalcap.com/role/INTANGIBLEASSETSTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_PROPERTYPLANTANDEQUIPMENTTables" roleURI="http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_CLAIMSANDADVANCESTables" roleURI="http://www.indiaglobalcap.com/role/CLAIMSANDADVANCESTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_LEASESTables" roleURI="http://www.indiaglobalcap.com/role/LEASESTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ACCRUEDLIABILITIESANDOTHERSTables" roleURI="http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_LOANSANDOTHERLIABILITIESTables" roleURI="http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_STOCKBASEDCOMPENSATIONTables" roleURI="http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_FAIRVALUEOFFINANCIALINSTRUMENTSTables" roleURI="http://www.indiaglobalcap.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_INCOMETAXESTables" roleURI="http://www.indiaglobalcap.com/role/INCOMETAXESTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_REVENUERECOGNITIONTables" roleURI="http://www.indiaglobalcap.com/role/REVENUERECOGNITIONTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_SEGMENTINFORMATIONTables" roleURI="http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofInventoryCurrentTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofInventoryCurrentTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_DeferredCostsCapitalizedPrepaidandOtherAssetsDisclosureTable" roleURI="http://www.indiaglobalcap.com/role/DeferredCostsCapitalizedPrepaidandOtherAssetsDisclosureTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofIntangibleAssetsAndGoodwillTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_PropertyPlantandEquipmentTable" roleURI="http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofOtherAssetsNoncurrentTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofOtherAssetsNoncurrentTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_LeaseCostTable" roleURI="http://www.indiaglobalcap.com/role/LeaseCostTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_LesseeOperatingLeaseLiabilityMaturityTable" roleURI="http://www.indiaglobalcap.com/role/LesseeOperatingLeaseLiabilityMaturityTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofAccountsPayableandAccruedLiabilitiesTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofLoansandOtherLiabilitiesTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofLoansandOtherLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_NonvestedRestrictedStockSharesActivityTable" roleURI="http://www.indiaglobalcap.com/role/NonvestedRestrictedStockSharesActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_SharebasedPaymentArrangementOptionActivityTable" roleURI="http://www.indiaglobalcap.com/role/SharebasedPaymentArrangementOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofEffectiveIncomeTaxRateReconciliationTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofComponentsofIncomeTaxExpenseBenefitTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofComponentsofIncomeTaxExpenseBenefitTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_SummaryofOperatingLossCarryforwardsTable" roleURI="http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_DisaggregationofRevenueTable" roleURI="http://www.indiaglobalcap.com/role/DisaggregationofRevenueTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_RevenuefromExternalCustomersbyProductsandServicesTable" roleURI="http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyProductsandServicesTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_RevenuefromExternalCustomersbyGeographicAreasTable" roleURI="http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyGeographicAreasTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_SIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_INVENTORYDetails" roleURI="http://www.indiaglobalcap.com/role/INVENTORYDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_DEPOSITSANDADVANCESDetails" roleURI="http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCESDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_INTANGIBLEASSETSDetails" roleURI="http://www.indiaglobalcap.com/role/INTANGIBLEASSETSDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_PROPERTYPLANTANDEQUIPMENTDetails" roleURI="http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_LEASESDetails" roleURI="http://www.indiaglobalcap.com/role/LEASESDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ACCRUEDLIABILITIESANDOTHERSDetails" roleURI="http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_LOANSANDOTHERLIABILITIESDetails" roleURI="http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.indiaglobalcap.com/role/COMMITMENTSANDCONTINGENCIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_SECURITIESDetails" roleURI="http://www.indiaglobalcap.com/role/SECURITIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_STOCKBASEDCOMPENSATIONDetails" roleURI="http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_INCOMETAXESDetails" roleURI="http://www.indiaglobalcap.com/role/INCOMETAXESDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_SEGMENTINFORMATIONDetails" roleURI="http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_SUBSEQUENTEVENTSDetails" roleURI="http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_InventoryNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockValue" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStocksIncludingAdditionalPaidInCapital" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="26" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock" xlink:href="igc-20250331.xsd#igc_AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="igc_AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsForProceedsFromInvestments" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfDebt" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" order="27" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/NATUREOFOPERATIONS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/INVENTORY" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_DepositsAndAdvancesAbstract" xlink:href="igc-20250331.xsd#igc_DepositsAndAdvancesAbstract"/>
    <loc xlink:type="locator" xlink:label="igc_DepositsAndAdvancesTextBlock" xlink:href="igc-20250331.xsd#igc_DepositsAndAdvancesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_DepositsAndAdvancesAbstract" xlink:to="igc_DepositsAndAdvancesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/INTANGIBLEASSETS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENT" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/CLAIMSANDADVANCES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/LEASES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_AccruedLiabilitiesDisclosureAbstract" xlink:href="igc-20250331.xsd#igc_AccruedLiabilitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="igc_AccruedLiabilitiesDisclosureTextBlock" xlink:href="igc-20250331.xsd#igc_AccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_AccruedLiabilitiesDisclosureAbstract" xlink:to="igc_AccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_LoansAndOtherLiabilitiesAbstract" xlink:href="igc-20250331.xsd#igc_LoansAndOtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="igc_LoansAndOtherLiabilitiesTextBlock" xlink:href="igc-20250331.xsd#igc_LoansAndOtherLiabilitiesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_LoansAndOtherLiabilitiesAbstract" xlink:to="igc_LoansAndOtherLiabilitiesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/SECURITIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/INCOMETAXES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/REVENUERECOGNITION" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/SEGMENTINFORMATION" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_GoingConcernPolicyPolicyTextblock" xlink:href="igc-20250331.xsd#igc_GoingConcernPolicyPolicyTextblock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="igc_GoingConcernPolicyPolicyTextblock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_CybersecurityPolicyPolicyTextBlock" xlink:href="igc-20250331.xsd#igc_CybersecurityPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="igc_CybersecurityPolicyPolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="22" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/INVENTORYTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_DepositsAndAdvancesAbstract" xlink:href="igc-20250331.xsd#igc_DepositsAndAdvancesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_DepositsAndAdvancesAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/INTANGIBLEASSETSTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_PROPERTYPLANTANDEQUIPMENTTablesLineItems" xlink:href="igc-20250331.xsd#igc_PROPERTYPLANTANDEQUIPMENTTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="igc_PROPERTYPLANTANDEQUIPMENTTablesTable" xlink:href="igc-20250331.xsd#igc_PROPERTYPLANTANDEQUIPMENTTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="igc_PROPERTYPLANTANDEQUIPMENTTablesLineItems" xlink:to="igc_PROPERTYPLANTANDEQUIPMENTTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_PropertyPlantAndEquipmentTableTypeAxis" xlink:href="igc-20250331.xsd#igc_PropertyPlantAndEquipmentTableTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_PROPERTYPLANTANDEQUIPMENTTablesTable" xlink:to="igc_PropertyPlantAndEquipmentTableTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_PropertyPlantAndEquipmentTableTypeDomainDomain" xlink:href="igc-20250331.xsd#igc_PropertyPlantAndEquipmentTableTypeDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="igc_PropertyPlantAndEquipmentTableTypeAxis" xlink:to="igc_PropertyPlantAndEquipmentTableTypeDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_PropertyPlantAndEquipmentTableTypeDomainDomain_0" xlink:href="igc-20250331.xsd#igc_PropertyPlantAndEquipmentTableTypeDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="igc_PropertyPlantAndEquipmentTableTypeAxis" xlink:to="igc_PropertyPlantAndEquipmentTableTypeDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_PropertyPlantAndEquipmentTableMember" xlink:href="igc-20250331.xsd#igc_PropertyPlantAndEquipmentTableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_PropertyPlantAndEquipmentTableTypeDomainDomain" xlink:to="igc_PropertyPlantAndEquipmentTableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_PROPERTYPLANTANDEQUIPMENTTablesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/CLAIMSANDADVANCESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/LEASESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_AccruedLiabilitiesDisclosureAbstract" xlink:href="igc-20250331.xsd#igc_AccruedLiabilitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_AccruedLiabilitiesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_LoansAndOtherLiabilitiesAbstract" xlink:href="igc-20250331.xsd#igc_LoansAndOtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_LoansAndOtherLiabilitiesAbstract" xlink:to="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/INCOMETAXESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/REVENUERECOGNITIONTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofInventoryCurrentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_ScheduleOfInventoryCurrentAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfInventoryCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfInventoryCurrentAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfInventoryCurrentAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfInventoryCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/DeferredCostsCapitalizedPrepaidandOtherAssetsDisclosureTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherInventoryNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherInventoryNetOfReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherInventoryNetOfReserves" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems" xlink:href="igc-20250331.xsd#igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsTable" xlink:href="igc-20250331.xsd#igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems" xlink:to="igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_OtherIntangibleAssetsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofOtherAssetsNoncurrentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_ScheduleOfOtherAssetsNoncurrentAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfOtherAssetsNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfOtherAssetsNoncurrentAbstract" xlink:to="us-gaap_OtherReceivables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_OtherAdvances" xlink:href="igc-20250331.xsd#igc_OtherAdvances"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfOtherAssetsNoncurrentAbstract" xlink:to="igc_OtherAdvances" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfOtherAssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/LeaseCostTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/LesseeOperatingLeaseLiabilityMaturityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_LesseeOperatingLeaseLiabilityMaturityAbstract" xlink:href="igc-20250331.xsd#igc_LesseeOperatingLeaseLiabilityMaturityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_LesseeOperatingLeaseLiabilityMaturityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_LesseeOperatingLeaseLiabilityMaturityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_LesseeOperatingLeaseLiabilityMaturityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_LesseeOperatingLeaseLiabilityMaturityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_LesseeOperatingLeaseLiabilityMaturityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_LesseeOperatingLeaseLiabilityMaturityAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLAKD9Z7zGpK2qQstFsfCu8xSrtW9H2+v0Xv0rh9+KH/Pz8D0bXTVzCQTQCC6nPug5x2WprRNZyO0vKrGf3yPx7zySn86Xz+cpPHpOaLInCIyy5s5q8xj2k941QApP+Uc6E50B2zYbnR/55u68AGKs/8SiUy11i4tM/dKp4JuQDXDaZK3azYQ8+FvMTMkrrL0geMSLbxuaBiHnfKiwOz7ObQpA4fLVubjQ/8=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofLoansandOtherLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_ScheduleOfLoansAndOtherLiabilitiesAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfLoansAndOtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfLoansAndOtherLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfLoansAndOtherLiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/NonvestedRestrictedStockSharesActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_NonvestedRestrictedStockSharesActivityAbstract" xlink:href="igc-20250331.xsd#igc_NonvestedRestrictedStockSharesActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_NonvestedRestrictedStockSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_NonvestedRestrictedStockSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_NonvestedRestrictedStockSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_NonvestedRestrictedStockSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_NonvestedRestrictedStockSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_NonvestedRestrictedStockSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_NonvestedRestrictedStockSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_NonvestedRestrictedStockSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/SharebasedPaymentArrangementOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_ShareBasedPaymentArrangementOptionActivityAbstract" xlink:href="igc-20250331.xsd#igc_ShareBasedPaymentArrangementOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:href="igc-20250331.xsd#igc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="igc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsLineItems" xlink:href="igc-20250331.xsd#igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsTable" xlink:href="igc-20250331.xsd#igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsLineItems" xlink:to="igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_DebtFundsMember" xlink:href="igc-20250331.xsd#igc_DebtFundsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="igc_DebtFundsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MutualFundMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MutualFundMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MutualFundMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsLineItems" xlink:to="us-gaap_AssetsFairValueAdjustment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsLineItems" xlink:to="us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsForeign" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofComponentsofIncomeTaxExpenseBenefitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2029Member" xlink:href="igc-20250331.xsd#igc_Expiring2029Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="igc_Expiring2029Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2030Member" xlink:href="igc-20250331.xsd#igc_Expiring2030Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="igc_Expiring2030Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2031Member" xlink:href="igc-20250331.xsd#igc_Expiring2031Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="igc_Expiring2031Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2032Member" xlink:href="igc-20250331.xsd#igc_Expiring2032Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="igc_Expiring2032Member" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2033Member" xlink:href="igc-20250331.xsd#igc_Expiring2033Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="igc_Expiring2033Member" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2034Member" xlink:href="igc-20250331.xsd#igc_Expiring2034Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="igc_Expiring2034Member" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2035Member" xlink:href="igc-20250331.xsd#igc_Expiring2035Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="igc_Expiring2035Member" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2036Member" xlink:href="igc-20250331.xsd#igc_Expiring2036Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="igc_Expiring2036Member" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2037Member" xlink:href="igc-20250331.xsd#igc_Expiring2037Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="igc_Expiring2037Member" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2038Member" xlink:href="igc-20250331.xsd#igc_Expiring2038Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="igc_Expiring2038Member" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2039Member" xlink:href="igc-20250331.xsd#igc_Expiring2039Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="igc_Expiring2039Member" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2040Member" xlink:href="igc-20250331.xsd#igc_Expiring2040Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="igc_Expiring2040Member" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2041Member" xlink:href="igc-20250331.xsd#igc_Expiring2041Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="igc_Expiring2041Member" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2042Member" xlink:href="igc-20250331.xsd#igc_Expiring2042Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="igc_Expiring2042Member" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2043Member" xlink:href="igc-20250331.xsd#igc_Expiring2043Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="igc_Expiring2043Member" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2044Member" xlink:href="igc-20250331.xsd#igc_Expiring2044Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="igc_Expiring2044Member" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2045Member" xlink:href="igc-20250331.xsd#igc_Expiring2045Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="igc_Expiring2045Member" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/DisaggregationofRevenueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_WellnessAndLifestyleMember" xlink:href="igc-20250331.xsd#igc_WellnessAndLifestyleMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="igc_WellnessAndLifestyleMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_TollingWhiteLabelingServiceMember" xlink:href="igc-20250331.xsd#igc_TollingWhiteLabelingServiceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="igc_TollingWhiteLabelingServiceMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_OtherRevenueMember" xlink:href="igc-20250331.xsd#igc_OtherRevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="igc_OtherRevenueMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyProductsandServicesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="srt_ProductOrServiceAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_PlantAndCannabinoidMember" xlink:href="igc-20250331.xsd#igc_PlantAndCannabinoidMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="igc_PlantAndCannabinoidMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyGeographicAreasTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems" xlink:href="igc-20250331.xsd#igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsTable" xlink:href="igc-20250331.xsd#igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems" xlink:to="igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_IN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_IN"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_IN" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_CO" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CO"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CO" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_TotalRevenuePercentage" xlink:href="igc-20250331.xsd#igc_TotalRevenuePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems" xlink:to="igc_TotalRevenuePercentage" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeographicDistributionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_GeographicDistributionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeographicDistributionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeographicDistributionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeographicDistributionDomesticMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionDomesticMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionDomesticMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeographicDistributionForeignMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionForeignMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionForeignMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:href="igc-20250331.xsd#igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:href="igc-20250331.xsd#igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_TaxPeriodAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="srt_RangeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesInventoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_PublicUtilitiesInventoryAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_ClinicalTrialInventoryMember" xlink:href="igc-20250331.xsd#igc_ClinicalTrialInventoryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="igc_ClinicalTrialInventoryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_SharePurchaseAgreementMember" xlink:href="igc-20250331.xsd#igc_SharePurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="igc_SharePurchaseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_InvestorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_FiscalYear2026Member" xlink:href="igc-20250331.xsd#igc_FiscalYear2026Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="igc_FiscalYear2026Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_SharePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_RestrictedCash" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_CapitalizedComputerSoftwareGross" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_InventoryNet" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/INVENTORYDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_INVENTORYDetailsLineItems" xlink:href="igc-20250331.xsd#igc_INVENTORYDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="igc_INVENTORYDetailsTable" xlink:href="igc-20250331.xsd#igc_INVENTORYDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="igc_INVENTORYDetailsLineItems" xlink:to="igc_INVENTORYDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesInventoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_INVENTORYDetailsTable" xlink:to="us-gaap_PublicUtilitiesInventoryAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_ClinicalTrialInventoryMember" xlink:href="igc-20250331.xsd#igc_ClinicalTrialInventoryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="igc_ClinicalTrialInventoryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_INVENTORYDetailsLineItems" xlink:to="us-gaap_InventoryWriteDown" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_INVENTORYDetailsLineItems" xlink:to="us-gaap_InventoryNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_DepositsAndAdvancesAbstract" xlink:href="igc-20250331.xsd#igc_DepositsAndAdvancesAbstract"/>
    <loc xlink:type="locator" xlink:label="igc_StatutoryAdvances" xlink:href="igc-20250331.xsd#igc_StatutoryAdvances"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_DepositsAndAdvancesAbstract" xlink:to="igc_StatutoryAdvances" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/INTANGIBLEASSETSDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_INTANGIBLEASSETSDetailsLineItems" xlink:href="igc-20250331.xsd#igc_INTANGIBLEASSETSDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="igc_INTANGIBLEASSETSDetailsTable" xlink:href="igc-20250331.xsd#igc_INTANGIBLEASSETSDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="igc_INTANGIBLEASSETSDetailsLineItems" xlink:to="igc_INTANGIBLEASSETSDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_INTANGIBLEASSETSDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_INTANGIBLEASSETSDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_PROPERTYPLANTANDEQUIPMENTDetailsLineItems" xlink:href="igc-20250331.xsd#igc_PROPERTYPLANTANDEQUIPMENTDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="igc_PROPERTYPLANTANDEQUIPMENTDetailsTable" xlink:href="igc-20250331.xsd#igc_PROPERTYPLANTANDEQUIPMENTDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="igc_PROPERTYPLANTANDEQUIPMENTDetailsLineItems" xlink:to="igc_PROPERTYPLANTANDEQUIPMENTDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_PROPERTYPLANTANDEQUIPMENTDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_PROPERTYPLANTANDEQUIPMENTDetailsLineItems" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_PROPERTYPLANTANDEQUIPMENTDetailsLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandAvailableForSale" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandAvailableForSale"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_PROPERTYPLANTANDEQUIPMENTDetailsLineItems" xlink:to="us-gaap_LandAvailableForSale" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Land"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_PROPERTYPLANTANDEQUIPMENTDetailsLineItems" xlink:to="us-gaap_Land" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDepositsOnRealEstateSales" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDepositsOnRealEstateSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_PROPERTYPLANTANDEQUIPMENTDetailsLineItems" xlink:to="us-gaap_ProceedsFromDepositsOnRealEstateSales" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/LEASESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_ACCRUEDLIABILITIESANDOTHERSDetailsLineItems" xlink:href="igc-20250331.xsd#igc_ACCRUEDLIABILITIESANDOTHERSDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="igc_ACCRUEDLIABILITIESANDOTHERSDetailsTable" xlink:href="igc-20250331.xsd#igc_ACCRUEDLIABILITIESANDOTHERSDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="igc_ACCRUEDLIABILITIESANDOTHERSDetailsLineItems" xlink:to="igc_ACCRUEDLIABILITIESANDOTHERSDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_ACCRUEDLIABILITIESANDOTHERSDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ACCRUEDLIABILITIESANDOTHERSDetailsLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ACCRUEDLIABILITIESANDOTHERSDetailsLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDepositsOnRealEstateSales" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDepositsOnRealEstateSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_ACCRUEDLIABILITIESANDOTHERSDetailsLineItems" xlink:to="us-gaap_ProceedsFromDepositsOnRealEstateSales" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_LoansAndOtherLiabilitiesAbstract" xlink:href="igc-20250331.xsd#igc_LoansAndOtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_LoansAndOtherLiabilitiesAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_LoansAndOtherLiabilitiesAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_LoansAndOtherLiabilitiesAbstract" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_LoansAndOtherLiabilitiesAbstract" xlink:to="us-gaap_DebtInstrumentTerm" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_LoansAndOtherLiabilitiesAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_LoansAndOtherLiabilitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebt" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermLoansPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_LoansAndOtherLiabilitiesAbstract" xlink:to="us-gaap_LongTermLoansPayable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_LoansAndOtherLiabilitiesAbstract" xlink:to="us-gaap_LoansPayableCurrent" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/SECURITIESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_SECURITIESDetailsLineItems" xlink:href="igc-20250331.xsd#igc_SECURITIESDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="igc_SECURITIESDetailsTable" xlink:href="igc-20250331.xsd#igc_SECURITIESDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="igc_SECURITIESDetailsLineItems" xlink:to="igc_SECURITIESDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_SECURITIESDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_SECURITIESDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_SECURITIESDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_InvestorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_March2024SPAMember" xlink:href="igc-20250331.xsd#igc_March2024SPAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="igc_March2024SPAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_September2024SPAMember" xlink:href="igc-20250331.xsd#igc_September2024SPAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="igc_September2024SPAMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_SalesAgreementMember" xlink:href="igc-20250331.xsd#igc_SalesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="igc_SalesAgreementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_SharePurchaseAgreementsMember" xlink:href="igc-20250331.xsd#igc_SharePurchaseAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="igc_SharePurchaseAgreementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SECURITIESDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SECURITIESDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SECURITIESDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SECURITIESDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SECURITIESDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SECURITIESDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SECURITIESDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SECURITIESDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_UnitsOutstanding" xlink:href="igc-20250331.xsd#igc_UnitsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SECURITIESDetailsLineItems" xlink:to="igc_UnitsOutstanding" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_UnitDescription" xlink:href="igc-20250331.xsd#igc_UnitDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SECURITIESDetailsLineItems" xlink:to="igc_UnitDescription" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SECURITIESDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SECURITIESDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SECURITIESDetailsLineItems" xlink:to="us-gaap_SharePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SECURITIESDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SECURITIESDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_SalesAgreementMaximum" xlink:href="igc-20250331.xsd#igc_SalesAgreementMaximum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SECURITIESDetailsLineItems" xlink:to="igc_SalesAgreementMaximum" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SECURITIESDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:href="igc-20250331.xsd#igc_STOCKBASEDCOMPENSATIONDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="igc_STOCKBASEDCOMPENSATIONDetailsTable" xlink:href="igc-20250331.xsd#igc_STOCKBASEDCOMPENSATIONDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="igc_STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="igc_STOCKBASEDCOMPENSATIONDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_STOCKBASEDCOMPENSATIONDetailsTable" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_STOCKBASEDCOMPENSATIONDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_STOCKBASEDCOMPENSATIONDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_ESOP2008OmnibusPlanMember" xlink:href="igc-20250331.xsd#igc_ESOP2008OmnibusPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="igc_ESOP2008OmnibusPlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_WeightedAveragePricePerShare" xlink:href="igc-20250331.xsd#igc_WeightedAveragePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="igc_WeightedAveragePricePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/INCOMETAXESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_SEGMENTINFORMATIONDetailsLineItems" xlink:href="igc-20250331.xsd#igc_SEGMENTINFORMATIONDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="igc_SEGMENTINFORMATIONDetailsTable" xlink:href="igc-20250331.xsd#igc_SEGMENTINFORMATIONDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="igc_SEGMENTINFORMATIONDetailsLineItems" xlink:to="igc_SEGMENTINFORMATIONDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_SEGMENTINFORMATIONDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_InfrastructureSegmentMember" xlink:href="igc-20250331.xsd#igc_InfrastructureSegmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="igc_InfrastructureSegmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SEGMENTINFORMATIONDetailsLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SEGMENTINFORMATIONDetailsLineItems" xlink:to="us-gaap_Revenues" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="igc_SUBSEQUENTEVENTSDetailsLineItems" xlink:href="igc-20250331.xsd#igc_SUBSEQUENTEVENTSDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="igc_SUBSEQUENTEVENTSDetailsTable" xlink:href="igc-20250331.xsd#igc_SUBSEQUENTEVENTSDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="igc_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="igc_SUBSEQUENTEVENTSDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_SUBSEQUENTEVENTSDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="igc_SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_InvestorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="igc_SharePurchaseAgreementMember" xlink:href="igc-20250331.xsd#igc_SharePurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="igc_SharePurchaseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_SharePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCollateralFeesAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCollateralFeesAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityCollateralFeesAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="igc_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>28
<FILENAME>igc-20250331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Jun 27 19:48:35 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl1" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Deposits and advances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0" xml:lang="en-US">Total intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Net Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Claims and advances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Total non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities and others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating lease liability (non-current portion &#8211; operating lease liability)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies &#8211; See Note 12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStocksIncludingAdditionalPaidInCapital_lbl" xml:lang="en-US">Common stock and additional paid-in capital, $0.0001 par value: 150,000,000 shares authorized; 80,878,058 and 66,691,195 shares issued and outstanding as of March 31, 2025, and March 31, 2024, respectively.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:to="us-gaap_CommonStocksIncludingAdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Net Income Loss before tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss attributable to common stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted-average number of shares used in computing loss per share amounts: (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Common stock-based compensation and expenses, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivables, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Deposits and advances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Claims and advances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property, plant, and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Acquisition and development of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from the issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt_lbl" xml:lang="en-US">Repayment of long-term loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effects of exchange rate changes on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at the beginning of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents at the end of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_lbl" xml:lang="en-US">Common stock issued/granted for stock-based compensation, including patent acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:to="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expense and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total amortized intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_PropertyPlantAndEquipmentTableTypeAxis" xlink:href="igc-20250331.xsd#igc_PropertyPlantAndEquipmentTableTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_PropertyPlantAndEquipmentTableTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Table Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PropertyPlantAndEquipmentTableTypeAxis" xlink:to="igc_PropertyPlantAndEquipmentTableTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, plant and equipment, useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, plant and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Total lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Compensation and other contributions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Provision for expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Balance, non-vested shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Balance, non-vested shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Balance, Weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Balance, Weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding, shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Options outstanding, shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Options outstanding, Weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Options outstanding, Weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options outstanding, Weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Options outstanding, Weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Net deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeographicDistributionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeographicDistributionAxis_lbl" xml:lang="en-US">Geographic Distribution [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl" xml:lang="en-US">Asset held for sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl0" xml:lang="en-US">Asset, Held-for-Sale, Not Part of Disposal Group, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Non-current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Total lease assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long-term loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.0001 par value: authorized 1,000,000 shares, no shares issued or outstanding as of March 31, 2025, or March 31, 2024.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, authorized shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense/benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Effective income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net loss per share attributable to common stockholders:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted-average number of shares used in computing loss per share amounts: (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Common stock-based compensation &amp; expenses, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Common stock-based compensation &amp; expenses, net (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock through offering (net of expenses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Value, New Issues (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock through offering (net of expenses) (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Share money received but not allotted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xml:lang="en-US">Cancellation/forfeiture of shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock" xlink:href="igc-20250331.xsd#igc_AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock_lbl" xml:lang="en-US">Common stock subscribed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock" xlink:to="igc_AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Other adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustment to reconcile net loss to net cash:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for bad debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment of assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl0" xml:lang="en-US">Asset Impairment Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flow from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Sale of property, plant, and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from common stock subscribed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0" xml:lang="en-US">Proceeds from Issuance of Private Placement (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplementary information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_NonCashItemsAbstract" xlink:href="igc-20250331.xsd#igc_NonCashItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_NonCashItemsAbstract_lbl" xml:lang="en-US">Non-cash items:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_NonCashItemsAbstract" xlink:to="igc_NonCashItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US">Impairment loss on PPE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Profit/Loss on sale of fixed assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Operating lease asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_lbl" xml:lang="en-US">Proceeds from short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Common Stock Including Additional Paid in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:to="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_DepositsAndAdvancesTextBlock" xlink:href="igc-20250331.xsd#igc_DepositsAndAdvancesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_DepositsAndAdvancesTextBlock_lbl" xml:lang="en-US">Deposits and Advances [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_DepositsAndAdvancesTextBlock" xlink:to="igc_DepositsAndAdvancesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Advances to suppliers and consultants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherInventoryNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherInventoryNetOfReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherInventoryNetOfReserves_lbl" xml:lang="en-US">Other receivables and deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInventoryNetOfReserves" xlink:to="us-gaap_OtherInventoryNetOfReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Intangibles</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_UnamortizedIntangibleAssetsAbstract" xlink:href="igc-20250331.xsd#igc_UnamortizedIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_UnamortizedIntangibleAssetsAbstract_lbl" xml:lang="en-US">Unamortized intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_UnamortizedIntangibleAssetsAbstract" xlink:to="igc_UnamortizedIntangibleAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Unamortized intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">For the year ended 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">For the year ended 2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">For the year ended 2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">For the year ended 2029</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">For the year ended 2030</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Other Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xml:lang="en-US">Schedule of Other Assets, Noncurrent [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Claims receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_OtherAdvances" xlink:href="igc-20250331.xsd#igc_OtherAdvances"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_OtherAdvances_lbl" xml:lang="en-US">Non-current deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_OtherAdvances" xlink:to="igc_OtherAdvances_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short term lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermLeaseCost_lbl0" xml:lang="en-US">Short-Term Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Accrued liabilities and others (current portion &#8211; operating lease liability)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_NoncurrentLiabilitiesAbstract" xlink:href="igc-20250331.xsd#igc_NoncurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Noncurrent liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_NoncurrentLiabilitiesAbstract" xlink:to="igc_NoncurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="igc-20250331.xsd#igc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="igc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">&#8211;Operating cash flows from operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Mar-26</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Mar-27</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Mar-28</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Mar-29</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Present value discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_AccruedLiabilitiesDisclosureTextBlock" xlink:href="igc-20250331.xsd#igc_AccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_AccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_AccruedLiabilitiesDisclosureTextBlock" xlink:to="igc_AccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Short-term lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_LoansAndOtherLiabilitiesTextBlock" xlink:href="igc-20250331.xsd#igc_LoansAndOtherLiabilitiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_LoansAndOtherLiabilitiesTextBlock_lbl" xml:lang="en-US">Loans and Other Liabilities [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_LoansAndOtherLiabilitiesTextBlock" xlink:to="igc_LoansAndOtherLiabilitiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Assets and Other Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Statutory reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Vested options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Granted, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted, Weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Vested, Weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Cancelled/Forfeited, Weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted, shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted, Weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted, Weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Vested, Weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:href="igc-20250331.xsd#igc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Vested, Weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:to="igc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Cancelled/Forfeited, Weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Cancelled/Forfeited, Weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_Level1Abstract" xlink:href="igc-20250331.xsd#igc_Level1Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_Level1Abstract_lbl" xml:lang="en-US">Level 1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Level1Abstract" xlink:to="igc_Level1Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueAdjustment_lbl" xml:lang="en-US">Adjusted Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueAdjustment" xlink:to="us-gaap_AssetsFairValueAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_lbl" xml:lang="en-US">Gain</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" xlink:to="us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings_lbl" xml:lang="en-US">Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US">Cash &amp; Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US">Short Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_Level2Abstract" xlink:href="igc-20250331.xsd#igc_Level2Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_Level2Abstract_lbl" xml:lang="en-US">Level 2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Level2Abstract" xlink:to="igc_Level2Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_Level1Abstract0" xlink:href="igc-20250331.xsd#igc_Level1Abstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_Level1Abstract0_lbl" xml:lang="en-US">Level 1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Level1Abstract0" xlink:to="igc_Level1Abstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_Level2Abstract0" xlink:href="igc-20250331.xsd#igc_Level2Abstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_Level2Abstract0_lbl" xml:lang="en-US">Level 2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Level2Abstract0" xlink:to="igc_Level2Abstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Expected income tax recovery</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Tax rate changes and other adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Permanent differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_lbl" xml:lang="en-US">Net operating loss carry-forwards foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xml:lang="en-US">Non-capital loss carry-forwards &#8211; USA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Temporary differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_TotalRevenuePercentage" xlink:href="igc-20250331.xsd#igc_TotalRevenuePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_TotalRevenuePercentage_lbl" xml:lang="en-US">Total Revenue Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_TotalRevenuePercentage" xlink:to="igc_TotalRevenuePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Cancelled/Forfeited, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Vested, shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Cancelled/Forfeited, shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsForeign_lbl" xml:lang="en-US">Impact of tax rate differences in foreign jurisdictions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsForeign_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIntangibleAssetsMember_lbl" xml:lang="en-US">Other Intangible Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsMember" xlink:to="us-gaap_OtherIntangibleAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xml:lang="en-US">Software Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_PropertyPlantAndEquipmentTableMember" xlink:href="igc-20250331.xsd#igc_PropertyPlantAndEquipmentTableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_PropertyPlantAndEquipmentTableMember_lbl" xml:lang="en-US">Property Plant and Equipment Table [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PropertyPlantAndEquipmentTableMember" xlink:to="igc_PropertyPlantAndEquipmentTableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_lbl" xml:lang="en-US">Building and Building Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US">Vehicles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and Cash Equivalents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money Market Funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_DebtFundsMember" xlink:href="igc-20250331.xsd#igc_DebtFundsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_DebtFundsMember_lbl" xml:lang="en-US">Debt Funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_DebtFundsMember" xlink:to="igc_DebtFundsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MutualFundMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MutualFundMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MutualFundMember_lbl" xml:lang="en-US">Mutual Fund [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MutualFundMember" xlink:to="us-gaap_MutualFundMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xml:lang="en-US">Certificates of Deposit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2029Member" xlink:href="igc-20250331.xsd#igc_Expiring2029Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_Expiring2029Member_lbl" xml:lang="en-US">Expiring 2029 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2029Member" xlink:to="igc_Expiring2029Member_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2030Member" xlink:href="igc-20250331.xsd#igc_Expiring2030Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_Expiring2030Member_lbl" xml:lang="en-US">Expiring 2030 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2030Member" xlink:to="igc_Expiring2030Member_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2031Member" xlink:href="igc-20250331.xsd#igc_Expiring2031Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_Expiring2031Member_lbl" xml:lang="en-US">Expiring 2031 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2031Member" xlink:to="igc_Expiring2031Member_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2032Member" xlink:href="igc-20250331.xsd#igc_Expiring2032Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_Expiring2032Member_lbl" xml:lang="en-US">Expiring 2032 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2032Member" xlink:to="igc_Expiring2032Member_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2033Member" xlink:href="igc-20250331.xsd#igc_Expiring2033Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_Expiring2033Member_lbl" xml:lang="en-US">Expiring 2033 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2033Member" xlink:to="igc_Expiring2033Member_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2034Member" xlink:href="igc-20250331.xsd#igc_Expiring2034Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_Expiring2034Member_lbl" xml:lang="en-US">Expiring 2034 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2034Member" xlink:to="igc_Expiring2034Member_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2035Member" xlink:href="igc-20250331.xsd#igc_Expiring2035Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_Expiring2035Member_lbl" xml:lang="en-US">Expiring 2035 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2035Member" xlink:to="igc_Expiring2035Member_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2036Member" xlink:href="igc-20250331.xsd#igc_Expiring2036Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_Expiring2036Member_lbl" xml:lang="en-US">Expiring 2036 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2036Member" xlink:to="igc_Expiring2036Member_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2037Member" xlink:href="igc-20250331.xsd#igc_Expiring2037Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_Expiring2037Member_lbl" xml:lang="en-US">Expiring 2037 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2037Member" xlink:to="igc_Expiring2037Member_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2038Member" xlink:href="igc-20250331.xsd#igc_Expiring2038Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_Expiring2038Member_lbl" xml:lang="en-US">Expiring 2038 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2038Member" xlink:to="igc_Expiring2038Member_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2039Member" xlink:href="igc-20250331.xsd#igc_Expiring2039Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_Expiring2039Member_lbl" xml:lang="en-US">Expiring 2039 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2039Member" xlink:to="igc_Expiring2039Member_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2040Member" xlink:href="igc-20250331.xsd#igc_Expiring2040Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_Expiring2040Member_lbl" xml:lang="en-US">Expiring 2040 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2040Member" xlink:to="igc_Expiring2040Member_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2041Member" xlink:href="igc-20250331.xsd#igc_Expiring2041Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_Expiring2041Member_lbl" xml:lang="en-US">Expiring 2041 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2041Member" xlink:to="igc_Expiring2041Member_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2042Member" xlink:href="igc-20250331.xsd#igc_Expiring2042Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_Expiring2042Member_lbl" xml:lang="en-US">Expiring 2042 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2042Member" xlink:to="igc_Expiring2042Member_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2043Member" xlink:href="igc-20250331.xsd#igc_Expiring2043Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_Expiring2043Member_lbl" xml:lang="en-US">Expiring 2043 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2043Member" xlink:to="igc_Expiring2043Member_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2044Member" xlink:href="igc-20250331.xsd#igc_Expiring2044Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_Expiring2044Member_lbl" xml:lang="en-US">Expiring 2044 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2044Member" xlink:to="igc_Expiring2044Member_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_Expiring2045Member" xlink:href="igc-20250331.xsd#igc_Expiring2045Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_Expiring2045Member_lbl" xml:lang="en-US">Expiring 2045 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2045Member" xlink:to="igc_Expiring2045Member_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_WellnessAndLifestyleMember" xlink:href="igc-20250331.xsd#igc_WellnessAndLifestyleMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_WellnessAndLifestyleMember_lbl" xml:lang="en-US">Wellness and Lifestyle [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_WellnessAndLifestyleMember" xlink:to="igc_WellnessAndLifestyleMember_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_TollingWhiteLabelingServiceMember" xlink:href="igc-20250331.xsd#igc_TollingWhiteLabelingServiceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_TollingWhiteLabelingServiceMember_lbl" xml:lang="en-US">Tolling/White labeling service [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_TollingWhiteLabelingServiceMember" xlink:to="igc_TollingWhiteLabelingServiceMember_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_OtherRevenueMember" xlink:href="igc-20250331.xsd#igc_OtherRevenueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_OtherRevenueMember_lbl" xml:lang="en-US">Other Revenue [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_OtherRevenueMember" xlink:to="igc_OtherRevenueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_PlantAndCannabinoidMember" xlink:href="igc-20250331.xsd#igc_PlantAndCannabinoidMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_PlantAndCannabinoidMember_lbl" xml:lang="en-US">Plant and Cannabinoid [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PlantAndCannabinoidMember" xlink:to="igc_PlantAndCannabinoidMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_IN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_IN"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_IN_lbl" xml:lang="en-US">INDIA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IN" xlink:to="country_IN_lbl"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:label="country_CO" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CO"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_CO_lbl" xml:lang="en-US">COLOMBIA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CO" xlink:to="country_CO_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeographicDistributionDomesticMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionDomesticMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeographicDistributionDomesticMember_lbl" xml:lang="en-US">Geographic Distribution, Domestic [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionDomesticMember" xlink:to="us-gaap_GeographicDistributionDomesticMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeographicDistributionForeignMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionForeignMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeographicDistributionForeignMember_lbl" xml:lang="en-US">Geographic Distribution, Foreign [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionForeignMember" xlink:to="us-gaap_GeographicDistributionForeignMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US">Tax Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesInventoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilitiesInventoryAxis_lbl" xml:lang="en-US">Inventory [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_lbl" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xml:lang="en-US">Capitalized Computer Software, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Inventory Write-down</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_StatutoryAdvances" xlink:href="igc-20250331.xsd#igc_StatutoryAdvances"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_StatutoryAdvances_lbl" xml:lang="en-US">Statutory Advances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_StatutoryAdvances" xlink:to="igc_StatutoryAdvances_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandAvailableForSale" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandAvailableForSale"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandAvailableForSale_lbl" xml:lang="en-US">Real Estate, Land, Held-for-Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandAvailableForSale" xlink:to="us-gaap_LandAvailableForSale_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Land"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Land_lbl" xml:lang="en-US">Land</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Land" xlink:to="us-gaap_Land_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDepositsOnRealEstateSales" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDepositsOnRealEstateSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDepositsOnRealEstateSales_lbl" xml:lang="en-US">Proceeds from Deposits on Real Estate Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDepositsOnRealEstateSales" xlink:to="us-gaap_ProceedsFromDepositsOnRealEstateSales_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Debt Instrument, Periodic Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt Instrument, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest Expense, Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayments of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermLoansPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US">Loans Payable, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansPayableCurrent_lbl" xml:lang="en-US">Loans Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_UnitsOutstanding" xlink:href="igc-20250331.xsd#igc_UnitsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_UnitsOutstanding_lbl" xml:lang="en-US">Units Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_UnitsOutstanding" xlink:to="igc_UnitsOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_UnitDescription" xlink:href="igc-20250331.xsd#igc_UnitDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_UnitDescription_lbl" xml:lang="en-US">Unit, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_UnitDescription" xlink:to="igc_UnitDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_SalesAgreementMaximum" xlink:href="igc-20250331.xsd#igc_SalesAgreementMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_SalesAgreementMaximum_lbl" xml:lang="en-US">Sales Agreement, Offering, Maximum (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_SalesAgreementMaximum" xlink:to="igc_SalesAgreementMaximum_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_lbl" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Number of Committed-to-be-Released Shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_WeightedAveragePricePerShare" xlink:href="igc-20250331.xsd#igc_WeightedAveragePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_WeightedAveragePricePerShare_lbl" xml:lang="en-US">Weighted Average Price per Share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_WeightedAveragePricePerShare" xlink:to="igc_WeightedAveragePricePerShare_lbl"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLAKD9Z7zGpK2qQstFsfCu8xSrtW9H2+v0Xv0rh9+KH/Pz8D0bXTVzCQTQCC6nPug5x2WprRNZyO0vKrGf3yPx7zySn86Xz+cpPHpOaLInCIyy5s5q8xj2k941QApP+Uc6E50B2zYbnR/55u68AGKs/8SiUy11i4tM/dKp4JuQDXDaZK3azYQ8+FvMTMkrrL0geMSLbxuaBiHnaAgrUqiHRVBXIh1zqucCAQ=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCollateralFeesAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCollateralFeesAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityCollateralFeesAmount_lbl" xml:lang="en-US">Line of Credit Facility, Collateral Fees, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCollateralFeesAmount" xlink:to="us-gaap_LineOfCreditFacilityCollateralFeesAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_GoingConcernPolicyPolicyTextblock" xlink:href="igc-20250331.xsd#igc_GoingConcernPolicyPolicyTextblock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_GoingConcernPolicyPolicyTextblock_lbl" xml:lang="en-US">Going Concern, Policy [Policy Textblock}</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_GoingConcernPolicyPolicyTextblock" xlink:to="igc_GoingConcernPolicyPolicyTextblock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_CybersecurityPolicyPolicyTextBlock" xlink:href="igc-20250331.xsd#igc_CybersecurityPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_CybersecurityPolicyPolicyTextBlock_lbl" xml:lang="en-US">Cyber-security Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_CybersecurityPolicyPolicyTextBlock" xlink:to="igc_CybersecurityPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_SharePurchaseAgreementMember" xlink:href="igc-20250331.xsd#igc_SharePurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_SharePurchaseAgreementMember_lbl" xml:lang="en-US">Share Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_SharePurchaseAgreementMember" xlink:to="igc_SharePurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_FiscalYear2026Member" xlink:href="igc-20250331.xsd#igc_FiscalYear2026Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_FiscalYear2026Member_lbl" xml:lang="en-US">Fiscal Year 2026 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_FiscalYear2026Member" xlink:to="igc_FiscalYear2026Member_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_ClinicalTrialInventoryMember" xlink:href="igc-20250331.xsd#igc_ClinicalTrialInventoryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_ClinicalTrialInventoryMember_lbl" xml:lang="en-US">Clinical Trial Inventory [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ClinicalTrialInventoryMember" xlink:to="igc_ClinicalTrialInventoryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US">Land [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_March2024SPAMember" xlink:href="igc-20250331.xsd#igc_March2024SPAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_March2024SPAMember_lbl" xml:lang="en-US">March 2024 SPA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_March2024SPAMember" xlink:to="igc_March2024SPAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_September2024SPAMember" xlink:href="igc-20250331.xsd#igc_September2024SPAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_September2024SPAMember_lbl" xml:lang="en-US">September 2024 SPA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_September2024SPAMember" xlink:to="igc_September2024SPAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_SalesAgreementMember" xlink:href="igc-20250331.xsd#igc_SalesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_SalesAgreementMember" xlink:to="igc_SalesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_SharePurchaseAgreementsMember" xlink:href="igc-20250331.xsd#igc_SharePurchaseAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_SharePurchaseAgreementsMember_lbl" xml:lang="en-US">2025 Share Purchase Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_SharePurchaseAgreementsMember" xlink:to="igc_SharePurchaseAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_ESOP2008OmnibusPlanMember" xlink:href="igc-20250331.xsd#igc_ESOP2008OmnibusPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_ESOP2008OmnibusPlanMember_lbl" xml:lang="en-US">ESOP 2008 Omnibus Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ESOP2008OmnibusPlanMember" xlink:to="igc_ESOP2008OmnibusPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_InfrastructureSegmentMember" xlink:href="igc-20250331.xsd#igc_InfrastructureSegmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="igc_InfrastructureSegmentMember_lbl" xml:lang="en-US">Infrastructure Segment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_InfrastructureSegmentMember" xlink:to="igc_InfrastructureSegmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_PropertyPlantAndEquipmentTableTypeDomainDomain" xlink:href="igc-20250331.xsd#igc_PropertyPlantAndEquipmentTableTypeDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_PropertyPlantAndEquipmentTableTypeDomainDomain_lbl" xml:lang="en-US">PropertyPlantAndEquipmentTableTypeDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PropertyPlantAndEquipmentTableTypeDomainDomain" xlink:to="igc_PropertyPlantAndEquipmentTableTypeDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_PROPERTYPLANTANDEQUIPMENTTablesTable" xlink:href="igc-20250331.xsd#igc_PROPERTYPLANTANDEQUIPMENTTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_PROPERTYPLANTANDEQUIPMENTTablesTable_lbl" xml:lang="en-US">PROPERTY, PLANT, AND EQUIPMENT (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PROPERTYPLANTANDEQUIPMENTTablesTable" xlink:to="igc_PROPERTYPLANTANDEQUIPMENTTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_PROPERTYPLANTANDEQUIPMENTTablesLineItems" xlink:href="igc-20250331.xsd#igc_PROPERTYPLANTANDEQUIPMENTTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_PROPERTYPLANTANDEQUIPMENTTablesLineItems_lbl" xml:lang="en-US">PROPERTY, PLANT, AND EQUIPMENT (Tables) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PROPERTYPLANTANDEQUIPMENTTablesLineItems" xlink:to="igc_PROPERTYPLANTANDEQUIPMENTTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsTable" xlink:href="igc-20250331.xsd#igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsTable_lbl" xml:lang="en-US">INTANGIBLE ASSETS - Schedule of Intangible Assets And Goodwill (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsTable" xlink:to="igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems" xlink:href="igc-20250331.xsd#igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems_lbl" xml:lang="en-US">INTANGIBLE ASSETS - Schedule of Intangible Assets And Goodwill (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems" xlink:to="igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsTable" xlink:href="igc-20250331.xsd#igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsTable_lbl" xml:lang="en-US">FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsTable" xlink:to="igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsLineItems" xlink:href="igc-20250331.xsd#igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsLineItems_lbl" xml:lang="en-US">FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsLineItems" xlink:to="igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_lbl" xml:lang="en-US">Segment Reporting, Revenue from External Customer, Product and Service [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_lbl" xml:lang="en-US">Revenue from External Customer [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsTable" xlink:href="igc-20250331.xsd#igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsTable_lbl" xml:lang="en-US">SEGMENT INFORMATION - Revenue from External Customers by Geographic Areas (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsTable" xlink:to="igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems" xlink:href="igc-20250331.xsd#igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems_lbl" xml:lang="en-US">SEGMENT INFORMATION - Revenue from External Customers by Geographic Areas (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems" xlink:to="igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeographicDistributionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeographicDistributionDomain_lbl" xml:lang="en-US">Geographic Distribution [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodDomain_lbl" xml:lang="en-US">Tax Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain_lbl" xml:lang="en-US">Inventory [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:href="igc-20250331.xsd#igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:href="igc-20250331.xsd#igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_INVENTORYDetailsTable" xlink:href="igc-20250331.xsd#igc_INVENTORYDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_INVENTORYDetailsTable_lbl" xml:lang="en-US">INVENTORY (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_INVENTORYDetailsTable" xlink:to="igc_INVENTORYDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_INVENTORYDetailsLineItems" xlink:href="igc-20250331.xsd#igc_INVENTORYDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_INVENTORYDetailsLineItems_lbl" xml:lang="en-US">INVENTORY (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_INVENTORYDetailsLineItems" xlink:to="igc_INVENTORYDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_INTANGIBLEASSETSDetailsTable" xlink:href="igc-20250331.xsd#igc_INTANGIBLEASSETSDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_INTANGIBLEASSETSDetailsTable_lbl" xml:lang="en-US">INTANGIBLE ASSETS (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_INTANGIBLEASSETSDetailsTable" xlink:to="igc_INTANGIBLEASSETSDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_INTANGIBLEASSETSDetailsLineItems" xlink:href="igc-20250331.xsd#igc_INTANGIBLEASSETSDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_INTANGIBLEASSETSDetailsLineItems_lbl" xml:lang="en-US">INTANGIBLE ASSETS (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_INTANGIBLEASSETSDetailsLineItems" xlink:to="igc_INTANGIBLEASSETSDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_PROPERTYPLANTANDEQUIPMENTDetailsTable" xlink:href="igc-20250331.xsd#igc_PROPERTYPLANTANDEQUIPMENTDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_PROPERTYPLANTANDEQUIPMENTDetailsTable_lbl" xml:lang="en-US">PROPERTY, PLANT, AND EQUIPMENT (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PROPERTYPLANTANDEQUIPMENTDetailsTable" xlink:to="igc_PROPERTYPLANTANDEQUIPMENTDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_PROPERTYPLANTANDEQUIPMENTDetailsLineItems" xlink:href="igc-20250331.xsd#igc_PROPERTYPLANTANDEQUIPMENTDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_PROPERTYPLANTANDEQUIPMENTDetailsLineItems_lbl" xml:lang="en-US">PROPERTY, PLANT, AND EQUIPMENT (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PROPERTYPLANTANDEQUIPMENTDetailsLineItems" xlink:to="igc_PROPERTYPLANTANDEQUIPMENTDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_ACCRUEDLIABILITIESANDOTHERSDetailsTable" xlink:href="igc-20250331.xsd#igc_ACCRUEDLIABILITIESANDOTHERSDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_ACCRUEDLIABILITIESANDOTHERSDetailsTable_lbl" xml:lang="en-US">ACCRUED LIABILITIES AND OTHERS (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ACCRUEDLIABILITIESANDOTHERSDetailsTable" xlink:to="igc_ACCRUEDLIABILITIESANDOTHERSDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_ACCRUEDLIABILITIESANDOTHERSDetailsLineItems" xlink:href="igc-20250331.xsd#igc_ACCRUEDLIABILITIESANDOTHERSDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_ACCRUEDLIABILITIESANDOTHERSDetailsLineItems_lbl" xml:lang="en-US">ACCRUED LIABILITIES AND OTHERS (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ACCRUEDLIABILITIESANDOTHERSDetailsLineItems" xlink:to="igc_ACCRUEDLIABILITIESANDOTHERSDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_SECURITIESDetailsTable" xlink:href="igc-20250331.xsd#igc_SECURITIESDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_SECURITIESDetailsTable_lbl" xml:lang="en-US">SECURITIES (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_SECURITIESDetailsTable" xlink:to="igc_SECURITIESDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_SECURITIESDetailsLineItems" xlink:href="igc-20250331.xsd#igc_SECURITIESDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_SECURITIESDetailsLineItems_lbl" xml:lang="en-US">SECURITIES (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_SECURITIESDetailsLineItems" xlink:to="igc_SECURITIESDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_lbl" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Plan [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Statement of Income Location, Balance [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_STOCKBASEDCOMPENSATIONDetailsTable" xlink:href="igc-20250331.xsd#igc_STOCKBASEDCOMPENSATIONDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_STOCKBASEDCOMPENSATIONDetailsTable_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_STOCKBASEDCOMPENSATIONDetailsTable" xlink:to="igc_STOCKBASEDCOMPENSATIONDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:href="igc-20250331.xsd#igc_STOCKBASEDCOMPENSATIONDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_STOCKBASEDCOMPENSATIONDetailsLineItems_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="igc_STOCKBASEDCOMPENSATIONDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_SEGMENTINFORMATIONDetailsTable" xlink:href="igc-20250331.xsd#igc_SEGMENTINFORMATIONDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_SEGMENTINFORMATIONDetailsTable_lbl" xml:lang="en-US">SEGMENT INFORMATION (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_SEGMENTINFORMATIONDetailsTable" xlink:to="igc_SEGMENTINFORMATIONDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_SEGMENTINFORMATIONDetailsLineItems" xlink:href="igc-20250331.xsd#igc_SEGMENTINFORMATIONDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_SEGMENTINFORMATIONDetailsLineItems_lbl" xml:lang="en-US">SEGMENT INFORMATION (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_SEGMENTINFORMATIONDetailsLineItems" xlink:to="igc_SEGMENTINFORMATIONDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_SUBSEQUENTEVENTSDetailsTable" xlink:href="igc-20250331.xsd#igc_SUBSEQUENTEVENTSDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_SUBSEQUENTEVENTSDetailsTable_lbl" xml:lang="en-US">SUBSEQUENT EVENTS (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_SUBSEQUENTEVENTSDetailsTable" xlink:to="igc_SUBSEQUENTEVENTSDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="igc_SUBSEQUENTEVENTSDetailsLineItems" xlink:href="igc-20250331.xsd#igc_SUBSEQUENTEVENTSDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_SUBSEQUENTEVENTSDetailsLineItems_lbl" xml:lang="en-US">SUBSEQUENT EVENTS (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="igc_SUBSEQUENTEVENTSDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_AccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Disclosure for accrued liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_AccruedLiabilitiesDisclosureTextBlock" xlink:to="igc_AccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock_lbl0" xml:lang="en-US">Amount of other increase (decrease) in additional paid in capital (APIC).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock" xlink:to="igc_AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_CybersecurityPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy related to cyber-security.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_CybersecurityPolicyPolicyTextBlock" xlink:to="igc_CybersecurityPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_DepositsAndAdvancesTextBlock_lbl0" xml:lang="en-US">Disclosure of deposits and advances.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_DepositsAndAdvancesTextBlock" xlink:to="igc_DepositsAndAdvancesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_GoingConcernPolicyPolicyTextblock_lbl0" xml:lang="en-US">Policy for going concern.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_GoingConcernPolicyPolicyTextblock" xlink:to="igc_GoingConcernPolicyPolicyTextblock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_LoansAndOtherLiabilitiesTextBlock_lbl0" xml:lang="en-US">Disclosure of loans and other liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_LoansAndOtherLiabilitiesTextBlock" xlink:to="igc_LoansAndOtherLiabilitiesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_OtherAdvances_lbl0" xml:lang="en-US">The amount of other noncurrent advances.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_OtherAdvances" xlink:to="igc_OtherAdvances_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_SalesAgreementMaximum_lbl0" xml:lang="en-US">Maximum offering under sales agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_SalesAgreementMaximum" xlink:to="igc_SalesAgreementMaximum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:to="igc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_StatutoryAdvances_lbl0" xml:lang="en-US">Statutory advances.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_StatutoryAdvances" xlink:to="igc_StatutoryAdvances_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_TotalRevenuePercentage_lbl0" xml:lang="en-US">Percentage of segment to total revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_TotalRevenuePercentage" xlink:to="igc_TotalRevenuePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_UnitDescription_lbl0" xml:lang="en-US">Description of unit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_UnitDescription" xlink:to="igc_UnitDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_UnitsOutstanding_lbl0" xml:lang="en-US">Number of units outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_UnitsOutstanding" xlink:to="igc_UnitsOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_WeightedAveragePricePerShare_lbl0" xml:lang="en-US">Weighted average price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_WeightedAveragePricePerShare" xlink:to="igc_WeightedAveragePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_PropertyPlantAndEquipmentTableTypeAxis_lbl0" xml:lang="en-US">Information by property, plant and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PropertyPlantAndEquipmentTableTypeAxis" xlink:to="igc_PropertyPlantAndEquipmentTableTypeAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_ESOP2008OmnibusPlanMember_lbl0" xml:lang="en-US">Name of the equity-based compensation arrangement plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ESOP2008OmnibusPlanMember" xlink:to="igc_ESOP2008OmnibusPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_PlantAndCannabinoidMember_lbl0" xml:lang="en-US">Represents of the Company&apos;s segments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PlantAndCannabinoidMember" xlink:to="igc_PlantAndCannabinoidMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_PropertyPlantAndEquipmentTableMember_lbl0" xml:lang="en-US">Description of property, plant and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PropertyPlantAndEquipmentTableMember" xlink:to="igc_PropertyPlantAndEquipmentTableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_TollingWhiteLabelingServiceMember_lbl0" xml:lang="en-US">Type of product or service.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_TollingWhiteLabelingServiceMember" xlink:to="igc_TollingWhiteLabelingServiceMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="igc_WellnessAndLifestyleMember_lbl0" xml:lang="en-US">Type of product or service.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_WellnessAndLifestyleMember" xlink:to="igc_WellnessAndLifestyleMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_DepositsAndAdvancesTextBlock_lbl1" xml:lang="en-US">Deposits And Advances Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_DepositsAndAdvancesTextBlock" xlink:to="igc_DepositsAndAdvancesTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl0" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Level1Abstract_lbl0" xml:lang="en-US">Level1 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Level1Abstract" xlink:to="igc_Level1Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xml:lang="en-US">Disclosure Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_UnitsOutstanding_lbl1" xml:lang="en-US">Units Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_UnitsOutstanding" xlink:to="igc_UnitsOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl0" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Expiring2038Member_lbl0" xml:lang="en-US">Expiring2038 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2038Member" xlink:to="igc_Expiring2038Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_UnamortizedIntangibleAssetsAbstract_lbl0" xml:lang="en-US">Unamortized Intangible Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_UnamortizedIntangibleAssetsAbstract" xlink:to="igc_UnamortizedIntangibleAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_TollingWhiteLabelingServiceMember_lbl1" xml:lang="en-US">Tolling White Labeling Service Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_TollingWhiteLabelingServiceMember" xlink:to="igc_TollingWhiteLabelingServiceMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl1" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl0" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Expiring2033Member_lbl0" xml:lang="en-US">Expiring2033 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2033Member" xlink:to="igc_Expiring2033Member_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_ScheduleOfOtherAssetsNoncurrentAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfOtherAssetsNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_ScheduleOfOtherAssetsNoncurrentAbstract_lbl" xml:lang="en-US">Schedule Of Other Assets Noncurrent Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ScheduleOfOtherAssetsNoncurrentAbstract" xlink:to="igc_ScheduleOfOtherAssetsNoncurrentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl1" xml:lang="en-US">Asset Impairment Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_TotalRevenuePercentage_lbl1" xml:lang="en-US">Total Revenue Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_TotalRevenuePercentage" xlink:to="igc_TotalRevenuePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Expiring2031Member_lbl0" xml:lang="en-US">Expiring2031 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2031Member" xlink:to="igc_Expiring2031Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl0" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl0" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl0" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityCollateralFeesAmount_lbl0" xml:lang="en-US">Line of Credit Facility, Collateral Fees, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCollateralFeesAmount" xlink:to="us-gaap_LineOfCreditFacilityCollateralFeesAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl0" xml:lang="en-US">Repayments of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_RevenueFromExternalCustomersByGeographicAreasAbstract" xlink:href="igc-20250331.xsd#igc_RevenueFromExternalCustomersByGeographicAreasAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_RevenueFromExternalCustomersByGeographicAreasAbstract_lbl" xml:lang="en-US">Revenue From External Customers By Geographic Areas Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_RevenueFromExternalCustomersByGeographicAreasAbstract" xlink:to="igc_RevenueFromExternalCustomersByGeographicAreasAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xml:lang="en-US">Disclosure Text Block Supplement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DisclosureTextBlockSupplementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl1" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl1" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl0" xml:lang="en-US">Capitalized Computer Software, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_LoansAndOtherLiabilitiesAbstract" xlink:href="igc-20250331.xsd#igc_LoansAndOtherLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_LoansAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US">Loans And Other Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_LoansAndOtherLiabilitiesAbstract" xlink:to="igc_LoansAndOtherLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeographicDistributionForeignMember_lbl0" xml:lang="en-US">Geographic Distribution, Foreign [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionForeignMember" xlink:to="us-gaap_GeographicDistributionForeignMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl0" xml:lang="en-US">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_SummaryOfOperatingLossCarryforwardsAbstract" xlink:href="igc-20250331.xsd#igc_SummaryOfOperatingLossCarryforwardsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_SummaryOfOperatingLossCarryforwardsAbstract_lbl" xml:lang="en-US">Summary Of Operating Loss Carryforwards Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_SummaryOfOperatingLossCarryforwardsAbstract" xlink:to="igc_SummaryOfOperatingLossCarryforwardsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Vested In Period Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:to="igc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MutualFundMember_lbl0" xml:lang="en-US">Mutual Fund [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MutualFundMember" xlink:to="us-gaap_MutualFundMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_WellnessAndLifestyleMember_lbl1" xml:lang="en-US">Wellness And Lifestyle Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_WellnessAndLifestyleMember" xlink:to="igc_WellnessAndLifestyleMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_March2024SPAMember_lbl0" xml:lang="en-US">March2024 SPAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_March2024SPAMember" xlink:to="igc_March2024SPAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_lbl0" xml:lang="en-US">Fair Value, Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" xlink:to="us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandAvailableForSale_lbl0" xml:lang="en-US">Real Estate, Land, Held-for-Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandAvailableForSale" xlink:to="us-gaap_LandAvailableForSale_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl0" xml:lang="en-US">Vehicles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract_lbl" xml:lang="en-US">Schedule Of Effective Income Tax Rate Reconciliation Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="igc_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Expiring2035Member_lbl0" xml:lang="en-US">Expiring2035 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2035Member" xlink:to="igc_Expiring2035Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl0" xml:lang="en-US">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_lbl0" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Number of Committed-to-be-Released Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl0" xml:lang="en-US">Investor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Expiring2043Member_lbl0" xml:lang="en-US">Expiring2043 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2043Member" xlink:to="igc_Expiring2043Member_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansPayable_lbl0" xml:lang="en-US">Loans Payable, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Land_lbl0" xml:lang="en-US">Land</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Land" xlink:to="us-gaap_Land_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Expiring2029Member_lbl0" xml:lang="en-US">Expiring2029 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2029Member" xlink:to="igc_Expiring2029Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings_lbl0" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis, Gain (Loss) Included in Earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIntangibleAssetsMember_lbl0" xml:lang="en-US">Other Intangible Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsMember" xlink:to="us-gaap_OtherIntangibleAssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_AccruedLiabilitiesDisclosureTextBlock_lbl1" xml:lang="en-US">Accrued Liabilities Disclosure Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_AccruedLiabilitiesDisclosureTextBlock" xlink:to="igc_AccruedLiabilitiesDisclosureTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl0" xml:lang="en-US">Land [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl0" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl0" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0" xml:lang="en-US">Cash Paid For Amounts Included In The Measurement Of Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="igc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Expiring2034Member_lbl0" xml:lang="en-US">Expiring2034 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2034Member" xlink:to="igc_Expiring2034Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Expiring2044Member_lbl0" xml:lang="en-US">Expiring2044 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2044Member" xlink:to="igc_Expiring2044Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Level2Abstract0_lbl0" xml:lang="en-US">Level2 Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Level2Abstract0" xlink:to="igc_Level2Abstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Common Stock Including Additional Paid in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:to="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Expiring2041Member_lbl0" xml:lang="en-US">Expiring2041 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2041Member" xlink:to="igc_Expiring2041Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Expiring2037Member_lbl0" xml:lang="en-US">Expiring2037 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2037Member" xlink:to="igc_Expiring2037Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl0" xml:lang="en-US">Inventory Write-down</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_CybersecurityPolicyPolicyTextBlock_lbl1" xml:lang="en-US">Cybersecurity Policy Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_CybersecurityPolicyPolicyTextBlock" xlink:to="igc_CybersecurityPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl0" xml:lang="en-US">Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsForeign_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsForeign_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Expiring2036Member_lbl0" xml:lang="en-US">Expiring2036 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2036Member" xlink:to="igc_Expiring2036Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl0" xml:lang="en-US">Cash and Cash Equivalents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Expiring2042Member_lbl0" xml:lang="en-US">Expiring2042 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2042Member" xlink:to="igc_Expiring2042Member_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_ScheduleOfRevenueFromExternalCustomersAndLongLivedAssetsByGeographicalAreasAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfRevenueFromExternalCustomersAndLongLivedAssetsByGeographicalAreasAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_ScheduleOfRevenueFromExternalCustomersAndLongLivedAssetsByGeographicalAreasAbstract_lbl" xml:lang="en-US">Schedule Of Revenue From External Customers And Long Lived Assets By Geographical Areas Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ScheduleOfRevenueFromExternalCustomersAndLongLivedAssetsByGeographicalAreasAbstract" xlink:to="igc_ScheduleOfRevenueFromExternalCustomersAndLongLivedAssetsByGeographicalAreasAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_SalesAgreementMaximum_lbl1" xml:lang="en-US">Sales Agreement Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_SalesAgreementMaximum" xlink:to="igc_SalesAgreementMaximum_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeographicDistributionDomesticMember_lbl0" xml:lang="en-US">Geographic Distribution, Domestic [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionDomesticMember" xlink:to="us-gaap_GeographicDistributionDomesticMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_NonvestedRestrictedStockSharesActivityAbstract" xlink:href="igc-20250331.xsd#igc_NonvestedRestrictedStockSharesActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_NonvestedRestrictedStockSharesActivityAbstract_lbl" xml:lang="en-US">Nonvested Restricted Stock Shares Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_NonvestedRestrictedStockSharesActivityAbstract" xlink:to="igc_NonvestedRestrictedStockSharesActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl0" xml:lang="en-US">Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Lease, Cost [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_ScheduleOfIntangibleAssetsAndGoodwillAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfIntangibleAssetsAndGoodwillAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_ScheduleOfIntangibleAssetsAndGoodwillAbstract_lbl" xml:lang="en-US">Schedule Of Intangible Assets And Goodwill Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ScheduleOfIntangibleAssetsAndGoodwillAbstract" xlink:to="igc_ScheduleOfIntangibleAssetsAndGoodwillAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_PropertyPlantAndEquipmentTableMember_lbl1" xml:lang="en-US">Property Plant And Equipment Table Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PropertyPlantAndEquipmentTableMember" xlink:to="igc_PropertyPlantAndEquipmentTableMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Finite Lived Intangible Assets Future Amortization Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="igc_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl0" xml:lang="en-US">Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueAbstract_lbl" xml:lang="en-US">Disaggregation of Revenue [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_DisaggregationOfRevenueAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_NonCashItemsAbstract_lbl0" xml:lang="en-US">Non Cash Items Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_NonCashItemsAbstract" xlink:to="igc_NonCashItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDepositsOnRealEstateSales_lbl0" xml:lang="en-US">Proceeds from Deposits on Real Estate Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDepositsOnRealEstateSales" xlink:to="us-gaap_ProceedsFromDepositsOnRealEstateSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl1" xml:lang="en-US">Asset, Held-for-Sale, Not Part of Disposal Group, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl0" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Expiring2040Member_lbl0" xml:lang="en-US">Expiring2040 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2040Member" xlink:to="igc_Expiring2040Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl2" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Expiring2032Member_lbl0" xml:lang="en-US">Expiring2032 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2032Member" xlink:to="igc_Expiring2032Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Schedule Of Components Of Income Tax Expense Benefit Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:to="igc_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Expiring2039Member_lbl0" xml:lang="en-US">Expiring2039 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2039Member" xlink:to="igc_Expiring2039Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock_lbl1" xml:lang="en-US">Adjustments To Additional Paid In Capita For Subscribed Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock" xlink:to="igc_AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl0" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Expiring2045Member_lbl0" xml:lang="en-US">Expiring2045 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2045Member" xlink:to="igc_Expiring2045Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl1" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_ClinicalTrialInventoryMember_lbl0" xml:lang="en-US">Clinical Trial Inventory Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ClinicalTrialInventoryMember" xlink:to="igc_ClinicalTrialInventoryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherInventoryNetOfReserves_lbl0" xml:lang="en-US">Other Inventory, Net of Reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInventoryNetOfReserves" xlink:to="us-gaap_OtherInventoryNetOfReserves_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl0" xml:lang="en-US">Schedule of Other Assets, Noncurrent [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl0" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl0" xml:lang="en-US">Assets, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl0" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl0" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <loc xlink:type="locator" xlink:label="igc_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Accounts Payable And Accrued Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="igc_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_lbl0" xml:lang="en-US">Payments for (Proceeds from) Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CO_lbl0" xml:lang="en-US">COLOMBIA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CO" xlink:to="country_CO_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_GoingConcernPolicyPolicyTextblock_lbl1" xml:lang="en-US">Going Concern Policy Policy Textblock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_GoingConcernPolicyPolicyTextblock" xlink:to="igc_GoingConcernPolicyPolicyTextblock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_RevenueFromExternalCustomersByProductsAndServicesAbstract" xlink:href="igc-20250331.xsd#igc_RevenueFromExternalCustomersByProductsAndServicesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_RevenueFromExternalCustomersByProductsAndServicesAbstract_lbl" xml:lang="en-US">Revenue From External Customers By Products And Services Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_RevenueFromExternalCustomersByProductsAndServicesAbstract" xlink:to="igc_RevenueFromExternalCustomersByProductsAndServicesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl0" xml:lang="en-US">Machinery and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl0" xml:lang="en-US">Software Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl0" xml:lang="en-US">Investments, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Level1Abstract0_lbl0" xml:lang="en-US">Level1 Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Level1Abstract0" xlink:to="igc_Level1Abstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl0" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl1" xml:lang="en-US">Short-Term Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_LesseeOperatingLeaseLiabilityMaturityAbstract" xlink:href="igc-20250331.xsd#igc_LesseeOperatingLeaseLiabilityMaturityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_LesseeOperatingLeaseLiabilityMaturityAbstract_lbl" xml:lang="en-US">Lessee Operating Lease Liability Maturity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_LesseeOperatingLeaseLiabilityMaturityAbstract" xlink:to="igc_LesseeOperatingLeaseLiabilityMaturityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl0" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl0" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_lbl0"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CertificatesOfDepositMember_lbl0" xml:lang="en-US">Certificates of Deposit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_PropertyPlantAndEquipmentTableTypeAxis_lbl1" xml:lang="en-US">Property Plant And Equipment Table Type Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PropertyPlantAndEquipmentTableTypeAxis" xlink:to="igc_PropertyPlantAndEquipmentTableTypeAxis_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Level2Abstract_lbl0" xml:lang="en-US">Level2 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Level2Abstract" xlink:to="igc_Level2Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_StatutoryAdvances_lbl1" xml:lang="en-US">Statutory Advances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_StatutoryAdvances" xlink:to="igc_StatutoryAdvances_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_WeightedAveragePricePerShare_lbl1" xml:lang="en-US">Weighted Average Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_WeightedAveragePricePerShare" xlink:to="igc_WeightedAveragePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_Expiring2030Member_lbl0" xml:lang="en-US">Expiring2030 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_Expiring2030Member" xlink:to="igc_Expiring2030Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_September2024SPAMember_lbl0" xml:lang="en-US">September2024 SPAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_September2024SPAMember" xlink:to="igc_September2024SPAMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:to="igc_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl0" xml:lang="en-US">Debt Instrument, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Assets and Other Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_InfrastructureSegmentMember_lbl0" xml:lang="en-US">Infrastructure Segment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_InfrastructureSegmentMember" xlink:to="igc_InfrastructureSegmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl0" xml:lang="en-US">Money Market Funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_ScheduleOfInventoryCurrentAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfInventoryCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_ScheduleOfInventoryCurrentAbstract_lbl" xml:lang="en-US">Schedule Of Inventory Current Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ScheduleOfInventoryCurrentAbstract" xlink:to="igc_ScheduleOfInventoryCurrentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl0" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_ShareBasedPaymentArrangementOptionActivityAbstract" xlink:href="igc-20250331.xsd#igc_ShareBasedPaymentArrangementOptionActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_ShareBasedPaymentArrangementOptionActivityAbstract_lbl" xml:lang="en-US">Share Based Payment Arrangement Option Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="igc_ShareBasedPaymentArrangementOptionActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_OtherAdvances_lbl1" xml:lang="en-US">Other Advances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_OtherAdvances" xlink:to="igc_OtherAdvances_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueAdjustment_lbl0" xml:lang="en-US">Assets, Fair Value Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueAdjustment" xlink:to="us-gaap_AssetsFairValueAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_LoansAndOtherLiabilitiesTextBlock_lbl1" xml:lang="en-US">Loans And Other Liabilities Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_LoansAndOtherLiabilitiesTextBlock" xlink:to="igc_LoansAndOtherLiabilitiesTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="igc_AccruedLiabilitiesDisclosureAbstract" xlink:href="igc-20250331.xsd#igc_AccruedLiabilitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_AccruedLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US">Accrued Liabilities Disclosure Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_AccruedLiabilitiesDisclosureAbstract" xlink:to="igc_AccruedLiabilitiesDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Other Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_OtherRevenueMember_lbl0" xml:lang="en-US">Other Revenue Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_OtherRevenueMember" xlink:to="igc_OtherRevenueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl0" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl0" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl1" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_DebtFundsMember_lbl0" xml:lang="en-US">Debt Funds Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_DebtFundsMember" xlink:to="igc_DebtFundsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_SharePurchaseAgreementMember_lbl0" xml:lang="en-US">Share Purchase Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_SharePurchaseAgreementMember" xlink:to="igc_SharePurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_ESOP2008OmnibusPlanMember_lbl1" xml:lang="en-US">ESOP2008 Omnibus Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ESOP2008OmnibusPlanMember" xlink:to="igc_ESOP2008OmnibusPlanMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="igc_DepositsAndAdvancesAbstract" xlink:href="igc-20250331.xsd#igc_DepositsAndAdvancesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_DepositsAndAdvancesAbstract_lbl" xml:lang="en-US">Deposits And Advances Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_DepositsAndAdvancesAbstract" xlink:to="igc_DepositsAndAdvancesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1"/>
    <loc xlink:type="locator" xlink:label="igc_ScheduleOfLoansAndOtherLiabilitiesAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfLoansAndOtherLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_ScheduleOfLoansAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Loans And Other Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ScheduleOfLoansAndOtherLiabilitiesAbstract" xlink:to="igc_ScheduleOfLoansAndOtherLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_NoncurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Noncurrent Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_NoncurrentLiabilitiesAbstract" xlink:to="igc_NoncurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl0" xml:lang="en-US">Debt Instrument, Periodic Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl1" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl0" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl0" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableCurrent_lbl0" xml:lang="en-US">Loans Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl0" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_lbl0" xml:lang="en-US">Building and Building Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_SharePurchaseAgreementsMember_lbl0" xml:lang="en-US">Share Purchase Agreements Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_SharePurchaseAgreementsMember" xlink:to="igc_SharePurchaseAgreementsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl0" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl0" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0" xml:lang="en-US">Payments to Acquire Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_SalesAgreementMember_lbl0" xml:lang="en-US">Sales Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_SalesAgreementMember" xlink:to="igc_SalesAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl0" xml:lang="en-US">Interest Expense, Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_IN_lbl0" xml:lang="en-US">INDIA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IN" xlink:to="country_IN_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl0" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl0" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="igc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract_lbl" xml:lang="en-US">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:to="igc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl0" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_FiscalYear2026Member_lbl0" xml:lang="en-US">Fiscal Year2026 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_FiscalYear2026Member" xlink:to="igc_FiscalYear2026Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_UnitDescription_lbl1" xml:lang="en-US">Unit Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_UnitDescription" xlink:to="igc_UnitDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl0" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="igc_PlantAndCannabinoidMember_lbl1" xml:lang="en-US">Plant And Cannabinoid Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="igc_PlantAndCannabinoidMember" xlink:to="igc_PlantAndCannabinoidMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>29
<FILENAME>igc-20250331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Jun 27 19:48:35 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ConsolidatedBalanceSheet" roleURI="http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ConsolidatedIncomeStatement" roleURI="http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ShareholdersEquityType2or3" roleURI="http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ConsolidatedCashFlow" roleURI="http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_NATUREOFOPERATIONS" roleURI="http://www.indiaglobalcap.com/role/NATUREOFOPERATIONS"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_SIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIES"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_INVENTORY" roleURI="http://www.indiaglobalcap.com/role/INVENTORY"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_DEPOSITSANDADVANCES" roleURI="http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCES"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_INTANGIBLEASSETS" roleURI="http://www.indiaglobalcap.com/role/INTANGIBLEASSETS"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_PROPERTYPLANTANDEQUIPMENT" roleURI="http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENT"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_CLAIMSANDADVANCES" roleURI="http://www.indiaglobalcap.com/role/CLAIMSANDADVANCES"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_LEASES" roleURI="http://www.indiaglobalcap.com/role/LEASES"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ACCRUEDLIABILITIESANDOTHERS" roleURI="http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERS"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_LOANSANDOTHERLIABILITIES" roleURI="http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIES"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_COMMITMENTSANDCONTINGENCIES" roleURI="http://www.indiaglobalcap.com/role/COMMITMENTSANDCONTINGENCIES"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_SECURITIES" roleURI="http://www.indiaglobalcap.com/role/SECURITIES"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_STOCKBASEDCOMPENSATION" roleURI="http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATION"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_FAIRVALUEOFFINANCIALINSTRUMENTS" roleURI="http://www.indiaglobalcap.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_INCOMETAXES" roleURI="http://www.indiaglobalcap.com/role/INCOMETAXES"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_REVENUERECOGNITION" roleURI="http://www.indiaglobalcap.com/role/REVENUERECOGNITION"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_SEGMENTINFORMATION" roleURI="http://www.indiaglobalcap.com/role/SEGMENTINFORMATION"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_SUBSEQUENTEVENTS" roleURI="http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTS"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_AccountingPoliciesByPolicy" roleURI="http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_INVENTORYTables" roleURI="http://www.indiaglobalcap.com/role/INVENTORYTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_DEPOSITSANDADVANCESTables" roleURI="http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCESTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_INTANGIBLEASSETSTables" roleURI="http://www.indiaglobalcap.com/role/INTANGIBLEASSETSTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_PROPERTYPLANTANDEQUIPMENTTables" roleURI="http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_CLAIMSANDADVANCESTables" roleURI="http://www.indiaglobalcap.com/role/CLAIMSANDADVANCESTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_LEASESTables" roleURI="http://www.indiaglobalcap.com/role/LEASESTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ACCRUEDLIABILITIESANDOTHERSTables" roleURI="http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_LOANSANDOTHERLIABILITIESTables" roleURI="http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_STOCKBASEDCOMPENSATIONTables" roleURI="http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_FAIRVALUEOFFINANCIALINSTRUMENTSTables" roleURI="http://www.indiaglobalcap.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_INCOMETAXESTables" roleURI="http://www.indiaglobalcap.com/role/INCOMETAXESTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_REVENUERECOGNITIONTables" roleURI="http://www.indiaglobalcap.com/role/REVENUERECOGNITIONTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_SEGMENTINFORMATIONTables" roleURI="http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONTables"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofInventoryCurrentTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofInventoryCurrentTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_DeferredCostsCapitalizedPrepaidandOtherAssetsDisclosureTable" roleURI="http://www.indiaglobalcap.com/role/DeferredCostsCapitalizedPrepaidandOtherAssetsDisclosureTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofIntangibleAssetsAndGoodwillTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_PropertyPlantandEquipmentTable" roleURI="http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofOtherAssetsNoncurrentTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofOtherAssetsNoncurrentTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_LeaseCostTable" roleURI="http://www.indiaglobalcap.com/role/LeaseCostTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_LesseeOperatingLeaseLiabilityMaturityTable" roleURI="http://www.indiaglobalcap.com/role/LesseeOperatingLeaseLiabilityMaturityTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofAccountsPayableandAccruedLiabilitiesTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofLoansandOtherLiabilitiesTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofLoansandOtherLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_NonvestedRestrictedStockSharesActivityTable" roleURI="http://www.indiaglobalcap.com/role/NonvestedRestrictedStockSharesActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_SharebasedPaymentArrangementOptionActivityTable" roleURI="http://www.indiaglobalcap.com/role/SharebasedPaymentArrangementOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofEffectiveIncomeTaxRateReconciliationTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofComponentsofIncomeTaxExpenseBenefitTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofComponentsofIncomeTaxExpenseBenefitTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_SummaryofOperatingLossCarryforwardsTable" roleURI="http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_DisaggregationofRevenueTable" roleURI="http://www.indiaglobalcap.com/role/DisaggregationofRevenueTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_RevenuefromExternalCustomersbyProductsandServicesTable" roleURI="http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyProductsandServicesTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_RevenuefromExternalCustomersbyGeographicAreasTable" roleURI="http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyGeographicAreasTable"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasTable" roleURI="http://www.indiaglobalcap.com/role/ScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasTable"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_SIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_INVENTORYDetails" roleURI="http://www.indiaglobalcap.com/role/INVENTORYDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_DEPOSITSANDADVANCESDetails" roleURI="http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCESDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_INTANGIBLEASSETSDetails" roleURI="http://www.indiaglobalcap.com/role/INTANGIBLEASSETSDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_PROPERTYPLANTANDEQUIPMENTDetails" roleURI="http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_LEASESDetails" roleURI="http://www.indiaglobalcap.com/role/LEASESDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_ACCRUEDLIABILITIESANDOTHERSDetails" roleURI="http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_LOANSANDOTHERLIABILITIESDetails" roleURI="http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.indiaglobalcap.com/role/COMMITMENTSANDCONTINGENCIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_SECURITIESDetails" roleURI="http://www.indiaglobalcap.com/role/SECURITIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_STOCKBASEDCOMPENSATIONDetails" roleURI="http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_INCOMETAXESDetails" roleURI="http://www.indiaglobalcap.com/role/INCOMETAXESDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_SEGMENTINFORMATIONDetails" roleURI="http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONDetails"/>
  <roleRef xlink:type="simple" xlink:href="igc-20250331.xsd#igc_r_SUBSEQUENTEVENTSDetails" roleURI="http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStocksIncludingAdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock" xlink:href="igc-20250331.xsd#igc_AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="NonCashItemsAbstract" xlink:href="igc-20250331.xsd#igc_NonCashItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="NonCashItemsAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCashItemsAbstract" xlink:to="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/NATUREOFOPERATIONS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NatureOfOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/INVENTORY" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DepositsAndAdvancesAbstract" xlink:href="igc-20250331.xsd#igc_DepositsAndAdvancesAbstract"/>
    <loc xlink:type="locator" xlink:label="DepositsAndAdvancesTextBlock" xlink:href="igc-20250331.xsd#igc_DepositsAndAdvancesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsAndAdvancesAbstract" xlink:to="DepositsAndAdvancesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/INTANGIBLEASSETS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENT" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/CLAIMSANDADVANCES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/LEASES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="AccruedLiabilitiesDisclosureAbstract" xlink:href="igc-20250331.xsd#igc_AccruedLiabilitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="AccruedLiabilitiesDisclosureTextBlock" xlink:href="igc-20250331.xsd#igc_AccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesDisclosureAbstract" xlink:to="AccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="LoansAndOtherLiabilitiesAbstract" xlink:href="igc-20250331.xsd#igc_LoansAndOtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="LoansAndOtherLiabilitiesTextBlock" xlink:href="igc-20250331.xsd#igc_LoansAndOtherLiabilitiesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoansAndOtherLiabilitiesAbstract" xlink:to="LoansAndOtherLiabilitiesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/SECURITIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/INCOMETAXES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/REVENUERECOGNITION" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/SEGMENTINFORMATION" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GoingConcernPolicyPolicyTextblock" xlink:href="igc-20250331.xsd#igc_GoingConcernPolicyPolicyTextblock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="GoingConcernPolicyPolicyTextblock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CybersecurityPolicyPolicyTextBlock" xlink:href="igc-20250331.xsd#igc_CybersecurityPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="CybersecurityPolicyPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/INVENTORYTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DepositsAndAdvancesAbstract" xlink:href="igc-20250331.xsd#igc_DepositsAndAdvancesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsAndAdvancesAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/INTANGIBLEASSETSTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="PROPERTYPLANTANDEQUIPMENTTablesTable" xlink:href="igc-20250331.xsd#igc_PROPERTYPLANTANDEQUIPMENTTablesTable"/>
    <loc xlink:type="locator" xlink:label="PROPERTYPLANTANDEQUIPMENTTablesLineItems" xlink:href="igc-20250331.xsd#igc_PROPERTYPLANTANDEQUIPMENTTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="PROPERTYPLANTANDEQUIPMENTTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentTableTypeAxis" xlink:href="igc-20250331.xsd#igc_PropertyPlantAndEquipmentTableTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PROPERTYPLANTANDEQUIPMENTTablesTable" xlink:to="PropertyPlantAndEquipmentTableTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentTableMember" xlink:href="igc-20250331.xsd#igc_PropertyPlantAndEquipmentTableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTableTypeAxis" xlink:to="PropertyPlantAndEquipmentTableMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PROPERTYPLANTANDEQUIPMENTTablesTable" xlink:to="PROPERTYPLANTANDEQUIPMENTTablesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PROPERTYPLANTANDEQUIPMENTTablesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/CLAIMSANDADVANCESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/LEASESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="AccruedLiabilitiesDisclosureAbstract" xlink:href="igc-20250331.xsd#igc_AccruedLiabilitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="LoansAndOtherLiabilitiesAbstract" xlink:href="igc-20250331.xsd#igc_LoansAndOtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoansAndOtherLiabilitiesAbstract" xlink:to="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/INCOMETAXESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/REVENUERECOGNITIONTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofInventoryCurrentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfInventoryCurrentAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfInventoryCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryCurrentAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryCurrentAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/DeferredCostsCapitalizedPrepaidandOtherAssetsDisclosureTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherInventoryNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherInventoryNetOfReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherInventoryNetOfReserves" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsAndGoodwillAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfIntangibleAssetsAndGoodwillAbstract"/>
    <loc xlink:type="locator" xlink:label="INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsTable" xlink:href="igc-20250331.xsd#igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsTable"/>
    <loc xlink:type="locator" xlink:label="INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems" xlink:href="igc-20250331.xsd#igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsAndGoodwillAbstract" xlink:to="INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_OtherIntangibleAssetsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentsMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_SoftwareDevelopmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsTable" xlink:to="INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="UnamortizedIntangibleAssetsAbstract" xlink:href="igc-20250331.xsd#igc_UnamortizedIntangibleAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems" xlink:to="UnamortizedIntangibleAssetsAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UnamortizedIntangibleAssetsAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_VehiclesMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofOtherAssetsNoncurrentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherAssetsNoncurrentAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfOtherAssetsNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAssetsNoncurrentAbstract" xlink:to="us-gaap_OtherReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherAdvances" xlink:href="igc-20250331.xsd#igc_OtherAdvances"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAssetsNoncurrentAbstract" xlink:to="OtherAdvances" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/LeaseCostTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_AssetsAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LiabilitiesAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/LesseeOperatingLeaseLiabilityMaturityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="LesseeOperatingLeaseLiabilityMaturityAbstract" xlink:href="igc-20250331.xsd#igc_LesseeOperatingLeaseLiabilityMaturityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseLiabilityMaturityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseLiabilityMaturityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseLiabilityMaturityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLAKD9Z7zGpK2qQstFsfCu8xSrtW9H2+v0Xv0rh9+KH/Pz8D0bXTVzCQTQCC6nPug5x2WprRNZyO0vKrGf3yPx7zySn86Xz+cpPHpOaLInCIyy5s5q8xj2k941QApP+Uc6E50B2zYbnR/55u68AGKs/8SiUy11i4tM/dKp4JuQDXDaZK3azYQ8+FvMTMkrrL0geMSLbxuaBiHnbm5CGMQ19XmbYGYYv6OGsI=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseLiabilityMaturityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseLiabilityMaturityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseLiabilityMaturityAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofLoansandOtherLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfLoansAndOtherLiabilitiesAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfLoansAndOtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLoansAndOtherLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLoansAndOtherLiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/NonvestedRestrictedStockSharesActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="NonvestedRestrictedStockSharesActivityAbstract" xlink:href="igc-20250331.xsd#igc_NonvestedRestrictedStockSharesActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonvestedRestrictedStockSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonvestedRestrictedStockSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonvestedRestrictedStockSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonvestedRestrictedStockSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonvestedRestrictedStockSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonvestedRestrictedStockSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonvestedRestrictedStockSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonvestedRestrictedStockSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonvestedRestrictedStockSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonvestedRestrictedStockSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/SharebasedPaymentArrangementOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentArrangementOptionActivityAbstract" xlink:href="igc-20250331.xsd#igc_ShareBasedPaymentArrangementOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:href="igc-20250331.xsd#igc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentArrangementOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract"/>
    <loc xlink:type="locator" xlink:label="FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsTable" xlink:href="igc-20250331.xsd#igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsTable"/>
    <loc xlink:type="locator" xlink:label="FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsLineItems" xlink:href="igc-20250331.xsd#igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:to="FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_MoneyMarketFundsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtFundsMember" xlink:href="igc-20250331.xsd#igc_DebtFundsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="DebtFundsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MutualFundMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MutualFundMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_MutualFundMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CertificatesOfDepositMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsTable" xlink:to="FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="Level1Abstract" xlink:href="igc-20250331.xsd#igc_Level1Abstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsLineItems" xlink:to="Level1Abstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Level1Abstract" xlink:to="us-gaap_AssetsFairValueAdjustment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Level1Abstract" xlink:to="us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Level1Abstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Level1Abstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Level1Abstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Level1Abstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsForeign" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofComponentsofIncomeTaxExpenseBenefitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="SummaryOfOperatingLossCarryforwardsAbstract" xlink:href="igc-20250331.xsd#igc_SummaryOfOperatingLossCarryforwardsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryOfOperatingLossCarryforwardsAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="Expiring2029Member" xlink:href="igc-20250331.xsd#igc_Expiring2029Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="Expiring2029Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Expiring2030Member" xlink:href="igc-20250331.xsd#igc_Expiring2030Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="Expiring2030Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Expiring2031Member" xlink:href="igc-20250331.xsd#igc_Expiring2031Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="Expiring2031Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Expiring2032Member" xlink:href="igc-20250331.xsd#igc_Expiring2032Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="Expiring2032Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Expiring2033Member" xlink:href="igc-20250331.xsd#igc_Expiring2033Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="Expiring2033Member" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Expiring2034Member" xlink:href="igc-20250331.xsd#igc_Expiring2034Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="Expiring2034Member" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Expiring2035Member" xlink:href="igc-20250331.xsd#igc_Expiring2035Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="Expiring2035Member" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Expiring2036Member" xlink:href="igc-20250331.xsd#igc_Expiring2036Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="Expiring2036Member" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Expiring2037Member" xlink:href="igc-20250331.xsd#igc_Expiring2037Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="Expiring2037Member" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Expiring2038Member" xlink:href="igc-20250331.xsd#igc_Expiring2038Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="Expiring2038Member" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Expiring2039Member" xlink:href="igc-20250331.xsd#igc_Expiring2039Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="Expiring2039Member" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Expiring2040Member" xlink:href="igc-20250331.xsd#igc_Expiring2040Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="Expiring2040Member" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Expiring2041Member" xlink:href="igc-20250331.xsd#igc_Expiring2041Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="Expiring2041Member" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Expiring2042Member" xlink:href="igc-20250331.xsd#igc_Expiring2042Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="Expiring2042Member" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Expiring2043Member" xlink:href="igc-20250331.xsd#igc_Expiring2043Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="Expiring2043Member" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Expiring2044Member" xlink:href="igc-20250331.xsd#igc_Expiring2044Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="Expiring2044Member" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Expiring2045Member" xlink:href="igc-20250331.xsd#igc_Expiring2045Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="Expiring2045Member" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/DisaggregationofRevenueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WellnessAndLifestyleMember" xlink:href="igc-20250331.xsd#igc_WellnessAndLifestyleMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="WellnessAndLifestyleMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TollingWhiteLabelingServiceMember" xlink:href="igc-20250331.xsd#igc_TollingWhiteLabelingServiceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="TollingWhiteLabelingServiceMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherRevenueMember" xlink:href="igc-20250331.xsd#igc_OtherRevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="OtherRevenueMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyProductsandServicesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="RevenueFromExternalCustomersByProductsAndServicesAbstract" xlink:href="igc-20250331.xsd#igc_RevenueFromExternalCustomersByProductsAndServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromExternalCustomersByProductsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PlantAndCannabinoidMember" xlink:href="igc-20250331.xsd#igc_PlantAndCannabinoidMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="PlantAndCannabinoidMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyGeographicAreasTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="RevenueFromExternalCustomersByGeographicAreasAbstract" xlink:href="igc-20250331.xsd#igc_RevenueFromExternalCustomersByGeographicAreasAbstract"/>
    <loc xlink:type="locator" xlink:label="SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsTable" xlink:href="igc-20250331.xsd#igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems" xlink:href="igc-20250331.xsd#igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromExternalCustomersByGeographicAreasAbstract" xlink:to="SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_IN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_IN"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_IN" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_CO" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CO"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_CO" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsTable" xlink:to="SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="TotalRevenuePercentage" xlink:href="igc-20250331.xsd#igc_TotalRevenuePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems" xlink:to="TotalRevenuePercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/ScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRevenueFromExternalCustomersAndLongLivedAssetsByGeographicalAreasAbstract" xlink:href="igc-20250331.xsd#igc_ScheduleOfRevenueFromExternalCustomersAndLongLivedAssetsByGeographicalAreasAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenueFromExternalCustomersAndLongLivedAssetsByGeographicalAreasAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeographicDistributionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_GeographicDistributionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeographicDistributionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeographicDistributionDomesticMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionDomesticMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomesticMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeographicDistributionForeignMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionForeignMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionForeignMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:href="igc-20250331.xsd#igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:href="igc-20250331.xsd#igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_TaxPeriodAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FiscalYear2026Member" xlink:href="igc-20250331.xsd#igc_FiscalYear2026Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="FiscalYear2026Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_InvestorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SharePurchaseAgreementMember" xlink:href="igc-20250331.xsd#igc_SharePurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="SharePurchaseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesInventoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="us-gaap_PublicUtilitiesInventoryAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ClinicalTrialInventoryMember" xlink:href="igc-20250331.xsd#igc_ClinicalTrialInventoryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="ClinicalTrialInventoryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" xlink:to="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_SharePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_RestrictedCash" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_CapitalizedComputerSoftwareGross" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_InventoryNet" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/INVENTORYDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="INVENTORYDetailsTable" xlink:href="igc-20250331.xsd#igc_INVENTORYDetailsTable"/>
    <loc xlink:type="locator" xlink:label="INVENTORYDetailsLineItems" xlink:href="igc-20250331.xsd#igc_INVENTORYDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="INVENTORYDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesInventoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INVENTORYDetailsTable" xlink:to="us-gaap_PublicUtilitiesInventoryAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ClinicalTrialInventoryMember" xlink:href="igc-20250331.xsd#igc_ClinicalTrialInventoryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="ClinicalTrialInventoryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INVENTORYDetailsTable" xlink:to="INVENTORYDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INVENTORYDetailsLineItems" xlink:to="us-gaap_InventoryWriteDown" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INVENTORYDetailsLineItems" xlink:to="us-gaap_InventoryNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DepositsAndAdvancesAbstract" xlink:href="igc-20250331.xsd#igc_DepositsAndAdvancesAbstract"/>
    <loc xlink:type="locator" xlink:label="StatutoryAdvances" xlink:href="igc-20250331.xsd#igc_StatutoryAdvances"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsAndAdvancesAbstract" xlink:to="StatutoryAdvances" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/INTANGIBLEASSETSDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="INTANGIBLEASSETSDetailsTable" xlink:href="igc-20250331.xsd#igc_INTANGIBLEASSETSDetailsTable"/>
    <loc xlink:type="locator" xlink:label="INTANGIBLEASSETSDetailsLineItems" xlink:href="igc-20250331.xsd#igc_INTANGIBLEASSETSDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="INTANGIBLEASSETSDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INTANGIBLEASSETSDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INTANGIBLEASSETSDetailsTable" xlink:to="INTANGIBLEASSETSDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="INTANGIBLEASSETSDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="PROPERTYPLANTANDEQUIPMENTDetailsTable" xlink:href="igc-20250331.xsd#igc_PROPERTYPLANTANDEQUIPMENTDetailsTable"/>
    <loc xlink:type="locator" xlink:label="PROPERTYPLANTANDEQUIPMENTDetailsLineItems" xlink:href="igc-20250331.xsd#igc_PROPERTYPLANTANDEQUIPMENTDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="PROPERTYPLANTANDEQUIPMENTDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PROPERTYPLANTANDEQUIPMENTDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PROPERTYPLANTANDEQUIPMENTDetailsTable" xlink:to="PROPERTYPLANTANDEQUIPMENTDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PROPERTYPLANTANDEQUIPMENTDetailsLineItems" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PROPERTYPLANTANDEQUIPMENTDetailsLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandAvailableForSale" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandAvailableForSale"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PROPERTYPLANTANDEQUIPMENTDetailsLineItems" xlink:to="us-gaap_LandAvailableForSale" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Land"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PROPERTYPLANTANDEQUIPMENTDetailsLineItems" xlink:to="us-gaap_Land" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDepositsOnRealEstateSales" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDepositsOnRealEstateSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PROPERTYPLANTANDEQUIPMENTDetailsLineItems" xlink:to="us-gaap_ProceedsFromDepositsOnRealEstateSales" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/LEASESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="AccruedLiabilitiesDisclosureAbstract" xlink:href="igc-20250331.xsd#igc_AccruedLiabilitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ACCRUEDLIABILITIESANDOTHERSDetailsTable" xlink:href="igc-20250331.xsd#igc_ACCRUEDLIABILITIESANDOTHERSDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ACCRUEDLIABILITIESANDOTHERSDetailsLineItems" xlink:href="igc-20250331.xsd#igc_ACCRUEDLIABILITIESANDOTHERSDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesDisclosureAbstract" xlink:to="ACCRUEDLIABILITIESANDOTHERSDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ACCRUEDLIABILITIESANDOTHERSDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ACCRUEDLIABILITIESANDOTHERSDetailsTable" xlink:to="ACCRUEDLIABILITIESANDOTHERSDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ACCRUEDLIABILITIESANDOTHERSDetailsLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ACCRUEDLIABILITIESANDOTHERSDetailsLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDepositsOnRealEstateSales" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDepositsOnRealEstateSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ACCRUEDLIABILITIESANDOTHERSDetailsLineItems" xlink:to="us-gaap_ProceedsFromDepositsOnRealEstateSales" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="LoansAndOtherLiabilitiesAbstract" xlink:href="igc-20250331.xsd#igc_LoansAndOtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoansAndOtherLiabilitiesAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoansAndOtherLiabilitiesAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoansAndOtherLiabilitiesAbstract" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoansAndOtherLiabilitiesAbstract" xlink:to="us-gaap_DebtInstrumentTerm" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoansAndOtherLiabilitiesAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoansAndOtherLiabilitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebt" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermLoansPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoansAndOtherLiabilitiesAbstract" xlink:to="us-gaap_LongTermLoansPayable" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoansAndOtherLiabilitiesAbstract" xlink:to="us-gaap_LoansPayableCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/SECURITIESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="SECURITIESDetailsTable" xlink:href="igc-20250331.xsd#igc_SECURITIESDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SECURITIESDetailsLineItems" xlink:href="igc-20250331.xsd#igc_SECURITIESDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="SECURITIESDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SECURITIESDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="us-gaap_InvestorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SECURITIESDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SECURITIESDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="March2024SPAMember" xlink:href="igc-20250331.xsd#igc_March2024SPAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="March2024SPAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="September2024SPAMember" xlink:href="igc-20250331.xsd#igc_September2024SPAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="September2024SPAMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SalesAgreementMember" xlink:href="igc-20250331.xsd#igc_SalesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="SalesAgreementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePurchaseAgreementsMember" xlink:href="igc-20250331.xsd#igc_SharePurchaseAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="SharePurchaseAgreementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SECURITIESDetailsTable" xlink:to="SECURITIESDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SECURITIESDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SECURITIESDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SECURITIESDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SECURITIESDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SECURITIESDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SECURITIESDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SECURITIESDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SECURITIESDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="UnitsOutstanding" xlink:href="igc-20250331.xsd#igc_UnitsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SECURITIESDetailsLineItems" xlink:to="UnitsOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnitDescription" xlink:href="igc-20250331.xsd#igc_UnitDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SECURITIESDetailsLineItems" xlink:to="UnitDescription" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SECURITIESDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SECURITIESDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SECURITIESDetailsLineItems" xlink:to="us-gaap_SharePrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SECURITIESDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SECURITIESDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="14.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="SalesAgreementMaximum" xlink:href="igc-20250331.xsd#igc_SalesAgreementMaximum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SECURITIESDetailsLineItems" xlink:to="SalesAgreementMaximum" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SECURITIESDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="STOCKBASEDCOMPENSATIONDetailsTable" xlink:href="igc-20250331.xsd#igc_STOCKBASEDCOMPENSATIONDetailsTable"/>
    <loc xlink:type="locator" xlink:label="STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:href="igc-20250331.xsd#igc_STOCKBASEDCOMPENSATIONDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="STOCKBASEDCOMPENSATIONDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="STOCKBASEDCOMPENSATIONDetailsTable" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ESOP2008OmnibusPlanMember" xlink:href="igc-20250331.xsd#igc_ESOP2008OmnibusPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="ESOP2008OmnibusPlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="STOCKBASEDCOMPENSATIONDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="STOCKBASEDCOMPENSATIONDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="STOCKBASEDCOMPENSATIONDetailsTable" xlink:to="STOCKBASEDCOMPENSATIONDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAveragePricePerShare" xlink:href="igc-20250331.xsd#igc_WeightedAveragePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="WeightedAveragePricePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="STOCKBASEDCOMPENSATIONDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/INCOMETAXESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="SEGMENTINFORMATIONDetailsTable" xlink:href="igc-20250331.xsd#igc_SEGMENTINFORMATIONDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SEGMENTINFORMATIONDetailsLineItems" xlink:href="igc-20250331.xsd#igc_SEGMENTINFORMATIONDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="SEGMENTINFORMATIONDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SEGMENTINFORMATIONDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="InfrastructureSegmentMember" xlink:href="igc-20250331.xsd#igc_InfrastructureSegmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="InfrastructureSegmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SEGMENTINFORMATIONDetailsTable" xlink:to="SEGMENTINFORMATIONDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SEGMENTINFORMATIONDetailsLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SEGMENTINFORMATIONDetailsLineItems" xlink:to="us-gaap_Revenues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SUBSEQUENTEVENTSDetailsTable" xlink:href="igc-20250331.xsd#igc_SUBSEQUENTEVENTSDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SUBSEQUENTEVENTSDetailsLineItems" xlink:href="igc-20250331.xsd#igc_SUBSEQUENTEVENTSDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SUBSEQUENTEVENTSDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_InvestorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SharePurchaseAgreementMember" xlink:href="igc-20250331.xsd#igc_SharePurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="SharePurchaseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="SUBSEQUENTEVENTSDetailsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_SharePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCollateralFeesAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCollateralFeesAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityCollateralFeesAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended"/>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended"/>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>30
<FILENAME>igc-20250331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Jun 27 19:48:35 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2025" targetNamespace="http://www.indiaglobalcap.com/20250331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:igc="http://www.indiaglobalcap.com/20250331" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="igc-20250331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="igc-20250331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="igc-20250331_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="igc-20250331_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet" id="igc_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet_Parentheticals" id="igc_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement" id="igc_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3" id="igc_r_ShareholdersEquityType2or3">
        <link:definition>995304 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/ConsolidatedCashFlow" id="igc_r_ConsolidatedCashFlow">
        <link:definition>995305 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/NATUREOFOPERATIONS" id="igc_r_NATUREOFOPERATIONS">
        <link:definition>995306 - Disclosure - NATURE OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIES" id="igc_r_SIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>995307 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/INVENTORY" id="igc_r_INVENTORY">
        <link:definition>995308 - Disclosure - INVENTORY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCES" id="igc_r_DEPOSITSANDADVANCES">
        <link:definition>995309 - Disclosure - DEPOSITS AND ADVANCES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/INTANGIBLEASSETS" id="igc_r_INTANGIBLEASSETS">
        <link:definition>995310 - Disclosure - INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENT" id="igc_r_PROPERTYPLANTANDEQUIPMENT">
        <link:definition>995311 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/CLAIMSANDADVANCES" id="igc_r_CLAIMSANDADVANCES">
        <link:definition>995312 - Disclosure - CLAIMS AND ADVANCES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/LEASES" id="igc_r_LEASES">
        <link:definition>995313 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERS" id="igc_r_ACCRUEDLIABILITIESANDOTHERS">
        <link:definition>995314 - Disclosure - ACCRUED LIABILITIES AND OTHERS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIES" id="igc_r_LOANSANDOTHERLIABILITIES">
        <link:definition>995315 - Disclosure - LOANS AND OTHER LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/COMMITMENTSANDCONTINGENCIES" id="igc_r_COMMITMENTSANDCONTINGENCIES">
        <link:definition>995316 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/SECURITIES" id="igc_r_SECURITIES">
        <link:definition>995317 - Disclosure - SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATION" id="igc_r_STOCKBASEDCOMPENSATION">
        <link:definition>995318 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS" id="igc_r_FAIRVALUEOFFINANCIALINSTRUMENTS">
        <link:definition>995319 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/INCOMETAXES" id="igc_r_INCOMETAXES">
        <link:definition>995320 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/REVENUERECOGNITION" id="igc_r_REVENUERECOGNITION">
        <link:definition>995321 - Disclosure - REVENUE RECOGNITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/SEGMENTINFORMATION" id="igc_r_SEGMENTINFORMATION">
        <link:definition>995322 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTS" id="igc_r_SUBSEQUENTEVENTS">
        <link:definition>995323 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy" id="igc_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/INVENTORYTables" id="igc_r_INVENTORYTables">
        <link:definition>996001 - Disclosure - INVENTORY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCESTables" id="igc_r_DEPOSITSANDADVANCESTables">
        <link:definition>996002 - Disclosure - DEPOSITS AND ADVANCES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/INTANGIBLEASSETSTables" id="igc_r_INTANGIBLEASSETSTables">
        <link:definition>996003 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTTables" id="igc_r_PROPERTYPLANTANDEQUIPMENTTables">
        <link:definition>996004 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/CLAIMSANDADVANCESTables" id="igc_r_CLAIMSANDADVANCESTables">
        <link:definition>996005 - Disclosure - CLAIMS AND ADVANCES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/LEASESTables" id="igc_r_LEASESTables">
        <link:definition>996006 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSTables" id="igc_r_ACCRUEDLIABILITIESANDOTHERSTables">
        <link:definition>996007 - Disclosure - ACCRUED LIABILITIES AND OTHERS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESTables" id="igc_r_LOANSANDOTHERLIABILITIESTables">
        <link:definition>996008 - Disclosure - LOANS AND OTHER LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONTables" id="igc_r_STOCKBASEDCOMPENSATIONTables">
        <link:definition>996009 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables" id="igc_r_FAIRVALUEOFFINANCIALINSTRUMENTSTables">
        <link:definition>996010 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/INCOMETAXESTables" id="igc_r_INCOMETAXESTables">
        <link:definition>996011 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/REVENUERECOGNITIONTables" id="igc_r_REVENUERECOGNITIONTables">
        <link:definition>996012 - Disclosure - REVENUE RECOGNITION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONTables" id="igc_r_SEGMENTINFORMATIONTables">
        <link:definition>996013 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails" id="igc_r_SIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>996014 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/INVENTORYDetails" id="igc_r_INVENTORYDetails">
        <link:definition>996015 - Disclosure - INVENTORY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/ScheduleofInventoryCurrentTable" id="igc_r_ScheduleofInventoryCurrentTable">
        <link:definition>996016 - Disclosure - INVENTORY - Schedule of Inventory, Current (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCESDetails" id="igc_r_DEPOSITSANDADVANCESDetails">
        <link:definition>996017 - Disclosure - DEPOSITS AND ADVANCES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/DeferredCostsCapitalizedPrepaidandOtherAssetsDisclosureTable" id="igc_r_DeferredCostsCapitalizedPrepaidandOtherAssetsDisclosureTable">
        <link:definition>996018 - Disclosure - DEPOSITS AND ADVANCES - Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/INTANGIBLEASSETSDetails" id="igc_r_INTANGIBLEASSETSDetails">
        <link:definition>996019 - Disclosure - INTANGIBLE ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable" id="igc_r_ScheduleofIntangibleAssetsAndGoodwillTable">
        <link:definition>996020 - Disclosure - INTANGIBLE ASSETS - Schedule of Intangible Assets And Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTable" id="igc_r_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTable">
        <link:definition>996021 - Disclosure - INTANGIBLE ASSETS - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLAKD9Z7zGpK2qQstFsfCu8xSrtW9H2+v0Xv0rh9+KH/Pz8D0bXTVzCQTQCC6nPug5x2WprRNZyO0vKrGf3yPx7zySn86Xz+cpPHpOaLInCIyy5s5q8xj2k941QApP+Uc6E50B2zYbnR/55u68AGKs/8SiUy11i4tM/dKp4JuQDXDaZK3azYQ8+FvMTMkrrL0geMSLbxuaBiHnWmmVQK7uOFvYdU9Zrp6BIQ=] CSR-->
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTDetails" id="igc_r_PROPERTYPLANTANDEQUIPMENTDetails">
        <link:definition>996022 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable" id="igc_r_PropertyPlantandEquipmentTable">
        <link:definition>996023 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/ScheduleofOtherAssetsNoncurrentTable" id="igc_r_ScheduleofOtherAssetsNoncurrentTable">
        <link:definition>996024 - Disclosure - CLAIMS AND ADVANCES - Schedule of Other Assets, Noncurrent (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/LEASESDetails" id="igc_r_LEASESDetails">
        <link:definition>996025 - Disclosure - LEASES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/LeaseCostTable" id="igc_r_LeaseCostTable">
        <link:definition>996026 - Disclosure - LEASES - Lease, Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/LesseeOperatingLeaseLiabilityMaturityTable" id="igc_r_LesseeOperatingLeaseLiabilityMaturityTable">
        <link:definition>996027 - Disclosure - LEASES - Lessee, Operating Lease, Liability, Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSDetails" id="igc_r_ACCRUEDLIABILITIESANDOTHERSDetails">
        <link:definition>996028 - Disclosure - ACCRUED LIABILITIES AND OTHERS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable" id="igc_r_ScheduleofAccountsPayableandAccruedLiabilitiesTable">
        <link:definition>996029 - Disclosure - ACCRUED LIABILITIES AND OTHERS - Schedule of Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESDetails" id="igc_r_LOANSANDOTHERLIABILITIESDetails">
        <link:definition>996030 - Disclosure - LOANS AND OTHER LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/ScheduleofLoansandOtherLiabilitiesTable" id="igc_r_ScheduleofLoansandOtherLiabilitiesTable">
        <link:definition>996031 - Disclosure - LOANS AND OTHER LIABILITIES - Schedule of Loans and Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/COMMITMENTSANDCONTINGENCIESDetails" id="igc_r_COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>996032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/SECURITIESDetails" id="igc_r_SECURITIESDetails">
        <link:definition>996033 - Disclosure - SECURITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails" id="igc_r_STOCKBASEDCOMPENSATIONDetails">
        <link:definition>996034 - Disclosure - STOCK-BASED COMPENSATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsTable" id="igc_r_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsTable">
        <link:definition>996035 - Disclosure - STOCK-BASED COMPENSATION  - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/NonvestedRestrictedStockSharesActivityTable" id="igc_r_NonvestedRestrictedStockSharesActivityTable">
        <link:definition>996036 - Disclosure - STOCK-BASED COMPENSATION  - Nonvested Restricted Stock Shares Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/SharebasedPaymentArrangementOptionActivityTable" id="igc_r_SharebasedPaymentArrangementOptionActivityTable">
        <link:definition>996037 - Disclosure - STOCK-BASED COMPENSATION  - Share-based Payment Arrangement, Option, Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable" id="igc_r_ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable">
        <link:definition>996038 - Disclosure -  FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/INCOMETAXESDetails" id="igc_r_INCOMETAXESDetails">
        <link:definition>996039 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable" id="igc_r_ScheduleofEffectiveIncomeTaxRateReconciliationTable">
        <link:definition>996040 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/ScheduleofComponentsofIncomeTaxExpenseBenefitTable" id="igc_r_ScheduleofComponentsofIncomeTaxExpenseBenefitTable">
        <link:definition>996041 - Disclosure - INCOME TAXES - Schedule of Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable" id="igc_r_SummaryofOperatingLossCarryforwardsTable">
        <link:definition>996042 - Disclosure - INCOME TAXES - Summary of Operating Loss Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/DisaggregationofRevenueTable" id="igc_r_DisaggregationofRevenueTable">
        <link:definition>996043 - Disclosure - REVENUE RECOGNITION - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONDetails" id="igc_r_SEGMENTINFORMATIONDetails">
        <link:definition>996044 - Disclosure - SEGMENT INFORMATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyProductsandServicesTable" id="igc_r_RevenuefromExternalCustomersbyProductsandServicesTable">
        <link:definition>996045 - Disclosure - SEGMENT INFORMATION - Revenue from External Customers by Products and Services (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyGeographicAreasTable" id="igc_r_RevenuefromExternalCustomersbyGeographicAreasTable">
        <link:definition>996046 - Disclosure - SEGMENT INFORMATION - Revenue from External Customers by Geographic Areas (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/ScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasTable" id="igc_r_ScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasTable">
        <link:definition>996047 - Disclosure - SEGMENT INFORMATION - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails" id="igc_r_SUBSEQUENTEVENTSDetails">
        <link:definition>996048 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.indiaglobalcap.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd"/>
  <xs:element name="ScheduleOfInventoryCurrentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_ScheduleOfInventoryCurrentAbstract"/>
  <xs:element name="DepositsAndAdvancesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_DepositsAndAdvancesAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsAndGoodwillAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_ScheduleOfIntangibleAssetsAndGoodwillAbstract"/>
  <xs:element name="ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
  <xs:element name="ScheduleOfOtherAssetsNoncurrentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_ScheduleOfOtherAssetsNoncurrentAbstract"/>
  <xs:element name="LesseeOperatingLeaseLiabilityMaturityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_LesseeOperatingLeaseLiabilityMaturityAbstract"/>
  <xs:element name="AccruedLiabilitiesDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_AccruedLiabilitiesDisclosureAbstract"/>
  <xs:element name="ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract"/>
  <xs:element name="LoansAndOtherLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_LoansAndOtherLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfLoansAndOtherLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_ScheduleOfLoansAndOtherLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract"/>
  <xs:element name="NonvestedRestrictedStockSharesActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_NonvestedRestrictedStockSharesActivityAbstract"/>
  <xs:element name="ShareBasedPaymentArrangementOptionActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_ShareBasedPaymentArrangementOptionActivityAbstract"/>
  <xs:element name="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract"/>
  <xs:element name="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract"/>
  <xs:element name="ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract"/>
  <xs:element name="SummaryOfOperatingLossCarryforwardsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_SummaryOfOperatingLossCarryforwardsAbstract"/>
  <xs:element name="RevenueFromExternalCustomersByProductsAndServicesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_RevenueFromExternalCustomersByProductsAndServicesAbstract"/>
  <xs:element name="RevenueFromExternalCustomersByGeographicAreasAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_RevenueFromExternalCustomersByGeographicAreasAbstract"/>
  <xs:element name="ScheduleOfRevenueFromExternalCustomersAndLongLivedAssetsByGeographicalAreasAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_ScheduleOfRevenueFromExternalCustomersAndLongLivedAssetsByGeographicalAreasAbstract"/>
  <xs:element name="NonCashItemsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_NonCashItemsAbstract"/>
  <xs:element name="UnamortizedIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_UnamortizedIntangibleAssetsAbstract"/>
  <xs:element name="NoncurrentLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_NoncurrentLiabilitiesAbstract"/>
  <xs:element name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
  <xs:element name="Level1Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_Level1Abstract"/>
  <xs:element name="Level2Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_Level2Abstract"/>
  <xs:element name="Level1Abstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_Level1Abstract0"/>
  <xs:element name="Level2Abstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_Level2Abstract0"/>
  <xs:element name="AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="igc_AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock"/>
  <xs:element name="DepositsAndAdvancesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_DepositsAndAdvancesTextBlock"/>
  <xs:element name="AccruedLiabilitiesDisclosureTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_AccruedLiabilitiesDisclosureTextBlock"/>
  <xs:element name="LoansAndOtherLiabilitiesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_LoansAndOtherLiabilitiesTextBlock"/>
  <xs:element name="GoingConcernPolicyPolicyTextblock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_GoingConcernPolicyPolicyTextblock"/>
  <xs:element name="CybersecurityPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_CybersecurityPolicyPolicyTextBlock"/>
  <xs:element name="PropertyPlantAndEquipmentTableTypeDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_PropertyPlantAndEquipmentTableTypeDomainDomain"/>
  <xs:element name="PROPERTYPLANTANDEQUIPMENTTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="igc_PROPERTYPLANTANDEQUIPMENTTablesTable"/>
  <xs:element name="PROPERTYPLANTANDEQUIPMENTTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_PROPERTYPLANTANDEQUIPMENTTablesLineItems"/>
  <xs:element name="INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsTable"/>
  <xs:element name="INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems"/>
  <xs:element name="OtherAdvances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="igc_OtherAdvances"/>
  <xs:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice"/>
  <xs:element name="FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsTable"/>
  <xs:element name="FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsLineItems"/>
  <xs:element name="SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsTable"/>
  <xs:element name="SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems"/>
  <xs:element name="TotalRevenuePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_TotalRevenuePercentage"/>
  <xs:element name="SIGNIFICANTACCOUNTINGPOLICIESDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable"/>
  <xs:element name="SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems"/>
  <xs:element name="INVENTORYDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="igc_INVENTORYDetailsTable"/>
  <xs:element name="INVENTORYDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_INVENTORYDetailsLineItems"/>
  <xs:element name="StatutoryAdvances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="igc_StatutoryAdvances"/>
  <xs:element name="INTANGIBLEASSETSDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="igc_INTANGIBLEASSETSDetailsTable"/>
  <xs:element name="INTANGIBLEASSETSDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_INTANGIBLEASSETSDetailsLineItems"/>
  <xs:element name="PROPERTYPLANTANDEQUIPMENTDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="igc_PROPERTYPLANTANDEQUIPMENTDetailsTable"/>
  <xs:element name="PROPERTYPLANTANDEQUIPMENTDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_PROPERTYPLANTANDEQUIPMENTDetailsLineItems"/>
  <xs:element name="ACCRUEDLIABILITIESANDOTHERSDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="igc_ACCRUEDLIABILITIESANDOTHERSDetailsTable"/>
  <xs:element name="ACCRUEDLIABILITIESANDOTHERSDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_ACCRUEDLIABILITIESANDOTHERSDetailsLineItems"/>
  <xs:element name="SECURITIESDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="igc_SECURITIESDetailsTable"/>
  <xs:element name="SECURITIESDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_SECURITIESDetailsLineItems"/>
  <xs:element name="UnitsOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_UnitsOutstanding"/>
  <xs:element name="UnitDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_UnitDescription"/>
  <xs:element name="SalesAgreementMaximum" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="igc_SalesAgreementMaximum"/>
  <xs:element name="STOCKBASEDCOMPENSATIONDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="igc_STOCKBASEDCOMPENSATIONDetailsTable"/>
  <xs:element name="STOCKBASEDCOMPENSATIONDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_STOCKBASEDCOMPENSATIONDetailsLineItems"/>
  <xs:element name="WeightedAveragePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_WeightedAveragePricePerShare"/>
  <xs:element name="SEGMENTINFORMATIONDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="igc_SEGMENTINFORMATIONDetailsTable"/>
  <xs:element name="SEGMENTINFORMATIONDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_SEGMENTINFORMATIONDetailsLineItems"/>
  <xs:element name="SUBSEQUENTEVENTSDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="igc_SUBSEQUENTEVENTSDetailsTable"/>
  <xs:element name="SUBSEQUENTEVENTSDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_SUBSEQUENTEVENTSDetailsLineItems"/>
  <xs:element name="PropertyPlantAndEquipmentTableTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="igc_PropertyPlantAndEquipmentTableTypeAxis"/>
  <xs:element name="ClinicalTrialInventoryMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_ClinicalTrialInventoryMember"/>
  <xs:element name="DebtFundsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_DebtFundsMember"/>
  <xs:element name="ESOP2008OmnibusPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_ESOP2008OmnibusPlanMember"/>
  <xs:element name="Expiring2029Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_Expiring2029Member"/>
  <xs:element name="Expiring2030Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_Expiring2030Member"/>
  <xs:element name="Expiring2031Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_Expiring2031Member"/>
  <xs:element name="Expiring2032Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_Expiring2032Member"/>
  <xs:element name="Expiring2033Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_Expiring2033Member"/>
  <xs:element name="Expiring2034Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_Expiring2034Member"/>
  <xs:element name="Expiring2035Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_Expiring2035Member"/>
  <xs:element name="Expiring2036Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_Expiring2036Member"/>
  <xs:element name="Expiring2037Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_Expiring2037Member"/>
  <xs:element name="Expiring2038Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_Expiring2038Member"/>
  <xs:element name="Expiring2039Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_Expiring2039Member"/>
  <xs:element name="Expiring2040Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_Expiring2040Member"/>
  <xs:element name="Expiring2041Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_Expiring2041Member"/>
  <xs:element name="Expiring2042Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_Expiring2042Member"/>
  <xs:element name="Expiring2043Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_Expiring2043Member"/>
  <xs:element name="Expiring2044Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_Expiring2044Member"/>
  <xs:element name="Expiring2045Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_Expiring2045Member"/>
  <xs:element name="FiscalYear2026Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_FiscalYear2026Member"/>
  <xs:element name="InfrastructureSegmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_InfrastructureSegmentMember"/>
  <xs:element name="March2024SPAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_March2024SPAMember"/>
  <xs:element name="OtherRevenueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_OtherRevenueMember"/>
  <xs:element name="PlantAndCannabinoidMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_PlantAndCannabinoidMember"/>
  <xs:element name="PropertyPlantAndEquipmentTableMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_PropertyPlantAndEquipmentTableMember"/>
  <xs:element name="SalesAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_SalesAgreementMember"/>
  <xs:element name="September2024SPAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_September2024SPAMember"/>
  <xs:element name="SharePurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_SharePurchaseAgreementMember"/>
  <xs:element name="SharePurchaseAgreementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_SharePurchaseAgreementsMember"/>
  <xs:element name="TollingWhiteLabelingServiceMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_TollingWhiteLabelingServiceMember"/>
  <xs:element name="WellnessAndLifestyleMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_WellnessAndLifestyleMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 20, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IGC PHARMA, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001326205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-32830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-2760393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,724,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10224 Falls Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Potomac<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">983-0998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IGC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,891,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorTable', window );"><strong>Auditor [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Manohar
Chowdhry & Associates<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">5341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Chennai, India<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 405<span></span>
</td>
<td class="nump">$ 1,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,360<span></span>
</td>
<td class="nump">1,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Asset held for sale</a></td>
<td class="nump">702<span></span>
</td>
<td class="nump">720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Deposits and advances</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,896<span></span>
</td>
<td class="nump">3,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">1,852<span></span>
</td>
<td class="nump">1,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,220<span></span>
</td>
<td class="nump">3,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Claims and advances</a></td>
<td class="nump">681<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease asset</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">5,851<span></span>
</td>
<td class="nump">6,197<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">8,747<span></span>
</td>
<td class="nump">9,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">883<span></span>
</td>
<td class="nump">773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities and others</a></td>
<td class="nump">1,374<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,257<span></span>
</td>
<td class="nump">2,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term loans</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,417<span></span>
</td>
<td class="nump">2,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies &#8211; See Note 12</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value: authorized 1,000,000 shares, no shares issued or outstanding as of March 31, 2025, or March 31, 2024.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital', window );">Common stock and additional paid-in capital, $0.0001 par value: 150,000,000 shares authorized; 80,878,058 and 66,691,195 shares issued and outstanding as of March 31, 2025, and March 31, 2024, respectively.</a></td>
<td class="nump">130,570<span></span>
</td>
<td class="nump">124,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(3,496)<span></span>
</td>
<td class="num">(3,423)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(120,744)<span></span>
</td>
<td class="num">(113,665)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">6,330<span></span>
</td>
<td class="nump">7,321<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 8,747<span></span>
</td>
<td class="nump">$ 9,902<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482309/360-10-15-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of par value plus amounts in excess of par value or issuance value for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStocksIncludingAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">80,878,058<span></span>
</td>
<td class="nump">66,691,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">80,878,058<span></span>
</td>
<td class="nump">66,691,195<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 1,271<span></span>
</td>
<td class="nump">$ 1,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="num">(652)<span></span>
</td>
<td class="num">(612)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">619<span></span>
</td>
<td class="nump">733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="num">(4,410)<span></span>
</td>
<td class="num">(6,758)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(3,655)<span></span>
</td>
<td class="num">(3,773)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(7,446)<span></span>
</td>
<td class="num">(9,798)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment loss on PPE</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,345)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(7,121)<span></span>
</td>
<td class="num">(13,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense/benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(7,121)<span></span>
</td>
<td class="num">(13,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (7,151)<span></span>
</td>
<td class="num">$ (13,034)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share attributable to common stockholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares used in computing loss per share amounts: (in Shares)</a></td>
<td class="nump">76,517,175<span></span>
</td>
<td class="nump">58,839,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares used in computing loss per share amounts: (in Shares)</a></td>
<td class="nump">76,517,175<span></span>
</td>
<td class="nump">58,839,868<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Common Stock Including Additional Paid in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,965<span></span>
</td>
<td class="num">$ (100,665)<span></span>
</td>
<td class="num">$ (3,389)<span></span>
</td>
<td class="nump">$ 14,911<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2023</a></td>
<td class="nump">53,077,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Common stock-based compensation &amp; expenses, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock-based compensation &amp; expenses, net (in Shares)</a></td>
<td class="nump">3,534,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock through offering (net of expenses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock through offering (net of expenses) (in Shares)</a></td>
<td class="nump">10,580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Share money received but not allotted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Cancellation/forfeiture of shares (in Shares)</a></td>
<td class="num">(500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock', window );">Common stock subscribed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Other adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,409<span></span>
</td>
<td class="num">(113,665)<span></span>
</td>
<td class="num">(3,423)<span></span>
</td>
<td class="nump">$ 7,321<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2024</a></td>
<td class="nump">66,691,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,691,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Common stock-based compensation &amp; expenses, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock through offering (net of expenses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock through offering (net of expenses) (in Shares)</a></td>
<td class="nump">14,187,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Share money received but not allotted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock', window );">Common stock subscribed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Other adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,122)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,570<span></span>
</td>
<td class="num">$ (120,744)<span></span>
</td>
<td class="num">$ (3,496)<span></span>
</td>
<td class="nump">$ 6,330<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2025</a></td>
<td class="nump">80,878,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,878,058<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (7,121)<span></span>
</td>
<td class="num">$ (13,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">618<span></span>
</td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debt</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of assets</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">3,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Common stock-based compensation and expenses, net</a></td>
<td class="nump">1,640<span></span>
</td>
<td class="nump">1,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Profit/Loss on sale of fixed assets, net</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivables, net</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Deposits and advances</a></td>
<td class="num">(187)<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Claims and advances</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="num">(196)<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Operating lease asset</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(4,795)<span></span>
</td>
<td class="num">(5,199)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flow from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant, and equipment</a></td>
<td class="num">(112)<span></span>
</td>
<td class="num">(138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sale of property, plant, and equipment</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Proceeds from short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition and development of intangible assets</a></td>
<td class="num">(370)<span></span>
</td>
<td class="num">(377)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(442)<span></span>
</td>
<td class="num">(317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from the issuance of common stock</a></td>
<td class="nump">4,454<span></span>
</td>
<td class="nump">3,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from common stock subscribed</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfDebt', window );">Repayment of long-term loan</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,451<span></span>
</td>
<td class="nump">3,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effects of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(793)<span></span>
</td>
<td class="num">(1,998)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the beginning of the period</a></td>
<td class="nump">1,198<span></span>
</td>
<td class="nump">3,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the end of the period</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_NonCashItemsAbstract', window );"><strong>Non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1', window );">Common stock issued/granted for stock-based compensation, including patent acquisition</a></td>
<td class="nump">$ 1,640<span></span>
</td>
<td class="nump">$ 1,773<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_NonCashItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_NonCashItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 </b>&#8211; <b>NATURE OF OPERATIONS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IGC
Pharma is on a mission to transform Alzheimer&#8217;s treatment. We are building a robust pipeline of drug candidates, each targeting
different aspects of the disease. Our product candidate pipeline and anticipated milestones include the following: -</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 0pt; width: 10%; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Asset</b></span></td>
    <td style="vertical-align: bottom; text-align: center; padding-right: 0pt; padding-bottom: 0pt; width: 1%; padding-left: 0pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 0pt; width: 28%; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Target
    Indication</b></span></td>
    <td style="vertical-align: bottom; text-align: center; padding-right: 0pt; padding-bottom: 0pt; width: 1%; padding-left: 0pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 0pt; width: 22%; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mechanism
    of Action</b></span></td>
    <td style="vertical-align: bottom; text-align: center; padding-right: 0pt; padding-bottom: 0pt; width: 1%; padding-left: 0pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 0pt; width: 15%; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Development
    Stage</b></span></td>
    <td style="vertical-align: bottom; text-align: center; padding-right: 0pt; padding-bottom: 0pt; width: 1%; padding-left: 0pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 0pt; width: 21%; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
    Milestones</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IGC-
    AD1</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agitation
    in Alzheimer&#8217;s dementia</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CB1
    receptor partial agonist; reduces neuroinflammation and restores neurotransmitter balance</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    2 clinical trial (CALMA study)</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    Phase 2 data analysis suggests cognitive improvements in the active treatment group versus the placebo group,</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TGR-63</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Early
    to moderate Alzheimer&#8217;s disease</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disrupts
    amyloid-beta (A&#946;) plaque formation; crosses blood-brain barrier</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Demonstrated
    favorable safety profile; advancing towards clinical trials</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LMP</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alzheimer&#8217;s
    disease</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Targets
    neuroinflammation, neurotransmitter imbalance, and inflammasome-3</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bioequivalence
    to IGC-AD1 anticipated in 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IGC-M3</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Early-stage
    Alzheimer&#8217;s disease</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inhibits
    A&#946; plaque aggregation</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Toxicology
    studies planned for mid-2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IGC-1C</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alzheimer&#8217;s
    disease and metabolic disorders</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Targets
    tau protein phase separation; potential GLP-1 receptor agonist</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits
    strong binding affinity to tau protein; potential for weight loss applications</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IGC-1A</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Metabolic
    disorders (e.g., type 2 diabetes, obesity)</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
    GLP-1 and GIP receptor agonist; CB1 receptor inverse agonist</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical</span></td>
    <td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt">&#160;</td>
    <td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identified
    through AI modeling; toxicology and dosing studies underway</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
pipeline reflects IGC Pharma&#8217;s strategic focus on addressing neurodegenerative diseases, particularly Alzheimer&#8217;s, through
innovative mechanisms targeting key pathological features like amyloid plaques and tau protein aggregation. Additionally, their expansion
into metabolic disorders showcases the versatility of their drug discovery platform, leveraging artificial intelligence to identify promising
therapeutic candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, the Company had the following operating subsidiaries: Techni Bharathi Private Limited (TBL), HH Processors, LLC, IGCare
LLC, Sunday Seltzer LLC, IGC Pharma IP, LLC, IGC Pharma, LLC, SAN Holdings, LLC, Hamsa Biopharma India Pvt. Ltd. And Colombia-based beneficially-owned
subsidiary IGC Pharma SAS. The Company&#8217;s fiscal year is the 52- or 53-week period that ends on March 31. The Company&#8217; principal
office is in Maryland established in 2005. Additionally, the Company has offices in Washington state, Colombia, South America, and India.
The Company&#8217;s filings are available on www.sec.gov.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal 2025, the Company reassessed its reportable segment structure in connection with its strategic realignment toward Life Sciences.
As a result, management determined that the Company operates as a <b>single reportable segment</b>, focused on the vision to make the
world free from Alzheimer&#8217;s. Historically, the Company reported two operating segments: Life Sciences and Infrastructure. While
the Infrastructure segment generated revenues in fiscal 2024, it did not generate any revenues in fiscal 2025 and is no longer actively
managed or evaluated as a discrete operating segment by the Company&#8217;s Chief Operating Decision Maker. For more information, please
refer to &#8220;Note 18 &#8211; Segment Information&#8221;.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2</b> &#8211; <b>SIGNIFICANT ACCOUNTING POLICIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a)
Principles of consolidation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of the Company and all its subsidiaries. Intercompany accounts and transactions
have been eliminated. In the opinion of the Company&#8217;s management, the consolidated financial statements reflect all adjustments,
which are normal and recurring in nature, necessary for fair financial statement presentation. Transactions between the Company and its
subsidiaries are eliminated in the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b)
Use of estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with accounting principles generally accepted in the U.S. (U.S. GAAP) requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual
results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
believes that the estimates and assumptions used in the preparation of the consolidated financial statements are prudent and reasonable.
Significant estimates and assumptions are generally used for, but not limited to, allowance for uncollectible accounts receivable; sales
returns; normal loss during production; future obligations under employee benefit plans; the useful lives of property, plant, and equipment;
intangible assets; valuations; impairment of goodwill and investments; recoverability of advances; the valuation of options granted,
and warrants issued; and income tax and deferred tax valuation allowances, if any. Actual results could differ from those estimates.
Appropriate changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. Critical
accounting estimates could change from period to period and could have a material impact on IGC&#8217;s results, operations, financial
position, and cash flows. Changes in estimates are reflected in the financial statements in the period in which changes are made, and
if material, their effects are disclosed in the notes to the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c)
Revenue recognition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue under ASC 606, <i>Revenue from Contracts with Customers </i>(ASC 606). The core principle of this standard
is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects
the consideration to which the Company expects to be entitled in exchange for those goods or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
606 prescribes a 5-step process to achieve its core principle. The Company recognizes revenue from trading, rental, or product sales
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.
Identify the contract with the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.
Identify the contractual performance obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">III.
Determine the amount of consideration/price for the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IV.
Allocate the determined amount of consideration/price to the contractual obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">V.
Recognize revenue when or as the performing party satisfies performance obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consideration/price for the transaction (performance obligation(s)) is determined as per the agreement or invoice (contract) for the
services and products. Refer to Note 17 &#8211; &#8220;Revenue Recognition.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>d)
Cost of Revenue</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cost of revenue includes costs associated with in-house and outsourced distribution, labor expenses, components, manufacturing overhead,
and outbound freight for our products division. In our products division, the cost of revenue also includes the cost of refurbishing
or repackaging, if required, on products returned by customers that will be offered for resale.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>e)
Loss per Share</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
computation of basic loss per share for Fiscal 2025 excludes potentially dilutive securities of approximately shares, which includes
share options, unvested shares such as restricted shares and restricted share units granted to employees, non-employees, and advisors,
and shares from the conversion of outstanding units, if any, because their inclusion would be anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average number of shares outstanding for Fiscal 2025 and 2024, used for the computation of basic earnings per share (EPS) is
76,517,175 and 58,839,868, respectively. Due to the loss incurred during Fiscal 2025 and 2024, all the potential equity shares are anti-dilutive,
and accordingly, the fully diluted EPS is equal to the basic EPS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f)
Going Concern:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses and determines its ability to continue as a going concern in accordance with the provisions of ASC Subtopic 205-40,
&#8220;<i>Presentation of Financial Statements</i>&#8212;<i>Going Concern</i>&#8221;, which requires the Company to evaluate whether there
are conditions or events that raise substantial doubt about its ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is currently in a clinical trial stage and, thus, has not yet achieved profitability. The Company expects to continue to incur
significant operating and net losses and negative cash flows from operations in the near future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended March 31, 2025, and March 31, 2024, the Company incurred net losses of $7.1 million and $13 million, respectively. During
fiscal 2025, the Company renewed the facility with O-bank. In addition, the Company raised approximately $4.64 million through private
placements and an at-the-market offering program. The at-the-market program and the credit facility serve to minimize ongoing liquidity
requirements and ensure the Company&#8217;s ability to sustain its operations. The Company has taken several steps to extend its operational
runway, including narrowing its strategic focus to Life Sciences, limiting investment in non-core infrastructure operations, and managing
expenses related to clinical development with a disciplined approach. While management believes these actions improve the Company&#8217;s
financial position, there can be no assurance that additional financing will be available on acceptable terms, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
first quarter of Fiscal 2026, the Company entered into the 2025 Share Purchase Agreement with multiple investors, relating to the sale
and issuance by our company to the investors of an aggregate of 2,803,333 shares of our common stock, for a total purchase price of $841,000,
or $0.30 per share, subject to the terms and conditions set forth in the 2025 SPA. The investment is subject to customary closing conditions,
including NYSE approval. As per the 2025 SPA, the investor received piggyback registration rights subject to certain restrictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates that its current cash and cash equivalents balance, with the working capital and investments, and with an available
overdraft facility of $12 million from O-Bank, is sufficient to support operations beyond the twelve months following the date these
consolidated financial statements and footnotes were issued. These estimates are based on assumptions that may prove to be wrong, and
the Company could use its available capital resources sooner than it currently expects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>g)
Income taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes under the asset and liability method, in accordance with ASC 740, Income Taxes, which requires an entity
to recognize deferred tax liabilities and assets. Deferred tax assets and liabilities are recognized for the future tax consequence attributable
to the differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases and operating
loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using the enacted tax rate expected to apply to
taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax
assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance
is established and recorded when management determines that some or all of the deferred tax assets are not likely to be realized and,
therefore, it is necessary to reduce deferred tax assets to the amount expected to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
evaluating a tax position for recognition, management evaluates whether it is more-likely-than-not that a position will be sustained
upon examination, including the resolution of related appeals or litigation processes, based on the technical merits of the position.
If the tax position meets the more-likely-than-not recognition threshold, the tax position is measured and recognized in the Company&#8217;s
financial statements as the largest amount of tax benefit that, in management&#8217;s judgment, is greater than 50% likely to be realized
upon settlement. As of March 31, 2025, and 2024, there was no significant liability for income tax associated with unrecognized tax benefits.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the last quarter of fiscal 2025, the Company received a tax credit of approximately $194 thousand, which has been recorded as other income
in the accompanying consolidated statements of operations. The credit relates to qualifying expenditures under applicable federal tax
incentive programs. The Company has submitted additional claims and expects to receive approximately $600 thousand in tax credits during
fiscal 2026. However, there can be no assurance as to the timing or certainty of receipt, as the claims are subject to review and approval
by the Internal Revenue Service (IRS). The Company will recognize any additional credits as income when collection is deemed probable
in accordance with applicable accounting standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>h)
Accounts receivable</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
make estimates of the collectability of our accounts receivable by analyzing historical payment patterns, customer concentrations, customer
creditworthiness, and current economic trends. If the financial condition of a customer deteriorates, additional allowances may be required.
We had $34 thousand of accounts receivable, net of provision for doubtful debt of $12 thousand as of March 31, 2025, as compared to $39
thousand of accounts receivable, net of provision for doubtful debt of $24 thousand as of March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>i)
Cash and cash equivalents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
financial statement purposes, the Company considers all highly liquid debt instruments with a maturity of three months or less to be
cash equivalents. The Company maintains its cash in bank accounts in the U.S., India, and Colombia, which at times may exceed applicable
insurance limits. The cash and cash equivalents of the Company on March 31, 2025, and 2024 were approximately $405 thousand and $1.2
million, respectively. The company&#8217;s cash balance also includes approximately $8 thousand in restricted cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>j)
Short-term and long-term investments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
policy for short-term and long-term investments is to establish a high-quality portfolio that preserves principal, meets liquidity needs,
avoids inappropriate concentrations, and delivers an appropriate yield in relation to our investment guidelines and market conditions.
Short-term and long-term investments consist of corporate, various government agencies, and municipal debt securities, as well as certificates
of deposit that have maturity dates that are greater than 90 days. Certificates of deposit and commercial paper are carried at a cost
that approximates fair value. Available-for-sale securities: Investments in debt securities that are classified as available for sale
shall be measured subsequently at fair value in the statement of financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments
are initially measured at cost, which is the fair value of the consideration given for them, including transaction costs. Where the Company&#8217;s
ownership interest is in excess of 20% and the Company has a significant influence, the Company has accounted for the investment based
on the equity method in accordance with ASC Topic 323, &#8220;<i>Investments </i>&#8211; <i>Equity method and Joint Ventures.</i>&#8221;
Under the equity method, the Company&#8217;s share of the post-acquisition profits or losses of the equity investee is recognized in
the consolidated statements of operations, and its share of post-acquisition movements in accumulated other comprehensive income / (loss)
is recognized in other comprehensive income / (loss). Where the Company does not have significant influence, the Company has accounted
for the investment in accordance with ASC Topic 321, &#8220;<i>Investments-Equity Securities.</i>&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, had no marketable investments.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>k)
Property, plant, and equipment (PP&amp;E) </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PP&amp;E
are recorded at cost net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful
lives of the assets, which are reviewed periodically to ensure consistency with expected economic benefits. Depreciation begins when
the asset is available for use and continues until the asset is retired or fully depreciated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
retirement or disposition, cost and related accumulated depreciation of the PP&amp;E are de-recognized, and any gain or loss is reflected
in the results of the operation. The cost of additions and substantial improvements to property and equipment are capitalized. The cost
of maintenance and repairs of the property and equipment are charged to operating expenses as incurred. Please refer &#8220;Note 6 &#8211;
Property, Plant, and Equipment&#8221; for more information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>l)
Fair value of financial instruments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
820, &#8220;Fair Value Measurement&#8221; defines fair value as the exchange price that would be received for an asset or paid to transfer
a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between
market participants on the measurement date. It also establishes a three-tier fair value hierarchy, which prioritizes the inputs used
in measuring fair value as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Observable inputs such as quoted prices in active markets;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable,
and accrued liabilities, approximately their fair values due to the nature of the items. Please refer to Note 15, &#8220;Fair value of
financial instruments,&#8221; for further information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>m)
Concentration of credit risk and significant customers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments, which potentially expose the Company to concentrations of credit risk, are primarily comprised of cash and cash equivalents,
investments, accounts receivable, and unbilled accounts receivable, if any. The Company places its cash investments in highly rated financial
institutions. The Company adheres to a formal investment policy with the primary objective of preservation of principal, which contains
credit rating minimums and diversification requirements. Management believes its credit policies reflect normal industry terms and business
risk. The Company does not anticipate non-performance by the counterparties and, accordingly, does not require collateral. During Fiscal
2025, sales were spread across customers in Asia and U.S., and the credit concentration risk is low.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>n)
Stock </b>&#8211; <b>Based Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation to employees and non-employees in conformity with the provisions of ASC Topic 718, &#8220;<i>Stock-Based
Compensation.</i>&#8221; The Company expenses stock-based compensation to employees over the requisite vesting period based on the estimated
grant-date fair value of the awards. The Company accounts for forfeitures as they occur. Stock-based awards are recognized on a straight-line
basis over the requisite vesting period. For stock-based employee compensation, the cost recognized at any date will be at least equal
to the amount attributable to the share-based compensation that is vested at that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
performance-based awards, stock-based compensation expense is recognized over the expected performance achievement period of individual
performance milestones when the achievement of each individual performance milestone becomes probable. For performance-based awards with
a vesting schedule based entirely on the attainment of performance conditions, stock-based compensation expense associated with each
tranche is recognized over the expected achievement period for the operational milestone, beginning at the point in time when the relevant
operational milestone is considered probable to be achieved.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
market-based awards, stock-based compensation expense is recognized over the expected achievement period. The fair value of such awards
is estimated on the grant date using Monte Carlo simulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates the fair value of stock option grants using the Black-Scholes option-pricing model. The assumptions used in calculating
the fair value of stock-based awards represent Management&#8217;s best estimates. Generally, the closing share price of the Company&#8217;s
common stock on the date of grant is considered the fair value of the share. The volatility factor is determined based on the Company&#8217;s
historical stock prices. The expected term represents the period that our stock-based awards are expected to be outstanding. The Company
has never declared or paid any cash dividends. For further information, refer to Note 14, &#8220;Stock-Based Compensation&#8221; of Notes
to Consolidated Financial Statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>o)
Commitments and contingencies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities
for loss contingencies arising from claims, assessments, litigations, fines and penalties, and other sources are recorded when it is
probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. We record
associated legal fees as incurred. Information regarding our commitments and contingencies is incorporated by reference in Note 12, &#8220;Commitments
and contingencies&#8221; of this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>p)
Impairment of long </b>&#8211; <b>lived assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews its long-lived assets, with finite lives, for impairment whenever events or changes in business circumstances indicate
that the carrying amount of assets may not be fully recoverable. Such circumstances include, though are not limited to, significant or
sustained declines in revenues or earnings, future anticipated cash flows, business plans, and material adverse changes in the economic
climate, such as changes in the operating environment, competitive information, and the impact of changes in government policies. For
assets that the Company intends to hold for use, if the total of the expected future undiscounted cash flows produced by the assets or
subsidiary company is less than the carrying amount of the assets, a loss is recognized for the difference between the fair value and
carrying value of the assets. For assets, the Company intends to dispose of by sale, a loss is recognized for the amount by which the
estimated fair value less cost to sell is less than the carrying value of the assets. Fair value is determined based on quoted market
prices, if available, or other valuation techniques, including discounted future net cash flows. Unlike goodwill, long-lived assets are
assessed for impairment only where there are any specific indicators for impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>q)
Intangible assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s intangible assets are accounted for in accordance with ASC Topic 350, <i>Intangibles </i>&#8211; <i>Goodwill and Other.
</i>Intangible assets having indefinite lives are not amortized, but instead are reviewed annually or more frequently if events or changes
in circumstances indicate that the assets might be impaired, to assess whether their fair value exceeds their carrying value. We perform
an impairment analysis on March 1 annually on the indefinite-lived intangible assets following the steps laid out in ASC 350-30-35-18.
Our annual impairment analysis includes a qualitative assessment to determine if it is necessary to perform the quantitative impairment
test. In performing a qualitative assessment, we review events and circumstances that could affect the significant inputs used to determine
if the fair value is less than the carrying value of the intangible assets. If quantitative analysis is necessary, we would analyze various
aspects including revenues from the business, associated with the intangible assets. In addition, intangible assets will be tested on
an interim basis if an event or circumstance indicates that it is more likely than not that an impairment loss has been incurred. The
Company has analyzed a variety of factors on its business to determine if a circumstance could trigger an impairment loss, and, at this
time and based on the information presently known, does not believe it is more likely than not that an impairment loss has been incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets with finite useful lives are amortized using the straight-line method over their estimated period of benefit. In accordance with
ASC 360-10-35-21, definite lived intangibles are reviewed annually or more frequently if events or changes in circumstances indicate
that the assets might be impaired, to assess whether their fair value exceeds their carrying value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to capitalize trademarks and related expenses exceeding $2,500 per trademark. Management may also capitalize trademarks
and related expenses up to $2,500 per trademark based on its potential and benefit in coming years.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>r)
Software Development Costs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is developing two proprietary software platforms intended to be commercialized:-</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
A <b>clinical data management platform</b> designed for the collection, analysis, and real-time monitoring of clinical trial data; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
An <b>MINT- AD - AI-driven diagnostic and treatment personalization platform</b> aimed at assisting in the early detection of Alzheimer&#8217;s
disease and providing data-informed therapeutic suggestions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with <b>ASC 985-20</b>, <i>Software to Be Sold, Leased, or Marketed</i>, the Company capitalizes development costs incurred
after technological feasibility has been established and before the software is available for general release. Costs incurred during
the research, planning, or preliminary design phase are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized
costs include direct labor, third-party development services, cloud computing infrastructure directly related to model development and
deployment, and associated overhead. These costs are amortized on a straight-line basis over their estimated useful lives, typically
<b>five to ten years</b>, beginning when the software is ready for its intended commercial use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
Fiscal 2024, the Company began working on overlaying machine learning technologies and AI into the internal clinical trial software framework
for trial management with the expectation that this can lead to improved decision-making, contextual data entry, computational models,
trial design (Phase 3), and data analysis, the company believes it is probable that the project will be completed and the software will
be used to perform the function intended. As of Fiscal 2025, the Company capitalized approximately $863 thousand in software development
costs. For more information, please refer to Note 5, &#8220;Intangible Assets&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>s)
Inventory</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
is valued at the lower of cost or net realizable value, which is defined as estimated selling prices in the ordinary course of business,
less reasonably predictable costs of completion, disposal, and transportation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
consists of finished goods related to wellness products, hand sanitizers, finished hemp-based products, beverages. Work-and in-progress
consist of products in the manufacturing process as on reporting date, including but not limited to primary cost. Inventory is primarily
accounted for using the weighted average cost method. Primary costs include raw materials, packaging, direct labor, overhead, shipping,
and the depreciation of manufacturing equipment. Manufacturing overhead and related expenses include salaries, wages, employee benefits,
utilities, maintenance, and property taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
capitalize inventory costs related to our investigational drug, provided that management determines there is a potential alternative
use for the inventory in future research and development projects or other purposes. As of March 31, 2025, and 2024, our consolidated
balance sheet reported approximately $392 thousand of clinical trial-related inventory, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abnormal
amounts of idle facility expense, freight, handling costs, scrap, discontinued products, and wasted material (spoilage) are expensed
in the period they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
refer to Note 3, &#8220;Inventory,&#8221; for further information.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>t)
Cybersecurity Costs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains information technology systems and security protocols designed to protect sensitive clinical, corporate, and financial
data. Costs incurred in connection with the ongoing maintenance, enhancement, and monitoring of cybersecurity infrastructure are expensed
as incurred and classified within general and administrative expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews cybersecurity risks on an ongoing basis and implements technical and administrative controls in line with applicable
data protection standards. As of March 31, 2025, the Company had not capitalized any cybersecurity-related development costs, and no
material cybersecurity incidents have been identified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>u)
Research and Development Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development (R&amp;D) expenses include costs incurred to develop the Company&#8217;s clinical-stage drug candidates, including IGC-AD1
and other investigational therapies. These costs consist primarily of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
                                            trial site payments</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract
                                            research organization (CRO) fees</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
                                            compensation for R&amp;D personnel</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>

<tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
                                            and medical affairs consulting</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laboratory
                                            supplies and materials</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
                                            studies and formulation development</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D
expenses are expensed as incurred in accordance with ASC 730. Non-refundable advance payments for goods or services that will be used
in future R&amp;D activities are deferred and recognized as the related goods or services are received. During Fiscal 2025 and 2024,
the Company recorded research and development expenses of approximately $3.7 million and $3.8 million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>v)
Leases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lessor
Accounting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the current ASU guidance, contract consideration will be allocated to its lease components and non-lease components (such as maintenance).
For the Company as a lessor, any non-lease components will be accounted for under ASC Topic 606, &#8220;<i>Revenue from Contracts with
Customers,</i>&#8221; unless the Company elects a lessor practical expedient to not separate the non-lease components from the associated
lease component. The amendments in ASU 2018-11 also provide lessors with a practical expedient, by class of underlying asset, to not
separate non-lease components from the associated lease component and, instead, to account for those components as a single component
if the non-lease components otherwise would be accounted for under the new revenue guidance (Topic 606). To elect the practical expedient,
the timing and pattern of transfer of the lease and non-lease components must be the same and the lease component must meet the criteria
to be classified as an operating lease if accounted for separately. If these criteria are met, the single component will be accounted
for under either Topic 842 or Topic 606 depending on which component(s) are predominant. The lessor practical expedient to not separate
non-lease components from the associated component must be elected for all existing and new leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a lessor, the Company expects that post-adoption substantially all existing leases will have no change in the timing of revenue recognition
until their expiration or termination. The Company expects to elect the lessor practical expedient to not separate non-lease components
such as maintenance from the associated lease for all existing and new leases and to account for the combined component as a single lease
component. The timing of revenue recognition is expected to be the same for the majority of the Company&#8217;s new leases as compared
to similar existing leases; however, certain categories of new leases could have different revenue recognition patterns as compared to
similar existing leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
leases that are accounted for as operating leases, income is recognized on a straight-line basis over the term of the lease contract.
Generally, when a lease is more than 180 days delinquent (where more than three monthly payments are owed), the lease is classified as
being nonaccrual and the Company stops recognizing leasing income on that date. Payments received on leases in nonaccrual status generally
reduce the lease receivable. Leases on nonaccrual status remain classified as such until there is sustained payment performance that,
in the Company&#8217;s judgment, would indicate that all contractual amounts will be collected in full.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lessee
Accounting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted ASU 2016-02 effective April 1, 2019, using the modified retrospective approach. The standard establishes a right-of-use
model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer
than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense
recognition in the income statement. In connection with the adoption, the Company will elect to utilize the modified retrospective presentation
whereby the Company will continue to present prior period financial statements and disclosures under ASC Topic 840. In addition, the
Company will elect the transition package of three practical expedients permitted within the standard, which eliminates the requirements
to reassess prior conclusions about lease identification, lease classification and initial direct costs. Further, the Company will adopt
a short-term lease exception policy, permitting us to not apply the recognition requirements of this standard to short-term leases (i.e.,
leases with terms of 12 months or less), and an accounting policy to account for lease and non-lease components as a single component
for certain classes of assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASU 2016-02 (Topic 842), lessees are required to recognize the following for all leases (with the exception of short-term leases) on
the commencement date: (i) lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured
on a discounted basis; and (ii) right-of-use asset, which is an asset that represents the lessee&#8217;s right to use, or control the
use of, a specified asset for the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the commencement date, the Company recognizes the lease liability at the present value of the lease payments not yet paid, discounted
using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company&#8217;s incremental borrowing
rate for the same term as the underlying lease. The right-of-use asset is recognized initially at cost, which primarily comprises the
initial amount of the lease liability, plus any initial direct costs incurred, consisting mainly of brokerage commissions, less any lease
incentives received. All right-of-use assets are reviewed for impairment. There was no impairment for right-of-use lease assets as of
March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company categorizes leases at their inception as either operating or finance leases. On certain lease agreements, the Company may receive
rent holidays and other incentives. The Company recognizes lease costs on a straight-line basis without regard to deferred payment terms,
such as rent holidays, that defer the commencement date of required payments. Please refer to Note 9, &#8220;Leases,&#8221; for further
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>w)
Recently issued and adopted accounting pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
to U.S. GAAP are established by the Financial Accounting Standards Board (FASB) in the form of accounting standards updates (ASUs) to
the FASB&#8217;s Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. Newly issued ASUs
not listed are expected to have no impact on the Company&#8217;s consolidated financial position and results of operations because either
the ASU is not applicable or the impact is expected to be immaterial. Recent accounting pronouncements which may be applicable to us
are described in Note 2, &#8220;Significant Accounting Policies&#8221; in our Consolidated Financial Statements contained herein in Part
II, Item 8.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory Disclosure [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 </b>&#8211; <b>INVENTORY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center">(in thousands)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31, <br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,104</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,099</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Finished goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">256</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">441</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,360</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,540</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
Fiscal 2025, and Fiscal 2024, the Company wrote off approximately $217 thousand and $1 million of inventory due to abnormal loss, NRV
adjustment, product expiration, idle facility expense, freight, handling costs, scrap, and wasted material (spoilage). This charge was
recorded in Selling, General, and Administrative Expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
capitalize inventory costs related to our investigational drug, provided that management determines there is a potential alternative
use for the inventory in future research and development projects or other purposes. As of March 31, 2025, and March 31, 2024, our consolidated
balance sheet reported approximately $392 thousand of clinical trial-related inventory, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEPOSITS AND ADVANCES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_DepositsAndAdvancesAbstract', window );"><strong>Deposits And Advances Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_DepositsAndAdvancesTextBlock', window );">Deposits and Advances [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 </b>&#8211; <b>DEPOSITS AND ADVANCES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center">(in thousands)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
of <br/>
March 31,<br/>
2025<br/>
($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
of <br/>
March 31,<br/>
2024<br/>
($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Advances to suppliers and consultants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">41</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Other receivables and deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Prepaid expense and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">342</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">115</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">395</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">208</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Advances to suppliers and consultants primarily relate to advances to vendors. Prepaid expense and other current assets include approximately
$49 thousand and approximately $39 thousand in statutory advances for Fiscal 2025 and Fiscal 2024, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_DepositsAndAdvancesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_DepositsAndAdvancesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_DepositsAndAdvancesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of deposits and advances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_DepositsAndAdvancesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets Disclosure [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 </b>&#8211; <b>INTANGIBLE ASSETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Amortized intangible assets</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center">(in thousands)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31, <br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-left: 0.25pt">Patents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">530</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">836</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Other intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(205</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(181</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Total amortized intangible assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">359</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">689</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; font-style: italic; text-align: left; padding-left: 0.25pt">Unamortized intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">Patents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">630</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">521</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Software development cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">863</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">406</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Total unamortized intangible assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,493</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">927</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt">Total intangible assets</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,852</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,616</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of intangible assets includes the cost of acquiring patent rights, supporting data, and the expense associated with filing various
patent applications in different countries along with granted patents. It also includes acquisition costs related to domains and licenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amortization of patent and patent rights with finite life is up to 20 years, commencing from the date of grant or acquisition. The note
reflects the abandonment and expiration of certain non-core patent applications that management determined no longer aligned with the
Company&#8217;s strategic focus or had limited commercial potential. The related assets were fully impaired and removed from the balance
sheet. The expense was recognized in the consolidated statements of operations as part of general and administrative expenses. The Company
continues to evaluate its intellectual property portfolio to ensure alignment with its long-term development and commercialization strategy.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"><b>Estimated amortization expense</b></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><b>(in thousands)<br/>
 ($)</b></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0.25pt">For the year ended 2026</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">55</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">For the year ended 2027</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">60</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">For the year ended 2028</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">66</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">For the year ended 2029</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">73</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">For the year ended 2030</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">80</td>
    <td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT, AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 </b>&#8211; <b>PROPERTY, PLANT, AND EQUIPMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="10" style="font-weight: bold; font-style: italic; text-align: center">(in thousands, except useful life)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Useful Life<br/> (years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31,<br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0.25pt">Buildings and facilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">25</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,341</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,303</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Plant and machinery</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5-20</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,087</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,334</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Computer equipment&#8217;s</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">187</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Office equipment&#8217;s</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3-5</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Vehicles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt; padding-left: 0.25pt">Total gross value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">5,913</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">6,137</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,693</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,442</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt">Total property, plant, and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,220</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,695</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depreciation expense in Fiscal 2025 and 2024 amounted to approximately $567 thousand and $563 thousand, respectively. During Fiscal 2025,
the Company focused on liquidating all non-operating assets to reduce costs and generate cash. For more information, please refer to
Note 18, &#8220;Segment Information,&#8221; for the non-current assets other than financial instruments held in the country of domicile
and foreign countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Asset
Held For Sale</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
Fiscal 2024, the Company focused on liquidating all non-operating assets to reduce costs and generate cash. As a result, the Company
impaired the land situated in Nagpur, India, by approximately $3.3&#160;million to $720&#160;thousand from $4.1&#160;million to bring
it closer to the fair market value. The Company believes it can sell the above-said non-operating land as it is without any improvement.
Selling this land will give immediate cash, which the Company can use in its operating segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
Fiscal 2025, the Company entered into an agreement with the buyer to sell the said land for a net realizable value of approximately $702&#160;thousand.
The agreement is subject to the final registration and execution. The Company received a net of approximately $580&#160;thousand as a
deposit. The Company holds the ownership and possession of the said land. For further information, please refer to Note 19- &#8220;Subsequent
Events&#8221;.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CLAIMS AND ADVANCES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">Other Assets Disclosure [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 </b>&#8211; <b>CLAIMS AND ADVANCES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31,<br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Claims receivable (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">680</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">686</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Non-current deposits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25pt"><b>Total</b></td><td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 2.5pt double; text-align: right"><b>681</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 2.5pt double; text-align: right"><b>688</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
claims receivable is due from different vendors. While the Company has initiated collection proceedings internally or with the appropriate
authorities, it believes receiving the amount in the next 12 months will be challenging because of the time required for collection proceedings.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lessee, Operating Leases [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 </b>&#8211; <b>LEASES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has short-term leases primarily consisting of space with the remaining lease term being less than or equal to 12 months. The
Company has one short-term lease as of March 31, 2025. The total short-term lease expense and cash paid for Fiscal 2025 and 2024 are
approximately $39 thousand and $100 thousand, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has operating leases primarily consisting of spaces with the lease term being more than or equal to 12 months. The Company has
two operating leases as of March 31, 2025. The total operating leases expense and cash paid for Fiscal 2025 and 2024 are approximately
$135 thousand and $141 thousand, respectively.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">(in thousands) <br/> Year Ended <br/> March 31, <br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">(in thousands) <br/> Year Ended <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Operating lease costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">135</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">141</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Short term lease costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">39</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">100</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt">Total lease costs</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">174</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">241</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
of use assets and lease liabilities for our operating leases were recorded in the consolidated balance sheet as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended<br/> March 31, <br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Operating lease asset</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right">98</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right">198</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"><b>Total lease assets</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>98</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>198</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt"><b>Liabilities</b></td><td><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="text-align: left"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="text-align: left"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Accrued liabilities and others (current portion &#8211; operating lease liability)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">93</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">124</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Noncurrent liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Operating lease liability (non-current portion &#8211; operating lease liability)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">84</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"><b>Total lease liability</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>103</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>208</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">Supplemental cash flow and non-cash information related to leases is as follows:</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">(in thousands) <br/> Year Ended <br/> March 31, <br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">(in thousands) <br/> Year Ended<br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">&#8211;Operating cash flows from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">129</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">140</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Right-of-use assets obtained in exchange for operating lease obligations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td colspan="5">As of March 31, 2025, the following table summarizes the maturity of our lease liabilities:</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; padding-left: 0.25pt">Mar-26</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">96</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Mar-27</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">Mar-28</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Mar-29</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Less: Present value discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Total Lease liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">103</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED LIABILITIES AND OTHERS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_AccruedLiabilitiesDisclosureAbstract', window );"><strong>Accrued Liabilities Disclosure Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_AccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities Disclosure [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 </b>&#8211; <b>ACCRUED LIABILITIES AND OTHERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31, <br/> 2025 <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Compensation and other contributions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">160</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">816</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Provision for expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Short-term lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">124</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Other current liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,003</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">419</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25pt"><b>Total</b></td><td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 2.5pt double; text-align: right"><b>1,374</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 2.5pt double; text-align: right"><b>1,567</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
and other contribution-related liabilities consist of accrued salaries to employees. In addition, provision for expenses includes provision
for legal, professional, and marketing expenses. Other current liability also includes statutory payables of approximately $19 thousand
and $25 thousand as of March 31, 2025, and March 31, 2024, respectively, and approximately $3 thousand of short-term loans as of March
31, 2025, and March 31, 2024, respectively. &#160;In addition, Other current liabilities for Fiscal 2025 consist of approximately $580&#160;thousand
and $46 thousand related to asset held for sale and provision for a statutory liability, respectively. Please refer to Note 6 &#8211;
&#8220;Property, plant and, equipment&#8221;, for more information.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_AccruedLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_AccruedLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_AccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure for accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_AccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOANS AND OTHER LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_LoansAndOtherLiabilitiesAbstract', window );"><strong>Loans And Other Liabilities Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_LoansAndOtherLiabilitiesTextBlock', window );">Loans and Other Liabilities [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 </b>&#8211; <b>LOANS AND OTHER LIABILITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Loan
as of March 31, 2025:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 11, 2020, the Company received an Economic Injury Disaster Loan (EIDL) for approximately $150 thousand at an annual interest rate
of 3.75%. The Company must pay principal and interest payments of $731 every month beginning June 5, 2021. The SBA will apply each installment
payment first to pay interest accrued to the day SBA receives the payment and will then apply any remaining balance to reduce the principal.
All remaining principal and accrued interest are due and payable 30 years from the date of the loan. For Fiscal 2025, the interest expense
and principal payment for the EIDL were approximately $5 thousand and $3 thousand, respectively. As of March 31, 2025, approximately
$134 thousand of the loan is classified as Long-term loans and approximately $3 thousand as Short-term loans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Liability:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center">(in thousands)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Statutory reserve</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right">16</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right">20</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">16</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">20</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
statutory reserve is a gratuity reserve for employees in our subsidiaries in India.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_LoansAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_LoansAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_LoansAndOtherLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of loans and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_LoansAndOtherLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12 </b>&#8211; <b>COMMITMENTS AND CONTINGENCIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may be involved in legal proceedings, claims, and assessments arising in the ordinary course of business. Such matters are subject
to many uncertainties, and outcomes are not predictable with assurance. There are no such matters that are deemed material to the consolidated
financial statements as of March 31, 2025, except as disclosed in Item 3 &#8211; Legal Proceedings and Note 19 &#8211; Subsequent Events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., we provide health insurance, life insurance, and a 401(k) plan wherein the Company matches up to 6% of the employee&#8217;s
pre-tax contribution up to a maximum annual amount determined by the IRS. In addition, under applicable Indian laws, the Company provides
for gratuity, a defined benefit retirement plan (Gratuity Plan) covering certain categories of employees. The Gratuity Plan provides
a lump sum payment to vested employees, at retirement or termination of employment, an amount based on the respective employee&#8217;s
last drawn salary and the years of employment with the Company. In addition, employees receive benefits from a provident fund, a defined
contribution plan. The employee and employer each make monthly contributions to the plan as required by the law. The contribution is
made to the Foreign Government&#8217;s funds.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SECURITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13 </b>&#8211; <b>SECURITIES </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, the Company was authorized to issue up to 150,000,000 shares of common stock, par value of $0.0001 per share, and
80,878,058 shares of common stock were issued and outstanding. The Company is also authorized to issue up to 1,000,000 shares of preferred
stock, par value of $0.0001 per share, and no preferred shares were issued and outstanding as of March 31, 2025. We have one security
listed on the NYSE American: common stock, $0.0001 par value (ticker symbol: IGC). This security also trades on the Frankfurt, Stuttgart,
and Berlin stock exchanges (ticker symbol: IGS1).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also has 91,472 units outstanding that can be separated into common stock. Ten units may be separated into one share of common
stock. The unit holders are requested to contact the Company or our transfer agent, Continental Stock Transfer &amp; Trust, to separate
their units into common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 22, 2024, the Company entered into a Share Purchase Agreement (the March 2024 SPA) with Bradbury Strategic Investment Fund A, resulting
in approximately $3 million in gross proceeds. The completion of the private placement is subject to customary closing conditions, including
approval by the NYSE. Under the terms of the private placement, IGC will issue approximately 8.8 million shares of unregistered common
stock at a price of $0.34 per share. In addition, the Company issued 2 million shares of unregistered common stock for consulting services
related to raising capital, including the March 2024 capital raised. Shares are intended to be exempt from registration under the Securities
Act of 1933, as amended (the Securities Act), by virtue of the provisions of Section 4(a)(2) of the Securities Act and Regulation D and/or
Regulation S adopted thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 25, 2024, the Company entered into the Share Purchase Agreement (the September 2024 SPA) with Moran Global Strategies, Inc.,
a Virginia corporation (MGS), which is owned by James Moran, a director of IGC, relating to the sale and issuance by our company to the
investors of an aggregate of 588,235 shares of our common stock, for a total purchase price of $200,000 or $0.34 per share, subject to
the terms and conditions set forth in the September 2024 SPA. The investment is subject to customary closing conditions, including NYSE
approval. As per the September 2024 SPA, the investor received piggyback registration rights subject to certain restrictions. During
the fiscal year ended March 31, 2025, the Company received the purchase price, and the issuance of common stock is in process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 27, 2023, the Company entered into a Sales Agreement (the Sales Agreement) with A.G.P./Alliance Global Partners (the Agent) pursuant
to which the Company may offer and sell, from time to time, through the Agent, as sales agent and/or principal, shares of its common
stock, having an aggregate offering price of up to $60 million, subject to certain limitations on the amount of common stock that may
be offered and sold by the Company set forth in the Sales Agreement. During Fiscal 2025, the company raised approximately $1.8 million
against 5,363,334 shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the first quarter of Fiscal 2026, the Company entered into Share Purchase Agreements with multiple investors (the 2025 Share Purchase
Agreements), relating to the sale and issuance by our company to the investors of an aggregate of 2,803,333 shares of our common stock,
for a total purchase price of $841,000, or $0.30 per share, subject to the terms and conditions set forth in the 2025 Share Purchase
Agreements. The investment is subject to customary closing conditions, including NYSE approval. As per the 2025 Share Purchase Agreements,
the investor received piggyback registration rights subject to certain restrictions.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payment Arrangement [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
14 </b>&#8211; <b>STOCK-BASED COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, under both the Company&#8217;s previous 2008 and current 2018 Omnibus Incentive Plans, approximately 9.1 million shares
of common stock have been issued to employees, non-employees, and advisors. In addition, 7.3 million restricted share units (RSUs) fair
valued at $4.3 million with a weighted average value of $0.59 per share, have been granted but not yet issued from different Incentive
Plans and Grants. This includes 4.7 million RSUs granted to employees and directors, which consists of a vesting schedule based entirely
on the attainment of either operational milestones (performance conditions) or market conditions, assuming continued employment either
as an employee, or director with the Company. The performance-based RSUs are accounted for upon certification by the management, confirming
the probability of achievement of milestones. As of March 31, 2025, the management confirmed that five milestones had been achieved,
and the rest were probable to be achieved by March 31, 2028.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
options held by advisors and directors to purchase 4 million shares of common stock fair valued at $1 million with a weighted average
of $0.26 per share, which have been granted but are to be issued over a vesting period between Fiscal 2022 and Fiscal 2027. Options granted
and issued before the vesting period are expensed when issued.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
options are fair valued using a Black-Scholes Pricing Model, and market-based RSU are valued based on a lattice model with the following
assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td colspan="2" style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Granted
in <br/>
Fiscal 2025</b></span></p></td> <td style="padding: 0.25pt 0.25pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td colspan="2" style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Granted
in <br/>
Fiscal 2024</b></span></p></td> <td style="padding: 0.25pt 0.25pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life of options</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td colspan="2" style="padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td colspan="2" style="padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding: 0.25pt; width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested options</span></td> <td style="width: 1%; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="width: 1%; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="width: 9%; padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="white-space: nowrap; width: 1%; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="width: 1%; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="width: 1%; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="width: 9%; padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="white-space: nowrap; width: 1%; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk free interest rate</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.93</span></td> <td style="white-space: nowrap; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.24</span></td> <td style="white-space: nowrap; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">171</span></td> <td style="white-space: nowrap; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">175</span></td> <td style="white-space: nowrap; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td colspan="2" style="padding: 0.25pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-2; font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td colspan="2" style="padding: 0.25pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-3; font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expense associated with share-based payments to employees, directors, advisors, and contractors is allocated over the vesting or service
period and recognized in the Selling, general, and administrative expenses (including research and development). For Fiscal 2025, the
Company&#8217;s share-based expense and option-based expense, shown in Selling, general, and administrative expenses (including research
and development), were $1 million and $590 thousand, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Fiscal 2024, the Company&#8217;s share-based expenses and option-based expenses shown in Selling, general, and administrative expenses
(including research and development) were $1.7 million and $59 thousand, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Non-vested shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares <br/> (in thousands)<br/> (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <br/> average<br/> grant date <br/> fair value<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-left: 0.25pt">Non-vested shares as of March 31, 2024 </td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,452</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.61</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Granted </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">Vested </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,443</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.34</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">Cancelled/Forfeited </td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(212</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.33</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt"><b>Non-vested shares as of March 31, 2025</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>5,796</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>0.64</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Options</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares <br/> (in thousands) <br/> (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<br/> average <br/> grant date <br/> fair value<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<br/> average <br/> exercise <br/> price<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-left: 0.25pt">Options outstanding as of March 31, 2024</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">3,710</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.25</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.39</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.34</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(628</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.25</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">Cancelled/forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(150</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1.39</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.39</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt; padding-left: 0.25pt">Options outstanding as of March 31, 2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">3,182</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">0.30</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">0.34</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was a combined unrecognized expense of $1.7 million related to non-vested shares and share options that the Company expects to be recognized
over a life of up to 4 (four) years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
15 </b>&#8211; <b>FAIR VALUE OF FINANCIAL INSTRUMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, the Company&#8217;s marketable securities consist of liquid funds, which have been classified as Level 1 of the fair
value hierarchy because they have been valued using quoted prices in active markets. The Company&#8217;s cash and cash equivalents have
also been classified as Level 1 on the same principle. Financial instruments are classified as current if they are expected to be liquidated
within the next twelve months. The Company&#8217;s remaining investments have been classified as Level 3 instruments as there is little
or no market data. Level 3 investments are valued using the cost method. For further information refer Note 7, &#8220;Investments in
Non-Marketable Securities.&#8221;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s assets that are measured at fair value on a recurring basis as of March
31, 2025, and 2024, and indicates the fair value hierarchy of the valuation techniques the Company used to determine such fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(in
thousands)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>As
of March 31, 2025</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Particular</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Adjusted<br/> Cost<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gain <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Loss<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Cash &amp;<br/> Cash <br/> Equivalents<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Short Term<br/> Investments <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><b>Level 1</b></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; padding-left: 0.25pt">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">368</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">368</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">368</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Money Market Fund</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Debt Funds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">Mutual Fund</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt"><b>Level 2</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">Certificates of Deposit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">37</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">37</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">37</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt"><b>Level 3</b></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25pt"><b>TOTAL</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">405</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">405</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">405</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>As
of March 31, 2024</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Particular</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Adjusted<br/> Cost<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gain <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Loss<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Cash &amp; <br/> Cash<br/> Equivalents <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Short Term <br/> Investments<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Level 1</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; padding-left: 0.25pt">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">912</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">912</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">912</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Money Market Fund</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Debt Funds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">Mutual Fund</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">123</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">123</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">123</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0.25pt">Level 2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">Certificates of Deposit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">150</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">150</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">150</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt; padding-left: 0.25pt">Level 3</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt">TOTAL</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,198</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,198</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,198</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
16 </b>&#8211; <b>INCOME TAXES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company calculates its provision for foreign and U.S. federal income taxes based on the current tax law. As the Company maintains a full
valuation allowance against its deferred tax assets, there is no income tax expense recorded related to this change other than the Federal
AMT credit which are refundable due to the passage of tax reform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the Company&#8217;s history of losses and uncertainty of future taxable income, a valuation allowance sufficient to fully offset net
operating losses and other deferred tax assets has been established. The valuation allowance will be maintained until sufficient positive
evidence exists to support a conclusion that a valuation allowance is not necessary.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense/(benefit) for each of the years ended March 31 consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended March 31,<br/>
 (in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Income Tax Expense</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Net income loss before tax</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(7,121</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(13,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Tax rate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">21</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">21</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Expected income tax recovery</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,495</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,730</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Impact of tax rate differences in foreign jurisdictions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(72</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(151</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Tax rate changes and other adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,305</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,475</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,872</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,406</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
significant components of deferred income tax expense/(benefit) from operations before non-controlling interest for each of the years
ended March 31 are approximated as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">Year Ended March 31, <br/> (in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Deferred income taxes</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Net operating loss carry-forwards foreign</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">332</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">287</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Non-capital loss carry-forwards &#8211; U.S.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,272</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Temporary differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">427</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">418</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Net deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,124
</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,977</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(19,124</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(14,977</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth the details of expiration of the non-financial carried forward losses of the Company as of March 31, 2025, as
under:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><b>Year</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><b>Amount<br/>
 (in thousands)<br/>
 ($)</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0.25pt">2029</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">16</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">2030</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">37</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">2031</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,081</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">2032</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4,141</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">2033</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">627</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">2034</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,269</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">2035</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,735</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">2036</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,176</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">2037</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">819</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">No expiry</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,256</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">No expiry</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4,132</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">No expiry</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">7,932</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">No expiry</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8,841</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">No expiry</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">14,966</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">No expiry</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8,552</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">No expiry</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">6,884</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">No expiry</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">22,006</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">87,469</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Realization
of deferred tax assets, including those related to net operating loss carryforwards, are dependent upon future earnings, if any, of which
the timing and amount are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. Based
upon the Company&#8217;s current operating results management cannot conclude that it is more likely than not that such assets will be
realized. The Company files income tax returns in India, Colombia, and the U.S. The Company has a carry-forward R&amp;D tax credit of
approximately $4,542 thousand.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue from Contract with Customer [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
17 </b>&#8211; <b>REVENUE RECOGNITION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
in the renting business when the equipment is rented, and the terms of the agreement have been fulfilled during the period. Revenue from
the execution of infrastructure contracts is recognized on the basis of the output method as and when part of the performance obligation
has been completed, and approval from the contracting agency has been obtained after a survey of the performance completion as of that
date. The revenue from the wellness and lifestyle business is recognized once goods have been sold to the customer and the performance
obligation has been completed. In retail sales, we offer consumer products through our online stores. Revenue is recognized when control
of the goods is transferred to the customer. This generally occurs upon our delivery to a third-party carrier or to the customer directly.
Revenue from white labelling services is recognized when the performance obligation has been completed, and output material has been
transferred to the customer.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
sales disaggregated by significant products and services for Fiscal 2025 and 2024 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">(in thousands) <br/> Year ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wellness and lifestyle <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">113</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">228</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">White labeling services <sup>(2)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,158</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">953</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other<sup>(3)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">164</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,271</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,345</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from wellness and lifestyle consists of the sale of products such as gummies, hand sanitizers, bath bombs, lotions, beverages, hemp crude
extract, hemp isolate, and hemp distillate.</span></td>
</tr></table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from white labelling services consists of rebranding our formulations or the customer&#8217;s products as per the customer&#8217;s requirement.</span></td>
</tr></table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
consists of income from the rental of heavy construction equipment and the execution of contracts directly or through subcontractors.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting Disclosure [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
18 </b>&#8211; <b>SEGMENT INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB
ASC 280, &#8220;<i>Segment Reporting,</i>&#8221; establishes standards for reporting information about reportable segments. Operating
segments are defined as components of an enterprise about which separate financial information is available and is evaluated regularly
by the chief operating decision maker, or decision-making group (CODM), in deciding how to allocate resources and in assessing performance.
The CODM evaluates revenues and gross profits based on product lines and routes to market. The Company&#8217;s CODM is the Company&#8217;s
Chief Executive Officer (CEO). The CEO reviews financial information presented on an operating segment basis for the purposes of making
operating decisions and assessing financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal 2025, the Company reassessed its reportable segment structure in connection with its strategic realignment toward Life Sciences.
As a result, management determined that the Company operates as a <b>single reportable segment</b>. Historically, the Company reported
two operating segments: Life Sciences and Infrastructure. While the Infrastructure segment generated revenues in fiscal 2024, it did
not generate any revenues in fiscal 2025 and is no longer actively managed or evaluated as a discrete operating segment by the Company&#8217;s
Chief Operating Decision Maker.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has not made a formal decision to dispose of or exit the Infrastructure business, and therefore, the Infrastructure operations have not
been classified as discontinued operations. The results of the Infrastructure activities have been aggregated into the single reportable
segment presentation for all periods presented in this Annual Report on Form 10-K. This change in segment reporting has no impact on
the Company&#8217;s previously reported consolidated financial position, results of operations, or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following provides information required by ASC 280-10-50-38 &#8220;Entity-wide Information&#8221;:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)
The table below shows revenue reported by segments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
&amp; Service</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Segments</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Life Sciences segment</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right">1,271</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right">1,345</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25pt"><b>Total</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,271</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1345</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Fiscal 2024, $164 thousand belongs to the previously reported Infrastructure Segment.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
information on revenue by product and service, refer to Note 17, &#8220;Revenue Recognition.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)
The table below shows the attributes to the country of domicile (U.S.) and foreign countries. Revenue is generally attributed to the
geographic location of customers:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center">(in thousands)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Segments</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Country</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage&#160;of <br/> Total<br/> Revenue <br/> (%)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">Asia</td><td>&#160;</td>
    <td style="text-align: left">India</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 60%; padding-left: 0.25pt">America</td><td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: left">U.S.</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,269</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">99.8</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">Colombia</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.2</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,271</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">100</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Segments</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Country</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage&#160;of <br/> Total<br/> Revenue<br/> (%)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; padding-left: 0.25pt">Asia</td><td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: left">India</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">164</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">12</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">America</td><td>&#160;</td>
    <td style="text-align: left">U.S.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,179</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">Colombia</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,345</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)
The table below shows the non-current assets other than financial instruments held in the country of domicile and foreign countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="10" style="font-weight: bold; font-style: italic; text-align: center">(in thousands)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Nature of Assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">U.S. <br/> (Country of <br/> Domicile)<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Foreign <br/> Countries <br/> (India and <br/> Colombia) <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total as of <br/> March 31, <br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0.25pt">Intangible assets, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,852</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,852</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Property, plant, and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,171</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,220</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Claims and advances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">410</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">271</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">681</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Operating lease asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">80</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">98</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt">Total non-current assets</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">5,513</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">338</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">5,851</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Nature of Assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">U.S. <br/> (Country of <br/> Domicile) <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Foreign <br/> Countries<br/> (India and <br/> Colombia)<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total as of <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0.25pt">Intangible assets, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,616</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,616</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Property, plant, and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,620</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,695</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Claims and advances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">410</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">278</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">688</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Operating lease asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">193</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">198</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt"><b>Total non-current assets</b></td><td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 2.5pt double; text-align: right"><b>5,839</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 2.5pt double; text-align: right"><b>358</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 2.5pt double; text-align: right"><b>6,197</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
19 </b>&#8211; <b>SUBSEQUENT EVENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the first quarter of Fiscal 2026, the Company entered into a Share Purchase Agreement (the &#8220;2025 SPA&#8221;) with multiple investors,
relating to the sale and issuance by our company to investors of an aggregate of 2,803,333 shares of our common stock, for a total purchase
price of $841,000, or $0.30 per share, subject to the terms and conditions set forth in the 2025 SPA. The investment is subject to customary
closing conditions, including NYSE approval. As per the 2025 SPA, the investor received piggyback registration rights subject to certain
restrictions. Shares are intended to be exempt from registration under the Securities Act, by virtue of the provisions of Section 4(a)(2)
of Securities Act.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2025, IGC Pharma expanded its CALMA Phase 2 trial for agitation in Alzheimer&#8217;s dementia to two renowned research sites: Butler
Hospital&#8217;s Memory and Aging Program (a nationally recognized research center affiliated with the Warren Alpert Medical School of
Brown University) in Rhode Island and the MIND Institute at Miami Jewish Health in Florida.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Asset held for sale has been sold for a value of approximately $701 thousand, and the ownership of the land has been wholly transferred
to the respective purchasers.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">On June 24, 2025, IGC Pharma, Inc. (&#8220;IGC&#8221; or the &#8220;Company&#8221;) entered into an amendment to extend its existing Master Loan and Security Agreement along with the General Banking Facility Letter (collectively called the &#8220;Loan Agreement&#8221;) with O-Bank, CO., LTD., a banking corporation incorporated under the laws of Taiwan, as administrative agent and lender (the &#8220;Lender&#8217;), effective June 24, 2024. The amendment extends the term of the Loan Agreement, which was set to expire, under the same terms and conditions as previously disclosed on the Company&#8217;s Current Report on Form 8-K filed with the Securities Exchange Commission on August 2, 2024, with the exception of i) a reduction in the facility fees from $84,000 to $48,000 and ii) interest, calculated according to the interest rate mentioned in the Certificate of Deposit, as the case may be, plus an applicable margin of 1.2%, instead of 1% . All other material terms of the Loan Agreement remain unchanged.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (7,122)<span></span>
</td>
<td class="num">$ (13,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At IGC, we are committed to
maintaining the confidentiality, integrity, and availability of our information systems and data. As part of this commitment, we have
implemented a comprehensive cybersecurity program to protect against unauthorized access, use, disclosure, modification, or destruction
of our information assets. We are committed to ensuring the security and protection of our company&#8217;s information assets and the
personal information of our employees, customers, and stakeholders.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At IGC, we are committed to
maintaining the confidentiality, integrity, and availability of our information systems and data. As part of this commitment, we have
implemented a comprehensive cybersecurity program to protect against unauthorized access, use, disclosure, modification, or destruction
of our information assets. We are committed to ensuring the security and protection of our company&#8217;s information assets and the
personal information of our employees, customers, and stakeholders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognize that cybersecurity
threats are constantly evolving and have the potential to cause significant harm to our company and our stakeholders. In order to address
these risks, we have established a cybersecurity risk management framework that is aligned with industry best practices and regulatory
requirements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our program includes regular
risk assessments, vulnerability management, access controls, incident response planning, and employee training and awareness programs.
We also work closely with third-party service providers to ensure that they are meeting our cybersecurity standards.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of a cybersecurity
incident, we have established procedures for prompt investigation, containment, and remediation to minimize the impact on our operations
and stakeholders. We believe that our cybersecurity program is robust and effective, and we will continue to invest in and improve our
capabilities to address evolving threats, although there can be no assurance, that our cybersecurity program will prevent all incidents.
We are committed to transparency and will provide updates on any material cybersecurity incidents that may impact our company or our stakeholders.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors addresses
the Company&#8217;s cybersecurity risk management as part of its general oversight function. The board of directors&#8217; audit committee
is responsible for overseeing Company&#8217;s cybersecurity risk management processes, including oversight and mitigation of risks from
cybersecurity threats.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors addresses
the Company&#8217;s cybersecurity risk management as part of its general oversight function. The board of directors&#8217; audit committee
is responsible for overseeing Company&#8217;s cybersecurity risk management processes, including oversight and mitigation of risks from
cybersecurity threats.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors addresses
the Company&#8217;s cybersecurity risk management as part of its general oversight function. The board of directors&#8217; audit committee
is responsible for overseeing Company&#8217;s cybersecurity risk management processes, including oversight and mitigation of risks from
cybersecurity threats.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cybersecurity risk assessment
and management processes are implemented and maintained by certain Company management, including our IT Lead. Our IT Lead has 5 years
of experience in roles that include oversight of cybersecurity risk management programs. In addition, the IT Lead is assisted by an external
agency with about 15 years of expertise in cybersecurity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our IT Lead is responsible
for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management
strategy, communicating key priorities to relevant personnel, helping prepare for cybersecurity incidents, approving cybersecurity processes,
and reviewing security assessments and other security-related reports.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors addresses
the Company&#8217;s cybersecurity risk management as part of its general oversight function. The board of directors&#8217; audit committee
is responsible for overseeing Company&#8217;s cybersecurity risk management processes, including oversight and mitigation of risks from
cybersecurity threats.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cybersecurity risk assessment
and management processes are implemented and maintained by certain Company management, including our IT Lead. Our IT Lead has 5 years
of experience in roles that include oversight of cybersecurity risk management programs. In addition, the IT Lead is assisted by an external
agency with about 15 years of expertise in cybersecurity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our IT Lead is responsible
for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management
strategy, communicating key priorities to relevant personnel, helping prepare for cybersecurity incidents, approving cybersecurity processes,
and reviewing security assessments and other security-related reports.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cybersecurity incident
response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including
the CEO, who help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the Company&#8217;s
incident response processes include reporting to the audit committee for certain cybersecurity incidents.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors addresses
the Company&#8217;s cybersecurity risk management as part of its general oversight function. The board of directors&#8217; audit committee
is responsible for overseeing Company&#8217;s cybersecurity risk management processes, including oversight and mitigation of risks from
cybersecurity threats.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cybersecurity risk assessment
and management processes are implemented and maintained by certain Company management, including our IT Lead. Our IT Lead has 5 years
of experience in roles that include oversight of cybersecurity risk management programs. In addition, the IT Lead is assisted by an external
agency with about 15 years of expertise in cybersecurity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our IT Lead is responsible
for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management
strategy, communicating key priorities to relevant personnel, helping prepare for cybersecurity incidents, approving cybersecurity processes,
and reviewing security assessments and other security-related reports.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cybersecurity incident
response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including
the CEO, who help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the Company&#8217;s
incident response processes include reporting to the audit committee for certain cybersecurity incidents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The audit committee will receive
periodic reports from our management concerning cybersecurity issues, including certain threats and risks and the processes the Company
has implemented to address them, as applicable. The audit committee also has access to various reports, summaries or presentations related
to cybersecurity threats, risk, and mitigation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">The board of directors&#8217; audit committee
is responsible for overseeing Company&#8217;s cybersecurity risk management processes, including oversight and mitigation of risks from
cybersecurity threats.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cybersecurity risk assessment
and management processes are implemented and maintained by certain Company management, including our IT Lead. Our IT Lead has 5 years
of experience in roles that include oversight of cybersecurity risk management programs. In addition, the IT Lead is assisted by an external
agency with about 15 years of expertise in cybersecurity.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a)
Principles of consolidation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of the Company and all its subsidiaries. Intercompany accounts and transactions
have been eliminated. In the opinion of the Company&#8217;s management, the consolidated financial statements reflect all adjustments,
which are normal and recurring in nature, necessary for fair financial statement presentation. Transactions between the Company and its
subsidiaries are eliminated in the consolidated financial statements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b)
Use of estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with accounting principles generally accepted in the U.S. (U.S. GAAP) requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual
results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
believes that the estimates and assumptions used in the preparation of the consolidated financial statements are prudent and reasonable.
Significant estimates and assumptions are generally used for, but not limited to, allowance for uncollectible accounts receivable; sales
returns; normal loss during production; future obligations under employee benefit plans; the useful lives of property, plant, and equipment;
intangible assets; valuations; impairment of goodwill and investments; recoverability of advances; the valuation of options granted,
and warrants issued; and income tax and deferred tax valuation allowances, if any. Actual results could differ from those estimates.
Appropriate changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. Critical
accounting estimates could change from period to period and could have a material impact on IGC&#8217;s results, operations, financial
position, and cash flows. Changes in estimates are reflected in the financial statements in the period in which changes are made, and
if material, their effects are disclosed in the notes to the consolidated financial statements.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue [Policy Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c)
Revenue recognition</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue under ASC 606, <i>Revenue from Contracts with Customers </i>(ASC 606). The core principle of this standard
is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects
the consideration to which the Company expects to be entitled in exchange for those goods or services.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
606 prescribes a 5-step process to achieve its core principle. The Company recognizes revenue from trading, rental, or product sales
as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.
Identify the contract with the customer.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.
Identify the contractual performance obligations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">III.
Determine the amount of consideration/price for the transaction.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IV.
Allocate the determined amount of consideration/price to the contractual obligations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">V.
Recognize revenue when or as the performing party satisfies performance obligations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consideration/price for the transaction (performance obligation(s)) is determined as per the agreement or invoice (contract) for the
services and products. Refer to Note 17 &#8211; &#8220;Revenue Recognition.&#8221;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods and Service [Policy Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>d)
Cost of Revenue</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cost of revenue includes costs associated with in-house and outsourced distribution, labor expenses, components, manufacturing overhead,
and outbound freight for our products division. In our products division, the cost of revenue also includes the cost of refurbishing
or repackaging, if required, on products returned by customers that will be offered for resale.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>e)
Loss per Share</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
computation of basic loss per share for Fiscal 2025 excludes potentially dilutive securities of approximately shares, which includes
share options, unvested shares such as restricted shares and restricted share units granted to employees, non-employees, and advisors,
and shares from the conversion of outstanding units, if any, because their inclusion would be anti-dilutive.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average number of shares outstanding for Fiscal 2025 and 2024, used for the computation of basic earnings per share (EPS) is
76,517,175 and 58,839,868, respectively. Due to the loss incurred during Fiscal 2025 and 2024, all the potential equity shares are anti-dilutive,
and accordingly, the fully diluted EPS is equal to the basic EPS.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_GoingConcernPolicyPolicyTextblock', window );">Going Concern, Policy [Policy Textblock}</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f)
Going Concern:</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses and determines its ability to continue as a going concern in accordance with the provisions of ASC Subtopic 205-40,
&#8220;<i>Presentation of Financial Statements</i>&#8212;<i>Going Concern</i>&#8221;, which requires the Company to evaluate whether there
are conditions or events that raise substantial doubt about its ability to continue as a going concern.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is currently in a clinical trial stage and, thus, has not yet achieved profitability. The Company expects to continue to incur
significant operating and net losses and negative cash flows from operations in the near future.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended March 31, 2025, and March 31, 2024, the Company incurred net losses of $7.1 million and $13 million, respectively. During
fiscal 2025, the Company renewed the facility with O-bank. In addition, the Company raised approximately $4.64 million through private
placements and an at-the-market offering program. The at-the-market program and the credit facility serve to minimize ongoing liquidity
requirements and ensure the Company&#8217;s ability to sustain its operations. The Company has taken several steps to extend its operational
runway, including narrowing its strategic focus to Life Sciences, limiting investment in non-core infrastructure operations, and managing
expenses related to clinical development with a disciplined approach. While management believes these actions improve the Company&#8217;s
financial position, there can be no assurance that additional financing will be available on acceptable terms, or at all.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
first quarter of Fiscal 2026, the Company entered into the 2025 Share Purchase Agreement with multiple investors, relating to the sale
and issuance by our company to the investors of an aggregate of 2,803,333 shares of our common stock, for a total purchase price of $841,000,
or $0.30 per share, subject to the terms and conditions set forth in the 2025 SPA. The investment is subject to customary closing conditions,
including NYSE approval. As per the 2025 SPA, the investor received piggyback registration rights subject to certain restrictions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates that its current cash and cash equivalents balance, with the working capital and investments, and with an available
overdraft facility of $12 million from O-Bank, is sufficient to support operations beyond the twelve months following the date these
consolidated financial statements and footnotes were issued. These estimates are based on assumptions that may prove to be wrong, and
the Company could use its available capital resources sooner than it currently expects.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>g)
Income taxes</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes under the asset and liability method, in accordance with ASC 740, Income Taxes, which requires an entity
to recognize deferred tax liabilities and assets. Deferred tax assets and liabilities are recognized for the future tax consequence attributable
to the differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases and operating
loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using the enacted tax rate expected to apply to
taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax
assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance
is established and recorded when management determines that some or all of the deferred tax assets are not likely to be realized and,
therefore, it is necessary to reduce deferred tax assets to the amount expected to be realized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
evaluating a tax position for recognition, management evaluates whether it is more-likely-than-not that a position will be sustained
upon examination, including the resolution of related appeals or litigation processes, based on the technical merits of the position.
If the tax position meets the more-likely-than-not recognition threshold, the tax position is measured and recognized in the Company&#8217;s
financial statements as the largest amount of tax benefit that, in management&#8217;s judgment, is greater than 50% likely to be realized
upon settlement. As of March 31, 2025, and 2024, there was no significant liability for income tax associated with unrecognized tax benefits.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the last quarter of fiscal 2025, the Company received a tax credit of approximately $194 thousand, which has been recorded as other income
in the accompanying consolidated statements of operations. The credit relates to qualifying expenditures under applicable federal tax
incentive programs. The Company has submitted additional claims and expects to receive approximately $600 thousand in tax credits during
fiscal 2026. However, there can be no assurance as to the timing or certainty of receipt, as the claims are subject to review and approval
by the Internal Revenue Service (IRS). The Company will recognize any additional credits as income when collection is deemed probable
in accordance with applicable accounting standards.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable [Policy Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>h)
Accounts receivable</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
make estimates of the collectability of our accounts receivable by analyzing historical payment patterns, customer concentrations, customer
creditworthiness, and current economic trends. If the financial condition of a customer deteriorates, additional allowances may be required.
We had $34 thousand of accounts receivable, net of provision for doubtful debt of $12 thousand as of March 31, 2025, as compared to $39
thousand of accounts receivable, net of provision for doubtful debt of $24 thousand as of March 31, 2024.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>i)
Cash and cash equivalents</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
financial statement purposes, the Company considers all highly liquid debt instruments with a maturity of three months or less to be
cash equivalents. The Company maintains its cash in bank accounts in the U.S., India, and Colombia, which at times may exceed applicable
insurance limits. The cash and cash equivalents of the Company on March 31, 2025, and 2024 were approximately $405 thousand and $1.2
million, respectively. The company&#8217;s cash balance also includes approximately $8 thousand in restricted cash.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>j)
Short-term and long-term investments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
policy for short-term and long-term investments is to establish a high-quality portfolio that preserves principal, meets liquidity needs,
avoids inappropriate concentrations, and delivers an appropriate yield in relation to our investment guidelines and market conditions.
Short-term and long-term investments consist of corporate, various government agencies, and municipal debt securities, as well as certificates
of deposit that have maturity dates that are greater than 90 days. Certificates of deposit and commercial paper are carried at a cost
that approximates fair value. Available-for-sale securities: Investments in debt securities that are classified as available for sale
shall be measured subsequently at fair value in the statement of financial position.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments
are initially measured at cost, which is the fair value of the consideration given for them, including transaction costs. Where the Company&#8217;s
ownership interest is in excess of 20% and the Company has a significant influence, the Company has accounted for the investment based
on the equity method in accordance with ASC Topic 323, &#8220;<i>Investments </i>&#8211; <i>Equity method and Joint Ventures.</i>&#8221;
Under the equity method, the Company&#8217;s share of the post-acquisition profits or losses of the equity investee is recognized in
the consolidated statements of operations, and its share of post-acquisition movements in accumulated other comprehensive income / (loss)
is recognized in other comprehensive income / (loss). Where the Company does not have significant influence, the Company has accounted
for the investment in accordance with ASC Topic 321, &#8220;<i>Investments-Equity Securities.</i>&#8221;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, had no marketable investments.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>k)
Property, plant, and equipment (PP&amp;E) </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PP&amp;E
are recorded at cost net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful
lives of the assets, which are reviewed periodically to ensure consistency with expected economic benefits. Depreciation begins when
the asset is available for use and continues until the asset is retired or fully depreciated.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
retirement or disposition, cost and related accumulated depreciation of the PP&amp;E are de-recognized, and any gain or loss is reflected
in the results of the operation. The cost of additions and substantial improvements to property and equipment are capitalized. The cost
of maintenance and repairs of the property and equipment are charged to operating expenses as incurred. Please refer &#8220;Note 6 &#8211;
Property, Plant, and Equipment&#8221; for more information.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>l)
Fair value of financial instruments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
820, &#8220;Fair Value Measurement&#8221; defines fair value as the exchange price that would be received for an asset or paid to transfer
a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between
market participants on the measurement date. It also establishes a three-tier fair value hierarchy, which prioritizes the inputs used
in measuring fair value as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Observable inputs such as quoted prices in active markets;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable,
and accrued liabilities, approximately their fair values due to the nature of the items. Please refer to Note 15, &#8220;Fair value of
financial instruments,&#8221; for further information.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>m)
Concentration of credit risk and significant customers</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments, which potentially expose the Company to concentrations of credit risk, are primarily comprised of cash and cash equivalents,
investments, accounts receivable, and unbilled accounts receivable, if any. The Company places its cash investments in highly rated financial
institutions. The Company adheres to a formal investment policy with the primary objective of preservation of principal, which contains
credit rating minimums and diversification requirements. Management believes its credit policies reflect normal industry terms and business
risk. The Company does not anticipate non-performance by the counterparties and, accordingly, does not require collateral. During Fiscal
2025, sales were spread across customers in Asia and U.S., and the credit concentration risk is low.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>n)
Stock </b>&#8211; <b>Based Compensation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation to employees and non-employees in conformity with the provisions of ASC Topic 718, &#8220;<i>Stock-Based
Compensation.</i>&#8221; The Company expenses stock-based compensation to employees over the requisite vesting period based on the estimated
grant-date fair value of the awards. The Company accounts for forfeitures as they occur. Stock-based awards are recognized on a straight-line
basis over the requisite vesting period. For stock-based employee compensation, the cost recognized at any date will be at least equal
to the amount attributable to the share-based compensation that is vested at that date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
performance-based awards, stock-based compensation expense is recognized over the expected performance achievement period of individual
performance milestones when the achievement of each individual performance milestone becomes probable. For performance-based awards with
a vesting schedule based entirely on the attainment of performance conditions, stock-based compensation expense associated with each
tranche is recognized over the expected achievement period for the operational milestone, beginning at the point in time when the relevant
operational milestone is considered probable to be achieved.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
market-based awards, stock-based compensation expense is recognized over the expected achievement period. The fair value of such awards
is estimated on the grant date using Monte Carlo simulations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates the fair value of stock option grants using the Black-Scholes option-pricing model. The assumptions used in calculating
the fair value of stock-based awards represent Management&#8217;s best estimates. Generally, the closing share price of the Company&#8217;s
common stock on the date of grant is considered the fair value of the share. The volatility factor is determined based on the Company&#8217;s
historical stock prices. The expected term represents the period that our stock-based awards are expected to be outstanding. The Company
has never declared or paid any cash dividends. For further information, refer to Note 14, &#8220;Stock-Based Compensation&#8221; of Notes
to Consolidated Financial Statements.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>o)
Commitments and contingencies</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities
for loss contingencies arising from claims, assessments, litigations, fines and penalties, and other sources are recorded when it is
probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. We record
associated legal fees as incurred. Information regarding our commitments and contingencies is incorporated by reference in Note 12, &#8220;Commitments
and contingencies&#8221; of this Annual Report on Form 10-K.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>p)
Impairment of long </b>&#8211; <b>lived assets</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews its long-lived assets, with finite lives, for impairment whenever events or changes in business circumstances indicate
that the carrying amount of assets may not be fully recoverable. Such circumstances include, though are not limited to, significant or
sustained declines in revenues or earnings, future anticipated cash flows, business plans, and material adverse changes in the economic
climate, such as changes in the operating environment, competitive information, and the impact of changes in government policies. For
assets that the Company intends to hold for use, if the total of the expected future undiscounted cash flows produced by the assets or
subsidiary company is less than the carrying amount of the assets, a loss is recognized for the difference between the fair value and
carrying value of the assets. For assets, the Company intends to dispose of by sale, a loss is recognized for the amount by which the
estimated fair value less cost to sell is less than the carrying value of the assets. Fair value is determined based on quoted market
prices, if available, or other valuation techniques, including discounted future net cash flows. Unlike goodwill, long-lived assets are
assessed for impairment only where there are any specific indicators for impairment.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>q)
Intangible assets</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s intangible assets are accounted for in accordance with ASC Topic 350, <i>Intangibles </i>&#8211; <i>Goodwill and Other.
</i>Intangible assets having indefinite lives are not amortized, but instead are reviewed annually or more frequently if events or changes
in circumstances indicate that the assets might be impaired, to assess whether their fair value exceeds their carrying value. We perform
an impairment analysis on March 1 annually on the indefinite-lived intangible assets following the steps laid out in ASC 350-30-35-18.
Our annual impairment analysis includes a qualitative assessment to determine if it is necessary to perform the quantitative impairment
test. In performing a qualitative assessment, we review events and circumstances that could affect the significant inputs used to determine
if the fair value is less than the carrying value of the intangible assets. If quantitative analysis is necessary, we would analyze various
aspects including revenues from the business, associated with the intangible assets. In addition, intangible assets will be tested on
an interim basis if an event or circumstance indicates that it is more likely than not that an impairment loss has been incurred. The
Company has analyzed a variety of factors on its business to determine if a circumstance could trigger an impairment loss, and, at this
time and based on the information presently known, does not believe it is more likely than not that an impairment loss has been incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets with finite useful lives are amortized using the straight-line method over their estimated period of benefit. In accordance with
ASC 360-10-35-21, definite lived intangibles are reviewed annually or more frequently if events or changes in circumstances indicate
that the assets might be impaired, to assess whether their fair value exceeds their carrying value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to capitalize trademarks and related expenses exceeding $2,500 per trademark. Management may also capitalize trademarks
and related expenses up to $2,500 per trademark based on its potential and benefit in coming years.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Research, Development, and Computer Software, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>r)
Software Development Costs</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is developing two proprietary software platforms intended to be commercialized:-</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
A <b>clinical data management platform</b> designed for the collection, analysis, and real-time monitoring of clinical trial data; and</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
An <b>MINT- AD - AI-driven diagnostic and treatment personalization platform</b> aimed at assisting in the early detection of Alzheimer&#8217;s
disease and providing data-informed therapeutic suggestions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with <b>ASC 985-20</b>, <i>Software to Be Sold, Leased, or Marketed</i>, the Company capitalizes development costs incurred
after technological feasibility has been established and before the software is available for general release. Costs incurred during
the research, planning, or preliminary design phase are expensed as incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized
costs include direct labor, third-party development services, cloud computing infrastructure directly related to model development and
deployment, and associated overhead. These costs are amortized on a straight-line basis over their estimated useful lives, typically
<b>five to ten years</b>, beginning when the software is ready for its intended commercial use.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
Fiscal 2024, the Company began working on overlaying machine learning technologies and AI into the internal clinical trial software framework
for trial management with the expectation that this can lead to improved decision-making, contextual data entry, computational models,
trial design (Phase 3), and data analysis, the company believes it is probable that the project will be completed and the software will
be used to perform the function intended. As of Fiscal 2025, the Company capitalized approximately $863 thousand in software development
costs. For more information, please refer to Note 5, &#8220;Intangible Assets&#8221;.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>s)
Inventory</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
is valued at the lower of cost or net realizable value, which is defined as estimated selling prices in the ordinary course of business,
less reasonably predictable costs of completion, disposal, and transportation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
consists of finished goods related to wellness products, hand sanitizers, finished hemp-based products, beverages. Work-and in-progress
consist of products in the manufacturing process as on reporting date, including but not limited to primary cost. Inventory is primarily
accounted for using the weighted average cost method. Primary costs include raw materials, packaging, direct labor, overhead, shipping,
and the depreciation of manufacturing equipment. Manufacturing overhead and related expenses include salaries, wages, employee benefits,
utilities, maintenance, and property taxes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
capitalize inventory costs related to our investigational drug, provided that management determines there is a potential alternative
use for the inventory in future research and development projects or other purposes. As of March 31, 2025, and 2024, our consolidated
balance sheet reported approximately $392 thousand of clinical trial-related inventory, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abnormal
amounts of idle facility expense, freight, handling costs, scrap, discontinued products, and wasted material (spoilage) are expensed
in the period they are incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
refer to Note 3, &#8220;Inventory,&#8221; for further information.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_CybersecurityPolicyPolicyTextBlock', window );">Cyber-security Policy [Policy Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>t)
Cybersecurity Costs</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains information technology systems and security protocols designed to protect sensitive clinical, corporate, and financial
data. Costs incurred in connection with the ongoing maintenance, enhancement, and monitoring of cybersecurity infrastructure are expensed
as incurred and classified within general and administrative expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews cybersecurity risks on an ongoing basis and implements technical and administrative controls in line with applicable
data protection standards. As of March 31, 2025, the Company had not capitalized any cybersecurity-related development costs, and no
material cybersecurity incidents have been identified.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>u)
Research and Development Expenses</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development (R&amp;D) expenses include costs incurred to develop the Company&#8217;s clinical-stage drug candidates, including IGC-AD1
and other investigational therapies. These costs consist primarily of:</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
                                            trial site payments</span></td></tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract
                                            research organization (CRO) fees</span></td></tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
                                            compensation for R&amp;D personnel</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>

<tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
                                            and medical affairs consulting</span></td></tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laboratory
                                            supplies and materials</span></td></tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
                                            studies and formulation development</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D
expenses are expensed as incurred in accordance with ASC 730. Non-refundable advance payments for goods or services that will be used
in future R&amp;D activities are deferred and recognized as the related goods or services are received. During Fiscal 2025 and 2024,
the Company recorded research and development expenses of approximately $3.7 million and $3.8 million, respectively.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lessee, Leases [Policy Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>v)
Leases</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lessor
Accounting</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the current ASU guidance, contract consideration will be allocated to its lease components and non-lease components (such as maintenance).
For the Company as a lessor, any non-lease components will be accounted for under ASC Topic 606, &#8220;<i>Revenue from Contracts with
Customers,</i>&#8221; unless the Company elects a lessor practical expedient to not separate the non-lease components from the associated
lease component. The amendments in ASU 2018-11 also provide lessors with a practical expedient, by class of underlying asset, to not
separate non-lease components from the associated lease component and, instead, to account for those components as a single component
if the non-lease components otherwise would be accounted for under the new revenue guidance (Topic 606). To elect the practical expedient,
the timing and pattern of transfer of the lease and non-lease components must be the same and the lease component must meet the criteria
to be classified as an operating lease if accounted for separately. If these criteria are met, the single component will be accounted
for under either Topic 842 or Topic 606 depending on which component(s) are predominant. The lessor practical expedient to not separate
non-lease components from the associated component must be elected for all existing and new leases.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a lessor, the Company expects that post-adoption substantially all existing leases will have no change in the timing of revenue recognition
until their expiration or termination. The Company expects to elect the lessor practical expedient to not separate non-lease components
such as maintenance from the associated lease for all existing and new leases and to account for the combined component as a single lease
component. The timing of revenue recognition is expected to be the same for the majority of the Company&#8217;s new leases as compared
to similar existing leases; however, certain categories of new leases could have different revenue recognition patterns as compared to
similar existing leases.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
leases that are accounted for as operating leases, income is recognized on a straight-line basis over the term of the lease contract.
Generally, when a lease is more than 180 days delinquent (where more than three monthly payments are owed), the lease is classified as
being nonaccrual and the Company stops recognizing leasing income on that date. Payments received on leases in nonaccrual status generally
reduce the lease receivable. Leases on nonaccrual status remain classified as such until there is sustained payment performance that,
in the Company&#8217;s judgment, would indicate that all contractual amounts will be collected in full.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lessee
Accounting</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted ASU 2016-02 effective April 1, 2019, using the modified retrospective approach. The standard establishes a right-of-use
model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer
than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense
recognition in the income statement. In connection with the adoption, the Company will elect to utilize the modified retrospective presentation
whereby the Company will continue to present prior period financial statements and disclosures under ASC Topic 840. In addition, the
Company will elect the transition package of three practical expedients permitted within the standard, which eliminates the requirements
to reassess prior conclusions about lease identification, lease classification and initial direct costs. Further, the Company will adopt
a short-term lease exception policy, permitting us to not apply the recognition requirements of this standard to short-term leases (i.e.,
leases with terms of 12 months or less), and an accounting policy to account for lease and non-lease components as a single component
for certain classes of assets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASU 2016-02 (Topic 842), lessees are required to recognize the following for all leases (with the exception of short-term leases) on
the commencement date: (i) lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured
on a discounted basis; and (ii) right-of-use asset, which is an asset that represents the lessee&#8217;s right to use, or control the
use of, a specified asset for the lease term.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the commencement date, the Company recognizes the lease liability at the present value of the lease payments not yet paid, discounted
using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company&#8217;s incremental borrowing
rate for the same term as the underlying lease. The right-of-use asset is recognized initially at cost, which primarily comprises the
initial amount of the lease liability, plus any initial direct costs incurred, consisting mainly of brokerage commissions, less any lease
incentives received. All right-of-use assets are reviewed for impairment. There was no impairment for right-of-use lease assets as of
March 31, 2025.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company categorizes leases at their inception as either operating or finance leases. On certain lease agreements, the Company may receive
rent holidays and other incentives. The Company recognizes lease costs on a straight-line basis without regard to deferred payment terms,
such as rent holidays, that defer the commencement date of required payments. Please refer to Note 9, &#8220;Leases,&#8221; for further
information.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>w)
Recently issued and adopted accounting pronouncements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
to U.S. GAAP are established by the Financial Accounting Standards Board (FASB) in the form of accounting standards updates (ASUs) to
the FASB&#8217;s Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. Newly issued ASUs
not listed are expected to have no impact on the Company&#8217;s consolidated financial position and results of operations because either
the ASU is not applicable or the impact is expected to be immaterial. Recent accounting pronouncements which may be applicable to us
are described in Note 2, &#8220;Significant Accounting Policies&#8221; in our Consolidated Financial Statements contained herein in Part
II, Item 8.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_CybersecurityPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to cyber-security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_CybersecurityPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_GoingConcernPolicyPolicyTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Policy for going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_GoingConcernPolicyPolicyTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org/705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-40/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/730/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center">(in thousands)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31, <br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,104</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,099</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Finished goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">256</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">441</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,360</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,540</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEPOSITS AND ADVANCES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_DepositsAndAdvancesAbstract', window );"><strong>Deposits And Advances Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center">(in thousands)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
of <br/>
March 31,<br/>
2025<br/>
($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
of <br/>
March 31,<br/>
2024<br/>
($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Advances to suppliers and consultants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">41</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Other receivables and deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Prepaid expense and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">342</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">115</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">395</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">208</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_DepositsAndAdvancesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_DepositsAndAdvancesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets and Goodwill [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Amortized intangible assets</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center">(in thousands)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31, <br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-left: 0.25pt">Patents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">530</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">836</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Other intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(205</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(181</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Total amortized intangible assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">359</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">689</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; font-style: italic; text-align: left; padding-left: 0.25pt">Unamortized intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">Patents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">630</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">521</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Software development cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">863</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">406</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Total unamortized intangible assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,493</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">927</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt">Total intangible assets</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,852</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,616</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"><b>Estimated amortization expense</b></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><b>(in thousands)<br/>
 ($)</b></td>
    <td style="white-space: nowrap; padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0.25pt">For the year ended 2026</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">55</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">For the year ended 2027</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">60</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">For the year ended 2028</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">66</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">For the year ended 2029</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">73</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">For the year ended 2030</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">80</td>
    <td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT, AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_PropertyPlantAndEquipmentTableTypeAxis=igc_PropertyPlantAndEquipmentTableMember', window );">Property Plant and Equipment Table [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_PROPERTYPLANTANDEQUIPMENTTablesLineItems', window );"><strong>PROPERTY, PLANT, AND EQUIPMENT (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="10" style="font-weight: bold; font-style: italic; text-align: center">(in thousands, except useful life)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Useful Life<br/> (years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31,<br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0.25pt">Buildings and facilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">25</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,341</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,303</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Plant and machinery</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5-20</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,087</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,334</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Computer equipment&#8217;s</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">187</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Office equipment&#8217;s</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3-5</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Vehicles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt; padding-left: 0.25pt">Total gross value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">5,913</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">6,137</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,693</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,442</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt">Total property, plant, and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,220</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,695</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_PROPERTYPLANTANDEQUIPMENTTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_PROPERTYPLANTANDEQUIPMENTTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_PropertyPlantAndEquipmentTableTypeAxis=igc_PropertyPlantAndEquipmentTableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_PropertyPlantAndEquipmentTableTypeAxis=igc_PropertyPlantAndEquipmentTableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CLAIMS AND ADVANCES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock', window );">Schedule of Other Assets, Noncurrent [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31,<br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Claims receivable (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">680</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">686</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Non-current deposits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25pt"><b>Total</b></td><td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 2.5pt double; text-align: right"><b>681</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 2.5pt double; text-align: right"><b>688</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
claims receivable is due from different vendors. While the Company has initiated collection proceedings internally or with the appropriate
authorities, it believes receiving the amount in the next 12 months will be challenging because of the time required for collection proceedings.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">(in thousands) <br/> Year Ended <br/> March 31, <br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">(in thousands) <br/> Year Ended <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Operating lease costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">135</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">141</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Short term lease costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">39</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">100</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt">Total lease costs</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">174</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">241</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended<br/> March 31, <br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Operating lease asset</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right">98</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right">198</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"><b>Total lease assets</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>98</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>198</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt"><b>Liabilities</b></td><td><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="text-align: left"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="text-align: left"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Accrued liabilities and others (current portion &#8211; operating lease liability)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">93</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">124</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Noncurrent liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Operating lease liability (non-current portion &#8211; operating lease liability)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">84</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"><b>Total lease liability</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>103</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>208</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">Supplemental cash flow and non-cash information related to leases is as follows:</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">(in thousands) <br/> Year Ended <br/> March 31, <br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">(in thousands) <br/> Year Ended<br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">&#8211;Operating cash flows from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">129</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">140</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Right-of-use assets obtained in exchange for operating lease obligations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td colspan="5">As of March 31, 2025, the following table summarizes the maturity of our lease liabilities:</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; padding-left: 0.25pt">Mar-26</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">96</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Mar-27</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">Mar-28</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Mar-29</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Less: Present value discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Total Lease liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">103</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED LIABILITIES AND OTHERS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_AccruedLiabilitiesDisclosureAbstract', window );"><strong>Accrued Liabilities Disclosure Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31, <br/> 2025 <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Compensation and other contributions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">160</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">816</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Provision for expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Short-term lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">124</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Other current liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,003</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">419</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25pt"><b>Total</b></td><td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 2.5pt double; text-align: right"><b>1,374</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 2.5pt double; text-align: right"><b>1,567</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_AccruedLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_AccruedLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOANS AND OTHER LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_LoansAndOtherLiabilitiesAbstract', window );"><strong>Loans And Other Liabilities Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock', window );">Schedule of Other Assets and Other Liabilities [Table Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Liability:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center">(in thousands)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Statutory reserve</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right">16</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right">20</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">16</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">20</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_LoansAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_LoansAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
options are fair valued using a Black-Scholes Pricing Model, and market-based RSU are valued based on a lattice model with the following
assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td colspan="2" style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Granted
in <br/>
Fiscal 2025</b></span></p></td> <td style="padding: 0.25pt 0.25pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td colspan="2" style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Granted
in <br/>
Fiscal 2024</b></span></p></td> <td style="padding: 0.25pt 0.25pt 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life of options</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td colspan="2" style="padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td colspan="2" style="padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding: 0.25pt; width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested options</span></td> <td style="width: 1%; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="width: 1%; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="width: 9%; padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="white-space: nowrap; width: 1%; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="width: 1%; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="width: 1%; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="width: 9%; padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="white-space: nowrap; width: 1%; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk free interest rate</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.93</span></td> <td style="white-space: nowrap; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.24</span></td> <td style="white-space: nowrap; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">171</span></td> <td style="white-space: nowrap; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">175</span></td> <td style="white-space: nowrap; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td colspan="2" style="padding: 0.25pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-2; font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td colspan="2" style="padding: 0.25pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-3; font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td> <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Nonvested Restricted Stock Shares Activity [Table Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Fiscal 2024, the Company&#8217;s share-based expenses and option-based expenses shown in Selling, general, and administrative expenses
(including research and development) were $1.7 million and $59 thousand, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Non-vested shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares <br/> (in thousands)<br/> (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <br/> average<br/> grant date <br/> fair value<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-left: 0.25pt">Non-vested shares as of March 31, 2024 </td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,452</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.61</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Granted </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">Vested </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,443</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.34</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">Cancelled/Forfeited </td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(212</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.33</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt"><b>Non-vested shares as of March 31, 2025</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>5,796</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b>0.64</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Options</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares <br/> (in thousands) <br/> (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<br/> average <br/> grant date <br/> fair value<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<br/> average <br/> exercise <br/> price<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-left: 0.25pt">Options outstanding as of March 31, 2024</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">3,710</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.25</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.39</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.34</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(628</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.25</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">Cancelled/forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(150</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1.39</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.39</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt; padding-left: 0.25pt">Options outstanding as of March 31, 2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">3,182</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">0.30</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">0.34</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the Company&#8217;s assets that are measured at fair value on a recurring basis as of March
31, 2025, and 2024, and indicates the fair value hierarchy of the valuation techniques the Company used to determine such fair value:</span></p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Particular</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Adjusted<br/> Cost<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gain <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Loss<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Cash &amp;<br/> Cash <br/> Equivalents<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Short Term<br/> Investments <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><b>Level 1</b></td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; padding-left: 0.25pt">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">368</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">368</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">368</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Money Market Fund</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Debt Funds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">Mutual Fund</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt"><b>Level 2</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">Certificates of Deposit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">37</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">37</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">37</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt"><b>Level 3</b></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25pt"><b>TOTAL</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">405</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">405</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">405</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Particular</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Adjusted<br/> Cost<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gain <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Loss<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Cash &amp; <br/> Cash<br/> Equivalents <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Short Term <br/> Investments<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Level 1</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; padding-left: 0.25pt">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">912</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">912</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">912</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">Money Market Fund</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Debt Funds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">Mutual Fund</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">123</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">123</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">123</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0.25pt">Level 2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">Certificates of Deposit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">150</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">150</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">150</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt; padding-left: 0.25pt">Level 3</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt">TOTAL</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,198</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,198</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,198</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense/(benefit) for each of the years ended March 31 consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended March 31,<br/>
 (in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Income Tax Expense</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Net income loss before tax</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(7,121</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(13,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Tax rate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">21</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">21</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Expected income tax recovery</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,495</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,730</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Impact of tax rate differences in foreign jurisdictions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(72</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(151</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Tax rate changes and other adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,305</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,475</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,872</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,406</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
significant components of deferred income tax expense/(benefit) from operations before non-controlling interest for each of the years
ended March 31 are approximated as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">Year Ended March 31, <br/> (in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Deferred income taxes</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt">Net operating loss carry-forwards foreign</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">332</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">287</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Non-capital loss carry-forwards &#8211; U.S.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,272</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Temporary differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">427</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">418</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Net deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,124
</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,977</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(19,124</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(14,977</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Summary of Operating Loss Carryforwards [Table Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth the details of expiration of the non-financial carried forward losses of the Company as of March 31, 2025, as
under:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><b>Year</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><b>Amount<br/>
 (in thousands)<br/>
 ($)</b></td>
    <td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0.25pt">2029</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">16</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">2030</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">37</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">2031</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,081</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">2032</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4,141</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">2033</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">627</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">2034</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,269</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">2035</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,735</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">2036</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,176</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">2037</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">819</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">No expiry</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,256</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">No expiry</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4,132</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">No expiry</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">7,932</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">No expiry</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8,841</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">No expiry</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">14,966</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">No expiry</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8,552</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">No expiry</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">6,884</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">No expiry</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">22,006</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">87,469</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue [Table Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
sales disaggregated by significant products and services for Fiscal 2025 and 2024 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">(in thousands) <br/> Year ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024<br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wellness and lifestyle <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">113</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">228</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">White labeling services <sup>(2)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,158</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">953</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other<sup>(3)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">164</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,271</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,345</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from wellness and lifestyle consists of the sale of products such as gummies, hand sanitizers, bath bombs, lotions, beverages, hemp crude
extract, hemp isolate, and hemp distillate.</span></td>
</tr></table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from white labelling services consists of rebranding our formulations or the customer&#8217;s products as per the customer&#8217;s requirement.</span></td>
</tr></table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
consists of income from the rental of heavy construction equipment and the execution of contracts directly or through subcontractors.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Revenue from External Customers by Products and Services [Table Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)
The table below shows revenue reported by segments:</span></p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Segments</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Life Sciences segment</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right">1,271</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right">1,345</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25pt"><b>Total</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,271</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1345</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas [Table Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)
The table below shows the attributes to the country of domicile (U.S.) and foreign countries. Revenue is generally attributed to the
geographic location of customers:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="6" style="font-weight: bold; font-style: italic; text-align: center">(in thousands)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Segments</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Country</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage&#160;of <br/> Total<br/> Revenue <br/> (%)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25pt">Asia</td><td>&#160;</td>
    <td style="text-align: left">India</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 60%; padding-left: 0.25pt">America</td><td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: left">U.S.</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,269</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">99.8</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">Colombia</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.2</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,271</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">100</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Segments</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Country</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage&#160;of <br/> Total<br/> Revenue<br/> (%)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; padding-left: 0.25pt">Asia</td><td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: left">India</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">164</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">12</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25pt">America</td><td>&#160;</td>
    <td style="text-align: left">U.S.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,179</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.25pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">Colombia</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,345</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)
The table below shows the non-current assets other than financial instruments held in the country of domicile and foreign countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="10" style="font-weight: bold; font-style: italic; text-align: center">(in thousands)</td><td style="font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Nature of Assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">U.S. <br/> (Country of <br/> Domicile)<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Foreign <br/> Countries <br/> (India and <br/> Colombia) <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total as of <br/> March 31, <br/> 2025<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0.25pt">Intangible assets, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,852</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,852</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Property, plant, and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,171</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,220</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Claims and advances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">410</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">271</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">681</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Operating lease asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">80</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">98</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt">Total non-current assets</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">5,513</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">338</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">5,851</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Nature of Assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">U.S. <br/> (Country of <br/> Domicile) <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Foreign <br/> Countries<br/> (India and <br/> Colombia)<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total as of <br/> March 31,<br/> 2024<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0.25pt">Intangible assets, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,616</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,616</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25pt">Property, plant, and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,620</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,695</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25pt">Claims and advances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">410</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">278</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">688</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt">Operating lease asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">193</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">198</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt"><b>Total non-current assets</b></td><td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 2.5pt double; text-align: right"><b>5,839</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 2.5pt double; text-align: right"><b>358</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 2.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 2.5pt double; text-align: right"><b>6,197</b></td><td style="padding-bottom: 2.5pt; text-align: left"><b>&#160;</b></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Number of Shares Outstanding, Basic (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,517,175<span></span>
</td>
<td class="nump">58,839,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,122,000)<span></span>
</td>
<td class="num">$ (13,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,252,000<span></span>
</td>
<td class="nump">3,027,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 194,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts Receivable, after Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts Receivable, Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,000<span></span>
</td>
<td class="nump">405,000<span></span>
</td>
<td class="nump">1,198,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Capitalized Computer Software, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">863,000<span></span>
</td>
<td class="nump">863,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,360,000<span></span>
</td>
<td class="nump">1,360,000<span></span>
</td>
<td class="nump">1,540,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,655,000<span></span>
</td>
<td class="nump">3,773,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=igc_ClinicalTrialInventoryMember', window );">Clinical Trial Inventory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 392,000<span></span>
</td>
<td class="nump">$ 392,000<span></span>
</td>
<td class="nump">$ 392,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Investor [Member] | Share Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in Shares)</a></td>
<td class="nump">2,803,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">$ 841,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in Dollars per share)</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=igc_FiscalYear2026Member', window );">Fiscal Year 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=igc_ClinicalTrialInventoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=igc_ClinicalTrialInventoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=igc_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=igc_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=igc_FiscalYear2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=igc_FiscalYear2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_INVENTORYDetailsLineItems', window );"><strong>INVENTORY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory Write-down</a></td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, Net</a></td>
<td class="nump">1,360<span></span>
</td>
<td class="nump">1,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=igc_ClinicalTrialInventoryMember', window );">Clinical Trial Inventory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_INVENTORYDetailsLineItems', window );"><strong>INVENTORY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, Net</a></td>
<td class="nump">$ 392<span></span>
</td>
<td class="nump">$ 392<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_INVENTORYDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_INVENTORYDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=igc_ClinicalTrialInventoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=igc_ClinicalTrialInventoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORY - Schedule of Inventory, Current (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_ScheduleOfInventoryCurrentAbstract', window );"><strong>Schedule Of Inventory Current Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 1,104<span></span>
</td>
<td class="nump">$ 1,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 1,360<span></span>
</td>
<td class="nump">$ 1,540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_ScheduleOfInventoryCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_ScheduleOfInventoryCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEPOSITS AND ADVANCES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_DepositsAndAdvancesAbstract', window );"><strong>Deposits And Advances Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_StatutoryAdvances', window );">Statutory Advances</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_DepositsAndAdvancesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_DepositsAndAdvancesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_StatutoryAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Statutory advances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_StatutoryAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEPOSITS AND ADVANCES - Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Advances to suppliers and consultants</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventoryNetOfReserves', window );">Other receivables and deposits</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expense and other current assets</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 395<span></span>
</td>
<td class="nump">$ 208<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after of valuation reserves and allowances, of inventory, classified as other, expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_INTANGIBLEASSETSDetailsLineItems', window );"><strong>INTANGIBLE ASSETS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_INTANGIBLEASSETSDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_INTANGIBLEASSETSDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS - Schedule of Intangible Assets And Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems', window );"><strong>INTANGIBLE ASSETS - Schedule of Intangible Assets And Goodwill (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">$ (205)<span></span>
</td>
<td class="num">$ (181)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total amortized intangible assets</a></td>
<td class="nump">359<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_UnamortizedIntangibleAssetsAbstract', window );"><strong>Unamortized intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Unamortized intangible assets</a></td>
<td class="nump">1,493<span></span>
</td>
<td class="nump">927<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets</a></td>
<td class="nump">1,852<span></span>
</td>
<td class="nump">1,616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_UnamortizedIntangibleAssetsAbstract', window );"><strong>Unamortized intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Unamortized intangible assets</a></td>
<td class="nump">630<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember', window );">Software Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_UnamortizedIntangibleAssetsAbstract', window );"><strong>Unamortized intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Unamortized intangible assets</a></td>
<td class="nump">863<span></span>
</td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems', window );"><strong>INTANGIBLE ASSETS - Schedule of Intangible Assets And Goodwill (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangibles</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems', window );"><strong>INTANGIBLE ASSETS - Schedule of Intangible Assets And Goodwill (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangibles</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_UnamortizedIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_UnamortizedIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Schedule Of Finite Lived Intangible Assets Future Amortization Expense Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">For the year ended 2026</a></td>
<td class="nump">$ 55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">For the year ended 2027</a></td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">For the year ended 2028</a></td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">For the year ended 2029</a></td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">For the year ended 2030</a></td>
<td class="nump">$ 80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT, AND EQUIPMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_PROPERTYPLANTANDEQUIPMENTDetailsLineItems', window );"><strong>PROPERTY, PLANT, AND EQUIPMENT (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 567<span></span>
</td>
<td class="nump">$ 563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">3,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandAvailableForSale', window );">Real Estate, Land, Held-for-Sale</a></td>
<td class="nump">702<span></span>
</td>
<td class="nump">720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDepositsOnRealEstateSales', window );">Proceeds from Deposits on Real Estate Sales</a></td>
<td class="nump">580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_PROPERTYPLANTANDEQUIPMENTDetailsLineItems', window );"><strong>PROPERTY, PLANT, AND EQUIPMENT (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDepositsOnRealEstateSales', window );">Proceeds from Deposits on Real Estate Sales</a></td>
<td class="nump">$ 580<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_PROPERTYPLANTANDEQUIPMENTDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_PROPERTYPLANTANDEQUIPMENTDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in land held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDepositsOnRealEstateSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash inflow related to amounts received in advance from a potential buyer showing or confirming an intention to complete an acquisition of land, buildings, other structures, or any item classified as real estate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDepositsOnRealEstateSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY, PLANT, AND EQUIPMENT - Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 5,913<span></span>
</td>
<td class="nump">$ 6,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(2,693)<span></span>
</td>
<td class="num">(2,442)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Assets</a></td>
<td class="nump">$ 3,220<span></span>
</td>
<td class="nump">3,695<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and Building Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 2,341<span></span>
</td>
<td class="nump">2,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 3,087<span></span>
</td>
<td class="nump">3,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 187<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 144<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CLAIMS AND ADVANCES - Schedule of Other Assets, Noncurrent (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_ScheduleOfOtherAssetsNoncurrentAbstract', window );"><strong>Schedule Of Other Assets Noncurrent Abstract</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Claims receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 680<span></span>
</td>
<td class="nump">$ 686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_OtherAdvances', window );">Non-current deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 681<span></span>
</td>
<td class="nump">$ 688<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
claims receivable is due from different vendors. While the Company has initiated collection proceedings internally or with the appropriate
authorities, it believes receiving the amount in the next 12 months will be challenging because of the time required for collection proceedings.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_OtherAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other noncurrent advances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_OtherAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_ScheduleOfOtherAssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_ScheduleOfOtherAssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-Term Lease, Cost</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating Lease, Cost</a></td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Lease, Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term lease costs</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease asset</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Total lease assets</a></td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Accrued liabilities and others (current portion &#8211; operating lease liability)</a></td>
<td class="text">Accrued liabilities and others<span></span>
</td>
<td class="text">Accrued liabilities and others<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability (non-current portion &#8211; operating lease liability)</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">&#8211;Operating cash flows from operating leases</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease obligations</a></td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Lessee, Operating Lease, Liability, Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_LesseeOperatingLeaseLiabilityMaturityAbstract', window );"><strong>Lessee Operating Lease Liability Maturity Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Mar-26</a></td>
<td class="nump">$ 96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Mar-27</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Mar-28</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Mar-29</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Present value discount</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total Lease liabilities</a></td>
<td class="nump">$ 103<span></span>
</td>
<td class="nump">$ 208<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_LesseeOperatingLeaseLiabilityMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_LesseeOperatingLeaseLiabilityMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED LIABILITIES AND OTHERS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_ACCRUEDLIABILITIESANDOTHERSDetailsLineItems', window );"><strong>ACCRUED LIABILITIES AND OTHERS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Accounts Payable, Other, Current</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-Term Debt</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDepositsOnRealEstateSales', window );">Proceeds from Deposits on Real Estate Sales</a></td>
<td class="nump">580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_ACCRUEDLIABILITIESANDOTHERSDetailsLineItems', window );"><strong>ACCRUED LIABILITIES AND OTHERS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDepositsOnRealEstateSales', window );">Proceeds from Deposits on Real Estate Sales</a></td>
<td class="nump">$ 580<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_ACCRUEDLIABILITIESANDOTHERSDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_ACCRUEDLIABILITIESANDOTHERSDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDepositsOnRealEstateSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash inflow related to amounts received in advance from a potential buyer showing or confirming an intention to complete an acquisition of land, buildings, other structures, or any item classified as real estate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDepositsOnRealEstateSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED LIABILITIES AND OTHERS - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract', window );"><strong>Schedule Of Accounts Payable And Accrued Liabilities Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and other contributions</a></td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Provision for expenses</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term lease liability</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liability</a></td>
<td class="nump">1,003<span></span>
</td>
<td class="nump">419<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,374<span></span>
</td>
<td class="nump">$ 1,567<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOANS AND OTHER LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 11, 2020</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_LoansAndOtherLiabilitiesAbstract', window );"><strong>Loans And Other Liabilities Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt Instrument, Periodic Payment</a></td>
<td class="nump">$ 731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Loans Payable, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loans Payable, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_LoansAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_LoansAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LOANS AND OTHER LIABILITIES - Schedule of Loans and Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_ScheduleOfLoansAndOtherLiabilitiesAbstract', window );"><strong>Schedule Of Loans And Other Liabilities Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Statutory reserve</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_ScheduleOfLoansAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_ScheduleOfLoansAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SECURITIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 25, 2024</div></th>
<th class="th"><div>Mar. 22, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Oct. 27, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SECURITIESDetailsLineItems', window );"><strong>SECURITIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,878,058<span></span>
</td>
<td class="nump">66,691,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,878,058<span></span>
</td>
<td class="nump">66,691,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_UnitsOutstanding', window );">Units Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_UnitDescription', window );">Unit, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Ten units may be separated into one share of common
stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,252,000<span></span>
</td>
<td class="nump">$ 3,027,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SalesAgreementMaximum', window );">Sales Agreement, Offering, Maximum (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=igc_March2024SPAMember', window );">March 2024 SPA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SECURITIESDetailsLineItems', window );"><strong>SECURITIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=igc_SalesAgreementMember', window );">Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SECURITIESDetailsLineItems', window );"><strong>SECURITIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,363,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | 2025 Share Purchase Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SECURITIESDetailsLineItems', window );"><strong>SECURITIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,803,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 841,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=us-gaap_InvestorMember', window );">Investor [Member] | September 2024 SPA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SECURITIESDetailsLineItems', window );"><strong>SECURITIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">588,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in Dollars per share)</a></td>
<td class="nump">$ 0.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues (in Dollars)</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_SECURITIESDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_SECURITIESDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_SalesAgreementMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum offering under sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_SalesAgreementMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_UnitDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_UnitDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_UnitsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of units outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_UnitsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=igc_March2024SPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=igc_March2024SPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=igc_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=igc_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=igc_SharePurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=igc_SharePurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=igc_September2024SPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=igc_September2024SPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_STOCKBASEDCOMPENSATIONDetailsLineItems', window );"><strong>STOCK-BASED COMPENSATION (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in Shares)</a></td>
<td class="nump">3,182<span></span>
</td>
<td class="nump">3,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares', window );">Employee Stock Ownership Plan (ESOP), Number of Committed-to-be-Released Shares (in Shares)</a></td>
<td class="nump">7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-Based Payment Arrangement, Noncash Expense</a></td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_WeightedAveragePricePerShare', window );">Weighted Average Price per Share (in Dollars per share)</a></td>
<td class="nump">$ 0.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares)</a></td>
<td class="nump">4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in Shares)</a></td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in Dollars per share)</a></td>
<td class="nump">$ 0.34<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="nump">$ 1,640<span></span>
</td>
<td class="nump">$ 1,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_STOCKBASEDCOMPENSATIONDetailsLineItems', window );"><strong>STOCK-BASED COMPENSATION (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-Based Payment Arrangement, Noncash Expense</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_STOCKBASEDCOMPENSATIONDetailsLineItems', window );"><strong>STOCK-BASED COMPENSATION (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_STOCKBASEDCOMPENSATIONDetailsLineItems', window );"><strong>STOCK-BASED COMPENSATION (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</a></td>
<td class="nump">$ 590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=igc_ESOP2008OmnibusPlanMember', window );">ESOP 2008 Omnibus Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_STOCKBASEDCOMPENSATIONDetailsLineItems', window );"><strong>STOCK-BASED COMPENSATION (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in Shares)</a></td>
<td class="nump">9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-Based Payment Arrangement, Noncash Expense</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in Shares)</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in Dollars per share)</a></td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_STOCKBASEDCOMPENSATIONDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_STOCKBASEDCOMPENSATIONDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_WeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_WeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares that, although not legally released, will be released by a future scheduled and committed debt service payment and will be allocated to employees for service rendered in the current accounting period. The ESOP documents typically define the period of service to which the shares relate. ESOP shares are released to compensate employees directly, to settle employer liabilities for other employee benefits, and to replace dividends on allocated shares that are used for debt service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480459/718-40-55-20<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480459/718-40-55-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost expensed and capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=igc_ESOP2008OmnibusPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=igc_ESOP2008OmnibusPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION  - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract', window );"><strong>Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vested options</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">3.93%<span></span>
</td>
<td class="nump">5.24%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">171.00%<span></span>
</td>
<td class="nump">175.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION  - Nonvested Restricted Stock Shares Activity (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_NonvestedRestrictedStockSharesActivityAbstract', window );"><strong>Nonvested Restricted Stock Shares Activity Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance, non-vested shares | shares</a></td>
<td class="nump">7,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance, Weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 0.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted, shares | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, shares | shares</a></td>
<td class="num">(1,443)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 0.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Cancelled/Forfeited, shares | shares</a></td>
<td class="num">(212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Cancelled/Forfeited, Weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 0.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance, non-vested shares | shares</a></td>
<td class="nump">5,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance, Weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 0.64<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_NonvestedRestrictedStockSharesActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_NonvestedRestrictedStockSharesActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION  - Share-based Payment Arrangement, Option, Activity (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_ShareBasedPaymentArrangementOptionActivityAbstract', window );"><strong>Share Based Payment Arrangement Option Activity Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, shares (in Shares) | shares</a></td>
<td class="nump">3,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Options outstanding, Weighted average grant date fair value</a></td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted average exercise price</a></td>
<td class="nump">$ 0.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, shares (in Shares) | shares</a></td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted average grant date fair value</a></td>
<td class="nump">$ 0.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted average exercise price</a></td>
<td class="nump">$ 0.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested, shares (in Shares) | shares</a></td>
<td class="num">(628)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested, Weighted average grant date fair value</a></td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice', window );">Vested, Weighted average exercise price</a></td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled/Forfeited, shares (in Shares) | shares</a></td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Cancelled/Forfeited, Weighted average grant date fair value</a></td>
<td class="nump">$ 1.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled/Forfeited, Weighted average exercise price</a></td>
<td class="nump">$ 0.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, shares (in Shares) | shares</a></td>
<td class="nump">3,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Options outstanding, Weighted average grant date fair value</a></td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted average exercise price</a></td>
<td class="nump">$ 0.34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_ShareBasedPaymentArrangementOptionActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_ShareBasedPaymentArrangementOptionActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong> FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_Level1Abstract', window );"><strong>Level 1</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueAdjustment', window );">Adjusted Cost</a></td>
<td class="nump">$ 405<span></span>
</td>
<td class="nump">$ 1,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss', window );">Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings', window );">Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short Term Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_Level1Abstract', window );"><strong>Level 1</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueAdjustment', window );">Adjusted Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss', window );">Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings', window );">Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short Term Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_Level1Abstract', window );"><strong>Level 1</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueAdjustment', window );">Adjusted Cost</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss', window );">Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings', window );">Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short Term Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_Level1Abstract', window );"><strong>Level 1</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueAdjustment', window );">Adjusted Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss', window );">Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings', window );">Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short Term Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=igc_DebtFundsMember', window );">Debt Funds [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_Level1Abstract', window );"><strong>Level 1</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueAdjustment', window );">Adjusted Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss', window );">Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings', window );">Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short Term Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember', window );">Mutual Fund [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_Level1Abstract', window );"><strong>Level 1</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueAdjustment', window );">Adjusted Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss', window );">Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings', window );">Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short Term Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_Level1Abstract', window );"><strong>Level 1</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueAdjustment', window );">Adjusted Cost</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss', window );">Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings', window );">Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short Term Investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_Level1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_Level1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in income from asset (liability) measured at fair value on recurring basis using unobservable input (level 3) and still held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset and liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=igc_DebtFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=igc_DebtFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 4,542<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract', window );"><strong>Schedule Of Effective Income Tax Rate Reconciliation Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net Income Loss before tax</a></td>
<td class="num">$ (7,121)<span></span>
</td>
<td class="num">$ (13,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Expected income tax recovery</a></td>
<td class="num">$ (1,495)<span></span>
</td>
<td class="num">$ (2,730)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign', window );">Impact of tax rate differences in foreign jurisdictions</a></td>
<td class="num">(72)<span></span>
</td>
<td class="num">(151)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Tax rate changes and other adjustments</a></td>
<td class="num">(2,305)<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Change in valuation allowance</a></td>
<td class="nump">3,872<span></span>
</td>
<td class="nump">1,406<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Effective income tax rate</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract', window );"><strong>Schedule Of Components Of Income Tax Expense Benefit Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign', window );">Net operating loss carry-forwards foreign</a></td>
<td class="nump">$ 332<span></span>
</td>
<td class="nump">$ 287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Non-capital loss carry-forwards &#8211; USA</a></td>
<td class="nump">18,365<span></span>
</td>
<td class="nump">14,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Temporary differences</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">418<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Net deferred tax asset</a></td>
<td class="nump">19,124<span></span>
</td>
<td class="nump">14,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(19,124)<span></span>
</td>
<td class="num">(14,977)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Summary of Operating Loss Carryforwards (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 87,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2029Member', window );">Expiring 2029 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating Loss Carryforwards</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2030Member', window );">Expiring 2030 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating Loss Carryforwards</a></td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2031Member', window );">Expiring 2031 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating Loss Carryforwards</a></td>
<td class="nump">3,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2032Member', window );">Expiring 2032 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating Loss Carryforwards</a></td>
<td class="nump">4,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2033Member', window );">Expiring 2033 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating Loss Carryforwards</a></td>
<td class="nump">627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2034Member', window );">Expiring 2034 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating Loss Carryforwards</a></td>
<td class="nump">1,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2035Member', window );">Expiring 2035 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating Loss Carryforwards</a></td>
<td class="nump">1,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2036Member', window );">Expiring 2036 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating Loss Carryforwards</a></td>
<td class="nump">1,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2037Member', window );">Expiring 2037 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating Loss Carryforwards</a></td>
<td class="nump">819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2038Member', window );">Expiring 2038 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating Loss Carryforwards</a></td>
<td class="nump">1,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2039Member', window );">Expiring 2039 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating Loss Carryforwards</a></td>
<td class="nump">4,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2040Member', window );">Expiring 2040 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating Loss Carryforwards</a></td>
<td class="nump">7,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2041Member', window );">Expiring 2041 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating Loss Carryforwards</a></td>
<td class="nump">8,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2042Member', window );">Expiring 2042 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating Loss Carryforwards</a></td>
<td class="nump">14,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2043Member', window );">Expiring 2043 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating Loss Carryforwards</a></td>
<td class="nump">8,552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2044Member', window );">Expiring 2044 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating Loss Carryforwards</a></td>
<td class="nump">6,884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2045Member', window );">Expiring 2045 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 22,006<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2032Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2032Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2045Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=igc_Expiring2045Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,271<span></span>
</td>
<td class="nump">$ 1,345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=igc_WellnessAndLifestyleMember', window );">Wellness and Lifestyle [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">113<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=igc_TollingWhiteLabelingServiceMember', window );">Tolling/White labeling service [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,158<span></span>
</td>
<td class="nump">953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=igc_OtherRevenueMember', window );">Other Revenue [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 164<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from wellness and lifestyle consists of the sale of products such as gummies, hand sanitizers, bath bombs, lotions, beverages, hemp crude
extract, hemp isolate, and hemp distillate.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from white labelling services consists of rebranding our formulations or the customer&#8217;s products as per the customer&#8217;s requirement.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
consists of income from the rental of heavy construction equipment and the execution of contracts directly or through subcontractors.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=igc_WellnessAndLifestyleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=igc_WellnessAndLifestyleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=igc_TollingWhiteLabelingServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=igc_TollingWhiteLabelingServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=igc_OtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=igc_OtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SEGMENTINFORMATIONDetailsLineItems', window );"><strong>SEGMENT INFORMATION (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,271<span></span>
</td>
<td class="nump">$ 1,345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=igc_InfrastructureSegmentMember', window );">Infrastructure Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SEGMENTINFORMATIONDetailsLineItems', window );"><strong>SEGMENT INFORMATION (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_SEGMENTINFORMATIONDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_SEGMENTINFORMATIONDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=igc_InfrastructureSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=igc_InfrastructureSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Revenue from External Customers by Products and Services (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,271<span></span>
</td>
<td class="nump">$ 1,345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=igc_PlantAndCannabinoidMember', window );">Plant and Cannabinoid [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,271<span></span>
</td>
<td class="nump">$ 1,345<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=igc_PlantAndCannabinoidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=igc_PlantAndCannabinoidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Revenue from External Customers by Geographic Areas (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems', window );"><strong>SEGMENT INFORMATION - Revenue from External Customers by Geographic Areas (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 1,271<span></span>
</td>
<td class="nump">$ 1,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_TotalRevenuePercentage', window );">Total Revenue Percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IN', window );">INDIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems', window );"><strong>SEGMENT INFORMATION - Revenue from External Customers by Geographic Areas (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_TotalRevenuePercentage', window );">Total Revenue Percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems', window );"><strong>SEGMENT INFORMATION - Revenue from External Customers by Geographic Areas (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 1,269<span></span>
</td>
<td class="nump">$ 1,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_TotalRevenuePercentage', window );">Total Revenue Percentage</a></td>
<td class="nump">99.80%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CO', window );">COLOMBIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems', window );"><strong>SEGMENT INFORMATION - Revenue from External Customers by Geographic Areas (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_TotalRevenuePercentage', window );">Total Revenue Percentage</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_TotalRevenuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of segment to total revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_TotalRevenuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 1,852<span></span>
</td>
<td class="nump">$ 1,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,220<span></span>
</td>
<td class="nump">3,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Claims and advances</a></td>
<td class="nump">681<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease asset</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">5,851<span></span>
</td>
<td class="nump">6,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionDomesticMember', window );">Geographic Distribution, Domestic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">1,852<span></span>
</td>
<td class="nump">1,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,171<span></span>
</td>
<td class="nump">3,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Claims and advances</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease asset</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">5,513<span></span>
</td>
<td class="nump">5,839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember', window );">Geographic Distribution, Foreign [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Claims and advances</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease asset</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">$ 338<span></span>
</td>
<td class="nump">$ 358<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionDomesticMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionDomesticMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 24, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SUBSEQUENTEVENTSDetailsLineItems', window );"><strong>SUBSEQUENT EVENTS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Asset, Held-for-Sale, Not Part of Disposal Group, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Investor [Member] | Share Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SUBSEQUENTEVENTSDetailsLineItems', window );"><strong>SUBSEQUENT EVENTS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,803,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 841,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SUBSEQUENTEVENTSDetailsLineItems', window );"><strong>SUBSEQUENT EVENTS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCollateralFeesAmount', window );">Line of Credit Facility, Collateral Fees, Amount</a></td>
<td class="nump">$ 84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_igc_SUBSEQUENTEVENTSDetailsLineItems', window );"><strong>SUBSEQUENT EVENTS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCollateralFeesAmount', window );">Line of Credit Facility, Collateral Fees, Amount</a></td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_igc_SUBSEQUENTEVENTSDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">igc_SUBSEQUENTEVENTSDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>igc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482309/360-10-15-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCollateralFeesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fees associated with providing collateral for the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCollateralFeesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=igc_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=igc_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>145</ContextCount>
  <ElementCount>327</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995300 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995301 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995302 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995303 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995304 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>CONSOLIDATED STATEMENT OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995305 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/ConsolidatedCashFlow</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995306 - Disclosure - NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/NATUREOFOPERATIONS</Role>
      <ShortName>NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995307 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995308 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/INVENTORY</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995309 - Disclosure - DEPOSITS AND ADVANCES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCES</Role>
      <ShortName>DEPOSITS AND ADVANCES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995310 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/INTANGIBLEASSETS</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995311 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENT</Role>
      <ShortName>PROPERTY, PLANT, AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995312 - Disclosure - CLAIMS AND ADVANCES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/CLAIMSANDADVANCES</Role>
      <ShortName>CLAIMS AND ADVANCES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995313 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995314 - Disclosure - ACCRUED LIABILITIES AND OTHERS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERS</Role>
      <ShortName>ACCRUED LIABILITIES AND OTHERS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995315 - Disclosure - LOANS AND OTHER LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIES</Role>
      <ShortName>LOANS AND OTHER LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995316 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995317 - Disclosure - SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/SECURITIES</Role>
      <ShortName>SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995318 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995319 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995320 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995321 - Disclosure - REVENUE RECOGNITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/REVENUERECOGNITION</Role>
      <ShortName>REVENUE RECOGNITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995322 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/SEGMENTINFORMATION</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995323 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996001 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/INVENTORYTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/INVENTORY</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996002 - Disclosure - DEPOSITS AND ADVANCES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCESTables</Role>
      <ShortName>DEPOSITS AND ADVANCES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCES</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996003 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/INTANGIBLEASSETSTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/INTANGIBLEASSETS</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996004 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY, PLANT, AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENT</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996005 - Disclosure - CLAIMS AND ADVANCES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/CLAIMSANDADVANCESTables</Role>
      <ShortName>CLAIMS AND ADVANCES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/CLAIMSANDADVANCES</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996006 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/LEASES</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996007 - Disclosure - ACCRUED LIABILITIES AND OTHERS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSTables</Role>
      <ShortName>ACCRUED LIABILITIES AND OTHERS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERS</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996008 - Disclosure - LOANS AND OTHER LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESTables</Role>
      <ShortName>LOANS AND OTHER LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIES</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996009 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996010 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996011 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/INCOMETAXES</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996012 - Disclosure - REVENUE RECOGNITION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/REVENUERECOGNITIONTables</Role>
      <ShortName>REVENUE RECOGNITION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/REVENUERECOGNITION</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996013 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/SEGMENTINFORMATION</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996014 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996015 - Disclosure - INVENTORY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/INVENTORYDetails</Role>
      <ShortName>INVENTORY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/INVENTORYTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996016 - Disclosure - INVENTORY - Schedule of Inventory, Current (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/ScheduleofInventoryCurrentTable</Role>
      <ShortName>INVENTORY - Schedule of Inventory, Current (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996017 - Disclosure - DEPOSITS AND ADVANCES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCESDetails</Role>
      <ShortName>DEPOSITS AND ADVANCES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCESTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996018 - Disclosure - DEPOSITS AND ADVANCES - Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/DeferredCostsCapitalizedPrepaidandOtherAssetsDisclosureTable</Role>
      <ShortName>DEPOSITS AND ADVANCES - Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996019 - Disclosure - INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/INTANGIBLEASSETSDetails</Role>
      <ShortName>INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/INTANGIBLEASSETSTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996020 - Disclosure - INTANGIBLE ASSETS - Schedule of Intangible Assets And Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable</Role>
      <ShortName>INTANGIBLE ASSETS - Schedule of Intangible Assets And Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996021 - Disclosure - INTANGIBLE ASSETS - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTable</Role>
      <ShortName>INTANGIBLE ASSETS - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996022 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTDetails</Role>
      <ShortName>PROPERTY, PLANT, AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996023 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable</Role>
      <ShortName>PROPERTY, PLANT, AND EQUIPMENT - Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996024 - Disclosure - CLAIMS AND ADVANCES - Schedule of Other Assets, Noncurrent (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/ScheduleofOtherAssetsNoncurrentTable</Role>
      <ShortName>CLAIMS AND ADVANCES - Schedule of Other Assets, Noncurrent (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996025 - Disclosure - LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/LEASESDetails</Role>
      <ShortName>LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/LEASESTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996026 - Disclosure - LEASES - Lease, Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/LeaseCostTable</Role>
      <ShortName>LEASES - Lease, Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996027 - Disclosure - LEASES - Lessee, Operating Lease, Liability, Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/LesseeOperatingLeaseLiabilityMaturityTable</Role>
      <ShortName>LEASES - Lessee, Operating Lease, Liability, Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996028 - Disclosure - ACCRUED LIABILITIES AND OTHERS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSDetails</Role>
      <ShortName>ACCRUED LIABILITIES AND OTHERS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996029 - Disclosure - ACCRUED LIABILITIES AND OTHERS - Schedule of Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable</Role>
      <ShortName>ACCRUED LIABILITIES AND OTHERS - Schedule of Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996030 - Disclosure - LOANS AND OTHER LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESDetails</Role>
      <ShortName>LOANS AND OTHER LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996031 - Disclosure - LOANS AND OTHER LIABILITIES - Schedule of Loans and Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/ScheduleofLoansandOtherLiabilitiesTable</Role>
      <ShortName>LOANS AND OTHER LIABILITIES - Schedule of Loans and Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996033 - Disclosure - SECURITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/SECURITIESDetails</Role>
      <ShortName>SECURITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/SECURITIES</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996034 - Disclosure - STOCK-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996035 - Disclosure - STOCK-BASED COMPENSATION  - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsTable</Role>
      <ShortName>STOCK-BASED COMPENSATION  - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996036 - Disclosure - STOCK-BASED COMPENSATION  - Nonvested Restricted Stock Shares Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/NonvestedRestrictedStockSharesActivityTable</Role>
      <ShortName>STOCK-BASED COMPENSATION  - Nonvested Restricted Stock Shares Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996037 - Disclosure - STOCK-BASED COMPENSATION  - Share-based Payment Arrangement, Option, Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/SharebasedPaymentArrangementOptionActivityTable</Role>
      <ShortName>STOCK-BASED COMPENSATION  - Share-based Payment Arrangement, Option, Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996038 - Disclosure -  FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable</Role>
      <ShortName> FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996039 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/INCOMETAXESDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/INCOMETAXESTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996040 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable</Role>
      <ShortName>INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996041 - Disclosure - INCOME TAXES - Schedule of Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/ScheduleofComponentsofIncomeTaxExpenseBenefitTable</Role>
      <ShortName>INCOME TAXES - Schedule of Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996042 - Disclosure - INCOME TAXES - Summary of Operating Loss Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable</Role>
      <ShortName>INCOME TAXES - Summary of Operating Loss Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996043 - Disclosure - REVENUE RECOGNITION - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/DisaggregationofRevenueTable</Role>
      <ShortName>REVENUE RECOGNITION - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996044 - Disclosure - SEGMENT INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONDetails</Role>
      <ShortName>SEGMENT INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996045 - Disclosure - SEGMENT INFORMATION - Revenue from External Customers by Products and Services (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyProductsandServicesTable</Role>
      <ShortName>SEGMENT INFORMATION - Revenue from External Customers by Products and Services (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996046 - Disclosure - SEGMENT INFORMATION - Revenue from External Customers by Geographic Areas (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyGeographicAreasTable</Role>
      <ShortName>SEGMENT INFORMATION - Revenue from External Customers by Geographic Areas (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996047 - Disclosure - SEGMENT INFORMATION - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/ScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasTable</Role>
      <ShortName>SEGMENT INFORMATION - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="igc10k033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996048 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>77</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>igc-20250331.xsd</File>
    <File>igc-20250331_cal.xml</File>
    <File>igc-20250331_def.xml</File>
    <File>igc-20250331_lab.xml</File>
    <File>igc-20250331_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="igc10k033125.htm">igc10k033125.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
    <File>image_010.jpg</File>
    <File>image_011.jpg</File>
    <File>image_012.jpg</File>
    <File>image_013.jpg</File>
    <File>image_014.jpg</File>
    <File>image_015.jpg</File>
    <File>image_016.jpg</File>
    <File>image_017.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="683">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>114
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "igc10k033125.htm": {
   "nsprefix": "igc",
   "nsuri": "http://www.indiaglobalcap.com/20250331",
   "dts": {
    "schema": {
     "local": [
      "igc-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_def.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_lab.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_pre.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "igc-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "igc-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "igc-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "igc-20250331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "igc10k033125.htm"
     ]
    }
   },
   "keyStandard": 313,
   "keyCustom": 14,
   "axisStandard": 21,
   "axisCustom": 1,
   "memberStandard": 33,
   "memberCustom": 32,
   "hidden": {
    "total": 7,
    "http://xbrl.sec.gov/dei/2025": 3,
    "http://fasb.org/us-gaap/2025": 4
   },
   "contextCount": 145,
   "entityCount": 1,
   "segmentCount": 67,
   "elementCount": 754,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 683,
    "http://xbrl.sec.gov/dei/2025": 37,
    "http://xbrl.sec.gov/cyd/2025": 15,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation",
     "longName": "995300 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R5": {
     "role": "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3",
     "longName": "995304 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS\u2019 EQUITY",
     "shortName": "CONSOLIDATED STATEMENT OF STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow",
     "longName": "995305 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.indiaglobalcap.com/role/NATUREOFOPERATIONS",
     "longName": "995306 - Disclosure - NATURE OF OPERATIONS",
     "shortName": "NATURE OF OPERATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "995307 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.indiaglobalcap.com/role/INVENTORY",
     "longName": "995308 - Disclosure - INVENTORY",
     "shortName": "INVENTORY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCES",
     "longName": "995309 - Disclosure - DEPOSITS AND ADVANCES",
     "shortName": "DEPOSITS AND ADVANCES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "igc:DepositsAndAdvancesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "igc:DepositsAndAdvancesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.indiaglobalcap.com/role/INTANGIBLEASSETS",
     "longName": "995310 - Disclosure - INTANGIBLE ASSETS",
     "shortName": "INTANGIBLE ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENT",
     "longName": "995311 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT",
     "shortName": "PROPERTY, PLANT, AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.indiaglobalcap.com/role/CLAIMSANDADVANCES",
     "longName": "995312 - Disclosure - CLAIMS AND ADVANCES",
     "shortName": "CLAIMS AND ADVANCES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.indiaglobalcap.com/role/LEASES",
     "longName": "995313 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERS",
     "longName": "995314 - Disclosure - ACCRUED LIABILITIES AND OTHERS",
     "shortName": "ACCRUED LIABILITIES AND OTHERS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "igc:AccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "igc:AccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIES",
     "longName": "995315 - Disclosure - LOANS AND OTHER LIABILITIES",
     "shortName": "LOANS AND OTHER LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "igc:LoansAndOtherLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "igc:LoansAndOtherLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.indiaglobalcap.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "995316 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.indiaglobalcap.com/role/SECURITIES",
     "longName": "995317 - Disclosure - SECURITIES",
     "shortName": "SECURITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATION",
     "longName": "995318 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.indiaglobalcap.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS",
     "longName": "995319 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.indiaglobalcap.com/role/INCOMETAXES",
     "longName": "995320 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.indiaglobalcap.com/role/REVENUERECOGNITION",
     "longName": "995321 - Disclosure - REVENUE RECOGNITION",
     "shortName": "REVENUE RECOGNITION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.indiaglobalcap.com/role/SEGMENTINFORMATION",
     "longName": "995322 - Disclosure - SEGMENT INFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTS",
     "longName": "995323 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R27": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c30",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c30",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesIntegratedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
       "cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesIntegratedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
       "cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.indiaglobalcap.com/role/INVENTORYTables",
     "longName": "996001 - Disclosure - INVENTORY (Tables)",
     "shortName": "INVENTORY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCESTables",
     "longName": "996002 - Disclosure - DEPOSITS AND ADVANCES (Tables)",
     "shortName": "DEPOSITS AND ADVANCES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "igc:DepositsAndAdvancesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "igc:DepositsAndAdvancesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.indiaglobalcap.com/role/INTANGIBLEASSETSTables",
     "longName": "996003 - Disclosure - INTANGIBLE ASSETS (Tables)",
     "shortName": "INTANGIBLE ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTTables",
     "longName": "996004 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY, PLANT, AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c45",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c45",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.indiaglobalcap.com/role/CLAIMSANDADVANCESTables",
     "longName": "996005 - Disclosure - CLAIMS AND ADVANCES (Tables)",
     "shortName": "CLAIMS AND ADVANCES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.indiaglobalcap.com/role/LEASESTables",
     "longName": "996006 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSTables",
     "longName": "996007 - Disclosure - ACCRUED LIABILITIES AND OTHERS (Tables)",
     "shortName": "ACCRUED LIABILITIES AND OTHERS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "igc:AccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "igc:AccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESTables",
     "longName": "996008 - Disclosure - LOANS AND OTHER LIABILITIES (Tables)",
     "shortName": "LOANS AND OTHER LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "igc:LoansAndOtherLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "igc:LoansAndOtherLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONTables",
     "longName": "996009 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.indiaglobalcap.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables",
     "longName": "996010 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.indiaglobalcap.com/role/INCOMETAXESTables",
     "longName": "996011 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.indiaglobalcap.com/role/REVENUERECOGNITIONTables",
     "longName": "996012 - Disclosure - REVENUE RECOGNITION (Tables)",
     "shortName": "REVENUE RECOGNITION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONTables",
     "longName": "996013 - Disclosure - SEGMENT INFORMATION (Tables)",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
     "longName": "996014 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c30",
      "name": "us-gaap:IncomeTaxReconciliationTaxCredits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.indiaglobalcap.com/role/INVENTORYDetails",
     "longName": "996015 - Disclosure - INVENTORY (Details)",
     "shortName": "INVENTORY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.indiaglobalcap.com/role/ScheduleofInventoryCurrentTable",
     "longName": "996016 - Disclosure - INVENTORY - Schedule of Inventory, Current (Details)",
     "shortName": "INVENTORY - Schedule of Inventory, Current (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCESDetails",
     "longName": "996017 - Disclosure - DEPOSITS AND ADVANCES (Details)",
     "shortName": "DEPOSITS AND ADVANCES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "igc:StatutoryAdvances",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "igc:DepositsAndAdvancesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "igc:StatutoryAdvances",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "igc:DepositsAndAdvancesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.indiaglobalcap.com/role/DeferredCostsCapitalizedPrepaidandOtherAssetsDisclosureTable",
     "longName": "996018 - Disclosure - DEPOSITS AND ADVANCES - Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure (Details)",
     "shortName": "DEPOSITS AND ADVANCES - Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "igc:DepositsAndAdvancesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "igc:DepositsAndAdvancesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.indiaglobalcap.com/role/INTANGIBLEASSETSDetails",
     "longName": "996019 - Disclosure - INTANGIBLE ASSETS (Details)",
     "shortName": "INTANGIBLE ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c36",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c36",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable",
     "longName": "996020 - Disclosure - INTANGIBLE ASSETS - Schedule of Intangible Assets And Goodwill (Details)",
     "shortName": "INTANGIBLE ASSETS - Schedule of Intangible Assets And Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.indiaglobalcap.com/role/ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTable",
     "longName": "996021 - Disclosure - INTANGIBLE ASSETS - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)",
     "shortName": "INTANGIBLE ASSETS - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTDetails",
     "longName": "996022 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Details)",
     "shortName": "PROPERTY, PLANT, AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable",
     "longName": "996023 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT - Property, Plant and Equipment (Details)",
     "shortName": "PROPERTY, PLANT, AND EQUIPMENT - Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.indiaglobalcap.com/role/ScheduleofOtherAssetsNoncurrentTable",
     "longName": "996024 - Disclosure - CLAIMS AND ADVANCES - Schedule of Other Assets, Noncurrent (Details)",
     "shortName": "CLAIMS AND ADVANCES - Schedule of Other Assets, Noncurrent (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:OtherReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:OtherReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.indiaglobalcap.com/role/LEASESDetails",
     "longName": "996025 - Disclosure - LEASES (Details)",
     "shortName": "LEASES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShortTermLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R55": {
     "role": "http://www.indiaglobalcap.com/role/LeaseCostTable",
     "longName": "996026 - Disclosure - LEASES - Lease, Cost (Details)",
     "shortName": "LEASES - Lease, Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.indiaglobalcap.com/role/LesseeOperatingLeaseLiabilityMaturityTable",
     "longName": "996027 - Disclosure - LEASES - Lessee, Operating Lease, Liability, Maturity (Details)",
     "shortName": "LEASES - Lessee, Operating Lease, Liability, Maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSDetails",
     "longName": "996028 - Disclosure - ACCRUED LIABILITIES AND OTHERS (Details)",
     "shortName": "ACCRUED LIABILITIES AND OTHERS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AccountsPayableOtherCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "igc:AccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AccountsPayableOtherCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "igc:AccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.indiaglobalcap.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable",
     "longName": "996029 - Disclosure - ACCRUED LIABILITIES AND OTHERS - Schedule of Accounts Payable and Accrued Liabilities (Details)",
     "shortName": "ACCRUED LIABILITIES AND OTHERS - Schedule of Accounts Payable and Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "igc:AccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "igc:AccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESDetails",
     "longName": "996030 - Disclosure - LOANS AND OTHER LIABILITIES (Details)",
     "shortName": "LOANS AND OTHER LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c63",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "igc:LoansAndOtherLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c63",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "igc:LoansAndOtherLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.indiaglobalcap.com/role/ScheduleofLoansandOtherLiabilitiesTable",
     "longName": "996031 - Disclosure - LOANS AND OTHER LIABILITIES - Schedule of Loans and Other Liabilities (Details)",
     "shortName": "LOANS AND OTHER LIABILITIES - Schedule of Loans and Other Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:OtherAccruedLiabilitiesNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
       "igc:LoansAndOtherLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:OtherAccruedLiabilitiesNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
       "igc:LoansAndOtherLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.indiaglobalcap.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "longName": "996032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.indiaglobalcap.com/role/SECURITIESDetails",
     "longName": "996033 - Disclosure - SECURITIES (Details)",
     "shortName": "SECURITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "igc:UnitsOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails",
     "longName": "996034 - Disclosure - STOCK-BASED COMPENSATION (Details)",
     "shortName": "STOCK-BASED COMPENSATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.indiaglobalcap.com/role/ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsTable",
     "longName": "996035 - Disclosure - STOCK-BASED COMPENSATION  - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)",
     "shortName": "STOCK-BASED COMPENSATION  - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.indiaglobalcap.com/role/NonvestedRestrictedStockSharesActivityTable",
     "longName": "996036 - Disclosure - STOCK-BASED COMPENSATION  - Nonvested Restricted Stock Shares Activity (Details)",
     "shortName": "STOCK-BASED COMPENSATION  - Nonvested Restricted Stock Shares Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.indiaglobalcap.com/role/SharebasedPaymentArrangementOptionActivityTable",
     "longName": "996037 - Disclosure - STOCK-BASED COMPENSATION  - Share-based Payment Arrangement, Option, Activity (Details)",
     "shortName": "STOCK-BASED COMPENSATION  - Share-based Payment Arrangement, Option, Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable",
     "longName": "996038 - Disclosure -  FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "shortName": " FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AssetsFairValueAdjustment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AssetsFairValueAdjustment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.indiaglobalcap.com/role/INCOMETAXESDetails",
     "longName": "996039 - Disclosure - INCOME TAXES (Details)",
     "shortName": "INCOME TAXES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable",
     "longName": "996040 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.indiaglobalcap.com/role/ScheduleofComponentsofIncomeTaxExpenseBenefitTable",
     "longName": "996041 - Disclosure - INCOME TAXES - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "shortName": "INCOME TAXES - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable",
     "longName": "996042 - Disclosure - INCOME TAXES - Summary of Operating Loss Carryforwards (Details)",
     "shortName": "INCOME TAXES - Summary of Operating Loss Carryforwards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.indiaglobalcap.com/role/DisaggregationofRevenueTable",
     "longName": "996043 - Disclosure - REVENUE RECOGNITION - Disaggregation of Revenue (Details)",
     "shortName": "REVENUE RECOGNITION - Disaggregation of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c121",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONDetails",
     "longName": "996044 - Disclosure - SEGMENT INFORMATION (Details)",
     "shortName": "SEGMENT INFORMATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyProductsandServicesTable",
     "longName": "996045 - Disclosure - SEGMENT INFORMATION - Revenue from External Customers by Products and Services (Details)",
     "shortName": "SEGMENT INFORMATION - Revenue from External Customers by Products and Services (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c128",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyGeographicAreasTable",
     "longName": "996046 - Disclosure - SEGMENT INFORMATION - Revenue from External Customers by Geographic Areas (Details)",
     "shortName": "SEGMENT INFORMATION - Revenue from External Customers by Geographic Areas (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "igc:TotalRevenuePercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.indiaglobalcap.com/role/ScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasTable",
     "longName": "996047 - Disclosure - SEGMENT INFORMATION - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)",
     "shortName": "SEGMENT INFORMATION - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c136",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails",
     "longName": "996048 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c140",
      "name": "us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c140",
      "name": "us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "igc10k033125.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "igc_ACCRUEDLIABILITIESANDOTHERSDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "ACCRUEDLIABILITIESANDOTHERSDetailsLineItems",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED LIABILITIES AND OTHERS (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "igc_ACCRUEDLIABILITIESANDOTHERSDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "ACCRUEDLIABILITIESANDOTHERSDetailsTable",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED LIABILITIES AND OTHERS (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r890"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable, Other, Current",
        "label": "Accounts Payable, Other, Current",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, after Allowance for Credit Loss",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r708",
      "r762",
      "r913",
      "r1272",
      "r1273"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1155"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.indiaglobalcap.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet",
      "http://www.indiaglobalcap.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued liabilities and others",
        "totalLabel": "Total",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "igc_AccruedLiabilitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "AccruedLiabilitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities Disclosure Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "igc_AccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "AccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Liabilities Disclosure [Text Block]",
        "documentation": "Disclosure for accrued liabilities.",
        "label": "Accrued Liabilities Disclosure Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r131",
      "r642"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r56",
      "r137",
      "r637",
      "r669",
      "r670",
      "r1236"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AOCI Attributable to Parent [Member]",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r10",
      "r18",
      "r470",
      "r473",
      "r541",
      "r665",
      "r666",
      "r1091",
      "r1092",
      "r1093",
      "r1145",
      "r1146",
      "r1147",
      "r1148"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "igc_AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock subscribed",
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).",
        "label": "Adjustments To Additional Paid In Capita For Subscribed Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share money received but not allotted",
        "label": "Adjustments to Additional Paid in Capital, Other",
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock-based compensation &amp; expenses, net",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1187",
      "r1192"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to reconcile net loss to net cash:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r952",
      "r963",
      "r979",
      "r1014"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r955",
      "r966",
      "r982",
      "r1017"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r956",
      "r967",
      "r983",
      "r1009",
      "r1018",
      "r1022",
      "r1030"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow",
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock-based compensation and expenses, net",
        "terseLabel": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r406",
      "r415"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r230",
      "r264",
      "r267",
      "r269",
      "r1273"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIESDetails",
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow",
      "http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of assets",
        "verboseLabel": "Asset Impairment Charges",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r29",
      "r900",
      "r901"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r93",
      "r134",
      "r164",
      "r165",
      "r166",
      "r197",
      "r209",
      "r218",
      "r221",
      "r261",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r458",
      "r462",
      "r510",
      "r625",
      "r626",
      "r633",
      "r713",
      "r806",
      "r807",
      "r820",
      "r890",
      "r907",
      "r908",
      "r920",
      "r1184",
      "r1185",
      "r1259"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet",
      "http://www.indiaglobalcap.com/role/LeaseCostTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "verboseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r142",
      "r164",
      "r165",
      "r166",
      "r261",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r458",
      "r462",
      "r510",
      "r890",
      "r1184",
      "r1185",
      "r1259"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjusted Cost",
        "label": "Assets, Fair Value Adjustment",
        "documentation": "Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r486",
      "r876"
     ]
    },
    "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet",
      "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset held for sale",
        "verboseLabel": "Asset, Held-for-Sale, Not Part of Disposal Group, Current",
        "label": "Asset, Held-for-Sale, Not Part of Disposal Group, Current",
        "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r890"
     ]
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet",
      "http://www.indiaglobalcap.com/role/ScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "terseLabel": "Total non-current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r261",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r458",
      "r462",
      "r510",
      "r1184",
      "r1185",
      "r1259"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets:",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r933",
      "r936",
      "r959"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r933",
      "r936",
      "r959"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r933",
      "r936",
      "r959"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BuildingAndBuildingImprovementsMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building and Building Improvements [Member]",
        "label": "Building and Building Improvements [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r936",
      "r959"
     ]
    },
    "country_CO": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "CO",
     "presentation": [
      "http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyGeographicAreasTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COLOMBIA",
        "label": "COLOMBIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedComputerSoftwareGross",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized Computer Software, Gross",
        "label": "Capitalized Computer Software, Gross",
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r776"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet",
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "terseLabel": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r129",
      "r781"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash &amp; Cash Equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r505",
      "r506",
      "r1239",
      "r1240"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Member]",
        "label": "Cash and Cash Equivalents [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at the beginning of the period",
        "periodEndLabel": "Cash and cash equivalents at the end of the period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r66",
      "r161"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash and cash equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r66"
     ]
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificates of Deposit [Member]",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r914",
      "r915",
      "r916",
      "r917"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "igc_ClinicalTrialInventoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "ClinicalTrialInventoryMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/INVENTORYDetails",
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Trial Inventory [Member]",
        "label": "Clinical Trial Inventory Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies \u2013 See Note 12",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r86",
      "r635",
      "r698"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Text Block]",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r296",
      "r297",
      "r763",
      "r1179",
      "r1181"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies, Policy [Policy Text Block]",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r764"
     ]
    },
    "us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockIncludingAdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Including Additional Paid in Capital [Member]",
        "label": "Common Stock Including Additional Paid in Capital [Member]",
        "documentation": "Common stock held by shareholders with par value plus amounts in excess of par value or issuance value (in cases of no-par value stock)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r910",
      "r911",
      "r912",
      "r914",
      "r915",
      "r916",
      "r917",
      "r1145",
      "r1146",
      "r1148",
      "r1237",
      "r1304",
      "r1307"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.indiaglobalcap.com/role/SECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value (in Dollars per share)",
        "terseLabel": "Common Stock, Par or Stated Value Per Share (in Dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.indiaglobalcap.com/role/SECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "terseLabel": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r699"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.indiaglobalcap.com/role/SECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "terseLabel": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.indiaglobalcap.com/role/SECURITIESDetails",
      "http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "terseLabel": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r45",
      "r699",
      "r719",
      "r1307",
      "r1308"
     ]
    },
    "us-gaap_CommonStocksIncludingAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStocksIncludingAdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock and additional paid-in capital, $0.0001 par value: 150,000,000 shares authorized; 80,878,058 and 66,691,195 shares issued and outstanding as of March 31, 2025, and March 31, 2024, respectively.",
        "documentation": "Amount of par value plus amounts in excess of par value or issuance value for common stock issued."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r79"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r144",
      "r146",
      "r152",
      "r623",
      "r649",
      "r650"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer Equipment [Member]",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r508"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation, Policy [Policy Text Block]",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r793"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of revenue",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r164",
      "r165",
      "r166",
      "r261",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r510",
      "r806",
      "r1184"
     ]
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Goods and Service [Policy Text Block]",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r170",
      "r171",
      "r313",
      "r331",
      "r544",
      "r564",
      "r632",
      "r783",
      "r784",
      "r785",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1232",
      "r1233",
      "r1234",
      "r1235"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "igc_CybersecurityPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "CybersecurityPolicyPolicyTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cyber-security Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy related to cyber-security.",
        "label": "Cybersecurity Policy Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]",
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r944",
      "r1041"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Board of Directors Oversight [Text Block]",
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r944",
      "r1041"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]",
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r1043"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]",
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r1043"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]",
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r948",
      "r1045"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]",
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r1043"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]",
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r939",
      "r1036"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes Integrated [Flag]",
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r940",
      "r1037"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes Integrated [Text Block]",
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r940",
      "r1037"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r1035"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r1035"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r1035"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Third Party Engaged [Flag]",
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r1038"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]",
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r943",
      "r1040"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]",
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r944",
      "r1041"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]",
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r947",
      "r1044"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Role of Management [Text Block]",
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r945",
      "r1042"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]",
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r942",
      "r1039"
     ]
    },
    "igc_DebtFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "DebtFundsMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Funds [Member]",
        "label": "Debt Funds Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Face Amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r524",
      "r525",
      "r816",
      "r817",
      "r888"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESDetails",
      "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r312"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Periodic Payment",
        "label": "Debt Instrument, Periodic Payment",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r34"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Term",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofComponentsofIncomeTaxExpenseBenefitTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofComponentsofIncomeTaxExpenseBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-capital loss carry-forwards \u2013 USA",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1228"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofComponentsofIncomeTaxExpenseBenefitTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofComponentsofIncomeTaxExpenseBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax asset",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofComponentsofIncomeTaxExpenseBenefitTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofComponentsofIncomeTaxExpenseBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax expense",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1226"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1228"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofComponentsofIncomeTaxExpenseBenefitTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofComponentsofIncomeTaxExpenseBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary differences",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1228"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsForeign",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofComponentsofIncomeTaxExpenseBenefitTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofComponentsofIncomeTaxExpenseBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carry-forwards foreign",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Foreign",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1228"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofComponentsofIncomeTaxExpenseBenefitTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofComponentsofIncomeTaxExpenseBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.indiaglobalcap.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r971",
      "r972",
      "r986"
     ]
    },
    "igc_DepositsAndAdvancesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "DepositsAndAdvancesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits And Advances Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "igc_DepositsAndAdvancesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "DepositsAndAdvancesTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits and Advances [Text Block]",
        "documentation": "Disclosure of deposits and advances.",
        "label": "Deposits And Advances Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r30",
      "r157",
      "r786",
      "r787",
      "r789",
      "r791"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r158",
      "r197",
      "r212",
      "r221",
      "r786",
      "r806",
      "r807"
     ]
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.indiaglobalcap.com/role/DisaggregationofRevenueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r353",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.indiaglobalcap.com/role/DisaggregationofRevenueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r353",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/REVENUERECOGNITIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table Text Block]",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1188"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement [Text Block]",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369",
      "r401",
      "r402",
      "r404",
      "r836"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureTextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureTextBlockSupplementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureTextBlockSupplementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block Supplement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r971",
      "r972",
      "r986"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r936",
      "r959"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r936",
      "r959",
      "r1010"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r936",
      "r959",
      "r1010"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "igc_ESOP2008OmnibusPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "ESOP2008OmnibusPlanMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESOP 2008 Omnibus Plan [Member]",
        "documentation": "Name of the equity-based compensation arrangement plan.",
        "label": "ESOP2008 Omnibus Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to common stockholders:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted (in Dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r153",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r188",
      "r190",
      "r192",
      "r193",
      "r194",
      "r196",
      "r319",
      "r405",
      "r452",
      "r455",
      "r482",
      "r483",
      "r624",
      "r651",
      "r796"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and diluted (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r153",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r190",
      "r192",
      "r193",
      "r194",
      "r196",
      "r319",
      "r405",
      "r452",
      "r455",
      "r482",
      "r483",
      "r624",
      "r651",
      "r796"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share, Policy [Policy Text Block]",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r195"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of exchange rate changes on cash and cash equivalents",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1253"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r839"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and other contributions",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-Based Payment Arrangement, Option [Member]",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218"
     ]
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Ownership Plan (ESOP) Name [Axis]",
        "documentation": "Information by name of employee stock ownership plan."
       }
      }
     },
     "auth_ref": [
      "r1220"
     ]
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Ownership Plan (ESOP), Number of Committed-to-be-Released Shares (in Shares)",
        "label": "Employee Stock Ownership Plan (ESOP), Number of Committed-to-be-Released Shares",
        "documentation": "The shares that, although not legally released, will be released by a future scheduled and committed debt service payment and will be allocated to employees for service rendered in the current accounting period. The ESOP documents typically define the period of service to which the shares relate. ESOP shares are released to compensate employees directly, to settle employer liabilities for other employee benefits, and to replace dividends on allocated shares that are used for debt service."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r837",
      "r838"
     ]
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOwnershipPlanESOPPlanDomain",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Ownership Plan (ESOP), Plan [Domain]",
        "documentation": "Entities identify multiple employee stock ownership plans by unique name."
       }
      }
     },
     "auth_ref": [
      "r1220"
     ]
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1051"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1053"
     ]
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "presentation": [
      "http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyProductsandServicesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from External Customer [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r122",
      "r123",
      "r124",
      "r148",
      "r149",
      "r150",
      "r172",
      "r173",
      "r174",
      "r176",
      "r183",
      "r185",
      "r187",
      "r198",
      "r262",
      "r263",
      "r292",
      "r318",
      "r343",
      "r405",
      "r442",
      "r443",
      "r449",
      "r450",
      "r451",
      "r453",
      "r454",
      "r455",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r481",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r526",
      "r528",
      "r541",
      "r647",
      "r665",
      "r666",
      "r667",
      "r683",
      "r738"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r952",
      "r963",
      "r979",
      "r1014"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r960",
      "r976",
      "r1011"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "igc_Expiring2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "Expiring2029Member",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiring 2029 [Member]",
        "label": "Expiring2029 Member"
       }
      }
     },
     "auth_ref": []
    },
    "igc_Expiring2030Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "Expiring2030Member",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiring 2030 [Member]",
        "label": "Expiring2030 Member"
       }
      }
     },
     "auth_ref": []
    },
    "igc_Expiring2031Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "Expiring2031Member",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiring 2031 [Member]",
        "label": "Expiring2031 Member"
       }
      }
     },
     "auth_ref": []
    },
    "igc_Expiring2032Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "Expiring2032Member",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiring 2032 [Member]",
        "label": "Expiring2032 Member"
       }
      }
     },
     "auth_ref": []
    },
    "igc_Expiring2033Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "Expiring2033Member",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiring 2033 [Member]",
        "label": "Expiring2033 Member"
       }
      }
     },
     "auth_ref": []
    },
    "igc_Expiring2034Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "Expiring2034Member",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiring 2034 [Member]",
        "label": "Expiring2034 Member"
       }
      }
     },
     "auth_ref": []
    },
    "igc_Expiring2035Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "Expiring2035Member",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiring 2035 [Member]",
        "label": "Expiring2035 Member"
       }
      }
     },
     "auth_ref": []
    },
    "igc_Expiring2036Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "Expiring2036Member",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiring 2036 [Member]",
        "label": "Expiring2036 Member"
       }
      }
     },
     "auth_ref": []
    },
    "igc_Expiring2037Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "Expiring2037Member",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiring 2037 [Member]",
        "label": "Expiring2037 Member"
       }
      }
     },
     "auth_ref": []
    },
    "igc_Expiring2038Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "Expiring2038Member",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiring 2038 [Member]",
        "label": "Expiring2038 Member"
       }
      }
     },
     "auth_ref": []
    },
    "igc_Expiring2039Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "Expiring2039Member",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiring 2039 [Member]",
        "label": "Expiring2039 Member"
       }
      }
     },
     "auth_ref": []
    },
    "igc_Expiring2040Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "Expiring2040Member",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiring 2040 [Member]",
        "label": "Expiring2040 Member"
       }
      }
     },
     "auth_ref": []
    },
    "igc_Expiring2041Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "Expiring2041Member",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiring 2041 [Member]",
        "label": "Expiring2041 Member"
       }
      }
     },
     "auth_ref": []
    },
    "igc_Expiring2042Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "Expiring2042Member",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiring 2042 [Member]",
        "label": "Expiring2042 Member"
       }
      }
     },
     "auth_ref": []
    },
    "igc_Expiring2043Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "Expiring2043Member",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiring 2043 [Member]",
        "label": "Expiring2043 Member"
       }
      }
     },
     "auth_ref": []
    },
    "igc_Expiring2044Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "Expiring2044Member",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiring 2044 [Member]",
        "label": "Expiring2044 Member"
       }
      }
     },
     "auth_ref": []
    },
    "igc_Expiring2045Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "Expiring2045Member",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiring 2045 [Member]",
        "label": "Expiring2045 Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsLineItems",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "igc_FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailsTable",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain",
        "label": "Fair Value, Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) recognized in income from asset (liability) measured at fair value on recurring basis using unobservable input (level 3) and still held."
       }
      }
     },
     "auth_ref": [
      "r1245"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from asset and liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r1244"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r484",
      "r486",
      "r487",
      "r488",
      "r489",
      "r495",
      "r496",
      "r498",
      "r504",
      "r551",
      "r552",
      "r553",
      "r777",
      "r816",
      "r817",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r876",
      "r880",
      "r887"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Text Block]",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r491",
      "r493",
      "r494",
      "r495",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r622",
      "r876",
      "r881"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r356",
      "r361",
      "r363",
      "r486",
      "r496",
      "r504",
      "r551",
      "r777",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r876",
      "r887"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r356",
      "r361",
      "r363",
      "r365",
      "r486",
      "r487",
      "r496",
      "r504",
      "r552",
      "r777",
      "r816",
      "r817",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r876",
      "r887"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r486",
      "r487",
      "r488",
      "r489",
      "r496",
      "r504",
      "r553",
      "r777",
      "r816",
      "r817",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r876",
      "r880",
      "r887"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement, Policy [Policy Text Block]",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r484",
      "r486",
      "r487",
      "r488",
      "r489",
      "r495",
      "r496",
      "r498",
      "r504",
      "r551",
      "r552",
      "r553",
      "r777",
      "r816",
      "r817",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r876",
      "r880",
      "r887"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r265",
      "r266",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r316",
      "r341",
      "r468",
      "r479",
      "r503",
      "r509",
      "r512",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r631",
      "r648",
      "r815",
      "r876",
      "r878",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r891",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1238",
      "r1241",
      "r1242",
      "r1243",
      "r1246",
      "r1247",
      "r1248",
      "r1249"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.indiaglobalcap.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Asset, Useful Life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r280",
      "r287",
      "r780"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "For the year ended 2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r776",
      "r780"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "For the year ended 2030",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r776",
      "r780"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "For the year ended 2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r776",
      "r780"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "For the year ended 2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r776",
      "r780"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "For the year ended 2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r776",
      "r780"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.indiaglobalcap.com/role/INTANGIBLEASSETSDetails",
      "http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r290",
      "r291",
      "r586",
      "r587",
      "r673",
      "r776",
      "r780",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangibles",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r287",
      "r587",
      "r780"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r290",
      "r291",
      "r673",
      "r776",
      "r780",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total amortized intangible assets",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r1173"
     ]
    },
    "igc_FiscalYear2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "FiscalYear2026Member",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fiscal Year 2026 [Member]",
        "label": "Fiscal Year2026 Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r956",
      "r967",
      "r983",
      "r1018"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r956",
      "r967",
      "r983",
      "r1018"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r956",
      "r967",
      "r983",
      "r1018"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r956",
      "r967",
      "r983",
      "r1018"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r956",
      "r967",
      "r983",
      "r1018"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r935",
      "r970"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and Fixtures [Member]",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Profit/Loss on sale of fixed assets, net",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expense [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_GeographicDistributionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeographicDistributionAxis",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Distribution [Axis]",
        "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r625",
      "r626",
      "r627",
      "r628",
      "r812",
      "r813",
      "r814"
     ]
    },
    "us-gaap_GeographicDistributionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeographicDistributionDomain",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Distribution [Domain]",
        "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r625",
      "r626",
      "r627",
      "r628",
      "r813",
      "r814"
     ]
    },
    "us-gaap_GeographicDistributionDomesticMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeographicDistributionDomesticMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographic Distribution, Domestic [Member]",
        "label": "Geographic Distribution, Domestic [Member]",
        "documentation": "Allocation of business activity identified as domestic."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r813"
     ]
    },
    "us-gaap_GeographicDistributionForeignMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeographicDistributionForeignMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographic Distribution, Foreign [Member]",
        "label": "Geographic Distribution, Foreign [Member]",
        "documentation": "Allocation of business activity identified as foreign."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r625",
      "r626",
      "r627",
      "r628",
      "r814"
     ]
    },
    "igc_GoingConcernPolicyPolicyTextblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "GoingConcernPolicyPolicyTextblock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Going Concern, Policy [Policy Textblock}",
        "documentation": "Policy for going concern.",
        "label": "Going Concern Policy Policy Textblock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/INTANGIBLEASSETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1165",
      "r1166"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r59",
      "r92",
      "r164",
      "r165",
      "r166",
      "r261",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r510",
      "r802",
      "r806",
      "r1149",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1184"
     ]
    },
    "country_IN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "IN",
     "presentation": [
      "http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyGeographicAreasTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INDIA",
        "label": "INDIA"
       }
      }
     },
     "auth_ref": []
    },
    "igc_INTANGIBLEASSETSDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "INTANGIBLEASSETSDetailsLineItems",
     "presentation": [
      "http://www.indiaglobalcap.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "igc_INTANGIBLEASSETSDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "INTANGIBLEASSETSDetailsTable",
     "presentation": [
      "http://www.indiaglobalcap.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsLineItems",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS - Schedule of Intangible Assets And Goodwill (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "igc_INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "INTANGIBLEASSETSScheduleofIntangibleAssetsAndGoodwillDetailsTable",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS - Schedule of Intangible Assets And Goodwill (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "igc_INVENTORYDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "INVENTORYDetailsLineItems",
     "presentation": [
      "http://www.indiaglobalcap.com/role/INVENTORYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORY (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "igc_INVENTORYDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "INVENTORYDetailsTable",
     "presentation": [
      "http://www.indiaglobalcap.com/role/INVENTORYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORY (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r933",
      "r936",
      "r959"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment loss on PPE",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r29",
      "r75",
      "r155",
      "r787",
      "r877"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r76"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement",
      "http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "terseLabel": "Net Income Loss before tax",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r88",
      "r92",
      "r625",
      "r627",
      "r644",
      "r788",
      "r790",
      "r792",
      "r802",
      "r806",
      "r1149",
      "r1151",
      "r1152",
      "r1153",
      "r1154"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r464",
      "r465",
      "r466",
      "r467",
      "r490",
      "r492",
      "r497",
      "r511",
      "r512",
      "r513",
      "r662",
      "r664",
      "r723",
      "r776",
      "r777",
      "r840",
      "r841",
      "r874",
      "r875",
      "r879",
      "r887",
      "r1230",
      "r1231",
      "r1275"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295",
      "r464",
      "r465",
      "r466",
      "r467",
      "r490",
      "r492",
      "r497",
      "r511",
      "r512",
      "r513",
      "r662",
      "r664",
      "r723",
      "r776",
      "r777",
      "r840",
      "r841",
      "r874",
      "r875",
      "r879",
      "r887",
      "r1230",
      "r1231",
      "r1275"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/INCOMETAXES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Text Block]",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r167",
      "r420",
      "r425",
      "r431",
      "r432",
      "r433",
      "r434",
      "r439",
      "r444",
      "r446",
      "r447",
      "r448",
      "r630",
      "r672",
      "r681",
      "r839"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement",
      "http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense/benefit",
        "totalLabel": "Effective income tax rate",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r102",
      "r164",
      "r186",
      "r187",
      "r197",
      "r213",
      "r221",
      "r424",
      "r425",
      "r445",
      "r653",
      "r788",
      "r790",
      "r792",
      "r839"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax, Policy [Policy Text Block]",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r422",
      "r423",
      "r434",
      "r435",
      "r438",
      "r441",
      "r678"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax rate changes and other adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r425",
      "r427",
      "r839"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected income tax recovery",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r839"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430",
      "r1222"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r1222",
      "r1223"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r430",
      "r1222"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impact of tax rate differences in foreign jurisdictions",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit."
       }
      }
     },
     "auth_ref": [
      "r1222",
      "r1224"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivables, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1138"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating lease asset",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Claims and advances",
        "label": "Increase (Decrease) in Other Receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deposits and advances",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r285",
      "r289",
      "r780",
      "r844",
      "r845",
      "r846",
      "r855",
      "r856",
      "r870"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized intangible assets",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r289",
      "r780"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r285",
      "r289",
      "r780",
      "r844",
      "r845",
      "r846",
      "r855",
      "r856",
      "r870"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r956",
      "r967",
      "r983",
      "r1009",
      "r1018",
      "r1022",
      "r1030"
     ]
    },
    "igc_InfrastructureSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "InfrastructureSegmentMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Infrastructure Segment [Member]",
        "label": "Infrastructure Segment Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r937",
      "r1034"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r937",
      "r1034"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r937",
      "r1034"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r583",
      "r584",
      "r586",
      "r794",
      "r1166"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet",
      "http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable",
      "http://www.indiaglobalcap.com/role/ScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "totalLabel": "Total intangible assets",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r1173",
      "r1175"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Expense, Debt",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r315",
      "r317",
      "r818",
      "r819",
      "r1306"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/INVENTORY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory Disclosure [Text Block]",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofInventoryCurrentTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofInventoryCurrentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.indiaglobalcap.com/role/ScheduleofInventoryCurrentTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet",
      "http://www.indiaglobalcap.com/role/INVENTORYDetails",
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.indiaglobalcap.com/role/ScheduleofInventoryCurrentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory",
        "totalLabel": "Total",
        "terseLabel": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r782",
      "r890"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, Policy [Policy Text Block]",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r128",
      "r139",
      "r276",
      "r277",
      "r279",
      "r581",
      "r795"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofInventoryCurrentTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofInventoryCurrentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/INVENTORYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory Write-down",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r973",
      "r974",
      "r975"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Policy [Policy Text Block]",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r652",
      "r674",
      "r675",
      "r676",
      "r677",
      "r746",
      "r747"
     ]
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short Term Investments",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r1239",
      "r1240",
      "r1246",
      "r1248",
      "r1249",
      "r1250",
      "r1251"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestorMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIESDetails",
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investor [Member]",
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r1256",
      "r1257"
     ]
    },
    "us-gaap_Land": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Land",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land",
        "label": "Land",
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale."
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "us-gaap_LandAvailableForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LandAvailableForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real Estate, Land, Held-for-Sale",
        "label": "Real Estate, Land, Held-for-Sale",
        "documentation": "Amount of investment in land held for sale."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LandMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSDetails",
      "http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land [Member]",
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r1188",
      "r1189"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/LeaseCostTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/LeaseCostTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease costs",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r889"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, Cost [Table Text Block]",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1254"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Leases [Policy Text Block]",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "igc_LesseeOperatingLeaseLiabilityMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "LesseeOperatingLeaseLiabilityMaturityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Liability Maturity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1255"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LesseeOperatingLeaseLiabilityMaturityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mar-26",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r1141",
      "r1144",
      "r1269"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LesseeOperatingLeaseLiabilityMaturityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mar-29",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r1141",
      "r1144",
      "r1269"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LesseeOperatingLeaseLiabilityMaturityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mar-28",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r1141",
      "r1144",
      "r1269"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LesseeOperatingLeaseLiabilityMaturityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mar-27",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r1141",
      "r1144",
      "r1269"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LesseeOperatingLeaseLiabilityMaturityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Present value discount",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LEASES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Operating Leases [Text Block]",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "igc_Level1Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "Level1Abstract",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Level1 Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r36",
      "r37",
      "r38",
      "r40",
      "r41",
      "r42",
      "r43",
      "r164",
      "r165",
      "r166",
      "r261",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r459",
      "r462",
      "r463",
      "r510",
      "r697",
      "r801",
      "r820",
      "r920",
      "r1184",
      "r1259",
      "r1260"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LeaseCostTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r87",
      "r639",
      "r890",
      "r907",
      "r908",
      "r1140",
      "r1143",
      "r1163",
      "r1252"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r127",
      "r164",
      "r165",
      "r166",
      "r261",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r459",
      "r462",
      "r463",
      "r510",
      "r890",
      "r1184",
      "r1259",
      "r1260"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r40",
      "r41",
      "r42",
      "r43",
      "r164",
      "r165",
      "r166",
      "r261",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r459",
      "r462",
      "r463",
      "r510",
      "r1184",
      "r1259",
      "r1260"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityCollateralFeesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityCollateralFeesAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility, Collateral Fees, Amount",
        "label": "Line of Credit Facility, Collateral Fees, Amount",
        "documentation": "Amount of the fees associated with providing collateral for the credit facility."
       }
      }
     },
     "auth_ref": []
    },
    "igc_LoansAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "LoansAndOtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans And Other Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "igc_LoansAndOtherLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "LoansAndOtherLiabilitiesTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans and Other Liabilities [Text Block]",
        "documentation": "Disclosure of loans and other liabilities.",
        "label": "Loans And Other Liabilities Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoansPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans Payable, Current",
        "label": "Loans Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term loans",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_LongTermLoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermLoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans Payable, Noncurrent",
        "label": "Loans Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and Equipment [Member]",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "igc_March2024SPAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "March2024SPAMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 2024 SPA [Member]",
        "label": "March2024 SPAMember"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable",
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r204",
      "r298",
      "r299",
      "r300",
      "r301",
      "r367",
      "r395",
      "r396",
      "r397",
      "r417",
      "r489",
      "r580",
      "r661",
      "r663",
      "r671",
      "r689",
      "r690",
      "r744",
      "r748",
      "r750",
      "r751",
      "r753",
      "r757",
      "r758",
      "r760",
      "r761",
      "r774",
      "r775",
      "r811",
      "r821",
      "r835",
      "r840",
      "r842",
      "r843",
      "r880",
      "r881",
      "r885",
      "r886",
      "r903",
      "r1186",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable",
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r204",
      "r298",
      "r299",
      "r300",
      "r301",
      "r367",
      "r395",
      "r396",
      "r397",
      "r417",
      "r489",
      "r580",
      "r661",
      "r663",
      "r671",
      "r689",
      "r690",
      "r744",
      "r748",
      "r750",
      "r751",
      "r753",
      "r757",
      "r758",
      "r760",
      "r761",
      "r774",
      "r775",
      "r811",
      "r821",
      "r835",
      "r840",
      "r842",
      "r843",
      "r880",
      "r881",
      "r885",
      "r903",
      "r1186",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Funds [Member]",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1190",
      "r1191"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "us-gaap_MutualFundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MutualFundMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mutual Fund [Member]",
        "label": "Mutual Fund [Member]",
        "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective."
       }
      }
     },
     "auth_ref": [
      "r1190",
      "r1191"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.indiaglobalcap.com/role/NATUREOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Operations [Text Block]",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r200",
      "r798",
      "r799"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow from investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r68"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss",
        "netLabel": "Net Income (Loss) Attributable to Parent",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r68",
      "r89",
      "r124",
      "r125",
      "r143",
      "r145",
      "r150",
      "r164",
      "r165",
      "r166",
      "r169",
      "r175",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r186",
      "r187",
      "r191",
      "r261",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r319",
      "r322",
      "r324",
      "r327",
      "r405",
      "r452",
      "r455",
      "r483",
      "r510",
      "r646",
      "r720",
      "r736",
      "r737",
      "r788",
      "r790",
      "r792",
      "r918",
      "r1184"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r973",
      "r974",
      "r975"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "igc_NonCashItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "NonCashItemsAbstract",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash items:",
        "label": "Non Cash Items Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r956",
      "r967",
      "r983",
      "r1009",
      "r1018"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "igc_NonvestedRestrictedStockSharesActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "NonvestedRestrictedStockSharesActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested Restricted Stock Shares Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Operating Segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r1150"
     ]
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office Equipment [Member]",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r788",
      "r792",
      "r802",
      "r1149",
      "r1151",
      "r1152",
      "r1153",
      "r1154"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/LeaseCostTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/LEASESDetails",
      "http://www.indiaglobalcap.com/role/LeaseCostTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease costs",
        "verboseLabel": "Operating Lease, Cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r889"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LeaseCostTable",
      "http://www.indiaglobalcap.com/role/LesseeOperatingLeaseLiabilityMaturityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Lease liabilities",
        "verboseLabel": "Total lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LeaseCostTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities and others (current portion \u2013 operating lease liability)",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet",
      "http://www.indiaglobalcap.com/role/LeaseCostTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "verboseLabel": "Operating lease liability (non-current portion \u2013 operating lease liability)",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LeaseCostTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u2013Operating cash flows from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r537"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet",
      "http://www.indiaglobalcap.com/role/LeaseCostTable",
      "http://www.indiaglobalcap.com/role/ScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease asset",
        "verboseLabel": "Total lease assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for expenses",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofLoansandOtherLiabilitiesTable": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofLoansandOtherLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory reserve",
        "label": "Other Accrued Liabilities, Noncurrent",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "igc_OtherAdvances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "OtherAdvances",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofOtherAssetsNoncurrentTable": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofOtherAssetsNoncurrentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current deposits",
        "documentation": "The amount of other noncurrent advances.",
        "label": "Other Advances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/DeferredCostsCapitalizedPrepaidandOtherAssetsDisclosureTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/DeferredCostsCapitalizedPrepaidandOtherAssetsDisclosureTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expense and other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r890"
     ]
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/CLAIMSANDADVANCES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Assets Disclosure [Text Block]",
        "label": "Other Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.indiaglobalcap.com/role/ScheduleofOtherAssetsNoncurrentTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet",
      "http://www.indiaglobalcap.com/role/ScheduleofOtherAssetsNoncurrentTable",
      "http://www.indiaglobalcap.com/role/ScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Claims and advances",
        "totalLabel": "Total",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r54",
      "r55",
      "r56",
      "r514",
      "r515",
      "r516"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustments",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r647"
     ]
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIntangibleAssetsMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Intangible Assets [Member]",
        "label": "Other Intangible Assets [Member]",
        "documentation": "Intangible assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1175",
      "r1176",
      "r1177"
     ]
    },
    "us-gaap_OtherInventoryNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherInventoryNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/DeferredCostsCapitalizedPrepaidandOtherAssetsDisclosureTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/DeferredCostsCapitalizedPrepaidandOtherAssetsDisclosureTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables and deposits",
        "label": "Other Inventory, Net of Reserves",
        "documentation": "Amount, after of valuation reserves and allowances, of inventory, classified as other, expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r1079"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liability",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r890"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.indiaglobalcap.com/role/ScheduleofLoansandOtherLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet",
      "http://www.indiaglobalcap.com/role/ScheduleofLoansandOtherLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "totalLabel": "Total",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r873"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/DeferredCostsCapitalizedPrepaidandOtherAssetsDisclosureTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/DeferredCostsCapitalizedPrepaidandOtherAssetsDisclosureTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advances to suppliers and consultants",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1080",
      "r1164"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ScheduleofOtherAssetsNoncurrentTable": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofOtherAssetsNoncurrentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Claims receivable",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r707",
      "r807",
      "r907",
      "r908",
      "r1272"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "igc_OtherRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "OtherRevenueMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/DisaggregationofRevenueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Revenue [Member]",
        "label": "Other Revenue Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherSignificantNoncashTransactionValueOfConsiderationGiven1",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued/granted for stock-based compensation, including patent acquisition",
        "documentation": "The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r954",
      "r965",
      "r981",
      "r1016"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r957",
      "r968",
      "r984",
      "r1019"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r957",
      "r968",
      "r984",
      "r1019"
     ]
    },
    "igc_PROPERTYPLANTANDEQUIPMENTDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "PROPERTYPLANTANDEQUIPMENTDetailsLineItems",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY, PLANT, AND EQUIPMENT (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "igc_PROPERTYPLANTANDEQUIPMENTDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "PROPERTYPLANTANDEQUIPMENTDetailsTable",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY, PLANT, AND EQUIPMENT (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "igc_PROPERTYPLANTANDEQUIPMENTTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "PROPERTYPLANTANDEQUIPMENTTablesLineItems",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY, PLANT, AND EQUIPMENT (Tables) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "igc_PROPERTYPLANTANDEQUIPMENTTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "PROPERTYPLANTANDEQUIPMENTTablesTable",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY, PLANT, AND EQUIPMENT (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PatentsMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/INTANGIBLEASSETSDetails",
      "http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents [Member]",
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1172",
      "r1173",
      "r1176",
      "r1177"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_PaymentsForProceedsFromInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForProceedsFromInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Proceeds from short-term investments",
        "label": "Payments for (Proceeds from) Investments",
        "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition and development of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property, plant, and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "igc_PlantAndCannabinoidMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "PlantAndCannabinoidMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyProductsandServicesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plant and Cannabinoid [Member]",
        "documentation": "Represents of the Company's segments.",
        "label": "Plant And Cannabinoid Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.indiaglobalcap.com/role/SECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in Dollars per share)",
        "verboseLabel": "Preferred Stock, Par or Stated Value Per Share (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r329"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.indiaglobalcap.com/role/SECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, authorized shares",
        "verboseLabel": "Preferred Stock, Shares Authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r699"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.indiaglobalcap.com/role/SECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "verboseLabel": "Preferred Stock, Shares Issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r329"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.indiaglobalcap.com/role/SECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "verboseLabel": "Preferred Stock, Shares Outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r699",
      "r719",
      "r1307",
      "r1308"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.0001 par value: authorized 1,000,000 shares, no shares issued or outstanding as of March 31, 2025, or March 31, 2024.",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r321",
      "r326",
      "r636",
      "r890"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.indiaglobalcap.com/role/DeferredCostsCapitalizedPrepaidandOtherAssetsDisclosureTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet",
      "http://www.indiaglobalcap.com/role/DeferredCostsCapitalizedPrepaidandOtherAssetsDisclosureTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits and advances",
        "totalLabel": "Total",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement [Member]",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDepositsOnRealEstateSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromDepositsOnRealEstateSales",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSDetails",
      "http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Deposits on Real Estate Sales",
        "label": "Proceeds from Deposits on Real Estate Sales",
        "documentation": "Cash inflow related to amounts received in advance from a potential buyer showing or confirming an intention to complete an acquisition of land, buildings, other structures, or any item classified as real estate."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from the issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow",
      "http://www.indiaglobalcap.com/role/SECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from common stock subscribed",
        "verboseLabel": "Proceeds from Issuance of Private Placement (in Dollars)",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Issuance or Sale of Equity (in Dollars)",
        "label": "Proceeds from Issuance or Sale of Equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r679"
     ]
    },
    "us-gaap_ProceedsFromRepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromRepaymentsOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of long-term loan",
        "documentation": "The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of property, plant, and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.indiaglobalcap.com/role/DisaggregationofRevenueTable",
      "http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyProductsandServicesTable",
      "http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r585",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r778",
      "r787",
      "r790",
      "r792",
      "r822",
      "r823",
      "r902",
      "r903",
      "r904",
      "r906",
      "r909",
      "r1064",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1182",
      "r1183",
      "r1274",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.indiaglobalcap.com/role/DisaggregationofRevenueTable",
      "http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyProductsandServicesTable",
      "http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r585",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r778",
      "r787",
      "r790",
      "r792",
      "r822",
      "r823",
      "r902",
      "r903",
      "r904",
      "r906",
      "r909",
      "r1064",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1182",
      "r1183",
      "r1274",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow",
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to common stockholders",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r143",
      "r145",
      "r159",
      "r164",
      "r165",
      "r166",
      "r169",
      "r175",
      "r183",
      "r186",
      "r187",
      "r261",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r319",
      "r405",
      "r452",
      "r455",
      "r457",
      "r460",
      "r461",
      "r483",
      "r510",
      "r625",
      "r627",
      "r645",
      "r682",
      "r720",
      "r736",
      "r737",
      "r871",
      "r872",
      "r919",
      "r1093",
      "r1184"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSDetails",
      "http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTDetails",
      "http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r540"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment Disclosure [Text Block]",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r99",
      "r100",
      "r101"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r130",
      "r643"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet",
      "http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable",
      "http://www.indiaglobalcap.com/role/ScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment, net",
        "totalLabel": "Net Assets",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r540",
      "r629",
      "r643",
      "r890"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r99",
      "r100",
      "r641"
     ]
    },
    "igc_PropertyPlantAndEquipmentTableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "PropertyPlantAndEquipmentTableMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property Plant and Equipment Table [Member]",
        "documentation": "Description of property, plant and equipment.",
        "label": "Property Plant And Equipment Table Member"
       }
      }
     },
     "auth_ref": []
    },
    "igc_PropertyPlantAndEquipmentTableTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "PropertyPlantAndEquipmentTableTypeAxis",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Table Type [Axis]",
        "documentation": "Information by property, plant and equipment.",
        "label": "Property Plant And Equipment Table Type Axis"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table Text Block]",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSDetails",
      "http://www.indiaglobalcap.com/role/PROPERTYPLANTANDEQUIPMENTDetails",
      "http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r540"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable",
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, useful life",
        "verboseLabel": "Property, Plant and Equipment, Useful Life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for bad debt",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r156",
      "r268"
     ]
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PublicUtilitiesInventoryAxis",
     "presentation": [
      "http://www.indiaglobalcap.com/role/INVENTORYDetails",
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Axis]",
        "documentation": "Information by type of inventory held."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "presentation": [
      "http://www.indiaglobalcap.com/role/INVENTORYDetails",
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Domain]",
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable",
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r204",
      "r298",
      "r299",
      "r300",
      "r301",
      "r355",
      "r367",
      "r395",
      "r396",
      "r397",
      "r404",
      "r417",
      "r489",
      "r554",
      "r563",
      "r580",
      "r661",
      "r663",
      "r671",
      "r689",
      "r690",
      "r744",
      "r748",
      "r750",
      "r751",
      "r753",
      "r757",
      "r758",
      "r760",
      "r761",
      "r774",
      "r775",
      "r811",
      "r821",
      "r835",
      "r840",
      "r842",
      "r843",
      "r880",
      "r881",
      "r885",
      "r886",
      "r903",
      "r912",
      "r1180",
      "r1186",
      "r1242",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable",
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r204",
      "r298",
      "r299",
      "r300",
      "r301",
      "r355",
      "r367",
      "r395",
      "r396",
      "r397",
      "r404",
      "r417",
      "r489",
      "r554",
      "r563",
      "r580",
      "r661",
      "r663",
      "r671",
      "r689",
      "r690",
      "r744",
      "r748",
      "r750",
      "r751",
      "r753",
      "r757",
      "r758",
      "r760",
      "r761",
      "r774",
      "r775",
      "r811",
      "r821",
      "r835",
      "r840",
      "r842",
      "r843",
      "r880",
      "r881",
      "r885",
      "r886",
      "r903",
      "r912",
      "r1180",
      "r1186",
      "r1242",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r960",
      "r976",
      "r1011"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r168",
      "r169",
      "r229",
      "r362",
      "r366",
      "r542",
      "r543",
      "r634",
      "r640",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r718",
      "r743",
      "r1305"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r168",
      "r169",
      "r229",
      "r362",
      "r366",
      "r542",
      "r543",
      "r634",
      "r640",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r718",
      "r743",
      "r1258",
      "r1305"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of Debt",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r170",
      "r171",
      "r313",
      "r331",
      "r544",
      "r564",
      "r632",
      "r783",
      "r784",
      "r785",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1232",
      "r1233",
      "r1234",
      "r1235"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement",
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development expenses",
        "terseLabel": "Research and Development Expense",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r776",
      "r788",
      "r789",
      "r806",
      "r1267"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expense, Policy [Policy Text Block]",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination."
       }
      }
     },
     "auth_ref": [
      "r1178",
      "r1221",
      "r1309"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r950",
      "r961",
      "r977",
      "r1012"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r951",
      "r962",
      "r978",
      "r1013"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r969",
      "r985",
      "r1020"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1074",
      "r1139",
      "r1268",
      "r1271"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r79",
      "r638",
      "r668",
      "r670",
      "r680",
      "r700",
      "r890"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings [Member]",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r172",
      "r173",
      "r174",
      "r176",
      "r183",
      "r185",
      "r187",
      "r262",
      "r263",
      "r292",
      "r318",
      "r405",
      "r442",
      "r443",
      "r449",
      "r450",
      "r451",
      "r453",
      "r454",
      "r455",
      "r469",
      "r471",
      "r472",
      "r474",
      "r481",
      "r526",
      "r528",
      "r665",
      "r667",
      "r683",
      "r1307"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/REVENUERECOGNITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Text Block]",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r354"
     ]
    },
    "igc_RevenueFromExternalCustomersByGeographicAreasAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "RevenueFromExternalCustomersByGeographicAreasAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From External Customers By Geographic Areas Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "igc_RevenueFromExternalCustomersByProductsAndServicesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "RevenueFromExternalCustomersByProductsAndServicesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From External Customers By Products And Services Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue [Policy Text Block]",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement",
      "http://www.indiaglobalcap.com/role/DisaggregationofRevenueTable",
      "http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyGeographicAreasTable",
      "http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyProductsandServicesTable",
      "http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "terseLabel": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r151",
      "r164",
      "r165",
      "r166",
      "r197",
      "r210",
      "r211",
      "r217",
      "r221",
      "r224",
      "r226",
      "r228",
      "r261",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r510",
      "r625",
      "r627",
      "r806",
      "r873",
      "r907",
      "r908",
      "r1184"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LeaseCostTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligations",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r889"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "igc_SECURITIESDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "SECURITIESDetailsLineItems",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SECURITIES (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "igc_SECURITIESDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "SECURITIESDetailsTable",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SECURITIES (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "igc_SEGMENTINFORMATIONDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "SEGMENTINFORMATIONDetailsLineItems",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT INFORMATION (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "igc_SEGMENTINFORMATIONDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "SEGMENTINFORMATIONDetailsTable",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT INFORMATION (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsLineItems",
     "presentation": [
      "http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyGeographicAreasTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT INFORMATION - Revenue from External Customers by Geographic Areas (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "igc_SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "SEGMENTINFORMATIONRevenuefromExternalCustomersbyGeographicAreasDetailsTable",
     "presentation": [
      "http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyGeographicAreasTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT INFORMATION - Revenue from External Customers by Geographic Areas (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "SIGNIFICANTACCOUNTINGPOLICIESDetailsLineItems",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "igc_SIGNIFICANTACCOUNTINGPOLICIESDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "SIGNIFICANTACCOUNTINGPOLICIESDetailsTable",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "igc_STOCKBASEDCOMPENSATIONDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "STOCKBASEDCOMPENSATIONDetailsLineItems",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK-BASED COMPENSATION (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "igc_STOCKBASEDCOMPENSATIONDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "STOCKBASEDCOMPENSATIONDetailsTable",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK-BASED COMPENSATION (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "igc_SUBSEQUENTEVENTSDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "SUBSEQUENTEVENTSDetailsLineItems",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "igc_SUBSEQUENTEVENTSDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "SUBSEQUENTEVENTSDetailsTable",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "igc_SalesAgreementMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "SalesAgreementMaximum",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Agreement, Offering, Maximum (in Dollars)",
        "documentation": "Maximum offering under sales agreement.",
        "label": "Sales Agreement Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "igc_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Agreement [Member]",
        "label": "Sales Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "igc_ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Accounts Payable And Accrued Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "igc_ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Components Of Income Tax Expense Benefit Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1229"
     ]
    },
    "igc_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r839",
      "r1222"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "presentation": [
      "http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyProductsandServicesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Revenue from External Customer, Product and Service [Table]",
        "documentation": "Disclosure of information about revenue from external customer by product and service when not provided as part of reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from External Customers by Products and Services [Table Text Block]",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "igc_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1239",
      "r1240"
     ]
    },
    "igc_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Finite Lived Intangible Assets Future Amortization Expense Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "igc_ScheduleOfIntangibleAssetsAndGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Intangible Assets And Goodwill Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/INTANGIBLEASSETSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r1165",
      "r1166"
     ]
    },
    "igc_ScheduleOfInventoryCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "ScheduleOfInventoryCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Inventory Current Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/INVENTORYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory, Current [Table Text Block]",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r51",
      "r52",
      "r53"
     ]
    },
    "igc_ScheduleOfLoansAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "ScheduleOfLoansAndOtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Loans And Other Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/LOANSANDOTHERLIABILITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Assets and Other Liabilities [Table Text Block]",
        "label": "Schedule of Other Assets and Other Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "igc_ScheduleOfOtherAssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "ScheduleOfOtherAssetsNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Other Assets Noncurrent Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/CLAIMSANDADVANCESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Assets, Noncurrent [Table Text Block]",
        "label": "Schedule of Other Assets, Noncurrent [Table Text Block]",
        "documentation": "Tabular disclosure of noncurrent assets."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r540"
     ]
    },
    "igc_ScheduleOfRevenueFromExternalCustomersAndLongLivedAssetsByGeographicalAreasAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "ScheduleOfRevenueFromExternalCustomersAndLongLivedAssetsByGeographicalAreasAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Revenue From External Customers And Long Lived Assets By Geographical Areas Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SEGMENTINFORMATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r57"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r57"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r80"
     ]
    },
    "igc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/INTANGIBLEASSETSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r1174"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyGeographicAreasTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r201",
      "r226",
      "r227",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r625",
      "r626",
      "r627",
      "r628",
      "r686",
      "r687",
      "r688",
      "r745",
      "r749",
      "r752",
      "r754",
      "r757",
      "r759",
      "r760",
      "r761",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r779",
      "r797",
      "r822",
      "r824",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r905",
      "r912",
      "r1274",
      "r1276",
      "r1277",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SEGMENTINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Disclosure [Text Block]",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r197",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r214",
      "r215",
      "r216",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r228",
      "r803",
      "r804",
      "r805",
      "r806",
      "r808",
      "r809",
      "r810"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Selling, general and administrative expenses",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r787",
      "r788",
      "r789",
      "r792",
      "r1131"
     ]
    },
    "igc_September2024SPAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "September2024SPAMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "September 2024 SPA [Member]",
        "label": "September2024 SPAMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Noncash Expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.indiaglobalcap.com/role/NonvestedRestrictedStockSharesActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled/Forfeited, Weighted average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.indiaglobalcap.com/role/NonvestedRestrictedStockSharesActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted, Weighted average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.indiaglobalcap.com/role/NonvestedRestrictedStockSharesActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, non-vested shares",
        "periodEndLabel": "Balance, non-vested shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.indiaglobalcap.com/role/NonvestedRestrictedStockSharesActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, Weighted average grant date fair value",
        "periodEndLabel": "Balance, Weighted average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.indiaglobalcap.com/role/NonvestedRestrictedStockSharesActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested, shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.indiaglobalcap.com/role/NonvestedRestrictedStockSharesActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested, Weighted average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "presentation": [
      "http://www.indiaglobalcap.com/role/NonvestedRestrictedStockSharesActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled/Forfeited, shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations",
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://www.indiaglobalcap.com/role/NonvestedRestrictedStockSharesActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted, shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SharebasedPaymentArrangementOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled/Forfeited, shares (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1199"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SharebasedPaymentArrangementOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled/Forfeited, Weighted average exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1199"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails",
      "http://www.indiaglobalcap.com/role/SharebasedPaymentArrangementOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted, shares (in Shares)",
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SharebasedPaymentArrangementOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted, Weighted average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails",
      "http://www.indiaglobalcap.com/role/SharebasedPaymentArrangementOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, shares (in Shares)",
        "periodEndLabel": "Options outstanding, shares (in Shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails",
      "http://www.indiaglobalcap.com/role/SharebasedPaymentArrangementOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, Weighted average exercise price",
        "periodEndLabel": "Options outstanding, Weighted average exercise price",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SharebasedPaymentArrangementOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted, Weighted average exercise price",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "igc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SharebasedPaymentArrangementOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested, Weighted average exercise price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Vested In Period Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement [Policy Text Block]",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r373",
      "r392",
      "r393",
      "r394",
      "r395",
      "r398",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414"
     ]
    },
    "igc_ShareBasedPaymentArrangementOptionActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "ShareBasedPaymentArrangementOptionActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payment Arrangement Option Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIESDetails",
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Price (in Dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "igc_SharePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "SharePurchaseAgreementMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Purchase Agreement [Member]",
        "label": "Share Purchase Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "igc_SharePurchaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "SharePurchaseAgreementsMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Share Purchase Agreements [Member]",
        "label": "Share Purchase Agreements Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1193"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount",
        "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life of options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SharebasedPaymentArrangementOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled/Forfeited, Weighted average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited."
       }
      }
     },
     "auth_ref": [
      "r1219"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SharebasedPaymentArrangementOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, Weighted average grant date fair value",
        "periodEndLabel": "Options outstanding, Weighted average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": [
      "r1219"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SharebasedPaymentArrangementOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested, shares (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": [
      "r1219"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SharebasedPaymentArrangementOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested, Weighted average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": [
      "r1219"
     ]
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ACCRUEDLIABILITIESANDOTHERSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term Debt",
        "label": "Short-Term Debt",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r85",
      "r890",
      "r1270"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/LeaseCostTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/LEASESDetails",
      "http://www.indiaglobalcap.com/role/LeaseCostTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short term lease costs",
        "verboseLabel": "Short-Term Lease, Cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r889"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Accounting Policies [Text Block]",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163"
     ]
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software Development [Member]",
        "label": "Software Development [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r45",
      "r48",
      "r49",
      "r122",
      "r123",
      "r124",
      "r148",
      "r149",
      "r150",
      "r172",
      "r173",
      "r174",
      "r176",
      "r183",
      "r185",
      "r187",
      "r198",
      "r262",
      "r263",
      "r292",
      "r318",
      "r343",
      "r405",
      "r442",
      "r443",
      "r449",
      "r450",
      "r451",
      "r453",
      "r454",
      "r455",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r481",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r526",
      "r528",
      "r541",
      "r647",
      "r665",
      "r666",
      "r667",
      "r683",
      "r738"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyGeographicAreasTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r201",
      "r226",
      "r227",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r625",
      "r626",
      "r627",
      "r628",
      "r686",
      "r687",
      "r688",
      "r745",
      "r749",
      "r752",
      "r754",
      "r757",
      "r759",
      "r760",
      "r761",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r779",
      "r797",
      "r822",
      "r824",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r905",
      "r912",
      "r1274",
      "r1276",
      "r1277",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r198",
      "r320",
      "r321",
      "r323",
      "r325",
      "r528",
      "r585",
      "r674",
      "r684",
      "r685",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r699",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r709",
      "r710",
      "r711",
      "r712",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r721",
      "r722",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r738",
      "r790",
      "r792",
      "r913",
      "r1305"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r198",
      "r229",
      "r320",
      "r321",
      "r323",
      "r325",
      "r528",
      "r585",
      "r674",
      "r684",
      "r685",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r699",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r709",
      "r710",
      "r711",
      "r712",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r721",
      "r722",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r738",
      "r790",
      "r792",
      "r913",
      "r1305"
     ]
    },
    "igc_StatutoryAdvances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "StatutoryAdvances",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/DEPOSITSANDADVANCESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory Advances",
        "documentation": "Statutory advances.",
        "label": "Statutory Advances"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r953",
      "r964",
      "r980",
      "r1015"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Issued During Period, Shares, Issued for Services",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIESDetails",
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock through offering (net of expenses) (in Shares)",
        "verboseLabel": "Stock Issued During Period, Shares, New Issues (in Shares)",
        "netLabel": "Stock Issued During Period, Shares, New Issues",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r44",
      "r45",
      "r79",
      "r679",
      "r738",
      "r755"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r79"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock-based compensation &amp; expenses, net (in Shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r44",
      "r45",
      "r79"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancellation/forfeiture of shares (in Shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited",
        "documentation": "Number of shares (or other type of equity) forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r1187"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIESDetails",
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock through offering (net of expenses)",
        "verboseLabel": "Stock Issued During Period, Value, New Issues",
        "netLabel": "Stock Issued During Period, Value, New Issues (in Dollars)",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r44",
      "r45",
      "r79",
      "r683",
      "r738",
      "r755",
      "r919"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other adjustments",
        "label": "Stock Issued During Period, Value, Other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet",
      "http://www.indiaglobalcap.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r48",
      "r49",
      "r70",
      "r701",
      "r719",
      "r739",
      "r740",
      "r890",
      "r920",
      "r1140",
      "r1142",
      "r1143",
      "r1163",
      "r1252",
      "r1307"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Text Block]",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r328",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r468",
      "r480",
      "r741",
      "r742",
      "r756"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIESDetails",
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r546"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIESDetails",
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r546"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIESDetails",
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r546"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Text Block]",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r547"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "igc_SummaryOfOperatingLossCarryforwardsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "SummaryOfOperatingLossCarryforwardsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Operating Loss Carryforwards Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "presentation": [
      "http://www.indiaglobalcap.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r1227"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.indiaglobalcap.com/role/INCOMETAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Amount",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SummaryofOperatingLossCarryforwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r1225"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r1225"
     ]
    },
    "igc_TollingWhiteLabelingServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "TollingWhiteLabelingServiceMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/DisaggregationofRevenueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tolling/White labeling service [Member]",
        "documentation": "Type of product or service.",
        "label": "Tolling White Labeling Service Member"
       }
      }
     },
     "auth_ref": []
    },
    "igc_TotalRevenuePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "TotalRevenuePercentage",
     "presentation": [
      "http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyGeographicAreasTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Revenue Percentage",
        "documentation": "Percentage of segment to total revenue.",
        "label": "Total Revenue Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable [Policy Text Block]",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r1156",
      "r1157",
      "r1158"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r316",
      "r341",
      "r468",
      "r479",
      "r503",
      "r509",
      "r512",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r631",
      "r648",
      "r876",
      "r878",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r891",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1238",
      "r1241",
      "r1242",
      "r1243",
      "r1246",
      "r1247",
      "r1248",
      "r1249"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIESDetails",
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.indiaglobalcap.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://www.indiaglobalcap.com/role/RevenuefromExternalCustomersbyGeographicAreasTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UNITED STATES",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "igc_UnamortizedIntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "UnamortizedIntangibleAssetsAbstract",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ScheduleofIntangibleAssetsAndGoodwillTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized intangible assets",
        "label": "Unamortized Intangible Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "igc_UnitDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "UnitDescription",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unit, description",
        "documentation": "Description of unit.",
        "label": "Unit Description"
       }
      }
     },
     "auth_ref": []
    },
    "igc_UnitsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "UnitsOutstanding",
     "presentation": [
      "http://www.indiaglobalcap.com/role/SECURITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Units Outstanding",
        "documentation": "Number of units outstanding.",
        "label": "Units Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.indiaglobalcap.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates, Policy [Policy Text Block]",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r199",
      "r202",
      "r203",
      "r204",
      "r625",
      "r627",
      "r800"
     ]
    },
    "us-gaap_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VehiclesMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/PropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vehicles [Member]",
        "label": "Vehicles [Member]",
        "documentation": "Equipment used primarily for road transportation."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of shares used in computing loss per share amounts: (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r194"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.indiaglobalcap.com/role/ConsolidatedIncomeStatement",
      "http://www.indiaglobalcap.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of shares used in computing loss per share amounts: (in Shares)",
        "verboseLabel": "Weighted Average Number of Shares Outstanding, Basic (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r194"
     ]
    },
    "igc_WeightedAveragePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "WeightedAveragePricePerShare",
     "presentation": [
      "http://www.indiaglobalcap.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Price per Share (in Dollars per share)",
        "documentation": "Weighted average price per share.",
        "label": "Weighted Average Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "igc_WellnessAndLifestyleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.indiaglobalcap.com/20250331",
     "localname": "WellnessAndLifestyleMember",
     "presentation": [
      "http://www.indiaglobalcap.com/role/DisaggregationofRevenueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wellness and Lifestyle [Member]",
        "documentation": "Type of product or service.",
        "label": "Wellness And Lifestyle Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482309/360-10-15-4"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Subparagraph": "(Instruction 5)",
   "Publisher": "SEC"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(4)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(5)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(1)(i)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(1)(ii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Subparagraph": "(Instruction 5)",
   "Publisher": "SEC"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(5)",
   "Publisher": "SEC"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "c",
   "Publisher": "SEC"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-9"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-12"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-4"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480459/718-40-55-20"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480459/718-40-55-9"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480095/942-10-S50-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480035/942-10-S99-6"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-40/tableOfContent"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/730/tableOfContent"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>115
<FILENAME>0001185185-25-000706-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001185185-25-000706-xbrl.zip
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M*\5%?@D9:V'B U16C0H#26F5H0B)NM:ZHT]:[Z$SN+[N]O%2MZOUNOWQ9/1
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M"8H*N3]DPH/<W,IJ[U+:SGNN[J#X,$;.MOE5Q+/W(1/"XY&:MF;:=N*H1M:
M!4S\[08 YZ4Z.78L45J"=O95<+P7\51TEDHHB]^=DY>.Q-R46$@?YN20Q6(J
M5_FB)/8\BK@%)6R+S14K3&2OS&H'-TD_#$"^]F+B920)E&K?=<\<^Z[QQV!)
MD*%/NAU0C!I"P2*\QG&B+Q$H,1Z8,%/A>,@X6(JK1H&!"!F@T/8!!0<B=/M@
M@P\D %8;YQ(OQW>=)XA\:([POYYEX%^TBRD%2#-\ZRDO8%*FFB@<><A$P'CC
M9-,RV#8=C8JP<1"W7GF(,I\E24T#GJ<[<_H1BM#2"L=!V:HR3I]]*1]OVLB;
M*K88]J.I8E]N5%1S0T%RAFYY9*J-,BCPUB>QY[F'.B'*=)T1)(<ZEC._U)'%
M<SPOD"><39BPG-0#6)ET#8R/^A:X'R?XD.U><J,7HP38]VQP @JT\C\[/<V5
MFZ/'W!7RGY.>EWR8J[+^TM;?F<T@F3UA^(FQB;X:Z3[$@]YU#&P.%!S'V.6K
M"T-Q+>Z+##-&O&D7A T#W#(@38-TV]68V&%,D*\,NPY6'I$<S(C7*&/M$CI8
M.U[R@71MF?23%O_QS?2@V+8<YG%N!L8FVRYJ_^=JDUIF8 2+A>ZMW=GV#-5%
MJ*U[WGKF>F3KEK,<D*TC-0B8P%YV$(2MT524[>$K;A"D6JQ8+_.8AH7T^=R#
M<]JX.QO!)^@$.8]A\,J)''J+"0+F/?=+BR0:(3Q'S53S^PN>"<X-Y185DC)4
M-DJ8]UQP987RS]V'PWSFN8O.RH>>H]OM /G8L7EHNAYZKAD8=(\UAMZ39>0<
MJ^TH01P";+$AP!RR:QM+)0A # %L,-"7AD8HZ$8LQE'MM%YKF-Q =^[IRT?+
MT#R\LRTY1')K2\T&;.QOUP&RQ0 HB&IL[+*NY_%,PC0N7J61AUC"J$B2>=W.
M'SFO+EMJ7.5\V2-O7"6W!J(Q1B- &&/T%$^<RIP:>KB">/!5(Z_X3>%YZXV"
M(L*%(_L9D>QKPZNEH?Q:WS4"&N!WS([C6_ZZZ^ ]TX)""=GBEA 9;?3Z\$A$
M\B=YLC*4!Q("_P89ZN_K*W2N+Y<6UCJZ&%YR'#?4)/9C[_%5:[%T/1\X^@*B
MI6[ %*FKJ6>_<[UYO=EH'-8M!_FZ8^!9&N'I;Z'W7(.*XU0A?]7B>C5RJ7;0
MK!T>O%LA<Z_^81<41&ER;E,615QO%Q0S'4VIN #5?-S7",MM'N4C0+@\;3Y9
M::[K2UJG#FT?;<34R*7=^L+TO3J10:2V:HT#K$XQ'E%-^C?: )$8'<D./J)_
MF;XT(W$%0L56?7D6D.?O0 .NE:!@(R/-@:SJ"!KOYNY3'5F&#(AL<?(CU7"I
M1HVU6=-G9=K%-<)VPZKEQEU*$C3,,@W'Q<F/W14FE5$PW;EA7#=+<ZGV36B5
M;1]7"=N/ZA:T#VUZWDP!7.S%R\H!\VH@;8I\3S>PC9%!>[%'VK+.22*#,^_Z
M<$$\P![0HU(7>[X7X+_#4DOH6:XYH?7,P(M<KV/9-ED7QV4Q1H2]94#NWGAN
ML(P;L;#X[;I* N*6W;1V5W#I(HN^:T$SGXA'0,JHQ<.6L)%BN@I?)Z&,BN70
M)F?D(JUW>5F"@MWQ(C5D^BGWF5D%.X*/L\BLI1Z"4T;;<FB+V64?"=IN&951
M5@ID>ME3-(8S#T5I>0]%*:/WCK +1SAY<$-C'QI11E\A0 D7IKR2):!*J$L3
M "_+YC KV!DO5*2PJ^12=97ID))PN9,>TZ-%R:G*:+\#9*D%7CK?4LO-MQQD
M\BW5Z917TD/.0<JDJRG8-:5@%SG(K;AMGM2@*$-+P4XH@YJW?0]SA0:<S"1U
ME"^!E:-R=/AUG7<V=[E) ="V*0#*=,#NR M=)E]DYK#[_TA'%*&6BF+Q1&O,
MR>TE>W*K3"?]")TX78A7,VT=/1(5U>F#7%#%RX@'_!^-F[!A%654DL%8K.$V
M2*+B?HF/KLB5$X:'NF5>NYZVH%MG[!#MP"0=-'F$T6*)KBMGJ>")2JJ_BA(<
M\^SA.< ^4$;=#)SB0!TNUE0+=5,.]4:YAAJP$WB*IX>T@HH@;\H@U\QOV*61
M"VCB:J9)TQATFYA4UPG?0(]-:XR;-3QK2MZ3OUBX#MUOI[7$5Z&/EYEY>LYT
M&PD4#>]-=9L<R%SL&7B79OF[1T-?H%7AFB_GX&@"5_ZEG>@+T_?._?CBCEWQ
M>N=:6WA%)L<+&ZNDG!Q.WCQ>$$A424DQQB(:;UP\P[3Q*@ O4H>N;1GK\%]2
M<ZJ(=F*,A0N5]12ON$G$QO+7V:JJD"<!LG@63KUB6<N^8ID@O'(7NN6$_R:U
M->F5-W4N)<%RM.9_FCW*$WYC5VKZYX^XIF<$4]A-ZRT#EQ=!% CH60YM$?WE
MRP=IH,7<9K^=(O4]CBC55C7B7Z[+C^DG=0;,ZVA1-/^'R0K1FN855IUAEJK/
M+#I-.'W!FC.-DG/FLCG (;%HZ* P\+X]Q4&7Z_R3OOB0CQY^=9TA5>DSM.:/
M^&_M"7KZ''96> 1;" X]RX!)1X$[@$I]6Z_XELH6=[G@T\TO?.N(HK/6&RK-
M<WIO D.=F?"-U>5,,\PSN*4>T%-T4+^F5C^Z[]09E*^M3Y&CGKB^;D>B\81M
MD.=IYEDO1*Z^K1,J@%6<.B3Q863E#$,:,S?'04**0L.Z%%K>&CS]+675N,W'
MQ^,Q6T,=SHJ1<:9C7\=R76^M_!Z 15HT519\6U2]H<>!R0FW%M13:1P* !9Z
M!]%7[52C4 [OSNJJ0ZD\4M[4*?[RBVH$RR(N/ ,2UE>'XS)8>7E+V7?-J\9I
M <#B)6NVO#J4<:#Q[/#!L7PT"'SBIDV,.:,'S?5^VVT$@ZC(H$C!*TB.EI=A
M@W(,_%CD24 \R]!MB+2Y!^G%>WUE+8+%#UQOO?"@/Q\N=XO#^X:!<M. &&QA
MHC:OJD*S@QQ,SHC-Q(1I+'@8!;O_^@ X%QUWG!:]0T^Y,<H'6B;*IM[H%$,L
MM+_\=Q(IQQX/)L]/Y-=3B#H1P.(=CS"_05M9;Z\@YM"T, R$+V=V>'* .6RV
M;<LA6>L3S]+MS=L>[N%B"KV_.-N$"XV3JS?UKP/'1$KHD$53-&=TQH-AL]$X
M'2P<:QH@PJ<2^(MQ%6JR6EK$(IJ-YID:*K" "@?/MNQA0S'P&T RX ]4 W]0
M GQ3-?#-$N /50-_6 )\2S7PK1+@CU0#?U0"_+%JX(]+@#]1#?Q)"?"GJH$_
M+0%>-0][6,+#ME3SL*T2'K:EFH=ME?"P+=4\;*N$AVVIYF%;)3QL2S4/VRKA
M85NJ>=B6T,->6PAO(+]"W<.K?S5\;"ZDPEP!9^;I&%)@D%?4C>&<QKI54(.'
MC!?<O-<]XY&\E'8\U)10) =0X7"BB=Y1.ID2X', %0>WHAA16W<<?6HYKF4J
MH4,QKB*KX$>]U%!*!B(G0)X^W%)!HUQ(A2%PN/1I"94LO0"4\"UAPP#/$#J"
MBO'!@U:<+9!;2XU8*1\;)X8]<6T;+P@^/V)Y/7T*R1_1"WV44$R,KY"OS]"V
M'8C"MYG-(/+7BDQP'&#%TQKO*Q#*O+)""F0\:="/+H3O"J=:_P=02P,$%
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MPNH1S17'7TD_ TJ9]XK0[?G>X:9'$;3^^7<2?NU#1FG03*;I#YX]1#FN:@A
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MI.UUMO_H+RD5AM,^"V)(Q,= RZMIKMO%.Y @=,O?VP\%ONUVMAAH=9 ?1\Z
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MF.)#Y>X/9AYF$32*/NR^7MS57P >"C?=')"<O<1L"O&($WR&O68X?X=JCP+
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M4RPMM#ZJG!P"&+I22QN+7JC3J:JU91*R"AN )I>+4V=.#'OH^89/.- ('I
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MT)Q$-5G1(O)$>Y7V%V_N*;A;U$I+X 4S$#K//3Z?>WP^]_@4]GUL?L$^XZW
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M>OM6E+- %:6LL9XJI$@8-X^6">V>"8V,1E&,V'A$ 2 " 5$0;8+\XTFRP_-
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MK""*ZCS:;/PTQ7@>W^\>%_F_[G"RC<+$?PPPN<-8T6Q32FPE9?1.N>Y2*-#
MJ5%%A"J8Z)W]LU@G'35/OH*ZB$0[-(1+1G9S(6AF(9')AMSUQ[/@^B;.];G3
M\WS45V:&F*ZZ G7OZ]7Y@AU(F85K> AY]G%D<N@J+X'SN" OJ5!D;PEKD.+8
MZ=")^*ZKL^*H(+\O<=66Y5@?BGK10)UUIRF7_OP=A3,=>G!!-HH _Z /_RJX
M1^/ 4Z'6[$4H!RQ;,'6GA.MU8J8_*F\[JDSN:R7<19 <6/$U#G.>B-$XO6 )
MR5)79  !?H2*0H_4S&H5M5 _Y6SJYT:CO@:&?]A7)N"SV9P[OMFK[-"C] 5T
MT*H>=FO7QLL=WD9Q^A#1VXU+2Z9)B.L[?0?:!UM"#!,\T+ K_J@?-8UUKX=U
MQ1=)OV_WER];:->;U X^FZ>0.@&C.864239:0@7T W/K<SJ%M+5*8;7H<=W@
M%"J2\)^\&-_&?JE,?555* $[*$!48A=EY< 'B'Z!OO1#= $9[W&""-M1 G_[
MRG%26%,PM=H)]?F9EGYA23P/WLL=!I+\P*<Q5.07YS%>^NDP:5PR? /D.;<J
M2RM5HC1#&BX %1*RM"[(E+_S4CCUJX F] \,U@1--Y#XXK:&FK+<FQE?;6PR
MSK3/,H*(3;# _K-'-KD;/%#2UP$.VT7ZN%3(\[W J,P_GB!O17"@:1!$GVCR
M('BKF0S0=90D;G5+*D=."AB'#>89J05/KJ+X(MH]IJM=T,33MU:I(76QM:F1
MIJ-[*EKG1.VT)%_30W4>&6]NQ'1+R6F=XN6YESSUK'\'P*U%2/+Q"VNBY1\A
M^,IY]3.>/.H5SAJ3ZF!FGWM;/_4"_W<,+]+;'>'I?;1*/Q$K[GU,%D_/&M&*
MSM[U4I4DT?6Q'(;R<2@?.$%TJ-OS3E6T5>528H9A!GU1N>8G<JW$%]&GL'<C
MOH' C=5^2$9K82+ZY=&2?.K:_!:)J&YO<R>H?09!2P*HT["CY8R6SW#4'6PX
MW-X1S3$VQ<RE0%)B@WZ'\@]=]8@0\CGO#<&?DK%=<>6'T$Z&W$&7LS E/ 'G
M$"00IA\33.P8:$S4\_)70FG[2J5"E$!YV- C.A:5@VD:*[FNL_&T197;34-'
MU-5M1)DUYK>N"[R-\8*Y WK6MAIH^U9+%;U ?ZJ?.+9J>7*HJD)C-H8FQK47
M+J?/GA]X+'X2JE'W+'<N"@>.9!X=PAN.%Z#+!"HB31",FZ ?<+ \(O?D(QCF
MY.U"1615%1'.U]3%#  'T W[MUS *I \_,GMX5#E\J$XN]Y=:8@G7B97!"/9
M0> =-YF'H.U,V4%%>J^%JH33_GF@1)>HJUDV%H'H4#X:12&J[!R(0G!=85=+
MY+4JJLK\Z58?+KGU]K!#T9K5Y[LX)C>E@=X*>)CL*YZ$FC;O;39DP@I\3U V
MS+6_MEV0O,<"T?Q-.PP\0= )CC=G41Q'G_QPW7MW 0X&ZV<7APCANSCY\@@^
M)3O4HVLED8BG_AK.GUZ'0P\F/PN3--Y!Y,65M\#LW;;WZXT C745$5$BO/4\
MIJC\?H)@1.-MV\D=2"ZX^GU(,N?>E ?JJ1&1I1 90.NE+F\QD1ZYBZ_[OC5I
M('9QEU8E3E7G<A@TZ&*"&!A4PG%9#E5?!\2:V<HKP].OCH6U3/ 7Y(C=]&].
MR7$YWNX.R%'5OWP8RL:-:.,3"%.L8SP6]+8%PMD\J#Y1!"Y>H9IDJ"H/?.O<
M7R@2DEA/BBD:OUGDNQG$N(8)!O"]OU V,5C?83A$"!\HLV,L^W12-[V=/% *
M151_H>1/L<.^<8>W; -*YJL!-*,!WO9#U2$!0E]R_AFM9^3^)B:22SUDAC,W
M\U>EZRA<PVYS'7EA?N_OVY/,0^'BE8%#A\C7#)^4/IT;(KJF/\>)"UHBKII+
M6C17XQ>&"J!A7($\#/;?'YI$J*G(H;_/B6X(1517#?X4.]FA*S^$**NP:+A,
M.^*P7CGQ!R]=//GANO9W=K>"S!ORQ][-UJ[T.-B>.A,MM(DI7%0=2'LT35 .
M&^7 :Q]-\DL^2QLC7[C>_7K3L[KEW0??=?=5"%/Z&,+#S2Y-4B]<$A3U5< -
M%VL,L>=AXJ$7J!S]#%6^<V17R9B<QXIQIZ3IZLGA7.!D$?O;9H2.4);5$;:L
M9 YNB1PG:%E^Y^;]7<+>JA0/YV-N%-/F;K,DV>'EQ2Z&]DG4;T/S 1/V>XC:
MP/&SWXCR[/Z6I8?<]MU*CSQA+"FT#&1?(P8F\_--$(,TR?\*"3 Y-*<]MXUT
MHO: IL\Y?16FX:_P_C]=QY@F-'_P7OS-;J.P(?''V3UAN#2(M B^1<7'$S1?
MK7!,VZ!D ZM9QZYRC5LE4D0M"Z=N^/)0C1,!_8)0Z#D--INO+O^Y\]/]@ %%
M H36;W3M-"E%$N5#:=%0CU6N8L,%.N8XH$@N;U$TD81!':Z'\IZI-[O-(X[G
MJ[Q@R?(A.L-W.,!>@K/-L6<U[4Z/@^MA9Z([M/&=( 8?E+[ <)1&1X_X*$>2
MG=MT-; ?OW)Y7/>F<^K-?U5E8.J"HR#. !BDL^$P&2(50(#$?B #GQ!9H9$C
M^G7^3(RF<4P^R2P#\.!ZR5/^^./:D2$79:,&"9\-!I?4GS 48,;+Z3..O36K
M;4*L4(I$P4"4#K=VLK=1(M"1? C*QF1U:: 6#:M3,ZH*-:K2RHW'5H;DY_=?
M_O?1$?KEIP\_?OL_O_Q]L=V]_!Q^\V[Y^W?/ZY_WX<>+W:?WW\7OOOOKZU\_
M/NR3X+OGQ>_'P7^E[W;/=\E_/?S] _Z /UWO?WCWPU]__7;V[?;Q>7'Q\NOU
M]*\7[_[[N]_?;__Z^I]_2]*K9'6^>_MR'Z<_O?OA];\_'__]^3A^>O?O?_WA
MU>WO;R^.'__^\./OYW][^-OY^;?A[6[]S<OKG[;QW<U_[^?'SW^-WZ_>[&]?
MOOM]?Q^^_?;OO__[8GO[PW;N7<_"\]E^_TWRS3_?OOSZ^K=WIR=_FVYO__WC
MXMO+;X[/7O_^\V-X]^J;;W;?OIV^_VORZNV]_W%_<N*?IA]>+?^Z/?VOW=\N
M_G[A_?=?WWB___RWM_]^]?SAX<-O<7Q]O,8?[J\?7W;>F?]#Z!$3_.,__1_N
M?CS[^^SIY/=_[A;GT[_]Q_^@\_N[HR/#"%C9U:],@J>?33]Y\7*(?'5#(NS'
MT1K1V<'34*F:P#ZG4+.\][$8--U42-D/(>=OUQIHCX<'6>60/MN7GV1G.,5>
M_?P\2M*3(2R>?@AS$'+>%^VFAE5F4"UIV\Q*Q05."2YGAE:O6M<PSOIC?Q]7
M;.8]Y%N-Q A^)LN;& E 0_(0$5D=4G(3I3_C%(J/K4.0XU!7[][IM+[V!IM*
MASL.PY6?7P"<_#9%>YRB$CYO:3J]H@^EL]RK^R#2ZGHN-BAI[B%GAWL(_;\?
M";G%"3[(R=@7:=;?J7HD7F%%5I%4ER5ZW"/NRF5+E/X'9=@RP]1MDO,0^MCN
MT.@@%_-GWJ*HYKD7Q_M5%%,T0V2@R3#9=ZU)J!%H>EE:%57'C*/.JH(8JPK8
M-GO#Q[;<^SO?XM@#';W':QJFV[,JB?$X>)00$B/0H_(9H1B!\B%NE:A5?%45
MDD_;.,36#_%\Q73SRH/2O^G^'/R11 Q><(5Q,LC>I(S61<BV(FVB&%TRG+Y9
ML:TKAP"6<0X# 9!Q[&.Z\J\%]>HPRE1!SZ,PB0)_24_L6_+38J_2S,&HMJ8,
ME8L4-!E!HJJ:U2$3Q :A7[+_NF]DJ"/66EW--E88)ZU]A%8,E\3"VQ"][?O@
M/ !NW5]0QR^*N&1-.HK/%-7&@=;P9575$\Z$.^6L/>-PA[.+]_ [4#L^%]M0
M*U7"5#<ZKFWW<9/TIBC8>A:<"A^,-R)P],Q7-"!OZ'-.B,BVPT1,BO!\2VAJ
MR/LH6B;4_Y\YUZ1:YN2 :Y-F_7B3\L'<W7#IQ2%4S<F?Y8?5K#9LMM6KA1Y1
M=%HV"EQCS(^F=B*Z<&>KB;?FE%;@B5D(^/N(I2PM<)SMC"7LQZ:V<:-]VF%8
M#?EI)4>@0G0<R@9RM8>._O\<!OHH2RN/]E'C10=KJVA#-.PF)43CH) $GQ)A
M-8F\%]5H]Z,V$7*[3HEW(#,/>^PM\31<TDJ"S78O#%O?OG8EG Z\[BITJ3<)
M&IN1I27JFC]>F2^&GGEH+4/@PW\@G^&96'90XW)8NUX)IXL&,0IT";O$)$]9
MF ]$4I?#57U;;AK': B_WCU&E5,=6L@D*>O:.^P9*\+CP*$O)$;25H9]/UY/
M6*L@#_O-B!E@ZIF_C2-H9;N'5)24:"UH['9XU5)&ZT#35&D39__1X1.:!Y72
M?:\ ,5J;3U</#O( U1EFJJA7GA__Z 4[_ %[R2[&)?QA-54=K_6F.JJ4B3KK
MD/&( D 5"$H:ZJ*_CJ[\:TUVM%AE[JBC%^LPC>D#%[0,9^^J\%/_SYQ"3 Z,
M0S$UXB?.<@3M.S_)']O9/\:IA0H"/GCPE/+%N"P^+Q)N3@N8D/UW1I'ZSQ@V
MY&20J[()!>.(XY32:!9 /;K#O(-^M =<MC.PR_X)"= T( IN4%$((5(X7/C#
MOZ8I(W:QNZH2)]QL"P#L&EX%,>KX$EUUJ&^^6FPSO8QOML2X "SS^,)/ME'B
M!?,55-&D/?UH)[^!E=>(!/MJ;$*FZ')?@(*J*CDP>%(&<%FS2 9PQ+?_#II3
M<PR8\M78_51K4YE4.E@.8FNTXW/3W[B%*G$U\5H+4Z*@U1:GHW40*$O]H *Y
M I.,@VWN<(+)%)XN\#,.(NIRH#M]O67WT-%>)C2XB0 SH%08%<9@02W\ MHD
M,RX:;>#'Z^3OI$'UL#)3YG9HU) U(!_^%8"+QL%+.Y^2ML;R8W4FM F0VVV^
MIW=VB 4YWS\"RQ>[V$_W"KY4;JR/ A"+/GPUBD37)!AXE(\<F=+H"2P/]U'D
MA:E3/M_UR%97V?BRR@Z#&(,J&!V\&2F0U7*2TK.S,K;L-C/^TU-!_+RSLHU9
MQNEPF!B;^!JJYPU\\Y9ALG_!EE C2G.C(R:(C1G+5J<AQUHF6\OT3=-S\:<L
MM@C2Q^,H)#\NJ-\WL?'^J(W>Q=5"ETA1DB_^A$HXJ YHS!NAJ8[44H-->&A\
M>;B-_6<O!=<]P_$!0V)R[U$>7"0N^L+S"!$&<-"/4?$U^H5][]A?*!=9/2!#
M.-U.(6=1/(B:' !W<J\L\4OCR:*XJ0S. L<.Q=&,%JO-J4NIH=UC@O^Y ROM
M>:C-@H_#^J,QCPK1LW#Q+:(?CT(UI**JO>X*9VK8.X+F(1&!/!$#K&Q&P%$5
M?@L)V7"KZ4(R2F0! B@?4S:6X)P<MOM'*$BE:"/1-G%#/].5GRR\X&=RYR-2
M_U99([C#;+8ZXA$@BJ6CGR+X%L''3K>"-I[G\A;.SVP#.">_\ G A]CW@L)?
MJ2QNZ7"K&X",$I'K,!N"Z!A4#'*_ :A(I? 6MDV\@PEQ[87+0>R&"F 7=88*
M["(7"_CUQG&!:(J@YCZIS\2D+>$'\.H1 9W>WTZ5USUGD-75WL0OD"3]$';W
M4T0^=;^RQ=S.U[-@:H;'^#VAA0+1E;!@H$U'E9@,D467?RP3N-UEW"Z#PI 3
MSU3;8<3I+Z8L=]XPFP8<CP"UCG#C$+:$[8+6;\-<XI*.M[C$_OG<2HQ #V!&
M2'2=2[AJ,8H;72)0CU86F)SST+.*D/QVO@G]QUT"\=_*&B(>:W-G$%(AJB9#
MOD<P &4C6),SYS9 JR1R19!/V#QB_ST.H4[D-%Q.EQMR>TAHLLLSSEYS!['X
MU7#:?V50HDM4:X:-I5$ ]=%Y((#S(\E(Y-4;ACI_#%\IZEWV:)[*( HHQM/_
M"?>,X\=(I\%CA1S3?A ,QF@4KE6LXDZ+A\PP.>UFX2KVB*[N%NDNQEG!9N7S
M3C;:]@U(0HOPU:LZ(J^X/08S2$$J^=G7-FWC1W36Y!:"?*.0@+R(-I[?=UM-
M/HZ>;:5 MKOP"!"92:RO<?$Q^H5][O1%3"JEVM8AG*FY?72?>BG=51^@)%'?
M3Z9UX'V[S61:44<M;*&7?81^H9^Y?1CE2J+>WJXQIRYOYCFT:S_$,_)C_UT9
M&P@&.%"4E*"@H%T1X%-$OW5N5X@EQ-6*^B2-'&G"2BE4XQ[(:+;I\$X2KG6A
M";#W.Q%/._3I:JFDTP;$Z2EC+M;</#'@E4$#Y]N[^>WEW<//M]?3FX?IS<7E
MWS[.;C]<WCQ0+ GG>.(KG H8>VJF0(U(N;*A$T0'3Q 9CHKQZ$L&X:O&R67?
MTM617*%3JHSI7Y,$QYV)-M4.MA'H4]LQIZQ3_$-P7'K%/12UF61N.<_")5Z5
M^<*'J<0?O%^C^#SPDN3&V^!!KEXF%%B\F!F0)[SEYY"RT@F<)'4*#E%X"  V
M#UTW@;#&2E*/EC5CI;EV7SG5;%WL5@YT0^*$$7F=]=F)1ALJ1JW:G9DF:_M%
M8?=_/SN[OIS>WU\^W-\OGO!R%^!H=8B5&+70ZN.3'P07./7\0-G<[([#DN70
MF5#1UES 10PP.D(Y;*AWT]!L1."C' 'Z,D/1M&-MNVO[4I;"J=L+P\VB)+K@
MUC&/^\'3_YO4$(N@S;;N;R&,P /5NQ+UL2J:AKO.NDCB]!]W\(2H_N)*AE2,
M%?*OTE YA&;)L7F 5N+-]).4QGM7"LJZMB $$@#5X,W+\(U=[*TJ'%4]&ZLJ
M&.WL<1H4B:+!R_)T#[7MRK7R&(A7J03X 4=,2SKD^]A\)?>6]OW$HHK6KOZI
MDF52H;[I\'3Q,J,I[MI[C0YS>F^;,-1CGP)"F\^_[>28Z1[/-AO3+BA]*51D
M2K>N6&&RPC%8;ZQEIA^NYRMRX??"!<W9@C 7&N(+&V_"_],@IW2OI%GTHO9)
MM]@5Q0:@RHA1A,8,H4\'';KZ96X'ARNG!412_/(''\>0++4?QMVJA=NN+:%%
M6WLGD6( W=EOIC^.XYW 2/IM'43D;#()-;V:SNY^G%Y_O)Q?7<UNIC?GL^GU
M[.;^X>XCO*]5;O,%9G:9)[R^]KU'/_!3'R<9B<LHO(/*?S%9<V=>XB>:OE>+
MQ%@+&+ W)]%2(00@2@&:7Z&"!E0AXL"Q52ZN2>[9@J55(2=W0BP1M%+)*4*4
M)(D'V'I) NO*710ZL"MU@[<4*Q3JN)XM$V3IE<;NK$:X!3B^7[E3=:M; >^^
M9W3=\UY8PZAS+X[WJRC^Y,7+P8("VK#9O)3)21$L+#(J[R%6'3<9U?N^HDQK
MMR@%;I@KV7R+(0TO7%]'25+%P#,4.RM9&S:+2M9"BD#)BE$(AM44+1F%[U11
MGE4%4^'$$ HVE+-4!:/=6[8"14;Z-A)_J8:(U?2N^UOT;1PM=XNT]#QA#;]G
MR\NT&+:5BZR4!+'?';ZG=F,VP/6)J"2E_/5:/E_SS>G"3[SU.L9KUMMP=8>?
M<;C#0QQ]4E26,[=DM @TJ#X$KB79H#$D]ZF(L;KSM,[?."=8 'FHHZX5G=70
MW39J]%6+=\ YLMQ5):N@9XWCK5M,Q&68^NG^)W^)9R$Y03>LW3!#=47F</F2
MXCCT@O-=DD8;'"=G>\Y^.FP 19\TNHJVZ'$.PK)SK,#"'=Y&,5A&DV(I@#*B
M' /*44P0]V1O)*TY#>(80#_Y$1]]"\@T/$27CJ%.!W,ZK!X;QF0*>RK)ELRH
M#I7.FE(K8-&)CYK'$%CEV7;U'D?KV-L^041L;Y<L,6QKERPA"<(B7N6';M^]
ME823WZWDTS0L)'GY'ASJLYNK^=V'Z<-L?I/IX8JW#3_N2^33&'NZ3]5]8K/T
M%-4CR2);@F% %13HJ,6<2-#C'I6H$,4UHC?D =2J*)79LT!<KAN!/3'@VK'M
M6!V <IO+R+'?=D!-ZW<Y=?,#EX4G<]@74'32?]R!833((ZH4E64GGXR65@L&
M5<=P7<5N:H^V2[)><K2%!<9^OO+2F>EUPKU@DFLEY/S0E!\623"LF\6(&*N7
MO6ZTBC;I2K1,#E:X-]/8F3(1*XNH&8$7NQ^=XKM&C)EMZ)W4Q#>4!\28#(N!
M"*8TRKT?VOK/]XHX6 9=5:?>:[H#;_5-^,5^6>^Y?N<GOWWP0H^55KZ'BM=X
MO:?)U\] #&%&VX% 0'V]CIY?$=A,X\D/I:*;8[2RZQN3)VJT586% !@JH4U0
M#F]"E;P$Z?3BVEDI0*&[,=(@Y\P$H<HNWK\Z6]VT.Q'8MU([OD;VHB*FRLW9
MJHWL> ^L(UHM'D(JYRN:L^8M!KLA*B"T6LBYE1Q)QR0PM^G0460SJHNR9B*K
M,:!+UJ[W<HMC/UH.%;9=@V[W<?P NR0RFWWF.NBL128'8=>-J1G7KZ@W6QZL
M5HH8C^68"1$=JJVT8<1HO$ZMTI/TU>ZI ,H=#L@1N+SUXG28'&4. LONRB8%
MP@LN_9!E&$=AG/T3!D(JU"@2CL7RJM].N5,V-F8J77S@<DN8XY6_J9QKW(9^
MG55(%[M5MZ,F<2)+/0H(W"CKS%6!R1IW5?X]3Y]PC-(G+T3U0:-03T-%J>JN
M"4--:X[M'@-_\3'-LN^*SM3#E1QK1VBUVDXK.<+"SD4?\C%HG;H<:V5UU&9O
MVM5X]OYF=C4[AUKFY^?SC_!D^?YV?CT[GUW>ZX:A*,.R5O! F22185:.1R4
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MJ$4K'RUFF+BL+\\_WE%MUD[$Y0ZT:-KS*1#F]N4?C\=NE_.^3*\33M/(,F_
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MWE3L=A9O"^,017$4-M.4+-8-,[3@KGP58SR#LEK$XKHCMI5TU^MF1@,)B-*
M*D1,F&,"Z$ Y(0@H<6O,#,UGH>$\O'!M5IU@+:>K"X9W1\O;<W.L'@>RK]/,
M$Q1O5A:MFH-[$0M)F*_8H5MYY"=ZXB]$/&_<8,O(ALS"J4""8A\$EMN:-5K3
MYHG-@&_&;>HX^5:'&M53B1D9)JMGDX0007)D)<:]O,6.Y_*C(,.J>K7-WUWG
M;G("^%X0[*>K%5Z0!3"/[["71"&Y,^^O_=]PL'^(#K^ZPVL?B _3J\ 3AD-Q
MVWKG@%".#YZ 2HR(H81HP,:WJ$2+?@'$SJH*#<;*UN>+_N1E,3V:%V#&.W;H
M=]6CQ75LHF[4W(E5^VF^Q=!3,UQ?0Q)K[ES9GS._2E&Z:KZZ\J%C/-&'6WAX
M(0;@Y4M*+$C_,2"C$N&MJX"/*())X6#<3U"&9()J9< *1"C'A'XI<:'+<+>A
M(".W%1[[8AQOH^]7*+:NX9<O6Q\\-*^/W[R5^SVJ7R+VJ</0UB;=C4@PP<Q<
M';@/3W[,&A[/B:69@-$Y#9>S)=$)?^6S(G.W<;3 Y!J1:)ZN%#;M [U'!73Z
M1%"'CPH$G'/4]3&JS:#6,].0Y;;6WL?0VT1QZO\.&33D,%G#%M"\1?)TH#(4
ME6-1=F5NN,N<G**MDVL>K(K\L/RV=X%7F&SBRP?OA5'S/HX281AT_C4BGV<"
MF2 ZPO7%A3L-[IU%,F%;BT,I[HUG2V8#$1V)\J$H&]LXN?X0\7]6'4W2UYT;
M_(G^B6K+:Y[+F"9BLN&(C4<,0/EJ1H"P+Q)7.YC>7+7?P ZX9"?Z1G"MS./A
MRH,PBF'5)PDA.CLK(;.6G)ST8_+CPU.,O;2]6@'7#U"$&):V"%28*%!.4 7I
MA!HQ.5Z4(1YM=&(OW%1P!?0F,YNW5G+O@3W,?^8<[^S<]]AM"!XY\,_8BQ\^
M12+58L".*+2&!31! (3ZF*J0)PB (@+5Y1W4B V\':8#/^V&^Q4/41_(S7@7
M,\W5J>=4>2.L@)B@K$#-+]E_QQ+SI#Q?KE3UF&79%&;J5<;PR-_NJM%+KD_R
M0\K%+WB'L[/$XI:MOKS+7H9K\KNEM@.^.'BKWH(,V*$[8#P'*7?>&D>DA&\V
M;>;==AM0>KS@W$N>KH+H4R5?MNVZ7QV.8#P" *B:<<M_'W-B,ZO-E6LTZ[#)
M]I7G*0J61,LN:<9LF\385Q,T3=/8?]RE-"@WC6#5"4,Y7=UON!,3WFDD;+!\
M&,UH1'AY0+;:$>4 -=O!4<,2P:QX$FEA@;4F=!5G^QOE9X0WHWI&>-/ZC/"&
M_XR@7ONZB%UG5=<.K U^) B_!+8B)(N5]=4H$M7#SC,=YBM$Q^>>[$KT.\^I
M;;LNDYX BVI-&KRQ>2&_!M<!%KQ;?O!2:DVII:HP4) 4)7XY)J??(T90<'B"
M<NAC2U<Q8 EO6S;F;*<&9L]$F:)X7T8<#11;)L-D-;9,0HA@HRE&H$J4V5B,
M,04)'I[]LME;M(]O< KF^FT</?M+O#S;?TS *54L@.DB]9]I^D^;W4PO-SD<
M"!W_$D A/_RJLK=DX,B>,@L7P0Z"<*@\(ZCR#>\*V:?\:Y$#R>KSAR=P4RZ/
M(!>!)7'"XWL(!?/\9PRE1A)FM*ID%W"2IUIL]]'D!TCGSKUFF;+0A3-PMMEZ
M?DP[L1.RU^Q)2^@21.7G*/O>?51_8PI"WZ!@LC:-M@NH#K7P/7FUQ_(;U]Z@
M*BW\6(/#^=B+,! 5\N2'%8#O+?L<E=^[*U[3M5SIB>5G(#B[:"FPY F<1\]>
M $7,BO>.THJ1V@;P'DQ_J,"H99&5<%RKOO*$>>M"DUN6MWZ!*<+<4353Q,#0
M*Z!H&'I.3Q%U;FB8=4)>.@@-/E'VZ9V,RJ=WTNK3.[$<&IS$Z3\^^"&4^Y?S
M-/NHF5QND9L-8JN,%,S$XJVSN !#)$3RA)?OHV@I*4^;?3U!^?>(#N!$9SJ]
M_==F([WX<^9M-0T%O)EP18GQ$R0P/&/6._TJBK&_#EGFPV+_0&YL";F,LML+
M_5= ]^SWGA]>$\Y/8Q_BEJIA<F1/G*\>O!=AA@IU$M=PYZWHOP207]'*&D %
MRLE %3JH%5&A! $IV4B4D7,8G$A(@DP70I1K3;' =Y[:61.WQ2TD<RM 2SS6
M3T18"578TR"# .[M# :Z+0K#4C LB+& Y-9'H3YCG@[H\LM964Q.C"34/%C'
MT.JEM\#5$J0P)'5$H30R3FA$U+0SU/)EY'*S#:(]QEE8/-]]5M2/H[4Q$GHM
MKO[]/$K2FRC]&:=W>!&M0\A",71,5FH"YE5. #KY;8KV&+*9<P03Q'J4.BTA
M.13W>/O'P*)R87QJ=!3FOSZ-Y>U3-B/%]R<G-75I&<!X_X^/]\)LN9O9P^4%
MNG^8/ES>.XEQ+$BL[;,'A%M]^_=#/%^=QWCIIU?>@J4J1P'TQ8V]X KCA.U,
MXAJ%(:U+R2"@' 3L=#D0!% :.YP;JT=UNMS'?"U66:Y<M\T,LOGJ C\*I55^
M!S*#+UW?80XIYS&>/SN#$ GP^60N\"M"!>3;QR$Y4W9)2NXO<7*V?X\C8LEL
MG_S%%!J#:X1BF<&UY<,SHDX0.Y&_?0 PE$-#!3ATMD<E0$0ACB%HJY/@<X^A
M.1\MV\+% \$LW.[2A)8F?"WW-)9O)^!FAU$31,>AUV,I;2F9%6_C:&5"9?EU
MK=]5AJS;J^3%P>FZIE>3)*WJ7N7P$24R:$F[I>:7@#\V75UQEM5/H_@;Y>U$
M[][%,$3'33AU )W>6EJFQ75BJ7#"=OUX_9+)?9>B]E;D8,L+4A\\GX\M]9[/
M$9ZPC1EK/9D%?.D/WHMR+@M][2 #%'-9G'@4^'/B>Q-D\[?JV%F $8<O,/OO
M+&SV%9 (A8Y!7^:COT)^R.O3X#S)J'V2 BDI,L?R\N'MZ=-=^A3%N7=0YW K
M1[JV0>3S4CW=#CEAUTD!=;?FJX\)*TXP?V3%YV?AY<OB"8X?<N0(4B6$_@P
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M4<CJRQ_\0BVK35ZLJI?K)GL4E9B L%+N^!+WUT63\6TVMF^QERC; ='(=3N
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M@A")S[:6OT,UB]JG]1QWP#7)J1;Z7T%SU=.EC>I$48X>?Q-X1PY&H3(R AW
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M?=D/HU*)9D]UY=.1E('KWFC^N3>^&TZOKT>3'C5>>^/19+&<WP5V+7 T[MK
M),A3/<.K:F&7DJIQ&Y0WKJIE64Y+ZWT/CR3CZZD"MB[$*T83>BH.E[W?P(/4
M87>9I?'40,I9,:4Z76+2@ZI+.2LAI?L4XA!CJAIL"6P=.3_FP\_#R=UP/NQ/
M;R:C*G-12KWF:(]L'['Z!\Q797#^BKV'ON]Z%#^B:*7P4I5]?%DQOJH%Q$U6
M\VV/H-#CZXH?V6Z$&1?#&V:+C2;7T_EMI4<F%QM &V:_SM&.M3*U-ZIB&T5D
M9!=1>L &HAD<%'6_>:\09B*(P0-@1Y;)W=5B^,L=72GL2 )W71;^O8O^\BF'
MP[W">$0A&>DEDAI0V<(HI*-[.50(+K$<BL'JQB+(ONJY.@0_'8"70X>?D[$7
MLG2H50!R"(ZZ6Z424KK=%;&G8^6H@:X.88G>N6BZ'KH>WAH>>,&QU.!:HRYB
M(DO# E84L);'P]KJ;FRL?O%5T^O6"N3 #Z[]N-S&ZGK3-:M/[ZK>5@L)Z;Q#
M%-U0B]&J4<ZY=H_?H4%L.@56FBBXX% KRBIJW9%G)6Y0U9A%A'KCL,Y4CFTB
M$NT69[;N.7/.JL?06_.(3TP<2(#UW:L;1U>[Y K)=,BT*89*OB@DB)&S),;J
MW*LWT\H[Z8L!"92/9A<6J2"*6IOD1=71T@7]U!H^7#2[)&E.%.7+S(&T1#UV
MV5&],1?1T1Q"$]V;"^$"K%4'^Y17K6"YR79*SOQ@'@,/$.D=\@D[M\A@%QMG
M#M4*G9]N=WP< 2R/,M?3@B(P]-G=;Y"SA]T_^Y0X]MA/\"'>0DJ=.HC+$#L*
M4U-@Z9QH&4_%G.X",%F%#L8YWK,&*+:KQ,26X: [RUH*WZ-.U Y203\64AU[
MY";<K>7/C^=1\O7[BLF9X]L=/8:">LGDV"IBNAX[]F9,=7055D%0;*G+L- E
M=9##^*@8 !$T.3\M6:GI&MO80P'#2@Z%:GK=NF#BP.\H85WAM3F%D$[_88#V
MR'+" D-V<&KY=/R%L_8>E5]9R/'0+560Q/FH'O4C<C6+GZH/U.22Z50$O0BJ
MHQ#K!]L$I=@_W+/OFS[!WH'#1<^]K>(8I!M+D0>-HZCJ!]3J;,:L1==YGQ@^
M,0]"S4T'#\5.Q="X(#QF=6@)GX5UE,+R26IWU3)*7;*=2Q$[RA(@"4M&FA/T
M&)L,<6SZ8]@SUFTB)BI,OAM;M3RZ1W4 "*PI?OL8E=I?LOO74XHE3'V-CE?<
M7Y@/:.5;:+H^#=_W"=.L "QE"?>\9#4?B(*%^/G1[,*;X9R*_) KJ#6%^8_2
M&T1B".HC](T=]@P+?T6K&4$[ Z].*1T-57NMS8X6AXZS)P <YF#9^VJ/H&3[
M@*IU]-Q%@.? 2I*AE(],-'9V\7+0Z7X"4I #EXV2UA-G'8L$9X+$/NN]UMNR
M]Z-? YE$WFLC"@3"VD5H%HR0 )\(*3T,"OM85)X*H&EC76IG40%9\%\.HY%K
M&/&SJ6)8JB,HZ)%:G\/S4-UIF,$G._G%:\D>%86S"#<6^LW>$^82&M] >N*
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MT51?8,/*!_#9CX)P3LAE$-K<8L]#JZ5SA>;(8ET%H^O=1N,\//SHNK23UBH
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M_;,?"YT<Y)7YM""ZSHV@B>%1F#7[.1;<"_.YH<,\IYV;_32">)N?'>W:W"0
MS#0_:D(*!5D<\_.@G0!?S2]<8W\2TG]FOSJ/B.9Q] 6%6[+%BYX(<.2BI*Q>
M")8X"[,H=-ADM*5C_CBG5\5A9O9+-MP"7'!UU;7/K5?'2?MOSFLP=UY_)Y$0
MEGQ;3]/2HFL0/4E6E$F_Y++<" XE)<552U[;,(C0F++4")<3Q FQB1-SC&J'
M*C G#:LVS"6G@@YRV+>G!Z)CF(;&8>^=0;PGS">1'":@=P -@C[$"H9EB  Z
M[$@2'C3Z.$(8G \1GP$W9. -R=O9A9@K6A"V2U;*;_&0.+,H_R+3*XE*[!(
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M5&>\S9@5=]*P@'O_Z?R'MB)T]J&7S7\^'"P?1@^TX%"6)?-@AK-[<1B-O;0
M<+JDCAK$."+0^_U=/]?3&X$6/M+C"8_$?Z!YT($H:KFA9*DG)-F2-.H3MY^"
MNY?,8@'0&9=V 7**';,,*+3 "08,LV6$OR0)=&N5!/H8DD"_\D0]B#;T7O]J
M]")LWT_7:K]U\/WUGK[=Y5PJ_'Z.WA[.W"]E$I-"%4@R28(?630Y<^&<1PRB
M&<<5<%X^B[M'0NGGY]%;@]B'M_RZUW"?5(B/] U>9 !:ECQQKOTO@NH+NF-J
M/Z&/(.SJ;R[SF4=XUI@AMZAGEVA#'2:]%MV%Z5 +F"H$J !\=4E1BD(NF<5
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MC,6"2%>S.VWV&/LSA'7^U(7#C=(-=E:9!;.9!3NKS(+[;V+PT ^5]82'-8\
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MHHNJF29:K6VVURT:9 U%$I6NSB7%T'YI5@S(1$FM*D0VXKE&D>Y:N[-.MK)
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M# NX)F8I,M<$#45$(\G%0ID+3V#A29[TH[_^DA<8/8P+5*TNQBUFN)\,$7=
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M"4VF8L"A2@?&70#(BD3%*Y?U8FW,=S\5//BE341E?C.M>:0M#[:<SF0NC;T
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MY "X6V9@EME2[\4?RA?VM.X@=AJX?949,U\0E8#G6#$6T% G=-60N9!K@_L
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MGXE><]%C56/5V?G)G"]UYJ#=UF:"9>NMV;?/9&%6J3<<"-KGT*/U4YA\/0$
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M*NOZQJ,;&,/ \I9-IHW@'K19)1=@<*=<;#*=H5SN!.GE?C5ES".KYY"/7J-
MH9.,'5=+H+6V\/4P:C*ZN0FN/@>,#8N)+[;]M"WR(FL4W1"AJZXUIWJ#&@GN
M<P7$D?AFJ^S7WOFM?^5'BWLO4;C[JV[DQXJ.0T\R/ZOK;@0',^@/%RB_]-?C
M1*_&96?\^);.^)U>>K51TC=ZZ;^V>4.^77+.T=VZFCG_H0D]C<3R?TZ;O]#H
M28*^,N&LOWK-(OJ"]FP7AQY&"W)=3!O8YWCK/[8<Z%)_"6Z$RQPZ?O5C>_%'
MMO9CXQI"E >E8S^K\?A))#B7GL"N:_.1F7R6MJ+,'V13,PCD9VM:RD\_-7S<
M.\;'_?AYG_XS\-\O8L0>;1O,)FS@O9]?O+Y/-[1A9*-A>#[GZ^,B% :Y]LBX
M<4!DNQGK73@;9GQ^[GU\KHA8>M5).:O)C4C_V9)#(O+PQ_2"A3Z^DI5^_*>%
MR<NZ<L=W68K3GA79313CSZMYD]%IZF=L+0(@!9DP(>.IZ@3JLW39V2:%+:6H
M7Z[PHO_<Q/GLNX0W<:P_V1@;MR@8=,2E0N+<9Q_2K =VD\N"8/^<99+=!8!*
M?O/93]7A5G_2K3ZM2V!N;^3%/MAG\?7_["JX[8JN)^7Z,IM)/#9WZ;^*15%R
M.05^DLX)6-VZ33>DJ@O]][WG+__U_,7)?1Z.*.W/;2(\JZL\&ML3ESYMNW[M
M4&<()XP&\>SET_OV]JLQ"PZ;_Q5O_D%[7(9M-LMOI.X8^:%W1CO(B1>L\R\N
M*T'CRYL -TGKU,Q5@GTE?_S,?K .0IKIU4W(Y1<D(.)7WJ@C$48]7B<IK;QX
M,C?90OTXA^?-3ZKM G9?4/GTZ,&A\FE<^?3HP:'RZ3HJGZZ8K_-G0 $8>D"B
MZ8T4%;-7?8<1*<\%L(!, 5>. \2@; (H7,"*M$Q@*."310":(;O-U::HXA*F
M2\%D<,*0:^ZUF&I>@Z?3V,S(D&SI:CT]G4@T(I1OTS=>_I^W3R?ILW?TQV?/
M7[XY$024\E<>D^)=K8754YOAK,EL[H[3?]*DI#KVT8.'?TN?9<TJ_:DHRTGX
M1@E@R;P0'M!L] 3#2[2T+(__ S-BLI1WOYQB#GFSH:7!*EQ7I?B-.!KO=BPG
M VF2\ZR-6*3^9U;U:-3[<(*/_\!5^QVCW3SFR*@PP1Q1A! TZ)PFY/+,N37"
M)?9E'N]+$O9E0K]?@.+.\U,M==_Y]ZERG<Y=SDX>.+=H,BO BS0BQE@9IINB
MD8COY[D?G&>IF@D3F95B@P '/ 6)_LGSFX%_1L*?J[7"1E;KHQP]4B,*@J_J
M-*%P$?+!'&R6-D#")H'WUY(>7,$I^R*(&= TN+808D"LNN!?%66%Q55NT@\9
MX%83PV&)@ &,H2G^31[M)#QOT2B?V,1(!Q,/] '1[O:@5 (6C)7U*"IY!9\&
M5Q]YI ^]DX4BS5@@/B(T WZM8^Z5BDLC#9Y&AX6N5H()"L*7#ZWG=]+!R^>8
MYW#JH68N-VZ[2$BS-'=G=7G&)U/PQ.+"_-XW19L7,ZMMBW\6H1MI C;=A3/F
MUA]98QI"INO$,EVO91'O.#'W0-</B74B]K'AMBO;[5E\KDROLTJ&EGBF<O59
M7>>3]$G3JQ@\K=N5 R/0";)"*C2?/3F5G_GP,P3:Y#*.G=PG_+?OPJ4+9L>"
MC30E+Q-NF4DZ();Q[#$CAAD@0YDUM'$S\CG>.[<6@>U9RHWRAP7ZJNZ,XSNB
MLLPC$KW)B.!X55<@SO%:0.KEY-V02_X/XN^:?G$?["<@=G=O"WV/GK[0]>K
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M*;J"SW\^/3IY\I"SVCZ)%USL<\FK()L6N6$1W__;R,\5AX4%EI"GX/<BHQ3
M*VYVB*!;^):,3Q(-!4?Y]\Y,>?J*)C_"0S?).MMP5Q%-:BJY16A8:??;2D_\
MI%]P'2'8*N5?!8G:=V^>GYZ\>1HX*/X%T0(>CI-!-YE!@S':>QIKGC _1]TL
M,I(462 X)LU[ANGI. KF$FG Z]YPPR[/,G7.5BDVC%185Z^XIE'6?+ "^J'M
M#<4_D^FX@[$@I="W3[GSA0G-5:R&@ '$ GY5B:IW2]]#FI<S4B")V2*9+(R<
M9'/^_,'4J('!(^.F@2T(3OD\&Z5D_*HVHB(8[FM(#R%:%+\\VWC/)X(%^BN@
M.\AWE'5M&":@@8%C1\'NS'L3DO@,\:\;ZZ8'XC%M_,D)&0%VR:U2I!R7-HYQ
M7<94N+-Y )K4M_4DOKCQJ+G5+(_6ORF=TK7+#=_+03Q7A$$B]S-HLH5>M'2?
M.E^)"/Q4J\GZP;/ 7@7HH5"RM:C%WT8TBRC44$BIW9/.'-)V/DQX[$4(,LU=
M^F3B?^%!;G7?^=+(<;6G>9F3@+W01DP6=%'>H?WB,)&( H)TE7#R1H6F9IC*
MX':\7QB&QB4?4L Q;&')]JUTJ^Z*HQDLN(9Y9-&0YA<EVT_TROC)>WQ4U%M@
MSPWR(8&">R1*V7<5=,..J^+Y;L-^O!91JSI!(><-V$=5][ F5+,MJ ANK[/1
M$HL&OE,C? M[M= @I]R: @Q=*D7+)/M4ZP[1C=DHB &>@C&/C?9!I\%<JIW0
M/AH$!$?9:_QU*&SA)A TOT+A.N,+"+=O6;@S(;HSF-K'-;!+3SEK)_?>WP1\
MWO0IQ/09Z[A[&M<Z??%60UCWT;3H+RK5_+=/AO[+J?::YJV)96P6DVF@+0&3
M$K%GX&-$/0N >;_=."8;(*R_+L6W)7\%8FMM:LI-8B:#3_7#3%&FADR]+/P^
M\#!@G7U+2S!@;16RV&?]N>3XA9X.+H;RZ"DQ;HMF5_=5)BWVW2BT8\9%1U5O
MW:",B=7: $TYZ'$T,7,7_!* :UJACT$.XH88X]8DG[(FT<"\^2KH%*X)&*](
M(A<<>2T+[N@"1)D13PFVUT#0#(P0/.XQ(Z5P2.=2;B+,!,=:X\E(#$PUAZI+
MGT;KN/2(:3,]TG2*I0K=4MJ!ZD%3>-!U;(LA&_H&Z6M:NL1K!KD*W/!&\WN-
M_[237&"O&0PA/] #72('&%.;2X:(;M&_ \<D?52T#VKUN$=,WRA=@75KU[BP
MKW&_,7U$OCW 0+9@(-\>8"#7TT?D2F-#OW"+MU,2+3#=7K#[[>F$GE9G15-7
M$H43"A,QA=^R/KD3@:-OD'G9MPJ2=KF!F+5K',)OSEIYBLZ'V#:.3WB$'9N5
MB(E (\CY4!FN@6NE3!9G$*5'"-#.)-Z,IZEY.8G\768M%TS#C+.F?53XNXL%
MA?MV1J%MRQHRNRW=YQ><0GS\<)(^>O#HNPD_D.S9\HBCSXX\I7KC.+"4S^J>
M'GQ>-V5^#C<+P>"_/OBJ;-O?8/L+55*JG>TY.U:79(W4&K=+4"9,2Z6'07:^
MJ"HRFB1.\9LBBC<*QD>(+Y38\),F&LJ;Q%T,41FD1*]2HN^WAQ&ITBG6JMKG
MI?N S'Y"&_8^79/VG!F8E9E[\6MRSF?.=^AH>61B>>"4^:='YVHB1&C\(B/O
MQ2/)Z96*WYI'UE>"%#9R8SI52><0&5TT]?F 8+@T^Y4<J&+:"YDF1Y1]3S:]
M!SP\JQWW[-OB]'.%!UIDCP; UCD*<'4N[7'RJI<N3:YJ,T_0# -16CI* )=!
M2!&_G%QBNZL2]4".=-0]KEW2%Z5$+D7ZT!W_[38I I;Y'U%NZ;VGO[R]?S4*
M@-]OD_O"&F;76=,[J6ZC,F.'Y=+: 65$AIQ&2(N.6TW.B$;KHP3&A(RILEY-
MBXP?])Q\HXS.^!+D7*-O<1UP:, Z>"?2JJQHSCETNZH#YS\C>_SU9@>%KNP*
MWL<YV&UU I[.NV/M@G</P"4UW!<7OY7N8F02U=QWU;4)ODFG(WHEOMZO<\,H
M,34'G%Y93U E#EQ+[O6JL^;6/:&5XJU*+^ZSJ*;_=>(]UP&9X548C#=7C2(W
M<BK EL":4U4DOI,W3LAGJO09F%P>/CCZ7Y/T?_=D #D8/_+G-O[[_Z9[I!U.
MQG_]&[[,PMI:4K4BS.5C4FT5-YUZJX'QY.'C>YEP43_\[EY^W^*Y3S]H.IWQ
M#8T5;/DT^%L$%[2Q"_P$^_@II(ATGN#^8&^?GEJ,4@!UNAK:FDXS:PRJB4 D
MHQNQ>U  +A>EI"[F/2GE=LD1$)XRPWX^; )K0QMS(<;4&&%*3T^/D[?2;T>6
M;?<7M'1-@((VG?@I4HCHC_\<& 783DOT+[:H\_A4&*LD$ICGY\?%8B9<+L<D
M:!/.LK2#H0U>H<_4Q8Z?)XN.05G$AD&<SQ$;J-#>MK \F4^;C%90;+I A?GQ
M%0TL%AQ$;I3+D;D8F62#9*L&PX;+)E-OW>QX49]9I\.JBXX $,(R,;+WE4>H
MJ&9U@Z[V4IC- 3XI?025?OJL;S#"R<Y5CVI6%0?PSS>_>A:GZ&T:V0U8, XK
M"KHYP<WO^<SZIX'QYUH%.?\G2XO\']]D__?!@\?H/IK]U^<,%#Q_]_1%^O#D
M.'WS_.W_2I^=G+Y[]>;MG8@ [);=9*']G[K7GE_<+P3NXL8'?%EHA2X.W U%
MNDUQ3^B%9+Z]X[-]3ZS3C:>=DIO'$7S#Y&EZP,0,7S@QZU?<8J6>O1?86^4+
M#X9#4LO$0U^XK%&=<[XL:,S$K:X\WPNFB"FK+6;]/T9MYRV .^U;= MH)TD,
M.?$E+MQ\S5-Y!4N/LP\B>!CG+F"^3*E\E2YC/-5(X+21 @(T>Z;!_D1'Z;N5
MH/[Y-T2VWSO?-CO(,+_VRO4S\<1[QMZ;PD#7C!L="=J^<Y)N1V5=<YU+>-2Q
M_^##'Q. >=WXN\_TN[_J=]_N_.YMNDXL&-[P,7L3R(SA>/YDQP+F?B]=;;%[
MK_P)^/N=D!T&W:8CQO>%+G7/+&]Q3K6L6^U,G\BE8D::?J5TUM+V2TB:SIWG
M'N!,LALVU9&+HO4C^^^)W(:<2WS=L%?"\5U'DN^,]IUC>X J:Y=*HD?_B#CW
M/ GDAP+RCJ3'__CVP7>TV"0NV*Y&-73=\+6=:91X^RO?/_XA?"5.Y@W>FXS>
M^S\>'C\B?[4L+4:SXT7TF6_#9[:G^*WTN82Y5%2]Q*>\J+VC.VU7CC:6U!0)
M<7:M@Y:I%HE<O&.62#!W]2+2Q4"*7LSX\1[Z969LQO]X^-C_ CST18L -%:<
MT5##[_[U^.'N#W]WG/QF993*=XE],G'!BB3N.XF\-$L,&/(:!9>D^,X8.,W9
MH#%F(>S#QDA8T!"CK/]%S'!)9JLYW4CB*':F-7VO,4JN#_"5GQ--GT>=H^,,
M.LZF]3&W5G;%O[%!NY/F$:O.LE@LN>^950-IIW/#9,9B5KK#J10%QCN>WW!2
M0(9KSQB$;'>;+L.%:C) XZ(6D'8]E=)$8U8![OJGI'0R[+AJ!R:W(RS?E8C8
M>*0^.3]N6Q8%WV4$SCSJ4JB<KSH0=;L27UZS1T0X 0F5: 0Q$RH<:1E!<H >
M["0LRGQQX&H*5B7SI8PLU*$9#2^@[S)O/8>CJ7;T%2KPFQM(TR"U%I<'T$B+
M73AY/ESL4 $J936,K3EY/N&6C!E7)]9:(H7ZS$EHL Q\HSO38H&ZJMA_L" $
MB9*F!MPHP@1.4E<MN>:'CT+.+8Q:J?JJ2^YY*KY6!))KARE2_&7N,J38)/+
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M /16GUF33GWA$<O$X,N'$W([3@B[V]+))O#0Q"D?Z_BK@='4>CR=>19&-!]
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MVXA]O^N#S \$=I?NG(S>I2AW0P!)&3?G&IV:/'FVPAX,@R]7J)AOA X>;4K
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MNO-46*2-EJ.9]:N6J2T  $)ZG+X4O'FN_D/4NEH(GRO9YC)CL3>D#D\^+P@
M,2X<>JS+CM'K8@#S.6.:U5B!XN#R,T;TD:S7<)@&>*?:Q)@3WMS;"C^P.G'2
M\'Y00L]_WOAD=RNK--%X=[BN$TY/A[PY(Q!P0GF%I<''_\_>F_:VC65KH]_Y
M*XA"U8$-T&I+GI*JZ@)<CI/V.:G$-TZ=>OM>7!Q0XI;,$XI4<["C_O7OFO;
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MIRHDZ#$*]>B\DLE7G+,-U:-<53+'QSA1YO9#.+2C@]5%+7.O*4HI=/A2-Y_
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M;P2R+[5!M,',V(=> 1:Z2FT0 \=U/];CQS9F1D%)V)$(O9=I!DX6$Y*W%J!
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MW<66>F=.NL]DXE!WU=0,19_"/%JH#9[(9?D01V/G88_&B=257TCI8N,&\+2
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M\?_IO<9\JJPD[E]12OV*$_#@.>F][5I?"LZW0QXVI8K/Y[)]'7%J#=^CG+^
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MRCZ-8[7*D;HSYO#/J7<&?IF:DHV]UW6#ULP"_ /KY2NM Z,BS:-%E]=]^#_
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M&T+<?GX2#E5BG<KZ#M \5EI8#OI6Y:PJ/1U8M1^[:NKK2,DC5#^0[&.B(YR
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MI7F6(^LX)ZN,\@'.T<;I?X33V2\?:<AHB6VN1>]%C.P9B-[O[(+2D-D-[13
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MV'=XW(2AR;-+&*L^Q6TW0CFQ@N'TX_)C+=-_+-.Q_[YG_:M6;\*K"1=WJ_8
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MW2N;>5AD'/6$ZX@'J11259/4FUJFI@&(LB21--=S=_/77#5_BH99WW(-*N0
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M_?Q(MG,I(BEVBYTC",QF:^8ASMK[2]!MF8NP/-V:0+?C)>FV$6#IL1MPX3W
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M;)]Q_5RW"[MN2]CU)?S5\\% ]*,037'QJT_HB68 'HG9ETB*>(M0<6+-!/V
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MT$@J_P,Q<*EC(&T82N(\G&"Z \M_X/=C;G&P[4"$=(04V+;%G?"H;>8AZ3:
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M3Q.K7A*FH@+4<!Z5]$X9(Y^G-%32T:@#(#*N=!III-6?WN!I:C4=3HC_8I]
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MC<PC&7+\&PWNP/-1B!LW#-AAOKOX<;.?/5MR!M)($$6GM .66[5"92Z2IZW
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ME-R)#2R(X(,)BGD/4STB# T\W2PMD@HHC#7C!B)!$SI&(B#*2#!_+OW"JJ>
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M<EQ1,CP'X2@2^H034X80\R*'HCFSD?PX(C1B(%8F.&%@#["'D,Z(4N1:LHF
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M-DCR$72R'=WC\VJ_)0$<H 8.G\!/_/J(ZPG4RQ]$$!'CR6."9^^=&)\B6WU
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M,1D?H&:[-S_-N]BQN5JH+V.SR0AM2Y88L2UAN4 "U4I$8_NHX1ZC5KZ73/L
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M;D=PJW8E-U '-AUK6]#\/3\(2,@8]#!U#2BW0:)$EF]JB7XYLPO-[,E;.Q8
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MVQ5!Z7@6R/',1Q9Z9Y>]^BJBTK%=T8Q4V?:"[4P4V/NHW4VGR%9")?L);(L
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ME#95UPDO2F(BX2<"F0FX:?&Q.^(2+PWI(R"2'/A(M6<7#+N(YX@SI1F"%+!
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MF+B6'#:]WB%@PB'HG?L.@3NT"9[$40;/J)RD-Q#646LP<3( \2B&^LKY??+
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M:,7MTFPV=KG(F@;##I^Y,38M^X+],=/@1^'<T Q3B+#OQ"A%#!EQL>T7(HU
M")(XA\PR5)RN9EI!TH@R&@L++U54UYF9%B%,5C GZ2<TQ>)$"I++(B^OO,8
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MR!KX.W0G>1,?NT5EP&@'TU!SO#+PGR:FKM/42D4-"/W+Z7@+&X<')%]O9);
MAID#\<,#DN"UQ\Q1#\U*SXM&SOC(#X[!3U\Z7(?+8,M+BPS^TTQ]NL2/1,@T
MK_%%FI>:P02Z>ZA29BF)L8T]WG]JI8B\%Q%I%E5$"&LWJ]D"!Y(WG/,U$N/3
M)V0TRK.VT**_M(AX^.<,)PIMM.823IDC<VZX/?@P7+;XKL'@(<<M9.5Y7,.)
M8+5H."$\ARTZK*XX+"UE*4Z66H63I7:Q92FQOMVH37W#MM/^*<OU_BX:XK?H
MT]7A$H??AP5:0V]U#8?9D9GCPNZ]1^F/WT6(]8'JT78>G-O%F8\QM8EKB3_3
M'$X.&Y#%,%\L=1&X>_E*Q4\G()1%6$/!-D;K1#=&]S0WQBEZ%@^:_1>;6#PT
M]!B;? MA.13QP84YYW8#>=L[J1IGBZ+,7(/(A(?')]W:/1P6WULM%=MI;Q_C
MI"N* +Y+R6^=ON3WJN"F7=17"TD**?G9.&VYA,">3>SGPMJUHN^8=[E5TSIC
M66U53UY^]\5EE\V*H_\ZJY51A=RK193 =RGZ:=VM8H@^MH]W5B%H"BGZI^AQ
M^0?96*.I+V/VBF4]Q=E8683?,2Y^KOTXGVEC>,5?F/@OK'3DG-?E4O9=]JVF
M%X=8;Y9+C3?"):DBU@U6+71)T$F6@<DB8^R,,4<:@2Q2C1852<OB+CG<RUYJ
M"PQU^WC-!A6OL]W!@PC[#6@>@&Z.Z,Y411VN=C8M#^-1\0J?X7JXK3DU:':
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MM7)N]5'F5A_6W%N=49W4KMO-6@PZ.<*8SW"@]8WQ5PU$4">U]XVK^,#QG?&
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M:5BF>\LG7-^C6S*)J:_=:'LF=I)$:TZ37YENZGWYU4B\PW?C5YE4/TC:=D\
M]Q7Q 4LAF;PTRZDF>4\UV1,=<W^>[C^]*A-$S#!RUAO!PTRYS)T@LAHE1-8*
M1%:CA,C*&R+KB&A8R7&MZNEPK=PYO.[KW>3.RTVM!#5CZV=:B&]PFO4SHLAC
MR,&&9(3*""_JS*BT9<P=5=.IEH;_6&BB0L:K>\$"F8EF@-VIJ3KE"S0^9I)*
M'OZC_*T'?*K2)T$- R:E*_"I J8@MTKHJV)#7VW/N?]C2+4J KHXQDJ+M>K^
M,?2IN7Q93'7 RTQS.+TTT- P7RQUL?=:^W/P09QX/"SY(98.I'N9PR3?N]T=
MDN^P[7J;$[>9I'?77+=/CK=6S38FOU:[/[K#?_.1\V0.?(67S*+&=.":6O6]
MT^.'R/S6J]CF'%KEWL'.33].QN,TO0>'X''G[+*Q)FJR6UBX&+D"8'VM**QO
M%YSU76PBJG;7=#/GQ?U4O*T7A;>=@O,6TZZ56O/ O,UY9S>*POUNL;G?!+>V
MO:Y.H9#[NED4SO8*SEGJ(*RW>V]J7[<*POU:FO[>0W"?0),ZC37E>87<V>VB
M\+96<-XV:*);)Z&_=2([NU,4[M<+SOWFV66W=F"MGJ:T6@1/7XO"WFP+0K-G
M+TWOK+?>T.8NG @4/)C6;)-'MJZ%I=SC6QE<\$A:LX-HX+U#,_A=[?&"1]2:
M73C%*]U#1UW>$(,+'E9K]D2=8;L\R/.3@8('UUI5W.2M5GF0[\O@@L?86K6S
MRW:EVUU3^WT:>SQ!27&\7!REM#C-S1+)7+W@D;U6_>RR7J]4UT'#):H<ST_5
M)"B0714].6Y^34NIZ:AZ[*LE*)RF.^\N0'09&YON4.>[%_UF_XC#=[IF+[<-
M. P[E6;2A,0:&<FZ +OHV&@G5U3YP.%Y_R&Y4,(H9.'9[1H.H$;N8LD9#6OW
M9[0;:Y!1//&K$+C8F"\XO0!S%SBH7@SQYJIEP%7X@ E3C=<*EEO2&'<%RS =
M;8[W1(ASE4K?Z%;^// +UA^-:([45'^MB"+/V'92G-S]S,7H[L@,\.%K_"SM
M"_9)M?E8H;7&32H?N? $(_SB%K=='9X$%%>G''%#@0P&#N06T[O'7,SNUAP<
MU#U'R#9=^XO#6FBD/?Z0OK==G&$O5BTGB"L6<<B;->X5ITXTG68BA&:6 %$-
M&I-P8XPUM0(_U<WY$/^&-,0704",R%UPIKD:A<]@#_^MSA>_?J:;C@A=! BF
MA/#A8-7_+S?5%@MI(DH?D^FM)D;C6LU5(]ZOEUP9C1[7T/$VAC1O*"R/CFQ^
MX,\<_N%-<4.:_:$YLRM8- B8M5JY7MM<FI[T?N&R]'8S%UC'+"G^C^'E[=W3
M0*EU&);,>D S\/'#X/?![?<!>QA<W7VYO7FZN;L51;6G I]X@B<7B9BB"26-
M&AE5\="U-8/#.?0RX^(;_K>K+4@G@^[%G_%QH!(=;LW]RG]U:G&AO2-'!NA:
M'4Z4L6N),Y S4/R:"1I9KH%@.>G0XC_XR/4:#S1C8JDV;(\1G7<CN1%LL8Z1
M.350KS-YR@Q56_-78KK.PG78G(/2(CQ.7"^]T4*U'.]7L Q2K=@[9 Z!^N(<
M1ZU.:T>$49W[[TLZ' X\@2**-_"61 ?ME!LC<230Q>80CUE$ YTX.& $#B?K
MF;_&/5L^ATY1^0JJHXSAK!#'C14B$UW\PG6=F(3+TK4))X$(>+=,('C&U#3'
MX:,<'$:R0.@UI%KQN1I:G!(0AJT2Y@(.2SPZ54UG-APN(&\OV,,$1@1-/4?E
MR8!J. 7 AEN#&S^= 7<L6)0.:P5)AL/<#B0ANG+BF 1F523AQ(O [X#RANU9
M*]$70;+!+X C."4*3981&!VV,)_PZ6.N:SBA#"]4X5+-&I^C9+S*WA98G[5"
MG;$&2W/TUPLE++>,FA28K@ZY (^UN?6LT<2EU7=9+W4QQ!52YXDR2(.%S3?>
M[Y1-[[]\1(=[,-_, 9W'VG=JS6R6K9DKK9G-LC4S[];,8^^[_3LN/VNV.@4C
M0:B\NXG4H^NARMOM[MF:!M$]3.X3;-J\Y8Y"!RN</C[M0.&#\QW&0O>/6#PQ
M_ ,(T<NO-?3ZJ/F2OD2D7(%87H*4'[3K<E4-[X"0<4+XY='62HE<3J#F4=C\
MRKX(%/GAEZ=B43%0L$O8[U0O7#SL[.STZ1_Q3N,_;'=Q^:$&Y,._^.HV2LLB
M0D'7ZKM5K@NKXL_ZGQ.XVYJ VWK<O,M:K?%>0+9K]=VJPB5E&WM2ME[?#H-Z
MY#;J!%4#&6[4(* 0B2>(G5K?O%/?"O)9K;Y;&D3*8'/?W5VIM;9+83E*C#BS
M6T6YY$QK3\[T6MOU[BE/!<Q.;Q#XM% 2C?>B)!+/M9-2V-Y3"LLQ@PD9LELE
MNN1*9U^MW<X,AS;'BK ]Z[].H/3KX%5?::H5MXI3N ZB+?K).VLZ%G*HW"JY
MG>EXXMVX3?WCC>;V\2XYU>D5O2YO8]QUU_5N3#LMQ6KC([ ;-#/<>TU^1%EU
M)ZN:<?9SC)N)RE@SXGB8'9E%R"7..HO/[H!@3DS3,4SP#>6Q6?O3^^2,_9CK
MO^@J,H8;Y]\?\Z@4$=GN^"@2)OLUV_$+,#!G@7_W$Q.R-(]-W?E<PZ?-*%6A
MPI:$1UGPP5!U9L#O^1#^KILTGQ4^A&=;ZI0NX/,%&UGNF"M (-R@\C,-C!75
MX2)=3I^,82F:CA\&F? 0_60)+FW"8 >60IZ#D-=3"WG]&$*^KJ0C+.86'UH@
M<?@]EI3@V>3JJI@KC-4CH7H,O_0UR-/96 <2_R,+*ZXL*J0JQ?>XXMM(+;Z-
MPX@O^?Y*6#QE;;-?,X:5>ZJ.W\RX^OQ*HDRU=6AV!35^7@E8I!(O*+WS:J"$
MA(MR+ML=>C\P+3NQR,;4#K_94J5=:HD?^10Y\< 7IH65A9L L+>4$2>X5;C:
MHM/NG$P%<7>Y@OAQ\.7;X/:)W=Q>WSU\ZY<5Q+G7IESW'S\I_<<K5N]6*S0U
MM [OI%U*J6.^V%5@8Q.KZL J,!AA^VOV#)X%?S7&W@!@T%#R]UCY2YX>5<0.
M3=>1W]$)9XO;VQ?,;]M2O,]DN\Q$%-[:5$MI&O2-B4TRC!++"TNSN;PQ-<S
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M4%"R?<L.'<E4\PD;J&^ +Z=+RP\/ZFN@))#[_']D2\YH!OXO:67O"8'5)YC
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MZP96Q<>?70N6? \4-L=$#QOH3U\%B'C5T!EETV^BQU3K[+)>Z58;E49C-1+
MQ!7X/O+=YR:R'U90P34#'QRR^1>2#\H"5#.]_^;)]CD0@(HI-[__RAG=/KOL
M-FN5:@S07(7!ZVUYB8AAF P8SW\)).P]$FO=2N&MXOC5P4E-C=7U,G!<!;LJ
MS':'_^8CQY-EV#<R_@[+']/T=IN!28/KA>T@P<&\O7+!$(!,R#9M*,T.WU",
MVU:M5P5+YW#'!#>MP&4R<\IN__4X8.IB89G/JG[!^C8M,/P@L;V]3<0L/N)8
M[<<6VG3ZB@XL?#35;,<2%7QDZ$67 JI7U0S8N_ CC<A@7PC% *]KX;T=;HS%
M!/$A9_P'G\,9,;',>?36X";+M3URL/'@9> &_9%3P4W_K%F.2R*-/\#WT6RB
M('P"/Z<;-#^H'S_4/RKBH] =+L+*52%3[1_^))GR1"Y/Y&*=R'U0WV*>=87=
M?+EB]["7YBIL''@&[B,--N!5_^NW/GX#IVZ=P<8#]4]'P51S9*VMP?KZ?V8<
M'F>1B=KYU09%B<I$4TDIO9BP 0WSQ8![PF;E5%%F:PZWP>%S'9U;RF^FO4#4
M./\&W_C<M%Y)C?6GJ&'N+2P'GK,/*NA6?+"JZZ^H1LRI :\5NK.H=6/J9*+I
M&IS/8V$'X'[^0T67#M:+&5MXQA@EASV.9J:IPPY7/EFP2O;= ,UDP0)?/^+;
M/<S,,6<WMDXY3?@?WNG;S>UG=F, 6QP73  5[J8!)]@_^8MFS]AO7-6%LKW6
M34L;J\=3#4L8EN="LDN%42J,W1X.=H)"L1$!,HI*@,QF4 UPW,*NLDWYL<J>
MT3HC.QE-@A]@$CD<=NMF ZO6K.YO)HJHS6^PLFO3>H1UW9K./;@9=Y//FKTP
M8:5?+--=7"W%=#;:B]VSRTYUM>O*+V6O^-H =1O8;]K",QQ(5_B4>9F9J*S
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MMOF^="^_YK'6O5"0=N&X/:E:;U?^[#V"(O=H<DC=BUEY#12 1<5)W^!_GB8
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M"=)'(B+M42R(%7RX[5]]_DC/43QM-]%=F2>E ,' F.(42[%JK-FS9Z5=<H0
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MAZ6CII !RE96<,@41Y9I^^A2P)&)%:(K.ES @47#!XKNB>DZ7P%H""3<Y'U
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M#X6^R^\)7-4-P8^=P._SGR6>)T4%J-\"I+4_V[BF*NDS["QI=!M31K<%J?:
M- WUMJ8K,I"Y0R';S.IF<8T"MR^"J3#54@SX3/$_#?_1TSI8 V9'<,_S!Z6&
M3FOA.>W(G/X+O4[X=[2%,C-O)#//KS9$PW#\-'3ZO$_-@WJ33'H'ZI:A>^2:
M*--T='^E]@MA=4&>%F1N@@\^,F1B87,7[L<BZ:+RDQ9%T,3R&+0\$FPZ(\6H
M-T"#KWG0[J"^LD8"U*8*V^AQTIJNV*$=BAG2W?K1$^[0D4_94%Q"&C\8XD2
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ML*@%XMER Z8'JO-%BDHCP,F5"KO!/8#!2OZEV6C4&HU&%9-ZON]DO"U8Q]Y
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MOV066V [_-]<:-\[]X/QT I&%E3_:[1;C7]U6IU^=]'B>\3"0>",X>A72A:
MO5QHT&7\@GQ:P/&".=%Q:(;Q>.P2T5M6\DC:.S7XS57R"Z84KU2J^_3@]F9(
M:+-1;S3_^M?226ESCVO59KO!U6JSL7AO![^H[=/P+T>>T^>"PNU;+E8@*%?
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MA%-LC;;Q;O9-$<.W46O-!OC6-U:8-C%F4VC]UFPT*WG<+'E\*T77VF3!6ED
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M!7WOQYW/8,*R*&!$.4E4CV9Y""JX3# ]Q+M/83N"'4SD'/<,-^G73".]G51
M=D"#19F3U6;"PZC:OX9?2J260F8+,9$&?@[*T-*:SH"BE:-#G:$J)<H;B_UL
MD6=*G.L<:!R'AG&-PLD8H8D9_@":%E4.TP!*SS.9B$3+B4YTM:!3C_(:=-E4
M1DI$I4XU/@'$*!.F->2S2GZ&*1K8G[PV0&:XE!QHZ8PF,;+$(RM<!7[GB 0V
M%:B^*-4Y""?!JRB9^G"J=M+ C;"."+@3/T7>PW?.)(QC*J M;68*QX?E?. A
MQ*D= 5]\["GVB#D"7BF-T:8"7DS$H9L+;CIN<++ 9^>ZFL%,9@KXKUE*A[?B
M''Z6Y15R18(;A(>FP6@YUW$-VP2\5L"/M-U->'$-ZJ6$6<.\>&_Q??0R^FVB
MSG!W+3V0',JSX<#NC"./)\E+S:Z34$$1]F=-0@W/,TF&@^8D@<R01$K8S3(&
M26HLX\%9%KG13)0)4!V8D2!*IW46,;>\)\$*@MLH^QO_VA$=$*C0U'&=?U_#
M>%%2Q\C1 8'G4Q"^<.;,!;$N@=UR_).?9DG*C[2?8 ';Z"J[*N"XRF\!+QWI
M(C,R8H(!,L;%-[)CA 3DWH4*!P2'J?+H,TRNX-^@0FE_@V(FAQ67H1#"<5,)
M_&U,K<2TS%-1P7GB-/!?NT0XVG.):C+\*>E8F #IN<[\4%?0JVC<&%6)7VAB
M\G"URU*1)\F2$3\B#J/G(EU&=8K,%L'G<"X@OB8XO$KR^1B\BV8?D8?SC&DI
M''Z>\71DYN6$V" FA6=ASR8J4W!V&O_>%)/:3K@SRCE,:#[3H"O#<=2%*B-M
MD%PB8)@R3W!$/GXDQJ?'Y$>) L6&AZ%879!(1$W5TIO# 2M.R]^L+UL"4K!5
MY^0^GC(=+6LX4,4@H)'OZ@I_MJR21QW1D9'PERC$1VS8P$^&@] \*I4SQ(#_
M9'LX:[>QN01J"STWL?_SX?&'=_N?GN YWZF[\9LL,SC,7>NSL<MQ2I9J2_E:
M$1>H=ZNMVY3C=$S@%C2$5(+* ?X$)[%"Z@,+(AC':7VOKL<P[=#Z,^)<E@L6
MFVB3_0'?F5@3MY,DSUB6X;M1RD8SF9TI%A\H7M'V *D&:X)I*!)J2)MYMD7K
MTBCG1 0B9J*<+892;@HB$;1+)9$P)T#S@:416#8CFI.9D;5GE/H,SL(YJ"6>
M+S\.IB"\/,'%J@(]Y:QRNI;<I1)U4!08L, 6$IYHL0KLQ&K0/-J.L&$J20KP
MBV#6?W^V_8S^-H6,W-]W$=:I>N8#G\UU7,UPC=O? 2E7I7L7''B%#IM;%(S2
MNTJ,0+^M8O<S.]RVSIYAD#O^L>>[\8O7.FL/EJ@I<]+.F#FH_<O>]\+3!]I$
M26YJ$'Q  C\#IY2@!L4G($?V(\$8]WZ('QBYM"KQOW'S'Y\&'O3=/P,+(AM:
M-PQ9>:J1B32I%F(4BB<8-"=-Z,BAKX:..SWK99FJ--I9(V=M+-@"8S$RJ8W.
M4($!#QIB<% ]<Z!N_+<C"=OLB6*C,:936!*(1R797V)AUTP,_EX #8$4#J1+
M$/Q HP9]/C\=\)0RZVQE&=LZ7HR"@<ZF,XI8"@&'>V2%3%Z .5RA*+4&8? V
M,!HSD%O 0#A W*+1UE#A$F"&($4MU89?H!16%^@-T,'X$%*S.6CIP<%3@ 5>
M" +],SFYV3EH!RM:Z6=PP/;/U1!^#_KNEO/>;)Y5-J"N\*!*I:KA@"CATI/"
MG41;'9^O@99TU<2M!+G@!NTS.&_XQJI"U)\SH,]XY TP!;Z?9"\,M;BLP7^J
MX ^88@:<@V$_]ILJ>:&MYR9UB92+(8_W=8D<-G+3(!JZ@K[:Z\SA;6<<OD%=
M4R<2WC@#Y6N0$)EWYV!ED/$9*]3!R)"G8""<YSH6&"QAY5H4L"S2^DARJ>.,
MOCTNU;1$ X"4N0U!PO-@L9"!S)H>7I_*SVSHH#<(&MX&0[VE32$1=)'!.#'T
M"R,3Y8R ( ;Y](@<C;,*XV/L?H#/8.5.1T0Y\3X<M,53ZE1H2[KFSDLI._$Z
M:Y*5=4)A-'C'!&0TT#<,Q<YF9$_>U FQ"083P!DF\O0A/N^/+\FVL3AF"YK%
MG,[0]B5?IU?,V_AO@?'ED16 +,7!<5H89"]'WL:9AU.= ?EJM)F1WNH,M2#I
M&^"5%+PIP0JF;_O@D9E,IM9MGY5Y?0:\75>SO 0'(0X,\E4CQCM*Z%SM8KFW
M_M?6EGBO51+OBB,0.WLP-#L/, .QM66Q$6]AK_JV9N=%C^WZ!C^;@$!7I?_L
M'R![/XN=\6M8E $7*H8IG.[_X^.A>'?X\>/1_@'FWLF>QK]/CO;?N;]/3G__
M>/CW9W8\S+'(PL#LW'^US.0^%_#TV(UQK=UL3=W3 _<+._3+E]\UQW5ZT/?$
MJVN?P#&0D6X4@X9#^?V04W\XVO/38_P_W##X%PZCYUR0O3]O310(!UA\08<9
MGM6;GJ/"\X,%=\B>W(^0/ENO#"CF.9(,4\E#$_#:5[O<5WLQOI&3=JU/M@K^
MV%\Q]6SS ]?LO\T:# <:S3Q0A:"TI.GX5NAT60>..(#U*BC2.2EW# :1L 'K
M#P2,I"R:,^+ _ W4<*PB399J$S4-3;GA(+#E.E%V&!)TAO$6.$T+\V]HBD\4
MF*.8PK.Y/VO48$:.O;,S!38U9K5X!] =-&P'S#5'>W&!L<;T]+G4":[39\/;
M/QY?%V? (%9$QO\$+5B8NQW P8I&Y-/Y#5V@H0$>'IA4/&$YG9)Y-5,V:(O9
M61U=LRMC<:C);N?LTCD9QIDZXRQ(UZ,DVX:7L6*6R4.\^[>93NB$--,/;)G1
M2-JP^\P&PP'&&2+8HK/<);[ZC.,1G)Q,'5*BRS<4[I">@-!.'@6>F.,<%3=C
M$SP#DV%)DL_-[G#PWMFGUHJ&Y7)0EDZ?[$N%(0F;(,S4W";J,3A*&8:2XA7$
M#JDJS]!IA*<P=4D!GQ*6/,$8ZA1FD)V9GC&(,?T@8;!!1C *9S,Y<V2:Y.8E
MSQE^D((3Z)Z@I9ZZR4YD]KFLBRJBB7G;''P%^'U,O@+, XXJ->T74(@$O9BX
MIF.44879;\+#8-Q(H6AK B C<8:N*"TR'"9*- BJUA8;E6GR2C,P1%+Z5E71
M$^2:#^U0(#$.2S\@*T5R+)(UBG'F+/#W$Q9JX)>5=4KYY%+4&>6:\50-IJ8X
MDV&],19X%$49BY^<W!RU.*M1'IS012P4'")R(?)118EN#+, $QNA.#=C&O:9
M:V#M-OL!P<PDB$E2).#S_5G#Q%B1&(5P$UP%16 F)B\GO*3.?$4US\6TYE0X
M32_&"(><5H0GP9"E,;4+E4CV4G$)E'!T^>;?,+,'6Z4X/*HNVDMB@0(L@) J
MDNRI_ ,V]2H^))&293FF8.(1G8Y5 9F*8 XVBBE1XB Z2W.BD=/J4XLHZP0$
M)NAEY_AKW@MG$U@P#J6.,/6-V2N8,- **# XQBGM(J8OX7 *CA;!(R,*_QBR
M&'R.7:8P94KN="=E<V!Q[^Q<EA^'Z=M(._WP:!F"=]79XO?L]H3XJ#8*H!N-
MH$V@$%:T(M"SM0<3># O;^;!=%SIM<=RK['+ -K4R8I[5Z6QID'!.'ZN%];4
M,4#,)$9\/@HCD>2UD)FG?*B\SXQOQ?E]B-&--/9Q%3NGX:"!!Q*[$_+&0K#<
M.BI=%,W\68JW+,A BCC9X@*9A!4)!U*Q'8<3 LU/&\0B_18,-5@W"$!M C&[
M]/+5$$L/^NY/>0-_PAT"0T7.93N#/!STNW:!Z6&UW,B"I1B*A?%>^]=& W?S
M@6%Q;-$<1W2NFR.Q(3?;B0QELYN]L?H0KK8QV11G>KH4 _>AZ=;#T:90V1D&
MTA" X6%UTN,^$#V+.AAL8'R*M)FLNAG*C7B3[.]S1BQU'L \ 8?60U!3,+<0
M;\CRBHAX"@Y6%IMKD(_2L8'=Q.& =[$+?$3.+W(P0\'-UADFJ8']XU)9"+!D
M++)*$(#,$"S:$D\4?@-G.,@,U-]>&X,/CW-NPV<IP'Q $ZL)%/#C0)0E4*)I
MLB%-2HQ_0-\KM4<S4X:!6I<]G2%:+ZK!R'J"7/LA\T;@B.D"G>D E=G(/^M)
M7%Z;T(/8!,D^#?8[GQ!2Z9I #SH0D2+O G'Q,/T<'"$PL($":YI8B61;Y)7-
MQ[I'B-/M$TV^U0'KX]RJ,D1D(A*!K5G^V",8*$<-0FCD (K>G3'$F8@ \QAP
MMG@I%L?ZR_&W>^<T+_O4D&=&H$]Z44DF\$C,U'-#%O+"NH$=$49ZQ@[>)[]L
MFK<QIKO)WD:6@ N@EQ$?+K36"NAEN4AR<-O+)K8E.A@25- 8VZ'D,Z+HT@DA
M=;NB##]PJPMB9<(F*CLA-'*?+C_2I\BOTZ[XNJF.'3&:ATX+B>TL)T'IP>6.
MOTL"4* 5'"@ZBTM =;L+*GB3\?+!C^>2P3^$J29B'@X2&R)P/MPU;+\' \/(
M*:@14OHAAX-NG#;N=9)C%IF)B)U05_T2S@F+MA[GD& =/5O4C0UP5%ZIU ZF
MR8F<LKGC(9@6X!7:/>#V*XZME!*C[+QC4]XR5^<S#<*;.,+FBC'+JB3*7^R)
M7[A08A>G<*(L[?Q;)C5^O<ZCWR:/WE>6"H,%^^]V?D^<+@J8X'XI)SK:$Y]D
MJOATP)& /7_1RE6[7^$WE^?H^Q:RSMK?4];^X4O$R#+U97F^\*.3Z9QRE5-0
M*X0DX%W3$_KR"%356/PSGX-B V.2?^%3GQRMCFPLU+F95PS506^A'0W^7%-M
M$%@\!N-^G:HCZR[?*)+RX4D'&<)2033C=5;;2CE+#1AQ7G8YKZZA8^N&\@EL
M8/N#06+ T)E-5 3P96^*&E42BM-:L.3P4 %1X";TA4(N\WU<!5+G9?8U-@@/
MRP"7V?LJS1Q-UX6PY=Y7&'?>$>B8ZLP(Z U<ZPP\/3K<S\)28$\OI3($$H8O
M.3/5+14C"U#:C'@3.7+>VBTBJJVDX72$K04P9Y/;8XZ4+BJNSEF*B\[8GYPQ
M?<L$$1H+07D^)#?,R#6>*DHW%J4GA^_$,8K@G>W)ZZV=L3BAO%G[49V=Y\DY
ML@,FFFK8,7AIU 014#RW8!:<? /_8=&4!09;Z\4]I1$92LY1,RZ\Y-K2#GH#
M6<UIA)C6"D(72TZ' P= )<N$D*0$?Q5G>8YU\,A0%,U": ZEQ#P_MOD9I[1T
M3NCQ7R>S03X,!XN\!N8U,\+>NGW'.&:SO:UM'0G\!<T=I1Y(,A'6DMA\KGAG
M2[C0%4#0CO)-">AL:&$8M#XGCPKHA: X'  Q^3WW!_+\1!]J\FZNZ)RUSK!=
MGF%[=;,,V[$R5:DCUVK ^3DM,_AD!E:P.)&),NL,W'VM*8B564/0*^4Z<Z7B
M,9<AL2EJ:_='PITA*1'\!C4*P^V/5$EB!=VBX#M7: \"$%$1E35,O+#X",I;
MG&(^\$.&#AIB'8Y(QA!BR=7W&S*E2;""9_8$5?P5AU;4B&2223*B& X;@DW
MQ5:$N_X+K!)=;BM04VB^82J45;<K;V"53K4\5\CXL=AWDMPK^9:52V"<)J5+
ME12@]\ZP&LH"/#@QPF$[BI\%OW_2!VYF"%+LE%4E"# LP81 (*UO0[)J55%K
M/1GHR=<WTY,4ET-&M)&@C::S%0K/0 1S9M1LKE7E?:UI>;.Y_08!+]+< /\E
M^K/BR _Y! C]3E3,R77P5#Q$W2>1IB#3;&;,?N)0J.1 8R\)'[AI%QRO!$L_
M7C4O)8QP^X/8E@0?"M%ZI3,NSU6GO\:XAV,<BJ!)'G&&L _?YU7>/W)9QOC
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MAL4K($:V;_1[ 'M$?? .> QXJ^S@LIG_X"JLETNK^&>I?F**?YTO4$L#!!0
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M,RT/%JKSJ7H<%;K3QDX3<M\ F7DNG1/B*_E'I)'RT_U$0D$O9!<A &QO*9W
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M54C=X:'P(Y?!0EN*V&M(<DOHIA/8"6>B;1E,FANQA>T6ML_V^?C-P5:P5!;
M!6%LCH,(F$V81K=I],LB!4UQ)R%'%K&J$O 9L-;P^0A E49-6 FH$,P)_DK-
M<5PCR ;DSF4C5B22)$<TI%+ (L"K@3"_GO4*Q=QF+%5Z;*?(-F(HK3,<*W%J
M#(I#S:@!4#O59DG=+42W$'VVS^]?":(/&=AL[L[OC/U4Z3-;@["N9XB(=)I*
M7.[:/>_K?<:-\+ "2B1Y [R?"4N>(6U&,VA8#B(F,J;K1-I8:5MA'E&TT2K
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MZ_3M4@$V5 E+0)0.B>F\.98"@*J3Z=DAV%CP1TJ.0QWJTV-?0_MGT].'46O
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M<:,1W#C )\&_5_&DB8 DZ@9,R5_J5-23E[N5SU6U[[,;!%6T_KX7+2BT7_J
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M_<./2.( $+R(%.%&:4A 4')?Z*>-T[/QK$,*^UN\&:D7P?Y.3)+!>3-7'8*
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MEVRM4XRKW42A@- %Y]PK_O*RZF^0"3_"'7],68E-#:?[O/O5W+RFJC8Y\WG
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MXQ[J*W0?E5]<>9@I^/%5LWU?,E?EJVSC=[2_A:.T;XV_Q>TK6UJRF=GWT@>
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MH9_4JA2,?#[LUOF*82*Y13!7XHU@AGA@J^KIE$/'Q(JR<M:6$_V^ULW&XW\
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M[%FK"OUZK>)&<IRM]>!-YU\UX;E!!).?:8_[!K"0.(,1,:ML.G8(WC;HW+O
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MB/,EC-J1AF@?TM=62K2B]$:HS/I7@7XW/BTN.]G:/X*^>]K0SB'C<GV/_-$
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M,:Q&BP/EWF8ARXM9_G'OLG(L[#^4M86K&]T C2L)<PR-!Q+9\#2M$T69'RI
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MT_WE].?10O?.4NKR#N[]]]WI1>35EOQHMBO0['<V,QT,&%BMH:1"X^(SDT^
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M>/:2B_Q3%*_DI"!7/\N65,AOFD+'6>I+>)#>@$$R'XE659Z;QG?U:O9NX5M
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M\XN%<=GT#+T6#T#&%+%!B1C;33(%+S%,=%D"MD!O['.#H:B+,V&DI=51;L4
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M.^&6/'Q=9Z"=^M#2$?Y2;<X!EI&>^,'$;<[Z5E*RQ[&?ZION])8+#[TC>6*
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M;66N75* 6^?DZ6YK3<IE_@4P[X#*T-ASO:ERR8J+AP0=!%W8BYPZ;R\6GYV
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M$YY*"CTZ1^T\*MAGEGB?(N60.%P:OK)8E+"Y(//#>UGLWT<;\>S#O2NO1ZB
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ME+FH$6-X(79D\N=6TY2L_%.O#]7WK-O?#='JE-*![HQBHFZ6J,^&!7:KOI2
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MBZ4?\>]^603XM'V8^)X!SF9+Q&W_MKI6"V=[9T'@J]SH+QY[2?M1^L$J6R<
M( &.D2"=C9F*JB1Y&I<HFV3E'&=M@H8,1H=@7M/GY#ZP#,:T@*.X3SHQQDAW
M VO+_U]6_O\@>@=T)/AM+Y=T0<'2,^']EOYX<'!)!-^*7=<6* 6XZK@_\.+/
MJY#5HC],1S=MZ=MOD^N1=*UZ:[9A'<QKLZ^ 9&F(IT#U[$ET*BTU<#ICZ2P6
M/[^L)5R;QF'GT=SX_@U#>N2)AJTJ>6KUB8UBRQ&+RBS.H=A5723B8,YX2IY7
MQE-[)NY"9&6GFRB,WM]\\\$YVJKX7<4L_V/%N3UU6G2X3D_%G6'?"[?P8#9+
M3(0L6KGY<TD4WB)"0G+$=<V;10BT)H/R:1U@([TOAF8_45")IV>&%HI"QGA\
M4,_3<\PRUCZ.,YM16??7"2M-H>[6(?[I(?&"9&']_/ 7*_UEMO+B\<SZTN*Z
M9\#)D&>W;X5T@0^#?8_N0*MMY\?7_J2M_P70Z:Q>2H!KN?J2MM$-!E$+MS*.
M:8/U?UL9+GVQ[:2,R"1RY]%:RA>+=<P.[/60?'LTKK6SD!VZU!DF!$E?(_S4
MF*&?+^3S-%M":H+5"BUB7ZJY *^GGIZDU]&>;8PTL)O)&H!^.#YG7_/:&R>M
MKZF_^8"V[?$7I+^%ME^6.K&FX<!^U:LW32RZ(^N92OR-$'7.050<"*<2G1'2
M7##]5U';D^V9 [;<!'3>^W&J%%W>R#55UA<FQT\Z>.'E'F!NZ<ZUNTW^5+N-
M9=H6Y)$!V<K(+BWF]PY5C5FF!EXVY5SR>'IWBP[)XQ%IH6A?:1&TF)VWTA"'
M*B6?6R5C-)JGA9Y'A)%(&$+Q/M'*N[8[GN-+,"TQ)9A.%/YGO^';V]G_UXZE
MLA?7]PGW%8Z9/5[6C7-@FD+8ZR<!J:7.#7Y*PD^; QTK1111WWMO1W9]HIJF
M.)O[+A?=KJBO[N?X+?$'B"=^/<=]*_O^:DZ5>H%/<]UE>6HV3X5]QO"E8!#.
MQ=E6&G15JCF<7SG3]_H:8[)79<?JWBY5FITOS=,+$S%8'/1I#$.:*EX9*HNW
MD$/TR_HF>>-$.>:_KKRPT?UVKY4R6,]#CG1B#6D<R];A,\'&PMYF94(DE N7
MY_0'R6_X4?POT:46J0EXM]F/B[LJ>CEXQ[14B[A6%5R88FIL\7::S,IV TDG
M@.5=[#!M8WYS=1,F<':.L?!SLTK$;0^R^]IX1*L"9L(B#KP_/AY4 C1C*N9E
M8Y&)^F#TU=[+ 3L&!NQ6U(ZJ_)[?.]A#>DHYPN*N?01/I AQT)AMJH<_'PJ\
MQD#W0JGB?N>Y&335UHPU' E&2>AG:R!HBY:>_P3-Z(^*LIJ?+Y74L;OPW#V[
M)9TFC%Y7)T07G6WKTHM/E$ 1$) .([B<YEV:Y$;3]S$FJ"]4#^H60L$$ 6+_
MG8'_^37- 60C9PO;-M>G<?/9I)SU"VM)J>71-J);55K\QKA+OAA*E]:^U+[Q
M_>#6($I(QK&A(6H?]E4Q'+5M:Y>ZA7XRB=FU$]FD\379*&QRSL3K%UI&',&,
ML7&_3GW=ES<[PJ.[X5UC<KO:(*CJ<,J* BR92\]U8=.L?FG"P'(>KI""%=[$
M^47KV&: J3L(-.<_#!H44MG@^/(Z7%W3[QX:<(AIY3MU+E<MZR//'&S1KK52
MMOYWQA3!+Y6)W/Z]#5(<_"0C1U[WO5+R+?6^?G36K>O2QSU3)5&$RWE['CM]
M]8IL$*1B,L'W.]DG-DX2+% N#I7+VRI9,7Z5-:4[H]ZES6+V;6"2DA5^O[&P
MN;'F#!N$BM&L4(@6>,^;I.D3T,]K(RI$"=0L XA9S"AR:N. 4PB(;9EC)5M+
M49W!3SU@1I#<WH+_]ZD:@U&UN0O:9"-M@?#_KB=0OLO1"2XV4L;:>2V/_W7G
M77%HS@/^MQC&&)1\I]AJU0/3-R@!\RM4DAP;()L/[QX(B60LOZA(VVE&G>PV
M&&J,#A C0^4/Z2ZTR4WG-]%IJQ3DW-/-(_;]%POQ;\]UU3L(&K$;M=/!C^2Y
M.??V:6H;N&RJ\$,Y I'6EHG(6TG>"CB5OP#$4\VC$.]V.E)NM)=?&[MVE!7Y
MK>GD21RSWLQ/4T-8T'?)#S5-TQ4XCD>ZA/>BC0@5=?-^2(4O,;<SY.V//Y-_
M :0.$9)^7-!14L\*@^W5IQ</&U]#*G3R;!YZR8_(JH358_]=(PA=!WY[KKG2
MO[7331NU+RT<W5Y!EEG+;%'R4M5")W5FA,EHX<6RJ"N06O=UY6;_"4EH*3_"
M_UU+.ONMIW\!3]&)Q#AUP;5VW@&CS@'*J.[-VB.E]_;NLY4&[+E;:(\:^CAS
M%"<\F:2L>O<,SM5.+]5SSJ/.9DH8WIE>O^7V%4/"4^N*C_H^43VZU:;RI<0(
M)VZRIF_BLR1L96U!SRI/R0-6,95)0<SUF9RFB!<;V\SJ+?"RO25%]E@\FDUK
M, @L65F4\Z7P%L=]:,00RD(7@$_.?.@F(A/GWC19LNY,&]D./QWIX7YO8NK=
MF-&8WB=/!3,SQ.!&UO5!8(;8%PLR9M4M_O#+5Q%<$5S2+"#-9$M]J](Q/0E1
MD44?_YVO9HX5_YC6._._397_9\ 5*HE25#V'A0,5[BK.B=)MA$57+AZ+N/VV
MPN;^!G22KGOA=J*>(.1E\2A=W6BWA:5DS67&PM;JA] 5! .%<\QQWE' (Y6
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M]7KM[[F8@]RUR@2;\5YVIH=JG^O(OBB1F-FO#!NA*QK5A38T+^TA%1C_[^7
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ML"KWM$N'O3QS5*$]->8H-/TW[1L/II6__';R]E<!SY>OE_0-2=*-?G_!/B#
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M/\4Z\FJ)'Q$P>L,$?=>'_N]G:S_Y,F.7.PZ]ZLIZBIM&I#= I])EF: 7ZVC
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MS)C&N?F67XGF&[7]\CY**:)R3OM#AIS/,]*YQ';U]W_-%%%*6>"II$&/N1Z
M&1SK$'I@NRM^ #YMM_<1J#LR9(R7J(T1? RA.IM8,N1K(<E-'GA"82NOB<PF
MJW7-)T;+ -DO #9*?'UEPB4FB.SRH#<F=)@;H/23;;38ZM;:I372].<1,_3=
M6 I#JW>R"A8?X3RM&*8DK_O76M5.?\&>/6*\O-@"UN!IEA51Z#:D,MBI#94D
MT83Y;ZW#BI5'\?JQZ_+-Y!?8_H46!7QUPXJ<C6+H]K9VG_!@/^YHAE53-A3T
MH< O"!T\#@5F(=0)21;KE\*-F: /Q]>8H+2IG\/4&0970*4;)'Z.CR;<J28
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MXZUYJ97Y<;$$>#H6I-EM+/_3#?UU?:N_W--*)CYHNL4NYU'A4E:3YKZ:]&1
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M2=L"ZU>OKQ68%=[U&E?>KL,)YZV=\^7_&41!;*H?N=-MLO<:J,-I+VC"J64
MACP_?=(@P/:(HAI33K\*/ ^HC21VSLD<8U!7>5Y&%FRX-(X;*N!6?_HZ!OM%
M0ZCAV0N-"3>2=_9O-M!.5L[E-U0Y\R=$+;FHGJI5+K7C3XJ7)3RP;E"PMJ_
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MK 3ZP=P UTQWT"NZ-02,0D [U[3A;#[ADI=HWO$-1+&9M;=K#_*30M-T[-[
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M3JEN=[SX,9P 0J*BOH018'U$0,@D7OCP-A&0(P-?(66%<H5P.\V -!T6)XD
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MYWZJJ''S&2-_WNC/E"SCPOP?$V[\FG"*CTRNIA6<FUS73:LLRVFIPG*%&LK
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MF>WG=K??/S7%05>Y#,#-:8=_0I2;IZ6M]?T^8F/#379N(\?T\Q)_M6ZKKZ-
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M7A59-I:5NIQ7*OD?Q5*LNL9FW&YH>FWKZ,EI*/K!%H3O)'GSU]BKA*@5#B(
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M:5;']<F11X^RY;(WLYU#\+8E 4-YU_/JED(SDZTNIUH&<1=%^D.6L&R5W3M
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M/WVX&,\9GMM#4F<$<@Y&!YN5D I'C\OTB[IS&S",B0^0G9T:/NA[H7$EKV]
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M!#Z_/7VIKD\1"@R4\"8@<IW2J,W=1N#5O/;15:HX3S:0!$9#:?"O6GM]8K,
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M8>;W0,2-+)GY=$UJ_'^E?TO%\V3=87E';OD?=H?7HA(3MMO*]32^HV]6 G<
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MVB!@Y*IME@\WF'.,#\K09\[P^C15^"#+OE@1WI2QVD087 )([W;-(416<GR
M5T3..6:*N''IT;_G+K&01<VZQ42J_\0,(NI!G&@UB2*7@U5?G7[%^VGG7Q/G
M@-\T___.E_G9PWZ"BI[?>YG95XM&,M/3.;XT3PTZ94W.-[%' =HOL)^ZU-.P
M55=L"<(P"G7TQT#ODPJ_I9$FZ9R]X[_:_^LR?QKMNN)UWDR"1@7[..CY"@D?
MK[R2LDIE']9^]"BNTC[E6V!_5H$"S(.50MLXNU!".L<L<_;N\U*W2BGO+O%-
M#LFYZ)#Z*^[T@U<5&W["SLO'!E.J;MGJ!C;;ABVO+[VC\RYPXPD<Z[= 16X?
MY S:CVW2U*?]=;,'+H&696 4!^A<;3BSZ;DN'R1% 5S@B;!8;#4BJB9M3J)A
MVE>N*+O*L[?S9N<C][Z#Q@X=\PCI78G_-97&&NJS^0OO4Z<XRQ4+7F<Q71E^
M/<!ZNVB9OV$NUEAMA7JJGG!B18,HLJ9]"( -T2^VE'N5C,UJ(/:PQ??< S[?
M%L?FYS1GJ*;OX/]GVS/=!Z^J^HQ,K_=7GW[_D#1+,!=-J.#Q0>ZY>0DG2^_<
MU)YMO;)81OM$,WR/MW7.RS&^:I]]4IAFZ%!XO'EYO[1(7@S;YR# E><1Y3.V
MAMEGG(/G*K>6JV2;^Q^5RC7XW+*"#I,V/K*PMP#+&,WTY/!A^6YC>8#$2AR
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M9M;?6)6"=V3(O\:A?X\QM&0^K:(=>#LQO]*ACXM4Q[1K-7V'PP^NL"^->@<
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MHX<]SQDI;GC81".D&D^L':XC= :D'P52&?!W\!/=K'N;%'F-,:B_\.,!!)W
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M]2L&4"I?Q)$D>FB## H=@RV8>'K&<4H^_D)1EXV]5K:J A C'Z=J0M#-"JF
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MZHWUISD^/-E$@!W0+T6MW)JLB2E5Z$PR;\@UJHL7,]:)7S1L%N$>=D9>4Z(
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M;YS8O!QZC7_;@N&$>I'EZ:DUBPZG<5\[T\#^/X,5\VW/(1_$JC+E\]?$JG"
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MPI5TUJ*C20.I&Z+K:G:%_YE @5C*H;<)*L!_L5WPNI7<4$U<'RO!8FY"_ED
M.^3&MG)>%Q#LN^-/Z(6/NVV^ S.G5PXC0#A%./4M#C3)@"DR[C2@3KS%5GU/
M<J\_EY14ID#SGGMPX>AC.+HVP"']P=KC6T_^.5]T"^GVU@&I[)9?;Z8XX=4<
M>\3Y'^>G/U0[J)-O2ZMLL:H!9)M9 GC2M&-EW'NM76&:M+1(9;M1HG&Q+*5"
M=%>7DRZ](!\>CW*X^Y+BIZY\>21S"@[Q4-/.C/[%*/YF4%F:]/6#  VQY,!T
M#!O<*5S6X@('QQC(#ON^+M65N)I@0DRC7@FZ?,D3=GYPPT+P"FF##=$?Y>><
M'/ S\DNE5@SA[=E^_=58^;!QK<4=DQ=E:!2%T$6$H,_?=?2,?U2*;=W/@+;&
MEPH5E;X-IV(A2(X(0[AZ]6V$Z28(B&QA88823!7091/-6.E Q$V=!"D>M)5Q
M6\<!?P2 T:\';=XNZF/;$%%M7< \[/R(;9<TDX^ N<P3,UBF6YO#:"WK&+(\
M;6Q- #&?>[C]R91-VQA>F+J*AIVPMDY&N?2=UZMZ97M'>XAVY5S)-4T"Y&EV
M1&36)];@V9V_NA+LLJ@>AV^*2Y10N?5:U>;ZZL C&\UQ.R'F]%2/*0.&4<\4
M@1[2#A?5_K*C4_A%!I$ .S3$47<Z93*@M2!_4/ZX9@=A]QTX/>6:3<<8W_7L
ML5L<>Q"WZ0/VT:#C@Q0ND.)/C)"'T27:5O:BV\P9Y80@:I/"7;KM)IU^NOH-
MDCPZ+L7@@^8&P:IIT%KEI<'IE7#BV#@A&E565BWHT'-ZB^E@ULBK&IES.4BF
M+W3U##LDS)^MP-HWS#G!>LQ.);K!D\+.]5>CI,"YZ^ 5"@*"7GU4)5CL],=7
MM%S()\-0JDIE/95F'#TUOE8<HUD'-<^</9^[K^V17IGL>$IH-%5RB%+,2%,V
M*=B]T'%%I>Y[SC6O[WZ3UWZ].KJ-T![<POPX+:U'V"P_<FK@ZWB:?>4L5GS0
MVJHFOFICO,O6C5$RC5W.*UD@[R6Z(Z*2\Y!;$L'1&=$Z0EH=TE]=/I@V] PX
MD_SVL52IH0<H&>^N]W>I?OA1<<0-[A'6"_VDO,1DJGMDL0DM&K'VV"AOP]L!
M&HVVY;\<_S0?9Y@F*+;<]D*U2R]WC-0^V;[_/5FK,UH\0>L@[@<YG+R+%4KC
M N.BK; SD:T[73$LB6F4R$*SXM#&LIO9\'J>8OWQG*PC4?<HB;IR^[L>Z'.6
M3CU[YKT[\IN>++25F(LFB;(S[.U,+#))03JW3PV?W4=Z_:&U\*SEZ]0BE9J5
M4Q6Q37N\/8RS7^&Q;8GB"3B29L6]A0^=EN=>)I>5^!#-'>T6O:.&K*]@KHWY
MK2[/K,(^JO[#4.,<KQSPAK;6>^<4+=[G\_ HFM*)R6W?^/6M[K-<&O_KEZ-'
MY7,3@&WJW[;-Y)B+@<+5]"G&K5W:7Q]OE*BE6.V,";XTO:XU]_[\0@B%W%%4
M/6DRUPK3Z.^*-D2^WW/8X^&<97,2/[-'VDS&[T,B2?'C[@U90?@13$B)NX^'
M_!$Z;LS;T)^ZF.>6[Z 5H>;'^GYB1-9OXM !/KV;'1]A%Y#=*U@WA(CG;J0]
MH3W'QH%QIO+CB36;BL<G"J1_U\04MA^=OQ(_?N3,[]07#:\?ESWZD?&>3,>4
M!U)&Q(O4;&;JJQYF-!;T3U"034M3]672.PN6,PJ$2UH[.)<4LOWW8;\&.815
MXZ"_ S*$*<@TJ6JHJKMQA['OV*LNH.2@]Y>O"D\Z-1&:+;RL$&BMZ239T.\S
M/.V3"V\[/-3=8FWTQ;:<:GLM1D](L;Q(_1R*HN%2=+J-C$T2IOI:.^Q*-QRR
M78<'V^U]G&/VZ*3%^QG2+[Z^]OVI]:O*UQ.?0@\WV%HR/1O\=%M^CS;>.:FF
MFI0S//[ZYB>/(@_5Y4_]9/,R^]\8)6J3%64E3F/%;W_9AB!?4(D[Z0Y)63JL
MNM ]J]+T[=GS,YBK(I,7!9ZW/Q56'<08,R\N9I5G;D(A[EUMI*T+9;-%@0$:
M';G38C5I'W9= [_N_G!C?ZOW=LEL:(C30*-J ;M^!UOI@.UZE5-0R"(R1G=P
MEN3HIQP9L(C2=QC!(XU!$OI>':0C6.3<,H=\<;EOT4GFA[V7X]_U;>(JW FW
MF^)CG:(S\]1;,WDFT'7()<@@A'!KQK4L+ ?RD>CF\3B? 4E2G\L,(P?F@W?'
M9/J:0A\0RN7LTD2JPH_N_GW_4*9,H,O2K=U)NBXOTJ7Z8&PN8&EPT':F_>=%
MW1T03B-Q#,$=CAZ,"^0$QT;Z627DZCJ A@;49:1EOYI&<L%L41&:8!^R]V2U
M9>K;?</_G-J5,/!QO.ZRFJ *+ 4J\J-T,'!QV&&'4\^"BSX92#EN5])S;)_!
M21./<H?3#E=4U=6J:DV;UK=M.8(GWX&55+>E#2YPH/:+?5@VU4KL3VV6:T69
MAVUZ\,@*!/12>JEG:-_.JX#W)CZER<LQW+IAF(ZOVSB&"\T+V@F#,+PZ7]&@
M5?-A1QNX@,6(N@#K>K4Y6P,.7O?C.$D2UB]_9&<?.VMVFD +-:&:IYU889[H
M6O(*L)KT\%</0(C_Z$Y]66PL\C/I+T&:$<L2-=CT9J 2O3%8_W<(O.2]9&7.
MB?&T_%N*\XK)"C//3:N=:<H^RG#_N^(%"5],14M>VI?I;&/-%D"\SQ<GE4>&
MHFG=)ZV#?A3\V-[6NYF6/3:FZV&P6&_;T !7QTXG02MCVXD0ENA(F (88CG4
M*!#*0-H-17.!A/(541O^UGJ94_-9LPF*IX@3')7=/']:5:PB=Q6=DJ18K5M/
M]PEZY K3V>GA[ZJVGHQ1R@G^!OC:/UDI;V;/#6U8/* YKU7'9SK.8G(&#N?=
MWCN\S06N9%#A7QJ$#"XT_%PV#*(O7JTR-W @'K![CZ=:"7K,GVVHTG:1S9*]
MI.:=8N(GH@*I$+.M!F6H@1$L#.DGZ.8@_6[''>J5R%2]._BH&NZ'LG :V:7Y
M^N 197ARL'PKXH[Y6X=)C#W*RP:1X;LZI=A;<<_XM6M0YXF3)_NNR*5Y_PHP
M?TBZ4ER]870I0:74*N> RMMG_]6.2=[^HIC:ZSN(#_-E:X(L"(,+3-?B"/Y&
MV':XL)^DH2V*BEIO<KBFFW4ZY\.XYU',)P4DL>'48H28^*/?8L!]]GJ SU!8
M*!SZ_GSAPSU]J'9_WI+%;_<$SM3E:IWLZ)**\K"<(%95!2R\CW^?L_*+UDYY
M,OI#^V.U^."@HSTYW^%/F#WG!Q?XM)4$$S-FJ%*Q[=F36JWU*W&&2B5HM[9Q
M]$@>FF54Z/ERE[]1H-V::6Q6@/MZ1.ZMIVH67B?32D[ELTP9-_N^T,'C4Z$G
M0D(2<14T]N$UQL(W5FA?,-N47:D&O4OOBEQWF,CSH!B4.=PF,DY/"[T:':B*
M/)<L\U'QV<-O!]X=.Z6GI(5(E,Z9V8IH='B'[KHV0*ST8PNV!SM5NGF4B!9Y
M$!D*DKRJ/A6GM_'[?@K1BH0V%4GZ(:\,[[J5-&/D<B3MUNT#ODGW<R:&"P,&
M U]-+KTE&O6Z1'<[&J;R'WE=*&EJNF+Y+G]@Q'O57I6HD 7BF/(8_9%F"8P!
M8ZO=2A#=[0@F4Y==VIN5Z'.QU19(.]3NA:E]/SO#W\YG$>.T#\$#*2O+[# )
M!&AN.6NG>VCO"*J0(X!Q!2OH E2K<(Q0"=AEST!%Z,BY6=!)<8UPJFK7T!"L
MJ:01.V%_=N_%O,6Y]M-_&'HJE#CG7R%HD$"G;;Y@G"-0C9!4;"Q,[NZDO8=M
MCQ<U^X-?F:WQ( 9>_)BNW.888LP0-!'4C;.Q!U_1'NCQ<T1N7&K7U8C^PY%A
M0GB0<+7Q&)4-I2HG&$)+9"8<$A'"B_PM^MX?VG+<PFJ6=+9DD_OKZ'>=7X7%
MY"OW,3!ND;WN/MJ/FDQ;^],>OLGV/F>S>2/JEOU,(E'?-K@$?[%##P:)3K>.
M_5+-)BCM]S&J]:EZ5-R\[%"_ML(62'[F(J<Y(1?4)]\<Q1&CU,H^@34WO\/B
M%A#/H95SR_D,,X[&/%PH3%-(%_&)D5Y5;Y):<M>]RV+(S]'&X<G.&?<M-:\W
MWQ,>:'T\>WHZ4/Q&X08SN<!L@40J#]7['?XSD-"M]3I;YH4+K#!E9G9F[F94
MW5OJ9-W;J1HK4^R)G)K-3[^Z!#,I=U0%:MM<RUS3>SR:&L(4YM\FK%K=4(6M
M]"'-.%VG6GPW?7_?Z^-[=*?SUF<#WZ]2-_?N[QV<N)0 T/L.@%J7Z,(E6"I.
M MVJ(8(F.>QW"Z02#ED5>!@;ONI?5U=2NNIW-V!Y\N#UF6=\GPKO;\:5'\T5
M45-3CJ]W43Z__G7N%W9C<:X/VE.&3KV5?35V$QO9M1/P^LBPX46:#'&?QX[[
M'2G?=R=JUI K=;7>F<<O'S03^AR!2;Q,QW5R@=V>HF30M$USOE[P)'_+N6;%
M09T>@/5&2Q69JQ!S]9^4,HGTH.VK N*?<+K85T0+HG&PV!$EQ^^:)$O7EZAJ
MU@ZF"C9K<+%E-Y,+O [D-+^:Y@*R+.6W?^0/#S=:&S4>&5^)6<_44-.YQ'?_
MD%;-:\NG+ID?-6M7] ^9S'9ECX8-[$QPJ',M^EY#M.(%IV/#]P(Y6S'[YTA&
MV^*SN>? AC+T^"#S]*8J!.)^?.:T21HIW%]F"!?MZ&9+$C^:=/#WMD_).2#@
M?K&$LFNSA??D.DN="_#)C]BENE9TMG1T[C?35;JI.FEQKBIG*F$DV+\Y;AM!
M<\T.#7+.)U_<T].++YCR)#[N8WUVP1$LFW-?K?*0O4R@<R>]:5/NZ<[$S<^<
M4>:CG,E"UF>/4!A^;K!P/DKKHC;B,]QC-W-KDR5\JO'<$V/\<4$D:F>]DL7&
M]HTTFXO&<(''S=^W%KTXM!U3=>I5RE-LD:K>TW?CE5BA7-(8N>A!<PJHPQ!L
MA<G3E_MB#8V+'>8SZ)X[T3,-GC>#[MCFWWW>+65ZM$3H!S/M%27>YIOX[UQ^
MNGP1K<<I1$7)"WYU4/)T17%99FO$$[]D.>),;AUT*OW2F<31B@-D\RM,.+C[
MRN\8AMB?"US 3'^IM)UYZ L7H,4TIQ[,,K?$OR4AN8!3(;71(7/F? T=78XL
M#!E$"#:$#JP4Y&:/SV^P-1S[J[-]8<G%"SNO!20_#Z(4FOD_[FZ]%ZJ'RJ-6
M"YZ\T/Z0;6D4[&)DM#B38[[I*^U'* (E.NR;7Q0[G%;C E4/3R/T[D!*YRO:
MJ#HW(0J]3R]V_GIJ6"^CNDB4A/*S'C.P.#_SD/QD^8&5NUTQ.G^[.,K/[C]'
MMRA\5C/8\&S$IR>NLW#1Z'LRMJVSN@FV/FG269/C(Y7;<"+A)U;8OY)*CN,"
MHIC;[W]M3XE45])K(];CAPB; 7E%\VX(DDZ/];XO!@\9NZT%ID4B[,Q_AW"
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M&$/D8Y_,_EXS\3^GA04P!T6WPY2SUB!1<)%UC43$098@ ]YVA[0Y+I'2J%>
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M583TETF#!,I38KRA60'Z3NL4T_%S74UM?:.T>DY!0<9F>B&V&/M3PO@G""_
M,!D"-'@"97"N@FX5-4)JMPT,OOVJ_$4QTEX+<ZUY4&?R(1:5+-BBB/Y8&V<:
MZQO#<$M,RRVXM;Z1V2R.WK5ZUG_R$)AZXRL3$6=X):C4T^D$=$N6"V1BC;@
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M\M"!6L!$L*Y7]+%B/L\5+G8B?^JLC,X99W\)CL:QE)S@@QBX?RGV/;;#C%U
MXG1"%ISR*(BQPLU'H!8%"_% T,LQ2E0C^8&^Y1K;,#4>]8Q*M:D8AL_KL.NH
M$-*ZSLZ0KSS4PLQXRL+HL/VDD>.KLCFO&KAN.]M7PB_WDT-@P*=^5(FCU/8,
M4P(C50,RF$]8JB";(;]#HM2V]@EX]C!T6W"E&J/^$-D_4WL%G'[Z92096KQ%
M>PD;WIE29-R*6X5 EDUN3F3L:/2O&%HS:+03D2'B4TV%(+PM:RJ#&D!G3_[]
M5.^4/6TDGJXAW$)E\P68EH)KU!CB#)@P!14MYF6S!(4+:$;5IIHK=<U!(PT%
MWV&L&4SD<H%'/2G6IMUB>F47>//OBKY;.R'^^WXO&> PQH "%\*!UPQ1S^[R
M<@1V!DY]0=MRHT#:A+0H5I%J&)U'OC[%B-T2]5MQ_F:)?^HWFX[G6Y7\6>5?
MZS8XE5KU7,2%;W\WOJ7Q#A6RD1\W;/[-6"7JI,V=:CT3B9>_7R;8S**RK+)\
MMAZ\2L=MI@A_<V[]=5+64E,YQPTSX!/0>'3=-\VI9!)3L76GK,#+;@FX+YRS
M-W3!_2U17_N__L47(B_#<&FO=XH]$>[C8T08U^X>#%;W#HDX;YCR#FL903R,
M$26PY!G*257;+)\\<*(]G:-9.<#I\@@,RL>Z8CTQ?NPWC:$,)!-Y#P;E D4X
MXY\[^.W#ZP?8NF!1D&$M#-Z<*XB,7W[,LMK4#,1MA[M_<9DH%]9W&0I'Q$,/
M5HUUX6 0\&EGJ/XXS6D$[@8[O6+@CMBSP0[!<0';"[!7.UW"3\H%I=*NW2TD
M*.L,>G_KO&EE&K92$KP#?>V&L<MVUBP1B*I^W>!73UP,M9J"U& ]N$ A3_-[
M,&UW4.,,4K,F6X^MIXK_Z9PK(XA6EK4?#R/2.*:RI(N('->@P,T[9^]J_RWG
MS$XV_,55=_M )"+O?O-0%R6'("?*-G^IO$U8@US]]R6T;8-6Z,? )8=I1+($
MM,HV OX(%1&LV\4DB/QI/ML$$I#3\&6X#%X4.<:98N3&E[W&0<#8CL:Y#GE1
MR=\[J_5<8,F**;T@X00%LZE68X.4L&Q?NN=:.Q<0K<**.(*^=OIN4?Y&J,ZL
MK8X<WT[LZ$.H(/@,V]HA3>:U 4OTT7T<U1>1"5T\V(["&($47M'5!"GTN<W'
MPQBSMY@G#!/<M+D&G^>4*&..I8H5O8OMZ*4+-Q&PSB"-\XC712&\UF +:KT=
M[L;<%3;"DX <=71^!U: =9NQ[BYMNQS*O()&4*KQ"40D#]R<=.@=L4O':+C1
M!B='P2N<-L96._8(/Q4.>LFA.(=?<M2@]&RT7G- 7[A=,A!6PC)B9Q ?],E@
M3M$Y)?3%:=-61]0T3QV@> @BH%;E_ [TY9S,P5*PX8:N8>HLP7Y30S"P%2OB
MW\8P;I'C A0MTK>.Q^B,36EVFJ&S1D=\HRE3#^2_^1F<I EI4 ,[!8E+H6X6
M0RP'AO$E+O!<HGT%+&29_0= MEMM"V,[;"A:TRO2ON2R,"UWQ"<B2TS",H'&
M.4**@+NC$N%BWD3GOF@BA.C*J][R^]F?^B(X4F$]<,EUC=$V)[IR!WX/Y@EX
M!Z8(7F#=!Q.IY'$5J"@N 4N/PSR0UX(=I=?!=.EH>KA-/,-W\Q"[ME&3 HW)
ME06=(<O&#,2].O9S0WX7>D/'N.GR6"E:U8:=19PND!XIUUE)X/$PB651*"Y,
MR91'.Q(I:WQY!-;Q*7%LXM1!.C:RD9^*XP=EIK.PK?== :A3&(E,-\-'<H&:
MF(;IE7T>3KJ@SC0DBKR/(P[:3KL2Z'T\UE:);8/+LJZ#R.F+97AY.5%*8.<(
M0X2AW HYA":T98W3.(?)^] _T :^:/*7!,, .$4;^PGC]=_:>O=X)O_X_W^]
M%96TG$.L(I3#.C@4LU62)):$T*@DA\4J9#%;*,=F22ABY9!WA86A& O#6Y(S
M-3';*F>NY71AF^_ZWKZ_V^=W^_V^?US;[;;;;M?M=7B^GH_[X[J>K^L"2$NZ
M@GCR(O2[; MJ"T*Q!&SB]>>^6?/W(AR29&:<)%<E+KT9Q6 _(:4&2?YPT#$4
MNJ(JWHM'L_P^B54E?RD2*T)!!RC?^ZGZ\K3/&D:H#JZL725X@%; $(_ZB.',
MY[#GEI1%;V\B,*,D]OY0V#9B%U.N7G$<M87)?2/>.EX/ V,%2.@T# 8R6:NJ
MCX3H4<XV/*TQ<?0G8(G'->SGNR.V)H\F(GQ:UB%EX3/?>27>C3 E\7[Q5V\Z
MJAF^@_J0!)R';?ON#]N*"K;2X,)8G#@O?7!LS0.6[%V>AR4IJ_*\'[BQ4-N)
M2@2+(%GQ?M)6\ -HWI#?]&]3@Q9<T@L[AL(G&*."*$'FLA]L[R815*R6R;W5
M+5; HWCQ,6*-";-<#7%'+T%O%"69OR$)(U<*55_])/U7RVLJQ5*!;-!S98#T
M:1T2+SD#3=+0.&\H$4G8"@:,&H5PYY*%MJ.H%)(<(0C+E<,ZRO)I#Y';<-&H
MK41=8PFC?>3!M@@MN[.YF3$R20GKD"3S$WKOS$A&"[AH)N 2)<.3<#M)%O\3
M7\N+H[PE2/ NY@K!#WRS9@LZ\UN2N<RX#*0*J SX' =@,^FC#:.W>=Y;\%28
M"E';GP0\I<CBT8U2#;DF6KNUCEW-E6D;413=)XV^&=D.C$T[CVIJLY!F@&T<
M<:=0!30?'=87Z@H&$E#<++'^. HF#.?34B+&4D)/K)TA: .M?\OG.N-6!QY0
MS6.9 4?XJ(UZB82M"/G17Y\@L+>H,JI0@2D9QG+O&2B/Q';\N]4-(O!C:3IS
MF4G(G>"=3BYJFC/*^<YLDK(7<,@F$K">:\D]VHV$@6G-3. ]<@]8L0:U'FLD
M 7$@O($DD%!QXZ91$OA.X%VLC/@V'XR@#%H=:;$J \7*FR!*3C8:$QPT\S@2
M+2HM;AYKRB9-UY+/#K6@;O8;,LS#"\;$)R)FDU#51*K D>1E.3AFGFC"(2]E
M>F\2X@!:LX=N=0B62U,4[A084;]5TJ;K(NU!YYS(D^(?*.!)" \.VIHR5]2/
MM1Q37@U9.X-O:LK=TLV O9VLH7UGG*#AF\0[F#(>(LJ:_<SJZUJ.^->1=8CR
M&:UT07@B L:C;1CW.@B,1<^:> 8==Y\@:=Z<G9U=I"QH.I]LC4:$ACI 9<2G
MF=NQSUJ.__P9VCJA9H2;GJ8^G+];6D[4_97>$^B461N L6P=J:[#)^M1ES+@
M2?B[JWZ[#H\I31>/OJ >J'^R[-;XM"32@&KH1<"+7ET%@E]%E>*E3GT$1'\K
M,PQJ'7S<>__&M6+^XL]E?G7@(EFF0:S-Z#=$&/#7(3N'//W%^@#Q#2_2DCE#
M5G7H1<APHV3%UC6#"Q,-J,QDPLEN9@ <O."U&Z OB3?WO:QD],,-Z]N*L1;A
MPK,?$1*?8LXIB>R8F^;X"+1';U  &1>P^0VI$17FQXW"\F5:X%#W<79*D0#;
MK*XJ;"/*#![[N]F%RWFPNK#J)S:P$%DG'S%4WOSKGJN+LN@=%=-6&/K*Z/I<
M^_65?9:3Q3/8!3!7KNU696X0ZQCCR>=RV7^;Z=DO-!X%J?1F,C?/J/S='#<Y
M8BQZ2QHM(E6X)@.JIVJZQ"KBSOJ# #/QYHS)_=!A\Y. 7LSV85R+EQG$3ZR
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MIASJB;;MH6Y=/<*C0''3P:;;0;THW]KK4EV[TGJ%"Z5W<0\/^IA9#+-@BX+
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M2<* FW6J/Z/&_R>6=8]/'A?Z2_TF)7E\C>9KAG!Q#VZ MR40C6ZH*2*;XA3
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MYFH%R5.$3N*_Y2U]:2UR$32ABB7/.TYH+4@^WA.:'>EPRLLLNV!$:/D!Z)*
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MX*X@9$/R)[6@\;:]AD*4V<-(97&&2<Y>4\H9C,69<X__2SV=H-QTB.5?6'!
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MM@'M;Y"9@B0^H<JXA"6?G,R!9S_1M7VQ[:#]55K\B"G_ *Q)TN'>A\/;FDU
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MZ2>']-2WIB&1B^M3LZ^J/-Z)_\UWZG/$IBASM)4QEP0>@Z.F2F!*>%+PB"3
MUR_J 7?==*Q13?]^CMENLM9M_QN+3YFGJ7UPJ$-T?"4F_$;"L&XCK%[:<K>0
MO&CL_?V?S9MAAK!0)V@$FT8"$W<=\5!KDZR_7SC27Q(%ON^PO(5S!D^GM#3O
MS&^_]5@K,:ENLA[4PRX>0+8QA''I1D+T-F3N!;\/&J%M!/O85VMXJ\+I#LSC
M#IM>G,C+;1OLKXK33U]MU)IX]I;UBW]V&\9 - Q\7#,WZ%Z+L&QQSB,X"]6Q
ML+"&]R%^GDY'/]K5F+>M;^1<N]#@ ,U'W>$E@N["C@?8K*GIQAU6;FU9339*
MLYQ:4Q1ZJ/)QR,B_#_]"!XF?799L\.6<'8HT?LL.N['@=SL#T=DK65V),V60
M8+62 =851$.(QXQW^\&E(IODA]05C8N'U?ICU@V;GP'G&8A9LPKH 'N+TM/^
M(FJM(:B";\B&':AQM1XTJ,3X+<!)"PW*_GXC27S7G'NG1JSEC?#A33!#Y+S-
M/Y_<3["<\/M1(4Y2;\-9Y'.86DY[3L-"*- %(F??A8*SDN%DT9'PVE78N=?*
M\DZ.QQD^!F5 2 #5#=6R**\LG]@)+ ,^J:9+!BSTUT0N(Y=.V^RWG6Q61W;V
MG 9IMP*-]7C@D,P=U>(:?GRAF2M_OB"_,WOB=/@EUS]1(E+U=J.M>29K5$9M
ME0B8B+YSVPO.IT\3=,<=)(7" .MV/[/,XO5P*<1H<[@C)5Z=F\; 6?Y==A64
M-K96I).+R%G53I"*QR(N$<)IO7'<^AJP$-ZVFZ+:'KK^:=2R! JBDRO9UE4"
MZ1RCJ7P*)&F_%P-U^Z-$1(- =6<C;N *B)?LY#+2N6QG[#Q!#XXW3VO>1/LK
MC2_T324*#4#SR[D=P^N4+&/4*NDYV&U=.RY81E@6DJ FL9-D]*.X.L@7,=O3
M3G,3]>"1]<=YQ4:RQ,1];BH< YGC\BUU!A7FL#LX%)C>_GN<@*WGM267!L"M
M[IW!?L\=./\X+B'!^_9]>L[Y@=.G<@]6W5AY,>%6UJ,QG.ZG60;VIYYZ:2@.
MUQWS%>O6$_&\<C TP=8SU'#[S8>WY(/W,\3KKRQ85K7%Z(DE.;#0H[I82J7S
M*.&,FAN[Q<9_RXE;X131X&C+5^V)(Q&^[M7/N^UTA#HC+>6$2O&",E;J6_$>
M(Z>_4L+$EP;HWPOKLL.("PG&/_>V\O7GZ]PI([O+AF'G"(I=-DPK/L"<FM;.
M>_,3$%J<LK%9NJI"]/Q50&EB:$1C]065J56Q&^=VT&3XZB %IF\:@<;:X]G9
M3D>)::(9!::;WA6KP. "U!ZC[#T)OA^:EWXB8,-\^/CEL\1%-1^+%)BE!A#S
M<PUE!?Q:2=,KY] OHVV)+]3P5-9CGETO[0+(Y# P5/=VU+KF.:1;FD7S$%EC
MOL+I@6!._XOF]8V]2AMPT79%]A3.2%FCK!#HR>. YF5DG>3K%RW&87+%7)T'
MK:X&39K]/"HGJJBU%6]'N_/E#HF%D<3OO]Z;"Q@S?_A].*R2H85-UJCIN0#_
M+V',L;K\.."W#ILKY@8*BFBDLG M:N[A>J76&+/7JV..*A-;)DMID;89<E-G
M91/X/PE5,OTQ_DX%QNG"L[BF1@7&^VY*(.Z@KWY/(9/N$,VC%_?-S',$V0MG
M1#5*E/U7M;,SM:_X\;8XWF<[#_4;1.-@]@X)RTE^OWDM#0?67;4SPN,U*.T)
M':5@^M%*@H[]?Q)F<X$G=.MB7/@Q2G[;B:%%SY?35E7\GCH3](/XXC5([,!G
MV.-VU(&$*Q%1X&B+ @.FPM$^-0YO^FSEU@$*S!5]R09>QILU<$QX_-C%_8NT
M+("_$06&=0U_CV":?K0' (*>C/L,&/M=<"8Z2:7TV(\ND)+Y_T(/E94TUVAN
MV1H6\W5?%.^-NUGBMS(3OO/.G+@1=JN'&F=PN0]A19HZ12U<702HN<8R]*=Z
M8@\3OVU_"2TY?^A\7-5R^2=')$^\A*X>6MN\IIM5[1@>06PWY"*FJ&FULFBY
MQQ484I^2?2* -V^GI//WD@X-3LN! ,[<$.^3W!RL:V.HP\^?ZMEG+2Y+$Y0$
MV#RZM\KX1M#.-R;F:Z"KYW:R<M$=Z&N@2G_*4H35H7)$T\F_:"[/J 7SDFAV
M?2\SL-]6\HG%/D,R1G;#*6#I\4]'K;ZAK_F+&R 25\G'(3>QAE3B,8H:_,ZQ
MT-B5'@<".<V+PH=-(,WZ*"%/8SQP#>3*4!: >\6.4AM.'(R3'E<:<Q-SQ%N!
MF=\H2UPA"&/J."T8"8AND3YB"C4(*'9YJ J'@&VJ[YL[U6]XS 0U91(SBLYS
M3GQ6VE'_*2?=-2LL3\9^SVLL(/U*H!-!S/<S2NS;3>_0,\15WJ527.'RD>1H
M<06IHX!0-\+,Q%F#HQF-V$<34G-&-5Z+9@=:L>]^:1<1L<AV")_6;($< F>'
M];7?X/ K7OV%GBE-<[J:U48&]PL^3[<)-&<5F+1@#G.%D]V]4+H9A&L^#9:V
M,PRIP>3F'B0:Y' 4&!7Z&MC>AU_M<=8BBY&N/(FH(=7\+Y"7C6R^O#?:V*CW
MQ,YKUJ]H)M7R8L*Z,3J^J]'NKG]H':K9Q\V>!30#J5E^#CEI3^,65*21M6[Q
M%ZQWWV]>D*GV!4^560I>,U*E.:S,S12:%?\684<_46@";=I>^32U=\Y'_<KI
M,_TMV)8=&4OHIW8:71"I?1BT1W18DJ.?SD!:74ZK*T)KT0V0KS)&[3#)K>)-
M_"%2@+?0;0K[%.VGJV8=./RN,F38 .X1>02UG2N+TCI(]:\Z47>MV!*R1I=,
MR+00,GB6 2HP[<4Z<':Q[B?$!!2\QG^6$MO)!J'L0=Q2V!L$ F'=D1SLB8$8
ME57HZO!NR\Z/V,S3+_/6ZV^L$>7.'A"/C'(:WLN!HTP..Z27YBEDPWMI>^/D
MK(I;O8U;;#2O;'#XH4W89?7O24;36]7-J ;-L6>Z<7W9 !Q_MQFTNA%#7CH,
MA(<OCZG8\N3'AGQ9R-*@U^8VEQ28G:;BD,/8&X!02=(O$@;:3S=K0@OW:C++
M?EZVST9.&W^>(%>#\JK3/G+IMG<"_'4GSY5M)]>0X+^V63[6>A0[C6@K,)*_
MFL#^'*$%0Y7Z-&1X-<AM$:B&Y(1".AVW"CJ8]Q L' "=&(GCK J"%E)3G?YB
M")GI B,G"L:G_EAQP*F=O,+O&>$3&80%B$5-CVV$GH!C8U4H[$RB>=\?Q&K!
MU8^8HFSC\'VD#/O;.S_RK1KO6&T*9R<+EMM9D/6/!\(!SRJ0V"=%0>WO8G/^
MMBHO$[H5[@PX;7MH:]'U",:/-<^VIV)@_&L!N(_R>?HU81EN(?@K%]K#X_!]
MR(;*QEQA@?A"563X!T>2U=6\@IHHJF6*0T]OGV+M%;%@+_)RFNM[*P'LBIP0
MPK^>%JRZG&5-%I)@,_/)>T+2E?W07G=P].I92#,%\CX %XTX>KB)?+-J*)HT
MZ]X8LCYU0K2\0(VC89!=BQJ ;E>4^+H+*LUR"A8NU:-:T0*>7N%D('8CLU4R
M+TH*$VO66Y/D1\%N[8V=UL N#IM/]^WGA!%6C:*FV<0Z^K&/=/!HI,.<[1 Y
M!="LEC&7!@Y2H]\T@9:YH>B*5PZUU=Q=/6\&3^5HOEQT_7I#]'9D]*[*R@5N
M(_FMY 7( GC_"/827F-S:4^C*EC:FD!*H9D_%(Q3RL;U'%Q3M3S6.9-\-I^.
M7^@V7Z0I^G;1=SY\R@!EL@[\Z1%:3PZ!*2,^=9!;('QBY ]B7T8[#44PLE 3
M,EX;KB,G4=H2+F3A4O2>7Q&1M0(TM/?>:U]I1+.U%$7G4\^$B-5^-@*DGI)@
M\F?@@V/S8$TD_U7#_D!)7\/QX:F'JBL]28+?R'^?Y7F^;,/]B_]SB&,'8O>7
M;#FAP#P8NEJ$'6(/X#@J5T<T/U=D-52>^=!VXYQE1 3U[&NNTX+9*=ZJITS'
MCYUM:+-822M[=QDW%3."5)7=^:Q<@=&QW,-'G3JPDC/)"LQC\^]29L+G0N\4
M.?!GDBA%@(LL)G(4.J2!/]Z[.;AX:%)2ROXS3RP]5#,#,(AATYK'79ROYB5%
M1#\&>(^<*^$$!68N!S-+@-'/E?UG9%@F>AVF$Q\1K>;:J.4MVZ7Y"-<JHD*J
MP'"9DGSV(PLQ>V!P2,1OXQF<@&5'9*14PNK01-)@[ F7'D:6G5E$Z;XNW:+]
M+G^N0/L<,WR6&%SMF2,K%4S0H\%Q_%@=@2U&5Q,W>3PL3#@>(#@TS;H+OCP>
M9/K J/Z 3V;_[[RITWE#$4-_%?XF!/<V'AT!DIN=>A"WT8F"KTU]HQ*KYY$*
M3&7Z9]NF& 7F38C8.(;G-/O3-8DIR:SN4^.H*S!:<!QW^["QN2^X%K=&@;EV
MR[5.3,*F=;%_A:^G;3X/_/A;W,\V46!"R$9 ZW[(MQ6GUST7'O 7E=F!6]7%
M&$C 3G6&W"D67-WW6L(:$%R9UT-7P:ZO7&\TKWCYLN<7HI9%,F+ C[*#.@;U
M)1])9'C?@:+A)?[7G,)0@P[7Z,Z+'YZ_?'KP84&89:EE7W=NV-C0[<=-UH]R
MRO$G[H"N4==._O['U4;;6[1DQCOE<D_4^<M';IP[]*4G.[(Z8L"1N4*!H9"/
MC^=KA1?X2B*X0T0Y,*K 5)"#D27\48AT\=?F&-9L8I+5_)$7AJR +3.?X\2L
MP#]CY%OX:O,I3V&G45O"U;P@9_8@80"1:BHPH_QL>9/YE#=8)21?KM;0&G\5
M66#;9.(N.WJWH4,?LWS.V14HU16?A'/5,CO<3[A:EC^J>! >,UG;T'>!(,MH
MQ(D.IFQ\6TE]^NC <>3(_?HS=)_[/=]?Y!7U%>2P^'NN-LFL8)5C</7?D +3
M%D'IZ)\/5.FS*Q>DUP&0I2Q>*4=Z=BLPF3WH1@3XS/J,+FY@I!'!4KK*!)^P
M$KR0IY0!PPQ1#OG@"Z7*N])159:4<D2!^7>)\G]2^";('(P7Q2$K4X0?"T59
M.3X:)SAQ#@"R)J$D7U*'?& /,H?(OU7?X'];%<N3PG\3_YM[*2F(6^ D70VB
MO!K(+%\)B=?Z'5%G!<8_<X::SCA_Y]GA2PGO/#/=+PRYNR3^ZG_+ZIDE+T,S
MT'74++>=%:GO3M]SS3M0%_KL6$^)P]7Y \-3A(IXYF<@F] :4\X@J(??8?Q)
M'.LI-6=P7TZ1;Q!Q!.Q/^A:(G3I:">7PTA#BDW \="R4_(\R#3(P2>3\X?<P
MM=FAO"5 JW6\4\+7YR?_+DP?4M.H/ATS>=Y1=C4/3A%;#S8<Z%5Z[H7<(WV
MR#,6PK=*_%[*SFY[!/QS9[F$MR<>\8@)@JO,WQL3ZM?'ORQYPB^\U=_?WYB?
MA+TU0GG 70T-8QTZSNS\:XKSKNJ&9^Z%!U-'9CWCP@<\',G#'O[HI1B\&K(
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M7,B<EF/Q4K,:./7922RZ6ND,B22VU\\1'08X-PI55:H'_(J]"9HC(E7#O?E
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M0UGB"39I';(*(GQEU895D7=@'1@7ES^AEB&5;_5%2)R;I)29N&@%+M@RUDM
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MP&HN%9*U[_8KURIPB=!WYJ8*B",(J(+<*QXS#:&&RE!*K,$:.$2\@2QVA]_
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M7?<.DL,9G;A?KI":J(Z\D&4->XKU^R&LNPNG5>1;?:!P 5FUM"R/8;H=OC"
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M3=H !T,=->& .C,$S-G=ACA(MI'T",N/P28#<=&H)D-60]4,JU*IHZHC'E(
M[_*8&0RJ?&=<\*.NA ,_$#UM]MYX[A?;A*IXR*S=K0K[YL-%M$@ HC2R<%!J
MW#E/\2.2";B.T^\;(%X7;YMLG:=%OM$B+Q9V(!?@8Y;763H,1Z(OE%Z/JD#S
MH.]E=1"F+*HME[:3:>NY E5;5.4RN"*8XPN%5T_T.%3S\?W@+])&^@VOYS&@
M2'#E MC\KE_$YMF#K!(Y&YR1 (G,HQX-6@I<86/CRCSU2B/1B6"5.LN!++$5
MY%NYZ8IM]01L2JUFWZ0N4^ ")N(ND?$\,QCO)7]*9X8_@:F>4#.G?]RPM@>X
M@2B1>"./26_0]0^)N[F,\M[MG26B1>Q%0.VQH6>G*=^M6.NT5A.XUO-%HY16
M8"-<(7$>=US J:4G]YF!>N=A@@!82G]=Z7 B#_WBMP)^")J*S2<2F4[<ST\"
MFZTG5L">M1<9PKHF[@>]\X0%GT"XW#3CGX]XK=K,]67ESUGO1<55+>,K9*N9
M=O+G3/KC$98&'R)',9WSX;$Z5"^83NT(#?:H[ADL>@IS]K;G]5B.C_1L%5>Y
M/&TSU'0OI)B_ FI=XMZFY E?(:V$/8A)V1=STBK&PMY#;4P'<=X>4:V!OC9+
M'TQ?@4%2I/SV.>/VXOU[R!*7<Y34,XTF3?,*JZ\YFM=L(W&$*R:=?Z4.B.8Q
M/>1I+&7&I#@LMN0Y0H(\Z_!+SI#4VYD[:*]VO^H>P6?MNAV4]K;+Z9MVC,=[
M_\T[!XE/NDN<.PY!BP^^[ACM$0H_\%LF<$\3-F[?F#*$7/9A#;20 \C#E4P%
M;L-L9"2_GQC2/GZP"M,M4^Z<E"Y?\$*IA;?2RZ\'L0&U,EXPZ/M!UI/@OTN%
MO?I@S[T/J6Y@WMPP^+IGX1T?=;;:^*:<C[;/3MU._T^8XWD7T75=S])D;H[;
MUSZ=K.E>!D?VOYW*,Q%LYRP++/>"@9U_IH!E&D.H2<&>IZ:9N*U/JK<_LWW]
M_UXN.7_+Q44GO[UKU)N9&R "TP74- 6NA(YH4J17Y"_"M@XD)J^CXI@>ATZ_
MA8:N__KOIF_8P;6UA)6![VZ*!('[7C4:6I'6^8YJC/O_JSQBOV:^N$:_D9R)
M]U/@,EQ*(AT=@??YGXIL/U\D>C7\M$O>[[@K[=RC;W3M2J.GLV=V?._3O-[Y
MJSTIS_##I\*SN8YU1(O@U)W%'N[$C[:)OOZF-IF)IRN"GT"-=?CNB5I.T= U
M\TKU?D!-)?*?KTJYHX^C7X[U9-IUE61]F9Y_N^;]3/['E2=B31FKL8Z-H$^9
M;OYV1=@>=_K"2&-(TJ6Q:7V'I%#K^!#Q=QW94%K#/,S5W@<?.Z_$A>FSLY0X
M?C2B^U;MFPW$TS;GGF7T7CSG5I8;?C>B5&;T^HZ+4?F;!SX&R@O?,+:MWV.S
MK\O+./CL_0_ ?G#4M#,;-+]);ILXEX=>7\9Z=AM&'TQ@U6>) H<^Q=@'UX'0
M,D8OF>-U()/87\3#C^%HITS9P38+ZW'=0VV > TX/22EQ[^VJ@I'KUX9,JQ#
MT(S/ :-^2N"E*BW.7U,29]6BX1-TZ8IORO.\O_\']YAH(,]U3@3UFUY RPZ]
M"QDV/Q1N,#NTFG6X*$ALKJ96.CB,557"JA/-CLO5!B;U)BECEC2^*Q_=R_'7
MQXIH5V/R\)SVG*7T2%RVMZI#578>!W%U0#.V^J4_8UCT:0Z=2;)062J_TVOH
MKO3%8IZCG1ZP<6)-['K#/T]N[(Q^^D))SY^H^2CRS)7_V_WX\(AOZC?^^_5/
M$[;_/6CR4-KZ@*0:,S^F-H%AL.-],\7PYM9;>Q9>F?2C*]=28Y?M]@_"UP'S
M>KV#RLAG"DI*P7,WUQ:?UM&(7JFS\VEI*%ZM<'SO#9)^JSL%,;P_:.GQ]"KQ
M("6*L\#;P_YS8RT^-MQKLF?4WI5FR\*!SWKN73F7/]><]W+8V2MRON^ZZ/,]
MS<7KHEQWG)^K:GWH14N/MMS.TF8ZNKXH.06:1/-+S>G6IA7Z'JAZI'&)KJ.K
M5U?#N]S1@L_V%?$6Q.V> HWW1L>(OSX^^]B;WC[\&+^*!QN" ?^^;5_WA;6<
M:?7EMY7YGH:9NHM]#,/:M.AA[7+WVP8QSTF)1CU;@1/FO.CG%E'S[_.<N_-N
MGPW>MWK)I\3^N.KAU'VNY.OD)7G"G= '^,G3&R1=>,?":,CJ,7X@>;5E7*<5
MAZ QZEVOOI'Q(OG#T*-D7@>U)7AH_  F7E9@0#VY)Z(>4] <03"M7RBP7#6B
MQ2\*@IQK7U:>$'.C,N?#'A![-^P,N3;T--:V1'< M3 D87K  )?-ON^G!9WE
MK8!2$])$@@+$84-_>NB=9?AO#)86TZYXT^[@?O("[[RBH.=MC\&;]V-;9/HE
MTO8#ZXZ6K2ZE+AO+5:M^B_9!.K\IL(O%"JB8?8VSD$@F1].)=F"ZF!MG H?0
M7_8PR57@S-5*X^=E46;60GQN?7]1\%,!:A G\-[E>0MF[$EU^G'[0664 J>?
M3PZ<@#<:BP3FX3('L:7TATTJN@ +U3K\8LXU!4Z3I<\P8M $Y#?<>M$-+VG,
M %\/CG]8@K#:O$C18 -Y\6:0GH2H_F^BX3#SO(9YKH_R38!.AS%['I\6K"T.
M^.68#ZO-2$Q^#4!W)<+K81QM9"W,EIA[BCT3 ?%\>'*@)2I3%9+LEJQ'UHDT
M/I&4X,-@2P-&/X+_=L&- X,WS>_'?5A-:,5PQ%$\L2(PC1/+]'@RW&?<:BT+
MLJKRV &IL7-&R]W+<K8<_SL]F&_52EMF?S_@YLE-'QX5)MD,!98OC!+[+JFK
MZ]-NL^*KP8!381RE?8J #[H==.7<[9RUS/)S=[,#$^=['5Q=M[KTQOS3#H=>
M_,N)Y8#?1:#'2L07HCFQI9NO#50;J+62M,EQ)%,*R!F0G;'MH2=-\Z-O,Z('
MUC+7A=\5^-F#[\&A9-(&QD,>CN%0'P]E51<A)G=K>-O^<(V#6H8M$<T! 5D/
M.24S9MI SN-V-$FDPT!F41YRA ^%I294KLEGZ ILKO@S_:$YAHTQZ'GC!F09
M-ZY<][72GFBN'+^B\BAQ2W"FV.W#O67X;!3O54,#.>*J9'Z<-5^YMX>A6UMZ
M'XLNXW8_.+6V/M3["!4_YEXS0V/IQVMTB6_N8#S:""Z_\OFR=DW0+SI+G6G%
M:P_[3!.41PJC*C>'!4DL-<Z1C+M^$7:5_ GSI:FSX8Q/BRZC,\W'+D9<&3=S
M[ID&7OQOV^T[]C*GO.^!7I_Y<?F_IB:6?0OR2BEE7W[1&\EW+^HDEMKO+W^T
ML?Y'LL'>GJ---E,!$N=%A:%3F(__+O-A_H.A;@E%+%I$9:Z$<U\R.AI1-7D,
MTPV,ECARKC$#M.O82LS3</V :-6P :&+2.__>SD*1Q,APHT@O^XC:3U#19*X
M]7WC'H@0M>@(%)]@_@-^B"5G,<B/9UDPH@4BY4J5 ?*B(,X*XN4LF%"3B2N!
M@[#"K3\3,TV?SV2UD9;3_)8(*YTAT]H#8WR\IV0IIU"8P*1CKPE'UF3:_E$6
M( 0+]?ZWZ"OY:W*@94^3F#ZNU(^?A[80%GM*W%,&N(LP"M#A))DS3_(7(?J2
MC'#)SN$T82(2GL=0$?,3F/ORQ,#2((/P.^B&TOC=M47;7WMY(J,0'EG>@2[9
M_7R4O(3HGX>^OP/O:T&712AP*^%$,2NUG\\VL&TE&9_A+&?AF4IP 5C6WYP\
M\%FS/XMQMYI?C(^MW/T:\8!7>M>WP0[B)?!'UWCB!<MT<:!_E&<5SY=T/%+Y
M-0T O?1-]X+GGBQ,%SL&"*Y,U+<LKPL3.RK5D!?MR1"3%\.1Q 7*UZRXNC1T
M+9R:"F^&#KE!'O4D1XAZ_1$2!.XJMZV=6,C0K5$QXVVZ/>NK9?GW'N8HEBZR
M\]J8P#Z./:W *<$.DD<D7?0[R*T^#(D$;(,Q:O'$#<2N/X]>5_Z+9&*@$[T#
M#/_U<UTR1*Y!]2#;Z('4^KZMRC4:[Q.7@6<NH.O_GE',ZA:*5I%6!WE1?MV&
M:'4B-0"3Z 2.YN]S&!V(Z8*\0TQ/T#::M!3M^LA4?Y7.B=-\(_P)<T"NF)+P
M%"+4?K# (VOZR."CC9\)"2?8]7)N+1_>T#@N&JA2JD6W\+$/ 48;Z\!O0>4F
MB8A#L*U@0@V6U?<9_C^E75U,4P<4KL LFT#Y42J(7**XJL#XG4RXMI'*;X?,
MJ%.+4E&'DDX:(YT7N.,"0DM%Z1Q!U+%6!PM*P,*T=$.$EA99#*Q6-HA4H#\J
MH"*W0O JM[>[9,G>]K2'\WIRSLF7[^0[#^<;QK,7.9 @<;A[Y10YAGR8M?1Y
MG$G%:'U1J1:YWW'"BU8UOOIB?9JYRFF;\T$RT7..:3^I^K?%JCMIU3FH-Y0T
M9Q9=,2G*91^GLW0V8H!@V#RQ(8\;)'>"C$"E)7(Q:3K0'1V0NYEM1Z#(5OBT
M)3R*G?M57M"Q61*Q.EN&:'[".S=.5HK>W5?7ZY]S);Q4F2'N<0*S;XQC\C3[
M5?A;ZP%0T,(76"XWB'6R,'MC#%#1XV;4^BZ"ZTVSR\E6O/N>IYN%-D6Y"EZZ
MDT7:VX1Z4H&.AO)^^0BZK[4JJH52&C9GH8GS >DX%656-$H#8-;#W6F&3,ND
M1O AUK3=QBC'8ZWII_NR(@5TB$-XSOHEHTU]$I-@30AG,Q3[MKF$5:^7(!XL
M4WM=.[YC&%QF10!\ZZ\V^M*9N#L8'2GK<F4Z8<:T)2,0 .-+P)//ICHG^WJ\
MY-ZI%II/\1^C5NBXIOTWIFM'I)3Z /3,3J4_ :.;'11-CM)!N9 %&I1/46HI
MT^,@82AV,>!AE@+0!YW5715)%N/9K3"[ACL<LRJC<JA#90%6X?&/F+[AU8"N
MXTVJ27J^DZS"1^T%C:@CM-Z$V?#OF]'EU*9W#DI0\9[#A;0Y!^4%4/L?MNX\
M"4NEP%?Z+#38+R$G> %P-,9:9"7:&C0C0/MXK37#^47GEBK+6.9N5#P3;Y6N
MP;,,3%_IN8LG@A*O%^OI_K3>L<*Y?ED8;YVU-VIJ5T$- ]_@5>F@G&R6UY#4
M F9/+^3)M7;]W2&C8G'/,FP3VD^LH!8AB*G' V9C_&RA OIILB\V[E8;$?*P
MV&=ZL&F*RRC],5]:Q@4JE8K56(-57]G:Q;Z52A(5(H(W1=AX9_&U0O.LWT%-
MQ/>?/:WBDB!]AB'J]V'2RN)UQ( L%JTSLHZ/,19*[Z*#$[I9EPE,__DC4(#J
M>9C2))1JI[QP-OH^PWV*8T8"\/WHGS58N(;E+W10/& /%<\7LGR99I\D'@RM
M,*;EOPP8=5Y(\CTENO.NP%B2X*"H$XXZ*(&*:.PFN8?Z[_-<H+-FJ4Z^?#HP
M DT^-Z]IA&JT;T\]X?;?R/W:]M(I/#H%$@Y^FJ3Z>?HT\(E0U[9C;W MG0)4
MS"&:G.Z@$W&OB*U8%2KFH&)MB+2"R]/-T-5;]HEU61O#;L&AV#WK(>?D$6+S
MCJ-H=QF\5P&MU[@V$9XH[-D=M+Y_@^MJ>Z[]DH.2*T'X\L<A:@?E3E,9Z'[&
M-,BV)(OA74@C%G)?M<:XT[:SM 43:QB<82%">SUV'?"&BL[@P=^TI1Q#;X<2
M"74YO&R,CPK,<@TBYM)[]:)N5T-7M(GFUM_,G0Y<V]Y1=#D&4QI;^9DCU!]:
MN][P >/H:U7+O0>W/Y =RGM:GC)65OC$D^V6M'%=F6MD25C;M8#Y=U\X%4Q6
MB]%KM "[[ C6V^-"^#%FG 6FEX(+WT$<SAVLCF\*D>3!OK+-B<X'_.GU%W\_
M'-J2M*?DE3'U_$S@1#JODP4\S_UKE3PF\_6X[.8K$K9[2_YQ5OW?L<SQ^&]0
M2P,$%     @ S(';6O,Y\3E7:P  L6\   T   !I;6%G95\P,#8N:G!GI+L)
M5!-;U"9:BHJ*$ &9AZ@@J BH@"A#HJ(@<C'.*%.N(C)$C A(@)"(",B8JXA<
M4<A5!%2&R*Q,$<*@*(0Y C(D40&94@RA($GEU?W_U]UK_:M?OU[=R3JL0)VU
M.?OLO;_]?:<JTF_246#S27M'>V#5JE7 G\@;D X"=O_^]G_U^M?(_ZV-5=*/
M@.)Z0+)*76;5=F"UXBH9Q5721@ - *O6_N<$X/]]K5HMLV;M.MGU&S;*(1/*
M-P.K5\G(K%XCLW;MFC7(U4CD.K!&<:W2MGU'UBF?N2*[/7#+_JB'+];K'2VN
M5SG;*= WNWK[WH:-JFKJ&IH[# QW[MIM;G' \N A*[MCQ^T=3CB>/'?^PD67
M2Y==O:YY7_?Q]?,/"@ZY$TH*"X^^'Q,;]R ^X5'JX[0GZ7\_S7B9_2HG-^_U
MF[<EI67E%97O/U0UL!J;FEL^?6[MZN[I[>-\ZQ_@\O@_?OX:&Y_X#<[-+RP*
MEZ#EE7_]6@7(_'?7_Z=^*2)^K5ZS1F:-[+]^K5H=^N\$Q35KM^U;IW3DC.R5
M0.7M^Z/6;SGZ\$5Q_08]L[,"E:NW.S>JZIMS=X#_NO8?GOWO.7;O_\BS_^[8
M__!K -@DLPH)GHPB@ 5@>.?+!."_#K]M]H=GDX(7I8 ,?K4G9=#*EC'U4^0)
M=QH+)MT"L$('T&7:EEOHUC#FV<GK(=^FEQ*%4%^YL]K%CXG'\%NDP-5/?9]O
ME]AF)[>7J!K4K7@OW[+6IG'$! &MA2EPQ*\5'X-0(BJ+C[W'7%OC+'*D=* W
M2X$;6 VR&A3UUB[9"9?*>\-A?UQ>3 Z]DGJ,8[._% J[1NKG5<Q1KGMTJ\Q\
MV>F]^%,*;$QNWGU^3X^>=9YK[U7^[L==M-*^<\Y5?H=>?Q[>8408;A\8S,U$
M>V:2:>_*V /=PKO@4A,CD8FJDZ=\&=8!\^[#&Z'NCQ0Y,"Y9["*RLQ/PS_6$
M4+7%VE H2+FT0%QGV" %U.S?<*4 2GRFZVR@8:(=V^3I[F,3>H?C.\G')!_(
M:,&8L TR$VWUA*P;-6/83:A-F-)\\?F*FNYS'YD*9!QO%;\2<A2,-%*N.AP"
ML4V/(1?P/&3AM:$,VCS8:I#:>,N&JC0$?T(KDBU%E\3^T)=\F#6RANI;#K(;
MB5%9Y@++9K02^597C0Y_9+4?118R$SSC"AG9>7'ELW&>N]/2&X9W"0RJ>7\?
M)7UH&YBLW[KC;XO34)X46#,L>479U4_I'5&7;4GVJF>6H1JQM"I\"RTZ:W67
M,K<H3Y#UY;+DR:)$!E;_X@ R$LJI,6P0>]R-CH+03NF\+</*(%G1'K8%#R:=
M.LX1Z\.-@D.:3>V]>IJ>K2>5'2NG#74O.3T]=?NQE\$K*1#JK)]!;OWZJ\*H
M9%@X)[;RJU[$GK0Q%AV!LGEZ<*\5BD6+4W5M2:'ZH!+:!*D.'38._!Q!W5/0
MZ!(QAKF!8N20GWS'5)Z42UU#(C.:+ 7]7ERZRE>#CFMI6E]\N='\9#UXHQT8
MCHJAZE#,R(<EC\K8<B334;7&:=QHY0.38-2 W!_@+V81^6P'9C_)B'N@/'M\
M9;?84I#0Q$W#;_X./23CC+\'U82;?21OG6M/BI3C6L9* 7]B-%T'ZRLY0@$@
MER8\"NM+'T U,%4'FX4C.N;.AJ<%L4\+R5L@E*#2HTM?0(!.5Y3 BARQ#..3
MAW>\V#U'6SWCQ-,:!D]VZ@A(;*(6MTSGBS#. :/);GA)-I/ C,>KB&U?^5>5
M.G&K9V,H%M#2*!.M8^UI:$\T<L.B@IVO&@H$*>36";DO!J-"J./%(\E-)Z74
MG%T_GC\:JT[:H5]:Z&7<XT9XZF&>E9Y@Y.0Z\WMHJ52">X?UPPXDGH-T>,R-
M9*Q@K'XZE(]*L0D5T(1Q4#Y71^8PIZQPXY)GCQ3PJ37BSA1DK4MQ>A:F*#[.
M/\)/HS4\D]GN^+*5LREN3 .]#GMC=A7<056QT1JE1ULIY/--UQ.HI7$Q6#^<
MBM@AHJFLBRR?0S[?]PAUOTZ>8WY9Z1<.NI2U+]$.''MPO6.?-JQ0)K"3Y&$%
MJ1\%R_;Q2/K!T#E!G+!1DE5WD,+&RE+4R?L$]/L854HG91.4%\*M-H4<Q,<+
M?V?94N_+C^Z3T#;].1F_&M)K)IIW[=Q;$&_P2UZ#:">)97KW2?Z>8OHM4#>2
MW%AZ?/1T&)C*)\9=$=1,?7E-LFQNRT:MEP($T_Z^ )U_$C3ND;RW$_#R1KL'
MQ2E?O\_E/(H\>3&:M*A^D'W\ZYAKP6[[6P'O1;M/YYQ54%JJ+<@V7SYG*,D=
MG S-77%S"NY;63':4B,ON@.I-:/+.=.&(KW?L *H%F-#$&R41[L+XN(M\ANI
M"N3;W=<@[U&L#C2,7G5HXZEJ00$D!>HOPA:"TO1'.VN<N&RUAI=&3_:&X5CT
M01$?W>+$D!T4RTC2RNCJ4N F_ 5;&C=MS4-#E[!EJFF"41*%):01'^"_>:).
MC$($GI#S4S F-I(/-"$[;[YDHG4UI\KL?:H6CS:U#S1J<8V;CN13Y4C91Z%(
MD.8J>65C*K*'6ZA*6ZNLG@KHR<'H_CBN0_V2KEE7= %5<$]\\KU@++E.77Q4
M\/K).1Y[U63Z:M)%QX!7^+_(IDBL%J#/HU]HT1PIH$2]BK^++2]OB9$"?V*_
MC0G)'RI TY838BTU%BT!O0;+O6G:)*]G!P]#0;QN!A3:5$*:/3Q7<_):BN.Z
MNZVG'VE$AJM3-"]9T9Z*/$_NWNP_<5YX6MAF-W ZB;^K-2#H0BYWI\7L\ :F
M,)TPP FEN'2['2BH*7>8I$9C_?ULG(M@#D6[3J"]8E\LTO]-T>@DGWS#T!*A
M5$8FF:52X&Z=-4.X*=H^_M%!+W"0Y.EPQ=JV/:G[Y<Z0*(H1$=IMV>@1Q*K;
M 2ZQZ/VZL\W#,E"@:!?,II:'-FG%0B#70Z9Q!1V#.40^B&#QOI<D(_L^\EXR
MEM\640_K".Z4&835^(P.XI7;+UPE4>\XT[7).I(RBJ[XL*0@!!<E!=9C-HM/
M=$B!@ "UCQD)GA"3;T12,.W_PKL8(S!D,5>5QX!UT4AG$C45@LK<%2BH7E<;
M5'_6H,1(W%&#V2;XJT1D4U&WA_$<LYU:O]7&I9#DQE=XZ)U/(C12C 6<J3;1
M>O%>268(41%B-@W@HV ]*$]HTT4^;'-EE)E"E3,WBN(6AHYRFOKMX[DH39)+
MTS[2=QP7O1EZ>N[+1UF;M0JZ8_2^[THW-]+W^)@S-!5?_US?ESMP0>?\LS<S
MQ]^\[DW2?.,Y737B,51>4U".YT[D=]LOB.J9 6PM\7DP)9N+ZE<3DFJA9<35
M%M9L'%X1LXW4TB(%E!=&HCQ7"?+%YP2TN#I]DBPWBU;@3B*T8':#AHUL13&F
M9P&O F6S[L"*Y0+BO7\X8H.L_>!CM""-M<73(Y]:[T91@<Y2^SMM(@2LEN'5
M4B F'\SFM4Q) ? SV>ZUGW&0:(<8!_V184[9ELZK6;%VAX@>4(CE@Q#VF@:Z
M<HTI[P-9W4:-3U<0'R8\M=$(U7\R9%MY#TL8Z9_D&S;C$M!KX?4D6;X/BST0
M JN3QAJEP"8#B)5+W@GBZ]$IGALA-R[C?MW6 "VW/O$N'E$>&N2J)2R@9:!M
MS%O#2B QNN8<=U;1?S-DW2S'U[A:#([$T04X8H(:71'6(,WS:[ ;Q<$V5%!9
MR(&211Z0G5--+RUJ"LM]35$DZ8W.Q A8'T'_86UX".3$V5@*QCYF(,#AP2,J
M,Z(-P,?W\!I??$N@!*>#[[(=#&^_64P+/Y,\\;K'<^#VC[=C&OX3>1IO_9_]
M///\\;G;]R7]3LJY W45Y46%8^6S@_,20^@RV-?"LVRF#^!&OU.T:[H-))ED
M!T'+L0^@_$^QRPHU$=4X$IMAV@BL8)Y$>7>FLB8*J0U8JY-=^27I1N7/T;F'
MU3].#"YS?N:)E3E"1ZA;M)?T1<B(X[4DW\#HD_!-4F S1LV/N;HF0+_+DS3;
MB%Z'42-K"2JC;-30368V_JFD^88WV;2-0]#34)2&(W>>[WC''7K*IRWNO04L
M,%#[LV-9/'SOM;=-]AG"^-MO*D]IS[ O#;NW-4VJ?J=\KA;55%/Q@O"8+6?<
M>1MWOKS[OQZ?;->;GUYU?,M_#KR5^ J4"3IPIV?C4KFS4WP0S?]J535<41@T
MRM 0:PC**"K7SA1;!(%>/)=[FB'I;_/B/,?7J2O^5:TV_C8&!L78M/,[6F>]
M30TKN:_1RE* =1+NQB[03&E2  J5 EXT.!Y%'1OWE0*Q:9)<ZH0N'BT%!+.4
M%K1$$98"[ [.X+/(=!BIC,G.RGY<Q7>?Q4),I2/U:UT6'>'*>;EZ<\L*X#3$
MF,/H(S8>2W*8$SI2 ,T4"/ZUH80>HY_[ [F0_A\7J&4H6-?TVX@4>&D]N+R2
M(0HUGI4"D:;0V9O8GZGB75+ EWL _I(]('[*&(%!(F9D:V4>O"9%K7Z@KI@!
M$>WZ;(YSD[T^5K7GY5X:\1^6[V.8&]M=$#1GZT=<[UST.,>B; 5=8G(>#7CD
MX%EU^A^2>[)?/7JJ;AAY7"5V93HR8&!ED3/+>7\O8><_,D"P^LN$G<#_<B31
MSL!!L.R<^6F9==]'J0>DP&+X$DP^5!R=]?>AE:MOV[;7*SY[+_Z$^29<:+<6
M,M:_A_I?^%<&72*A#H/4QJ?3KFYRS^AK_7;;'+KANK6Z)9E\!!M#WG%0[I.S
M3)-RJX:3RKGR_)-;]JFDII4E#_;?8%S_>2WKB>M0M?XS/^U%PIGLG0T'QIYG
MJ_?C1QX_]BI?^/68XA(P'MZ<S<.A?%7S,<4%?N&V%8ZHM_Z;+\4>.K3U*_CC
MFO:?P7R;P)P\?U<*PUM%^#2"\-IO:=]3XYO3)A>%[;_,FH\5%SL ]Q3ZFAWV
M.*A &P0NPM]0-1C$Y]"VTD?S8D((TU8B5U GA?[#BI3*9<?"&M9^2KX#'.'\
MGBS2K?:DPM%YM22+97+Y:2=4'S66JBBV^&<W1&B2*X LFR@[..7&%]F.H&7<
M-8$P.C+_]X_V 6RT18\21, /W'I83^2YY<>%R0167YT;+98S9]EX:CA&=#F?
MW/]KR7MGK;?*UW2CFXX6=RIZ5H8M1L63K.^<79^AM"ZXJYUT,UWIJ#GA3*'Z
MF7SU4QFI+\Z^S-EUU+_G]_OS_B;N12;&D9?[$@X?EM%7D,7G:.AFSZL4SSL.
M&0X9+OTVWG+F\/H3VED]?:=O!=%P=N.RV"^%5SRA./O2,V/XCPHGMAM\)\T<
M4-5]/S;85T/GX9L#S#[JK@*IR5*@M(CXCR T+B3@QL!W]]PLSN1+VO#VLH1Z
M.\L=K=<0!6!]XM(-&Y"4<S_W>9[!8[T(RUT6*K5IC!T,)UOSXB<&50U7O),R
M>P\:#$Y<>T:]C7M9%_<^K.#4QFO!V"\,=%9$ACL-]TD*/,"V,V7*&9"1;+/<
MTWTOR2901*["*0MGG >(^G&A9MLB>[YH(]+K7:;W7!N4I['498^B8BQ^K2B0
M3Y'0KA)#%-=!O<=EI7QG;JK[(F\V)/+0KHJ"@L7AWT.XK_E0=?WI.R&_!@*L
M[:X_P[E-OJ4&2C1,.J<B/RVNK"3<Y-5HWPKLYDPDP&'!L]!NXC1*34PE!7%3
M7@8..G',NRC_0']+ 9-(PD*U\+3D[2*#-H(JIZF0GK%<[1\6^&*VPZSJL@ZB
MQ9'<-YH&M**9BWT\!_F*.[B:PQ>.OKB<XV=#GKW[/G4K$FI,DHJM[>)9X_"#
M<TV,VA7=$10XBPI4,/I-TDS^/-VF%5I:OB@._;"4K-+L"G%./D=9LRNPTR8.
M_'O[EB-<G FO+WO>NS%SA<[\-%*TC]Y59R.Z/8V$=NW_S]">*2X:SUC[NHX3
M8B2OV?AP554/0^\=S1"Z\&OG_O"D_7^M/R3#R!(? \U\-4\]C""^N3P^</'%
MV^A\:"#B#-6;6[BC+*+2(^#OJETIO&-=XD.Z[^<^;Y)U_]YTDF:"BY\;'SB
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M:,*X[N\1X>$FF443&95?UF2WZSWS:^Y;0RTY(LOPROK&V/3RT7=Y!B .AH)
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MZ8SV88/BOBM5WN\XYAU4'N[5[Q6;&[2RL-<::5NRQT\.7RU+2"M]0]@/4?\
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M=-?$N4.@#;I1O78?64_W;:NBARX==6X LXWR[Y/PY:8C$Z?=?.!,K.E\O9B
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MG$U-@I]A5:%HQP\">UH^._N+07*!X8.7+J"1_EDSL]?E89L2\G_IOZ#<9>R
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M!M5Q!T>F3%4<(3OY^8XT(%FF2RF)_*F)IFJ%'[%\,J#HCMDIT?I%PHS/%A[
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M"ET=VIG46$17$*\BV@5,2W9#0W2 :=,VHU1D1U%XH W=K#(Y+WB)L*C@.3C
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ME.O+'%P(#B?**V)R>DQ/RU)BMQJBY>Z[N"%8Z\RIFE='N*,3PJ)7T"4^\ S
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M3V)5U(JJ1F]S%N ;\S1!2A#*$Q+3\;ET18DG\E.W#(6P#!1&)R,9*PW('18
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M6/453\-+-IH^U^JLF*%55E'Y'PAR?[[)=KO-<5F?(R%/S7Z(P\WXLUUA!,;
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MG(,ZWEPY1\F,^IWREQ^<%78$O?+G>1X(7Y9/O5KZ3$J2(Q[.L>/W4VFGBX/
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MYZTROO<P1U]^QF5>H4C_1?:+0?D#E])6^8O6\OOZYF6?7.L-UFN$LW= &V0
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M-I2XC)A&..T&C&H2=/O#^DQI"7+>"Y5BAIN8GV_554SZV$[5-67Z\H%WZJ)
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M>B1V)"Z/@$8SD>&"V<[,1>PQG OFW+1<<I\?[RC],9U^8(0/8&=,-]$!;\B
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MJ![ 1_SP@;%!M":6#$!!&4]YS3!I9\EH:)$,2&6#='/Q':O4S(J?U6BY?62
MJ"@EADX<C3KADI[/GZDYZ%<^,V$K'M[H>6%!GC'G_?N\P+[;>G\P+SX0RD84
M'B8QNUB0T@HV@:)39M_S)*9 ]A\1A#;SD"#3$#/;+R?Z2_:/LCFW;?HOSUZ$
MM@^*UC?&BS_/O,LEBN/[-^:O"MN CVZ8GHR&EKL.J]X8VIP<M-UV"S[8""G0
M_.LU"__L5!&)<Y@,&)D(G;8E!&]K'-V^=2:LBQ HA);$/7<:VV>CAL-&80.>
MB-9/>-Q3TC\M==>,%&HQR[[WY81WLN^> _!>SK3_E SDQ) $;W4DI97:!EOB
M'#B.5W]WUKG%EPH&H<JU76_D#3<8_<CQN-;1F#P]G^2H.Y*8:*!NAS<CLMJB
M.J'$V_;H&G9BZ&EU8S[3>BMH@:]VXD:H"N(=9N\=UNQA^B"SO.;;Z'9;^?LC
M62F^2<6Q/,GB7ES:1!9MI&+T%+24Z'):<TUIZJ UM==VAMJB];K74RK%)MJ7
M[KY9^E55T,9V)HL9RR-_7!_7)_Y-79OC$M>J//SD!MRYW@#C7E5/[:IJFU."
M<9VQW \]%*MKBC<XC#'<EV>ZQ1]!0\7D30.*H$%&J'!9$!I">S6-KY$F;)L>
MTA68D:1RO_&+TLD:A/_\NO0^.5!9<*SS;\@Y55Q?'V;?JNE(PS1NU7B(+RR8
M_M=@D0SX&S2NGD*Y^<]@84*:OL6P!.G::5D=R]]BB/-#AZF/_'L^5 1;H]2H
M^VRN3!+YT+',Y>"@[Q;!QS8U=DYY<];F5M73!;L8AVBTY%?&[.M&;ZIE+S*^
M@5'BL%UD "7!$K7ZVJZU$=<7Z6LI27FGJ:/CRWCUAS%YPFO%S_ 0\,Z\-<@K
M+._E#B@.,,!C]DOC#T3^U[F[!?DU$H\\!D(/5M+:K _IA<>"BD=#'J48Z 8J
M<38O#-0>1+'C(429 C*@Z--I72?N: ZR$_'WI 'XBPK[N)J#$ WZ8&T?M "^
M^2"<$'L %0N1.F%$9WPO/YOW;]!)K&L"ACM$<J]-*,'XS=;"/8X\%YG9.:M>
MIJ/BA(+G@,(84<K_R)]< (XC__2N%+,5,N"UNB@X'\G1DS"3\@#/N(4_T09W
MC?7E\YJAJ:."]7&SJ/DW,>V2%03W$Y1&%Y916P%600;0JKVN"+Q0B^IX-G0P
M%"3JT!SD8#<JV-\]KH&J9SSERO]KY:)M!LB '#' R9T80B>)6_J,Z^6D,ZX[
M;G4>U17]ZQ?_#W7_>O__6/P?B_^I%H^:_\0;\3,M<NI\C6 !:9RH!)\;#M9&
MGEIVDZZ.J-,%BX\JS%.:G@BJ5+^K7(>='WZYKR_P*(:^XNVS<?G9->>Z]GCN
M=VB]3(<G*VD ?U%*\O3_ E!+ P04    " #,@=M:EL<;);N]  "MP0  #0
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M_&_!+&#@X 4>JV/J,<1_N&[2U7UF!/DGOPHT3A%'21O_X&]'O-BP"N;B,-Q
M*PQBPTCK4<_W;ECBRVLS88/D"5(_R@:C!D</L6'QERI(G436LUYBT.R$$3-I
M4P^VIH;]MT+ @*6[:_^^.U:E?!=&MCNMFUG 7#>N;.VBH2\IYV/&8J Q^8M(
M4A$;MA]6:^'ZWU2[D_FB&I>,EKOD\Z_[ENN9270%K#1N3JRWJ+=6_'QRW_K'
MJ]^FA*U>7V.MMWU7KSR\->DT0>J(?;LX_7K0/>K*SX>WZVM1=__$SY,5HR_M
M!LZQ85-4UGXSAG)TKZ')C6R&.=Z"#8O#8,8W%[YL5HO8 ;,I>/-7F,4S3G9P
MAHT^P(K!T97>/+2DM;^HJ3E0IV;S=;SGRFN<VU707DT4*E4^V-AJLQYBP]!T
M"C)5+E^Y+J=+ @NQMHDX)^7!^F^_*+JE\>].;/1,Y)5)F*0[OBQ3M7QLMC-B
MFY,/UUO@6[JW_6GZW3L%H^E\>709&87I*TJ]>?.JM+&TD9D)J^,.@P7GB>ZE
M !=0DW^WEX!?'37,0Z#BA PI/L):K^-N]YWE2_ZL$W5)!N'5WEZ" 6'G6K4Z
MQ*4;OOLU9]U]$!<K[<?:R#PBU8+\ND ^G]$)[>2IC%-=J?WB"8]]I*WR3A*I
MFHZM.2G6R]59=GHCMUMZ//5)0$[4$^#OH>M05:K1!\4B5Z'4,C6CE-" DS_+
M[>W=W[QIZX[P'[ VB?#U_?C<"';'!8\"&2$00:U6L#/\^E]6-&FD@LJ&P25G
MB>O5P=6MC$&YD8K:F%N(T3X<W+YSAD+7O;"AU_F:<!)%96Y6[[]\T,$"QLO<
M2&'.0:EL&,_)W9Q.23QZ]R52&,IU \]CQ @^6!&\%$CH(0NZX[S6&M5G]^-O
MC3-113A#3^"*VQ>F11$NS /,B9=,/YZ^-UKXWE41(ZD4I;NNJ\F,*TR^W=A.
M'D[%-Z!6I>FI%#ZF)M!93EL56V?8 BPRW<YFP1D4)A]*+UJ4L4Q^8:79,R'V
M[9Q!^@NE%$/_$W2C4B8=*F7#]O[>)7$Z5Z7=C7$!\ICO),M$CQ2>V'W*AOD-
MQA$.(+1IT^;"B7-H'KPQ%/(\8.8 UFR>1.>ESA([)0#OARPC@))R6"&">/H[
M5K'S8%U&9^JQCW4M8\[U?Y/*'MMX9G3LMR^M.%VJ:B]T=R+EQ9+QA_==-EK"
MSF(O5S6U5IL&IFU-49WC:Q-VZ"^\NT71>]BP(%SE*4Z730#%+#&1O4NMQY/G
M"2+$).2!W(M -)D<"/^:ATRG"\$9-P=H W=[3+9?Z?%9T,].N 8=;MI\0I7*
M0T]QSWF1DC;)^SV9OI SEM[AX0)J)X93]L_@S8$4*(\-ZXD6S+-#]>0)9[WX
M!B5Y6M= Y^NI](^7+D>M_/!Q&W8Y4P\6CK+XXH&V<Z!V/UP""MR._:(W*,8\
M \J7S6/C\U;78C;AHA"1ADF)F)VZ1IUMK R8T<O%@'J)]+7$Q!XRCU\ 0D<-
MI^K1!1HJ]*UT&B/;:&1($4.=+D#3M2K!N_/9?WLQ!YB.D!<CD*D#:B>MXH5H
MVGMQJ:?'4,'HY"E)(AX[K[WG SIE]NW,4:#BMTQ_/%,F=*GSBMA31:ND':FJ
MLMAC^>6@YIT*CLI(/FP-R_]IPM\G'/98029\P<4QXGA)F;E3HDFYS(OACI$V
M1D[;U,#FXOB?\=H=739,Z"Y#53LVB'5L@'&>-4BE[7XN+_>[[6U"2&/#A)VZ
M#&6:DH_O8BU3>S# (S:LVVAG-K&]:+LR)/S&?;ZX2LDGO<C84?U H1O=@\XC
MV.H((91#@T>U[H7Z-LDFUQRM1Q^%UL_%7WMX(B0S8Q;'?73O*M,9"N+4&A'P
M3<"C:=I)2!0T4(1W NUC0/$+8&%9F1M3&O*9(R2Z,PA4M>79.FS,9H<R+2=M
M!'*B3I$2$-ID0K>'=O)5,2\<N>>CHLLX2QR(M;@BN>B[4@XDGM_-)_BB8N#U
MZ8EIF+YEP)7F&H.4]L#EL3X?-G2>T&/#N/U"H&!-]WN'^*\3S_D[6>Y_89BI
M&"Z:X'OQVOR-KQJIPKG;EKY.!HTM^;\92E77?WXH*'@QYJKW.&JL(2WJ>J:_
M5OF.*1OFA7[I]Z*2OYW&R((*21-P5NUX^Q4!O1G7?ZSH[Z9.>++I;L@<$?H[
M%Y-AO)"_M:(Z1/U)X BI]];5^_M57OR/\;G!@;]0/"WVT;]K6V:FMZME!O+Y
M_EQ^=CB4;_.=\0(XN/Y<2$WUI)G5+Q5%T;0,\S\F%^ _";D$M%D*SPE\[U?=
M=TMA_[AC=\(F7IY:6CJ8O6%Y\L2EB$&@L#!1+A1M \*)\ ;>;M0DA<9J!FWG
MM=,WT5PX!6I.IMVKY3O??UQ02$,WVX_^K<I<:FU8[Q;3/#1Y_$WVN_4<\\,$
M"0+@@(+4RU:-&>ZL47_ =5L:(M(KM>,+)2;"^P#+4N X5M(-&J3_JJ[VEU%\
M_RJ KE(=,5L'F?9$ZDZG\Q\E4B5UJAR7A$S/IB $V;"D$T\/R9#&[RU^OCC/
MY^0Y&AQQ4&)>4E7E>]/"A_%T]0Z1:;SD#@IL3G]:ZBZ-JG^WCC SV=)!>/2,
M%L(3_#3,I,>S#9,?7[-QSDMI5)E(*Y(VR0I)-S[%6J_K?V BQYV].%VH,OF-
M:^+K_#HB?'DH6A_"T$0R,( [-JE0'/AF0*B;72$"\CMVW-:IER8Z$4P_$)/&
MM-I]J7=KZG,%7A2@\U%JBZV^'ZON3UO("JLW?:U.C$-8,*S9L*Y/!BS%\2 ]
MTF387&EOQK/* )-[C7\>T=@P/J)0@#>&O]JOOP<NRX;1E+.HRZ-W]^%#,M6W
M-$@Q.FZ]G$*IPJMF-_)=;%).*G>R/YF2W5#L.+CRAFD]L^@WNR!AA)&TA7MP
M[9*[_UP,&"]9LD(5&Z&_CE7:?4:4ETFWVCN,,^LR_BQLA3[[6D#CXZW(A[^[
MMCEX9/OWHG.2H,$;[UM?I10*6P[K="W$K*8PT:-(!4)7,%.B[%+ G34J!E+^
MV^_O4UO;,8Y'T40.,VT@:[J9&2EWY',C71',C9_\DBIQVRGS\RU:W:P\;H$E
M; I% +%]MD#_O.%*(ZA +40--P:=L8(*7N*LZ%BJ2/(==)R7@D";!0A/9)[9
M3:6KON0KO!&+*)3,TV6\3?O8P!P\X+-9)Z?^*:2E7["]Q=ABG'C ,7K3P_5B
M=H75T[*/C*:IOR0-S^N[?X2 W(QVRT]+/G("F:[TFQ\*ZQ.%528"$",8"5>;
M[.FX>:G/#<9ELDH=E%,$+!92IZST,_B_V\Z1#\T$=)I"'RL@A5[YX\#$ [ST
MC;P,4E#Y[T<5?E.NZ1&_%?V84H6J$^==AFQO$8\'35ES:P2L,1&$KE.$N1>=
MJFS8@P=X9X"8@E1@ZLD@\D1BT _^-!!YES4K</XI@?)'P7VI826+[A_ZM1)U
M:\B"WMJ:]"@77,-EV[ZAYR@C)H8CQ@Q;9B $@I%=*.%V-WA"(^$P](SNF[IJ
M][EV7@A%0\7C(^;W!7'AK\R?M'1H'+B)BS[^]3[/-:EIT:N#,9AZ-JR71$1)
M(*0!*DTD41OA.\^&22ZG!](&1<Y$ED!AD=O(AZWS 2NL(WS)1>:T[QO)<DF3
M!X4^]UXC_/)6I*\L&.:]'4XKV)^=^>!EJ9*^3,H)/!#;4>P;9)P5['"GD35_
M[S KK? @3N!1C7Z?;WA1_U-YD2D0*P9JJ1^-#Y:,,(IRI=O+%5&S0VS5+^0X
MY=E(EUK)S91D&]D4X)J-R+\_LH1&=^-1@01NUI#WD5UR(^,PZNULW4(R$K94
M* @Y[VL)+!$Y@*,Z@_LZ: 51$6;B%D0,0=3C-U(RZ-!9K"BN2"&K%[#)2"VH
MZ]_-&Y2O.W<@X'45=#1Z^.6YRG<_TM,ZC+KFE0O[X4A6/QL&VUR;?+8= &D#
MNNB-CTQCX'A!\1(ZI+RI;)LDZG7T"^*:>D!BR)M(4*NXZEW=H\:8*0D'GGNG
M"R]P7<R\[JEE+9NMN[$N/**3T6*DD)&]RY/C5(U6_GBB<3HT7BJLTJL_;W\Q
M$9F3/OHS/3/%L\G>$-5#E,-M>RM"I7UR+K,&#DBU/C:L4C.L%RE7E-+C\.[J
MO*IU17#<%</L%A,'YX..%])-PTR\*Q%UGD(N PV[I\=X6IH,C4?7LLC;G1F?
M;$\H'K#>#QVUE4:&E1[>.=)'F/^UMN?'+9U^[ 7>UUT_KKTT3-4\LJ'GY41X
M9/:R0B-6OGJW=5^<]<(;GR.WR3^;MY<@<X;J$DJ:$(@1P\W.*_>D!]+_IK1'
MEN]F];J+=*U-.?5U\NWF,'6?,T] ?/@0\%D?!;B/2T?HD*T9JE"DE[P*I K:
M=E. 1'(75AH?-3W? ,;61NQTPM^]\M4O34S+ER'J9I:M1KE4K-ZU"?GI6!\T
M%CQE*:%(XX_VS)Z=66V.G-R=3:G=O48]D*#[;9Y8AEUT41>WSD2M=""-UCPN
M3OM<ICJ^46_=%?1#-1!1Q@^)NH@K /?E?:81<]:A'QQ8;C:F^O6!OA73OA63
M2T^/6AQTY/X4K8)7AWS LJ[6?NI@:B<,\.V9A4$/](GN0"2QW; 8>D8U'%ZX
MTU19% B@@W0$+QW_G0KSX(H\<"==_=PHPK1T<4HKV?=:\:*)3VEV3G;)8D[(
MI4N3_COG,-KV(YNO3FNHRCD\R32ZH&;IX'KK+/?E&?.#M>9Z0R43<'"9Z\BA
M*1.5'X7?YH2+[ESDO5"_>I+0O_#5WI6%8</:6'\G4D:VOMU+;*>!2FMOMH,T
M6ZHEHY2J"VO>>L&7+<U0VP%/7DO]$2G%%S"<HB=('"=Z#9,X3\?V$Z7(L4S=
MB,I+OUO-&;I+,@DME1_V?5>VBC'X]^?<WL1,A,^[RSVN>:R/%,"!/(G=?M-*
M&>D4AV;\(SQ,VZ;1*T312Y3$1M/R(U[2>>=>A"[DC-,N\DVONR5^XL*:_9)"
M5^^BGX95:T9$4FQG"4N<JIR$^N-WIM+R30:T(T<89J9>FMCZYMG&U$JWQ3O9
M98\J)CV\/ KM&K]*,7G-:OO,7K6-7;GO2>B?V#$PO)<WUG32)-1X!S#3]=PE
MIC#-PA#;(CC-+=N+HWG+]F/5LW9C%Y:-UG-OU#E:<__X<^X]]Q7TDVS>6O?M
MC-T<-BQT C@Q-3$*,!(7RRX\V/&27W>(O#KN'UGZW;.6-3QU;K9D69K'\]75
MM_=+APY87ZXPO=/5FFQ?7^HIWMO15/HM/"(M;.NP:@3J@%_KZ=CRI=;;!8\>
M1LC^W@3,I?=*&SP0\8PY,S(QPL#8[GA/_//4"![V['Q$IPCBB(/R<% ^M4;6
M*96\$N1A.V;QJ-_U1/LSUZ8%J?FR@*^Q#K7M&_&EWSN&FXW>'/J[OT\W;?W"
MHR'Y4)-K$:;ZK8%?4.L"-<MKF%]^#A8'[ZN\2-%J(W<0GO XMR8.I&TL0L)L
MV,)XM6LJKI(^$_,RP!4I#ZPVE<Y3I-P2&:X)>#66W[#TF#I<*O HA08'>LS-
M5? .(<&A)VOK"K:$$\?U7#LZQ+:^*)%=1E;6K@^8K$Z,DFEA7XX]4IKJUF55
MK5Q%&RFN'I'SW?H124Y@PP*(T^0YRDK;7&5!I'O'E_9 ,K+^)4Z=ZLT+2!"W
MF^KI!/GE0$43PP>;%B)URSV9]=*Y5&]XSD;O*<6C-R_M"?Q)FHK<S@&%JNX0
M'VBW7QS?B?G"AM5&W%/OLG+G)'K9M_LO%13J@4^<07A&X]:%9$8C@(V54]'%
M/L1B8_30J3)F$^G1TOA+K<!X$2@P3TZH:7<J8QZR)>Q+=^J>V0>=F.H:0N Z
M^<<;1,3@ H9)T@1Z&3:%MZN_[Z;NG*>\!38MK:[T?HZN,OW\XL6X%DEAIU_X
M);&?V=;V8*;CCV U+8.TK-8@N.1]4"%&H:<EP8$X<%0I\V*IR? OAW2WBL?Y
M=;Q*:Z>=C^7[Z-\N-BV9(AK21%8)#!M"UQG*7&6G(05 4/CQ;O=H:['(XV-,
M-BP6(]RN7U6/LW*=T&_1\Q)W!KL_[*^I2_(!?LBL)74.\+1@#CXI3I<Y12C5
MAA3(*V6O6.](=7]R(QBG<*;=T5Q0UZO F2/MM6.-SRA\<)G?2 'P4Y["[TZ1
M\<8<KG!EUJP*;T+S"6N#^VU9/^>BC["^H"29D<!RKP%&L%V([G6!:34NV149
MK0&)ERR*$;H5Z(_[9E?)*7?$<>=5/Y1??8,4"@K'*7TT$(K"/(B68@WG]=57
M097]\G+@D?%PBA1.G"7:1CDP$XC4'^6''%YP F:J^Q#'&QYAPXKJ&9&>;%B*
M1V]!)6 =(B\9N[&_W:KW'_K0E^W,_(L!MWY4AEHZU?U(L);)KSE1A\V^^VU
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M<_>:*(?U9#'BD&_W7_7(>0&_?=@JA%G1TC!1>NFUP3O[K!H<0F-&Y?*GS 2
MM6]DR:D;85XS&SWHK3O4[C5/.+2$/+;[="O(ZL)8#2*HTMNN? DEA BC+PR%
M!\ERR*]<)44/0EXS5(>G*@AV'@+M.R38L QW6Q]Y[=@2L'^%#7MI5;WD;=P*
M58.I%N"^LA*M1^7??R.UA_4$A"Y)V21D==WAI?[#Z]!5L]WH40@[FG$D]IU&
MVB=\ "J.(HT_#!BW'P7@/7<,5^&<.#'##1HFH+O7IM1=,<+0S(3=>/B], L[
MWK,0B1.DD?=W]H.T;* Y%7]@VN'ZE?D2%Z[.+%Y;H2V<I7&<4[G^H0K+"XD:
MQ0&D3IL7\>?*5)W^7MG_R#&M5"9#E<DZ2O\RTQI8W%G^7=T_?/5&JY>'+>D)
M!KBE3!U,E_E)>;L&]Z>O]9+J_\:S88TB1(31E D;=@/'>_&(!)1=O<+=\^R8
MXS&OE@N2/$]CKD$<[=C;B4Z-A'/$0M.7YGL_:$N41A(-F.HGZI&%B9)-S^Z5
M_LY[#Y^^$J[DHUR85FH]]^"DR-8&8S]$L@-1;['\T1_9,)D@\G%HD6&"X^Z2
MWP]US,&3=I!$5)*,;= A+Q$;L/!A$*G'6Q8DQ2"<RBQ.XEQ[9J0SEZ:NQZR^
M]*L)]E;I?$*B56&$-A<;* ^F?+O9,-[O@=%'QO3Y@OX@Y=)/+PTZCU.E]>_G
M22:W'W<Y87[CJD2:S\5WU%#B9[!=1 WALB&R:JQ2WGACJDQE0\NM#_O]1[[[
MX^L[IE[U?]99'&.0YC"'JAM]YF+_\:EA1,7WAK]K+6$TR54)8)I>_?-OXN;T
M*IK:B1SA?4IF:H"=Q"J<(5WK@8&E@(C(<FW/SJ^X&AUX,EYK0O[ ]>OK6 &]
MI,+ FN4[S7V4]'6<+NWGMP.0-DT/>0S([4/+GYLN3>TI/$*DRJQ0!-HE%,\=
MA)+#]XX&(WSIHHJQ74/+WG /?]ZT*^M!DG3TBC]M+6W*,@^I@O>&NBHADGDG
MAR@*-8"RI 82+&"&'Y1*T]X>?/",RI)/9J)"W\+D.H:GG@;][,1DHN9(K*,@
MX>UL&J4!M6+,. .EXUU!Y'R_O,IN::<DWJ9SF)AHU3\8ASFH1;-S=3_49E<+
M+L0B'.MP=_O=-4Z2'^M[>*2&A?G]'-U$&/#"?M\P+G1UOOBI;LJA4=)^Y&>$
M<:!SJ:.UVE"QM-/C(C6;$N,O;LHVFN2XGJLZMA(YM!#;1];-QPMSO_0_57[9
MX5$?,)W%&D/5#28&4["#DUG;6^/__3DS964^%LV/<_6",,71G^!"F^D>/?*\
M4/4KB(X^H'HC[O3S%I/-=/K:]V\6>O(R0/Y@%.TH[?+&/2'0=CL- FDBO%!6
MGRNFSKX@:LY+C+HZ8>!M!JT!"]3.XV.73V2;7/TMHYR(#Z3%UE@;X)%YNM#[
MN)&ZL\''9YO0-<'MFB6+>4] GY?QJ"1]1B"F]FOJ@/7:VHK>7XU/K:;+]5%W
MK'U_74\Y*[;GW;]O7YFCT")HVHUI$.GWLIVS":0T\,;I:4_.6G+:>DT\ ,Z/
M$*<OK\FBP<1^]S?P_9NYZ^VJ]-_', *XL#,3[6X:WL>:;2,Y92[W9OT14U?7
MU7Y/0QAQ9>E2>\N-Q^L!B/KMNEOI:@[Y)9ENME0;[<(7WN,=[EEA68XA<1>O
MW[B4YB)!AAR:=?\>>]$8Y/YA\;M_@VM!S>1FV?UH67<H/1R509)"RD-8VO'B
M,BBJ="1:QA]=YE_\ME!V?!/WS&L4J0H13U^JPH=560A\7L<1?@&N<1\T7 *C
M(@Z YTF7<<'SUFW#5=IZE3I7KKR:TOQ26EO/X%;*XE'OU*=%N[HN"4\XGBC1
M87X"FI.1O!"V+UI\!(F$ZK<KQTK&VZW\BYG&K;N5#:IX%$#R #]EK"_F(0)I
M! '(B=;.4LV[KCWW!JE"7?AXBY=YY+CU?=ZZW5I*$#D>SMUHICQG@G<$UN*0
M)YCHID)TXZSM\5?1'-5*DOG;*^1[=OCQAYT/"3G:7#B?3[;S*"F^%P]4-6B@
MWJ.-\8^Z<OW2@O)BV:Z# RJ6>C]7:#;:><%"8Q7YJA;N3MGN68];CJRYE%Q1
M.G.">N4U63SU=LYX\'K;]'=_6Y?MG]8!VZ[(#\!LSZIV#TH$@0)YWS',R"F$
M^ES;4;N1&;/QXIJ ,HL1/=H19VMYC\0X5,ZKBD\#S3J=]VZ]@2\LDFY9%?7;
M,,M&47Z*8/9@MP@?ZQ,&AC1EG@'*WK)AXOXA 2<#9\1&6 >@ZXMPH IQI@@7
M(EP-)F#Y<$_0\&U6*MWR+H'_3[Y:YX]W&:;RRKLUG(9X1A!?;'6I!K@QD-O+
MZ=1?;4#W[&^**%(9U]-?G2ZA.#3U[0Q Y;3[;:IA"L)AGB<YYFV:PLG\BEO;
M)TOF[2Q%GZ65J5RLM)'P[[5^%3;B[..BY6"#X<D]V6;M/VQE0#5J]E?<#CA9
MOUP<8FO[%^64,#RZ>9/@,-HL\2-:$R+3*/PS1)%I@;5#N-YJBRE.VC_05$O7
M3^L[)+WUZLLAE,CO\S0)ICG=6G/U0UO=AY7GAKTLL7:(!FKWF0S\38W6#D *
MC#;'^@#R$^?@PLRP,LC'!YOK/N'5CMEM+U0,[478TL3*]Q"U1&3*97E'6;)#
M&@C#EX0;_N[RSUY<$J#B-,.?\W?R!D<4W)R#'\#%IY1?*3PG/0=#3+5$R&G^
M^RGM$6RAF&6W^W+KR[T"[;:FLJ*$FEK#NN;J+4N?W3)B^RT1YO&=#9P3=<+B
M 02G_7E=^6JF6"YNO#U0II]^JG+8HSMU[I_.WP*BLN.@W4B[<3'A"A3:;P?,
MD +9,/G;>7:D;>Q7G=6Q1Z/,C2'77.9IT%->!""E()SQT:-E$(9ZIRQY#36*
MJB?078O\*-,SE-,FX^$5],=%?*42JGUJ[P,'5/H[IOUGIIJ#GK9/I2FK'I^7
MLG>TC93J#LW.6?N>UG2>:0D-E'@,,,R9%YI'VJVK<9G4N712 HIV'9?(4&"8
M4DT2^U!RORE H9^W(,?Y$7IB63[4:N@Y&]9[F B]0FCICJ+0>$6(DW9PF[A8
M:J%Q&["RDY!; OG@X24!+$4O4Y:HIK)'D$#_G7D<// $ &7UN'\%!M.-9^=U
MBK2?O.IZC"<P%'%G^C '.N669P_C+4JA>CJJ^^Z@%%0V;U:8]087: _5@F?Z
MO76NU002#EZLQ#W=%(F;D?,2^'GYH IV+[/+H/DYDQ_B!;LWYBV(Q,YC.-Z^
M0GT@J>X+ CVG$%4)&7(D'),@LYV\VU$-Z5IB1 QCWT,)"*O=./P!WCC)KNM[
MS@C;13_-OV'LXL43TWN#T_E\H6_<UQ_/BT1&J.JKNMLI-EK?_3;!ND(C"(/Y
MUOV-1LOQ1M[J<?5WLA4<Y9STI55'"]#^/5KB>9%9Z5:9??ZF/E%AM]%\@]/5
MAMV=<J-7*+$V(PW30:B+[:RI]H:&>OBD[\7#$37[>,DV_6 B=588MV'9-+1%
MK?;PWVXF!7$>]=U+XW@#P@\!\F\S/(H-NS)H_V9A(AVZ B[,L6$]R[8X!/>\
MD+9C:^.-NOH1K2>+4]D[O]&[]X4Y<8M_#S==" ;%RDLCE;NXZIY]A2U,56[(
MN?<,]6)D>53L6BSL^5\6_&C(=_]BU#;YA^ T>BE-[G)YJ,E=J\GUN\:A>B3M
M^G8E?[]_47G!GP>6-SI(;V=Y\0B&&;&;$E_(W\3 Q(@D:",\Z'(![J4)Y7->
M4O^]VPTF?!JDRX7O"&[]ZE"P&\)?U7]V#^L,IC=/]BY,8Q'*);^G#+>Q3'2X
M%XQP];_I7_MW6^@9G'S)R0'G79\[V"XWY+O^>?Z");ERY6/-0/1:]E^7CM72
M3[7("?'D2U4>%845_'>ME!4+'KM.9=[VMS ,KVK205B7?L41S<<0JE%WD;F\
M*7KI:$N&=U8EP3?@;%:"B;RT/;U%MOY1?OY<+*B=W"G&>C?%F]$N5+QTB^,L
MV+"#^,!Y.R=GX&\\P@N,V!(1"YR*S)@G6H+CC;1=V1YO!7XZ6E@[H2%"B!:G
M44F#@9GRAL[0*$N BPWCD80D&6H0X31D6XT[-CT/[T-)3IUT]SO4>23+&B74
MKD\YS?H^WE@==@8.9/FITI.VR4P%/Z_CH;TV2=ND!<EMSUTBY>;@],)VU@CR
M9,!?;TT(5130^BN[YC=%!G^W=-D=G=BN0+LG&=TR=T^RR[:H.8[FETO]W'D8
MN'P6S=>Z;.'P\0WO+QV\4\+'6EO^;$?JKY:&4JD6_81B*<L@5>.+><62[WGS
MD,X.>JN5_DJ[;K3<X4$X"3# ]G<>!17;M>;>W1KP/D:+/D8_9XC4H)N$O"JV
MC%/,N4U?$*R0:\]<<,ME*CF&I+TD8.7Y@<8%IL+XH<Z#HT@QG/IIC!".U)76
MR8>%K(5)Y7ZMTT)<#79^\@ACFF,ZIP#)\>^ZU.;NC?!VN%'O"260>+;ZMPN+
M WU93R.V=5[N4BZR.NX1LO&\#+UEF:W<]"VA2,\1ELCO7/@AO#S>)\J79H;I
MW0G.G@O2?;OS 2=N/A+N)>+M1*LFL,2:6-] ;::2&D(*<</M_>FB2]'Q%G)U
M!XXE!PN$,]15!H/CTEB'P9G.C)<^B96I&?NETA _YJO\KZK8.[3:53J1C17)
M09DC"^L^,ED]\_6X5Y_QF<\<+Y2OO?I@.S79]6'4YN2OS#8GUZ#Z]6NL_8;S
M1$%6O[SI;B%EKCAD:=Y\K%W@OY\^8P[K+7MF@>CMNU!Y]:MQO?3@$ZZ?)ECB
MT$-2BK< 6H>+GYZ4?_)S%P&[66"%GM!C"+G:M3=WUHYIC"^-+WU;JV^MO_7F
M^BTWF\>/;A?^6QQS_8%E2IC.)<93_$E?V^9]WSZ;#/\%I44?QCVC#W:O'O\A
M7D$49ZJCI@/"]>?C;V,$34-%(WX9L5;1T%'TZN$0QFDVK$N?M7?I3@<XAD<#
M-1-.D +=]ME[*D8: 0-ZGXO?YXL$]L[(/KR><,,EZ*NKP@H8=5M<'_BK33_[
M;>-\5K(Z\$M+LT5EJ)+_XCNU-N]@R?A+!C]&G *?6NHX[*39'[J4EJK9M_[^
M8FRZ26YJ6F9@WG[7-*_=B8\#OH'5+JE;RSU&,IZ7Y@@W<7["3.(!OTF6)>41
M 5(]G@O\[4,=)@2,@=Z5#%WFT=U2O#1H9=T)*0'-KKMIR /X\[M%;%@@6LBP
MBQQ7#5B=!ER:04D:.94TOY=P,%J7* .Y]B$U@(;, 0#+X*8Z?#X F97F[F1
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M7HF.V!?+5J&EH2)80;CW4:MSX)[&$JCQ=)"J&Z\/>L+2P]BDFV[;9C[PJN7
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MT[Z>S3M?INX@_=G5'"VPE E5Q.[QJH0[<VCE&9HR2K/$8W1:L1"8XN[E;1M
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M2!--\ 87(%PE]R@4"PIUB+&QDK]YN@,\([QXC+ UH/_H#4I]0@YT33Q%5(H
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M,R,CI,G+>BC&04L"G,!*Z"?R[/^DK)3L2A '5N',5#%6D_0'(&(K5.J1Q'G
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M'SWQQ?N"=UO I5WF7,_<^3!LV/42SU'%.^O7%')@AP[O['?PL4E&'1;T:LE
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MD^._MS#'QJC'E-OI  E7WWG%@K>O6$YD! KD6\_!O&9Q-%4PZ @%Z6J'3+E
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M.1MK\76R+_C-^^E>S^+^S;G,C[@ @=1)NP*.\9<@%JD3'3^]=9P7L(F&4-Q
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M7^EM)*9GZJ*JKX0R#>DESP^Z.#\)7-2#WXERT;=WLEU&/?[QOJ;I3=&!QI4
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MS\;*'JADWL&J8L0@+8!ES]5JR//9=$C$R#.,M,VBE1^_#!DZ]>@OL;W'.K2
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M[-Q1+.-A<PO-WPG@'EI;T&UL9?2ZX+(81;J6M@B:2D-M=PRMXF3FL$5F<C*
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MT1BS-F(BDFAR2P(XNN8<2$B.P&B57X1\>EO7N#?R!/HC'..,LC"KS[6:NFN
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MN]:_";G993ZX&[KGL1]436<)Y-7*[9:5M[\,%G@)8?0Z N!-TZ)A_@)QB])
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M# ;=FU$:4@SW<$M)UA#H7^M52IT\.X!YR-TEH" 4L=J_J9+,EQP:\ _43R$
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M!HB;)=J.#IL#%&VD)/Y-ZD1(S8=L5R4EAPUWYK^HO3RPEJ#3DXKYVC3[^Y+
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M,;DNS\K1Z%EV.22<QF:L3H]_G!S,\CW$Y!@\^5'>>'U\2/ &6I+DG5>2^?R
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MJJW8S@X*WQB8])3&?F3;"')EL<?!"_D1MU'J,\NKI$]+T"&$8,\A]#BB360
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MX;E-:6G3XWH(L.4:/'AQK52K?U4(G!FJ[:VO>A[\,.C%W$C-;56S@:L.K*B
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M@GR9$C+M: M)O?8M;51J1%JMW8PE;B+WPZM-!]))KA_)^A4SEL)91?IFB":
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M?:D.;ZJP9$5$-WGX?S$CX>RNCU-UG;F+8LERXL4FR0X'JD3\0D*%_$;P0';
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M>I./'06L+/DHIMU,8^:G:2(K!;RU6<XHNGAA6'!/;4K#?.W1R(:/7-@^VIF
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M[. ;T*9#G.(CJ/79?XPVJT[AZ2A%;(>%2R-.C5O9K*K<"%U(1(U5=_%/7L#
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M$?"RI71NA  W;!AC7RV9[22GA_B4#)7[+%G],M%5CFD(R*24?(4-3'3Y&HJ
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M%6J;+G Z3Q?K& E,8I+^+/^W].==_'G<:SPCN8N,9TL7=&(8:760#;6@W-6
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MWA6EVNA,T8]S+F+4D$SIITHFZA$'B(Y JTG)(M&J_@U44NBV0 <BE5$,;/"
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M#\]%1G!S(91A4ZO*">1Q#5D333E=[]9)/2VYXB+N1<<4ZTRGU2&W2SY7?MP
M!*WJDDF-W;G99J,N7AR8<D>.22+^HW+K%Y/I(,.I AXB;]$ 1@$EYT^I]2)\
M^LF!74]EJ*R!UR7>;4'#9C.C%\_^AMOOR8"8)XH*55TGQ$0^;O.1HRX']K,
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MHU"?C/KJO8:D:/I>W.(S]<,]?>'&L>MHQW*Y40?+<E+=E\RIWFEV08ZK)!N
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MJUF.W7#UA?T0*B_MT/VYF587CG?R2[1LB.B"ZM4&P?T\8=>O"@]W[37[<,-
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MX>;^VG$ R#,T:PY,1QM!X<,R9+;8>Q&>6);N.(1>LZX7X-.]3?A^8(<#$^;
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M%WQ 81N[I6PKVUHTIR\9]C<CMD*#>I%9DDX5XZC. /?_<8:OAE@L#@J;,C&
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MIID6[HBN2-^VB!<U.2[5 CDX[MU(YB5H@4T7IVN!>[?_"![FR]PB]W!#)K1
MY08E KUD1:9J3"?3,SP#%5<F)*O2X!<2!UF5G0F_ACA_.>Q],UG,B7OFUQ9N
MPX*D86/]8CC'5E@TN4"IU *=ANU=GE&IQ7/.U)BVG+=@PUV]+[([GJ1T76^G
M/GT\]RP=S?I 6GS2C95M["B8*AB12ZG(6A?4N,5141)?",Z *A?EH+O$2P@U
MV/*F\I5L$%U'M'*'.7$YGNU]X95JO9L?BD.Z2(F4K* [+?-OO#VSL2AMY;B'
M,5I[)LET]OC0('MT=#L\AI5T!7#2-*#] #M:"^3+Y"?46_JY!NAR8A5U*NJ%
M!,,\Y:^(I?KGCGXM,)4>+/8PD[D+LI#-"ETQG]<_!(H?D0[T7'M&JZXES@'%
M"Y N^OIR^\=]O<,\LQ7J:<.=W,9AT$D+G*5$FUDAI\56<:'I&V'L3H^^%HB'
MS,AKZ:>:.4:T<"W@U&;-C581;CE&R^4HT6XBEJ=<V$9N>D0T0AXBC*'A*O,Z
ML^5MT7%M@0R>9#F*ST&U .P14U2[/6*QLU3,=S41/L9&MAZ]@W=\I:'UNR]U
MIT-Q:GTPLG]K%'A>L0BEC/1[_O8Z<,.-;4]'B&=*5)RP?9++ ^?LRI,]MJ==
M>KOZ2' I5]K/;3BBJGS$.:-)Q%;20Y &M35JCCQ6[Z>O @&.+:W,OJQ,@5_@
M]1ZV,E!'U#[0O2R_N1!"_O!W":4JK&&D>;QG&ENQ6/:5UU+4LY^UTJ_09BS4
MC>KKR?<79;\U<G8XK^-BK040#8Y8>5&3)EG_L@8T*0AH9"TFPQI<CY5)B(@Z
M0</7)+U\!CR*7_WWY2GW=Z]?>5A!_6]9[ =?,&EG2U9+2LBY 1?;MM* VKK4
M<YJ,,.+]+QTXAEQHT&.E(PMP1"DU:SW$)$TNUU!5GPCQ4"#[.G$!>3W-6,S)
MA*?SJT?HKC"UQCUW^I(#KFU+<;AH)\^AGX%S)ZHHMXU_]2O1&Q1UFE!OD(*T
M@+Z]0S."M;>1"$_[PHC^[$2ZJ7H*NA<.K0KL+!"?3^X9UN>):Q$'J\$WZIE]
MOPZ8F;8M+]:DK0LD!2E,]Q>V!HPO[NQ3Q<;@JT>.(2&:Y! ML &*\30=H.:P
MX+LT*79C^.OW9MRJ!3)V3+H$?O(?_JOIMFG*8BLZ#[B7C',G??M,CKWJZ$_Q
M^&U!_HE<3JH_QW2S7H?8C')'!Y<YD,H6C:C48_R^>&:CU[R<]+.7]IG5ASXB
M-0TSL;).5F$G2Q5>J%*R;8L4YK>B6[E"DOE78>KOG'9<\"13MT:67^Y70B :
M136'*AW))(: 5<!Z:V?!@_*]!QM!?S AV0QL)&T,@[\%RJT*LFX,62<,= 77
M/58OZVTYC%_?,V/Z_4QF@0=QO.=2\*T^\;GC16LWA+=I@8=)+Q'_@3:E1Y[0
MPWW'AG%R24< A_4U^XL(=@8[[BE_USP/X0,T+_%9:.8@W1)F575;(FD9R O)
M[=QLW@56(6J;9&:*N$C8LY'@*J4@7"!DS&OOH#&/FIDK$K.4=L/*]GSCXJ0]
MRI'7:S!=K)DUIXB2T&W<!ITO Z=] TT@?ZL.OO(AY9:0?0LC#)C85IM28\T(
MF@=#)$CL3AP<-O43S45W*8C8/$)T^@8DY)$F63P<@]J0MN41YT-5OCF07[?/
M!.M!HA:8YH[#<O0FKN+)!]*H%CA&9#;4L#P+Z[3 ]5Q\NJJ68[\D9V$@G,\;
M52R)L(@.MO"<U#V.3^I74\V?X=SU2L=0I=\0YPOD&N.0.O&BK.%N0..3:F.S
MHQA]U"DB'>>4/LUF5GZ*&_8+#B$L9#4?7?!8(I(38::8*Y^+(U)&"S:3/D\1
M&_^HF;."?O0&(G@/4V/)O AK53+J-%Y68:M9*_G!^K.'VV(-5]?XB<O8E=E-
M6(%\WMZ1AV^T0'J3*S]RZBB#V&?S>%0UN35G_L_SOF2O+NG>?$/*W;?G\/%)
MN?<G28VSJ^^(K>J;I9'SR56[_D:P:SX)U%DP=N;JCD""%N#]QAW7X&SUV,F(
M!F&D3%RJ#? U)CX/9X/8"5R0#!\-,?\/PNW[ET[&E[(A; ([973D[ ZO.]RP
MD6H+-*[W-PU?-4Q]J IAZV@RL,VTJ!XANJ8%)<)#E#A\3NH5_IB1+)J."VH?
M.B'+9X0X%<$',8&M: UI2/5P5Q,I14W88I&'9Y>;KVUR;+T6V*4%#JKG[^ ,
M#T.]%NL;AJA?(G4<&)?H4_"YBNX3+2%;H)O@::Q*ZCS$V!%A]:16!-HK8N-(
M]MZ!1NF;FLMMGP^D;T0B,EW[5('H,O*/GT@++^\8H!IV^C(LRA4K17>>(D_Q
M*0\'HRTO)YYI&?-@J!G@>V?^D5*U%N@A!!2.K7@4OT:]/TT+&&/V?\5\VL'H
MZ,W5C^*!M;TL+4 LU@+CC=#RH]_^>6VG"7FI%F"^YG[&R=I_9@G='M\6!.%3
M]ZIM/H"CZ?^R[-R*T[: D&ZI!<Z'/7X]4CXLFB1Z\U2.1D-J;H46^/W$E5T.
MC M(,C93-TC,7TS_&?["TBEWB>C1 K&L!>25]"DMY= CI*12Y*/(JF,"=+T*
M3<;E"MW=\)6*;-^I/M@F&+L?*8;DFB.NS9<3N O[K[1M'Q]/9X6&AGJ/"09K
MU3O=L2;N[#SZV>XYKQ$HEP;5F:V ;6^6+PK+L<_Q2S=M)6W3W+=5!M[4 H76
M7>:U*8R7ES5']K>"+^GGQ*#>P *J\+'-GK=]$Z65H5V:8;0:SUW+"/G67^GC
M?L"ER,:N"2@"ATS\&YMN.?>XJ+?]>OSJ)SK_\\I\-=[IG]!%<"TH:+6ZO.-%
MXEK,-"#0R<G&R?ZGWT[PM8!A E&>X%]!4-L?(/8?IPI9?="%J&_^"JKRHN8I
M9S-]MX![NL'IB/)U$^FT8K.$4LV=CO"EWF\[+EM%D<V:QH@W#&DN-=YU1,-R
M+[N2V'78FI,H!<E0+"/,AJHRS0RVV\:P'1+?!4[K=C45+70#&-V'(J%0]1N2
MK#O]+"UJ0HK*)N,G(2E53I"PKH=7E)?R!R<5MK70[/6D?3U6,[OI)V!N/&<>
M[CGZ4K)JJ*:^9)VK5 1T5O@HZ N4*;$W"]USSP^U5 N\U!ZY49:9-VV3(.?2
MR0M:H-P_L;E^YG[,)7G=(:C!!RQ0!"IO:8%'W5^F1%S;:;9+<<13$1.O!6:/
M05.^F9@EYR(-O"2SA>5M*$6<P)_7Z5MZTHR@(,:?TK5O&><23GZ;/J"V&.3V
ME1:QVO'S7-0"/ZO-VX?7<J+4>Y9/!BK<Q6O#(+]8"%T-+83X@6K+M%%A14H\
MH( &B4)C+%Y6!:$;TC?B\KG344F0XWK)(5@,8@LI"[7 J)SM\^@JR0D%U;NW
M6U^B>R"4K_4C3@4]YO%/[B]E8602LY >H,8I4!71=CP7GI"2WT 9WTJS;G.F
M^X7'7,OQ&. LXG(UZ2%V7MA<C_#(F;B:8G4*CTV@Z_E(\L"$)[$U<.R#]\LF
M]M"5'D/60Y^'A#C45KT*JC*5!IA+;&^,01V4*HS4.$897&)89T(8S [+0I*J
M][S&6D?%4<=:,)O(IZ)!WC&!=9GH%5Z%7]/?A)P)%[R&3F&-W#$7LJ$6$-]0
M,+4 6:B,7ZU;JP5>0CY4E05KAA: JV@\O#(#B.U@H95F/O\&KH].DW#/PR^N
MP-%"<1P7)_(Y#2O\%?YB>^NX FRO^:T58P.L1!96+B4=HY2@IV!!/-TX0(+W
M]P[%GE@)<XZH+UD93J@&YR'4HR_5QC'C[GVD!+F]A'DS($ +2$X'ZJ'T?MN8
M$;Y\@?E@F/H<J[1IIVYB7@-K/#AL&R_/D<V>Y!W&\?J?[PL<^9>;!#Y(+$;&
MK6NP%CB7L[;K'S+N*.#L8/37\L4TM>'\[:U?-#4?AV=%+&--X%G@\30[5!-+
M!F1.%FZ(3)H8(7%4$A,P4P2TAUDU'A%5;N3[N>@RA4O<EGIY82ZQ*IEWF--:
MJ 5NN3GD&WN?5*_&U<9./@MQ:;(^I(>[E?^:8/"_IC;"P4@''^M_3?#O0F/Y
MK'D4I(PXL]-O?]^O=#T%54ADC6\X25$4#"HGB&,XSZ^/TEC#09X"!X#.RL'X
MY#4"RR+W@#-0!].-Z:HX)KJUY?5%[OFT,U*U5VVI*)I=ON0Y4GU,"R1T8'=R
M/&C48ZUTJP@VU/#U_O@'' 69Y?I$ _)41-K#C5D.@U5VP<HPQ+M''?$@4 Q/
M7,61_ -4W4U4'YT<[9WCCEY0'\P(JO^H)ZN-Q"&?QOVOS?%8K:?$W<RC-S#.
M)+/,;T&32D'AZ=2A9^=)@UCZ[WQB;#-S[3EUD]QS^!:#I;FHL0-(U/]Z3&.*
ML?P',QO0F#SG^8MAR+8'3"SG6F!=V'9A\("_2O4]B;WXSD6L!7Y)9,N6<M^P
M)WXI@B@T&!(?;;,F$@Z((\DC509Z/PE^!.';?F8K% 8?\;,OY4^BZ ;_YM6/
MKL[TU[0@T,:#3[E=8.RHD4[GOV#TXVHMH/AJI8$\H;X6!R!(_."G<\<6OZBI
M-:-8XG.R67H'D'_H!65_CA*]RC$&-U"T$ E5>BF&$H,D$81$[F+.4G^&*1>)
M"U-0>=02L ;G4*(]'!L]_B&B]KB)2Q0VC^8NCBY!U^(%L-?:-'$FKVJBU!M=
M+B0S?<.DT%17I'!@NZBF<X>%J&_NGF'+T+VI3^-(?5";.]0B:Q-@9)PX?MXA
M9=:*D-74>(XU2VC?P[Z*&:)[FZVW>B,G( E2;IB-GD,B88ICT_B,<>;<OA+1
MO"WN5C=UU;:2Q.*H'$K/P&/<+\A<X,CA6%"\^B/]A,]JW7$O\;F8K"SZ)MB!
M>9-T(@?=^4F.VOK:9$KX"UU]VA@_*A:[E%XPR?P-6Q9%@;N>ICZC71=0TKN;
M5;TM^YN&4$?OS),#R9+!WH\Y5E64&PKDW@'%.I8^MD@+5!UY\L'(QFQ%X!3:
M"727=XB754=-F^HK)\XW%V]EO#LZH*:+^<I]0S0;V]"0UC[?;(?'/B\'ME_W
M-RE*9SYU]ROM*E'>^L6OE*<,25;F97H!> 4GFAY]7=N:V-JH-A?R5+,I'09^
MT"S64 ->4'B3A*HO-:Q@%60-F[[O4K"49Q_T7E:3U6S$AQU#?7-]"JV6FP5Y
M4;T]\@^DUAN_'UVJ/EI?H/%.G>X=I05RNSE;-*70%]%Z<+"8\8&J:F3-'!AL
MB+UC]22)=-']XV;>,A^0,BHPTFE DFO3E\ !1;FRN!#"H#HB\;A@?W'JH$E2
M=ACTG$)0%F(.MYD!H<\^GV1(,8^ [>$N-=A6Q![F\EB%TR9X'60;1DNZ<6L(
MY;IPHM(6)L9882M\,-TFL8+(FHIM:"['1=4/(G0?&N0?$$G.?O2-KF&Z1CEQ
M<,?TLXO0;"DL3R_%%J@=:K^6IQLJ[$IN7E!"O(K)_,80KL&'VZ*^8J&X]-NV
MJU<^A!""5Q34?_U\,L![]#;V6<KLV]AV%5Q?OEEMA2Z#VUZH-PPLQXU0_O@-
M38HU<Y&;Z],2*3%.> /">5V\-?;8=2^%"0'9@^-VAMJ2>VM:6T+V'T%Z-UY!
MC6_)?/4:E(QXJRWH6]\@+H]05T2LN+3D"(]CJ;A!7H&T!$L#%]#2UI=#$DK)
MKJ?MR O7)DOK3A:AS]:P,K,C\ODP9D_L#/TLHL5PQ*-YH.PQJ&9]:3WP[DE%
MB?\5M>.PV7(M<.<ARV[S.,\.!&:QYM*2'>&*W%S9S?7G2VZ/.)\.F%9\/RSL
MF5/(5#(=^\DDLJCK(X/?,EC,<OL"B2\@1(Q!^NDUAOLF]#2*AV-*QKC1H?=\
MTQD9C[_-BWS4+=V3H@7J<2AJ_2#KX'NUL,D0(RWRQ4ZGH#><"U!)NA:0=HJV
M/;P2R<(E\;M15\R2MN3L'JRQ+68QE]_#6G@PD:=Z\-#,M*<+XK$7D?\0\+F%
M_!MD4ZP%_(%-GON-:$2VH5L6?]I"G>U/D+!O)'7;P-!MDDB?HD[3D[=AIFH*
MNFPBU+#2/])?"VR,V#9T>3.NN4.44!IN_>UXDZC/][R\QB5C(C&OFY&&N<R=
M#):(.F+%8$(()-0_F:R\J\DK# -]"-'=!HA+MJN;/VN>)4Y9T^U[Y-N[JXCS
M:;K[S4Q .!:I/OKZNH&56^L&<L=CD=_QQ9$O4U1X4I@W&41T$Q+:PX^]PK%$
M8B4)H [BM1..3(Y#O1[1=RO,X^F[-+%G+3\^EEC-Y8LS I[Y+Y*EA[V5 I$$
MV4F('X1!)J0!YN00R)?N-#LI,B813/:9=Y)VTG]+.MN!:_V%BTCM2T?Q#P\N
M1*@CCC:AKK"^GPGY;FE;QKG(/#]N>\J1;EI@30JD3'IVN6.\7JR^DO'(S1U'
MB!I.%82HRN2>R;*/L[P_4KH^&&;\ K7MVC@G:%B$]^O)T'B2A;^$B>SN;2W2
M3X"07>CI3*3M(V4RE/MIS,[V6).Y*L$]TD6.#W/66#V U^;7'1>IZQV27#V)
M0S_IJ138'@.CS1>3*%U#T/9OWJG,<9>6R++.22]!V__!*IDM)?;_N&F8NLS%
MI\,V-J&^IEKW=AIT<!J-54?4$=$=X(L9X@B(2-\+FZ7:O7<)5^;#/-=41T5>
MD?C=4G4(+[I\FS0AV#=$/&.H_)J_)CNSJV-@RL<(UJ!IYXX6;YI=20VHF#!6
ML]26P0635<(OE4M+6(,ENTVS"FU[A?:SL)^JWIT2I5(0E<FI;64;].<$QP.H
M">XO:>C19H8YUF(BBR:;(H$2Q[>1>M68B2*P1I]+\&1T: '<ROL1$%?A1O(/
MS1D%2!,\('5@)VP!HU1U#Y[1,.% ]7965+F#F#NWFU9=#<U%Y[+U/Q#V5124
M:X9\0Q^L.#8BO6.S8CFX@CO:.1F"[G"1)*/SAFM$A7I,E"H%%]-:)$\3I%!,
M>%*BU*+!_P%G!V(OP?*E=A$UX1/79%&'&]$E3]R$M *Q7BQJ*DDD2 ):DZY)
MF(/,P0 B3T6\AA>E?CD'GD!7)$%%UH#SKKGY(T.0M-O^E6RBSD#A/3')>JG&
MQ3J3.DE?E-__;C+T;?C'HF#U:49SROS>[&?U&?W<:>"Y 'NGIO7>YH[-18GN
M1S09.2'UA;GK>OHE ]C<!F+QY[&ROJU&.N.&BZT\7623Z*T0+9#%'&TK9_+,
MUL-F^:>ES%C;]!4*&V:8YOYS&GBX'.;<D?XPSC>HE>1.5Q'EEK/5CL5EQ25M
M >6CP8^Z]$$$O=XIK A;=%_J,Q%V4[']@FPBJX^1-JIRV2'63!'M*E-,^YJ>
M8<V"[_H5E]9^2-4"#3$97@_[W8RP<KS4G^'>?3N -L*.@VDPLS) O=Z.*]^H
M]O"_@S6DL&Z%:+:-LPWI^_Y =R?7&7NN28&0$XU0E2UK3MKZSMK-72=\_X R
M7877-VP*6@=Y$:-4U"BZ58\KY$?IW$1!'$"??:"/:<#Y4=P./E%,SV13MHQ/
MH!9=P<=*8!%ZD&PLU)1A#I!J5EK@2>+(!@GW)/T_6GKOQ16W<NZ>7'W;.#XT
M%/OAE$8+I/'87"V0HQO5B"U''&N%7W$_?]ENMX0RU[W?V=][5WG3>*+5(:PN
MW6<=HV.J"1;GJXPD#[B.@,U8&[FCI3G;@WX4MLS%WN#JRY]*"1-KSEB:'L,:
M8%%\X*F77$XA]AG[F!))%HYT+A!=? >>6\C_T2S%OO(X!.<;2S9UG2QF&U\%
MQ>Y/_\ UVU"QX4";Y]HH5QEK+#6!B!N@97[\:+IMH#B.=&Q+8FTK#UU%WE"J
M2)/BB-%@JI83[1ME(V'$,5V6XN'L4&R! "\XV>A)7*V =2#Z\1!C'6*4DV"I
M?//UW=TJ-6FE] <M$ (.@7WNJ$/VPG+29;;SWT'9+(2'3A!EBH>$C\,WB5,P
M([H]4JWPDJZ4\?C"K)VOD7J8(>@IXD>AQ!Q:9Q5F"!],G-I(T0(S7*ZO"T!M
ME4Q]1#2ABYE/@EYX$1S<PD<W:_[@&**V"O:@3)I %>HKGPB>:O[ 9E-1X^9R
MV]QOU#E%!%UDI(YV^1DH7J' [@>)N06TZMH%3WGRXVY/H4:4.=M5"[S/HCXE
M_\?H'G_$!YLN13%KG5ZFPO_MX%FHF!9/V12XXR.DAU1S R<7J*4"U2?<Y+WM
M09-36O:^X)!H8)UH /H:BT;T);%4+NA "_H?%;%_U>M9K\*:)+;Q@=WAE6J,
MD3[Y<#98;;8)EB5DM(+B1:TK/Q%BQYF#3F>$_MMROK0$R@K2$4SJK 7V+0D/
M(4FSEC@$EQK'!(P94.I*<RN^=GWEW2+99R(Q6D!MG\8Z#7??%_,_0ST$MM1C
M/F#TMULL:?_YL*WX7Q^O.<;B+/TG5?6]B9J>Q@-2UXMST%=[Z7V<O:?5/S/5
M@V&K1(,"JF($^MHG'804&BJ3!1^F=,3BS/FPW+<GS:NGE^DMH>@C8*5S9+(3
MC/OC2DMB+4$:H07F^?_J^<V-?1/;0-.5!'S,P$FL0$1S.9)?U&)E'<%_12/R
MJMX*J=TGO)73=S^R'.QVJU%_Z;W D$YH@==JNP^9?*%=[D6U3+,9(PV#,[F^
M2[R4?&12$26UJB3$VE#GKB?/1;<KIM^7ZJO3MMM1WE(-CU!BWM-"ZQ%OJ<&4
M3K'L*AUZZ %=Q*LS#&ZH3&;8M**GMC"GXWK$A\9WS2?"N>A>'7686.UTN*%:
M-2WII9*?=Z)ONP'KYN'Z]T%/"S)]8-=O!;N45]>'Z.L^ZQ5^[&T3["W@=TP.
MN(/5YFJ\7?KNG$A9,7M=86I$0F>GFCG89>7TNG6XO&\XQ"+5:L?^UV6M%QZ6
M: ''3Y84EE)NI5[U9X.<U;D;FQA<-DJ\)<H7\5BWR-LU)>7.8BVP@'ZXK=Q%
M', (%')V:($8+LRJEA+GT$$M$'U.46 /RZKV,BS1)5$_P4]3U5::Y"I#Y+:@
MTFNW@G#+BDPZ\:U8V/O0$GSEHSO$[\S"G$:D6(/W8"O.]3/@/$Y]&8[Z+]BJ
M8=N1Z]PM6B"0.Y=^O@A>GRS66(EM;XPS;QRAG](DY858Q=N""[ABHL(!%W>H
M%3.6O"<UDVZ!#^(DHY'1>*JH C]3=/1CS>V/$:G#8_Q7D%<WXV[WC^[U'=3W
MMP_47W%ZK_Y*=ARB#XDH!S_I&!@=@:(P7<WJK[TMJA9JX_)ASL'D@9+QB<7\
M1'H@7A0QG'D*XQK"3;,5S71B#S2MWP5;KG")&^]$+E<0?VHJ?,;H@K*IU)/0
M8_=.86?E/1:\95(>J06FG<8IF^)__#CL3RQA#M[)<>UX<C#_,^H.HU?D7^S!
M.V%3B?[+Y<2.B19-R536P]Y2W#VNE8'PSZ+.$NQ#L"1?G7Y>#UT6'BMKCX I
M4[CUW@<][+"/)?/VF?4%A-8;Q#Y81A@+NH/=.S\;'!@4#&%SD /W::E)Y\/R
MK&QJSQ$[D,QHUPO67E:YMJ;=S<=%3L6A@W2E;ZIDI/1/H^U%7/^!-]A3$Q?4
MB(O-V!P@#33Q,V'*,]3FG7WAF:P8P]TI,@D+;\ "JY48OX*\S,1%Y?S.6%)C
M6&^W9[O+"S>\E=RU0,_])!OEE>,0'F'!DNBRR2M7%D#SQ_9B+3)6@>8N8=G@
M9\VC+^>%']M:,'"]:@KC"'9XO="TO1\76X&MQN\./-8"/WIH@1%1"7IP:/16
MB'J5A>6CZ+.)#WU7W.+/%6TR#0/;QD;L"JC/N8]G4_8GV>0N%MDI&RO_]-UZ
MFI$SN72;?T@(PR,LI#7ST>;W6U^8CI>O6/%XT'.^9UMX8>G$^'@K2[Y+M_.S
M.\^RHB:TZ1VC0_D.^LIF&=R2C/*UP._1%:U%X\QBO_TR^DJ<7=C1W,$3L Q[
MT),7S[WM?QK+C8^V'GLK&259#I?>DDT5#L##SSF\QI9L_I[[D17<@:^C@]?C
M5^<X38E?_?"O)<\7YRUUH!;PT!O9<O"?UZQU'O_C.:2[S@JSTS>,?E_TX,Q<
MGIHU>=&[I*QDSFQNOTW)E0=UA/TB@4+Y;@(*QNU+2R?:R_'09-.])!0 XXL,
MRT_T<)%]QG4IY/NG,-,W<-[]V6^>^[I,")7WO305D9DG:0?JM( OS(D*C"17
M2"FO:)2:Y"0&(;]M.&<=ITN)*Q&UYAKW'%68VL.4+U)8\;B++D>2^=7D=4@H
MY!V6VZ^*K=)G$KYQUK \X%FP#Z;3B!KT$*?2.G?"RJ@<7T^P%914E+6MQ]4<
M04&\?AF<G(U$U(2HYU+OB?(7,-6'$;:4$ ?Y$(3+1'6>2Z(D.,2Y!U"JA2MQ
M3_TCXJ.ZJ@5N'*];8EKK::0 $P*W@#%F2QL9;T.&8U4 [)"9)HLE!4DUP=B"
MZ?GXK'2Q7D.5>QA+D08Q_VVDX1&8<ML<"0ICHPSD@#@QN*[$; TXV]I.[ZWG
M,L6*B>ZUJ77$!7MB)89P5)6Q6V2B,ED+Z)-\;;E>Y>G"M_J;PY0-&PCE_E^@
M6.I(!%ADI?D5ZK#""1JW  -$Y6J%J(:_F%$'S49/O_ CP@7DM?N>HKM>OFPC
M421AN;C]6NB7/A^)EK!GTR[YD*# 1Y%9-6:$4NS/YESZ1L5.)'P46T")X<6@
M0<IUM)@WA(X7)Y$,"5$XH'Q9CKR 157X:$+:&;.P=W"[#WD>DI!-/]0X=)DH
MMQ(N;._>);%@3D7)Q26O1S_ ZC4P2\/IGGV5"#7]=>\36'-NE-Q/PR1AZ=RQ
M45]$6M)\=:9%??DQB2C!;9V;\G$FNAF.83_N@T7?KABK8FM]41!B6+_8-LQ$
M]\LQ4R1&^H3HIRL_*_O#+#BT*EP+U!KX.:T?\$2@'BX!B3C4$A"RACTFBM^>
M'+?E0*#<?4="'REQME0<&IO+QEJ#OKAUXW)6^.Y$!S\X GN@I.1W3\=X!T04
M*J+WU'F?N2L6-1GO9B.B'/E?GK/_=5ONV]_NTNU<4O*OO$["&<3LL!80C,NP
M1.M#>D3.3ZXH:_/[[L-ZCC;JE5+,79,R/"!BA:,IFHS+PQV@,DRQ/O_Q (O(
M]1-%"2DWY99T* <U1G2EU)NA9C^4-Y4?8_L)CRGS3XOY!"2X-CSY6F%BQ*%&
MU$N2Z+\;"980?_#$]74/%$>VY=;>OA=&S;F@O[M]E-1U=W"$U0#98JYA/Z9R
M[BG5*WO#(V_#Q/QN!A''NT.HTS-:L#2TLOA>#^L:&I:%I(I+$M&58N8\/^[4
M<6:"R=,*"7,Q5'5,AFX4A/ )_N$',WN@6&5IC=EL+1"7I62W8SPID=A![>[H
M@R[ W2]UU+KP0%7W#[!+5/E*G&2C50'%<3#&V]6R"DXK9H7:R9(S*><O6J*3
MX[H1V;0H]<\436F(TQ&7-M(>0;GHA)7*HV/P_8+^+;55[AV.(<&SN+[E+XM'
M.!V=N$QAT4,_G$<N^<<5$@F)CD[%S5OV%KHO^&3MON]R_YAF@1;X<\2J,($X
M.#E^X$A@QN==F@>/W3JZ(I_S]]HN0_X(?H-N@LJLL#@CG1$].6[95ZE!31*K
M V\G-V.Q1^2=4+QC7*CCW8%?I]$#U)>U0#WG)-1Q09/"'<\@SQ=TV$**<=QZ
M>?1BAPY-\PN$H;=0YO94E @3^]T.(]GA5I\(5\&>%ZR16^Q.'O;!7:J'90@K
MH+M/J-_N86_:H?YBW/6Z<7%21!];*!4X%1U'*K7 LRMLZI=L8]43+9!WA:@*
MB.$6,>*Y(Q3%=-'(%B:6^HCN: PU, =>K'A"&8_#KW\&K[)/A7%8/CB00U5M
MYSX/7A_X3+HC<G<)-#E^I&0<89FE47R73+@/EV)EN+[V8<Z WN6*F>KYY9NU
MP-.;%AEY$574$0N:%U8;.$L+]#^:V>>/)GP 10IH?'0Q!GFPV:CAN!"JQGN[
M?2WZJ[/#_*J0:4;.._]:3K;@U:X48:6$+WYI_[3B,V4X#A+( ZT:[BXZ_3L7
M=@@BW"&)E/W3+\9^Y6^1BN9S%M*62XVCUZ-6TF?CSW+DPY;T$Z?9"%3KN0*V
M322ME-C-GF/-6DASJ2,3/A6RYB&0<XMEC[&-V]/DT-1-0="YL'/*AAW\<W]_
MAG*R]5/R7+?/'P(OEK@L4#9_,$@M%_7?K22PIK%4H'"(KLX+"%8>X(]/JN?+
MT+!&O5["8%,.HX$XE[S5E2<>9H*%67(]!;'2<UXK*;C'E,GT7*'HDETKE$_7
M7"A,.^("3TODW6 0:;HG%)%9,>0?:1>'W3X-!9 \I$N65Q'G7FZP4,.DG1<#
MN,YYQP*]7L>HMGZY/;+9NE,ZNFYXD]X=&0X!N;SO975A^TP43_UUZH#;4+[B
MA20F.0S>\=93]S5\,4[ZP:)6F!S+(53#7&R._O!<Y(68'Y]#G]8COR2J[5[7
M1#9'J)Z*@R\4M@?:RIT?:N[)DUDS2+:YFA+'1M1!S#7HPGH/33WU:C+H.6_Q
M+YT.Y^,,2NX3A^Q>AJL9)WHY!Q"\9LT+U#@@=>AI[FJ!L6$%QGG-OH,M@>H'
ML4]<Y2XM<):KV8%"#PEYJQ_%;WL3.22"*ZVBM, 4]->R.V1?G4YD7 L0W([N
M6SCDX&NHOIGN_4#0W]^I:G$T'P[S;^HR6_AE+_2UO#'R,>9)OH_NP;&%SRT:
MEI]0VV$"L( 9S='%FE@+R;,0J 8J.":X.=Y%%&?=IN_KT5BXMIU",B6I%I9>
M1_-;>!U%!J?Z)XCG*KY!NM1CE:25MR5#*S.J7;>W^\U['Y:_H?;,1;B^;O8E
M-_^SI19@"W-#'>1]FI-/3FB!!-CT6&6VU&>($$7R4L>]PSF9ZJD%DD\3P?:)
M[ECN..HGB%WV@+Y%C-:"Z%7Z5H@P>"NH__HO$;KQ6F#E0JCG*15V3GC@5?):
M4PKZ'4@(^Z,Z*,"VCK P+'0CU$!SU$1"//;84S9JQ,-F;KR@!;P+-6_P'=TC
M</NUZJ,14B;)MASKU&>0>=B=A, Q9^P^4W6*\A0*C6URB?-K>W% <_[=/9>*
MWPI?<1(BU4KW@G=9M31HL &7-\,@R"UQXH^_L_CQYZGW B>0_EN&O,"! 6>!
MPE(+3.<R!-0B6[F!VA5KXA@CP^J?Z.>1>GSN,;Z;38'X U%"98Y;+?11>69'
M*G3M2SAMUELO@DVY6&N@=5O'0"UTX<5$IP([PYTI-3.J@5WF238MOKCF/.V6
MS2+SN'@_\DCO<8K'\G//1?XO; =Z-D+"#<>2VEK&,:['#+PB)C>__/X^QO=E
M#7N"@N=O>XH6N(P1WQ_2"\!!'AE)QKAL<,SW$?-?7RW0J:M_OV-)\;"9R_NF
M-61H:&L*X]28>B^_8_NL/UPDYNC\(S5)V[DWLY KW )6+&=3>S]8P(\G12I
MGKG2 X;JH,5T(^0T)#G0]0.MNK)[K8+/HT9%59G]6(95*RBW+A2:4@G^-CCS
MR-"5QK)!F]#D$'7$_6/4C6<#7@=]^: ,6\H[@6H!%=X"S#R:II;Q U3I2I^O
M<*F#YI8;A\+W[(OOV<.AU>X'K!8BL6]5L[,DS#E(BYRS7& 5R)F..C:1EBH*
MQ$DI#%/H E3%%4#BA0K'&^B!QT(W_W1049=Q_@+=+NPJH5T+7//<4*X058$
M\FB@$IQ#-DNTKQ9Z%)7$,E97]ZC!Q5MB[A/:<T+DEPBQ*AG.LM/XMW#U]7(
M[\LKG*7J<ZPLHI?9?W+4_&AQ^\6 0BN#ZI!ST^\'!3SR:1/>9@6L2O4]G4%-
M6$U"?LQ_Z6]G(\+F7B4W> 4\%79T=/?A*MG&MB19=);])_^:: Z^J@7F0I7[
MQOF(.W4&3@2$6&AVN0ML+#G'O5:^,L<_G? &(>*><#9-3R*(OLS5H]W#UD W
MC5D^R#6%_<%T=0VVRB3KQC#I]&-/&M,>WC+1/FB=T(#KS1SP(FO2MH&IMF05
MN&"%YE6EZE7#&#F/.U N^G,F*M9P4 =%DNBMC>>29LX\&M49<0E2A"I/EG.1
MM"!%K%J_YHJ I[R*!"7:'D".,TP[(9\-K$')!+9VP.I5QV</D;Q<;=Z>Q]TS
MU.HV(G'J/A/YE+HJ */=I7YF?#D8KL/#R?+JTJ=:0 _54QW)YN(\JH/=S[2*
M3WZDV8GH8C/?:('5?VK*H<%6S@;HVY(7@LFU#E@V.) 6BZ6>9H^_P-$X#_IS
M$S>0J-X2>(NHBO4;Q_;?@9Y35#+<Z#YM]U>[]^$[+</Y$:O#57O+94JL9'@R
M2!-R]K>_4V_2';#-7!.2H 4<7<;WG/N@2<,_OC3Y_NS_>5G8$)V^3?/D2LDF
M42M=0U'>A)/1^.Z%6B#?O1I4^5PO-9&5?S=I)3'@X'&8CZ7\F!?#?5?>HM$"
M\[4 =:-(E7I2$\Z"8:YR)G>%D;/#+VF[_O8BMO,O,]]DX8TFYVHN$]^U;O^G
ME<;IS+__[J!WZ,EMTQWU9]O/Q'_\YCUZ\2!+3T4Z<M?[^Y,Y_8N;0L Q>]\/
MPYV6Y'IE03/M'Z\IY!TY6E[4,J9N:.A,=?>G921/")*E^PM&O34U<_C/M<![
M4.YB6.FO9(^!K_ ^'Y&]_9%XC9O/K]%O4KLC!^J21*_,XSF+K6I%-QC+FU"=
M%ZB1YCY&8/"Q!0KOJM3A.(Y!JQ5G,_V(PBQ#[8BZ*$)O6:)6SPQF(58_%\/I
M=R^@VZ26P2>YK]33<Z^ID2<<$C=ID=FWLR-TYIJ5UT][:8$-J#OD_>UW[),4
M[/_ED@%#'ZJT*I^K8%41BRBU![@W,?V2)M*69W3;5M/JMAGB-,H^&*H4%=*J
MWYKDW8=%/=#-<2B1M>#R/M0@1'*3O*K/MGLJ',**J;TOJF89(#T=T&E$5'V>
M>PSTTP)SZ!=@G- Z$\". 1SLXE%?A6YM2F]R#UA(<T(MO"6$6$\#P50M -^G
M[RUI+H?R:%<ZJ0K'JV/7GG?2K Z4M>9:1XCF^96:*R<ZK3>_Z.BZ&KF9NAS=
MK@7N=6BRH<$HK!Y2A2):X"01-1RE(G>>897@U!"GX&J6H15YA9!F>N)EK!,R
M(7G3@UR3='E7ITS<',NU<%5,,+6 )$?-R& S) /JB"/&*74%WJSYFAAE38?0
MA%5P_HWB2 VQ2" _':;P%[-B. MH\:(>_F!24C@AAKR,%:>RZTT*L1(:RPT[
MD5N(A5A1S)*;.79:@F*C AZ*->J)QIP=M@Z/0/?6[D!97W@0$=57"6 #O.T"
M_V (1:^8FI1SB#K]-!_%6<I(B09]W$P5\7%I^Y:;"P%<.%0/32\9?*P%SJ="
M6N!%:.T6M6-3)W;0Q8"*T<^7X=BWX;Z<ZR7;>D]4[^ZQT8K!&6W$7"]DM/S4
M^'G?\[!+>[ K_)<SP$_>G>8LNBK(Z8U)1$-(<."SR$<'$EB%3\ .KK=("P1,
M#H_5V0V0<1IW,(\ZZO^I)B=4(6P67BQL\FU''!^PGVDH:KO0TI(/6-8X+L>F
M,Z%Z&>,3J+R0OE@+M-[)$$PT<R.YQ%Z+[V]$1SEROXQR_8AJ&\ILZ-N[Q@%U
M/Y4C8H[.QT(U2PL51T@E&MU3RA;,XQ"X"Z^'R06-_5G?ZG%R1/<JJ_YVWR3+
MNT/#1Z_^+V1Y^/]X/WB%%G#A_7YCK\W>_ \K?JV_\R _(/!R\(4W;_3R?TQM
M^#DRKP7VKA49C&M 9;M"5L.* U^R:BA,LQD*VYKAF]L/%J> @_5J:V18?$-D
M<!JFQ,B0?0KB6VSM:RV0\#A8H7M4\=Y80#9_(RB*]!X,=XS;DG/"I[>9&_8'
M)@]:6G)J\@#+7#Y=Z,Q<Y:Q34FH\O:TG\MGY3SJ?$C:0.Z@QU,*)6G:GG]4<
M]#Q,56;QF+&,^<WE7I)._M1N^E)-&ME\GR96_&&VO]RBIS@S VOL)C21ER*!
M-69ZBOL58\2YV'8ATK"O0!&+KL06OT&"LS3,*L[2\O)7@*:NR/6XL%W8^2'K
MA.:V57[_D=T!0^OD]%3BLD5C;$39]/U%L"_3E!Y6Q '8+U!\3],!C>W-25S@
M7U\8.=MI-^Q7&EV7<#KHF?\&G/.\F,Z?S*_KRBIUELGV%K7J=8: @Q7[6_9J
M@8-;E^ODU''A>FR0JUIQ2 ^GD1(*FOJ5ITGB=^!P[V:(&\%[_Q,C> 3A[*3K
M:(%I)[7 ;^<8W:#23[00')_=.H#>7Z8%CK+&/U9K :>7 E4K#BHNLZ&>!]22
MY)+!7 4=^IKVX@RW_K#5^#X<"P;!L4X#R#]R/O1E%RN/*_Q/#I*AA/^-%=R\
M'LKVLM(".[>4:0'^<Y8@L 9!@M6N<H4%]?^.A=2&>)GF-\@T62X4JB7*%/3C
M%D!?"YQZ,;)KCYQKBW/.\_A+!KR&\R/2>U]".Q;07S!QEZ!0H&_8-D\FEW[P
MEV>QOUV^.?_)EQ6WD1WSY_GJLG*,;9+QCA.(!CPI4O?AA'1C>.(FW=D[&]W^
MNJ1IW7KVPX(W<'%%T"]W=MU33\K1O1?#=3M+BJ!E$'R9+[=3[Z?K(1WJQ?A(
MIF!D^BG$/!/)$KO@B#^WD[X>29;BRHI1\=P5*:OZY40DA^?XIK#XM4WQA&$7
MQ!.A^?+;4/)-;B 763VM_O:2(\I>S8OUU@]>3?S:Q6@FSB._5T!L#4;?2^8R
MMZAY,Q&]M" F0;PU5C]-O.D]>7O_Z: U7:_W.R<)CI>;-(477$^B9?>"+DDZ
M._ROM+*.94Y@A6!;[$\MG.6='@\5.$3>N#CV^]+[RXN:2:!DA_Z-5;ZOKZOP
M>:THO,I<14"0(EX[3V_AEK;"X+5#/LIG&$AIO"S=QL,)9UF'%NC)H,*'7FQH
MKE=?8;3>M?=+O]( "2TD(37[UBUN9RWKK/E="_P*L01OV ,NF(&'YA'D0V$F
M4XNYJ!6%230F6T-51..W[RX;(6D*?5?%5V[L]!>!TAUXS;R4M6TI*TL-+/+2
M6&M^A78',:\M$OP ETGH>X+ONF3$UJZS;7WYI[_AB_W#J661=-4? Z#K^^8\
MPV]$N^V6K87NE]LQCM]__[H!-3J=*_[:V? U/Y,]I#X;L7T0_QXK4@S+"Q[2
M"FJIKTIJV0:(>:4JEDG:E7L"H3I!,_O2%\*AMTC[LFF7(%-:,&885[Y$S+^Y
M0,"8\8D4G(F0!E+8U_%.S;5:-XB>/OV(&AD_.GB=P_U^(Z!ZQ%OC8H%!Z]^P
M4[A^!OX262QC*M+BBBSW#HM0+/@HVS428D6@N3@J>+<N+S&1UKHM-MNH,(^F
M+Y$8'-C71'*6$O01,C1WH'MA8\B!?.\<?Y/CJ5Z0DH^,E@.3NM@,J=C)JG(!
M9PW,R5 O1=0]_$3K'7Q3WRN@*2D8UN_A5R4>D5A5<1%7MQS1K$*#T!JJWM#E
M##:-NQ^F->:5.S&G^F"FMB^)+ST3AO/OJ8*I]Z%7QC4$H2Z/5<A+**+<Q%8C
M];X/_8@SQP=26;JTT9[8.L)UUNS>)%Y=]_Q&=$DV?1L,UA*G]F]/CAV/\" >
M:"UW5MAZMH8$G!FN,UN!9&MBF8/@5)]Q5?;.:70F/(!1O)696N 508TW=K](
MJHD,^K=R8R?QI+.#D91;C_W\[#O'+T$AV&J ^M8*78++:?/<[^^0=CS%^?5;
ME\()@JB\[VU7A$[!<>LS<23\+_8/P.5QKLA(,,AU3-4"-8[B"BW0-1JH^2F/
M/C%7"[R[KP7:#VN!YB?0&EQ*0$^*CE;<;<D)#V-;B,;!3<F@>3I7$$BU(+:*
M4!,[_*)IZD/X15_1<!UZ?$\L5;1?HT2AW]D][IB!&1[ 1\TS:+"#M W7$LOM
MV<.9?_V:P&6R>BP&WYB=#K7;X ;4Z1#H_ [\XN[8,G[V-V<'QDIDTJS=V7[.
MXSC2=4>4'CB"\?&=PKYHDC$R5Q[-\/4#85<(637M-T%2$^,S6!"KC$D-LTS[
M>#]8&O34T]UAJJ#-L,./VS=Q]J1^PI+C HR$\_;H-KD'C5Y 3!$N7)>UR I7
MI3M_R2;M*=MV:;??FK%+7RG^-P+6C.RPLFE&3:G9*G<'AKL6J/Z*MW:*/+O^
M/'2!V%%WP+H@7HE+H05O;XL^L+#3W)'U7IJ%4&9XY-;<S3B'W,-=BKN]T5T1
MHXM:$)+SZY,":@YY6\DGXN"O# Q/T8_^]J(2P:_^3?0M-4$NZ4XU^@&>,U_L
M_Q,;53J-E57DW*N(RS[FS%HI$!%;QT9 )]^_"9(S2+!G$WHBPX>S&F[+Q@4L
M ;FW_Z5B=G1N_^V+UAJO78)U6%?&-_@DU-+-&@2E/4'NE+\.I'5_+%S;EGF3
MDSA\N65PZ)[3EO-I*;Y/"RU47 K7ZW^O;JYN%5 W63N<N^V88K5J#Z]^3>J$
M'NO526]<<*+A72>ZE+;%+ 4"F8-^S'9'B:R6G2 DU*7MD.2E*LJJPFUKM$ L
M=TX.>)X@-/,X(Q)C49FT8#[6"9M?-8=MA:A. !B'L@KO2?DQX%STU(9]"KNN
MX?8/C%=:H $<U7R[?759\:V;#W_K[#Q1@Q=MT^E7@84^RI<?+?/(M8\^!HSE
M-IXUK1"=+5VXE"%X,E?SZSEL$=B5K 5^BK]+FGPYJ@4LS^QI&-0(TM2C@!9@
M,2='%O6.WK88<53>T#S%MM+L\0$6>2>0K!1158P9S= YHB$Z"V9',Z;X,V;!
MW=G/Z(PB)%',C<66<]JV-,AW][;4%:L<;Q6Q;IJPJ_#@!)[&905J\UND)7E4
MJN853UY\66?<1=ZB!59-!N&NK$")4T/;#<2%>K8+MWNM DUHZN0NZA]@4293
MGJ$P?RO$RTL+Z&(?J'KC$?I@ E5_W$./6J9YNL72ZFCKY4" ?@J6Q0_2-;.E
M/0^PND^@F-C,^!3 Z,B!,OA!6.H?GBYY?@P;3<'XLZ\%KS4IV!Q?#KWJ2[</
MM4B?$C;KY0\_:H%## .A=P4;C?P2?(QR-[APHH+=R?^*Z,JRX/5: ,3GWHUU
MLN6O!] 6$O8.)9Z41Q9B*W0?J 6,C:Y#G8;8S:P;V!?N:)!,"Z1Q0:J"O7_K
MSV '[P^<&FLJW_!U(#L;;G)O,!$^]@H4=T E3#:ZB5T'D!]7EG*I;TVTP(H^
ML-51"USDJ@)*V.,S\!:Y=0)K+94-KE&[(*%NB),XTJRZ%IQ*=Q8OS;%7]%J&
MJE<-UQZR%S=8'HQ<*Q5KGJ5WMVF!8S&]8ZF5R@-[UP=NOOM0"UAMQ'$MBP4?
MJNU:PJT%.^X\3AS*<(1,D#K1QZ+KI[_\S."+3<L""Z&&W&'5JLC7['XV0!N.
MVFIN]6$YJ_=S4=#6S'6;! ==+]EHEJ3)BY+4]*2@ZW7GC\BJOZK)0UVJ@LD;
M_R3:6C4[H1IS*NR\7 ML<5%Z:H&JX;JH2=0F ^II&496WZ LSE78*T^]=O5<
MD])!"I7D*^_H#=>F7V0LZ.HD%DH'N8K^MZQTBXD_ A.QQ9\J);Y-DOENY2]#
MEAL-YV2:Q#GZ1SXI-7-:G+PQVN](.O5<9"3XHD"C@R[K+%\C#AX0LV8S&_9=
M99QT<:":]7M::XJM(XWW-S,'W\#VAR*M]C:/]1<M GWE>T3R$9]?*[V491%A
MF($P,JKWCWNI3TG2%:>.5R$RY?O7)S^H;=&U!0;,SYV,II@1$>Y@.FSTOM'&
MV:/WYJ_=DG]_OL&+WC?I%BD3I??WO_*,;S[.86:HR&:02]4E=W=+L^(F7\%[
MU?/X22HV3PMT&F.),G$@MF*I%I %.:*KJ,7+Z'*U';IY9'1TDE@X]?#>,\0!
MA(L$*@/YQ1;FL;]5M+?M"[U2G%[!M0<#OB)0)<AD(3ND1!CGH=.+H:;Y2">+
MC:[BSK:8G,8>-L1FXMIJZC=- 0[#>:+"T"C2FAZ-80]4R9W'J"?^,+A"X:L
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M'WX9B^\\JFP36-=ORFE>R IT?YK<-ARLNOS/OWFA0=7@/'JXH,@C@&Q)7XY
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M?"^%EG; <^^H+R+)_10AD/2#'\T >0):(7=X0^SQJF:)#Y,60<>K^%<*2$?
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M)CH)O]&C,73 XYS5!GWW8>G9VWB0TXI+H$Q_1<A[>7'I(P$,2T:K2#CZB_$
M!49,&*L5 ?%AQ)601;AH$N$/"A&Q@32+8BY['HW;);<](9M*."^OZT.9GNZD
M>"%!-1<X#P)J*R$7X95U<9*Z[>&O95_*("I24M('1QAUR!5@,M'0/S4VXUYX
MKJM_3=<*O\?Q8XNKL=U0\EDMBC4S0$;";XH8'&W,)M_<"S(S1W9BZK:WT[:"
MTCU@RL#K@%V'-6LJG?JEX)ZXN$TDI*;JJT/.]5-_\!R "9O@CG/$[,\VX\]$
MS_))&Y)MW2S6\;>71C:,M+2H/'<6?0G.X$N6AMN5#C>3'DY/8\?48H6XV7YO
MD8Q377L52<+J^E.8^4&4O>(\^DW,XB"*L[Q(3*K],1_6'W8[D)[G?B; 9$$;
MM,I+3 <?"H#' O\R6_Y4Q8[BG?7I@!Y0O0<ZG-N\;JR?$TNS3QPGF?BJ"-=A
M0W*:"[)T,2)AW2J# 4MZM3#.$PVVY8X8APKC(((6I4<XW4EKRO9/7<J/F[QI
MO\/FM43/TEO5WC+.V0LOH;V/,*H.#/B%CS,2L0P=_O 7+(P1)3FRL'/&.$K;
M>-PYI#XM&V+TG)Q0.RCCZ]"+?>A#_E7T48XHCQ3#)\Z2XGX4(X0V?HKAYQ,7
M_K6TR_(II\M'7BG@Q&,+OA587:'Z_"1?F'?N^5#J9($0.IG:G%1:NDUYQ*55
MO 7:Q5-7XG;%#)/-LHI<*JZJ7<#[8UE%."WJW.] I/2. I/$\6,E8G1P1\_)
M>&)&+2<^=;".;N+GYC%8G0)>% /Z#B+2LH *%AUG(?L*S"$_!1;I5074S*X6
MQ-\JMOQYRE-M.0BMRZ V3\;>[\NTW,3:B;[!68&WIRP#O1#%],F]HOB:72'B
M]1EY(NQ\RH(BF5E2"1T-FHJEMRJ=K0UW&L5).2*LFG@3MRI8E+1;Z.[YR8/Z
M\IUBU!:_4>U-5^[-IA\A=:?41OQ&6U<N_\1IH-_ F_.+/3"U<P>PQF"NPD4^
M&#5!6DA^2EI&=CD*AN8.P?JR]++K"V,0(^?'<3+)$0IN!"=AHF#;&8[<]L:E
M_7WTL._@6O;<KM "S&DPBB0_/!"4S93<"WBK11E/1@WP](3-^#M4$7&AAE-[
M#SS44>,&0&M5^+P\_U1+9NP$8T%/GQN9_K/\5%5DN#COL+U]BYL=':W ^KW+
M%UP]X>]R_\/]M"^G'&V>I_B_.X6>66HMZKL[(H2MEYG%I(F9U3STB.K8PRR*
M,<A5X]P@[[0!"\DB'I.,J=_6!,R)CZ;L?_Q1SASBTS"RP41.8>@9!'^+O$(?
M7Z:X)$[SG+2HZ/OD7O>.395[;&L1U\3,^U:" 7VI 0XRH(&D3^;#!FC#84"7
M$BEJ1K^!#66AR5&W*+M!!A+ARWTC--^BMUZ:#(=L(V.\_(@4/^"%2_7I*QJO
MVC+&/!M+K^J=7],T4;91E8X^X>']&M.:03$#LK)$.\A*[Y.R7(>[!(08"HE*
M#;V Y\/QX;O*OC>)I,^!FXS1,3@ D)O6LE?(8U,2;7K8JYMI*0: KY_2C5GO
MM)1LWX"W4\_'>+\N+5-C$ZSM%WLI\PXW'7E#$_J$>2F;[%O*DD4^Q]Q#7WHV
M^Z<%M+U^]IKM'/!L$OVGK_:KT&.V+'_/N47R_;Q:F[:9\T[^0AV8=Y>\]WBG
M=UGG1#/A3%I-J:W@/K>'*PC"$7-&3'[<WN7F^0?"F@!0SN$*6A J3J3W;0=[
MPL0>6*Z)H0P3/<E!^\)&7=)*,]$8L5ZI12W"S<TE O[5S\D&8E(,;1V95)/:
M^L$R%$V +7@Z6M0E,J$!X],<;WS0K%W*N8#6&\';5<@G^]+D1_.EE2%&]<TN
MHD^E95M UW#YLA[>G)0D5O$.ZT\6)U_)YQ14O:I0GTK)\U79Y'RI*E'&9@T;
M?\E)_W*?%PN\I*7+4NI(X@4;G6ZR-_'/RH)29$W[/K#7S[C:=?8\,.#QB N_
MPNP:A%'>#-S0>[#5ZI;ASL<EKXOE9C<(;6\X\IPO=,]Y#^..[C#?<]+9C32J
M+F!=M;C0'CG)SIT*WN<[8%#YD3,>0.#"R]0W^YTG6D(_X9Q*V[$;OJZ8#W#+
M,@X$#Z'+SB@D1 <^3ZA3:9\W?#1OQ#CG3L? Z_&"@M49&"O1]>6-9D-HO@X[
MBO6^2(\:5% 0,%'"68 NK"&.3$@C>UEOD7HFWOE3HGGF/-TLX!7G72)ZGQ85
M#-Q?@I)NT:(J?148=0/"/68>Z/]X(NL:>N;1;^1]3Z,9<S(K$97VCNA*D$YP
M((^?/@:=/6BVW)[.ZDHT7YIR<0H[;IP\5FSXEGMLU[9N9X8EE0C#CEI4_8G]
MLR[V4)N@F"8BDJLY=P'Y+^$!(UK4U+@3O#'17.\?X\=-W%0<#71/BTK,_O=E
M)W:[7B7^JD6MU44%F=HU#IKQ38KK[TR%2I)KR^W&QO8O\9@"(O_Y?B\MBMSV
ME3"5M.3XYO^FP'_4[']Z8<.ZC,H/&?]7GJS$.?]%?.?9P>51JQ]=^(;GN)EG
M;GJ-+0=N?P@+S"P]L#-X.*/FT5\7YD_I;%;U^EK>27X4X?.":;OB=_VY#<<&
M),AR?M?T4ITRO<#AJD#O@A?3Y.'HQB.,4UH4.PU"Y'@YROX"[_/\7Q7SM\NY
MO:_[_&:=+5&M='_SS/GQ&6<>]_WJE?!HSG*\F^+:%@2UZ&I[_@]02P,$%
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M]-MO1CZF;OVQK>S(N7$Z*2;&D/'\=OE(0&_9]&!>P3"/;@&W2/])[H(J-U5
M+<\:3I1,+*#6^9=U(UZ/D!W*/P;,57,+'GQ^40.%R$#8=YVG0^!G\1Y1T7#R
M9X'BI[^5,TMUIT_'*:S-CP7=FREVU>(D^MW$D]$H'BW^]OX7D_8A,6H$?! 5
MJ[LTPZY#*_<3ZCITVYG=#D; ;6KM/E9V(3BA-WA![%U)QWJ'47"MZ!FB_5X
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MT>MN&KC2C,/"8]SX9U:F>3A-.3LZ-C(*Y>&F&BZ(E9@3N%R(ER+5%:V.1D
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M/18V>>3(@&])4T*$MF02Z?O"?]V)T_GJ6(7=O$@X4;7*7]6A(;]&:TIN;)Q
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M\Y*)6NM!K,%&]BT[\[;)@NRC(UNC^1SF6/%U\,"XXK3+VI";:RJZ=#Y8"#6
MUR/?>8H ,$ GO :O1F_T&S@:QGQ#U*5RXX#Q,UZ"T5.$0; $^(L]Y(S,$Y&A
M>G+[ZHW4=P;#0V)!&XJ4GTB*O- M '9\J7D4 M1%QE?0Y=]09IS4Z"A#I'Z'
MJ_7,J@331U8SABTV#:WYN :-W2_]O=1,:FI#<!BWLC!_;'3ZQ 485/D+-%O
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MK#6G5R"_*'X$E@'G0;3014+9OBF!PAP^*0%FP>:*5RT40.TGL%2N8MSA+*,
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MQ8"1+SBWD!^-&$U-#H#2T>R8JXCUU#J16PJ7%*<T?$^.#M1C&J\I#6[I,45
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MO=//1C6(<L=$V&H]IM.[AK2(/I]"%G.'.T6,:50')>Z]*VDAU569EBJ^]BK
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M'XPUM6?T171;QC#&$>H&HG0'*!5.*, ,K HH1 ^3R-KRG^#4EHQ>X9OS*6L
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M?QP6I'47CCUJIOY*8:-8%)--P4T("SW9M8;G1Z^ B3V.QN? J\"X/+1%&X4
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MN,ZZ*-8-T)<_8ZH#>I^ RC_(-W2 ZAG:WU^I/US91=:#S_ K$0S$BNE]4+R
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M"K5/XPPI^AO(7;:]5,'6+#L0]+Y_-C[D/#A)![@0^A,TWXQU:Z2Y-)8$LS0
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M\IHUL4BC:;H#UZH^?I>I]KX7T@_FT])&1UN;FD2'"1?4H5M&%"G*):VCHX1
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M[\OJ'L3,4#BHC7NK; IB:K9FR7XZ8W50;8)\N+:M;^:."UK"<^5A*[^.GYY
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M(%<R",Q=D^@E>A8^?<03(RLS_VM6+?JWOU?0_[5CC*[K_P!02P,$%     @
MS(';6O0U'AHE/0  [D<   T   !I;6%G95\P,3,N:G!GQ;L)5!/9NC]:B("
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M54MY,>QIK%F:I%)GQ%_%@H=$QA+++I'<\YR@F#V=G'35^8460-U=ML@FR;1
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M+-(]>&P>OT5]W(<YID'EIKGQG3K;&^5WOUB,K6I<4.H>*$UUV_+.)1@J3]Y
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MS&ZHZUYUB[^Z3PN80X[070OS;?0OCORY4!)]9"?GP^2:>O9&PM D_&,)C;2
MLQ)=Z8QOOWL':GG&LB%<#^9.[]*E?]5H 0,">E_O<B)(@Q(K&"&?[1ZQ["3
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MQ]=A;:@KM4$B*@C-3D&S92*.DCH9C:W*G%E?ZC@A1WK=A%!W$X/<O9K*K:;
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MF1!Q&8@1H\\)+FMCYPEJ'[4LN.![E>WN*@.-F-XO?*WK2ZVE'%( WQQ.B'O
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M&<<WSDV=6CI7[<I<S;)$'L'*.$[4\$_NK?C<9YI")734PYH&DSC\E2A#%H5
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M9>]IR;J+U[^LT-YJ)MP&_1W:_XKL?Q;8[?]?D?U'8/\9%Q]8J;((73P538
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MTT$T@0J&O_,758R-UNT#8U'R()D=E>^MHDBW"1$J@<5P:?U"RRPKJQ]-%(-
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MG],O%/GSXQZ]Z?)?J*!'8%(M,@I<W4;2O+Y73"\OL%$8GZSH*.NY'[#:X]O
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MZ>,JR%X5,5.KC^@DI<.P8AXM[%."G.CYP+^D+1V4(1;H]*.=P&O'JH"U^Y3
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M%+YW6.>M:R/A[JPFRGPKV VZ="-$$]P0_8"+V!:$*@%=<LKXC1OAF>IA$N>
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MPG,SJVJ3YQM)#\XV<RQ\9IY%Z&A7;M 'OP07JI$JNE$H%5KP1UN"U09>Q;Z
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MO:K9_-3UL)-F"] K)"5>V=.F^9Z2][G?NLN*:.>3Z19@W%4(^ONJ@'B4@-8
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M?;T.ERY\C#;]=G5QX:N.PB[!AO_T!=FV9Z_IRVU/<%F%K&E: GB[_4,T-(B
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M70XIS+!EZZ^$26L1\]?VB7>_M-#4,'6X;WG_)KHL;(BI/#"P=B?1FC98\>7
MSV#W;8V>!(.:ON2'TD;Q6FW\H8I"=='+'9!8/ O,HU_>P_EG_WSS3[=8*GO_
ML<L!;D#Y7WW^- JW[?]Q./Y3NX2GMP!=[_\ 4$L#!!0    ( ,R!VUH\Z:RM
M5G0  -UX   -    :6UA9V5?,#$U+FIP9Z2[!U!3[?<N&D5%0(ATJ;$C4F*A
M*"TB'R @1D$!:5$1:4)46H"8J BA"%%04% B4@)2HE2E)$((J(A(UR"DJ4B3
M'86P)86;[W_N^=W_G3ESYLX].[,RD]GOO+.?O=:SUO/LV5G]O,J&;'9U<G&"
MK%FS!G).^H&LCD,<_OWU?W3\N\G_Z1YK5M] E#="^M;LE%FS';)6>8V,\IK5
M+@@, EFS_G\L@/S?QYJU,NO6;Y#=*">O(%W0N!FR=HV,S-IU,NO7KULG/7M=
M>AZR3GF]RK;]]AM43YV7W7Y5[<#->\4;=QQ]V:'N,0#L/'CAVBTY>0W-+5K:
MNW8;[#'<:V9N87GHL)7#/XY.SL=<7#U/G_'R]CGK&W0Q^%)(:%AX=$QL7#PF
M(3'Y=DHJ(2T](R?W_H.\_(>/"IZ5E):5DRLJG]?5-S0V-;]ZW=))[V)T][Q]
M]WYP:'AD=.SS%R:'R_OV_<?4S^D9_N\_BTN"9?#ORK^XUD!D_@/]?XE+68IK
M[;IU,NMD_\6U9FW\OPN4UZW?MG^#BOTIV?-75;<?N+E1[>B]XI<=<CL.>@#J
M%ZX-R&OL-./LXO\+[;^0_7\#=NO_%[+_ /M_<#$AFV362),GHPQ!0"22/<\R
M(/^&P]\8"7YJ?"Q#% @:K4+6'P1+^'#!QR;0OA9["+Q.EO0C-N-L<2.H>H-.
MHDKH2G[Z3K ]3+KDV&";;04X%,B?>/ 'WVEHD(P-VEU<PP2C3)3VF%_?M=@:
M9GXP07'E/:GAGQ#12C1* 925R/&$-J)#XO+8!68A?0"<06K-M+"(;>=+,/#3
M_+SB"JPA8- %S[1(W/V$'\2%W\0J;#?)2^;!T@3ZN@/S6/=*$T:7YTY+=$AD
MF&E)XF\R+GD(1>>O0F[@O+'.JY!;W\'6#E@CL@MZ0X.VKD&!I00>9.CO 2[K
M[R*='LWUIXXN*OA]V?JJT#7]CG*8=[S&P/B[ _?,O'Z;@Q/:">YBB.@ __*D
M'7@56(7TQ&NXE/?S4.M )*,^C/\^)+L3I1)JH?TA;_^']T2SN)S QI9C;VNV
M/[WP-$>6@Q2I\021X'X@@H><JQ>>.AM:@+MC<Y4_BDY&:,$OG3)+_%'(CZ>W
MC#X*J@K?R(ZR.IQY)B'$ZRRC[5YW[H[MV@)$,JO1()MV :KKA^O#-^9,N@OM
MSJ+"]+7 PT)DN+=%)EED%WGBERV\DR0GL?AZ236LY-A"9)GH$%A]CGBL=>@C
MZ2G8%!'@!9LW(K9Q=3<@,]_]OC-& $[1G8KTZ_H,*:%5KP>*8%!OU3TG&B].
M'VT-+ZULG..D%7N4;I._]Q@W12SN7-QGI_WCL?F]H ,VL,U UF7],&_UPC-]
M84&8?L+!\$>XQ/LSGK>O-%9Q9L_5:ZNQ.9M.:.J<4"YVK=T0H2ST=G3<Q/=W
MU 7>Z;[HTW;;]/)878^QARGX/?L?8Z)NFD//]H,[*M>[J)M@M\?;J?W/ZOOO
M8:BPOCNZ3[9XH6=J%3)+@?/IHL  IS&)^J*=0OYQ"_(\N>M:N&&BJ6BHX:C)
M?NB7KD,[F_RISO8%XU!'KI%33@V!_L?0C7GA^7,U[[WM9:<ZGV4F.5X3#GZB
M*Z-F%I^@@M(HE_+KZ1Z"$=+!1IX2)L#DV]^&K(E'TYR;@K<&.;979R57[<]M
MN)+(6X50QLCMV&1N+XK)G#TU\&V0U!G7!/R)U4].4/.ZM@HI-0KQ" BR5-J4
M<-(8__UNE,U7[5]=M(:W6W60*3;J[U1G@XQ(#^_\/M2/[FP_^^WQ_>G39S\Z
M6'H=S"7K]DR2>PW4M2Q3ZJ^YN%PKK9Y/*D^X\O'QS)GRWX]_R3]^6N+A XTC
M'W!_-:Z:Y$CU3IIC>K%^^NY5\+P2R;8\NNOU[R#A47KK.]4YU*%_4#_VRUFN
M,Y:)E+GR,3R1;]'2/L=L&;&VJ'WR8*AQJ*F2/"S(;3G1%V!PJ7ID,"ZBQ+L^
M0#OBZ2E'M4V&<MT'9S-\(T)TE?_^&0[2J]BPYN;.<_PY?)FI,_(G/A_50V['
M7<9ZM4M)5=W#UV%4 A''Q$13.PU%KU/L1]C(ZWQYA 8U\Z5-WAAO*,/']"GJ
MPY^\3PD[LFYG1_QPBT""IG6BX&'S=SJ"$_CU+ASK"#\\U*UBAL 9#+\0PKIZ
MZ6ZWW39XFGWO5V3L_H&=S1<S;!XPJ=\W$<<]!<3#;_=(>.-[O#X,[PVHH 7M
M$9_Y/;I<S?V^2\NQJKU_X, J1&GR?.I*+X^F>,7RC7',%5!BFJ7K;59\-&*]
MQYUKAX6Z%P2_S T_EAT;K'1J/.P:M1>Y+'ME-IDXVP\+/"AQ"D 5T.07$.RJ
M:]A_@!S1A0%:4"L^917"'(#JN+%[%](\,#5F[MFF.D?<?@M,*J/DOIFP-;[Q
MMRGD(%R=[;,?;NE'=;?-75)F3VVQ.:&@WJ^$PVKLNA#6X_4ZQ-PUY\XBS834
M,D1S^![]X=XWGX)#(8^O2*[-GHQMIT$OO>Q[,5SC<5K\('&@@_U@[S+1JNR=
M]>#]D ^4]WD9>VH=&/)[GMWX[X& KT+8U:SU4Z!0N!_?V3+D!D]#=6F/98H,
MS4)],39GV+!4'(*?ESKZ_<H[X^;$ ^.:R,>.-D_U?:M%T.3.54BS]YPU8,F-
M%.078Y*[6J8ZQ0;(T;DV9#ESU@J19FZB_R4&I09Z=FL'+T:/SUC%55:$C6W_
MH=-P=5/SVHM[NNX)G!FA)?G=> @GSSQ/2V(P>Z5/]<8[8T_1#C!?[65+\Z8<
MIP^UI9O?']N:G"$22LOEO!E)3A0@#,9U+[_Q)=Y$P1K[-3': ]2 5<@FW+Y'
M-G[%;I&JNC4/J*4K60WR3W=>W7)2?V3QRR73M@.7_8IWOM2RLT@-=CW@>K)(
M50\Z][7[@6NDN<?M;R^R&P\'JMX>S_$\^1@GA!+*NHHTKIJZ!)J61:GTUU&-
M.GS]&\."7W_#CU3_/KVS';2Q"W)._:.?&&D5G=\01C: 0\!(?C27(%+%S,AV
MO<3T<BESZ\DSVM]91-/8FJ-#GF#Q*F2=I#5'Y*)$,G_\)RN)BYCKGKUJ4W"I
M;)VW_C8P+$S>IUJ[*&O#=O$@0,D0F?.(BC\#]P%Q[:5@26>1P>#E1NF\(=K3
MFD;, M#.P^>R9^@>@TLZAW<UM=6U-C_8=0MS,2;FG/V/-@3/LK/2_+"I31(G
MP.C$\-+/F/$G< 9.?7A^:_N W4Z,TX^OXS-4G3&SV;1O#;2(S-UYD[M>9SCF
M'?SVXH(G+'<E,(L?))$35L\@]/$7LV2[2?KX"\@TJMGP$C&;]%)2@#4H0>&Z
M\[RHNJTCV%-\*-O8>ZS LY_S.=;=SD7D A1[L9 :T5)J$S)FE"HF<=8*1\MV
M/?H.7.T8*4C!VOXMR^.6/J92=B\8GG_.]'PSEB/^;OWI<='VVP^0O?L./1^H
M,FZ%[>3??S;EL#G?^*"NL6]&;3Y=U]VHL^C ?=1KCY$26-#9) 1+WJA;(BOY
MA))%A*Y"4O25P0D U2.!\5ETN,YGQO6G&)(+-:7F8LB:D"%TR;V<ZY9G7Q3&
MUI:5L)PW% ?%ZM[U/W*G;651TV+Y5'HD.96[_9B*O7&TD^MC9:I%\%M;IVL(
MFP2#Y^Z.:B?7_+>0Y<1WPT!#RWG58MP(7A]Q$94:J *Z(++)XG+\)?07FB".
MC\BJ%GG#4MJL5B$:B!"DJN@Z^("'S@PKC3BZT#7+Z3/JM"IK3FX[S.D!2IDC
M8D;VH]B*J(.!WKLX1-"0TK,*4?UI%=\!6P>R!/8@37@*;!9TU(OSL-;\'1U6
M: 8-*MH).#U!T)\D<6NKN/V9,'E1@#DQJP&M%::O!Y#38MIA;PHLL\T5$=W:
M=[RL4@@9D6;"&SEBHO ?W+M5"(#\*T+R48'@,B] AD,F_GO[M$6&8$TTUS:$
M=Q\E+PHNQ]J+22(K&W5@07HY<N9G8^>AIP%J,R< =DH[=D)R^X]? /7II_ !
MI#K/W@2EL KI,,=?B%C8*#H&ANB_YM'2)@_Q45TH EZO+9[O[0/^X3[!"]*&
M<+LQ$0[7$1Q$5RL^3=NK.8("'O0:Q)HU>]E!VP9J8JY;+3L4""8B&Q6T+OG*
M#X[;ML;^(D7-5BZ@UDD.@LN==MI#;;N$D5A'\<,V$W[^&3"?BX2 &@L<5G8Q
M,$:0P.W+LRQFCQ72<0K\R=9H;N2.[OZ0*C]G+A3B%T[=TS8X%>'W$/W+Q-S(
M5Y0'GI+*T4I^",,V2"*O$W&^5+0EP)H]U4'*DN8U2+5LMJ\F@FH'0-\$)'6Q
ME+!H@^Y(^1[&@<E0)F,J.\;=L@NG/VBB2F\NR*?WX<:\LBW^B1A8Z6?#/\,%
M86 \T.P)GBT%#\SZ$_S&;"*Y8F^N9O92U2H$AD6]YB]T62-?@!2N,4H5Z\^D
MI<_9Q%Z/T"O=ATD^WOJRJ-,$<2*;8<*K3]'L:O.6MHT.:=]+Q'B_P:U]V0:>
M9[-NXW3!,VRXFFC/2WYV2I4/UF9X";5.= + @.>Y>"C6GE^0:4W4)&?$M'X^
MEV"#O)X0:YFVLXE6GV?KY&@L=VTVJ?DO#@'T?$2L0Z"AXR@G/H*^L$84#88!
M\3Q:YBHD%/'Y/8K9(\ -(D)\8A=25MHE[27][-!8UNU > -8QNU7#;-P'94@
M!I=,$#WW(O)&]S.G6]HLM6W^&.M0OTDO]YID$+%Y%1*!_[P*X<3W]&=,PH#F
M%"R>9[V0EH?;#DS=FI2@%4/' C>#CWC0]?3SY1/A\?'-^9T*2.AXV<>G?XSC
MER\DM28EN264-&4@O]0+(*",T!1\@5F%O/DM.L$G9$?B]*9A&]L.<VEW4&HV
M*+ZS-^#<V:[!5>A%$B8WK$)N%TBX_9VX+3F"C^]__>X]UM"<\SO).NBJV;W.
MEV.MHC6@(C E" '//L7J@*?(J+# ]<#(<GJCWMX>C^%:\Z2WM6T!W*R0;JOQ
M=_B8X[^K5WZT5_2K[.]2=KV[>T>6(V1^Z'M9Z]\5_5YI6]CQ40('J5*DRYWH
M#'W;P9KYJ"7D.BEC*9F+XWZ<;76O:<!8:J/MI8^3P%'^A\B05W791C?5[O5^
MJ_\;14R%):_@1>J6@G*PG6WBQJ#)\<0/J*I?1'+BO%5(,"D;U8#(L$/0^193
MG44[P5RA!T;_3T^1$AC,WL\N_&L.70\>9;F\^!V+3[?;H;]+\G[8?,\Y-'3"
M+RQ_C"B=F3R$?)B=-8#/$$$I"JF?1,&<FOC.@O=,I""B:1#K6#81IIW6^/J+
MP9=?BD^^=<H)$ ],OUA8?(7U]>M(F6V("$ZBR(.!_2?XY![XK9606W9K,=&"
M)#XQW4Y3%$P%$Z[RK=G>]'G3'V-'@9[NJI&Z?%>^.9G0T)MU:AO_H.^T_O:A
M!J'8:5#QVOAQ?%V7HOE(W%@2ED9Y \P;"/ABRBHDC*0G.C:(N-"O)'D_UB([
M-PU4":+XRUT]((F["M&<273N1JKC/N%D8*J1HAT D6N02JM;A&_"P)V G+0Y
M.P.0X#3V;#0V\]49K'E$T/H/O4OX^5QA J@@B!072?:!/9VXO: G#\I4?<.,
M3VZ#%V/5T&E%>M3A:LE^K/?((DU6M!]@9<TUB'WUO(\.P$7>M6=[$RIF]O]\
M%UWL,Z,9U[SO;FW1]1I\QU[\>4H&3ALX".YE=4]J@!?L-DM=DCN^& L%A[C]
MFT16X'? C3-1C0)JL ;\0YAXGU?-8"YG NH>9F*6%=RH-AJUF#2;9149M^"6
M8XT1Q_.:YQR%:EB/,3M]L)"[<,-.][,]&Z:/075%AUGF494&;*SYL"Y^Z)A$
M#KSZ3.371!NZ0U,V,4MHM$?<$"$H@>_3N4G7+6:ZC0I;?2X\-1N4^)X-Q^I)
M]4:'*R*T/VL5L@%_KAO4*L6N!<;F982NV'"P56B#C:SGL_FH.U1=K"E8!2B\
MD=B-47>&)5ICX('U(_#YJ$82Q%]Q0U!EN#(^**+%_<.8:D4.I]Y\%0+N[9DW
M>H;[6(#.VBY^C-6KQAX'H//5JY"7R_.[N)$P1KPB@.8(?ZY"M.ST1?O1NF#X
MF"?)G4]+@W%M$)L;'HDT.6_9>=(*=:AQYR;Q-A#5J95+45+%L"Y#?#\*38%+
M8(&B0'!C'[\6R52@C[(@(CR,;@V%8-VH8,@J1#Z_2SN?/H\X_BFD$7A R+39
M&DQD: <^TO:=89:-3%;,ZO5]8(AS>B5RTT++,%K] ]I<*WE:W[@)C,(9@!$\
MI^9*-YZBIR=_X8Z=(2::&T7@Q[9%\N!:LS"F%2G-O'\SR*,+M GI4;\^SKN.
M][U,\_5[F+=C1=("?T#XM8@BB/0BGP4>$Z9F['EZ]UG&'LBS#-%7/GF^4'C"
MF0+>HT(E;W#[P9O 4&=BWFOR#$R9NA4W ).QV]#44J0]O&O(O,:S8U*9?Z*F
M>F;9UUCSY(O&$6P(XL9<+0<3HL+85/%-YA<Z Z^"-0*B.<W9$F/,CQEN;P=-
MR<: @AGJ6HZ+RV%-=!2#T>ZO1V(U&^IN:-7^HO9%;A\?+]]4?V!;C$< SDR<
M36,_(RFN0B[#E,,#-PY2]43.H!^O[V"G-BO[$M!,Y  373WT%5D&5!EK-+)F
M6"3=.]DUP \YVA!@)5@^(?3<[H/)=XVP;IW*/*GQ9"$;9XDI9.!?$KL1F2]%
MBGQHBLBO5&0,EES#R6.O#!B;?BRIP<0[C' D]-&:MEV5&)(3/_ZVC;/9FLOF
M",7PQ/)\;I;*+Z-,K0_QCD&B0NF(T W%RS7 -F,]\CFUKP';6)@F*--)W<LG
M)N,T)-*1!T,$VZ+I!7V3%0:O&D=$L?R2KLD=37Q<?CDKW"J5A.90E!2M-OZ:
M1&TVKW2Q/&D=*O$2)Y(&KAY:MB--B5;&?B [::"AW3T^0? 3;!9J@I;LI:7O
MY([KT;Y _QTJG,;HOWUUG%[S4U\#6$@S/W19HN+"/28Q"9QN*B"FFV#A\;5?
MP"B><_WHN5?9,[]V.A";))8B%<!R7@X0>H)!?/4V+ZK&R*^&V5XZFZ8#-G-^
MT*;"XL,2PDW:/-G7@^SYZO>=+IZZJEA.WA1_*NH6YV+Z(^@4ZQ:-_="%T\]<
M[H U7'K-;_K31=T(VG(I,,P?]A2] ;S*493I9AJD27: ^F,<27TI*.1Y9>=-
MFH"5[!J88\:/*?J*<^:Y5Z,Z7JT9JY N*\EKBWRRV=:PFN6?UZ?XCI_ *0'N
MR#1-HI%=S;!4%.(YGEC7OTWB>=I\D,R.G9=HAR0&F<0OJQ")_#1@S=UY30>U
M ?>9)AM+2\;M,8WS<^/+<@8D8T!F%-?B]>LAQH.L%HN=>(MOVR[?11R1=MH0
M>V0F#(+U:;F\H^N:Z.A(3/X(MI?8H&<M44=VI;N3\W]DHHW?IC'NZ$>=//_&
M&,I@ =XDN0#XW,!3+.[3TU=V)N+[5!,L IPJ]6<:Z50T7(?Z-];Q[^P9$$E.
M4_6HK0_NZVHTI1=:.]E^U+\?_+!:S^F!\9ABQONI/J R:,\K3NDJ9';2(D\I
M;.+L[%>Q+%V^889_QH:@?*A'KOML(+JC\:O4>FA_D<C'7"L8:G43D]+V):B'
M-@/O_=_W^8O/VK'UG5'OJ>? =$Z6-X>2%D7="\+<K8K2*[<1N/A;Q6DNZ*KI
M;)W^L<N1\@V1^*@[N.%;!W9G7HT-G3P?R&=3U*9Q5@ Q113Q['B^-B(3:UN"
MR75[I.5O1ZJ9%JQD54Z^WM1I=-M+ZWW=BT,[U(>LJDIV0-Z_/W._XMS[-ZD>
MY%M;5#;^4H*JTY,9([U7U0]7/K]?3D[M.3<3X-$UX'FUTNF9U]7[!DJ)9X*$
M'VP3KU2YNC J)2&/OG^DV>DW-W1R@=BIN>>,:V,=O'U+>SURZU&7RJSN1PSD
MO_8MJ'(M];UZ5;(5SV;#H'2A'"C;2=)!!!&U?4%+#FR>7+L*Z53FT;[\Z.W$
MZ<-D&Y!JF(/T>.8SK!>0EQFL?I^J">;&ZI,3@J]7?C9O_^ ] ]^9E'HZ%39"
M RV&!/TH)E&@]PJ8NH/&P<)H&I(M(F=^5'H-&-190_Y9D%?&>6?7$?L,?(^7
M91ST]_$-W\YUDT.?$SJVCWR_D]MGA3R<W4H!]X;,:0)&@OL#-H>!$FY*:E4T
MFS7?Y\#UOET\""]].6PCQVUMC?NTU$J"NC+F<U@^#?=L9I,R$R[<[H#=?Y[X
MES#'DHZ)&^*'-I;2*3O?//>=OZ,'M=8.(=(9HQI@*!Q:%O8@+X@<7H>IZHY[
M4?,0));;J_ICFCMA3"_M ,;H[>\FIHM@[;RVIE^^S.B'0]'JA-[I*0R*]0TD
MRYW_\;?(]''XX3*DZE$S9F:Q5:SAF>JRN8L<N4Z7,RX)&*7MG1?V7WOW,O)3
M'_#>35DMI_/CR>_+%5X/'/OF2SR>^,;X!X16GCB _#*Q"G$^[<U#=)+ /<[=
MJ"_]C!7XG%AJ.!P!NUR QR#3K3:0@X1!6,M!FZ.(B_ MD[,%^0+U(FD%:LQJ
M1Y$B %KW[UGH>?*[H.<NJY"-WP4E53X=04GG0C(FD5]T_*K\9B.2QHT*DWJM
MWVYK:6AM++#.C*B*2!OUD]XK;D@&QB!]]-BE=.;AH."82QYR?^LG)92A!8/_
M,:O^*V2 *8F\IE #>U%<0XNDW&HJDG\%T)*IVK2Y:*&SZ#!XDX_HH<G8V/)[
MZ-IG>K*QL<#+RR++DK!) ]K0(D417#XY.-<8Z6<_ENG?A];(CRD?Y*KN1//C
M&:@OO8+'XON-K&R2TBHDA)+*:FB^@U6,+\-WV$KD,1$\V9N-"-5Q3,Z?#M9&
MG")&2 _<RK=KF%R;C=#!-#O5CWV\20;);D#P:)I9;V^?[9+MB?XCJ3\.(RH3
M]VBCW6;RG6?P^V ;I-7,+NF'SQ4CYLW)DLFQHFT$02)H1,980),MF+L+RRGS
MBJ6B<'YC?G>8U(@45R9SA-?W3G&^-]_8Y;>@]G%E-YF=2^DM]@\ :_FFP7]+
MNJ7"@L9^CM*T4\4Q[11!.EDR4'1@I#%@^ZPPB,.@W5R:K5$(X!<5"GU ;Q08
M3\%"^#@:]R!GXR^L+4 XT5KH.(33 [$8WX!=EVMMT/'!7),]C&AQYJDCPS4#
M"'K-LJ_$%OK#,%<P=\STXEB-=$!'X^BR@C(P:^O+3UP380)11LK0>X.YG4['
M(CO!=HE2\_Q&K(/YL[/5!<^860=^Q*%E-CZ6<'&=TT*''N%.[$8DL_$7B?<;
MU/Z =8A$"LUF61'",RR!%5C6$"3.D>Q'21-P$9[Y;2@ZV"#=J4*P"FD]C_(9
M.$+Y/KSG6<8Z];\WI249-D@+1:71Z@8E_8AZ9WKK@CYF6?  3.% ;^.VMN4M
M>']JTV'WIWC'$[GPC(*I+JAV: NN)HE-@4;H;_IDCEIG7TLO9WVM?<FML5-P
M,TK_?AI&7CRI$X[?$[@.H,PO"1&B#6"D<!=FEI,_;PLTL[WG%H3NV*.?L&%5
M. :<BTB?M&H3/Q3A@2$4?Q4R]X4C]6Z!-OF=%KB=?!H!IR5R&![CC!&CS."*
MXX$_(XLQ(2?X9EZ^QLO+)N;+'7!F-HR(T+%!P9/QD;;H+I(FUDW:(@KYEQ[B
M=F#B^AE%6JT _!8VF--GS8LKYI8!DA0\,$:GJ8O61 ;'2X6*^R=TY*\VXX+R
M]NIIOG/D/AIQI?G9359\</SWE7#\/HGYH+34:@7Z2N*7-M:<>3_>[1KA[C 2
M4&&W'E,W$4+EP^;].*@,FEX#-"UP*SA0;*^>]GI,% D0!%&OT*G:QYEKW2KH
MW'&X<F])1S2EJ>C!2I_T"NEHYII5R*5X/%,U$+S'50RF[L*(V]9$\_$=15L!
MYZY"1 K9ZQ1'#][5@L]<J!4%/S<E;6DC./&A=VIBD.HS3,.7N;X#QK7;%2U_
M/E"3B?>JF^1(O>C6?PE.X5)X!:(D$%&%]0,3JD3>4KV5]),%M0G&"R-P/2U2
M%9]%"W_BYSH:,H8/Q]_1UP?[XU<A<M"4!NEW>$$4B:_*^75S=Q8Z]EF@OX["
MEMAAHM?(XCO=(ZL09AE>'Z6*VRB"@/$\&I/8@5+!AR'3$'*-"^IT/IV#ZH2O
MP:+$M^VV@YF> .D&(HR8M4]T0OS,YBP["]_1A-L%L'KPZ45F]?69=/Q&&WQ(
M$GD"C.@<#/4J^/C YMY7/[_UCJ5+(JDO5)S!B7!CN+5@$R(802B([^R3/<*W
M3,?I,3%>RUWNE9(!JJFXT,:D#(PX"I@6EV&(7?E2W:Q.GK%LMHIZ(-/X54/S
M2D_YH<VS*LA-+<&MQ!0:.XNZ Z\.CG$O-4=P64H8TE$:B ^RR++(E5)A \@2
MGOL:X/L9%/H!I<P&W":P_5GH.TZ X9+TMH"YSH1N*_]K[I638996T5QFZ,["
M15D&U18\P\.#!LT,Z&9,%:>YNPIZJPFVIBV:(_7>&S"S]JU@-#^:@8"*#G.,
M)E2LQP,.GBE0=*"/!1H/F6C\.3+<^'FQ-:VXI6DD-A*!3.N]3+I' ASFD9Q=
M8_-Z0@<_T/,D.,:;/X[9X9O+(3!0Z9+#X!FIS?("S\,8^>ATJTN$4JS)IT6W
MB)VY/,?YQ;A XQ$J2S:+^\E<AZA4GAM6RF(>7PL&3EA%++,6$63Y/<]N(=7
MLE7(#MJ_,RD8Z;4*&7'G[VU!99*@BZN0#)H"=9O(?.1\ZG5$3]$FOF5*5-"K
MDT#DF%EAU<;2>\>V5A_HT_V\]<^6MV\8T2@UVK=X,8DV5SG#6JFD[O)NU"?\
MO/Y\>OC)WKM5&WA6GBG'7*P/?7S,\U!Q]PL["O\6F=KEU<&]\OF#N8M'U_G]
M:OM]$N]&NC[!FB<>RE#?/N3N^B1<C:Q1$)^]0LHG <?0:2W-&;0@BI+H$#^8
MQ;1)$![&-'<C(%B4;FEF0_X;[3Y&4?+5N-KX_';@6X&_\.V9Z%>[C[Z@#+N*
M$L2/W7#]JQ#@-(FYP/;S<R1C$()< )6"#V.M55EW=0)\QO"F4Q$-#7?.;R+&
M+,</.F\63S1F'%1RQ'7>@HY1_G8[SP;2-@]E?)CAAI5I'WY@;!'AZ/3U^:&5
M4Q2/_75U)QG&P19Y'TVM?'LF,$\(Q?KP[DN?7:^2\_E14&.>S;IS.;<-K]IM
MR Z^4[(N)\/G^)0P:2-/;^O/BD;-7ST?L9$ Z0UM,\48+3I;HG=B]D1SSN@@
MJG'"[^'3/'NCGK3==_:%02Z_,(9>,;K;(BZD*B/)SD&RJ?CZ2S?>CC*;GEQ/
MB*@Y,K@_*,O1X*"58<>Q[Z89$$C0]G9FQO>2PDNO$D]7G/SP<KAB0**NC7D^
M4*9X<:[24&CG]7TWE[/'[=$?)^^0[TO7'M>UNSZH"@:M&JOP&M7 8IE7DM'[
M$H+MF''DKEV[WM?LNH@-X<,%02/86#9,563,-ZV22BR$7!NJW.(>%Y^"T&DX
MU.;"F8AW.=!C-3WFO9_RV./P^52_A!NI/E';,CB[SU[P1O619$46XI?2+EID
MMWO$ (0^FR&ITRXIHKOZ,*RZ^*RE69]%=+*O I-DT2L(!9^?H[4/-@Q3UT8@
M":S-_TA@V<PPCR&_H5\OS7%_3U\N[/"2/WWGP(NOU="3':]VZ&7C2N[$X"..
M4A_E!23WH)P#'^NC,E<AFLT=>SPJ[9IK;I,.@N-?Z4+3,L5K(AQ\XX/YH]42
MVNW%TU>C8L-Z@L.WM,2Y7*M1L4%S:#U$B.@8\#AP3R,UEY[K0&X7M')H:@G:
M(6EM9@+!O*VXMO+B[KS#BG>S \8L#@;X(K7EGA8<^^+RS0Z*^P*KFYI?P\UR
MZT"MIQX"9;G(C,4DG2RW,Y^P)E4Z8@=D76.13L2C7YS-Y+M;B[@;O[EH770P
MNUBNY_)7*)&WY^A9=Y#JT#VKD&S)^A<2.E@%$#DA=]KB.7I(IT;Q:%G-SY;C
MS7$M^+0&/XRDG^MN.LW=W!MT5?F)EW.2"_MQNNP?3>E0D0*_Q<4T<]&,8J"$
M9WE#HHKK8W;32B,DIB-4>/B^YMM4';"W^Y0O)L*5>)2O5U15VE,9IK]SM,;;
M/;4S%.MH^\QO.O,J]JZ]RF%]S3U=5>P_\@^UZUI]L,S<F-RAB>SSR2FN<8F_
M6T!7+Y2JU^4(Y<+SN9CJ=?L;AIJ;>_>6G8+_*)+1VANKTS23NK>\Q<ET&O;U
M$OZCHOH??YBNC3OGU39\.E[)/,OJHT])'D(-M/J'[YWZZ]P]C6._>$D.@C1V
MCH5*]<.<@UJ;ZC9'!U(X4G$@PV\(G]3F6SRJZ&O0K%.MH19K[5Q+";KZW7^#
MQY6.H'-0K;[S:>^C-YE;^F+BO94HDI&4^_L?>N6CJL\'^RI[U8NYSP;#^7XF
M5_XVR2@C@G2/EJ7-IC"<,,==?PNV/!PH3$3<'&$N1WBV/\O=P6I&!SY>%%]U
M(WTO8O%6(:-3-0G- :L0RA/B/U+%=$[ME"/D?Q?JX*SPXBJDPY%J@)43EW/%
MI#:94@EC99.V-YTBAUF%G.+'SR<)?:81]5^I6W,9*X+&$D8YUG*@#/C1;D';
MG:5/,!P-?O7J99%159_=H9I YHQ1OCB#\J-0(B_FP)BDD^+BQ>MX3G=-!!GC
M"H6 X5 9T+N#I8B_2-'%VH.9S]?SAXM,6U_AB5?Z>&;U@&7:/$ZO.<T  #+M
M@54(':^,R61L[C-M+;F><R0L8'P,<">UL/0;X6F6M'H80]&!4X>Q^,,MJ@&2
MN]#LB #?/\>&VU0K,:PS0'OG3]^$UC%?EL-(S'4'K]>W!ON6@C0>53J:P:(4
M(FRJ4%DHP)FV$3>,@X!"/HNSW.WN[<\WN$75$NT#FF^:-!ZFPG#O5R%0+)P3
MD(C8$FZW&R#2YS?T"!*&C!M=*(NDC1B"UVO^I13NP0T/V/T:=NV1)?3$EJGQ
MPEDXN&=Y;IY?*+@E?H0/H6P _=@$ M5F$H/@DNE0;6P@J,@EIC'CZ:L0)<S8
M$6 AV<8^HC*T@)"!^QA3E;:(UD2%,ANKY2Y=_E7;4&'0?%-C3Q/VM90O!''&
M*B0,\87$O;.RP&!]:7[#JO^1&2S< 2JPQS)CI8W+ZY-D.PJ;!/9PI*.(E;9@
M9XJAZFWO?C]O/DN$1N1,NS^/^#/3TG;WB GJ5,1Y]+HC8YU+ON,G6FS[OQ"S
M$ WD-ZPO'(F^/3^7BR"T0:_S0[BRJ50-D<5@HU'ZKM&V$!Y%8\9BQ2N].%3;
M_+ZW[Q-A;U+LVL!)1GC,_&Y#CZG3K?7-YPUY-@;"<-P'N\/B8ILS0B/0F_N1
M6"6* RY:-10LW]H^9..XMJR'<&%PBF^77X[)6W!J!O)HM1@/Q6BG0H:54DKM
MC%4/(=>ST:KQ0?&!C9)=XC+:.50F2\U&%C"=.LL7) N/B6)!;V$P5@5L#>+C
MN0:WVF2E/E5?$5252EN<)I^<9:</^J)E?W(_.Z\G$)@^HK+FX;8SUAUA51-M
M7J,<FW@V6J0J%-P%$/,3Y>!05P$^.=(.@C46DU<AD2AF3R=*=4YT*1:NA74:
M1ER.A-$3(\F=L_UK\1?&OX*15#WD^>HG$5W>+1/SV8WGT9R?#87!0=?RWE37
MT*[;+7P0Q_XO!$M[]6_HH65*$=4@3)7"0-ZP&A@S)VV3;)L910!$K7G\BW^2
M.=Y=\=HWFOWVQXN?0BZJZ Q!7'03=+)G5M1^;UQZZLPCB]3RON V23[A7Q#F
M'UV,BN0 L&X?W :1TVO"E9M4/6Q0AON!'8GL]?\TC^5L+ E3ZHR5G;T#^QRS
MK:GN1?!>+7EVE1'$P4AIRV;[M[-W[;=3#T@;<(I(!YU->DGNZ5_CZTP+L%L_
MC/7DN'0N%/0R</(*W"<;?@W)7)OH22K;?N3='\+=R,/F8S@&:LL8;WFN"MC!
MI1\0MS+P2C&:8]N])R/;7,K\3+.X1F%*+BH=U=/++]_6_#%:NT6F8'D_<O:L
MQMFTQ.'>JX>JGY=,/%?/^7#%>RZWR.)QHM'9.(3C1YV/-H<XQD.\KBM-Z,=
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MF8_GY-^Q@?)W<. B-4U!HG9\!_(&3;W-F8_B7"(#;:) X,XR2=MNY^>?DW(
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MBV[3D1/!?K8>DX-383^VVLLT&%":_TH:5$S4_YRH$OIAU0>H!QP!)<$JI,>
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M57MB=]^_H&79V5G4EQ1]&.FN\#Q6J@,</Q:BH4+I!<GWR)0/:'KZ*E3HYG9
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M%>J67(7ZXGWMFSMF)*!'J5=-4& [@:_[5"C)QDL32F/%&14J]2"@0O5<'B?
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M.."0<S=@H&9VQYC<-X[]O(#->J#S/T976UE,""??4 <80AO3E'H5AB2N=FW
M:JK>XZYKI9$& ;JC/B>:O[PGH=$4TL':S 7T&I@9F&L7\6@R\*)="/'=WSN*
M=K^V)^[S3T+Z,=I:?)_K3!/:VI&1270E943,SVK>+0YVZ\C6%TT)M5(5GF(;
M$K?Q8+/OPP)2@/UP[87+5\ZF7]-KZJ[K-CU0K@&)4H'Q1RI457P;QD"! 9.+
MQG;UERB+:C :5)*WOP^X@E4&DUN=K68U)'IVW#$41.B,BESQO!:.TLI2$$L#
M8+)GFN+?BG(R_66RT.XWP,L],V=]=4T/-8@G8../='(T: [?"R^Q<=0# S03
MRF4N01\Q/J5P@A@SL_*UU!^43TH$-M2C"+;OD3(3V1PN,K17"R[JNJ"5R3D
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MO'#;HYO?]ZLO^S]<:-7P_P-02P,$%     @ S(';6MPWR>0M80  ;&L   T
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M@.*BB%(# !+^;R/ _QYA=I[[_TWL(%2[QD"Z !)X\K+'TS_Q#,"AAMH&"E&
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M;$.XMY8B-Y4C",IV*G0<&(_9ZM-,<1>U*C>Q"LR3)_&_,N=Z4L.DIR'J)<W
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MG $D>Z@:9X Y!@J$+LJ.^ULMJ7*HX<;3T3/ D5XDQQE@\SUIA_O<(>-V^QE
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M2(;E7O[\8/<>@H8_EV>OWK51A5;E08R#P8<;8W]20Z3E0\7;QD$.A$;N/_Q
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MBX\JS%.:G@BJ5+^K7(>='WZYKR_P*(:^XNVS<?G9->>Z]GCN=VB]3(<G*VD
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MW2@GKR!=T+@9LG:-C,S:=3+KUZ];)SU[77H>LDYYO<JV_?8;5$^=E]U^5>W
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M'V.B;II#S_:#.RK7NZB;8+?'VZG]S^K[[V&HL+X[ND^V>*%G:A4R2X'SZ:+
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MU6+<"%X?<1&5&J@"NB"RR>)R_"7T%YH@CH_(JA9YPU+:K%8A&H@0I*KH.OB
MA\X,*XTXNM UR^DSZK0J:TYN.\SI 4J9(V)&]J/8BJB#@=Z[.$30D-*S"E']
M:17? 5L'L@3V($UX"FP6=-2+\[#6_!T=5F@&#2K:"3@]0="?)'%KJ[C]F3!Y
M48 Y,:L!K16FKP>0TV+:86\*++/-%1'=VG>\K%((&9%FPALY8J+P']R[50B
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M UA(,S]T6:+BPCTF,0F<;BH@IIM@X?&U7\ HGG/]Z+E7V3._=CH0FR26(A7
M<EX.$'J"07SU-B^JQLBOAME>.INF S9S?M"FPN+#$L)-VCS9UX/L^>KWG2Z>
MNJI83MX4?RKJ%N=B^B/H%.L6C?W0A=//7.Z -5QZS6_ZTT7="-IR*3#,'_84
MO0&\RE&4Z68:I$EV@/IC'$E]*2CD>67G39J E>P:F&/&CRGZBG/FN5>C.EZM
M&:N0+BO):XM\LMG6L)KEG]>G^(Z?P"D![L@T3:*17<VP5!3B.9Y8U[]-XGG:
M?)#,CIV7:(<D!IG$+ZL0B?PT8,W=>4T'M0'WF28;2TO&[3&-\W/CRW(&)&-
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MTP.Q&-^ 79=K;=#QP5R3/8QH<>:I(\,U PAZS;*OQ!;ZPS!7,'?,].)8C71
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ME$9^OV>?-#?08,Z-CMEMJ!,_0X02O^ F370$-##"@(C3G4YA$P058E*,HG<
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M_1:[B<:T7@)X#/M6( N $T/!:JF@LPQ-1YS98!H%#A?@T7!J95L)O'5A>PT
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M?",YO5QA18(,>7%W3M>V3PJC&UC$0#C(B\VI(]9XX'YOU6J*KE?G3,0C8IP
M;T\291(NYBCS.6(O!WJ[J[\TIQ,83FQ3H<P,^7&"QJ$R:&0<PWUM*/%AS%\C
MBALG]1T9XO7S^7Y?O<'%% GD]_!R?.ED_5GYX:HLR9K;%!:B0[Q4^+T(P#GE
M+7L&G8DV?OD22Y^NH!Z")CIOJX/8Z8%8@BF%' Q%(9G@1*L_HC&PL_G:4PIY
M?]^OS<^K$CN%P:-?@WO6UIC53*6#(-+)J<8SY1YPCRRI%X@DI%Q%#2F.08"$
M<Y.V(:)+7"@F)HEJ3/@$NA#@^J00S10.UV+%NIG <6BY@#[?%91OQAW;-.!
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M#)B9VYSVJ>_#L5?^COV==_;C?O]YV/HNW"/M>6LB^PRR9G(@.UF,\C[;2F$
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M8RTR,#(U,#,S,2YX<V102P$"% ,4    " #,@=M:H$O'G" /   _NP  %
M            @ $^%0  :6=C+3(P,C4P,S,Q7V-A;"YX;6Q02P$"% ,4
M" #,@=M:A< ^R 9&  "&1P0 %               @ &0)   :6=C+3(P,C4P
M,S,Q7V1E9BYX;6Q02P$"% ,4    " #,@=M: Q[&0FZ;  "YT < %
M        @ '(:@  :6=C+3(P,C4P,S,Q7VQA8BYX;6Q02P$"% ,4    " #,
M@=M:+#EC>7Q*  !HO@0 %               @ %H!@$ :6=C+3(P,C4P,S,Q
M7W!R92YX;6Q02P$"% ,4    " #,@=M:D_$(>JJ* @# _10 $
M    @ $640$ :6=C,3!K,#,S,3(U+FAT;5!+ 0(4 Q0    ( ,R!VUJG5SNP
M*B,  *71   -              "  >[; P!I9V-E>#$Y+3$N:'1M4$L! A0#
M%     @ S(';6M>K[]/K!   MBL   T              ( !0_\# &EG8V5X
M,C$M,2YH=&U02P$"% ,4    " #,@=M:IPQ^PA\#  #R#   #0
M    @ %9! 0 :6=C97@R,RTQ+FAT;5!+ 0(4 Q0    ( ,R!VUJH?C3<H0<
M $\W   -              "  :,'! !I9V-E>#,Q+3$N:'1M4$L! A0#%
M  @ S(';6C/FV)VB!P  ,S<   T              ( !;P\$ &EG8V5X,S$M
M,BYH=&U02P$"% ,4    " #,@=M:^:LH,_P#  "C&   #0
M@ $\%P0 :6=C97@S,BTQ+FAT;5!+ 0(4 Q0    ( ,R!VUID8K#@ P0  )(6
M   -              "  6,;! !I9V-E>#,R+3(N:'1M4$L! A0#%     @
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M2P$"% ,4    " #,@=M:93$/94B&  #GB@  #0              @ $8N08
M:6UA9V5?,# U+FIP9U!+ 0(4 Q0    ( ,R!VUKS.?$Y5VL  +%O   -
M          "  8L_!P!I;6%G95\P,#8N:G!G4$L! A0#%     @ S(';6MPW
MR>0M80  ;&L   T              ( !#:L' &EM86=E7S P-RYJ<&=02P$"
M% ,4    " #,@=M:EL<;);N]  "MP0  #0              @ %E# @ :6UA
M9V5?,# X+FIP9U!+ 0(4 Q0    ( ,R!VUJ=A:K+M[<  /"[   -
M      "  4O*" !I;6%G95\P,#DN:G!G4$L! A0#%     @ S(';6O)K%QRF
M?@  7X@   T              ( !+8() &EM86=E7S Q,"YJ<&=02P$"% ,4
M    " #,@=M:".!6K<IC  "G;0  #0              @ '^  H :6UA9V5?
M,#$Q+FIP9U!+ 0(4 Q0    ( ,R!VUJ*T,/+Z:L  !V_   -
M  "  ?-D"@!I;6%G95\P,3(N:G!G4$L! A0#%     @ S(';6O0U'AHE/0
M[D<   T              ( !!Q$+ &EM86=E7S Q,RYJ<&=02P$"% ,4
M" #,@=M:MTOMCUI=  "W9   #0              @ %73@L :6UA9V5?,#$T
M+FIP9U!+ 0(4 Q0    ( ,R!VUH\Z:RM5G0  -UX   -              "
M =RK"P!I;6%G95\P,34N:G!G4$L! A0#%     @ S(';6MPWR>0M80  ;&L
M  T              ( !72 , &EM86=E7S Q-BYJ<&=02P$"% ,4    " #,
M@=M:/.FLK59T  #=>   #0              @ &U@0P :6UA9V5?,#$W+FIP
79U!+!08     '@ >  P'   V]@P    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>igc10k033125_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:igc="http://www.indiaglobalcap.com/20250331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="igc-20250331.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
        </entity>
        <period>
            <instant>2025-06-20</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">igc:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">igc:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">igc:FiscalYear2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">igc:ClinicalTrialInventoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">igc:ClinicalTrialInventoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="igc:PropertyPlantAndEquipmentTableTypeAxis">igc:PropertyPlantAndEquipmentTableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
        </entity>
        <period>
            <instant>2020-06-11</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">igc:March2024SPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-22</startDate>
            <endDate>2024-03-22</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">igc:March2024SPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-22</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">igc:September2024SPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-25</startDate>
            <endDate>2024-09-25</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">igc:September2024SPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-25</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
        </entity>
        <period>
            <instant>2023-10-27</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">igc:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">igc:SharePurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">igc:SharePurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">igc:ESOP2008OmnibusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">igc:ESOP2008OmnibusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">igc:DebtFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">igc:DebtFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">igc:DebtFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">igc:DebtFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2032Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2042Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2044Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">igc:Expiring2045Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">igc:WellnessAndLifestyleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">igc:WellnessAndLifestyleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">igc:TollingWhiteLabelingServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">igc:TollingWhiteLabelingServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">igc:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">igc:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">igc:InfrastructureSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">igc:PlantAndCannabinoidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">igc:PlantAndCannabinoidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CO</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CO</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-24</startDate>
            <endDate>2025-06-24</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-24</startDate>
            <endDate>2025-06-24</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-24</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-24</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>igc:segment</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-14753">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-52">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-14754">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-14755">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-14756">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-68">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-14757">001-32830</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-94">IGC PHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-105">MD</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0" id="ixv-110">20-2760393</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-14758">10224 Falls Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-14759">Potomac</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0" id="ixv-14760">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-131">20854</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0" id="ixv-14761">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-14762">983-0998</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-14763">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-162">IGC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-167">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-14764">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-14765">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-14766">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-14767">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-14768">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-14769">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-14770">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-241">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-247">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c0" id="ixv-14771">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c1" decimals="0" id="ixv-14772" unitRef="usd">29724689</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-14773"
      unitRef="shares">83891586</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c0" id="ixv-4331">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At IGC, we are committed to
maintaining the confidentiality, integrity, and availability of our information systems and data. As part of this commitment, we have
implemented a comprehensive cybersecurity program to protect against unauthorized access, use, disclosure, modification, or destruction
of our information assets. We are committed to ensuring the security and protection of our company&#x2019;s information assets and the
personal information of our employees, customers, and stakeholders.&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c0" id="ixv-4332">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At IGC, we are committed to
maintaining the confidentiality, integrity, and availability of our information systems and data. As part of this commitment, we have
implemented a comprehensive cybersecurity program to protect against unauthorized access, use, disclosure, modification, or destruction
of our information assets. We are committed to ensuring the security and protection of our company&#x2019;s information assets and the
personal information of our employees, customers, and stakeholders.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We recognize that cybersecurity
threats are constantly evolving and have the potential to cause significant harm to our company and our stakeholders. In order to address
these risks, we have established a cybersecurity risk management framework that is aligned with industry best practices and regulatory
requirements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our program includes regular
risk assessments, vulnerability management, access controls, incident response planning, and employee training and awareness programs.
We also work closely with third-party service providers to ensure that they are meeting our cybersecurity standards.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In the event of a cybersecurity
incident, we have established procedures for prompt investigation, containment, and remediation to minimize the impact on our operations
and stakeholders. We believe that our cybersecurity program is robust and effective, and we will continue to invest in and improve our
capabilities to address evolving threats, although there can be no assurance, that our cybersecurity program will prevent all incidents.
We are committed to transparency and will provide updates on any material cybersecurity incidents that may impact our company or our stakeholders.&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c0" id="ixv-14774">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c0" id="ixv-4342">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c0" id="ixv-14775">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c0" id="ixv-14776">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c0" id="ixv-4363">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our board of directors addresses
the Company&#x2019;s cybersecurity risk management as part of its general oversight function. The board of directors&#x2019; audit committee
is responsible for overseeing Company&#x2019;s cybersecurity risk management processes, including oversight and mitigation of risks from
cybersecurity threats.&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c0" id="ixv-4364">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our board of directors addresses
the Company&#x2019;s cybersecurity risk management as part of its general oversight function. The board of directors&#x2019; audit committee
is responsible for overseeing Company&#x2019;s cybersecurity risk management processes, including oversight and mitigation of risks from
cybersecurity threats.&lt;/p&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c0" id="ixv-4365">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our board of directors addresses
the Company&#x2019;s cybersecurity risk management as part of its general oversight function. The board of directors&#x2019; audit committee
is responsible for overseeing Company&#x2019;s cybersecurity risk management processes, including oversight and mitigation of risks from
cybersecurity threats.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our cybersecurity risk assessment
and management processes are implemented and maintained by certain Company management, including our IT Lead. Our IT Lead has 5 years
of experience in roles that include oversight of cybersecurity risk management programs. In addition, the IT Lead is assisted by an external
agency with about 15 years of expertise in cybersecurity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our IT Lead is responsible
for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#x2019;s overall risk management
strategy, communicating key priorities to relevant personnel, helping prepare for cybersecurity incidents, approving cybersecurity processes,
and reviewing security assessments and other security-related reports.&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c0" id="ixv-4366">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our board of directors addresses
the Company&#x2019;s cybersecurity risk management as part of its general oversight function. The board of directors&#x2019; audit committee
is responsible for overseeing Company&#x2019;s cybersecurity risk management processes, including oversight and mitigation of risks from
cybersecurity threats.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our cybersecurity risk assessment
and management processes are implemented and maintained by certain Company management, including our IT Lead. Our IT Lead has 5 years
of experience in roles that include oversight of cybersecurity risk management programs. In addition, the IT Lead is assisted by an external
agency with about 15 years of expertise in cybersecurity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our IT Lead is responsible
for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#x2019;s overall risk management
strategy, communicating key priorities to relevant personnel, helping prepare for cybersecurity incidents, approving cybersecurity processes,
and reviewing security assessments and other security-related reports.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our cybersecurity incident
response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including
the CEO, who help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the Company&#x2019;s
incident response processes include reporting to the audit committee for certain cybersecurity incidents.&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c0" id="ixv-4367">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c0" id="ixv-4368">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our board of directors addresses
the Company&#x2019;s cybersecurity risk management as part of its general oversight function. The board of directors&#x2019; audit committee
is responsible for overseeing Company&#x2019;s cybersecurity risk management processes, including oversight and mitigation of risks from
cybersecurity threats.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our cybersecurity risk assessment
and management processes are implemented and maintained by certain Company management, including our IT Lead. Our IT Lead has 5 years
of experience in roles that include oversight of cybersecurity risk management programs. In addition, the IT Lead is assisted by an external
agency with about 15 years of expertise in cybersecurity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our IT Lead is responsible
for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#x2019;s overall risk management
strategy, communicating key priorities to relevant personnel, helping prepare for cybersecurity incidents, approving cybersecurity processes,
and reviewing security assessments and other security-related reports.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our cybersecurity incident
response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including
the CEO, who help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the Company&#x2019;s
incident response processes include reporting to the audit committee for certain cybersecurity incidents.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The audit committee will receive
periodic reports from our management concerning cybersecurity issues, including certain threats and risks and the processes the Company
has implemented to address them, as applicable. The audit committee also has access to various reports, summaries or presentations related
to cybersecurity threats, risk, and mitigation.&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c0" id="ixv-14777">The board of directors&#x2019; audit committee
is responsible for overseeing Company&#x2019;s cybersecurity risk management processes, including oversight and mitigation of risks from
cybersecurity threats.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c0" id="ixv-14778">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c0" id="ixv-4377">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our cybersecurity risk assessment
and management processes are implemented and maintained by certain Company management, including our IT Lead. Our IT Lead has 5 years
of experience in roles that include oversight of cybersecurity risk management programs. In addition, the IT Lead is assisted by an external
agency with about 15 years of expertise in cybersecurity.&lt;/p&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <dei:AuditorFirmId contextRef="c0" id="ixv-14779">5341</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c0" id="ixv-6529">Manohar Chowdhry &amp; Associates</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0" id="ixv-6548">Chennai, India</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" id="ixv-14780" unitRef="usd">405000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="-3" id="ixv-14781" unitRef="usd">1198000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="-3" id="ixv-14782" unitRef="usd">34000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c4" decimals="-3" id="ixv-14783" unitRef="usd">39000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c3" decimals="-3" id="ixv-14784" unitRef="usd">1360000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c4" decimals="-3" id="ixv-14785" unitRef="usd">1540000</us-gaap:InventoryNet>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent contextRef="c3" decimals="-3" id="ixv-14786" unitRef="usd">702000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent contextRef="c4" decimals="-3" id="ixv-14787" unitRef="usd">720000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" id="ixv-14788" unitRef="usd">395000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="-3" id="ixv-14789" unitRef="usd">208000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" id="ixv-14790" unitRef="usd">2896000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="-3" id="ixv-14791" unitRef="usd">3705000</us-gaap:AssetsCurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c3" decimals="-3" id="ixv-14792" unitRef="usd">1852000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c4" decimals="-3" id="ixv-14793" unitRef="usd">1616000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" id="ixv-14794" unitRef="usd">3220000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" id="ixv-14795" unitRef="usd">3695000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c3" decimals="-3" id="ixv-14796" unitRef="usd">681000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c4" decimals="-3" id="ixv-14797" unitRef="usd">688000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" id="ixv-14798" unitRef="usd">98000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="-3" id="ixv-14799" unitRef="usd">198000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent contextRef="c3" decimals="-3" id="ixv-14800" unitRef="usd">5851000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c4" decimals="-3" id="ixv-14801" unitRef="usd">6197000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c3" decimals="-3" id="ixv-14802" unitRef="usd">8747000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c4" decimals="-3" id="ixv-14803" unitRef="usd">9902000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="-3" id="ixv-14804" unitRef="usd">883000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c4" decimals="-3" id="ixv-14805" unitRef="usd">773000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-14806" unitRef="usd">1374000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-14807" unitRef="usd">1567000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-14808" unitRef="usd">2257000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-14809" unitRef="usd">2340000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c3" decimals="-3" id="ixv-14810" unitRef="usd">134000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c4" decimals="-3" id="ixv-14811" unitRef="usd">137000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c3" decimals="-3" id="ixv-14812" unitRef="usd">16000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c4" decimals="-3" id="ixv-14813" unitRef="usd">20000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-14814" unitRef="usd">10000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c4" decimals="-3" id="ixv-14815" unitRef="usd">84000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c3" decimals="-3" id="ixv-14816" unitRef="usd">160000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c4" decimals="-3" id="ixv-14817" unitRef="usd">241000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c3" decimals="-3" id="ixv-14818" unitRef="usd">2417000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c4" decimals="-3" id="ixv-14819" unitRef="usd">2581000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c3" decimals="-3" id="ixv-14820" unitRef="usd">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies contextRef="c4" decimals="-3" id="ixv-14821" unitRef="usd">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="4"
      id="ixv-14822"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c4"
      decimals="4"
      id="ixv-14823"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c3"
      decimals="0"
      id="ixv-14824"
      unitRef="shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c4"
      decimals="0"
      id="ixv-14825"
      unitRef="shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c3"
      decimals="0"
      id="ixv-14826"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c4"
      decimals="0"
      id="ixv-14827"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c3"
      decimals="0"
      id="ixv-14828"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c4"
      decimals="0"
      id="ixv-14829"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c3" decimals="-3" id="ixv-14830" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c4" decimals="-3" id="ixv-14831" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="4"
      id="ixv-14832"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c4"
      decimals="4"
      id="ixv-14833"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="0"
      id="ixv-14834"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c4"
      decimals="0"
      id="ixv-14835"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="0"
      id="ixv-14836"
      unitRef="shares">80878058</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="0"
      id="ixv-14837"
      unitRef="shares">80878058</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c4"
      decimals="0"
      id="ixv-14838"
      unitRef="shares">66691195</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c4"
      decimals="0"
      id="ixv-14839"
      unitRef="shares">66691195</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStocksIncludingAdditionalPaidInCapital contextRef="c3" decimals="-3" id="ixv-14840" unitRef="usd">130570000</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
    <us-gaap:CommonStocksIncludingAdditionalPaidInCapital contextRef="c4" decimals="-3" id="ixv-14841" unitRef="usd">124409000</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="-3" id="ixv-14842" unitRef="usd">-3496000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c4" decimals="-3" id="ixv-14843" unitRef="usd">-3423000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" id="ixv-14844" unitRef="usd">-120744000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c4" decimals="-3" id="ixv-14845" unitRef="usd">-113665000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-14846" unitRef="usd">6330000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" id="ixv-14847" unitRef="usd">7321000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" id="ixv-14848" unitRef="usd">8747000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="-3" id="ixv-14849" unitRef="usd">9902000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="-3" id="ixv-14850" unitRef="usd">1271000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c5" decimals="-3" id="ixv-14851" unitRef="usd">1345000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c0" decimals="-3" id="ixv-14852" unitRef="usd">652000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c5" decimals="-3" id="ixv-14853" unitRef="usd">612000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c0" decimals="-3" id="ixv-14854" unitRef="usd">619000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c5" decimals="-3" id="ixv-14855" unitRef="usd">733000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-14856" unitRef="usd">4410000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c5" decimals="-3" id="ixv-14857" unitRef="usd">6758000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-14858" unitRef="usd">3655000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="-3" id="ixv-14859" unitRef="usd">3773000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-14860" unitRef="usd">-7446000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="-3" id="ixv-14861" unitRef="usd">-9798000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c0" decimals="-3" id="ixv-14862" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c5" decimals="-3" id="ixv-14863" unitRef="usd">3345000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-14864" unitRef="usd">325000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c5" decimals="-3" id="ixv-14865" unitRef="usd">143000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="-3" id="ixv-14866" unitRef="usd">-7121000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c5" decimals="-3" id="ixv-14867" unitRef="usd">-13000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="-3" id="ixv-14868" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c5" decimals="-3" id="ixv-14869" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c0" decimals="-3" id="ixv-14870" unitRef="usd">-7121000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c5" decimals="-3" id="ixv-14871" unitRef="usd">-13000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c0" decimals="-3" id="ixv-14872" unitRef="usd">-30000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c5" decimals="-3" id="ixv-14873" unitRef="usd">-34000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="-3" id="ixv-14874" unitRef="usd">-7151000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c5" decimals="-3" id="ixv-14875" unitRef="usd">-13034000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-14876"
      unitRef="usdPershares">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-14877"
      unitRef="usdPershares">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="ixv-14878"
      unitRef="usdPershares">-0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c5"
      decimals="2"
      id="ixv-14879"
      unitRef="usdPershares">-0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="ixv-14880"
      unitRef="shares">76517175</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="0"
      id="ixv-14881"
      unitRef="shares">76517175</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c5"
      decimals="0"
      id="ixv-14882"
      unitRef="shares">58839868</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c5"
      decimals="0"
      id="ixv-14883"
      unitRef="shares">58839868</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c6"
      decimals="-3"
      id="ixv-14884"
      unitRef="shares">53077000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="-3" id="ixv-14885" unitRef="usd">118965000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="-3" id="ixv-14886" unitRef="usd">-100665000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="-3" id="ixv-14887" unitRef="usd">-3389000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="-3" id="ixv-14888" unitRef="usd">14911000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c11"
      decimals="-3"
      id="ixv-14889"
      unitRef="shares">3534000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c12" decimals="-3" id="ixv-14890" unitRef="usd">1917000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c5" decimals="-3" id="ixv-14891" unitRef="usd">1917000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c11"
      decimals="-3"
      id="ixv-14892"
      unitRef="shares">10580000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c12" decimals="-3" id="ixv-14893" unitRef="usd">3027000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c5" decimals="-3" id="ixv-14894" unitRef="usd">3027000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="c5" decimals="-3" id="ixv-14895" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="c11"
      decimals="-3"
      id="ixv-14896"
      unitRef="shares">-500000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <igc:AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock contextRef="c12" decimals="-3" id="ixv-14897" unitRef="usd">500000</igc:AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock>
    <igc:AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock contextRef="c5" decimals="-3" id="ixv-14898" unitRef="usd">500000</igc:AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c5" decimals="-3" id="ixv-14899" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:NetIncomeLoss contextRef="c13" decimals="-3" id="ixv-14900" unitRef="usd">-13000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" id="ixv-14901" unitRef="usd">-13000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c14" decimals="-3" id="ixv-14902" unitRef="usd">-34000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c5" decimals="-3" id="ixv-14903" unitRef="usd">-34000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c15"
      decimals="-3"
      id="ixv-14904"
      unitRef="shares">66691000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" id="ixv-14905" unitRef="usd">124409000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="-3" id="ixv-14906" unitRef="usd">-113665000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="-3" id="ixv-14907" unitRef="usd">-3423000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" id="ixv-14908" unitRef="usd">7321000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c15"
      decimals="-3"
      id="ixv-14909"
      unitRef="shares">66691000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" id="ixv-14910" unitRef="usd">124409000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="-3" id="ixv-14911" unitRef="usd">-113665000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="-3" id="ixv-14912" unitRef="usd">-3423000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" id="ixv-14913" unitRef="usd">7321000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c19" decimals="-3" id="ixv-14914" unitRef="usd">1709000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c0" decimals="-3" id="ixv-14915" unitRef="usd">1709000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20"
      decimals="-3"
      id="ixv-14916"
      unitRef="shares">14187000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c19" decimals="-3" id="ixv-14917" unitRef="usd">4252000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c0" decimals="-3" id="ixv-14918" unitRef="usd">4252000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="c19" decimals="-3" id="ixv-14919" unitRef="usd">200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="c0" decimals="-3" id="ixv-14920" unitRef="usd">200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <igc:AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock contextRef="c0" decimals="-3" id="ixv-14921" unitRef="usd">0</igc:AdjustmentsToAdditionalPaidInCapitaForSubscribedCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c21" decimals="-3" id="ixv-14922" unitRef="usd">43000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c22" decimals="-3" id="ixv-14923" unitRef="usd">-43000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:NetIncomeLoss contextRef="c21" decimals="-3" id="ixv-14924" unitRef="usd">-7122000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-14925" unitRef="usd">-7122000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c22" decimals="-3" id="ixv-14926" unitRef="usd">-30000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c0" decimals="-3" id="ixv-14927" unitRef="usd">-30000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c23"
      decimals="-3"
      id="ixv-14928"
      unitRef="shares">80878000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c24" decimals="-3" id="ixv-14929" unitRef="usd">130570000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c25" decimals="-3" id="ixv-14930" unitRef="usd">-120744000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="-3" id="ixv-14931" unitRef="usd">-3496000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-14932" unitRef="usd">6330000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss contextRef="c0" decimals="-3" id="ixv-14933" unitRef="usd">-7121000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c5" decimals="-3" id="ixv-14934" unitRef="usd">-13000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="-3" id="ixv-14935" unitRef="usd">618000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c5" decimals="-3" id="ixv-14936" unitRef="usd">637000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c0" decimals="-3" id="ixv-14937" unitRef="usd">13000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c5" decimals="-3" id="ixv-14938" unitRef="usd">93000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AssetImpairmentCharges contextRef="c0" decimals="-3" id="ixv-14939" unitRef="usd">152000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c5" decimals="-3" id="ixv-14940" unitRef="usd">3448000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="-3" id="ixv-14941" unitRef="usd">1640000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c5" decimals="-3" id="ixv-14942" unitRef="usd">1773000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c0" decimals="-3" id="ixv-14943" unitRef="usd">25000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c5" decimals="-3" id="ixv-14944" unitRef="usd">44000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="-3" id="ixv-14945" unitRef="usd">8000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c5" decimals="-3" id="ixv-14946" unitRef="usd">25000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="-3" id="ixv-14947" unitRef="usd">-180000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c5" decimals="-3" id="ixv-14948" unitRef="usd">-1008000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="-3" id="ixv-14949" unitRef="usd">187000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c5" decimals="-3" id="ixv-14950" unitRef="usd">-150000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c0" decimals="-3" id="ixv-14951" unitRef="usd">-7000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c5" decimals="-3" id="ixv-14952" unitRef="usd">-315000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="-3" id="ixv-14953" unitRef="usd">106000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c5" decimals="-3" id="ixv-14954" unitRef="usd">243000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c0" decimals="-3" id="ixv-14955" unitRef="usd">-196000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c5" decimals="-3" id="ixv-14956" unitRef="usd">197000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c0" decimals="-3" id="ixv-14957" unitRef="usd">-100000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c5" decimals="-3" id="ixv-14958" unitRef="usd">-129000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-14959" unitRef="usd">-74000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c5" decimals="-3" id="ixv-14960" unitRef="usd">-123000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-14961" unitRef="usd">-4795000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c5" decimals="-3" id="ixv-14962" unitRef="usd">-5199000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" id="ixv-14963" unitRef="usd">112000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c5" decimals="-3" id="ixv-14964" unitRef="usd">138000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c0" decimals="-3" id="ixv-14965" unitRef="usd">40000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c5" decimals="-3" id="ixv-14966" unitRef="usd">44000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="c0" decimals="-3" id="ixv-14967" unitRef="usd">0</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="c5" decimals="-3" id="ixv-14968" unitRef="usd">-154000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c0" decimals="-3" id="ixv-14969" unitRef="usd">370000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c5" decimals="-3" id="ixv-14970" unitRef="usd">377000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-14971" unitRef="usd">-442000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c5" decimals="-3" id="ixv-14972" unitRef="usd">-317000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="-3" id="ixv-14973" unitRef="usd">4454000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c5" decimals="-3" id="ixv-14974" unitRef="usd">3027000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c0" decimals="-3" id="ixv-14975" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c5" decimals="-3" id="ixv-14976" unitRef="usd">500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromRepaymentsOfDebt contextRef="c0" decimals="-3" id="ixv-14977" unitRef="usd">-3000</us-gaap:ProceedsFromRepaymentsOfDebt>
    <us-gaap:ProceedsFromRepaymentsOfDebt contextRef="c5" decimals="-3" id="ixv-14978" unitRef="usd">-3000</us-gaap:ProceedsFromRepaymentsOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-14979" unitRef="usd">4451000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c5" decimals="-3" id="ixv-14980" unitRef="usd">3524000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c0" decimals="-3" id="ixv-14981" unitRef="usd">-7000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c5" decimals="-3" id="ixv-14982" unitRef="usd">-6000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="-3" id="ixv-14983" unitRef="usd">-793000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c5" decimals="-3" id="ixv-14984" unitRef="usd">-1998000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="-3" id="ixv-14985" unitRef="usd">1198000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c10" decimals="-3" id="ixv-14986" unitRef="usd">3196000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" id="ixv-14987" unitRef="usd">405000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="-3" id="ixv-14988" unitRef="usd">1198000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1 contextRef="c0" decimals="-3" id="ixv-14989" unitRef="usd">1640000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1 contextRef="c5" decimals="-3" id="ixv-14990" unitRef="usd">1773000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <us-gaap:NatureOfOperations contextRef="c0" id="ixv-8279">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1 &lt;/b&gt;&#x2013; &lt;b&gt;NATURE OF OPERATIONS &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IGC
Pharma is on a mission to transform Alzheimer&#x2019;s treatment. We are building a robust pipeline of drug candidates, each targeting
different aspects of the disease. Our product candidate pipeline and anticipated milestones include the following: -&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 0pt; width: 10%; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Asset&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-right: 0pt; padding-bottom: 0pt; width: 1%; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 0pt; width: 28%; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Target
    Indication&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-right: 0pt; padding-bottom: 0pt; width: 1%; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 0pt; width: 22%; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Mechanism
    of Action&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-right: 0pt; padding-bottom: 0pt; width: 1%; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 0pt; width: 15%; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Development
    Stage&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-right: 0pt; padding-bottom: 0pt; width: 1%; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 0pt; width: 21%; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Key
    Milestones&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IGC-
    AD1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Agitation
    in Alzheimer&#x2019;s dementia&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;CB1
    receptor partial agonist; reduces neuroinflammation and restores neurotransmitter balance&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Phase
    2 clinical trial (CALMA study)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interim
    Phase 2 data analysis suggests cognitive improvements in the active treatment group versus the placebo group,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;TGR-63&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Early
    to moderate Alzheimer&#x2019;s disease&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Disrupts
    amyloid-beta (A&#x3b2;) plaque formation; crosses blood-brain barrier&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Preclinical&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Demonstrated
    favorable safety profile; advancing towards clinical trials&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;LMP&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Alzheimer&#x2019;s
    disease&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Targets
    neuroinflammation, neurotransmitter imbalance, and inflammasome-3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Preclinical&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bioequivalence
    to IGC-AD1 anticipated in 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IGC-M3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Early-stage
    Alzheimer&#x2019;s disease&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inhibits
    A&#x3b2; plaque aggregation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Preclinical&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Toxicology
    studies planned for mid-2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IGC-1C&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Alzheimer&#x2019;s
    disease and metabolic disorders&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Targets
    tau protein phase separation; potential GLP-1 receptor agonist&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Preclinical&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exhibits
    strong binding affinity to tau protein; potential for weight loss applications&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IGC-1A&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Metabolic
    disorders (e.g., type 2 diabetes, obesity)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Potential
    GLP-1 and GIP receptor agonist; CB1 receptor inverse agonist&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Preclinical&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-right: 0pt; padding-bottom: 4pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; padding-right: 0pt; padding-left: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identified
    through AI modeling; toxicology and dosing studies underway&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This
pipeline reflects IGC Pharma&#x2019;s strategic focus on addressing neurodegenerative diseases, particularly Alzheimer&#x2019;s, through
innovative mechanisms targeting key pathological features like amyloid plaques and tau protein aggregation. Additionally, their expansion
into metabolic disorders showcases the versatility of their drug discovery platform, leveraging artificial intelligence to identify promising
therapeutic candidates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2025, the Company had the following operating subsidiaries: Techni Bharathi Private Limited (TBL), HH Processors, LLC, IGCare
LLC, Sunday Seltzer LLC, IGC Pharma IP, LLC, IGC Pharma, LLC, SAN Holdings, LLC, Hamsa Biopharma India Pvt. Ltd. And Colombia-based beneficially-owned
subsidiary IGC Pharma SAS. The Company&#x2019;s fiscal year is the 52- or 53-week period that ends on March 31. The Company&#x2019; principal
office is in Maryland established in 2005. Additionally, the Company has offices in Washington state, Colombia, South America, and India.
The Company&#x2019;s filings are available on www.sec.gov.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
fiscal 2025, the Company reassessed its reportable segment structure in connection with its strategic realignment toward Life Sciences.
As a result, management determined that the Company operates as a &lt;b&gt;single reportable segment&lt;/b&gt;, focused on the vision to make the
world free from Alzheimer&#x2019;s. Historically, the Company reported two operating segments: Life Sciences and Infrastructure. While
the Infrastructure segment generated revenues in fiscal 2024, it did not generate any revenues in fiscal 2025 and is no longer actively
managed or evaluated as a discrete operating segment by the Company&#x2019;s Chief Operating Decision Maker. For more information, please
refer to &#x201c;Note 18 &#x2013; Segment Information&#x201d;.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-8432">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2&lt;/b&gt; &#x2013; &lt;b&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;a)
Principles of consolidation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of the Company and all its subsidiaries. Intercompany accounts and transactions
have been eliminated. In the opinion of the Company&#x2019;s management, the consolidated financial statements reflect all adjustments,
which are normal and recurring in nature, necessary for fair financial statement presentation. Transactions between the Company and its
subsidiaries are eliminated in the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;b)
Use of estimates&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with accounting principles generally accepted in the U.S. (U.S. GAAP) requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual
results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
believes that the estimates and assumptions used in the preparation of the consolidated financial statements are prudent and reasonable.
Significant estimates and assumptions are generally used for, but not limited to, allowance for uncollectible accounts receivable; sales
returns; normal loss during production; future obligations under employee benefit plans; the useful lives of property, plant, and equipment;
intangible assets; valuations; impairment of goodwill and investments; recoverability of advances; the valuation of options granted,
and warrants issued; and income tax and deferred tax valuation allowances, if any. Actual results could differ from those estimates.
Appropriate changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. Critical
accounting estimates could change from period to period and could have a material impact on IGC&#x2019;s results, operations, financial
position, and cash flows. Changes in estimates are reflected in the financial statements in the period in which changes are made, and
if material, their effects are disclosed in the notes to the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;c)
Revenue recognition&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue under ASC 606, &lt;i&gt;Revenue from Contracts with Customers &lt;/i&gt;(ASC 606). The core principle of this standard
is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects
the consideration to which the Company expects to be entitled in exchange for those goods or services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
606 prescribes a 5-step process to achieve its core principle. The Company recognizes revenue from trading, rental, or product sales
as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;I.
Identify the contract with the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;II.
Identify the contractual performance obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;III.
Determine the amount of consideration/price for the transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IV.
Allocate the determined amount of consideration/price to the contractual obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;V.
Recognize revenue when or as the performing party satisfies performance obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consideration/price for the transaction (performance obligation(s)) is determined as per the agreement or invoice (contract) for the
services and products. Refer to Note 17 &#x2013; &#x201c;Revenue Recognition.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;d)
Cost of Revenue&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
cost of revenue includes costs associated with in-house and outsourced distribution, labor expenses, components, manufacturing overhead,
and outbound freight for our products division. In our products division, the cost of revenue also includes the cost of refurbishing
or repackaging, if required, on products returned by customers that will be offered for resale.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;e)
Loss per Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
computation of basic loss per share for Fiscal 2025 excludes potentially dilutive securities of approximately shares, which includes
share options, unvested shares such as restricted shares and restricted share units granted to employees, non-employees, and advisors,
and shares from the conversion of outstanding units, if any, because their inclusion would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average number of shares outstanding for Fiscal 2025 and 2024, used for the computation of basic earnings per share (EPS) is
76,517,175 and 58,839,868, respectively. Due to the loss incurred during Fiscal 2025 and 2024, all the potential equity shares are anti-dilutive,
and accordingly, the fully diluted EPS is equal to the basic EPS.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;f)
Going Concern:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assesses and determines its ability to continue as a going concern in accordance with the provisions of ASC Subtopic 205-40,
&#x201c;&lt;i&gt;Presentation of Financial Statements&lt;/i&gt;&#x2014;&lt;i&gt;Going Concern&lt;/i&gt;&#x201d;, which requires the Company to evaluate whether there
are conditions or events that raise substantial doubt about its ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is currently in a clinical trial stage and, thus, has not yet achieved profitability. The Company expects to continue to incur
significant operating and net losses and negative cash flows from operations in the near future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended March 31, 2025, and March 31, 2024, the Company incurred net losses of $7.1 million and $13 million, respectively. During
fiscal 2025, the Company renewed the facility with O-bank. In addition, the Company raised approximately $4.64 million through private
placements and an at-the-market offering program. The at-the-market program and the credit facility serve to minimize ongoing liquidity
requirements and ensure the Company&#x2019;s ability to sustain its operations. The Company has taken several steps to extend its operational
runway, including narrowing its strategic focus to Life Sciences, limiting investment in non-core infrastructure operations, and managing
expenses related to clinical development with a disciplined approach. While management believes these actions improve the Company&#x2019;s
financial position, there can be no assurance that additional financing will be available on acceptable terms, or at all.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
first quarter of Fiscal 2026, the Company entered into the 2025 Share Purchase Agreement with multiple investors, relating to the sale
and issuance by our company to the investors of an aggregate of 2,803,333 shares of our common stock, for a total purchase price of $841,000,
or $0.30 per share, subject to the terms and conditions set forth in the 2025 SPA. The investment is subject to customary closing conditions,
including NYSE approval. As per the 2025 SPA, the investor received piggyback registration rights subject to certain restrictions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimates that its current cash and cash equivalents balance, with the working capital and investments, and with an available
overdraft facility of $12 million from O-Bank, is sufficient to support operations beyond the twelve months following the date these
consolidated financial statements and footnotes were issued. These estimates are based on assumptions that may prove to be wrong, and
the Company could use its available capital resources sooner than it currently expects.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;g)
Income taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes under the asset and liability method, in accordance with ASC 740, Income Taxes, which requires an entity
to recognize deferred tax liabilities and assets. Deferred tax assets and liabilities are recognized for the future tax consequence attributable
to the differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases and operating
loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using the enacted tax rate expected to apply to
taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax
assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance
is established and recorded when management determines that some or all of the deferred tax assets are not likely to be realized and,
therefore, it is necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
evaluating a tax position for recognition, management evaluates whether it is more-likely-than-not that a position will be sustained
upon examination, including the resolution of related appeals or litigation processes, based on the technical merits of the position.
If the tax position meets the more-likely-than-not recognition threshold, the tax position is measured and recognized in the Company&#x2019;s
financial statements as the largest amount of tax benefit that, in management&#x2019;s judgment, is greater than 50% likely to be realized
upon settlement. As of March 31, 2025, and 2024, there was no significant liability for income tax associated with unrecognized tax benefits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the last quarter of fiscal 2025, the Company received a tax credit of approximately $194 thousand, which has been recorded as other income
in the accompanying consolidated statements of operations. The credit relates to qualifying expenditures under applicable federal tax
incentive programs. The Company has submitted additional claims and expects to receive approximately $600 thousand in tax credits during
fiscal 2026. However, there can be no assurance as to the timing or certainty of receipt, as the claims are subject to review and approval
by the Internal Revenue Service (IRS). The Company will recognize any additional credits as income when collection is deemed probable
in accordance with applicable accounting standards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;h)
Accounts receivable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
make estimates of the collectability of our accounts receivable by analyzing historical payment patterns, customer concentrations, customer
creditworthiness, and current economic trends. If the financial condition of a customer deteriorates, additional allowances may be required.
We had $34 thousand of accounts receivable, net of provision for doubtful debt of $12 thousand as of March 31, 2025, as compared to $39
thousand of accounts receivable, net of provision for doubtful debt of $24 thousand as of March 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;i)
Cash and cash equivalents&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
financial statement purposes, the Company considers all highly liquid debt instruments with a maturity of three months or less to be
cash equivalents. The Company maintains its cash in bank accounts in the U.S., India, and Colombia, which at times may exceed applicable
insurance limits. The cash and cash equivalents of the Company on March 31, 2025, and 2024 were approximately $405 thousand and $1.2
million, respectively. The company&#x2019;s cash balance also includes approximately $8 thousand in restricted cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;j)
Short-term and long-term investments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
policy for short-term and long-term investments is to establish a high-quality portfolio that preserves principal, meets liquidity needs,
avoids inappropriate concentrations, and delivers an appropriate yield in relation to our investment guidelines and market conditions.
Short-term and long-term investments consist of corporate, various government agencies, and municipal debt securities, as well as certificates
of deposit that have maturity dates that are greater than 90 days. Certificates of deposit and commercial paper are carried at a cost
that approximates fair value. Available-for-sale securities: Investments in debt securities that are classified as available for sale
shall be measured subsequently at fair value in the statement of financial position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investments
are initially measured at cost, which is the fair value of the consideration given for them, including transaction costs. Where the Company&#x2019;s
ownership interest is in excess of 20% and the Company has a significant influence, the Company has accounted for the investment based
on the equity method in accordance with ASC Topic 323, &#x201c;&lt;i&gt;Investments &lt;/i&gt;&#x2013; &lt;i&gt;Equity method and Joint Ventures.&lt;/i&gt;&#x201d;
Under the equity method, the Company&#x2019;s share of the post-acquisition profits or losses of the equity investee is recognized in
the consolidated statements of operations, and its share of post-acquisition movements in accumulated other comprehensive income / (loss)
is recognized in other comprehensive income / (loss). Where the Company does not have significant influence, the Company has accounted
for the investment in accordance with ASC Topic 321, &#x201c;&lt;i&gt;Investments-Equity Securities.&lt;/i&gt;&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2025, had no marketable investments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;k)
Property, plant, and equipment (PP&amp;amp;E) &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PP&amp;amp;E
are recorded at cost net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful
lives of the assets, which are reviewed periodically to ensure consistency with expected economic benefits. Depreciation begins when
the asset is available for use and continues until the asset is retired or fully depreciated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
retirement or disposition, cost and related accumulated depreciation of the PP&amp;amp;E are de-recognized, and any gain or loss is reflected
in the results of the operation. The cost of additions and substantial improvements to property and equipment are capitalized. The cost
of maintenance and repairs of the property and equipment are charged to operating expenses as incurred. Please refer &#x201c;Note 6 &#x2013;
Property, Plant, and Equipment&#x201d; for more information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;l)
Fair value of financial instruments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
820, &#x201c;Fair Value Measurement&#x201d; defines fair value as the exchange price that would be received for an asset or paid to transfer
a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between
market participants on the measurement date. It also establishes a three-tier fair value hierarchy, which prioritizes the inputs used
in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1: Observable inputs such as quoted prices in active markets;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of the Company&#x2019;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable,
and accrued liabilities, approximately their fair values due to the nature of the items. Please refer to Note 15, &#x201c;Fair value of
financial instruments,&#x201d; for further information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;m)
Concentration of credit risk and significant customers&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments, which potentially expose the Company to concentrations of credit risk, are primarily comprised of cash and cash equivalents,
investments, accounts receivable, and unbilled accounts receivable, if any. The Company places its cash investments in highly rated financial
institutions. The Company adheres to a formal investment policy with the primary objective of preservation of principal, which contains
credit rating minimums and diversification requirements. Management believes its credit policies reflect normal industry terms and business
risk. The Company does not anticipate non-performance by the counterparties and, accordingly, does not require collateral. During Fiscal
2025, sales were spread across customers in Asia and U.S., and the credit concentration risk is low.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;n)
Stock &lt;/b&gt;&#x2013; &lt;b&gt;Based Compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based compensation to employees and non-employees in conformity with the provisions of ASC Topic 718, &#x201c;&lt;i&gt;Stock-Based
Compensation.&lt;/i&gt;&#x201d; The Company expenses stock-based compensation to employees over the requisite vesting period based on the estimated
grant-date fair value of the awards. The Company accounts for forfeitures as they occur. Stock-based awards are recognized on a straight-line
basis over the requisite vesting period. For stock-based employee compensation, the cost recognized at any date will be at least equal
to the amount attributable to the share-based compensation that is vested at that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
performance-based awards, stock-based compensation expense is recognized over the expected performance achievement period of individual
performance milestones when the achievement of each individual performance milestone becomes probable. For performance-based awards with
a vesting schedule based entirely on the attainment of performance conditions, stock-based compensation expense associated with each
tranche is recognized over the expected achievement period for the operational milestone, beginning at the point in time when the relevant
operational milestone is considered probable to be achieved.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
market-based awards, stock-based compensation expense is recognized over the expected achievement period. The fair value of such awards
is estimated on the grant date using Monte Carlo simulations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimates the fair value of stock option grants using the Black-Scholes option-pricing model. The assumptions used in calculating
the fair value of stock-based awards represent Management&#x2019;s best estimates. Generally, the closing share price of the Company&#x2019;s
common stock on the date of grant is considered the fair value of the share. The volatility factor is determined based on the Company&#x2019;s
historical stock prices. The expected term represents the period that our stock-based awards are expected to be outstanding. The Company
has never declared or paid any cash dividends. For further information, refer to Note 14, &#x201c;Stock-Based Compensation&#x201d; of Notes
to Consolidated Financial Statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;o)
Commitments and contingencies&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liabilities
for loss contingencies arising from claims, assessments, litigations, fines and penalties, and other sources are recorded when it is
probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. We record
associated legal fees as incurred. Information regarding our commitments and contingencies is incorporated by reference in Note 12, &#x201c;Commitments
and contingencies&#x201d; of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;p)
Impairment of long &lt;/b&gt;&#x2013; &lt;b&gt;lived assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews its long-lived assets, with finite lives, for impairment whenever events or changes in business circumstances indicate
that the carrying amount of assets may not be fully recoverable. Such circumstances include, though are not limited to, significant or
sustained declines in revenues or earnings, future anticipated cash flows, business plans, and material adverse changes in the economic
climate, such as changes in the operating environment, competitive information, and the impact of changes in government policies. For
assets that the Company intends to hold for use, if the total of the expected future undiscounted cash flows produced by the assets or
subsidiary company is less than the carrying amount of the assets, a loss is recognized for the difference between the fair value and
carrying value of the assets. For assets, the Company intends to dispose of by sale, a loss is recognized for the amount by which the
estimated fair value less cost to sell is less than the carrying value of the assets. Fair value is determined based on quoted market
prices, if available, or other valuation techniques, including discounted future net cash flows. Unlike goodwill, long-lived assets are
assessed for impairment only where there are any specific indicators for impairment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;q)
Intangible assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s intangible assets are accounted for in accordance with ASC Topic 350, &lt;i&gt;Intangibles &lt;/i&gt;&#x2013; &lt;i&gt;Goodwill and Other.
&lt;/i&gt;Intangible assets having indefinite lives are not amortized, but instead are reviewed annually or more frequently if events or changes
in circumstances indicate that the assets might be impaired, to assess whether their fair value exceeds their carrying value. We perform
an impairment analysis on March 1 annually on the indefinite-lived intangible assets following the steps laid out in ASC 350-30-35-18.
Our annual impairment analysis includes a qualitative assessment to determine if it is necessary to perform the quantitative impairment
test. In performing a qualitative assessment, we review events and circumstances that could affect the significant inputs used to determine
if the fair value is less than the carrying value of the intangible assets. If quantitative analysis is necessary, we would analyze various
aspects including revenues from the business, associated with the intangible assets. In addition, intangible assets will be tested on
an interim basis if an event or circumstance indicates that it is more likely than not that an impairment loss has been incurred. The
Company has analyzed a variety of factors on its business to determine if a circumstance could trigger an impairment loss, and, at this
time and based on the information presently known, does not believe it is more likely than not that an impairment loss has been incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets with finite useful lives are amortized using the straight-line method over their estimated period of benefit. In accordance with
ASC 360-10-35-21, definite lived intangibles are reviewed annually or more frequently if events or changes in circumstances indicate
that the assets might be impaired, to assess whether their fair value exceeds their carrying value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company intends to capitalize trademarks and related expenses exceeding $2,500 per trademark. Management may also capitalize trademarks
and related expenses up to $2,500 per trademark based on its potential and benefit in coming years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;r)
Software Development Costs&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is developing two proprietary software platforms intended to be commercialized:-&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.
A &lt;b&gt;clinical data management platform&lt;/b&gt; designed for the collection, analysis, and real-time monitoring of clinical trial data; and&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.
An &lt;b&gt;MINT- AD - AI-driven diagnostic and treatment personalization platform&lt;/b&gt; aimed at assisting in the early detection of Alzheimer&#x2019;s
disease and providing data-informed therapeutic suggestions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with &lt;b&gt;ASC 985-20&lt;/b&gt;, &lt;i&gt;Software to Be Sold, Leased, or Marketed&lt;/i&gt;, the Company capitalizes development costs incurred
after technological feasibility has been established and before the software is available for general release. Costs incurred during
the research, planning, or preliminary design phase are expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Capitalized
costs include direct labor, third-party development services, cloud computing infrastructure directly related to model development and
deployment, and associated overhead. These costs are amortized on a straight-line basis over their estimated useful lives, typically
&lt;b&gt;five to ten years&lt;/b&gt;, beginning when the software is ready for its intended commercial use.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
Fiscal 2024, the Company began working on overlaying machine learning technologies and AI into the internal clinical trial software framework
for trial management with the expectation that this can lead to improved decision-making, contextual data entry, computational models,
trial design (Phase 3), and data analysis, the company believes it is probable that the project will be completed and the software will
be used to perform the function intended. As of Fiscal 2025, the Company capitalized approximately $863 thousand in software development
costs. For more information, please refer to Note 5, &#x201c;Intangible Assets&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;s)
Inventory&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
is valued at the lower of cost or net realizable value, which is defined as estimated selling prices in the ordinary course of business,
less reasonably predictable costs of completion, disposal, and transportation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
consists of finished goods related to wellness products, hand sanitizers, finished hemp-based products, beverages. Work-and in-progress
consist of products in the manufacturing process as on reporting date, including but not limited to primary cost. Inventory is primarily
accounted for using the weighted average cost method. Primary costs include raw materials, packaging, direct labor, overhead, shipping,
and the depreciation of manufacturing equipment. Manufacturing overhead and related expenses include salaries, wages, employee benefits,
utilities, maintenance, and property taxes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
capitalize inventory costs related to our investigational drug, provided that management determines there is a potential alternative
use for the inventory in future research and development projects or other purposes. As of March 31, 2025, and 2024, our consolidated
balance sheet reported approximately $392 thousand of clinical trial-related inventory, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Abnormal
amounts of idle facility expense, freight, handling costs, scrap, discontinued products, and wasted material (spoilage) are expensed
in the period they are incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Please
refer to Note 3, &#x201c;Inventory,&#x201d; for further information.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;t)
Cybersecurity Costs&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains information technology systems and security protocols designed to protect sensitive clinical, corporate, and financial
data. Costs incurred in connection with the ongoing maintenance, enhancement, and monitoring of cybersecurity infrastructure are expensed
as incurred and classified within general and administrative expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews cybersecurity risks on an ongoing basis and implements technical and administrative controls in line with applicable
data protection standards. As of March 31, 2025, the Company had not capitalized any cybersecurity-related development costs, and no
material cybersecurity incidents have been identified.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;u)
Research and Development Expenses&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development (R&amp;amp;D) expenses include costs incurred to develop the Company&#x2019;s clinical-stage drug candidates, including IGC-AD1
and other investigational therapies. These costs consist primarily of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Clinical
                                            trial site payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Contract
                                            research organization (CRO) fees&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employee
                                            compensation for R&amp;amp;D personnel&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regulatory
                                            and medical affairs consulting&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Laboratory
                                            supplies and materials&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Preclinical
                                            studies and formulation development&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;R&amp;amp;D
expenses are expensed as incurred in accordance with ASC 730. Non-refundable advance payments for goods or services that will be used
in future R&amp;amp;D activities are deferred and recognized as the related goods or services are received. During Fiscal 2025 and 2024,
the Company recorded research and development expenses of approximately $3.7 million and $3.8 million, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;v)
Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Lessor
Accounting&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the current ASU guidance, contract consideration will be allocated to its lease components and non-lease components (such as maintenance).
For the Company as a lessor, any non-lease components will be accounted for under ASC Topic 606, &#x201c;&lt;i&gt;Revenue from Contracts with
Customers,&lt;/i&gt;&#x201d; unless the Company elects a lessor practical expedient to not separate the non-lease components from the associated
lease component. The amendments in ASU 2018-11 also provide lessors with a practical expedient, by class of underlying asset, to not
separate non-lease components from the associated lease component and, instead, to account for those components as a single component
if the non-lease components otherwise would be accounted for under the new revenue guidance (Topic 606). To elect the practical expedient,
the timing and pattern of transfer of the lease and non-lease components must be the same and the lease component must meet the criteria
to be classified as an operating lease if accounted for separately. If these criteria are met, the single component will be accounted
for under either Topic 842 or Topic 606 depending on which component(s) are predominant. The lessor practical expedient to not separate
non-lease components from the associated component must be elected for all existing and new leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a lessor, the Company expects that post-adoption substantially all existing leases will have no change in the timing of revenue recognition
until their expiration or termination. The Company expects to elect the lessor practical expedient to not separate non-lease components
such as maintenance from the associated lease for all existing and new leases and to account for the combined component as a single lease
component. The timing of revenue recognition is expected to be the same for the majority of the Company&#x2019;s new leases as compared
to similar existing leases; however, certain categories of new leases could have different revenue recognition patterns as compared to
similar existing leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
leases that are accounted for as operating leases, income is recognized on a straight-line basis over the term of the lease contract.
Generally, when a lease is more than 180 days delinquent (where more than three monthly payments are owed), the lease is classified as
being nonaccrual and the Company stops recognizing leasing income on that date. Payments received on leases in nonaccrual status generally
reduce the lease receivable. Leases on nonaccrual status remain classified as such until there is sustained payment performance that,
in the Company&#x2019;s judgment, would indicate that all contractual amounts will be collected in full.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Lessee
Accounting&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted ASU 2016-02 effective April 1, 2019, using the modified retrospective approach. The standard establishes a right-of-use
model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer
than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense
recognition in the income statement. In connection with the adoption, the Company will elect to utilize the modified retrospective presentation
whereby the Company will continue to present prior period financial statements and disclosures under ASC Topic 840. In addition, the
Company will elect the transition package of three practical expedients permitted within the standard, which eliminates the requirements
to reassess prior conclusions about lease identification, lease classification and initial direct costs. Further, the Company will adopt
a short-term lease exception policy, permitting us to not apply the recognition requirements of this standard to short-term leases (i.e.,
leases with terms of 12 months or less), and an accounting policy to account for lease and non-lease components as a single component
for certain classes of assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
ASU 2016-02 (Topic 842), lessees are required to recognize the following for all leases (with the exception of short-term leases) on
the commencement date: (i) lease liability, which is a lessee&#x2019;s obligation to make lease payments arising from a lease, measured
on a discounted basis; and (ii) right-of-use asset, which is an asset that represents the lessee&#x2019;s right to use, or control the
use of, a specified asset for the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the commencement date, the Company recognizes the lease liability at the present value of the lease payments not yet paid, discounted
using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company&#x2019;s incremental borrowing
rate for the same term as the underlying lease. The right-of-use asset is recognized initially at cost, which primarily comprises the
initial amount of the lease liability, plus any initial direct costs incurred, consisting mainly of brokerage commissions, less any lease
incentives received. All right-of-use assets are reviewed for impairment. There was no impairment for right-of-use lease assets as of
March 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company categorizes leases at their inception as either operating or finance leases. On certain lease agreements, the Company may receive
rent holidays and other incentives. The Company recognizes lease costs on a straight-line basis without regard to deferred payment terms,
such as rent holidays, that defer the commencement date of required payments. Please refer to Note 9, &#x201c;Leases,&#x201d; for further
information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;w)
Recently issued and adopted accounting pronouncements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Changes
to U.S. GAAP are established by the Financial Accounting Standards Board (FASB) in the form of accounting standards updates (ASUs) to
the FASB&#x2019;s Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. Newly issued ASUs
not listed are expected to have no impact on the Company&#x2019;s consolidated financial position and results of operations because either
the ASU is not applicable or the impact is expected to be immaterial. Recent accounting pronouncements which may be applicable to us
are described in Note 2, &#x201c;Significant Accounting Policies&#x201d; in our Consolidated Financial Statements contained herein in Part
II, Item 8.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0" id="ixv-8439">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;a)
Principles of consolidation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of the Company and all its subsidiaries. Intercompany accounts and transactions
have been eliminated. In the opinion of the Company&#x2019;s management, the consolidated financial statements reflect all adjustments,
which are normal and recurring in nature, necessary for fair financial statement presentation. Transactions between the Company and its
subsidiaries are eliminated in the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-8450">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;b)
Use of estimates&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with accounting principles generally accepted in the U.S. (U.S. GAAP) requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual
results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
believes that the estimates and assumptions used in the preparation of the consolidated financial statements are prudent and reasonable.
Significant estimates and assumptions are generally used for, but not limited to, allowance for uncollectible accounts receivable; sales
returns; normal loss during production; future obligations under employee benefit plans; the useful lives of property, plant, and equipment;
intangible assets; valuations; impairment of goodwill and investments; recoverability of advances; the valuation of options granted,
and warrants issued; and income tax and deferred tax valuation allowances, if any. Actual results could differ from those estimates.
Appropriate changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. Critical
accounting estimates could change from period to period and could have a material impact on IGC&#x2019;s results, operations, financial
position, and cash flows. Changes in estimates are reflected in the financial statements in the period in which changes are made, and
if material, their effects are disclosed in the notes to the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0" id="ixv-8466">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;c)
Revenue recognition&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue under ASC 606, &lt;i&gt;Revenue from Contracts with Customers &lt;/i&gt;(ASC 606). The core principle of this standard
is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects
the consideration to which the Company expects to be entitled in exchange for those goods or services.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
606 prescribes a 5-step process to achieve its core principle. The Company recognizes revenue from trading, rental, or product sales
as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;I.
Identify the contract with the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;II.
Identify the contractual performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;III.
Determine the amount of consideration/price for the transaction.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IV.
Allocate the determined amount of consideration/price to the contractual obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;V.
Recognize revenue when or as the performing party satisfies performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consideration/price for the transaction (performance obligation(s)) is determined as per the agreement or invoice (contract) for the
services and products. Refer to Note 17 &#x2013; &#x201c;Revenue Recognition.&#x201d;&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c0" id="ixv-8505">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;d)
Cost of Revenue&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
cost of revenue includes costs associated with in-house and outsourced distribution, labor expenses, components, manufacturing overhead,
and outbound freight for our products division. In our products division, the cost of revenue also includes the cost of refurbishing
or repackaging, if required, on products returned by customers that will be offered for resale.&lt;/span&gt;&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-8533">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;e)
Loss per Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
computation of basic loss per share for Fiscal 2025 excludes potentially dilutive securities of approximately shares, which includes
share options, unvested shares such as restricted shares and restricted share units granted to employees, non-employees, and advisors,
and shares from the conversion of outstanding units, if any, because their inclusion would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average number of shares outstanding for Fiscal 2025 and 2024, used for the computation of basic earnings per share (EPS) is
76,517,175 and 58,839,868, respectively. Due to the loss incurred during Fiscal 2025 and 2024, all the potential equity shares are anti-dilutive,
and accordingly, the fully diluted EPS is equal to the basic EPS.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="0"
      id="ixv-14991"
      unitRef="shares">76517175</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c5"
      decimals="0"
      id="ixv-14992"
      unitRef="shares">58839868</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <igc:GoingConcernPolicyPolicyTextblock contextRef="c0" id="ixv-8549">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;f)
Going Concern:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assesses and determines its ability to continue as a going concern in accordance with the provisions of ASC Subtopic 205-40,
&#x201c;&lt;i&gt;Presentation of Financial Statements&lt;/i&gt;&#x2014;&lt;i&gt;Going Concern&lt;/i&gt;&#x201d;, which requires the Company to evaluate whether there
are conditions or events that raise substantial doubt about its ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is currently in a clinical trial stage and, thus, has not yet achieved profitability. The Company expects to continue to incur
significant operating and net losses and negative cash flows from operations in the near future.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended March 31, 2025, and March 31, 2024, the Company incurred net losses of $7.1 million and $13 million, respectively. During
fiscal 2025, the Company renewed the facility with O-bank. In addition, the Company raised approximately $4.64 million through private
placements and an at-the-market offering program. The at-the-market program and the credit facility serve to minimize ongoing liquidity
requirements and ensure the Company&#x2019;s ability to sustain its operations. The Company has taken several steps to extend its operational
runway, including narrowing its strategic focus to Life Sciences, limiting investment in non-core infrastructure operations, and managing
expenses related to clinical development with a disciplined approach. While management believes these actions improve the Company&#x2019;s
financial position, there can be no assurance that additional financing will be available on acceptable terms, or at all.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
first quarter of Fiscal 2026, the Company entered into the 2025 Share Purchase Agreement with multiple investors, relating to the sale
and issuance by our company to the investors of an aggregate of 2,803,333 shares of our common stock, for a total purchase price of $841,000,
or $0.30 per share, subject to the terms and conditions set forth in the 2025 SPA. The investment is subject to customary closing conditions,
including NYSE approval. As per the 2025 SPA, the investor received piggyback registration rights subject to certain restrictions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimates that its current cash and cash equivalents balance, with the working capital and investments, and with an available
overdraft facility of $12 million from O-Bank, is sufficient to support operations beyond the twelve months following the date these
consolidated financial statements and footnotes were issued. These estimates are based on assumptions that may prove to be wrong, and
the Company could use its available capital resources sooner than it currently expects.&lt;/span&gt;&lt;/p&gt;</igc:GoingConcernPolicyPolicyTextblock>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-5" id="ixv-14993" unitRef="usd">-7100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-6" id="ixv-14994" unitRef="usd">-13000000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c27"
      decimals="-4"
      id="ixv-14995"
      unitRef="shares">4640000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c28"
      decimals="0"
      id="ixv-14996"
      unitRef="shares">2803333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c28" decimals="0" id="ixv-14997" unitRef="usd">841000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharePrice
      contextRef="c29"
      decimals="2"
      id="ixv-14998"
      unitRef="usdPershares">0.3</us-gaap:SharePrice>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-8582">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;g)
Income taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes under the asset and liability method, in accordance with ASC 740, Income Taxes, which requires an entity
to recognize deferred tax liabilities and assets. Deferred tax assets and liabilities are recognized for the future tax consequence attributable
to the differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases and operating
loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using the enacted tax rate expected to apply to
taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax
assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance
is established and recorded when management determines that some or all of the deferred tax assets are not likely to be realized and,
therefore, it is necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
evaluating a tax position for recognition, management evaluates whether it is more-likely-than-not that a position will be sustained
upon examination, including the resolution of related appeals or litigation processes, based on the technical merits of the position.
If the tax position meets the more-likely-than-not recognition threshold, the tax position is measured and recognized in the Company&#x2019;s
financial statements as the largest amount of tax benefit that, in management&#x2019;s judgment, is greater than 50% likely to be realized
upon settlement. As of March 31, 2025, and 2024, there was no significant liability for income tax associated with unrecognized tax benefits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the last quarter of fiscal 2025, the Company received a tax credit of approximately $194 thousand, which has been recorded as other income
in the accompanying consolidated statements of operations. The credit relates to qualifying expenditures under applicable federal tax
incentive programs. The Company has submitted additional claims and expects to receive approximately $600 thousand in tax credits during
fiscal 2026. However, there can be no assurance as to the timing or certainty of receipt, as the claims are subject to review and approval
by the Internal Revenue Service (IRS). The Company will recognize any additional credits as income when collection is deemed probable
in accordance with applicable accounting standards.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c30" decimals="-3" id="ixv-14999" unitRef="usd">194000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c31" decimals="-3" id="ixv-15000" unitRef="usd">600000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c0" id="ixv-8620">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;h)
Accounts receivable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
make estimates of the collectability of our accounts receivable by analyzing historical payment patterns, customer concentrations, customer
creditworthiness, and current economic trends. If the financial condition of a customer deteriorates, additional allowances may be required.
We had $34 thousand of accounts receivable, net of provision for doubtful debt of $12 thousand as of March 31, 2025, as compared to $39
thousand of accounts receivable, net of provision for doubtful debt of $24 thousand as of March 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AccountsReceivableNet contextRef="c3" decimals="-3" id="ixv-15001" unitRef="usd">34000</us-gaap:AccountsReceivableNet>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c3" decimals="-3" id="ixv-15002" unitRef="usd">12000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNet contextRef="c4" decimals="-3" id="ixv-15003" unitRef="usd">39000</us-gaap:AccountsReceivableNet>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c4" decimals="-3" id="ixv-15004" unitRef="usd">24000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-8631">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;i)
Cash and cash equivalents&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
financial statement purposes, the Company considers all highly liquid debt instruments with a maturity of three months or less to be
cash equivalents. The Company maintains its cash in bank accounts in the U.S., India, and Colombia, which at times may exceed applicable
insurance limits. The cash and cash equivalents of the Company on March 31, 2025, and 2024 were approximately $405 thousand and $1.2
million, respectively. The company&#x2019;s cash balance also includes approximately $8 thousand in restricted cash.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" id="ixv-15005" unitRef="usd">405000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="-5" id="ixv-15006" unitRef="usd">1200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="c3" decimals="-3" id="ixv-15007" unitRef="usd">8000</us-gaap:RestrictedCash>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c0" id="ixv-8642">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;j)
Short-term and long-term investments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
policy for short-term and long-term investments is to establish a high-quality portfolio that preserves principal, meets liquidity needs,
avoids inappropriate concentrations, and delivers an appropriate yield in relation to our investment guidelines and market conditions.
Short-term and long-term investments consist of corporate, various government agencies, and municipal debt securities, as well as certificates
of deposit that have maturity dates that are greater than 90 days. Certificates of deposit and commercial paper are carried at a cost
that approximates fair value. Available-for-sale securities: Investments in debt securities that are classified as available for sale
shall be measured subsequently at fair value in the statement of financial position.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investments
are initially measured at cost, which is the fair value of the consideration given for them, including transaction costs. Where the Company&#x2019;s
ownership interest is in excess of 20% and the Company has a significant influence, the Company has accounted for the investment based
on the equity method in accordance with ASC Topic 323, &#x201c;&lt;i&gt;Investments &lt;/i&gt;&#x2013; &lt;i&gt;Equity method and Joint Ventures.&lt;/i&gt;&#x201d;
Under the equity method, the Company&#x2019;s share of the post-acquisition profits or losses of the equity investee is recognized in
the consolidated statements of operations, and its share of post-acquisition movements in accumulated other comprehensive income / (loss)
is recognized in other comprehensive income / (loss). Where the Company does not have significant influence, the Company has accounted
for the investment in accordance with ASC Topic 321, &#x201c;&lt;i&gt;Investments-Equity Securities.&lt;/i&gt;&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2025, had no marketable investments.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-8683">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;k)
Property, plant, and equipment (PP&amp;amp;E) &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PP&amp;amp;E
are recorded at cost net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful
lives of the assets, which are reviewed periodically to ensure consistency with expected economic benefits. Depreciation begins when
the asset is available for use and continues until the asset is retired or fully depreciated.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
retirement or disposition, cost and related accumulated depreciation of the PP&amp;amp;E are de-recognized, and any gain or loss is reflected
in the results of the operation. The cost of additions and substantial improvements to property and equipment are capitalized. The cost
of maintenance and repairs of the property and equipment are charged to operating expenses as incurred. Please refer &#x201c;Note 6 &#x2013;
Property, Plant, and Equipment&#x201d; for more information.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-8699">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;l)
Fair value of financial instruments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
820, &#x201c;Fair Value Measurement&#x201d; defines fair value as the exchange price that would be received for an asset or paid to transfer
a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between
market participants on the measurement date. It also establishes a three-tier fair value hierarchy, which prioritizes the inputs used
in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1: Observable inputs such as quoted prices in active markets;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of the Company&#x2019;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable,
and accrued liabilities, approximately their fair values due to the nature of the items. Please refer to Note 15, &#x201c;Fair value of
financial instruments,&#x201d; for further information.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-8726">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;m)
Concentration of credit risk and significant customers&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments, which potentially expose the Company to concentrations of credit risk, are primarily comprised of cash and cash equivalents,
investments, accounts receivable, and unbilled accounts receivable, if any. The Company places its cash investments in highly rated financial
institutions. The Company adheres to a formal investment policy with the primary objective of preservation of principal, which contains
credit rating minimums and diversification requirements. Management believes its credit policies reflect normal industry terms and business
risk. The Company does not anticipate non-performance by the counterparties and, accordingly, does not require collateral. During Fiscal
2025, sales were spread across customers in Asia and U.S., and the credit concentration risk is low.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-8737">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;n)
Stock &lt;/b&gt;&#x2013; &lt;b&gt;Based Compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for stock-based compensation to employees and non-employees in conformity with the provisions of ASC Topic 718, &#x201c;&lt;i&gt;Stock-Based
Compensation.&lt;/i&gt;&#x201d; The Company expenses stock-based compensation to employees over the requisite vesting period based on the estimated
grant-date fair value of the awards. The Company accounts for forfeitures as they occur. Stock-based awards are recognized on a straight-line
basis over the requisite vesting period. For stock-based employee compensation, the cost recognized at any date will be at least equal
to the amount attributable to the share-based compensation that is vested at that date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
performance-based awards, stock-based compensation expense is recognized over the expected performance achievement period of individual
performance milestones when the achievement of each individual performance milestone becomes probable. For performance-based awards with
a vesting schedule based entirely on the attainment of performance conditions, stock-based compensation expense associated with each
tranche is recognized over the expected achievement period for the operational milestone, beginning at the point in time when the relevant
operational milestone is considered probable to be achieved.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
market-based awards, stock-based compensation expense is recognized over the expected achievement period. The fair value of such awards
is estimated on the grant date using Monte Carlo simulations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimates the fair value of stock option grants using the Black-Scholes option-pricing model. The assumptions used in calculating
the fair value of stock-based awards represent Management&#x2019;s best estimates. Generally, the closing share price of the Company&#x2019;s
common stock on the date of grant is considered the fair value of the share. The volatility factor is determined based on the Company&#x2019;s
historical stock prices. The expected term represents the period that our stock-based awards are expected to be outstanding. The Company
has never declared or paid any cash dividends. For further information, refer to Note 14, &#x201c;Stock-Based Compensation&#x201d; of Notes
to Consolidated Financial Statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c0" id="ixv-8782">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;o)
Commitments and contingencies&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liabilities
for loss contingencies arising from claims, assessments, litigations, fines and penalties, and other sources are recorded when it is
probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. We record
associated legal fees as incurred. Information regarding our commitments and contingencies is incorporated by reference in Note 12, &#x201c;Commitments
and contingencies&#x201d; of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0" id="ixv-8793">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;p)
Impairment of long &lt;/b&gt;&#x2013; &lt;b&gt;lived assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews its long-lived assets, with finite lives, for impairment whenever events or changes in business circumstances indicate
that the carrying amount of assets may not be fully recoverable. Such circumstances include, though are not limited to, significant or
sustained declines in revenues or earnings, future anticipated cash flows, business plans, and material adverse changes in the economic
climate, such as changes in the operating environment, competitive information, and the impact of changes in government policies. For
assets that the Company intends to hold for use, if the total of the expected future undiscounted cash flows produced by the assets or
subsidiary company is less than the carrying amount of the assets, a loss is recognized for the difference between the fair value and
carrying value of the assets. For assets, the Company intends to dispose of by sale, a loss is recognized for the amount by which the
estimated fair value less cost to sell is less than the carrying value of the assets. Fair value is determined based on quoted market
prices, if available, or other valuation techniques, including discounted future net cash flows. Unlike goodwill, long-lived assets are
assessed for impairment only where there are any specific indicators for impairment.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c0" id="ixv-8805">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;q)
Intangible assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s intangible assets are accounted for in accordance with ASC Topic 350, &lt;i&gt;Intangibles &lt;/i&gt;&#x2013; &lt;i&gt;Goodwill and Other.
&lt;/i&gt;Intangible assets having indefinite lives are not amortized, but instead are reviewed annually or more frequently if events or changes
in circumstances indicate that the assets might be impaired, to assess whether their fair value exceeds their carrying value. We perform
an impairment analysis on March 1 annually on the indefinite-lived intangible assets following the steps laid out in ASC 350-30-35-18.
Our annual impairment analysis includes a qualitative assessment to determine if it is necessary to perform the quantitative impairment
test. In performing a qualitative assessment, we review events and circumstances that could affect the significant inputs used to determine
if the fair value is less than the carrying value of the intangible assets. If quantitative analysis is necessary, we would analyze various
aspects including revenues from the business, associated with the intangible assets. In addition, intangible assets will be tested on
an interim basis if an event or circumstance indicates that it is more likely than not that an impairment loss has been incurred. The
Company has analyzed a variety of factors on its business to determine if a circumstance could trigger an impairment loss, and, at this
time and based on the information presently known, does not believe it is more likely than not that an impairment loss has been incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets with finite useful lives are amortized using the straight-line method over their estimated period of benefit. In accordance with
ASC 360-10-35-21, definite lived intangibles are reviewed annually or more frequently if events or changes in circumstances indicate
that the assets might be impaired, to assess whether their fair value exceeds their carrying value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company intends to capitalize trademarks and related expenses exceeding $2,500 per trademark. Management may also capitalize trademarks
and related expenses up to $2,500 per trademark based on its potential and benefit in coming years.&lt;/span&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock contextRef="c0" id="ixv-8845">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;r)
Software Development Costs&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is developing two proprietary software platforms intended to be commercialized:-&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.
A &lt;b&gt;clinical data management platform&lt;/b&gt; designed for the collection, analysis, and real-time monitoring of clinical trial data; and&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.
An &lt;b&gt;MINT- AD - AI-driven diagnostic and treatment personalization platform&lt;/b&gt; aimed at assisting in the early detection of Alzheimer&#x2019;s
disease and providing data-informed therapeutic suggestions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with &lt;b&gt;ASC 985-20&lt;/b&gt;, &lt;i&gt;Software to Be Sold, Leased, or Marketed&lt;/i&gt;, the Company capitalizes development costs incurred
after technological feasibility has been established and before the software is available for general release. Costs incurred during
the research, planning, or preliminary design phase are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Capitalized
costs include direct labor, third-party development services, cloud computing infrastructure directly related to model development and
deployment, and associated overhead. These costs are amortized on a straight-line basis over their estimated useful lives, typically
&lt;b&gt;five to ten years&lt;/b&gt;, beginning when the software is ready for its intended commercial use.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
Fiscal 2024, the Company began working on overlaying machine learning technologies and AI into the internal clinical trial software framework
for trial management with the expectation that this can lead to improved decision-making, contextual data entry, computational models,
trial design (Phase 3), and data analysis, the company believes it is probable that the project will be completed and the software will
be used to perform the function intended. As of Fiscal 2025, the Company capitalized approximately $863 thousand in software development
costs. For more information, please refer to Note 5, &#x201c;Intangible Assets&#x201d;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c32" id="ixv-15008">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c33" id="ixv-15009">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:CapitalizedComputerSoftwareGross contextRef="c3" decimals="-3" id="ixv-15011" unitRef="usd">863000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0" id="ixv-8884">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;s)
Inventory&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
is valued at the lower of cost or net realizable value, which is defined as estimated selling prices in the ordinary course of business,
less reasonably predictable costs of completion, disposal, and transportation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
consists of finished goods related to wellness products, hand sanitizers, finished hemp-based products, beverages. Work-and in-progress
consist of products in the manufacturing process as on reporting date, including but not limited to primary cost. Inventory is primarily
accounted for using the weighted average cost method. Primary costs include raw materials, packaging, direct labor, overhead, shipping,
and the depreciation of manufacturing equipment. Manufacturing overhead and related expenses include salaries, wages, employee benefits,
utilities, maintenance, and property taxes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
capitalize inventory costs related to our investigational drug, provided that management determines there is a potential alternative
use for the inventory in future research and development projects or other purposes. As of March 31, 2025, and 2024, our consolidated
balance sheet reported approximately $392 thousand of clinical trial-related inventory, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Abnormal
amounts of idle facility expense, freight, handling costs, scrap, discontinued products, and wasted material (spoilage) are expensed
in the period they are incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Please
refer to Note 3, &#x201c;Inventory,&#x201d; for further information.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryNet contextRef="c34" decimals="-3" id="ixv-15012" unitRef="usd">392000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c35" decimals="-3" id="ixv-15013" unitRef="usd">392000</us-gaap:InventoryNet>
    <igc:CybersecurityPolicyPolicyTextBlock contextRef="c0" id="ixv-8932">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;t)
Cybersecurity Costs&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains information technology systems and security protocols designed to protect sensitive clinical, corporate, and financial
data. Costs incurred in connection with the ongoing maintenance, enhancement, and monitoring of cybersecurity infrastructure are expensed
as incurred and classified within general and administrative expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews cybersecurity risks on an ongoing basis and implements technical and administrative controls in line with applicable
data protection standards. As of March 31, 2025, the Company had not capitalized any cybersecurity-related development costs, and no
material cybersecurity incidents have been identified.&lt;/span&gt;&lt;/p&gt;</igc:CybersecurityPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0" id="ixv-8948">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;u)
Research and Development Expenses&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development (R&amp;amp;D) expenses include costs incurred to develop the Company&#x2019;s clinical-stage drug candidates, including IGC-AD1
and other investigational therapies. These costs consist primarily of:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Clinical
                                            trial site payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Contract
                                            research organization (CRO) fees&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employee
                                            compensation for R&amp;amp;D personnel&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regulatory
                                            and medical affairs consulting&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Laboratory
                                            supplies and materials&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Preclinical
                                            studies and formulation development&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;R&amp;amp;D
expenses are expensed as incurred in accordance with ASC 730. Non-refundable advance payments for goods or services that will be used
in future R&amp;amp;D activities are deferred and recognized as the related goods or services are received. During Fiscal 2025 and 2024,
the Company recorded research and development expenses of approximately $3.7 million and $3.8 million, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-5" id="ixv-15014" unitRef="usd">3700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="-5" id="ixv-15015" unitRef="usd">3800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-9020">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;v)
Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Lessor
Accounting&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the current ASU guidance, contract consideration will be allocated to its lease components and non-lease components (such as maintenance).
For the Company as a lessor, any non-lease components will be accounted for under ASC Topic 606, &#x201c;&lt;i&gt;Revenue from Contracts with
Customers,&lt;/i&gt;&#x201d; unless the Company elects a lessor practical expedient to not separate the non-lease components from the associated
lease component. The amendments in ASU 2018-11 also provide lessors with a practical expedient, by class of underlying asset, to not
separate non-lease components from the associated lease component and, instead, to account for those components as a single component
if the non-lease components otherwise would be accounted for under the new revenue guidance (Topic 606). To elect the practical expedient,
the timing and pattern of transfer of the lease and non-lease components must be the same and the lease component must meet the criteria
to be classified as an operating lease if accounted for separately. If these criteria are met, the single component will be accounted
for under either Topic 842 or Topic 606 depending on which component(s) are predominant. The lessor practical expedient to not separate
non-lease components from the associated component must be elected for all existing and new leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a lessor, the Company expects that post-adoption substantially all existing leases will have no change in the timing of revenue recognition
until their expiration or termination. The Company expects to elect the lessor practical expedient to not separate non-lease components
such as maintenance from the associated lease for all existing and new leases and to account for the combined component as a single lease
component. The timing of revenue recognition is expected to be the same for the majority of the Company&#x2019;s new leases as compared
to similar existing leases; however, certain categories of new leases could have different revenue recognition patterns as compared to
similar existing leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
leases that are accounted for as operating leases, income is recognized on a straight-line basis over the term of the lease contract.
Generally, when a lease is more than 180 days delinquent (where more than three monthly payments are owed), the lease is classified as
being nonaccrual and the Company stops recognizing leasing income on that date. Payments received on leases in nonaccrual status generally
reduce the lease receivable. Leases on nonaccrual status remain classified as such until there is sustained payment performance that,
in the Company&#x2019;s judgment, would indicate that all contractual amounts will be collected in full.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Lessee
Accounting&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted ASU 2016-02 effective April 1, 2019, using the modified retrospective approach. The standard establishes a right-of-use
model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer
than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense
recognition in the income statement. In connection with the adoption, the Company will elect to utilize the modified retrospective presentation
whereby the Company will continue to present prior period financial statements and disclosures under ASC Topic 840. In addition, the
Company will elect the transition package of three practical expedients permitted within the standard, which eliminates the requirements
to reassess prior conclusions about lease identification, lease classification and initial direct costs. Further, the Company will adopt
a short-term lease exception policy, permitting us to not apply the recognition requirements of this standard to short-term leases (i.e.,
leases with terms of 12 months or less), and an accounting policy to account for lease and non-lease components as a single component
for certain classes of assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
ASU 2016-02 (Topic 842), lessees are required to recognize the following for all leases (with the exception of short-term leases) on
the commencement date: (i) lease liability, which is a lessee&#x2019;s obligation to make lease payments arising from a lease, measured
on a discounted basis; and (ii) right-of-use asset, which is an asset that represents the lessee&#x2019;s right to use, or control the
use of, a specified asset for the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the commencement date, the Company recognizes the lease liability at the present value of the lease payments not yet paid, discounted
using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company&#x2019;s incremental borrowing
rate for the same term as the underlying lease. The right-of-use asset is recognized initially at cost, which primarily comprises the
initial amount of the lease liability, plus any initial direct costs incurred, consisting mainly of brokerage commissions, less any lease
incentives received. All right-of-use assets are reviewed for impairment. There was no impairment for right-of-use lease assets as of
March 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company categorizes leases at their inception as either operating or finance leases. On certain lease agreements, the Company may receive
rent holidays and other incentives. The Company recognizes lease costs on a straight-line basis without regard to deferred payment terms,
such as rent holidays, that defer the commencement date of required payments. Please refer to Note 9, &#x201c;Leases,&#x201d; for further
information.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-9091">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;w)
Recently issued and adopted accounting pronouncements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Changes
to U.S. GAAP are established by the Financial Accounting Standards Board (FASB) in the form of accounting standards updates (ASUs) to
the FASB&#x2019;s Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. Newly issued ASUs
not listed are expected to have no impact on the Company&#x2019;s consolidated financial position and results of operations because either
the ASU is not applicable or the impact is expected to be immaterial. Recent accounting pronouncements which may be applicable to us
are described in Note 2, &#x201c;Significant Accounting Policies&#x201d; in our Consolidated Financial Statements contained herein in Part
II, Item 8.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c0" id="ixv-9104">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 &lt;/b&gt;&#x2013; &lt;b&gt;INVENTORY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; font-style: italic; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of &lt;br/&gt; March 31, &lt;br/&gt; 2025&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of &lt;br/&gt; March 31,&lt;br/&gt; 2024&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.25pt"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,104&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,099&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;256&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;441&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,360&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,540&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
Fiscal 2025, and Fiscal 2024, the Company wrote off approximately $217 thousand and $1 million of inventory due to abnormal loss, NRV
adjustment, product expiration, idle facility expense, freight, handling costs, scrap, and wasted material (spoilage). This charge was
recorded in Selling, General, and Administrative Expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
capitalize inventory costs related to our investigational drug, provided that management determines there is a potential alternative
use for the inventory in future research and development projects or other purposes. As of March 31, 2025, and March 31, 2024, our consolidated
balance sheet reported approximately $392 thousand of clinical trial-related inventory, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c0" id="ixv-9111">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; font-style: italic; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of &lt;br/&gt; March 31, &lt;br/&gt; 2025&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of &lt;br/&gt; March 31,&lt;br/&gt; 2024&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.25pt"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,104&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,099&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;256&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;441&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,360&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,540&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c3" decimals="-3" id="ixv-15016" unitRef="usd">1104000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c4" decimals="-3" id="ixv-15017" unitRef="usd">1099000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryFinishedGoods contextRef="c3" decimals="-3" id="ixv-15018" unitRef="usd">256000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c4" decimals="-3" id="ixv-15019" unitRef="usd">441000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet contextRef="c3" decimals="-3" id="ixv-15020" unitRef="usd">1360000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c4" decimals="-3" id="ixv-15021" unitRef="usd">1540000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown contextRef="c0" decimals="-3" id="ixv-15022" unitRef="usd">217000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c5" decimals="-6" id="ixv-15023" unitRef="usd">1000000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryNet contextRef="c34" decimals="-3" id="ixv-15024" unitRef="usd">392000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c35" decimals="-3" id="ixv-15025" unitRef="usd">392000</us-gaap:InventoryNet>
    <igc:DepositsAndAdvancesTextBlock contextRef="c0" id="ixv-9191">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 &lt;/b&gt;&#x2013; &lt;b&gt;DEPOSITS AND ADVANCES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; font-style: italic; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;As
of &lt;br/&gt;
March 31,&lt;br/&gt;
2025&lt;br/&gt;
($)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;As
of &lt;br/&gt;
March 31,&lt;br/&gt;
2024&lt;br/&gt;
($)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.25pt"&gt;Advances to suppliers and consultants&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;41&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Other receivables and deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Prepaid expense and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;342&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;115&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;395&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;208&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Advances to suppliers and consultants primarily relate to advances to vendors. Prepaid expense and other current assets include approximately
$49 thousand and approximately $39 thousand in statutory advances for Fiscal 2025 and Fiscal 2024, respectively.&lt;/span&gt;&lt;/p&gt;</igc:DepositsAndAdvancesTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c0" id="ixv-9198">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; font-style: italic; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;As
of &lt;br/&gt;
March 31,&lt;br/&gt;
2025&lt;br/&gt;
($)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;As
of &lt;br/&gt;
March 31,&lt;br/&gt;
2024&lt;br/&gt;
($)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.25pt"&gt;Advances to suppliers and consultants&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;41&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Other receivables and deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Prepaid expense and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;342&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;115&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;395&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;208&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c3" decimals="-3" id="ixv-15026" unitRef="usd">10000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c4" decimals="-3" id="ixv-15027" unitRef="usd">41000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherInventoryNetOfReserves contextRef="c3" decimals="-3" id="ixv-15028" unitRef="usd">43000</us-gaap:OtherInventoryNetOfReserves>
    <us-gaap:OtherInventoryNetOfReserves contextRef="c4" decimals="-3" id="ixv-15029" unitRef="usd">52000</us-gaap:OtherInventoryNetOfReserves>
    <us-gaap:OtherAssetsCurrent contextRef="c3" decimals="-3" id="ixv-15030" unitRef="usd">342000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c4" decimals="-3" id="ixv-15031" unitRef="usd">115000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" id="ixv-15032" unitRef="usd">395000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="-3" id="ixv-15033" unitRef="usd">208000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <igc:StatutoryAdvances contextRef="c3" decimals="-3" id="ixv-15034" unitRef="usd">49000</igc:StatutoryAdvances>
    <igc:StatutoryAdvances contextRef="c4" decimals="-3" id="ixv-15035" unitRef="usd">39000</igc:StatutoryAdvances>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c0" id="ixv-9273">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5 &lt;/b&gt;&#x2013; &lt;b&gt;INTANGIBLE ASSETS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; font-style: italic"&gt;Amortized intangible assets&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; font-style: italic; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of &lt;br/&gt; March 31, &lt;br/&gt; 2025&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of &lt;br/&gt; March 31,&lt;br/&gt; 2024&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; padding-left: 0.25pt"&gt;Patents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;530&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;836&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Other intangibles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(205&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(181&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Total amortized intangible assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;359&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;689&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-align: left; padding-left: 0.25pt"&gt;Unamortized intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Patents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;630&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;521&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Software development cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;863&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;406&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Total unamortized intangible assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;1,493&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;927&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;Total intangible assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,852&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,616&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
value of intangible assets includes the cost of acquiring patent rights, supporting data, and the expense associated with filing various
patent applications in different countries along with granted patents. It also includes acquisition costs related to domains and licenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
amortization of patent and patent rights with finite life is up to 20 years, commencing from the date of grant or acquisition. The note
reflects the abandonment and expiration of certain non-core patent applications that management determined no longer aligned with the
Company&#x2019;s strategic focus or had limited commercial potential. The related assets were fully impaired and removed from the balance
sheet. The expense was recognized in the consolidated statements of operations as part of general and administrative expenses. The Company
continues to evaluate its intellectual property portfolio to ensure alignment with its long-term development and commercialization strategy.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Estimated amortization expense&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;b&gt;(in thousands)&lt;br/&gt;
 ($)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-left: 0.25pt"&gt;For the year ended 2026&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;55&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;For the year ended 2027&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;60&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;For the year ended 2028&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;66&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;For the year ended 2029&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;73&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;For the year ended 2030&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;80&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="c0" id="ixv-9280">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; font-style: italic"&gt;Amortized intangible assets&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; font-style: italic; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of &lt;br/&gt; March 31, &lt;br/&gt; 2025&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of &lt;br/&gt; March 31,&lt;br/&gt; 2024&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; padding-left: 0.25pt"&gt;Patents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;530&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;836&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Other intangibles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(205&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(181&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Total amortized intangible assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;359&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;689&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-align: left; padding-left: 0.25pt"&gt;Unamortized intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Patents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;630&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;521&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Software development cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;863&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;406&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Total unamortized intangible assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;1,493&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;927&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;Total intangible assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,852&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,616&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c36" decimals="-3" id="ixv-15036" unitRef="usd">530000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c37" decimals="-3" id="ixv-15037" unitRef="usd">836000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c38" decimals="-3" id="ixv-15038" unitRef="usd">34000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c39" decimals="-3" id="ixv-15039" unitRef="usd">34000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c3" decimals="-3" id="ixv-15040" unitRef="usd">205000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c4" decimals="-3" id="ixv-15041" unitRef="usd">181000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c3" decimals="-3" id="ixv-15042" unitRef="usd">359000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c4" decimals="-3" id="ixv-15043" unitRef="usd">689000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c40" decimals="-3" id="ixv-15044" unitRef="usd">630000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c41" decimals="-3" id="ixv-15045" unitRef="usd">521000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c42" decimals="-3" id="ixv-15046" unitRef="usd">863000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c43" decimals="-3" id="ixv-15047" unitRef="usd">406000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c3" decimals="-3" id="ixv-15048" unitRef="usd">1493000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c4" decimals="-3" id="ixv-15049" unitRef="usd">927000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c3" decimals="-3" id="ixv-15050" unitRef="usd">1852000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c4" decimals="-3" id="ixv-15051" unitRef="usd">1616000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c36" id="ixv-15052">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c0" id="ixv-9411">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Estimated amortization expense&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;b&gt;(in thousands)&lt;br/&gt;
 ($)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-left: 0.25pt"&gt;For the year ended 2026&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;55&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;For the year ended 2027&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;60&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;For the year ended 2028&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;66&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;For the year ended 2029&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;73&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;For the year ended 2030&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;80&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c3" decimals="-3" id="ixv-15053" unitRef="usd">55000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c3" decimals="-3" id="ixv-15054" unitRef="usd">60000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c3" decimals="-3" id="ixv-15055" unitRef="usd">66000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c3" decimals="-3" id="ixv-15056" unitRef="usd">73000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c3" decimals="-3" id="ixv-15057" unitRef="usd">80000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-9470">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6 &lt;/b&gt;&#x2013; &lt;b&gt;PROPERTY, PLANT, AND EQUIPMENT&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; font-style: italic; text-align: center"&gt;(in thousands, except useful life)&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Useful Life&lt;br/&gt; (years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of &lt;br/&gt; March 31,&lt;br/&gt; 2025&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of &lt;br/&gt; March 31,&lt;br/&gt; 2024&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 0.25pt"&gt;Buildings and facilities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;25&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,341&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,303&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Plant and machinery&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5-20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,087&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Computer equipment&#x2019;s&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;187&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;166&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Office equipment&#x2019;s&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3-5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Vehicles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Total gross value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;5,913&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;6,137&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,693&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,442&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;Total property, plant, and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;3,220&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;3,695&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
depreciation expense in Fiscal 2025 and 2024 amounted to approximately $567 thousand and $563 thousand, respectively. During Fiscal 2025,
the Company focused on liquidating all non-operating assets to reduce costs and generate cash. For more information, please refer to
Note 18, &#x201c;Segment Information,&#x201d; for the non-current assets other than financial instruments held in the country of domicile
and foreign countries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Asset
Held For Sale&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
Fiscal 2024, the Company focused on liquidating all non-operating assets to reduce costs and generate cash. As a result, the Company
impaired the land situated in Nagpur, India, by approximately $3.3&#160;million to $720&#160;thousand from $4.1&#160;million to bring
it closer to the fair market value. The Company believes it can sell the above-said non-operating land as it is without any improvement.
Selling this land will give immediate cash, which the Company can use in its operating segments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
Fiscal 2025, the Company entered into an agreement with the buyer to sell the said land for a net realizable value of approximately $702&#160;thousand.
The agreement is subject to the final registration and execution. The Company received a net of approximately $580&#160;thousand as a
deposit. The Company holds the ownership and possession of the said land. For further information, please refer to Note 19- &#x201c;Subsequent
Events&#x201d;.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c45" id="ixv-9477">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; font-style: italic; text-align: center"&gt;(in thousands, except useful life)&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Useful Life&lt;br/&gt; (years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of &lt;br/&gt; March 31,&lt;br/&gt; 2025&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of &lt;br/&gt; March 31,&lt;br/&gt; 2024&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 0.25pt"&gt;Buildings and facilities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;25&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,341&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,303&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Plant and machinery&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5-20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,087&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Computer equipment&#x2019;s&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;187&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;166&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Office equipment&#x2019;s&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3-5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Vehicles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Total gross value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;5,913&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;6,137&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,693&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,442&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;Total property, plant, and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;3,220&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;3,695&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c46" id="ixv-15058">P25Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c46" decimals="-3" id="ixv-15059" unitRef="usd">2341000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c47" decimals="-3" id="ixv-15060" unitRef="usd">2303000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c48" id="ixv-15061">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c49" id="ixv-15062">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c50" decimals="-3" id="ixv-15063" unitRef="usd">3087000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c51" decimals="-3" id="ixv-15064" unitRef="usd">3334000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c52" id="ixv-15065">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c52" decimals="-3" id="ixv-15066" unitRef="usd">187000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c53" decimals="-3" id="ixv-15067" unitRef="usd">166000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c54" id="ixv-15068">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c55" id="ixv-15069">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c56" decimals="-3" id="ixv-15070" unitRef="usd">144000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c57" decimals="-3" id="ixv-15071" unitRef="usd">140000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c58" id="ixv-15072">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c58" decimals="-3" id="ixv-15073" unitRef="usd">96000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c59" decimals="-3" id="ixv-15074" unitRef="usd">93000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c60" id="ixv-15075">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c60" decimals="-3" id="ixv-15076" unitRef="usd">58000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c61" decimals="-3" id="ixv-15077" unitRef="usd">101000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="-3" id="ixv-15078" unitRef="usd">5913000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c4" decimals="-3" id="ixv-15079" unitRef="usd">6137000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="-3" id="ixv-15080" unitRef="usd">2693000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c4" decimals="-3" id="ixv-15081" unitRef="usd">2442000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" id="ixv-15082" unitRef="usd">3220000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" id="ixv-15083" unitRef="usd">3695000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c0" decimals="-3" id="ixv-15084" unitRef="usd">567000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c5" decimals="-3" id="ixv-15085" unitRef="usd">563000</us-gaap:Depreciation>
    <us-gaap:AssetImpairmentCharges contextRef="c44" decimals="-5" id="ixv-15086" unitRef="usd">3300000</us-gaap:AssetImpairmentCharges>
    <us-gaap:LandAvailableForSale contextRef="c4" decimals="-3" id="ixv-15087" unitRef="usd">720000</us-gaap:LandAvailableForSale>
    <us-gaap:Land contextRef="c4" decimals="-5" id="ixv-15088" unitRef="usd">4100000</us-gaap:Land>
    <us-gaap:LandAvailableForSale contextRef="c3" decimals="-3" id="ixv-15089" unitRef="usd">702000</us-gaap:LandAvailableForSale>
    <us-gaap:ProceedsFromDepositsOnRealEstateSales contextRef="c0" decimals="-3" id="ixv-15090" unitRef="usd">580000</us-gaap:ProceedsFromDepositsOnRealEstateSales>
    <us-gaap:OtherAssetsDisclosureTextBlock contextRef="c0" id="ixv-9660">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8 &lt;/b&gt;&#x2013; &lt;b&gt;CLAIMS AND ADVANCES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of &lt;br/&gt; March 31,&lt;br/&gt; 2025&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of &lt;br/&gt; March 31,&lt;br/&gt; 2024&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.25pt"&gt;Claims receivable (1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;680&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;686&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Non-current deposits&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;681&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;688&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
claims receivable is due from different vendors. While the Company has initiated collection proceedings internally or with the appropriate
authorities, it believes receiving the amount in the next 12 months will be challenging because of the time required for collection proceedings.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock contextRef="c0" id="ixv-9667">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of &lt;br/&gt; March 31,&lt;br/&gt; 2025&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of &lt;br/&gt; March 31,&lt;br/&gt; 2024&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.25pt"&gt;Claims receivable (1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;680&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;686&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Non-current deposits&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;681&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;688&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
claims receivable is due from different vendors. While the Company has initiated collection proceedings internally or with the appropriate
authorities, it believes receiving the amount in the next 12 months will be challenging because of the time required for collection proceedings.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <us-gaap:OtherReceivables contextRef="c3" decimals="-3" id="ix_0_fact" unitRef="usd">680000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables contextRef="c4" decimals="-3" id="ix_1_fact" unitRef="usd">686000</us-gaap:OtherReceivables>
    <igc:OtherAdvances contextRef="c3" decimals="-3" id="ixv-15093" unitRef="usd">1000</igc:OtherAdvances>
    <igc:OtherAdvances contextRef="c4" decimals="-3" id="ixv-15094" unitRef="usd">2000</igc:OtherAdvances>
    <us-gaap:OtherAssetsNoncurrent contextRef="c3" decimals="-3" id="ixv-15095" unitRef="usd">681000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c4" decimals="-3" id="ixv-15096" unitRef="usd">688000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0" id="ixv-9755">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9 &lt;/b&gt;&#x2013; &lt;b&gt;LEASES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has short-term leases primarily consisting of space with the remaining lease term being less than or equal to 12 months. The
Company has one short-term lease as of March 31, 2025. The total short-term lease expense and cash paid for Fiscal 2025 and 2024 are
approximately $39 thousand and $100 thousand, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has operating leases primarily consisting of spaces with the lease term being more than or equal to 12 months. The Company has
two operating leases as of March 31, 2025. The total operating leases expense and cash paid for Fiscal 2025 and 2024 are approximately
$135 thousand and $141 thousand, respectively.&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid"&gt;(in thousands) &lt;br/&gt; Year Ended &lt;br/&gt; March 31, &lt;br/&gt; 2025&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid"&gt;(in thousands) &lt;br/&gt; Year Ended &lt;br/&gt; March 31,&lt;br/&gt; 2024&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.25pt"&gt;Operating lease costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;135&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Short term lease costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;39&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;Total lease costs&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;174&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;241&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Right
of use assets and lease liabilities for our operating leases were recorded in the consolidated balance sheet as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year Ended&lt;br/&gt; March 31, &lt;br/&gt; 2025&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year Ended &lt;br/&gt; March 31,&lt;br/&gt; 2024&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Operating lease asset&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;98&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;198&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;&lt;b&gt;Total lease assets&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;98&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;198&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25pt"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Current liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Accrued liabilities and others (current portion &#x2013; operating lease liability)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-0"&gt;93&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-1"&gt;124&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Noncurrent liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Operating lease liability (non-current portion &#x2013; operating lease liability)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;84&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;&lt;b&gt;Total lease liability&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;103&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;208&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Supplemental cash flow and non-cash information related to leases is as follows:&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid"&gt;(in thousands) &lt;br/&gt; Year Ended &lt;br/&gt; March 31, &lt;br/&gt; 2025&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid"&gt;(in thousands) &lt;br/&gt; Year Ended&lt;br/&gt; March 31,&lt;br/&gt; 2024&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.25pt"&gt;&#x2013;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;129&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;140&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Right-of-use assets obtained in exchange for operating lease obligations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="5"&gt;As of March 31, 2025, the following table summarizes the maturity of our lease liabilities:&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; padding-left: 0.25pt"&gt;Mar-26&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Mar-27&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Mar-28&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Mar-29&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Less: Present value discount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Total Lease liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;103&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:ShortTermLeaseCost contextRef="c0" decimals="-3" id="ixv-15097" unitRef="usd">39000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c5" decimals="-3" id="ixv-15098" unitRef="usd">100000</us-gaap:ShortTermLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c0" decimals="-3" id="ixv-15099" unitRef="usd">135000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c5" decimals="-3" id="ixv-15100" unitRef="usd">141000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0" id="ixv-9769">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid"&gt;(in thousands) &lt;br/&gt; Year Ended &lt;br/&gt; March 31, &lt;br/&gt; 2025&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid"&gt;(in thousands) &lt;br/&gt; Year Ended &lt;br/&gt; March 31,&lt;br/&gt; 2024&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.25pt"&gt;Operating lease costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;135&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;141&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Short term lease costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;39&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;Total lease costs&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;174&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;241&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year Ended&lt;br/&gt; March 31, &lt;br/&gt; 2025&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year Ended &lt;br/&gt; March 31,&lt;br/&gt; 2024&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Operating lease asset&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;98&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;198&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;&lt;b&gt;Total lease assets&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;98&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;198&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25pt"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Current liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Accrued liabilities and others (current portion &#x2013; operating lease liability)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-0"&gt;93&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-1"&gt;124&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Noncurrent liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Operating lease liability (non-current portion &#x2013; operating lease liability)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;84&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;&lt;b&gt;Total lease liability&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;103&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;208&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Supplemental cash flow and non-cash information related to leases is as follows:&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid"&gt;(in thousands) &lt;br/&gt; Year Ended &lt;br/&gt; March 31, &lt;br/&gt; 2025&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid"&gt;(in thousands) &lt;br/&gt; Year Ended&lt;br/&gt; March 31,&lt;br/&gt; 2024&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.25pt"&gt;&#x2013;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;129&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;140&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Right-of-use assets obtained in exchange for operating lease obligations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c0" decimals="-3" id="ixv-15101" unitRef="usd">135000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c5" decimals="-3" id="ixv-15102" unitRef="usd">141000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c0" decimals="-3" id="ixv-15103" unitRef="usd">39000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c5" decimals="-3" id="ixv-15104" unitRef="usd">100000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost contextRef="c0" decimals="-3" id="ixv-15105" unitRef="usd">174000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c5" decimals="-3" id="ixv-15106" unitRef="usd">241000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" id="ixv-15107" unitRef="usd">98000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="-3" id="ixv-15108" unitRef="usd">198000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" id="ixv-15109" unitRef="usd">98000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="-3" id="ixv-15110" unitRef="usd">198000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-15111" unitRef="usd">10000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c4" decimals="-3" id="ixv-15112" unitRef="usd">84000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="-3" id="ixv-15113" unitRef="usd">103000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c4" decimals="-3" id="ixv-15114" unitRef="usd">208000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="-3" id="ixv-15115" unitRef="usd">129000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c5" decimals="-3" id="ixv-15116" unitRef="usd">140000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-15117" unitRef="usd">98000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c5" decimals="-3" id="ixv-15118" unitRef="usd">198000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-10023">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="5"&gt;As of March 31, 2025, the following table summarizes the maturity of our lease liabilities:&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; padding-left: 0.25pt"&gt;Mar-26&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Mar-27&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Mar-28&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Mar-29&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Less: Present value discount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Total Lease liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;103&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c3" decimals="-3" id="ixv-15119" unitRef="usd">96000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c3" decimals="-3" id="ixv-15120" unitRef="usd">10000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c3" decimals="-3" id="ixv-15121" unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c3" decimals="-3" id="ixv-15122" unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c3" decimals="-3" id="ixv-15123" unitRef="usd">3000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="-3" id="ixv-15124" unitRef="usd">103000</us-gaap:OperatingLeaseLiability>
    <igc:AccruedLiabilitiesDisclosureTextBlock contextRef="c0" id="ixv-10086">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10 &lt;/b&gt;&#x2013; &lt;b&gt;ACCRUED LIABILITIES AND OTHERS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of &lt;br/&gt; March 31, &lt;br/&gt; 2025 &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of &lt;br/&gt; March 31,&lt;br/&gt; 2024&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.25pt"&gt;Compensation and other contributions&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;160&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;816&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Provision for expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Short-term lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;124&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Other current liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,003&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;419&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;1,374&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;1,567&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compensation
and other contribution-related liabilities consist of accrued salaries to employees. In addition, provision for expenses includes provision
for legal, professional, and marketing expenses. Other current liability also includes statutory payables of approximately $19 thousand
and $25 thousand as of March 31, 2025, and March 31, 2024, respectively, and approximately $3 thousand of short-term loans as of March
31, 2025, and March 31, 2024, respectively. &#160;In addition, Other current liabilities for Fiscal 2025 consist of approximately $580&#160;thousand
and $46 thousand related to asset held for sale and provision for a statutory liability, respectively. Please refer to Note 6 &#x2013;
&#x201c;Property, plant and, equipment&#x201d;, for more information.&lt;/span&gt;&lt;/p&gt;</igc:AccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c0" id="ixv-10093">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of &lt;br/&gt; March 31, &lt;br/&gt; 2025 &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of &lt;br/&gt; March 31,&lt;br/&gt; 2024&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.25pt"&gt;Compensation and other contributions&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;160&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;816&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Provision for expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Short-term lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;124&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Other current liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,003&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;419&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;1,374&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;1,567&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-15125" unitRef="usd">160000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-15126" unitRef="usd">816000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-15127" unitRef="usd">117000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-15128" unitRef="usd">208000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" id="ixv-15129" unitRef="usd">94000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="-3" id="ixv-15130" unitRef="usd">124000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-15131" unitRef="usd">1003000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-15132" unitRef="usd">419000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-15133" unitRef="usd">1374000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-15134" unitRef="usd">1567000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c3" decimals="-3" id="ixv-15135" unitRef="usd">19000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c4" decimals="-3" id="ixv-15136" unitRef="usd">25000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:ShortTermBorrowings contextRef="c3" decimals="-3" id="ixv-15137" unitRef="usd">3000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c4" decimals="-3" id="ixv-15138" unitRef="usd">3000</us-gaap:ShortTermBorrowings>
    <us-gaap:ProceedsFromDepositsOnRealEstateSales contextRef="c62" decimals="-3" id="ixv-15139" unitRef="usd">580000</us-gaap:ProceedsFromDepositsOnRealEstateSales>
    <us-gaap:ProceedsFromDepositsOnRealEstateSales contextRef="c44" decimals="-3" id="ixv-15140" unitRef="usd">46000</us-gaap:ProceedsFromDepositsOnRealEstateSales>
    <igc:LoansAndOtherLiabilitiesTextBlock contextRef="c0" id="ixv-10181">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
11 &lt;/b&gt;&#x2013; &lt;b&gt;LOANS AND OTHER LIABILITIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Loan
as of March 31, 2025:&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 11, 2020, the Company received an Economic Injury Disaster Loan (EIDL) for approximately $150 thousand at an annual interest rate
of 3.75%. The Company must pay principal and interest payments of $731 every month beginning June 5, 2021. The SBA will apply each installment
payment first to pay interest accrued to the day SBA receives the payment and will then apply any remaining balance to reduce the principal.
All remaining principal and accrued interest are due and payable 30 years from the date of the loan. For Fiscal 2025, the interest expense
and principal payment for the EIDL were approximately $5 thousand and $3 thousand, respectively. As of March 31, 2025, approximately
$134 thousand of the loan is classified as Long-term loans and approximately $3 thousand as Short-term loans.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Other
Liability:&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; font-style: italic; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2025&lt;br/&gt;
($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2024&lt;br/&gt;
($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Statutory reserve&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;16&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;20&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
statutory reserve is a gratuity reserve for employees in our subsidiaries in India.&lt;/span&gt;&lt;/p&gt;</igc:LoansAndOtherLiabilitiesTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c63" decimals="-3" id="ixv-15141" unitRef="usd">150000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c63" decimals="4" id="ixv-15142" unitRef="pure">0.0375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPayment contextRef="c64" decimals="-3" id="ixv-15143" unitRef="usd">731000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentTerm contextRef="c64" id="ixv-15144">P30Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:InterestExpenseDebt contextRef="c0" decimals="-3" id="ixv-15145" unitRef="usd">5000</us-gaap:InterestExpenseDebt>
    <us-gaap:RepaymentsOfDebt contextRef="c0" decimals="-3" id="ixv-15146" unitRef="usd">3000</us-gaap:RepaymentsOfDebt>
    <us-gaap:LongTermLoansPayable contextRef="c3" decimals="-3" id="ixv-15147" unitRef="usd">134000</us-gaap:LongTermLoansPayable>
    <us-gaap:LoansPayableCurrent contextRef="c3" decimals="-3" id="ixv-15148" unitRef="usd">3000</us-gaap:LoansPayableCurrent>
    <us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock contextRef="c0" id="ixv-10197">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Other
Liability:&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; font-style: italic; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;As of March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2025&lt;br/&gt;
($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2024&lt;br/&gt;
($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Statutory reserve&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;16&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;20&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="c3" decimals="-3" id="ixv-15149" unitRef="usd">16000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="c4" decimals="-3" id="ixv-15150" unitRef="usd">20000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c3" decimals="-3" id="ixv-15151" unitRef="usd">16000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c4" decimals="-3" id="ixv-15152" unitRef="usd">20000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-10252">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
12 &lt;/b&gt;&#x2013; &lt;b&gt;COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may be involved in legal proceedings, claims, and assessments arising in the ordinary course of business. Such matters are subject
to many uncertainties, and outcomes are not predictable with assurance. There are no such matters that are deemed material to the consolidated
financial statements as of March 31, 2025, except as disclosed in Item 3 &#x2013; Legal Proceedings and Note 19 &#x2013; Subsequent Events.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the U.S., we provide health insurance, life insurance, and a 401(k) plan wherein the Company matches up to 6% of the employee&#x2019;s
pre-tax contribution up to a maximum annual amount determined by the IRS. In addition, under applicable Indian laws, the Company provides
for gratuity, a defined benefit retirement plan (Gratuity Plan) covering certain categories of employees. The Gratuity Plan provides
a lump sum payment to vested employees, at retirement or termination of employment, an amount based on the respective employee&#x2019;s
last drawn salary and the years of employment with the Company. In addition, employees receive benefits from a provident fund, a defined
contribution plan. The employee and employer each make monthly contributions to the plan as required by the law. The contribution is
made to the Foreign Government&#x2019;s funds.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch contextRef="c0" decimals="2" id="ixv-15153" unitRef="pure">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-10283">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
13 &lt;/b&gt;&#x2013; &lt;b&gt;SECURITIES &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2025, the Company was authorized to issue up to 150,000,000 shares of common stock, par value of $0.0001 per share, and
80,878,058 shares of common stock were issued and outstanding. The Company is also authorized to issue up to 1,000,000 shares of preferred
stock, par value of $0.0001 per share, and no preferred shares were issued and outstanding as of March 31, 2025. We have one security
listed on the NYSE American: common stock, $0.0001 par value (ticker symbol: IGC). This security also trades on the Frankfurt, Stuttgart,
and Berlin stock exchanges (ticker symbol: IGS1).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also has 91,472 units outstanding that can be separated into common stock. Ten units may be separated into one share of common
stock. The unit holders are requested to contact the Company or our transfer agent, Continental Stock Transfer &amp;amp; Trust, to separate
their units into common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 22, 2024, the Company entered into a Share Purchase Agreement (the March 2024 SPA) with Bradbury Strategic Investment Fund A, resulting
in approximately $3 million in gross proceeds. The completion of the private placement is subject to customary closing conditions, including
approval by the NYSE. Under the terms of the private placement, IGC will issue approximately 8.8 million shares of unregistered common
stock at a price of $0.34 per share. In addition, the Company issued 2 million shares of unregistered common stock for consulting services
related to raising capital, including the March 2024 capital raised. Shares are intended to be exempt from registration under the Securities
Act of 1933, as amended (the Securities Act), by virtue of the provisions of Section 4(a)(2) of the Securities Act and Regulation D and/or
Regulation S adopted thereunder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 25, 2024, the Company entered into the Share Purchase Agreement (the September 2024 SPA) with Moran Global Strategies, Inc.,
a Virginia corporation (MGS), which is owned by James Moran, a director of IGC, relating to the sale and issuance by our company to the
investors of an aggregate of 588,235 shares of our common stock, for a total purchase price of $200,000 or $0.34 per share, subject to
the terms and conditions set forth in the September 2024 SPA. The investment is subject to customary closing conditions, including NYSE
approval. As per the September 2024 SPA, the investor received piggyback registration rights subject to certain restrictions. During
the fiscal year ended March 31, 2025, the Company received the purchase price, and the issuance of common stock is in process.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 27, 2023, the Company entered into a Sales Agreement (the Sales Agreement) with A.G.P./Alliance Global Partners (the Agent) pursuant
to which the Company may offer and sell, from time to time, through the Agent, as sales agent and/or principal, shares of its common
stock, having an aggregate offering price of up to $60 million, subject to certain limitations on the amount of common stock that may
be offered and sold by the Company set forth in the Sales Agreement. During Fiscal 2025, the company raised approximately $1.8 million
against 5,363,334 shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the first quarter of Fiscal 2026, the Company entered into Share Purchase Agreements with multiple investors (the 2025 Share Purchase
Agreements), relating to the sale and issuance by our company to the investors of an aggregate of 2,803,333 shares of our common stock,
for a total purchase price of $841,000, or $0.30 per share, subject to the terms and conditions set forth in the 2025 Share Purchase
Agreements. The investment is subject to customary closing conditions, including NYSE approval. As per the 2025 Share Purchase Agreements,
the investor received piggyback registration rights subject to certain restrictions.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="0"
      id="ixv-15154"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="4"
      id="ixv-15155"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="0"
      id="ixv-15156"
      unitRef="shares">80878058</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="0"
      id="ixv-15157"
      unitRef="shares">80878058</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c3"
      decimals="0"
      id="ixv-15158"
      unitRef="shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="4"
      id="ixv-15159"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c3"
      decimals="0"
      id="ixv-15160"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c3"
      decimals="0"
      id="ixv-15161"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <igc:UnitsOutstanding
      contextRef="c0"
      decimals="0"
      id="ixv-15162"
      unitRef="shares">91472</igc:UnitsOutstanding>
    <igc:UnitDescription contextRef="c0" id="ixv-15163">Ten units may be separated into one share of common
stock.</igc:UnitDescription>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c65" decimals="-6" id="ixv-15164" unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c65"
      decimals="-5"
      id="ixv-15165"
      unitRef="shares">8800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="c66"
      decimals="2"
      id="ixv-15166"
      unitRef="usdPershares">0.34</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c65"
      decimals="-6"
      id="ixv-15167"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c67"
      decimals="0"
      id="ixv-15168"
      unitRef="shares">588235</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c67" decimals="0" id="ixv-15169" unitRef="usd">200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharePrice
      contextRef="c68"
      decimals="2"
      id="ixv-15170"
      unitRef="usdPershares">0.34</us-gaap:SharePrice>
    <igc:SalesAgreementMaximum contextRef="c69" decimals="-6" id="ixv-15171" unitRef="usd">60000000</igc:SalesAgreementMaximum>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c70" decimals="-5" id="ixv-15172" unitRef="usd">1800000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c70"
      decimals="0"
      id="ixv-15173"
      unitRef="shares">5363334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c71"
      decimals="0"
      id="ixv-15174"
      unitRef="shares">2803333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c71" decimals="0" id="ixv-15175" unitRef="usd">841000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharePrice
      contextRef="c72"
      decimals="2"
      id="ixv-15176"
      unitRef="usdPershares">0.3</us-gaap:SharePrice>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0" id="ixv-10316">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
14 &lt;/b&gt;&#x2013; &lt;b&gt;STOCK-BASED COMPENSATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2025, under both the Company&#x2019;s previous 2008 and current 2018 Omnibus Incentive Plans, approximately 9.1 million shares
of common stock have been issued to employees, non-employees, and advisors. In addition, 7.3 million restricted share units (RSUs) fair
valued at $4.3 million with a weighted average value of $0.59 per share, have been granted but not yet issued from different Incentive
Plans and Grants. This includes 4.7 million RSUs granted to employees and directors, which consists of a vesting schedule based entirely
on the attainment of either operational milestones (performance conditions) or market conditions, assuming continued employment either
as an employee, or director with the Company. The performance-based RSUs are accounted for upon certification by the management, confirming
the probability of achievement of milestones. As of March 31, 2025, the management confirmed that five milestones had been achieved,
and the rest were probable to be achieved by March 31, 2028.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
options held by advisors and directors to purchase 4 million shares of common stock fair valued at $1 million with a weighted average
of $0.26 per share, which have been granted but are to be issued over a vesting period between Fiscal 2022 and Fiscal 2027. Options granted
and issued before the vesting period are expensed when issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
options are fair valued using a Black-Scholes Pricing Model, and market-based RSU are valued based on a lattice model with the following
assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.4pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Granted
in &lt;br/&gt;
Fiscal 2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt 0.25pt 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.4pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Granted
in &lt;br/&gt;
Fiscal 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt 0.25pt 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected life of options&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="padding: 0.25pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5 years&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="padding: 0.25pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5 years&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding: 0.25pt; width: 76%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vested options&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; padding: 0.25pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; padding: 0.25pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.93&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.24&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;171&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;175&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="padding: 0.25pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-2; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nil&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="padding: 0.25pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-3; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nil&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
expense associated with share-based payments to employees, directors, advisors, and contractors is allocated over the vesting or service
period and recognized in the Selling, general, and administrative expenses (including research and development). For Fiscal 2025, the
Company&#x2019;s share-based expense and option-based expense, shown in Selling, general, and administrative expenses (including research
and development), were $1 million and $590 thousand, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
Fiscal 2024, the Company&#x2019;s share-based expenses and option-based expenses shown in Selling, general, and administrative expenses
(including research and development) were $1.7 million and $59 thousand, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Non-vested shares&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Shares &lt;br/&gt; (in thousands)&lt;br/&gt; (#)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted &lt;br/&gt; average&lt;br/&gt; grant date &lt;br/&gt; fair value&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; padding-left: 0.25pt"&gt;Non-vested shares as of March 31, 2024 &lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,452&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.61&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Granted &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Vested &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,443&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;Cancelled/Forfeited &lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(212&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.33&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;&lt;b&gt;Non-vested shares as of March 31, 2025&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;5,796&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;0.64&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Options&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Shares &lt;br/&gt; (in thousands) &lt;br/&gt; (#)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted&lt;br/&gt; average &lt;br/&gt; grant date &lt;br/&gt; fair value&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted&lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; padding-left: 0.25pt"&gt;Options outstanding as of March 31, 2024&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;3,710&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.25&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.39&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(628&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;Cancelled/forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(150&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1.39&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.39&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Options outstanding as of March 31, 2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;3,182&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;0.30&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;0.34&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
was a combined unrecognized expense of $1.7 million related to non-vested shares and share options that the Company expects to be recognized
over a life of up to 4 (four) years.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c73"
      decimals="-5"
      id="ixv-15177"
      unitRef="shares">9100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares
      contextRef="c3"
      decimals="-5"
      id="ixv-15178"
      unitRef="shares">7300000</us-gaap:EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-5" id="ixv-15179" unitRef="usd">4300000</us-gaap:ShareBasedCompensation>
    <igc:WeightedAveragePricePerShare
      contextRef="c0"
      decimals="2"
      id="ixv-15180"
      unitRef="usdPershares">0.59</igc:WeightedAveragePricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c0"
      decimals="-5"
      id="ixv-15181"
      unitRef="shares">4700000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c74"
      decimals="-6"
      id="ixv-15182"
      unitRef="shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensation contextRef="c74" decimals="-3" id="ixv-15183" unitRef="usd">1000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c73"
      decimals="2"
      id="ixv-15184"
      unitRef="usdPershares">0.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0" id="ixv-10348">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
options are fair valued using a Black-Scholes Pricing Model, and market-based RSU are valued based on a lattice model with the following
assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.4pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Granted
in &lt;br/&gt;
Fiscal 2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt 0.25pt 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.4pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Granted
in &lt;br/&gt;
Fiscal 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt 0.25pt 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected life of options&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="padding: 0.25pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5 years&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="padding: 0.25pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5 years&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding: 0.25pt; width: 76%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vested options&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; padding: 0.25pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 9%; padding: 0.25pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.93&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.24&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;171&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;175&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="padding: 0.25pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-2; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nil&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="padding: 0.25pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-3; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nil&lt;/span&gt;&lt;/td&gt; &lt;td style="padding: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0" id="ixv-15185">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c5" id="ixv-15186">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c0" decimals="2" id="ixv-15187" unitRef="pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c5" decimals="2" id="ixv-15188" unitRef="pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c0" decimals="4" id="ixv-15189" unitRef="pure">0.0393</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c5" decimals="4" id="ixv-15190" unitRef="pure">0.0524</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c0" decimals="2" id="ixv-15191" unitRef="pure">1.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c5" decimals="2" id="ixv-15192" unitRef="pure">1.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensation contextRef="c75" decimals="-6" id="ixv-15193" unitRef="usd">1000000</us-gaap:ShareBasedCompensation>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c76" decimals="-3" id="ixv-15194" unitRef="usd">590000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="c0" id="ixv-10468">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
Fiscal 2024, the Company&#x2019;s share-based expenses and option-based expenses shown in Selling, general, and administrative expenses
(including research and development) were $1.7 million and $59 thousand, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Non-vested shares&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Shares &lt;br/&gt; (in thousands)&lt;br/&gt; (#)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted &lt;br/&gt; average&lt;br/&gt; grant date &lt;br/&gt; fair value&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; padding-left: 0.25pt"&gt;Non-vested shares as of March 31, 2024 &lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,452&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.61&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Granted &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Vested &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,443&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;Cancelled/Forfeited &lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(212&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.33&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;&lt;b&gt;Non-vested shares as of March 31, 2025&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;5,796&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;b&gt;0.64&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensation contextRef="c77" decimals="-5" id="ixv-15195" unitRef="usd">1700000</us-gaap:ShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c78" decimals="-3" id="ixv-15196" unitRef="usd">59000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c4"
      decimals="-3"
      id="ixv-15197"
      unitRef="shares">7452000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c4"
      decimals="2"
      id="ixv-15198"
      unitRef="usdPershares">0.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c0"
      decimals="-3"
      id="ixv-15199"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c0"
      decimals="0"
      id="ixv-15200"
      unitRef="usdPershares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c0"
      decimals="-3"
      id="ixv-15201"
      unitRef="shares">1443000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c0"
      decimals="2"
      id="ixv-15202"
      unitRef="usdPershares">0.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="c0"
      decimals="-3"
      id="ixv-15203"
      unitRef="shares">212000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c0"
      decimals="2"
      id="ixv-15204"
      unitRef="usdPershares">0.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c3"
      decimals="-3"
      id="ixv-15205"
      unitRef="shares">5796000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c3"
      decimals="2"
      id="ixv-15206"
      unitRef="usdPershares">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-10549">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Options&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Shares &lt;br/&gt; (in thousands) &lt;br/&gt; (#)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted&lt;br/&gt; average &lt;br/&gt; grant date &lt;br/&gt; fair value&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted&lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; padding-left: 0.25pt"&gt;Options outstanding as of March 31, 2024&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;3,710&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.25&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.39&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(628&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;Cancelled/forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(150&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1.39&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.39&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Options outstanding as of March 31, 2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;3,182&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;0.30&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;0.34&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c4"
      decimals="-3"
      id="ixv-15207"
      unitRef="shares">3710000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c4"
      decimals="2"
      id="ixv-15208"
      unitRef="usdPershares">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c4"
      decimals="2"
      id="ixv-15209"
      unitRef="usdPershares">0.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c0"
      decimals="-3"
      id="ixv-15210"
      unitRef="shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c0"
      decimals="2"
      id="ixv-15211"
      unitRef="usdPershares">0.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-15212"
      unitRef="usdPershares">0.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c0"
      decimals="-3"
      id="ixv-15213"
      unitRef="shares">628000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="c0"
      decimals="2"
      id="ixv-15214"
      unitRef="usdPershares">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <igc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-15215"
      unitRef="usdPershares">0.25</igc:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c0"
      decimals="-3"
      id="ixv-15216"
      unitRef="shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="c0"
      decimals="2"
      id="ixv-15217"
      unitRef="usdPershares">1.39</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-15218"
      unitRef="usdPershares">0.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c3"
      decimals="-3"
      id="ixv-15219"
      unitRef="shares">3182000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c3"
      decimals="2"
      id="ixv-15220"
      unitRef="usdPershares">0.3</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c3"
      decimals="2"
      id="ixv-15221"
      unitRef="usdPershares">0.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c79" decimals="-5" id="ixv-15222" unitRef="usd">1700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c5" id="ixv-15223">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0" id="ixv-10650">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
15 &lt;/b&gt;&#x2013; &lt;b&gt;FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2025, the Company&#x2019;s marketable securities consist of liquid funds, which have been classified as Level 1 of the fair
value hierarchy because they have been valued using quoted prices in active markets. The Company&#x2019;s cash and cash equivalents have
also been classified as Level 1 on the same principle. Financial instruments are classified as current if they are expected to be liquidated
within the next twelve months. The Company&#x2019;s remaining investments have been classified as Level 3 instruments as there is little
or no market data. Level 3 investments are valued using the cost method. For further information refer Note 7, &#x201c;Investments in
Non-Marketable Securities.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information about the Company&#x2019;s assets that are measured at fair value on a recurring basis as of March
31, 2025, and 2024, and indicates the fair value hierarchy of the valuation techniques the Company used to determine such fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(in
thousands)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;As
of March 31, 2025&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Particular&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Adjusted&lt;br/&gt; Cost&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gain &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Loss&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Fair Value&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Cash &amp;amp;&lt;br/&gt; Cash &lt;br/&gt; Equivalents&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Short Term&lt;br/&gt; Investments &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; padding-left: 0.25pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;368&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;368&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;368&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Money Market Fund&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Debt Funds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;Mutual Fund&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25pt"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;Certificates of Deposit&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;37&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;37&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;37&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;&lt;b&gt;TOTAL&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;405&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;405&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;405&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;As
of March 31, 2024&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Particular&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Adjusted&lt;br/&gt; Cost&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gain &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Loss&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Fair Value &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Cash &amp;amp; &lt;br/&gt; Cash&lt;br/&gt; Equivalents &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Short Term &lt;br/&gt; Investments&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Level 1&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; padding-left: 0.25pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;912&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;912&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;912&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Money Market Fund&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Debt Funds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;Mutual Fund&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;123&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;123&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;123&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-left: 0.25pt"&gt;Level 2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;Certificates of Deposit&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;150&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;150&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;150&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;TOTAL&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,198&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,198&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,198&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c0" id="ixv-10678">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information about the Company&#x2019;s assets that are measured at fair value on a recurring basis as of March
31, 2025, and 2024, and indicates the fair value hierarchy of the valuation techniques the Company used to determine such fair value:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Particular&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Adjusted&lt;br/&gt; Cost&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gain &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Loss&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Fair Value&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Cash &amp;amp;&lt;br/&gt; Cash &lt;br/&gt; Equivalents&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Short Term&lt;br/&gt; Investments &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; padding-left: 0.25pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;368&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;368&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;368&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Money Market Fund&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Debt Funds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;Mutual Fund&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25pt"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;Certificates of Deposit&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;37&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;37&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;37&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;&lt;b&gt;TOTAL&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;405&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;405&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;405&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Particular&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Adjusted&lt;br/&gt; Cost&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gain &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Loss&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Fair Value &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Cash &amp;amp; &lt;br/&gt; Cash&lt;br/&gt; Equivalents &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Short Term &lt;br/&gt; Investments&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Level 1&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; padding-left: 0.25pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;912&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;912&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;912&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Money Market Fund&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Debt Funds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;Mutual Fund&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;123&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;123&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;123&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-left: 0.25pt"&gt;Level 2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;Certificates of Deposit&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;150&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;150&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;150&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;TOTAL&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,198&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,198&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,198&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueAdjustment contextRef="c80" decimals="-3" id="ixv-15224" unitRef="usd">368000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss contextRef="c80" decimals="-3" id="ixv-15225" unitRef="usd">0</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings contextRef="c80" decimals="-3" id="ixv-15226" unitRef="usd">0</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings>
    <us-gaap:AssetsFairValueDisclosure contextRef="c81" decimals="-3" id="ixv-15227" unitRef="usd">368000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c81" decimals="-3" id="ixv-15228" unitRef="usd">368000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c81" decimals="-3" id="ixv-15229" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueAdjustment contextRef="c82" decimals="-3" id="ixv-15230" unitRef="usd">0</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss contextRef="c82" decimals="-3" id="ixv-15231" unitRef="usd">0</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings contextRef="c82" decimals="-3" id="ixv-15232" unitRef="usd">0</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings>
    <us-gaap:AssetsFairValueDisclosure contextRef="c83" decimals="-3" id="ixv-15233" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c83" decimals="-3" id="ixv-15234" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c83" decimals="-3" id="ixv-15235" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueAdjustment contextRef="c84" decimals="-3" id="ixv-15236" unitRef="usd">0</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss contextRef="c84" decimals="-3" id="ixv-15237" unitRef="usd">0</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings contextRef="c84" decimals="-3" id="ixv-15238" unitRef="usd">0</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings>
    <us-gaap:AssetsFairValueDisclosure contextRef="c85" decimals="-3" id="ixv-15239" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c85" decimals="-3" id="ixv-15240" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c85" decimals="-3" id="ixv-15241" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueAdjustment contextRef="c86" decimals="-3" id="ixv-15242" unitRef="usd">0</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss contextRef="c86" decimals="-3" id="ixv-15243" unitRef="usd">0</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings contextRef="c86" decimals="-3" id="ixv-15244" unitRef="usd">0</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings>
    <us-gaap:AssetsFairValueDisclosure contextRef="c87" decimals="-3" id="ixv-15245" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c87" decimals="-3" id="ixv-15246" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c87" decimals="-3" id="ixv-15247" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueAdjustment contextRef="c88" decimals="-3" id="ixv-15248" unitRef="usd">37000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss contextRef="c88" decimals="-3" id="ixv-15249" unitRef="usd">0</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings contextRef="c88" decimals="-3" id="ixv-15250" unitRef="usd">0</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings>
    <us-gaap:AssetsFairValueDisclosure contextRef="c89" decimals="-3" id="ixv-15251" unitRef="usd">37000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c89" decimals="-3" id="ixv-15252" unitRef="usd">37000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c89" decimals="-3" id="ixv-15253" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueAdjustment contextRef="c90" decimals="-3" id="ixv-15254" unitRef="usd">0</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss contextRef="c90" decimals="-3" id="ixv-15255" unitRef="usd">0</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings contextRef="c90" decimals="-3" id="ixv-15256" unitRef="usd">0</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings>
    <us-gaap:AssetsFairValueDisclosure contextRef="c91" decimals="-3" id="ixv-15257" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c91" decimals="-3" id="ixv-15258" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c91" decimals="-3" id="ixv-15259" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueAdjustment contextRef="c0" decimals="-3" id="ixv-15260" unitRef="usd">405000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss contextRef="c0" decimals="-3" id="ixv-15261" unitRef="usd">0</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings contextRef="c0" decimals="-3" id="ixv-15262" unitRef="usd">0</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings>
    <us-gaap:AssetsFairValueDisclosure contextRef="c3" decimals="-3" id="ixv-15263" unitRef="usd">405000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c3" decimals="-3" id="ixv-15264" unitRef="usd">405000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c3" decimals="-3" id="ixv-15265" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueAdjustment contextRef="c92" decimals="-3" id="ixv-15266" unitRef="usd">912000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss contextRef="c92" decimals="-3" id="ixv-15267" unitRef="usd">0</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings contextRef="c92" decimals="-3" id="ixv-15268" unitRef="usd">0</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings>
    <us-gaap:AssetsFairValueDisclosure contextRef="c93" decimals="-3" id="ixv-15269" unitRef="usd">912000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c93" decimals="-3" id="ixv-15270" unitRef="usd">912000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c93" decimals="-3" id="ixv-15271" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueAdjustment contextRef="c94" decimals="-3" id="ixv-15272" unitRef="usd">0</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss contextRef="c94" decimals="-3" id="ixv-15273" unitRef="usd">0</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings contextRef="c94" decimals="-3" id="ixv-15274" unitRef="usd">0</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings>
    <us-gaap:AssetsFairValueDisclosure contextRef="c95" decimals="-3" id="ixv-15275" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c95" decimals="-3" id="ixv-15276" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c95" decimals="-3" id="ixv-15277" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueAdjustment contextRef="c96" decimals="-3" id="ixv-15278" unitRef="usd">13000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss contextRef="c96" decimals="-3" id="ixv-15279" unitRef="usd">0</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings contextRef="c96" decimals="-3" id="ixv-15280" unitRef="usd">0</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings>
    <us-gaap:AssetsFairValueDisclosure contextRef="c97" decimals="-3" id="ixv-15281" unitRef="usd">13000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c97" decimals="-3" id="ixv-15282" unitRef="usd">13000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c97" decimals="-3" id="ixv-15283" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueAdjustment contextRef="c98" decimals="-3" id="ixv-15284" unitRef="usd">123000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss contextRef="c98" decimals="-3" id="ixv-15285" unitRef="usd">0</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings contextRef="c98" decimals="-3" id="ixv-15286" unitRef="usd">0</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings>
    <us-gaap:AssetsFairValueDisclosure contextRef="c99" decimals="-3" id="ixv-15287" unitRef="usd">123000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c99" decimals="-3" id="ixv-15288" unitRef="usd">123000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c99" decimals="-3" id="ixv-15289" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="c100"
      decimals="-3"
      id="ixv-15290"
      unitRef="usd">150000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
      contextRef="c100"
      decimals="-3"
      id="ixv-15291"
      unitRef="usd">0</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings
      contextRef="c100"
      decimals="-3"
      id="ixv-15292"
      unitRef="usd">0</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c101"
      decimals="-3"
      id="ixv-15293"
      unitRef="usd">150000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c101"
      decimals="-3"
      id="ixv-15294"
      unitRef="usd">150000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c101"
      decimals="-3"
      id="ixv-15295"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="c102"
      decimals="-3"
      id="ixv-15296"
      unitRef="usd">0</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss
      contextRef="c102"
      decimals="-3"
      id="ixv-15297"
      unitRef="usd">0</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings
      contextRef="c102"
      decimals="-3"
      id="ixv-15298"
      unitRef="usd">0</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c103"
      decimals="-3"
      id="ixv-15299"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c103"
      decimals="-3"
      id="ixv-15300"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c103"
      decimals="-3"
      id="ixv-15301"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueAdjustment contextRef="c5" decimals="-3" id="ixv-15302" unitRef="usd">1198000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss contextRef="c5" decimals="-3" id="ixv-15303" unitRef="usd">0</us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings contextRef="c5" decimals="-3" id="ixv-15304" unitRef="usd">0</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings>
    <us-gaap:AssetsFairValueDisclosure contextRef="c4" decimals="-3" id="ixv-15305" unitRef="usd">1198000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c4" decimals="-3" id="ixv-15306" unitRef="usd">1198000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c4" decimals="-3" id="ixv-15307" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-11227">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
16 &lt;/b&gt;&#x2013; &lt;b&gt;INCOME TAXES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company calculates its provision for foreign and U.S. federal income taxes based on the current tax law. As the Company maintains a full
valuation allowance against its deferred tax assets, there is no income tax expense recorded related to this change other than the Federal
AMT credit which are refundable due to the passage of tax reform.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to the Company&#x2019;s history of losses and uncertainty of future taxable income, a valuation allowance sufficient to fully offset net
operating losses and other deferred tax assets has been established. The valuation allowance will be maintained until sufficient positive
evidence exists to support a conclusion that a valuation allowance is not necessary.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax expense/(benefit) for each of the years ended March 31 consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year Ended March 31,&lt;br/&gt;
 (in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Income Tax Expense&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2025&lt;br/&gt;
($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2024&lt;br/&gt;
($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.25pt"&gt;Net income loss before tax&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(7,121&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(13,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Tax rate&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Expected income tax recovery&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,495&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,730&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Impact of tax rate differences in foreign jurisdictions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(72&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(151&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Tax rate changes and other adjustments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,305&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,475&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,872&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,406&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
significant components of deferred income tax expense/(benefit) from operations before non-controlling interest for each of the years
ended March 31 are approximated as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid"&gt;Year Ended March 31, &lt;br/&gt; (in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Deferred income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2025&lt;br/&gt;
($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2024&lt;br/&gt;
($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.25pt"&gt;Net operating loss carry-forwards foreign&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;332&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;287&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Non-capital loss carry-forwards &#x2013; U.S.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,272&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Temporary differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;427&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;418&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,124
&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,977&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(19,124&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(14,977&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below sets forth the details of expiration of the non-financial carried forward losses of the Company as of March 31, 2025, as
under:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Year&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Amount&lt;br/&gt;
 (in thousands)&lt;br/&gt;
 ($)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-left: 0.25pt"&gt;2029&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;16&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;2030&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;37&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;2031&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,081&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;2032&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4,141&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;2033&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;627&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;2034&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,269&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;2035&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,735&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;2036&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,176&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;2037&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;819&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;No expiry&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,256&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;No expiry&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4,132&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;No expiry&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,932&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;No expiry&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8,841&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;No expiry&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;14,966&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;No expiry&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8,552&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;No expiry&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;6,884&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;No expiry&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;22,006&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;87,469&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Realization
of deferred tax assets, including those related to net operating loss carryforwards, are dependent upon future earnings, if any, of which
the timing and amount are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. Based
upon the Company&#x2019;s current operating results management cannot conclude that it is more likely than not that such assets will be
realized. The Company files income tax returns in India, Colombia, and the U.S. The Company has a carry-forward R&amp;amp;D tax credit of
approximately $4,542 thousand.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0" id="ixv-11259">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax expense/(benefit) for each of the years ended March 31 consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year Ended March 31,&lt;br/&gt;
 (in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Income Tax Expense&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2025&lt;br/&gt;
($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2024&lt;br/&gt;
($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.25pt"&gt;Net income loss before tax&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(7,121&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(13,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Tax rate&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Expected income tax recovery&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,495&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,730&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Impact of tax rate differences in foreign jurisdictions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(72&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(151&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Tax rate changes and other adjustments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,305&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,475&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,872&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,406&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="-3" id="ixv-15308" unitRef="usd">-7121000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c5" decimals="-3" id="ixv-15309" unitRef="usd">-13000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c0" decimals="2" id="ixv-15310" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c5" decimals="2" id="ixv-15311" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="-3" id="ixv-15312" unitRef="usd">-1495000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c5" decimals="-3" id="ixv-15313" unitRef="usd">-2730000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign contextRef="c0" decimals="-3" id="ixv-15314" unitRef="usd">72000</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign contextRef="c5" decimals="-3" id="ixv-15315" unitRef="usd">151000</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c0" decimals="-3" id="ixv-15316" unitRef="usd">-2305000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c5" decimals="-3" id="ixv-15317" unitRef="usd">1475000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c0" decimals="-3" id="ixv-15318" unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c5" decimals="-3" id="ixv-15319" unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c0" decimals="-3" id="ixv-15320" unitRef="usd">3872000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c5" decimals="-3" id="ixv-15321" unitRef="usd">1406000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="-3" id="ixv-15322" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c5" decimals="-3" id="ixv-15323" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c0" id="ixv-11381">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
significant components of deferred income tax expense/(benefit) from operations before non-controlling interest for each of the years
ended March 31 are approximated as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid"&gt;Year Ended March 31, &lt;br/&gt; (in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Deferred income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2025&lt;br/&gt;
($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2024&lt;br/&gt;
($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.25pt"&gt;Net operating loss carry-forwards foreign&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;332&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;287&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Non-capital loss carry-forwards &#x2013; U.S.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,272&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Temporary differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;427&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;418&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,124
&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,977&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(19,124&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(14,977&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign contextRef="c3" decimals="-3" id="ixv-15324" unitRef="usd">332000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign contextRef="c4" decimals="-3" id="ixv-15325" unitRef="usd">287000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c3" decimals="-3" id="ixv-15326" unitRef="usd">18365000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c4" decimals="-3" id="ixv-15327" unitRef="usd">14272000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOther contextRef="c3" decimals="-3" id="ixv-15328" unitRef="usd">427000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c4" decimals="-3" id="ixv-15329" unitRef="usd">418000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c3" decimals="-3" id="ixv-15330" unitRef="usd">19124000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c4" decimals="-3" id="ixv-15331" unitRef="usd">14977000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="-3" id="ixv-15332" unitRef="usd">19124000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="-3" id="ixv-15333" unitRef="usd">14977000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c3" decimals="-3" id="ixv-15334" unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c4" decimals="-3" id="ixv-15335" unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock contextRef="c0" id="ixv-11508">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below sets forth the details of expiration of the non-financial carried forward losses of the Company as of March 31, 2025, as
under:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Year&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Amount&lt;br/&gt;
 (in thousands)&lt;br/&gt;
 ($)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-left: 0.25pt"&gt;2029&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;16&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;2030&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;37&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;2031&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,081&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;2032&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4,141&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;2033&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;627&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;2034&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,269&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;2035&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,735&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;2036&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,176&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;2037&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;819&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;No expiry&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,256&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;No expiry&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4,132&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;No expiry&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,932&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;No expiry&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8,841&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;No expiry&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;14,966&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;No expiry&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8,552&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;No expiry&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;6,884&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;No expiry&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;22,006&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;87,469&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="c104"
      decimals="-3"
      id="ixv-15336"
      unitRef="usd">16000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="c105"
      decimals="-3"
      id="ixv-15337"
      unitRef="usd">37000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="c106"
      decimals="-3"
      id="ixv-15338"
      unitRef="usd">3081000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="c107"
      decimals="-3"
      id="ixv-15339"
      unitRef="usd">4141000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="c108"
      decimals="-3"
      id="ixv-15340"
      unitRef="usd">627000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="c109"
      decimals="-3"
      id="ixv-15341"
      unitRef="usd">1269000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="c110"
      decimals="-3"
      id="ixv-15342"
      unitRef="usd">1735000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="c111"
      decimals="-3"
      id="ixv-15343"
      unitRef="usd">1176000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="c112"
      decimals="-3"
      id="ixv-15344"
      unitRef="usd">819000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="c113"
      decimals="-3"
      id="ixv-15345"
      unitRef="usd">1256000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="c114"
      decimals="-3"
      id="ixv-15346"
      unitRef="usd">4132000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="c115"
      decimals="-3"
      id="ixv-15347"
      unitRef="usd">7932000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="c116"
      decimals="-3"
      id="ixv-15348"
      unitRef="usd">8841000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="c117"
      decimals="-3"
      id="ixv-15349"
      unitRef="usd">14966000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="c118"
      decimals="-3"
      id="ixv-15350"
      unitRef="usd">8552000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="c119"
      decimals="-3"
      id="ixv-15351"
      unitRef="usd">6884000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="c120"
      decimals="-3"
      id="ixv-15352"
      unitRef="usd">22006000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c3" decimals="-3" id="ixv-15353" unitRef="usd">87469000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c3" decimals="-3" id="ixv-15354" unitRef="usd">4542000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c0" id="ixv-11641">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
17 &lt;/b&gt;&#x2013; &lt;b&gt;REVENUE RECOGNITION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
in the renting business when the equipment is rented, and the terms of the agreement have been fulfilled during the period. Revenue from
the execution of infrastructure contracts is recognized on the basis of the output method as and when part of the performance obligation
has been completed, and approval from the contracting agency has been obtained after a survey of the performance completion as of that
date. The revenue from the wellness and lifestyle business is recognized once goods have been sold to the customer and the performance
obligation has been completed. In retail sales, we offer consumer products through our online stores. Revenue is recognized when control
of the goods is transferred to the customer. This generally occurs upon our delivery to a third-party carrier or to the customer directly.
Revenue from white labelling services is recognized when the performance obligation has been completed, and output material has been
transferred to the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
sales disaggregated by significant products and services for Fiscal 2025 and 2024 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid"&gt;(in thousands) &lt;br/&gt; Year ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2025&lt;br/&gt;
($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2024&lt;br/&gt;
($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Wellness and lifestyle &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;113&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;228&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;White labeling services &lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,158&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;953&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;164&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,271&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,345&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
from wellness and lifestyle consists of the sale of products such as gummies, hand sanitizers, bath bombs, lotions, beverages, hemp crude
extract, hemp isolate, and hemp distillate.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
from white labelling services consists of rebranding our formulations or the customer&#x2019;s products as per the customer&#x2019;s requirement.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
consists of income from the rental of heavy construction equipment and the execution of contracts directly or through subcontractors.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c0" id="ixv-11668">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
sales disaggregated by significant products and services for Fiscal 2025 and 2024 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid"&gt;(in thousands) &lt;br/&gt; Year ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2025&lt;br/&gt;
($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2024&lt;br/&gt;
($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Wellness and lifestyle &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;113&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;228&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;White labeling services &lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,158&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;953&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;164&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,271&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,345&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
from wellness and lifestyle consists of the sale of products such as gummies, hand sanitizers, bath bombs, lotions, beverages, hemp crude
extract, hemp isolate, and hemp distillate.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
from white labelling services consists of rebranding our formulations or the customer&#x2019;s products as per the customer&#x2019;s requirement.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
consists of income from the rental of heavy construction equipment and the execution of contracts directly or through subcontractors.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="c121"
      decimals="-3"
      id="ix_2_fact"
      unitRef="usd">113000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="c122"
      decimals="-3"
      id="ix_3_fact"
      unitRef="usd">228000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="c123"
      decimals="-3"
      id="ix_4_fact"
      unitRef="usd">1158000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="c124"
      decimals="-3"
      id="ix_5_fact"
      unitRef="usd">953000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="c125"
      decimals="-3"
      id="ix_6_fact"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="c126"
      decimals="-3"
      id="ix_7_fact"
      unitRef="usd">164000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c0" decimals="-3" id="ixv-15361" unitRef="usd">1271000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c5" decimals="-3" id="ixv-15362" unitRef="usd">1345000</us-gaap:Revenues>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c0" id="ixv-11767">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
18 &lt;/b&gt;&#x2013; &lt;b&gt;SEGMENT INFORMATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FASB
ASC 280, &#x201c;&lt;i&gt;Segment Reporting,&lt;/i&gt;&#x201d; establishes standards for reporting information about reportable segments. Operating
segments are defined as components of an enterprise about which separate financial information is available and is evaluated regularly
by the chief operating decision maker, or decision-making group (CODM), in deciding how to allocate resources and in assessing performance.
The CODM evaluates revenues and gross profits based on product lines and routes to market. The Company&#x2019;s CODM is the Company&#x2019;s
Chief Executive Officer (CEO). The CEO reviews financial information presented on an operating segment basis for the purposes of making
operating decisions and assessing financial performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
fiscal 2025, the Company reassessed its reportable segment structure in connection with its strategic realignment toward Life Sciences.
As a result, management determined that the Company operates as a &lt;b&gt;single reportable segment&lt;/b&gt;. Historically, the Company reported
two operating segments: Life Sciences and Infrastructure. While the Infrastructure segment generated revenues in fiscal 2024, it did
not generate any revenues in fiscal 2025 and is no longer actively managed or evaluated as a discrete operating segment by the Company&#x2019;s
Chief Operating Decision Maker.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
has not made a formal decision to dispose of or exit the Infrastructure business, and therefore, the Infrastructure operations have not
been classified as discontinued operations. The results of the Infrastructure activities have been aggregated into the single reportable
segment presentation for all periods presented in this Annual Report on Form 10-K. This change in segment reporting has no impact on
the Company&#x2019;s previously reported consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following provides information required by ASC 280-10-50-38 &#x201c;Entity-wide Information&#x201d;:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1)
The table below shows revenue reported by segments:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Product
&amp;amp; Service&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Segments&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Fiscal 2025&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Fiscal 2024&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Life Sciences segment&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;1,271&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;1,345&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,271&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1345&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
Fiscal 2024, $164 thousand belongs to the previously reported Infrastructure Segment.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
information on revenue by product and service, refer to Note 17, &#x201c;Revenue Recognition.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2)
The table below shows the attributes to the country of domicile (U.S.) and foreign countries. Revenue is generally attributed to the
geographic location of customers:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; font-style: italic; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"&gt;Segments&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;Country&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Fiscal 2025&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Percentage&#160;of &lt;br/&gt; Total&lt;br/&gt; Revenue &lt;br/&gt; (%)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Asia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;India&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 60%; padding-left: 0.25pt"&gt;America&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: left"&gt;U.S.&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,269&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;99.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Colombia&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,271&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"&gt;Segments&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;Country&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Fiscal 2024&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Percentage&#160;of &lt;br/&gt; Total&lt;br/&gt; Revenue&lt;br/&gt; (%)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; padding-left: 0.25pt"&gt;Asia&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: left"&gt;India&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;164&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25pt"&gt;America&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;U.S.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,179&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;87&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Colombia&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,345&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3)
The table below shows the non-current assets other than financial instruments held in the country of domicile and foreign countries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; font-style: italic; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"&gt;Nature of Assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;U.S. &lt;br/&gt; (Country of &lt;br/&gt; Domicile)&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Foreign &lt;br/&gt; Countries &lt;br/&gt; (India and &lt;br/&gt; Colombia) &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total as of &lt;br/&gt; March 31, &lt;br/&gt; 2025&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 0.25pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,852&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,852&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Property, plant, and equipment, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,171&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Claims and advances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;410&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;271&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;681&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Operating lease asset&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;80&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;98&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;Total non-current assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;5,513&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;338&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;5,851&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"&gt;Nature of Assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;U.S. &lt;br/&gt; (Country of &lt;br/&gt; Domicile) &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Foreign &lt;br/&gt; Countries&lt;br/&gt; (India and &lt;br/&gt; Colombia)&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total as of &lt;br/&gt; March 31,&lt;br/&gt; 2024&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 0.25pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,616&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,616&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Property, plant, and equipment, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,620&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,695&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Claims and advances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;410&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;278&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;688&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Operating lease asset&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;193&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;&lt;b&gt;Total non-current assets&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;5,839&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;358&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;6,197&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c0"
      decimals="0"
      id="ixv-15363"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="c0" id="ixv-11792">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1)
The table below shows revenue reported by segments:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Segments&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Fiscal 2025&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Fiscal 2024&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Life Sciences segment&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;1,271&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;1,345&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,271&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1345&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:Revenues
      contextRef="c128"
      decimals="-3"
      id="ixv-15364"
      unitRef="usd">1271000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="c129"
      decimals="-3"
      id="ixv-15365"
      unitRef="usd">1345000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c0" decimals="-3" id="ixv-15366" unitRef="usd">1271000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c5" decimals="-3" id="ixv-15367" unitRef="usd">1345000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="c127"
      decimals="-3"
      id="ixv-15368"
      unitRef="usd">164000</us-gaap:Revenues>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c0" id="ixv-11875">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2)
The table below shows the attributes to the country of domicile (U.S.) and foreign countries. Revenue is generally attributed to the
geographic location of customers:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; font-style: italic; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"&gt;Segments&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;Country&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Fiscal 2025&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Percentage&#160;of &lt;br/&gt; Total&lt;br/&gt; Revenue &lt;br/&gt; (%)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25pt"&gt;Asia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;India&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 60%; padding-left: 0.25pt"&gt;America&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: left"&gt;U.S.&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,269&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;99.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Colombia&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;1,271&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"&gt;Segments&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;Country&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Fiscal 2024&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Percentage&#160;of &lt;br/&gt; Total&lt;br/&gt; Revenue&lt;br/&gt; (%)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; padding-left: 0.25pt"&gt;Asia&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: left"&gt;India&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;164&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25pt"&gt;America&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;U.S.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,179&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;87&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.25pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Colombia&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,345&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="c130"
      decimals="-3"
      id="ixv-15369"
      unitRef="usd">0</us-gaap:Revenues>
    <igc:TotalRevenuePercentage
      contextRef="c130"
      decimals="2"
      id="ixv-15370"
      unitRef="pure">0</igc:TotalRevenuePercentage>
    <us-gaap:Revenues
      contextRef="c131"
      decimals="-3"
      id="ixv-15371"
      unitRef="usd">1269000</us-gaap:Revenues>
    <igc:TotalRevenuePercentage
      contextRef="c131"
      decimals="3"
      id="ixv-15372"
      unitRef="pure">0.998</igc:TotalRevenuePercentage>
    <us-gaap:Revenues
      contextRef="c132"
      decimals="-3"
      id="ixv-15373"
      unitRef="usd">2000</us-gaap:Revenues>
    <igc:TotalRevenuePercentage
      contextRef="c132"
      decimals="3"
      id="ixv-15374"
      unitRef="pure">0.002</igc:TotalRevenuePercentage>
    <us-gaap:Revenues contextRef="c0" decimals="-3" id="ixv-15375" unitRef="usd">1271000</us-gaap:Revenues>
    <igc:TotalRevenuePercentage contextRef="c0" decimals="2" id="ixv-15376" unitRef="pure">1</igc:TotalRevenuePercentage>
    <us-gaap:Revenues
      contextRef="c133"
      decimals="-3"
      id="ixv-15377"
      unitRef="usd">164000</us-gaap:Revenues>
    <igc:TotalRevenuePercentage
      contextRef="c133"
      decimals="2"
      id="ixv-15378"
      unitRef="pure">0.12</igc:TotalRevenuePercentage>
    <us-gaap:Revenues
      contextRef="c134"
      decimals="-3"
      id="ixv-15379"
      unitRef="usd">1179000</us-gaap:Revenues>
    <igc:TotalRevenuePercentage
      contextRef="c134"
      decimals="2"
      id="ixv-15380"
      unitRef="pure">0.87</igc:TotalRevenuePercentage>
    <us-gaap:Revenues
      contextRef="c135"
      decimals="-3"
      id="ixv-15381"
      unitRef="usd">2000</us-gaap:Revenues>
    <igc:TotalRevenuePercentage
      contextRef="c135"
      decimals="2"
      id="ixv-15382"
      unitRef="pure">0.01</igc:TotalRevenuePercentage>
    <us-gaap:Revenues contextRef="c5" decimals="-3" id="ixv-15383" unitRef="usd">1345000</us-gaap:Revenues>
    <igc:TotalRevenuePercentage contextRef="c5" decimals="2" id="ixv-15384" unitRef="pure">1</igc:TotalRevenuePercentage>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock contextRef="c0" id="ixv-12044">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3)
The table below shows the non-current assets other than financial instruments held in the country of domicile and foreign countries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; font-style: italic; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; font-style: italic"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"&gt;Nature of Assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;U.S. &lt;br/&gt; (Country of &lt;br/&gt; Domicile)&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Foreign &lt;br/&gt; Countries &lt;br/&gt; (India and &lt;br/&gt; Colombia) &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total as of &lt;br/&gt; March 31, &lt;br/&gt; 2025&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 0.25pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,852&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,852&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Property, plant, and equipment, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,171&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Claims and advances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;410&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;271&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;681&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Operating lease asset&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;80&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;98&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;Total non-current assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;5,513&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;338&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;5,851&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"&gt;Nature of Assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;U.S. &lt;br/&gt; (Country of &lt;br/&gt; Domicile) &lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Foreign &lt;br/&gt; Countries&lt;br/&gt; (India and &lt;br/&gt; Colombia)&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total as of &lt;br/&gt; March 31,&lt;br/&gt; 2024&lt;br/&gt; ($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 0.25pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,616&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,616&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Property, plant, and equipment, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,620&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,695&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25pt"&gt;Claims and advances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;410&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;278&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;688&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25pt"&gt;Operating lease asset&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;193&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25pt"&gt;&lt;b&gt;Total non-current assets&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;5,839&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;358&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;b&gt;6,197&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="c136"
      decimals="-3"
      id="ixv-15385"
      unitRef="usd">1852000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="c137"
      decimals="-3"
      id="ixv-15386"
      unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c3" decimals="-3" id="ixv-15387" unitRef="usd">1852000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c136"
      decimals="-3"
      id="ixv-15388"
      unitRef="usd">3171000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c137"
      decimals="-3"
      id="ixv-15389"
      unitRef="usd">49000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" id="ixv-15390" unitRef="usd">3220000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c136"
      decimals="-3"
      id="ixv-15391"
      unitRef="usd">410000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c137"
      decimals="-3"
      id="ixv-15392"
      unitRef="usd">271000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c3" decimals="-3" id="ixv-15393" unitRef="usd">681000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c136"
      decimals="-3"
      id="ixv-15394"
      unitRef="usd">80000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c137"
      decimals="-3"
      id="ixv-15395"
      unitRef="usd">18000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" id="ixv-15396" unitRef="usd">98000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent
      contextRef="c136"
      decimals="-3"
      id="ixv-15397"
      unitRef="usd">5513000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="c137"
      decimals="-3"
      id="ixv-15398"
      unitRef="usd">338000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c3" decimals="-3" id="ixv-15399" unitRef="usd">5851000</us-gaap:AssetsNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="c138"
      decimals="-3"
      id="ixv-15400"
      unitRef="usd">1616000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="c139"
      decimals="-3"
      id="ixv-15401"
      unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c4" decimals="-3" id="ixv-15402" unitRef="usd">1616000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c138"
      decimals="-3"
      id="ixv-15403"
      unitRef="usd">3620000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c139"
      decimals="-3"
      id="ixv-15404"
      unitRef="usd">75000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" id="ixv-15405" unitRef="usd">3695000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c138"
      decimals="-3"
      id="ixv-15406"
      unitRef="usd">410000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c139"
      decimals="-3"
      id="ixv-15407"
      unitRef="usd">278000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c4" decimals="-3" id="ixv-15408" unitRef="usd">688000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c138"
      decimals="-3"
      id="ixv-15409"
      unitRef="usd">193000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c139"
      decimals="-3"
      id="ixv-15410"
      unitRef="usd">5000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="-3" id="ixv-15411" unitRef="usd">198000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent
      contextRef="c138"
      decimals="-3"
      id="ixv-15412"
      unitRef="usd">5839000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="c139"
      decimals="-3"
      id="ixv-15413"
      unitRef="usd">358000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c4" decimals="-3" id="ixv-15414" unitRef="usd">6197000</us-gaap:AssetsNoncurrent>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-12280">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
19 &lt;/b&gt;&#x2013; &lt;b&gt;SUBSEQUENT EVENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the first quarter of Fiscal 2026, the Company entered into a Share Purchase Agreement (the &#x201c;2025 SPA&#x201d;) with multiple investors,
relating to the sale and issuance by our company to investors of an aggregate of 2,803,333 shares of our common stock, for a total purchase
price of $841,000, or $0.30 per share, subject to the terms and conditions set forth in the 2025 SPA. The investment is subject to customary
closing conditions, including NYSE approval. As per the 2025 SPA, the investor received piggyback registration rights subject to certain
restrictions. Shares are intended to be exempt from registration under the Securities Act, by virtue of the provisions of Section 4(a)(2)
of Securities Act.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2025, IGC Pharma expanded its CALMA Phase 2 trial for agitation in Alzheimer&#x2019;s dementia to two renowned research sites: Butler
Hospital&#x2019;s Memory and Aging Program (a nationally recognized research center affiliated with the Warren Alpert Medical School of
Brown University) in Rhode Island and the MIND Institute at Miami Jewish Health in Florida.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Asset held for sale has been sold for a value of approximately $701 thousand, and the ownership of the land has been wholly transferred
to the respective purchasers.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On June 24, 2025, IGC Pharma, Inc. (&#x201c;IGC&#x201d; or the &#x201c;Company&#x201d;) entered into an amendment to extend its existing Master Loan and Security Agreement along with the General Banking Facility Letter (collectively called the &#x201c;Loan Agreement&#x201d;) with O-Bank, CO., LTD., a banking corporation incorporated under the laws of Taiwan, as administrative agent and lender (the &#x201c;Lender&#x2019;), effective June 24, 2024. The amendment extends the term of the Loan Agreement, which was set to expire, under the same terms and conditions as previously disclosed on the Company&#x2019;s Current Report on Form 8-K filed with the Securities Exchange Commission on August 2, 2024, with the exception of i) a reduction in the facility fees from $84,000 to $48,000 and ii) interest, calculated according to the interest rate mentioned in the Certificate of Deposit, as the case may be, plus an applicable margin of 1.2%, instead of 1% . All other material terms of the Loan Agreement remain unchanged.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c28"
      decimals="0"
      id="ixv-15415"
      unitRef="shares">2803333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c28" decimals="0" id="ixv-15416" unitRef="usd">841000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharePrice
      contextRef="c29"
      decimals="2"
      id="ixv-15417"
      unitRef="usdPershares">0.3</us-gaap:SharePrice>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent contextRef="c140" decimals="0" id="ixv-15418" unitRef="usd">701</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:LineOfCreditFacilityCollateralFeesAmount contextRef="c141" decimals="0" id="ixv-15419" unitRef="usd">84000</us-gaap:LineOfCreditFacilityCollateralFeesAmount>
    <us-gaap:LineOfCreditFacilityCollateralFeesAmount contextRef="c142" decimals="0" id="ixv-15420" unitRef="usd">48000</us-gaap:LineOfCreditFacilityCollateralFeesAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c143"
      decimals="3"
      id="ixv-15421"
      unitRef="pure">0.012</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c144"
      decimals="2"
      id="ixv-15422"
      unitRef="pure">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c30" id="ixv-15423">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c30" id="ixv-15424">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c30" id="ixv-15425">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c30" id="ixv-15426">false</ecd:Rule10b51ArrAdoptedFlag>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c3" id="hidden-fact-0">http://fasb.org/us-gaap/2025#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c4" id="hidden-fact-1">http://fasb.org/us-gaap/2025#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c0"
      id="hidden-fact-2"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c5"
      id="hidden-fact-3"
      unitRef="pure"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-15433">0001326205</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-15434">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-15435">FY</dei:DocumentFiscalPeriodFocus>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
claims receivable is due from different vendors. While the Company has initiated collection proceedings internally or with the appropriate
authorities, it believes receiving the amount in the next 12 months will be challenging because of the time required for collection proceedings.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from wellness and lifestyle consists of the sale of products such as gummies, hand sanitizers, bath bombs, lotions, beverages, hemp crude
extract, hemp isolate, and hemp distillate.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from white labelling services consists of rebranding our formulations or the customer&#x2019;s products as per the customer&#x2019;s requirement.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
consists of income from the rental of heavy construction equipment and the execution of contracts directly or through subcontractors.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
